
Hepatocyte	O
nuclear	O
factor	O
-	O
6	O
:	O
associations	O
between	O
genetic	O
variability	O
and	O
type	B-Disease
II	I-Disease
diabetes	I-Disease
and	O
between	O
genetic	O
variability	O
and	O
estimates	O
of	O
insulin	O
secretion	O
.	O
	
The	O
transcription	O
factor	O
hepatocyte	O
nuclear	O
factor	O
(	O
HNF	O
)-	O
6	O
is	O
an	O
upstream	O
regulator	O
of	O
several	O
genes	O
involved	O
in	O
the	O
pathogenesis	O
of	O
maturity	B-Disease
-	I-Disease
onset	I-Disease
diabetes	I-Disease
of	O
the	O
young	O
.	O
	
We	O
therefore	O
tested	O
the	O
hypothesis	O
that	O
variability	O
in	O
the	O
HNF	O
-	O
6	O
gene	O
is	O
associated	O
with	O
subsets	O
of	O
Type	B-Disease
II	I-Disease
(	I-Disease
non	I-Disease
-	I-Disease
insulin	I-Disease
-	I-Disease
dependent	I-Disease
)	I-Disease
diabetes	I-Disease
mellitus	I-Disease
and	O
estimates	O
of	O
insulin	O
secretion	O
in	O
glucose	B-Chemical
tolerant	O
subjects	O
.	O
	
We	O
cloned	O
the	O
coding	O
region	O
as	O
well	O
as	O
the	O
intron	O
-	O
exon	O
boundaries	O
of	O
the	O
HNF	O
-	O
6	O
gene	O
.	O
	
We	O
then	O
examined	O
them	O
on	O
genomic	O
DNA	O
in	O
six	O
MODY	O
probands	O
without	O
mutations	O
in	O
the	O
MODY1	O
","	O
MODY3	O
and	O
MODY4	O
genes	O
and	O
in	O
54	O
patients	O
with	O
late	O
-	O
onset	O
Type	B-Disease
II	I-Disease
diabetes	I-Disease
by	O
combined	O
single	O
strand	O
conformational	O
polymorphism	O
-	O
heteroduplex	O
analysis	O
followed	O
by	O
direct	O
sequencing	O
of	O
identified	O
variants	O
.	O
	
An	O
identified	O
missense	O
variant	O
was	O
examined	O
in	O
association	O
studies	O
and	O
genotype	O
-	O
phenotype	O
studies	O
.	O
	
We	O
identified	O
two	O
silent	O
and	O
one	O
missense	O
(	O
Pro75	O
Ala	O
)	O
variant	O
.	O
	
In	O
an	O
association	O
study	O
the	O
allelic	O
frequency	O
of	O
the	O
Pro75Ala	O
polymorphism	O
was	O
3	O
.	O
2	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
","	O
1	O
.	O
9	O
-	O
4	O
.	O
5	O
)	O
in	O
330	O
patients	O
with	O
Type	B-Disease
II	I-Disease
diabetes	I-Disease
mellitus	I-Disease
compared	O
with	O
4	O
.	O
2	O
%	O
(	O
2	O
.	O
4	O
-	O
6	O
.	O
0	O
)	O
in	O
238	O
age	O
-	O
matched	O
glucose	B-Chemical
tolerant	O
control	O
subjects	O
.	O
	
Moreover	O
","	O
in	O
studies	O
of	O
238	O
middle	O
-	O
aged	O
glucose	B-Chemical
tolerant	O
subjects	O
","	O
of	O
226	O
glucose	B-Chemical
tolerant	O
offspring	O
of	O
Type	B-Disease
II	I-Disease
diabetic	I-Disease
patients	O
and	O
of	O
367	O
young	O
healthy	O
subjects	O
","	O
the	O
carriers	O
of	O
the	O
polymorphism	O
did	O
not	O
differ	O
from	O
non	O
-	O
carriers	O
in	O
glucose	B-Chemical
induced	O
serum	O
insulin	O
or	O
C	O
-	O
peptide	O
responses	O
.	O
	
Mutations	O
in	O
the	O
coding	O
region	O
of	O
the	O
HNF	O
-	O
6	O
gene	O
are	O
not	O
associated	O
with	O
Type	B-Disease
II	I-Disease
diabetes	I-Disease
or	O
with	O
changes	O
in	O
insulin	O
responses	O
to	O
glucose	B-Chemical
among	O
the	O
Caucasians	O
examined	O
.	O
	
	
Langerin	O
","	O
a	O
novel	O
C	O
-	O
type	O
lectin	O
specific	O
to	O
Langerhans	O
cells	O
","	O
is	O
an	O
endocytic	O
receptor	O
that	O
induces	O
the	O
formation	O
of	O
Birbeck	O
granules	O
.	O
	
We	O
have	O
identified	O
a	O
type	O
II	O
Ca2	O
+-	O
dependent	O
lectin	O
displaying	O
mannose	B-Chemical
-	O
binding	O
specificity	O
","	O
exclusively	O
expressed	O
by	O
Langerhans	O
cells	O
(	O
LC	O
)","	O
and	O
named	O
Langerin	O
.	O
	
LC	O
are	O
uniquely	O
characterized	O
by	O
Birbeck	O
granules	O
(	O
BG	O
)","	O
which	O
are	O
organelles	O
consisting	O
of	O
superimposed	O
and	O
zippered	O
membranes	O
.	O
	
Here	O
","	O
we	O
have	O
shown	O
that	O
Langerin	O
is	O
constitutively	O
associated	O
with	O
BG	O
and	O
that	O
antibody	O
to	O
Langerin	O
is	O
internalized	O
into	O
these	O
structures	O
.	O
	
Remarkably	O
","	O
transfection	O
of	O
Langerin	O
cDNA	O
into	O
fibroblasts	O
created	O
a	O
compact	O
network	O
of	O
membrane	O
structures	O
with	O
typical	O
features	O
of	O
BG	O
.	O
	
Langerin	O
is	O
thus	O
a	O
potent	O
inducer	O
of	O
membrane	O
superimposition	O
and	O
zippering	O
leading	O
to	O
BG	O
formation	O
.	O
	
Our	O
data	O
suggest	O
that	O
induction	O
of	O
BG	O
is	O
a	O
consequence	O
of	O
the	O
antigen	O
-	O
capture	O
function	O
of	O
Langerin	O
","	O
allowing	O
routing	O
into	O
these	O
organelles	O
and	O
providing	O
access	O
to	O
a	O
nonclassical	O
antigen	O
-	O
processing	O
pathway	O
.	O
	
	
Founder	O
mutations	O
in	O
the	O
BRCA1	O
gene	O
in	O
Polish	O
families	O
with	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
	
We	O
have	O
undertaken	O
a	O
hospital	O
-	O
based	O
study	O
","	O
to	O
identify	O
possible	O
BRCA1	O
and	O
BRCA2	O
founder	O
mutations	O
in	O
the	O
Polish	O
population	O
.	O
	
The	O
study	O
group	O
consisted	O
of	O
66	O
Polish	O
families	O
with	O
cancer	B-Disease
who	O
have	O
at	O
least	O
three	O
related	O
females	O
affected	O
with	O
breast	B-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
and	O
who	O
had	O
cancer	B-Disease
diagnosed	O
","	O
in	O
at	O
least	O
one	O
of	O
the	O
three	O
affected	O
females	O
","	O
at	O
age	O
<	O
50	O
years	O
.	O
	
A	O
total	O
of	O
26	O
families	O
had	O
both	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
","	O
4	O
families	O
had	O
ovarian	B-Disease
cancers	I-Disease
only	O
","	O
and	O
36	O
families	O
had	O
breast	B-Disease
cancers	I-Disease
only	O
.	O
	
Genomic	O
DNA	O
was	O
prepared	O
from	O
the	O
peripheral	O
blood	O
leukocytes	O
of	O
at	O
least	O
one	O
affected	O
woman	O
from	O
each	O
family	O
.	O
	
The	O
entire	O
coding	O
region	O
of	O
BRCA1	O
and	O
BRCA2	O
was	O
screened	O
for	O
the	O
presence	O
of	O
germline	O
mutations	O
","	O
by	O
use	O
of	O
SSCP	O
followed	O
by	O
direct	O
sequencing	O
of	O
observed	O
variants	O
.	O
	
Mutations	O
were	O
found	O
in	O
35	O
(	O
53	O
%)	O
of	O
the	O
66	O
families	O
studied	O
.	O
	
All	O
but	O
one	O
of	O
the	O
mutations	O
were	O
detected	O
within	O
the	O
BRCA1	O
gene	O
.	O
	
BRCA1	B-Disease
abnormalities	I-Disease
were	O
identified	O
in	O
all	O
four	O
families	O
with	O
ovarian	B-Disease
cancer	I-Disease
only	O
","	O
in	O
67	O
%	O
of	O
27	O
families	O
with	O
both	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
","	O
and	O
in	O
34	O
%	O
of	O
35	O
families	O
with	O
breast	B-Disease
cancer	I-Disease
only	O
.	O
	
The	O
single	O
family	O
with	O
a	O
BRCA2	O
mutation	O
had	O
the	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
syndrome	I-Disease
.	O
	
Seven	O
distinct	O
mutations	O
were	O
identified	O
";"	O
five	O
of	O
these	O
occurred	O
in	O
two	O
or	O
more	O
families	O
.	O
	
In	O
total	O
","	O
recurrent	O
mutations	O
were	O
found	O
in	O
33	O
(	O
94	O
%)	O
of	O
the	O
35	O
families	O
with	O
detected	O
mutations	O
.	O
	
Three	O
BRCA1	B-Disease
abnormalities	I-Disease
-	O
5382insC	O
","	O
C61G	O
","	O
and	O
4153delA	O
-	O
accounted	O
for	O
51	O
%","	O
20	O
%","	O
and	O
11	O
%	O
of	O
the	O
identified	O
mutations	O
","	O
respectively	O
..	O
	
	
Apomorphine	B-Chemical
:	O
an	O
underutilized	O
therapy	O
for	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
	
Apomorphine	B-Chemical
was	O
the	O
first	O
dopaminergic	B-Chemical
drug	I-Chemical
ever	O
used	O
to	O
treat	O
symptoms	O
of	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
	
While	O
powerful	O
antiparkinsonian	O
effects	O
had	O
been	O
observed	O
as	O
early	O
as	O
1951	O
","	O
the	O
potential	O
of	O
treating	O
fluctuating	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
by	O
subcutaneous	O
administration	O
of	O
apomorphine	B-Chemical
has	O
only	O
recently	O
become	O
the	O
subject	O
of	O
systematic	O
study	O
.	O
	
A	O
number	O
of	O
small	O
scale	O
clinical	O
trials	O
have	O
unequivocally	O
shown	O
that	O
intermittent	O
subcutaneous	O
apomorphine	B-Chemical
injections	O
produce	O
antiparkinsonian	O
benefit	O
close	O
if	O
not	O
identical	O
to	O
that	O
seen	O
with	O
levodopa	B-Chemical
and	O
that	O
apomorphine	B-Chemical
rescue	O
injections	O
can	O
reliably	O
revert	O
off	O
-	O
periods	O
even	O
in	O
patients	O
with	O
complex	O
on	O
-	O
off	O
motor	O
swings	O
.	O
	
Continuous	O
subcutaneous	O
apomorphine	B-Chemical
infusions	O
can	O
reduce	O
daily	O
off	O
-	O
time	O
by	O
more	O
than	O
50	O
%	O
in	O
this	O
group	O
of	O
patients	O
","	O
which	O
appears	O
to	O
be	O
a	O
stronger	O
effect	O
than	O
that	O
generally	O
seen	O
with	O
add	O
-	O
on	O
therapy	O
with	O
oral	O
dopamine	B-Chemical
agonists	I-Chemical
or	O
COMT	B-Chemical
inhibitors	I-Chemical
.	O
	
Extended	O
follow	O
-	O
up	O
studies	O
of	O
up	O
to	O
8	O
years	O
have	O
demonstrated	O
long	O
-	O
term	O
persistence	O
of	O
apomorphine	B-Chemical
efficacy	O
.	O
	
In	O
addition	O
","	O
there	O
is	O
convincing	O
clinical	O
evidence	O
that	O
monotherapy	O
with	O
continuous	O
subcutaneous	O
apomorphine	B-Chemical
infusions	O
is	O
associated	O
with	O
marked	O
reductions	O
of	O
preexisting	O
levodopa	B-Chemical
-	O
induced	O
dyskinesias	B-Disease
.	O
	
The	O
main	O
side	O
effects	O
of	O
subcutaneous	O
apomorphine	B-Chemical
treatment	O
are	O
related	O
to	O
cutaneous	O
tolerability	O
problems	O
","	O
whereas	O
sedation	O
and	O
psychiatric	B-Disease
complications	I-Disease
play	O
a	O
lesser	O
role	O
.	O
	
Given	O
the	O
marked	O
degree	O
of	O
efficacy	O
of	O
subcutaneous	O
apomorphine	B-Chemical
treatment	O
in	O
fluctuating	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
","	O
this	O
approach	O
seems	O
to	O
deserve	O
more	O
widespread	O
clinical	O
use	O
.	O
	
	
Rab6c	O
","	O
a	O
new	O
member	O
of	O
the	O
rab	O
gene	O
family	O
","	O
is	O
involved	O
in	O
drug	O
resistance	O
in	O
MCF7	O
/	O
AdrR	O
cells	O
.	O
	
A	O
new	O
Rab6	O
homolog	O
cDNA	O
","	O
Rab6c	O
","	O
was	O
discovered	O
by	O
a	O
hypermethylated	O
DNA	O
fragment	O
probe	O
that	O
was	O
isolated	O
from	O
a	O
human	O
multidrug	O
resistant	O
(	O
MDR	O
)	O
breast	B-Disease
cancer	I-Disease
cell	O
line	O
","	O
MCF7	O
/	O
AdrR	O
","	O
by	O
the	O
methylation	O
sensitive	O
-	O
representational	O
difference	O
analysis	O
(	O
MS	O
-	O
RDA	O
)	O
technique	O
.	O
	
Rab6c	O
was	O
found	O
to	O
be	O
under	O
-	O
expressed	O
in	O
MCF7	O
/	O
AdrR	O
and	O
MES	O
-	O
SA	O
/	O
Dx5	O
(	O
a	O
human	O
MDR	O
uterine	B-Disease
sarcoma	I-Disease
cell	O
line	O
)	O
compared	O
with	O
their	O
non	O
-	O
MDR	O
parental	O
cell	O
lines	O
.	O
	
MCF7	O
/	O
AdrR	O
cells	O
expressing	O
the	O
exogenous	O
Rab6c	O
exhibited	O
less	O
resistance	O
to	O
several	O
anti	O
-	O
cancer	O
drugs	O
","	O
such	O
as	O
doxorubicin	B-Chemical
(	O
DOX	B-Chemical
)","	O
taxol	B-Chemical
","	O
vinblastine	B-Chemical
","	O
and	O
vincristine	B-Chemical
","	O
than	O
the	O
control	O
cells	O
containing	O
the	O
empty	O
vector	O
.	O
	
Flow	O
cytometry	O
experiments	O
confirmed	O
that	O
the	O
transfectants	O
'	O
diminished	O
resistance	O
to	O
DOX	B-Chemical
was	O
caused	O
by	O
increased	O
drug	O
accumulation	O
induced	O
by	O
the	O
exogenous	O
Rab6c	O
.	O
	
These	O
results	O
indicate	O
that	O
Rab6c	O
is	O
involved	O
in	O
drug	O
resistance	O
in	O
MCF7	O
/	O
AdrR	O
cells	O
.	O
	
	
End	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
disease	I-Disease
(	O
ESRD	B-Disease
)	O
after	O
orthotopic	O
liver	O
transplantation	O
(	O
OLTX	O
)	O
using	O
calcineurin	O
-	O
based	O
immunotherapy	O
:	O
risk	O
of	O
development	O
and	O
treatment	O
.	O
	
BACKGROUND	O
:	O
The	O
calcineurin	O
inhibitors	O
cyclosporine	B-Chemical
and	O
tacrolimus	B-Chemical
are	O
both	O
known	O
to	O
be	O
nephrotoxic	B-Disease
.	O
	
Their	O
use	O
in	O
orthotopic	O
liver	O
transplantation	O
135(	O
OLTX	O
)	O
has	O
dramatically	O
improved	O
success	O
rates	O
.	O
	
Recently	O
","	O
however	O
","	O
we	O
have	O
had	O
an	O
increase	O
of	O
patients	O
who	O
are	O
presenting	O
after	O
OLTX	O
with	O
end	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
disease	I-Disease
(	O
ESRD	B-Disease
).	O
	
This	O
retrospective	O
study	O
examines	O
the	O
incidence	O
and	O
treatment	O
of	O
ESRD	B-Disease
and	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
(	O
CRF	B-Disease
)	O
in	O
OLTX	O
patients	O
.	O
	
METHODS	O
:	O
Patients	O
receiving	O
an	O
OLTX	O
only	O
from	O
June	O
1985	O
through	O
December	O
of	O
1994	O
who	O
survived	O
6	O
months	O
postoperatively	O
were	O
studied	O
(	O
n	O
=	O
834	O
).	O
	
Our	O
prospectively	O
collected	O
database	O
was	O
the	O
source	O
of	O
information	O
.	O
	
Patients	O
were	O
divided	O
into	O
three	O
groups	O
:	O
Controls	O
","	O
no	O
CRF	B-Disease
or	O
ESRD	B-Disease
","	O
n	O
=	O
748	O
";"	O
CRF	B-Disease
","	O
sustained	O
serum	O
creatinine	B-Chemical
>	O
2	O
.	O
5	O
mg	O
/	O
dl	O
","	O
n	O
=	O
41	O
";"	O
and	O
ESRD	B-Disease
","	O
n	O
=	O
45	O
.	O
	
Groups	O
were	O
compared	O
for	O
preoperative	O
laboratory	O
variables	O
","	O
diagnosis	O
","	O
postoperative	O
variables	O
","	O
survival	O
","	O
type	O
of	O
ESRD	B-Disease
therapy	O
","	O
and	O
survival	O
from	O
onset	O
of	O
ESRD	B-Disease
.	O
	
RESULTS	O
:	O
At	O
13	O
years	O
after	O
OLTX	O
","	O
the	O
incidence	O
of	O
severe	O
renal	B-Disease
dysfunction	I-Disease
was	O
18	O
.	O
1	O
%	O
(	O
CRF	B-Disease
8	O
.	O
6	O
%	O
and	O
ESRD	B-Disease
9	O
.	O
5	O
%).	O
	
Compared	O
with	O
control	O
patients	O
","	O
CRF	B-Disease
and	O
ESRD	B-Disease
patients	O
had	O
higher	O
preoperative	O
serum	O
creatinine	B-Chemical
levels	O
","	O
a	O
greater	O
percentage	O
of	O
patients	O
with	O
hepatorenal	B-Disease
syndrome	I-Disease
","	O
higher	O
percentage	O
requirement	O
for	O
dialysis	O
in	O
the	O
first	O
3	O
months	O
postoperatively	O
","	O
and	O
a	O
higher	O
1	O
-	O
year	O
serum	O
creatinine	B-Chemical
.	O
	
Multivariate	O
stepwise	O
logistic	O
regression	O
analysis	O
using	O
preoperative	O
and	O
postoperative	O
variables	O
identified	O
that	O
an	O
increase	O
of	O
serum	O
creatinine	B-Chemical
compared	O
with	O
average	O
at	O
1	O
year	O
","	O
3	O
months	O
","	O
and	O
4	O
weeks	O
postoperatively	O
were	O
independent	O
risk	O
factors	O
for	O
the	O
development	O
of	O
CRF	B-Disease
or	O
ESRD	B-Disease
with	O
odds	O
ratios	O
of	O
2	O
.	O
6	O
","	O
2	O
.	O
2	O
","	O
and	O
1	O
.	O
6	O
","	O
respectively	O
.	O
	
Overall	O
survival	O
from	O
the	O
time	O
of	O
OLTX	O
was	O
not	O
significantly	O
different	O
among	O
groups	O
","	O
but	O
by	O
year	O
13	O
","	O
the	O
survival	O
of	O
the	O
patients	O
who	O
had	O
ESRD	B-Disease
was	O
only	O
28	O
.	O
2	O
%	O
compared	O
with	O
54	O
.	O
6	O
%	O
in	O
the	O
control	O
group	O
.	O
	
Patients	O
developing	O
ESRD	B-Disease
had	O
a	O
6	O
-	O
year	O
survival	O
after	O
onset	O
of	O
ESRD	B-Disease
of	O
27	O
%	O
for	O
the	O
patients	O
receiving	O
hemodialysis	O
versus	O
71	O
.	O
4	O
%	O
for	O
the	O
patients	O
developing	O
ESRD	B-Disease
who	O
subsequently	O
received	O
kidney	O
transplants	O
.	O
	
CONCLUSIONS	O
:	O
Patients	O
who	O
are	O
more	O
than	O
10	O
years	O
post	O
-	O
OLTX	O
have	O
CRF	B-Disease
and	O
ESRD	B-Disease
at	O
a	O
high	O
rate	O
.	O
	
The	O
development	O
of	O
ESRD	B-Disease
decreases	O
survival	O
","	O
particularly	O
in	O
those	O
patients	O
treated	O
with	O
dialysis	O
only	O
.	O
	
Patients	O
who	O
develop	O
ESRD	B-Disease
have	O
a	O
higher	O
preoperative	O
and	O
1	O
-	O
year	O
serum	O
creatinine	B-Chemical
and	O
are	O
more	O
likely	O
to	O
have	O
hepatorenal	B-Disease
syndrome	I-Disease
.	O
	
However	O
","	O
an	O
increase	O
of	O
serum	O
creatinine	B-Chemical
at	O
various	O
times	O
postoperatively	O
is	O
more	O
predictive	O
of	O
the	O
development	O
of	O
CRF	B-Disease
or	O
ESRD	B-Disease
.	O
	
New	O
strategies	O
for	O
long	O
-	O
term	O
immunosuppression	O
may	O
be	O
needed	O
to	O
decrease	O
this	O
complication	O
.	O
	
	
D90A	O
-	O
SOD1	O
mediated	O
amyotrophic	B-Disease
lateral	I-Disease
sclerosis	I-Disease
:	O
a	O
single	O
founder	O
for	O
all	O
cases	O
with	O
evidence	O
for	O
a	O
Cis	O
-	O
acting	O
disease	O
modifier	O
in	O
the	O
recessive	O
haplotype	O
.	O
	
More	O
than	O
100	O
different	O
heterozygous	O
mutations	O
in	O
copper	O
/	O
zinc	O
superoxide	O
dismutase	O
(	O
SOD1	O
)	O
have	O
been	O
found	O
in	O
patients	O
with	O
amyotrophic	B-Disease
lateral	I-Disease
sclerosis	I-Disease
(	O
ALS	B-Disease
)","	O
a	O
fatal	O
neurodegenerative	B-Disease
disease	I-Disease
.	O
	
Uniquely	O
","	O
D90A	O
-	O
SOD1	O
has	O
been	O
identified	O
in	O
recessive	O
","	O
dominant	O
and	O
apparently	O
sporadic	O
pedigrees	O
.	O
	
The	O
phenotype	O
of	O
homozygotes	O
is	O
stereotyped	O
with	O
an	O
extended	O
survival	O
","	O
whereas	O
that	O
of	O
affected	O
heterozygotes	O
varies	O
.	O
	
The	O
frequency	O
of	O
D90A	O
-	O
SOD1	O
is	O
50	O
times	O
higher	O
in	O
Scandinavia	O
(	O
2	O
.	O
5	O
%)	O
than	O
elsewhere	O
","	O
though	O
ALS	B-Disease
prevalence	O
is	O
not	O
raised	O
there	O
.	O
	
Our	O
earlier	O
study	O
indicated	O
separate	O
founders	O
for	O
recessive	O
and	O
dominant	O
/	O
sporadic	O
ALS	B-Disease
and	O
we	O
proposed	O
a	O
disease	O
-	O
modifying	O
factor	O
linked	O
to	O
the	O
recessive	O
mutation	O
.	O
	
Here	O
we	O
have	O
doubled	O
our	O
sample	O
set	O
and	O
employed	O
novel	O
markers	O
to	O
characterise	O
the	O
mutation	O
'	O
s	O
origin	O
and	O
localise	O
any	O
modifying	O
factor	O
.	O
	
Linkage	O
disequilibrium	O
analysis	O
indicates	O
that	O
D90A	O
homozygotes	O
and	O
heterozygotes	O
share	O
a	O
rare	O
haplotype	O
and	O
are	O
all	O
descended	O
from	O
a	O
single	O
ancient	O
founder	O
(	O
alpha	O
0	O
.	O
974	O
)	O
c	O
.	O
895	O
generations	O
ago	O
.	O
	
Homozygotes	O
arose	O
subsequently	O
only	O
c	O
.	O
63	O
generations	O
ago	O
(	O
alpha	O
0	O
.	O
878	O
).	O
	
Recombination	O
has	O
reduced	O
the	O
region	O
shared	O
by	O
recessive	O
kindreds	O
to	O
97	O
-	O
265	O
kb	O
around	O
SOD1	O
","	O
excluding	O
all	O
neighbouring	O
genes	O
.	O
	
We	O
propose	O
that	O
a	O
cis	O
-	O
acting	O
regulatory	O
polymorphism	O
has	O
arisen	O
close	O
to	O
D90A	O
-	O
SOD1	O
in	O
the	O
recessive	O
founder	O
","	O
which	O
decreases	O
ALS	B-Disease
susceptibility	O
in	O
heterozygotes	O
and	O
slows	O
disease	O
progression	O
.	O
	
	
Late	O
-	O
onset	O
metachromatic	B-Disease
leukodystrophy	I-Disease
:	O
molecular	O
pathology	O
in	O
two	O
siblings	O
.	O
	
We	O
report	O
on	O
a	O
new	O
allele	O
at	O
the	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
locus	O
causing	O
late	O
-	O
onset	O
metachromatic	B-Disease
leukodystrophy	I-Disease
(	O
MLD	B-Disease
).	O
	
In	O
that	O
allele	O
arginine84	O
","	O
a	O
residue	O
that	O
is	O
highly	O
conserved	O
in	O
the	O
arylsulfatase	O
gene	O
family	O
","	O
is	O
replaced	O
by	O
glutamine	O
.	O
	
In	O
contrast	O
to	O
alleles	O
that	O
cause	O
early	O
-	O
onset	O
MLD	B-Disease
","	O
the	O
arginine84	O
to	O
glutamine	O
substitution	O
is	O
associated	O
with	O
some	O
residual	O
ARSA	O
activity	O
.	O
	
A	O
comparison	O
of	O
genotypes	O
","	O
ARSA	O
activities	O
","	O
and	O
clinical	O
data	O
on	O
4	O
individuals	O
carrying	O
the	O
allele	O
of	O
81	O
patients	O
with	O
MLD	B-Disease
examined	O
","	O
further	O
validates	O
the	O
concept	O
that	O
different	O
degrees	O
of	O
residual	O
ARSA	O
activity	O
are	O
the	O
basis	O
of	O
phenotypical	O
variation	O
in	O
MLD	B-Disease
..	O
	
	
Low	O
frequency	O
of	O
deafness	B-Disease
-	O
associated	O
GJB2	O
variants	O
in	O
Kenya	O
and	O
Sudan	O
and	O
novel	O
GJB2	O
variants	O
.	O
	
A	O
large	O
proportion	O
of	O
non	B-Disease
-	I-Disease
syndromic	I-Disease
autosomal	I-Disease
recessive	I-Disease
deafness	I-Disease
(	O
NSARD	B-Disease
)	O
in	O
many	O
populations	O
is	O
caused	O
by	O
variants	O
of	O
the	O
GJB2	O
gene	O
.	O
	
Here	O
","	O
the	O
frequency	O
of	O
GJB2	O
variants	O
was	O
studied	O
in	O
406	O
and	O
183	O
apparently	O
unrelated	O
children	O
from	O
Kenya	O
and	O
Sudan	O
","	O
respectively	O
","	O
with	O
mostly	O
severe	O
to	O
profound	O
non	B-Disease
-	I-Disease
syndromic	I-Disease
deafness	I-Disease
.	O
	
Nine	O
(	O
2	O
.	O
2	O
%)	O
Kenyan	O
and	O
12	O
(	O
6	O
.	O
6	O
%)	O
of	O
the	O
Sudanese	O
children	O
only	O
were	O
carriers	O
of	O
variants	O
within	O
the	O
coding	O
sequence	O
of	O
the	O
GJB2	O
gene	O
.	O
	
Variants	O
in	O
the	O
5	O
'-	O
adjacent	O
region	O
were	O
detected	O
in	O
further	O
115	O
individuals	O
.	O
	
A	O
total	O
of	O
10	O
novel	O
variants	O
was	O
recognized	O
","	O
among	O
them	O
four	O
variants	O
in	O
the	O
adjacent	O
5	O
'-	O
region	O
of	O
the	O
GJB2	O
coding	O
exon	O
2	O
(	O
g	O
.	O
3318	O
-	O
6T	O
>	O
A	O
","	O
g	O
.	O
3318	O
-	O
15C	O
>	O
T	O
","	O
g	O
.	O
3318	O
-	O
34C	O
>	O
T	O
","	O
g	O
.	O
3318	O
-	O
35T	O
>	O
G	O
)","	O
a	O
6	O
base	O
-	O
pair	O
deletion	O
(	O
g	O
.	O
3455_3460del	O
[	O
p	O
.	O
Asp46_Gln48delinsGlu	O
])","	O
a	O
variant	O
leading	O
to	O
a	O
stop	O
codon	O
(	O
g	O
.	O
3512C	O
>	O
A	O
[	O
p	O
.	O
Tyr65X	O
])","	O
synonymous	O
variants	O
(	O
g	O
.	O
3395C	O
>	O
T	O
[	O
p	O
.	O
Thr26	O
]","	O
g	O
.	O
3503C	O
>	O
T	O
[	O
p	O
.	O
Asn62	O
]","	O
g	O
.	O
3627A	O
>	O
C	O
[	O
p	O
.	O
Arg104	O
])","	O
and	O
one	O
non	O
-	O
synonymous	O
variant	O
(	O
g	O
.	O
3816C	O
>	O
A	O
[	O
p	O
.	O
Val167Met	O
]).	O
	
In	O
addition	O
","	O
the	O
previously	O
described	O
variants	O
g	O
.	O
3352delG	O
(	O
commonly	O
designated	O
30delG	O
or	O
35	O
delG	O
)","	O
g	O
.	O
3426G	O
>	O
A	O
[	O
p	O
.	O
Val37Ile	O
]","	O
g	O
.	O
3697G	O
>	O
A	O
[	O
p	O
.	O
Arg127His	O
]","	O
g	O
.	O
3774G	O
>	O
A	O
[	O
p	O
.	O
Val153Ile	O
]","	O
and	O
g	O
.	O
3795G	O
>	O
A	O
[	O
p	O
.	O
Gly160Ser	O
]	O
were	O
identified	O
.	O
	
With	O
the	O
exception	O
of	O
g	O
.	O
3318	O
-	O
34C	O
>	O
T	O
and	O
g	O
.	O
3352delG	O
","	O
all	O
variants	O
occurred	O
heterozygously	O
.	O
	
For	O
most	O
of	O
the	O
variants	O
identified	O
in	O
the	O
Kenyan	O
and	O
Sudanese	O
study	O
population	O
","	O
a	O
causative	O
association	O
with	O
NSARD	B-Disease
appears	O
to	O
be	O
unlikely	O
.	O
	
Compared	O
to	O
many	O
other	O
ethnic	O
groups	O
","	O
deafness	B-Disease
-	O
associated	O
variants	O
of	O
the	O
coding	O
region	O
of	O
GJB2	O
are	O
rare	O
in	O
Sudan	O
and	O
Kenya	O
","	O
suggesting	O
a	O
role	O
of	O
other	O
genetic	O
","	O
or	O
epigenetic	O
factors	O
as	O
a	O
cause	O
for	O
deafness	B-Disease
in	O
these	O
countries	O
.	O
	
	
Mutations	O
in	O
the	O
PCSK9	O
gene	O
in	O
Norwegian	O
subjects	O
with	O
autosomal	B-Disease
dominant	I-Disease
hypercholesterolemia	I-Disease
.	O
	
Proprotein	O
convertase	O
subtilisin	O
/	O
kexin	O
type	O
9	O
(	O
PCSK9	O
)	O
is	O
at	O
a	O
locus	O
for	O
autosomal	B-Disease
dominant	I-Disease
hypercholesterolemia	I-Disease
","	O
and	O
recent	O
data	O
indicate	O
that	O
the	O
PCSK9	O
gene	O
is	O
involved	O
in	O
cholesterol	B-Chemical
biosynthesis	O
.	O
	
Mutations	O
within	O
this	O
gene	O
have	O
previously	O
been	O
found	O
to	O
segregate	O
with	O
hypercholesterolemia	B-Disease
.	O
	
In	O
this	O
study	O
","	O
DNA	O
sequencing	O
of	O
the	O
12	O
exons	O
of	O
the	O
PCSK9	O
gene	O
has	O
been	O
performed	O
in	O
51	O
Norwegian	O
subjects	O
with	O
a	O
clinical	O
diagnosis	O
of	O
familial	B-Disease
hypercholesterolemia	I-Disease
where	O
mutations	O
in	O
the	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
gene	O
and	O
mutation	O
R3500Q	O
in	O
the	O
apolipoprotein	O
B	O
-	O
100	O
gene	O
had	O
been	O
excluded	O
.	O
	
Two	O
novel	O
missense	O
mutations	O
were	O
detected	O
in	O
the	O
catalytic	O
subdomain	O
of	O
the	O
PCSK9	O
gene	O
.	O
	
Two	O
patients	O
were	O
heterozygotes	O
for	O
D374Y	O
","	O
and	O
one	O
patient	O
was	O
a	O
double	O
heterozygote	O
for	O
D374Y	O
and	O
N157K	O
.	O
	
D374Y	O
segregated	O
with	O
hypercholesterolemia	B-Disease
in	O
the	O
two	O
former	O
families	O
where	O
family	O
members	O
were	O
available	O
for	O
study	O
.	O
	
Our	O
findings	O
support	O
the	O
notion	O
that	O
mutations	O
in	O
the	O
PCSK9	O
gene	O
cause	O
autosomal	B-Disease
dominant	I-Disease
hypercholesterolemia	I-Disease
.	O
	
	
Desmin	B-Disease
-	I-Disease
related	I-Disease
myopathy	I-Disease
with	O
Mallory	O
body	O
-	O
like	O
inclusions	O
is	O
caused	O
by	O
mutations	O
of	O
the	O
selenoprotein	O
N	O
gene	O
.	O
	
Desmin	B-Disease
-	I-Disease
related	I-Disease
myopathies	I-Disease
(	O
DRMs	B-Disease
)	O
are	O
a	O
heterogeneous	O
group	O
of	O
muscle	B-Disease
disorders	I-Disease
","	O
morphologically	O
defined	O
by	O
intrasarcoplasmic	O
aggregates	O
of	O
desmin	O
.	O
	
Mutations	O
in	O
the	O
desmin	O
and	O
the	O
alpha	O
-	O
B	O
crystallin	O
genes	O
account	O
for	O
approximately	O
one	O
third	O
of	O
the	O
DRM	B-Disease
cases	O
.	O
	
The	O
genetic	O
basis	O
of	O
the	O
other	O
forms	O
remain	O
unknown	O
","	O
including	O
the	O
early	O
-	O
onset	O
","	O
recessive	O
form	O
with	O
Mallory	O
body	O
-	O
like	O
inclusions	O
(	O
MB	O
-	O
DRMs	B-Disease
)","	O
first	O
described	O
in	O
five	O
related	O
German	O
patients	O
.	O
	
Recently	O
","	O
we	O
identified	O
the	O
selenoprotein	O
N	O
gene	O
(	O
SEPN1	O
)	O
as	O
responsible	O
for	O
SEPN	B-Disease
-	I-Disease
related	I-Disease
myopathy	I-Disease
(	O
SEPN	B-Disease
-	I-Disease
RM	I-Disease
)","	O
a	O
unique	O
early	O
-	O
onset	O
myopathy	B-Disease
formerly	O
divided	O
in	O
two	O
different	O
nosological	O
categories	O
:	O
rigid	B-Disease
spine	I-Disease
muscular	I-Disease
dystrophy	I-Disease
and	O
the	O
severe	O
form	O
of	O
classical	O
multiminicore	B-Disease
disease	I-Disease
.	O
	
The	O
finding	O
of	O
Mallory	O
body	O
-	O
like	O
inclusions	O
in	O
two	O
cases	O
of	O
genetically	O
documented	O
SEPN	B-Disease
-	I-Disease
RM	I-Disease
led	O
us	O
to	O
suspect	O
a	O
relationship	O
between	O
MB	O
-	O
DRM	B-Disease
and	O
SEPN1	O
.	O
	
In	O
the	O
original	O
MB	O
-	O
DRM	B-Disease
German	O
family	O
","	O
we	O
demonstrated	O
a	O
linkage	O
of	O
the	O
disease	O
to	O
the	O
SEPN1	O
locus	O
(	O
1p36	O
)","	O
and	O
subsequently	O
a	O
homozygous	O
SEPN1	O
deletion	O
(	O
del	O
92	O
nucleotide	O
-	O
19	O
/+	O
73	O
)	O
in	O
the	O
affected	O
patients	O
.	O
	
A	O
comparative	O
reevaluation	O
showed	O
that	O
MB	O
-	O
DRM	B-Disease
and	O
SEPN	B-Disease
-	I-Disease
RM	I-Disease
share	O
identical	O
clinical	O
features	O
.	O
	
Therefore	O
","	O
we	O
propose	O
that	O
MB	O
-	O
DRM	B-Disease
should	O
be	O
categorized	O
as	O
SEPN	B-Disease
-	I-Disease
RM	I-Disease
.	O
	
These	O
findings	O
substantiate	O
the	O
molecular	O
heterogeneity	O
of	O
DRM	B-Disease
","	O
expand	O
the	O
morphological	O
spectrum	O
of	O
SEPN	B-Disease
-	I-Disease
RM	I-Disease
","	O
and	O
implicate	O
a	O
necessary	O
reassessment	O
of	O
the	O
nosological	O
boundaries	O
in	O
early	O
-	O
onset	O
myopathies	B-Disease
.	O
	
	
Altered	O
replication	O
timing	O
of	O
the	O
HIRA	O
/	O
Tuple1	O
locus	O
in	O
the	O
DiGeorge	B-Disease
and	I-Disease
Velocardiofacial	I-Disease
syndromes	I-Disease
.	O
	
DiGeorge	B-Disease
and	I-Disease
Velocardiofacial	I-Disease
syndromes	I-Disease
(	O
DGS	B-Disease
/	O
VCFS	B-Disease
)	O
are	O
endowed	O
by	O
a	O
similar	O
complex	O
phenotype	O
including	O
cardiovascular	B-Disease
","	I-Disease
craniofacial	I-Disease
","	I-Disease
and	I-Disease
thymic	I-Disease
malformations	I-Disease
","	O
and	O
are	O
associated	O
with	O
heterozygous	O
deletions	O
of	O
22q11	O
chromosomal	O
band	O
.	O
	
The	O
Typically	O
Deleted	O
Region	O
in	O
the	O
22q11	O
.	O
21	O
subband	O
(	O
here	O
called	O
TDR22	O
)	O
is	O
very	O
gene	O
-	O
dense	O
","	O
and	O
the	O
extent	O
of	O
the	O
deletion	O
has	O
been	O
defined	O
precisely	O
in	O
several	O
studies	O
.	O
	
However	O
","	O
to	O
date	O
there	O
is	O
no	O
evidence	O
for	O
a	O
mechanism	O
of	O
haploinsufficiency	O
that	O
can	O
fully	O
explain	O
the	O
DGS	B-Disease
/	O
VCFS	B-Disease
phenotype	O
.	O
	
In	O
this	O
study	O
","	O
we	O
show	O
that	O
the	O
candidate	O
gene	O
HIRA	O
/	O
Tuple1	O
mapping	O
on	O
the	O
non	O
-	O
deleted	O
TDR22	O
","	O
in	O
DGS	B-Disease
/	O
VCFS	B-Disease
subjects	O
presents	O
a	O
delayed	O
replication	O
timing	O
.	O
	
Moreover	O
","	O
we	O
observed	O
an	O
increase	O
in	O
the	O
cell	O
ratio	O
showing	O
the	O
HIRA	O
/	O
Tuple1	O
locus	O
localised	O
toward	O
the	O
nuclear	O
periphery	O
.	O
	
It	O
is	O
known	O
that	O
replication	O
timing	O
and	O
nuclear	O
location	O
are	O
generally	O
correlated	O
to	O
the	O
transcription	O
activity	O
of	O
the	O
relative	O
DNA	O
region	O
.	O
	
We	O
propose	O
that	O
the	O
alteration	O
in	O
the	O
replication	O
/	O
nuclear	O
location	O
pattern	O
of	O
the	O
non	O
-	O
deleted	O
TDR22	O
indicates	O
an	O
altered	O
gene	O
regulation	O
hence	O
an	O
altered	O
transcritpion	O
in	O
DGS	B-Disease
/	O
VCFS	B-Disease
.	O
	
	
Severe	O
reversible	O
left	B-Disease
ventricular	I-Disease
systolic	I-Disease
and	I-Disease
diastolic	I-Disease
dysfunction	I-Disease
due	O
to	O
accidental	O
iatrogenic	O
epinephrine	B-Chemical
overdose	O
.	O
	
Catecholamine	B-Chemical
-	O
induced	O
cardiomyopathy	B-Disease
due	O
to	O
chronic	O
excess	O
of	O
endogenous	O
catecholamines	B-Chemical
has	O
been	O
recognized	O
for	O
decades	O
as	O
a	O
clinical	O
phenomenon	O
.	O
	
In	O
contrast	O
","	O
reports	O
of	O
myocardial	B-Disease
dysfunction	I-Disease
due	O
to	O
acute	O
iatrogenic	O
overdose	O
are	O
rare	O
.	O
	
A	O
35	O
-	O
year	O
-	O
old	O
woman	O
whose	O
cervix	O
uteri	O
was	O
inadvertently	O
injected	O
with	O
8	O
mg	O
of	O
epinephrine	B-Chemical
developed	O
myocardial	B-Disease
stunning	I-Disease
that	O
was	O
characterized	O
by	O
severe	O
hemodynamic	O
compromise	O
","	O
profound	O
","	O
albeit	O
transient	O
","	O
left	B-Disease
ventricular	I-Disease
systolic	I-Disease
and	I-Disease
diastolic	I-Disease
dysfunction	I-Disease
","	O
and	O
only	O
modestly	O
elevated	O
biochemical	O
markers	O
of	O
myocardial	B-Disease
necrosis	I-Disease
.	O
	
Our	O
case	O
illustrates	O
the	O
serious	O
consequences	O
of	O
medical	O
errors	O
that	O
can	O
be	O
avoided	O
through	O
improved	O
medication	O
labeling	O
and	O
staff	O
supervision	O
.	O
	
	
Effects	O
of	O
the	O
cyclooxygenase	O
-	O
2	O
specific	O
inhibitor	O
valdecoxib	B-Chemical
versus	O
nonsteroidal	B-Chemical
antiinflammatory	I-Chemical
agents	I-Chemical
and	O
placebo	O
on	O
cardiovascular	O
thrombotic	B-Disease
events	O
in	O
patients	O
with	O
arthritis	B-Disease
.	O
	
There	O
have	O
been	O
concerns	O
that	O
the	O
risk	O
of	O
cardiovascular	O
thrombotic	B-Disease
events	O
may	O
be	O
higher	O
with	O
cyclooxygenase	O
(	O
COX	O
)-	O
2	O
-	O
specific	O
inhibitors	O
than	O
nonselective	O
nonsteroidal	B-Chemical
antiinflammatory	I-Chemical
drugs	I-Chemical
(	O
NSAIDs	B-Chemical
).	O
	
We	O
evaluated	O
cardiovascular	O
event	O
data	O
for	O
valdecoxib	B-Chemical
","	O
a	O
new	O
COX	O
-	O
2	O
-	O
specific	O
inhibitor	O
in	O
approximately	O
8000	O
patients	O
with	O
osteoarthritis	B-Disease
and	O
rheumatoid	B-Disease
arthritis	I-Disease
treated	O
with	O
this	O
agent	O
in	O
randomized	O
clinical	O
trials	O
.	O
	
The	O
incidence	O
of	O
cardiovascular	O
thrombotic	B-Disease
events	O
(	O
cardiac	O
","	O
cerebrovascular	O
and	O
peripheral	O
vascular	O
","	O
or	O
arterial	O
thrombotic	B-Disease
)	O
was	O
determined	O
by	O
analyzing	O
pooled	O
valdecoxib	B-Chemical
(	O
10	O
-	O
80	O
mg	O
daily	O
)","	O
nonselective	O
NSAID	B-Chemical
(	O
diclofenac	B-Chemical
75	O
mg	O
bid	O
","	O
ibuprofen	B-Chemical
800	O
mg	O
tid	O
","	O
or	O
naproxen	B-Chemical
500	O
mg	O
bid	O
)	O
and	O
placebo	O
data	O
from	O
10	O
randomized	O
osteoarthritis	B-Disease
and	O
rheumatoid	B-Disease
arthritis	I-Disease
trials	O
that	O
were	O
6	O
-	O
52	O
weeks	O
in	O
duration	O
.	O
	
The	O
incidence	O
rates	O
of	O
events	O
were	O
determined	O
in	O
all	O
patients	O
(	O
n	O
=	O
7934	O
)	O
and	O
in	O
users	O
of	O
low	O
-	O
dose	O
(<	O
or	O
=	O
325	O
mg	O
daily	O
)	O
aspirin	B-Chemical
(	O
n	O
=	O
1051	O
)	O
and	O
nonusers	O
of	O
aspirin	B-Chemical
(	O
n	O
=	O
6883	O
).	O
	
Crude	O
and	O
exposure	O
-	O
adjusted	O
incidences	O
of	O
thrombotic	B-Disease
events	O
were	O
similar	O
for	O
valdecoxib	B-Chemical
","	O
NSAIDs	B-Chemical
","	O
and	O
placebo	O
.	O
	
The	O
risk	O
of	O
serious	O
thrombotic	B-Disease
events	O
was	O
also	O
similar	O
for	O
each	O
valdecoxib	B-Chemical
dose	O
.	O
	
Thrombotic	B-Disease
risk	O
was	O
consistently	O
higher	O
for	O
users	O
of	O
aspirin	B-Chemical
users	O
than	O
nonusers	O
of	O
aspirin	B-Chemical
(	O
placebo	O
","	O
1	O
.	O
4	O
%	O
vs	O
.	O
	
0	O
"%;"	O
valdecoxib	B-Chemical
","	O
1	O
.	O
7	O
%	O
vs	O
.	O
	
0	O
.	O
2	O
"%;"	O
NSAIDs	B-Chemical
","	O
1	O
.	O
9	O
%	O
vs	O
.	O
	
0	O
.	O
5	O
%).	O
	
The	O
rates	O
of	O
events	O
in	O
users	O
of	O
aspirin	B-Chemical
were	O
similar	O
for	O
all	O
3	O
treatment	O
groups	O
and	O
across	O
valdecoxib	B-Chemical
doses	O
.	O
	
Short	O
-	O
and	O
intermediate	O
-	O
term	O
treatment	O
with	O
therapeutic	O
(	O
10	O
or	O
20	O
mg	O
daily	O
)	O
and	O
supratherapeutic	O
(	O
40	O
or	O
80	O
mg	O
daily	O
)	O
valdecoxib	B-Chemical
doses	O
was	O
not	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
thrombotic	B-Disease
events	O
relative	O
to	O
nonselective	O
NSAIDs	B-Chemical
or	O
placebo	O
in	O
osteoarthritis	B-Disease
and	O
rheumatoid	B-Disease
arthritis	I-Disease
patients	O
in	O
controlled	O
clinical	O
trials	O
.	O
	
	
Identification	O
of	O
a	O
novel	O
WFS1	O
mutation	O
(	O
AFF344	O
-	O
345ins	O
)	O
in	O
Japanese	O
patients	O
with	O
Wolfram	B-Disease
syndrome	I-Disease
.	O
	
Wolfram	B-Disease
syndrome	I-Disease
(	O
WFS	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
characterized	O
by	O
early	O
onset	O
diabetes	B-Disease
mellitus	I-Disease
","	O
progressive	O
optic	B-Disease
atrophy	I-Disease
","	O
sensorineural	B-Disease
deafness	I-Disease
and	O
diabetes	B-Disease
insipidus	I-Disease
.	O
	
Affected	O
individuals	O
may	O
also	O
have	O
renal	B-Disease
tract	I-Disease
abnormalities	I-Disease
as	O
well	O
as	O
neurogical	O
and	O
psychiatric	B-Disease
syndromes	I-Disease
.	O
	
WFS1	O
encoding	O
a	O
transmembrane	O
protein	O
was	O
identified	O
as	O
the	O
gene	O
responsible	O
for	O
WFS	B-Disease
.	O
	
We	O
report	O
herein	O
a	O
Japanese	O
family	O
","	O
of	O
which	O
two	O
members	O
had	O
this	O
syndrome	O
.	O
	
In	O
the	O
WFS1	O
gene	O
of	O
these	O
patients	O
","	O
we	O
identified	O
a	O
novel	O
mutation	O
","	O
a	O
nine	O
nucleotide	O
insertion	O
(	O
AFF344	O
-	O
345ins	O
).	O
	
In	O
addition	O
","	O
one	O
of	O
these	O
patients	O
had	O
preclinical	O
hypopituitarism	B-Disease
","	O
which	O
is	O
an	O
unusual	O
feature	O
of	O
WFS	B-Disease
.	O
	
As	O
only	O
the	O
two	O
family	O
members	O
homozygous	O
for	O
the	O
mutation	O
showed	O
WFS	B-Disease
","	O
these	O
data	O
support	O
the	O
notion	O
that	O
this	O
mutation	O
is	O
the	O
cause	O
of	O
WFS	B-Disease
.	O
	
	
A	O
genetic	O
analysis	O
of	O
serotonergic	O
biosynthetic	O
and	O
metabolic	O
enzymes	O
in	O
migraine	B-Disease
using	O
a	O
DNA	O
pooling	O
approach	O
.	O
	
Migraine	B-Disease
is	O
a	O
common	O
debilitating	O
primary	O
headache	B-Disease
disorder	I-Disease
with	O
significant	O
mental	O
","	O
physical	O
and	O
social	O
health	O
implications	O
.	O
	
The	O
brain	O
neurotransmitter	B-Chemical
5	I-Chemical
-	I-Chemical
hydroxytryptamine	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
";"	O
serotonin	B-Chemical
)	O
is	O
involved	O
in	O
nociceptive	O
pathways	O
and	O
has	O
been	O
implicated	O
in	O
the	O
pathophysiology	O
of	O
migraine	B-Disease
.	O
	
With	O
few	O
genetic	O
studies	O
investigating	O
biosynthetic	O
and	O
metabolic	O
enzymes	O
governing	O
the	O
rate	O
of	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
activity	O
and	O
their	O
relationship	O
to	O
migraine	B-Disease
","	O
it	O
was	O
the	O
objective	O
of	O
this	O
study	O
to	O
assess	O
genetic	O
variants	O
within	O
the	O
human	O
tryptophan	O
hydroxylase	O
(	O
TPH	O
)","	O
amino	O
acid	O
decarboxylase	O
(	O
AADC	O
)	O
and	O
monoamine	O
oxidase	O
A	O
(	O
MAOA	O
)	O
genes	O
in	O
migraine	B-Disease
susceptibility	O
.	O
	
This	O
objective	O
was	O
undertaken	O
using	O
a	O
high	O
-	O
throughput	O
DNA	O
pooling	O
experimental	O
design	O
","	O
which	O
proved	O
to	O
be	O
a	O
very	O
accurate	O
","	O
sensitive	O
and	O
specific	O
method	O
of	O
estimating	O
allele	O
frequencies	O
for	O
single	O
nucleotide	O
polymorphism	O
","	O
insertion	O
deletion	O
and	O
variable	O
number	O
tandem	O
repeat	O
loci	O
.	O
	
Application	O
of	O
DNA	O
pooling	O
to	O
a	O
wide	O
array	O
of	O
genetic	O
loci	O
provides	O
greater	O
scope	O
in	O
the	O
assessment	O
of	O
population	O
-	O
based	O
genetic	O
association	O
study	O
designs	O
.	O
	
Despite	O
the	O
application	O
of	O
this	O
high	O
-	O
throughput	O
genotyping	O
method	O
","	O
negative	O
results	O
from	O
the	O
two	O
-	O
stage	O
DNA	O
pooling	O
design	O
used	O
to	O
screen	O
loci	O
within	O
the	O
TPH	O
","	O
AADC	O
and	O
MAOA	O
genes	O
did	O
not	O
support	O
their	O
role	O
in	O
migraine	B-Disease
susceptibility	O
.	O
	
	
5	B-Chemical
-	I-Chemical
Fluorouracil	I-Chemical
cardiotoxicity	B-Disease
induced	O
by	O
alpha	B-Chemical
-	I-Chemical
fluoro	I-Chemical
-	I-Chemical
beta	I-Chemical
-	I-Chemical
alanine	I-Chemical
.	O
	
Cardiotoxicity	B-Disease
is	O
a	O
rare	O
complication	O
occurring	O
during	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
treatment	O
for	O
malignancies	B-Disease
.	O
	
We	O
herein	O
report	O
the	O
case	O
of	O
a	O
70	O
-	O
year	O
-	O
old	O
man	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
","	O
in	O
whom	O
a	O
high	O
serum	O
level	O
of	O
alpha	B-Chemical
-	I-Chemical
fluoro	I-Chemical
-	I-Chemical
beta	I-Chemical
-	I-Chemical
alanine	I-Chemical
(	O
FBAL	B-Chemical
)	O
was	O
observed	O
.	O
	
The	O
patient	O
","	O
who	O
had	O
unresectable	O
colon	B-Disease
cancer	I-Disease
metastases	I-Disease
to	O
the	O
liver	O
and	O
lung	O
","	O
was	O
referred	O
to	O
us	O
for	O
chemotherapy	O
from	O
an	O
affiliated	O
hospital	O
";"	O
he	O
had	O
no	O
cardiac	O
history	O
.	O
	
After	O
admission	O
","	O
the	O
patient	O
received	O
a	O
continuous	O
intravenous	O
infusion	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
(	O
1000	O
mg	O
/	O
day	O
)","	O
during	O
which	O
precordial	B-Disease
pain	I-Disease
with	O
right	B-Disease
bundle	I-Disease
branch	I-Disease
block	I-Disease
occurred	O
concomitantly	O
with	O
a	O
high	O
serum	O
FBAL	B-Chemical
concentration	O
of	O
1955	O
ng	O
/	O
ml	O
.	O
	
Both	O
the	O
precordial	B-Disease
pain	I-Disease
and	O
the	O
electrocardiographic	O
changes	O
disappeared	O
spontaneously	O
after	O
the	O
discontinuation	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
.	O
	
As	O
the	O
precordial	B-Disease
pain	I-Disease
in	O
this	O
patient	O
was	O
considered	O
to	O
have	O
been	O
due	O
to	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
","	O
the	O
administration	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
was	O
abandoned	O
.	O
	
Instead	O
","	O
oral	O
administration	O
of	O
S	B-Chemical
-	I-Chemical
1	I-Chemical
(	O
a	O
derivative	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)","	O
at	O
200	O
mg	O
/	O
day	O
twice	O
a	O
week	O
","	O
was	O
instituted	O
","	O
because	O
S	B-Chemical
-	I-Chemical
1	I-Chemical
has	O
a	O
strong	O
inhibitory	O
effect	O
on	O
dihydropyrimidine	B-Chemical
dehydrogenase	O
","	O
which	O
catalyzes	O
the	O
degradative	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
into	O
FBAL	B-Chemical
.	O
	
The	O
serum	O
FBAL	B-Chemical
concentration	O
subsequently	O
decreased	O
to	O
352	O
ng	O
/	O
ml	O
","	O
the	O
same	O
as	O
the	O
value	O
measured	O
on	O
the	O
first	O
day	O
of	O
S	B-Chemical
-	I-Chemical
1	I-Chemical
administration	O
.	O
	
Thereafter	O
","	O
no	O
cardiac	B-Disease
symptoms	I-Disease
were	O
observed	O
.	O
	
The	O
patient	O
achieved	O
a	O
partial	O
response	O
6	O
months	O
after	O
the	O
initiation	O
of	O
the	O
S	B-Chemical
-	I-Chemical
1	I-Chemical
treatment	O
.	O
	
The	O
experience	O
of	O
this	O
case	O
","	O
together	O
with	O
a	O
review	O
of	O
the	O
literature	O
","	O
suggests	O
that	O
FBAL	B-Chemical
is	O
related	O
to	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O
	
S	B-Chemical
-	I-Chemical
1	I-Chemical
may	O
be	O
administered	O
safely	O
to	O
patients	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O
	
	
Pilocarpine	B-Chemical
seizures	B-Disease
cause	O
age	O
-	O
dependent	O
impairment	B-Disease
in	I-Disease
auditory	I-Disease
location	I-Disease
discrimination	I-Disease
.	O
	
Children	O
who	O
have	O
status	B-Disease
epilepticus	I-Disease
have	O
continuous	O
or	O
rapidly	O
repeating	O
seizures	B-Disease
that	O
may	O
be	O
life	O
-	O
threatening	O
and	O
may	O
cause	O
life	O
-	O
long	O
changes	O
in	O
brain	O
and	O
behavior	O
.	O
	
The	O
extent	O
to	O
which	O
status	B-Disease
epilepticus	I-Disease
causes	O
deficits	B-Disease
in	I-Disease
auditory	I-Disease
discrimination	I-Disease
is	O
unknown	O
.	O
	
A	O
naturalistic	O
auditory	O
location	O
discrimination	O
method	O
was	O
used	O
to	O
evaluate	O
this	O
question	O
using	O
an	O
animal	O
model	O
of	O
status	B-Disease
epilepticus	I-Disease
.	O
	
Male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
injected	O
with	O
saline	O
on	O
postnatal	O
day	O
(	O
P	O
)	O
20	O
","	O
or	O
a	O
convulsant	O
dose	O
of	O
pilocarpine	B-Chemical
on	O
P20	O
or	O
P45	O
.	O
	
Pilocarpine	B-Chemical
on	O
either	O
day	O
induced	O
status	B-Disease
epilepticus	I-Disease
";"	O
status	B-Disease
epilepticus	I-Disease
at	O
P45	O
resulted	O
in	O
CA3	O
cell	O
loss	O
and	O
spontaneous	O
seizures	B-Disease
","	O
whereas	O
P20	O
rats	O
had	O
no	O
cell	O
loss	O
or	O
spontaneous	O
seizures	B-Disease
.	O
	
Mature	O
rats	O
were	O
trained	O
with	O
sound	O
-	O
source	O
location	O
and	O
sound	O
-	O
silence	O
discriminations	O
.	O
	
Control	O
(	O
saline	O
P20	O
)	O
rats	O
acquired	O
both	O
discriminations	O
immediately	O
.	O
	
In	O
status	B-Disease
epilepticus	I-Disease
(	O
P20	O
)	O
rats	O
","	O
acquisition	O
of	O
the	O
sound	O
-	O
source	O
location	O
discrimination	O
was	O
moderately	O
impaired	O
.	O
	
Status	B-Disease
epilepticus	I-Disease
(	O
P45	O
)	O
rats	O
failed	O
to	O
acquire	O
either	O
sound	O
-	O
source	O
location	O
or	O
sound	O
-	O
silence	O
discriminations	O
.	O
	
Status	B-Disease
epilepticus	I-Disease
in	O
rat	O
causes	O
an	O
age	O
-	O
dependent	O
","	O
long	O
-	O
term	O
impairment	B-Disease
in	I-Disease
auditory	I-Disease
discrimination	I-Disease
.	O
	
This	O
impairment	O
may	O
explain	O
one	O
cause	O
of	O
impaired	B-Disease
auditory	I-Disease
location	I-Disease
discrimination	I-Disease
in	O
humans	O
.	O
	
	
No	O
independent	O
role	O
of	O
the	O
-	O
1123	O
G	O
>	O
C	O
and	O
+	O
2740	O
A	O
>	O
G	O
variants	O
in	O
the	O
association	O
of	O
PTPN22	O
with	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
and	O
juvenile	B-Disease
idiopathic	I-Disease
arthritis	I-Disease
in	O
two	O
Caucasian	O
populations	O
.	O
	
INTRODUCTION	O
:	O
The	O
PTPN22	O
is	O
a	O
negative	O
regulator	O
of	O
the	O
T	O
cell	O
response	O
.	O
	
Its	O
+	O
1858C	O
>	O
T	O
(	O
R620W	O
)	O
polymorphism	O
has	O
been	O
shown	O
to	O
associate	O
with	O
a	O
risk	O
for	O
multiple	O
autoimmune	B-Disease
diseases	I-Disease
","	O
including	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
(	O
T1D	B-Disease
)	O
and	O
juvenile	B-Disease
idiopathic	I-Disease
arthritis	I-Disease
(	O
JIA	B-Disease
).	O
	
The	O
minor	O
(	O
susceptibility	O
)	O
allele	O
is	O
absent	O
in	O
Asian	O
populations	O
","	O
but	O
a	O
recent	O
study	O
suggested	O
an	O
independent	O
involvement	O
of	O
another	O
polymorphism	O
located	O
within	O
the	O
promoter	O
-	O
1123	O
nucleotides	O
relative	O
to	O
the	O
translational	O
start	O
site	O
.	O
	
AIMS	O
:	O
We	O
aimed	O
to	O
analyse	O
the	O
association	O
of	O
three	O
PTPN22	O
polymorphisms	O
in	O
two	O
distinct	O
Caucasian	O
populations	O
","	O
the	O
Czechs	O
(	O
with	O
T1D	B-Disease
and	O
with	O
JIA	B-Disease
)	O
and	O
Azeri	O
(	O
with	O
T1D	B-Disease
).	O
	
METHODS	O
:	O
The	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNP	O
)	O
at	O
positions	O
-	O
1123	O
(	O
rs2488457	O
)","	O
+	O
1858	O
(	O
rs2476601	O
","	O
the	O
R620W	O
substitution	O
)","	O
and	O
+	O
2740	O
(	O
rs1217412	O
)	O
were	O
genotyped	O
using	O
TaqMan	O
assays	O
in	O
372	O
subjects	O
with	O
childhood	O
-	O
onset	O
T1D	B-Disease
","	O
130	O
subjects	O
with	O
JIA	B-Disease
","	O
and	O
400	O
control	O
subjects	O
of	O
Czech	O
origin	O
","	O
and	O
in	O
160	O
subjects	O
with	O
T1D	B-Disease
and	O
271	O
healthy	O
controls	O
of	O
Azeri	O
origin	O
.	O
	
RESULTS	O
:	O
In	O
the	O
Czechs	O
","	O
all	O
three	O
SNPs	O
were	O
in	O
a	O
tight	O
linkage	O
disequlibrium	O
","	O
while	O
in	O
the	O
Azeri	O
","	O
the	O
linkage	O
disequlibrium	O
was	O
limited	O
to	O
between	O
the	O
promoter	O
and	O
3	O
'-	O
UTR	O
polymorphism	O
","	O
D	O
'(-	O
1123	O
","	O
+	O
2740	O
)=	O
0	O
.	O
99	O
","	O
r	O
(	O
2	O
)=	O
0	O
.	O
72	O
.	O
	
Haplotype	O
reconstruction	O
via	O
the	O
expectation	O
-	O
maximization	O
algorithm	O
showed	O
in	O
both	O
populations	O
that	O
only	O
the	O
haplotype	O
containing	O
the	O
minor	O
(	O
W	O
)	O
allele	O
at	O
codon	O
620	O
was	O
associated	O
with	O
T1D	B-Disease
(	O
OR	O
=	O
2	O
.	O
26	O
","	O
95	O
%	O
CI	O
1	O
.	O
68	O
-	O
3	O
.	O
2	O
in	O
Czechs	O
","	O
OR	O
=	O
14	O
.	O
8	O
","	O
95	O
%	O
CI	O
2	O
.	O
0	O
-	O
651	O
in	O
Azeri	O
)	O
or	O
JIA	B-Disease
(	O
OR	O
=	O
2	O
.	O
43	O
","	O
95	O
%	O
CI	O
1	O
.	O
66	O
-	O
3	O
.	O
56	O
in	O
Czechs	O
).	O
	
The	O
haplotypes	O
having	O
the	O
wild	O
-	O
type	O
(	O
R	O
)	O
allele	O
at	O
codon	O
620	O
and	O
minor	O
alleles	O
at	O
-	O
1123	O
and	O
/	O
or	O
+	O
2740	O
were	O
neutral	O
as	O
to	O
the	O
risk	O
of	O
autoimmune	B-Disease
conditions	I-Disease
in	O
both	O
populations	O
.	O
	
CONCLUSIONS	O
:	O
In	O
two	O
different	O
Caucasian	O
populations	O
","	O
the	O
Czechs	O
and	O
the	O
Azeri	O
","	O
no	O
independent	O
contribution	O
can	O
be	O
detected	O
either	O
of	O
the	O
-	O
1123	O
promoter	O
SNP	O
or	O
the	O
+	O
2740	O
3	O
'-	O
UTR	O
SNP	O
","	O
and	O
only	O
the	O
minor	O
allele	O
at	O
PTPN22	O
codon	O
620	O
contributes	O
to	O
the	O
risk	O
of	O
autoimmunity	O
.	O
	
	
A	O
polymorphism	O
of	O
C	O
-	O
to	O
-	O
T	O
substitution	O
at	O
-	O
31	O
IL1B	O
is	O
associated	O
with	O
the	O
risk	O
of	O
advanced	O
gastric	B-Disease
adenocarcinoma	I-Disease
in	O
a	O
Japanese	O
population	O
.	O
	
Proinflammatory	O
cytokine	O
gene	O
polymorphisms	O
have	O
been	O
demonstrated	O
to	O
associate	O
with	O
gastric	B-Disease
cancer	I-Disease
risk	O
","	O
of	O
which	O
IL1B	O
-	O
31T	O
/	O
C	O
and	O
-	O
511C	O
/	O
T	O
changes	O
have	O
been	O
well	O
investigated	O
due	O
to	O
the	O
possibility	O
that	O
they	O
may	O
alter	O
the	O
IL1B	O
transcription	O
.	O
	
The	O
signal	O
transduction	O
target	O
upon	O
interleukin	O
1	O
beta	O
(	O
IL1beta	O
)	O
stimulation	O
","	O
the	O
nuclear	O
factor	O
of	O
kappa	O
B	O
(	O
NFkappaB	O
)	O
activation	O
","	O
supports	O
cancer	B-Disease
development	O
","	O
signal	O
transduction	O
in	O
which	O
is	O
mediated	O
by	O
FS	O
-	O
7	O
cell	O
-	O
associated	O
cell	O
surface	O
antigen	O
(	O
FAS	O
)	O
signaling	O
.	O
	
Based	O
on	O
recent	O
papers	O
describing	O
the	O
prognostic	O
roles	O
of	O
the	O
polymorphisms	O
and	O
the	O
NFkappaB	O
functions	O
on	O
cancer	B-Disease
development	O
","	O
we	O
sought	O
to	O
determine	O
if	O
Japanese	O
gastric	B-Disease
cancer	I-Disease
patients	O
were	O
affected	O
by	O
the	O
IL1B	O
-	O
31	O
/-	O
511	O
and	O
FAS	O
-	O
670	O
polymorphisms	O
.	O
	
A	O
case	O
-	O
control	O
study	O
was	O
conducted	O
on	O
incident	O
gastric	B-Disease
adenocarcinoma	I-Disease
patients	O
(	O
n	O
=	O
271	O
)	O
and	O
age	O
-	O
gender	O
frequency	O
-	O
matched	O
control	O
subjects	O
(	O
n	O
=	O
271	O
).	O
	
We	O
observed	O
strong	O
linkage	O
disequilibrium	O
between	O
the	O
T	O
allele	O
at	O
-	O
511	O
and	O
the	O
C	O
allele	O
at	O
-	O
31	O
and	O
between	O
the	O
C	O
allele	O
at	O
-	O
511	O
and	O
the	O
T	O
allele	O
at	O
-	O
31	O
in	O
IL1B	O
in	O
both	O
the	O
cases	O
and	O
controls	O
(	O
R	O
(	O
2	O
)=	O
0	O
.	O
94	O
).	O
	
Neither	O
IL1B	O
-	O
31	O
","	O
-	O
511	O
nor	O
FAS	O
-	O
670	O
polymorphisms	O
showed	O
significantly	O
different	O
risks	O
of	O
gastric	B-Disease
adenocarcinoma	I-Disease
.	O
	
Though	O
FAS	O
-	O
670	O
polymorphisms	O
did	O
not	O
show	O
any	O
significant	O
difference	O
","	O
the	O
proportion	O
of	O
subjects	O
with	O
IL1B	O
-	O
31TT	O
(	O
or	O
IL1B	O
-	O
511CC	O
)	O
increased	O
according	O
to	O
stage	O
(	O
trend	O
P	O
=	O
0	O
.	O
19	O
).	O
	
In	O
particular	O
","	O
subjects	O
with	O
stage	O
IV	O
had	O
a	O
two	O
times	O
higher	O
probability	O
of	O
having	O
either	O
IL1B	O
-	O
31TT	O
(	O
or	O
IL1B	O
-	O
511CC	O
)	O
genotype	O
compared	O
with	O
stage	O
I	O
subjects	O
.	O
	
These	O
observations	O
suggest	O
that	O
IL1B	O
-	O
31TT	O
and	O
IL1B	O
-	O
511CC	O
are	O
associated	O
with	O
disease	O
progression	O
.	O
	
	
Chloroacetaldehyde	B-Chemical
as	O
a	O
sulfhydryl	B-Chemical
reagent	I-Chemical
:	O
the	O
role	O
of	O
critical	O
thiol	B-Chemical
groups	O
in	O
ifosfamide	B-Chemical
nephropathy	B-Disease
.	O
	
Chloroacetaldehyde	B-Chemical
(	O
CAA	B-Chemical
)	O
is	O
a	O
metabolite	O
of	O
the	O
alkylating	B-Chemical
agent	I-Chemical
ifosfamide	I-Chemical
(	O
IFO	B-Chemical
)	O
and	O
putatively	O
responsible	O
for	O
renal	B-Disease
damage	I-Disease
following	O
anti	O
-	O
tumor	B-Disease
therapy	O
with	O
IFO	B-Chemical
.	O
	
Depletion	O
of	O
sulfhydryl	B-Chemical
(	O
SH	B-Chemical
)	O
groups	O
has	O
been	O
reported	O
from	O
cell	O
culture	O
","	O
animal	O
and	O
clinical	O
studies	O
.	O
	
In	O
this	O
work	O
the	O
effect	O
of	O
CAA	B-Chemical
on	O
human	O
proximal	O
tubule	O
cells	O
in	O
primary	O
culture	O
(	O
hRPTEC	O
)	O
was	O
investigated	O
.	O
	
Toxicity	B-Disease
of	O
CAA	B-Chemical
was	O
determined	O
by	O
protein	O
content	O
","	O
cell	O
number	O
","	O
LDH	B-Chemical
release	O
","	O
trypan	B-Chemical
blue	I-Chemical
exclusion	O
assay	O
and	O
caspase	O
-	O
3	O
activity	O
.	O
	
Free	O
thiols	B-Chemical
were	O
measured	O
by	O
the	O
method	O
of	O
Ellman	O
.	O
	
CAA	B-Chemical
reduced	O
hRPTEC	O
cell	O
number	O
and	O
protein	O
","	O
induced	O
a	O
loss	O
in	O
free	O
intracellular	O
thiols	B-Chemical
and	O
an	O
increase	O
in	O
necrosis	B-Disease
markers	O
.	O
	
CAA	B-Chemical
but	O
not	O
acrolein	B-Chemical
inhibited	O
the	O
cysteine	O
proteases	O
caspase	O
-	O
3	O
","	O
caspase	O
-	O
8	O
and	O
cathepsin	O
B	O
.	O
Caspase	O
activation	O
by	O
cisplatin	B-Chemical
was	O
inhibited	O
by	O
CAA	B-Chemical
.	O
	
In	O
cells	O
stained	O
with	O
fluorescent	O
dyes	O
targeting	O
lysosomes	O
","	O
CAA	B-Chemical
induced	O
an	O
increase	O
in	O
lysosomal	O
size	O
and	O
lysosomal	O
leakage	O
.	O
	
The	O
effects	O
of	O
CAA	B-Chemical
on	O
cysteine	O
protease	O
activities	O
and	O
thiols	B-Chemical
could	O
be	O
reproduced	O
in	O
cell	O
lysate	O
.	O
	
Acidification	O
","	O
which	O
slowed	O
the	O
reaction	O
of	O
CAA	B-Chemical
with	O
thiol	B-Chemical
donors	O
","	O
could	O
also	O
attenuate	O
effects	O
of	O
CAA	B-Chemical
on	O
necrosis	B-Disease
markers	O
","	O
thiol	B-Chemical
depletion	O
and	O
cysteine	O
protease	O
inhibition	O
in	O
living	O
cells	O
.	O
	
Thus	O
","	O
CAA	B-Chemical
directly	O
reacts	O
with	O
cellular	O
protein	O
and	O
non	O
-	O
protein	O
thiols	B-Chemical
","	O
mediating	O
its	O
toxicity	B-Disease
on	O
hRPTEC	O
.	O
	
This	O
effect	O
can	O
be	O
reduced	O
by	O
acidification	O
.	O
	
Therefore	O
","	O
urinary	O
acidification	O
could	O
be	O
an	O
option	O
to	O
prevent	O
IFO	B-Chemical
nephropathy	B-Disease
in	O
patients	O
.	O
	
	
Delayed	O
institution	O
of	O
hypertension	B-Disease
during	O
focal	O
cerebral	B-Disease
ischemia	I-Disease
:	O
effect	O
on	O
brain	B-Disease
edema	I-Disease
.	O
	
The	O
effect	O
of	O
induced	O
hypertension	B-Disease
instituted	O
after	O
a	O
2	O
-	O
h	O
delay	O
following	O
middle	B-Disease
cerebral	I-Disease
artery	I-Disease
occlusion	I-Disease
(	O
MCAO	B-Disease
)	O
on	O
brain	B-Disease
edema	I-Disease
formation	O
and	O
histochemical	O
injury	O
was	O
studied	O
.	O
	
Under	O
isoflurane	B-Chemical
anesthesia	O
","	O
the	O
MCA	O
of	O
14	O
spontaneously	O
hypertensive	B-Disease
rats	O
was	O
occluded	O
.	O
	
In	O
the	O
control	O
group	O
(	O
n	O
=	O
7	O
)","	O
the	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
was	O
not	O
manipulated	O
.	O
	
In	O
the	O
hypertensive	B-Disease
group	O
(	O
n	O
=	O
7	O
)","	O
the	O
MAP	O
was	O
elevated	O
by	O
25	O
-	O
30	O
mm	O
Hg	O
beginning	O
2	O
h	O
after	O
MCAO	B-Disease
.	O
	
Four	O
hours	O
after	O
MCAO	B-Disease
","	O
the	O
rats	O
were	O
killed	O
and	O
the	O
brains	O
harvested	O
.	O
	
The	O
brains	O
were	O
sectioned	O
along	O
coronal	O
planes	O
spanning	O
the	O
distribution	O
of	O
ischemia	B-Disease
produced	O
by	O
MCAO	B-Disease
.	O
	
Specific	O
gravity	O
(	O
SG	O
)	O
was	O
determined	O
in	O
the	O
subcortex	O
and	O
in	O
two	O
sites	O
in	O
the	O
cortex	O
(	O
core	O
and	O
periphery	O
of	O
the	O
ischemic	B-Disease
territory	O
).	O
	
The	O
extent	O
of	O
neuronal	B-Disease
injury	I-Disease
was	O
determined	O
by	O
2	B-Chemical
","	I-Chemical
3	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
triphenyltetrazolium	I-Chemical
staining	O
.	O
	
In	O
the	O
ischemic	B-Disease
core	O
","	O
there	O
was	O
no	O
difference	O
in	O
SG	O
in	O
the	O
subcortex	O
and	O
cortex	O
in	O
the	O
two	O
groups	O
.	O
	
In	O
the	O
periphery	O
of	O
the	O
ischemic	B-Disease
territory	O
","	O
SG	O
in	O
the	O
cortex	O
was	O
greater	O
(	O
less	O
edema	B-Disease
accumulation	O
)	O
in	O
the	O
hypertensive	B-Disease
group	O
(	O
1	O
.	O
41	O
+/-	O
0	O
.	O
1	O
vs	O
1	O
.	O
39	O
+/-	O
0	O
.	O
1	O
","	O
P	O
less	O
than	O
0	O
.	O
5	O
).	O
	
The	O
area	O
of	O
histochemical	O
injury	O
(	O
as	O
a	O
percent	O
of	O
the	O
cross	O
-	O
sectional	O
area	O
of	O
the	O
hemisphere	O
)	O
was	O
less	O
in	O
the	O
hypertensive	B-Disease
group	O
(	O
33	O
+/-	O
3	O
%	O
vs	O
21	O
+/-	O
2	O
%","	O
P	O
less	O
than	O
0	O
.	O
5	O
).	O
	
The	O
data	O
indicate	O
that	O
phenylephrine	B-Chemical
-	O
induced	O
hypertension	B-Disease
instituted	O
2	O
h	O
after	O
MCAO	B-Disease
does	O
not	O
aggravate	O
edema	B-Disease
in	O
the	O
ischemic	B-Disease
core	O
","	O
that	O
it	O
improves	O
edema	B-Disease
in	O
the	O
periphery	O
of	O
the	O
ischemic	B-Disease
territory	O
","	O
and	O
that	O
it	O
reduces	O
the	O
area	O
of	O
histochemical	O
neuronal	B-Disease
dysfunction	I-Disease
.	O
	
	
The	O
phosphatidylethanolamine	O
N	O
-	O
methyltransferase	O
gene	O
V175M	O
single	O
nucleotide	O
polymorphism	O
confers	O
the	O
susceptibility	O
to	O
NASH	B-Disease
in	O
Japanese	O
population	O
.	O
	
BACKGROUND	O
/	O
AIMS	O
:	O
The	O
genetic	O
predisposition	O
on	O
the	O
development	O
of	O
nonalcoholic	B-Disease
steatohepatitis	I-Disease
(	O
NASH	B-Disease
)	O
has	O
been	O
poorly	O
understood	O
.	O
	
A	O
functional	O
polymorphism	O
Val175Met	O
was	O
reported	O
in	O
phosphatidylethanolamine	O
N	O
-	O
methyltransferase	O
(	O
PEMT	O
)	O
that	O
catalyzes	O
the	O
conversion	O
of	O
phosphatidylethanolamine	B-Chemical
to	O
phosphatidylcholine	B-Chemical
.	O
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
the	O
carriers	O
of	O
Val175Met	O
variant	O
impaired	O
in	O
PEMT	O
activity	O
are	O
more	O
susceptible	O
to	O
NASH	B-Disease
.	O
	
METHODS	O
:	O
Blood	O
samples	O
of	O
107	O
patients	O
with	O
biopsy	O
-	O
proven	O
NASH	B-Disease
and	O
of	O
150	O
healthy	O
volunteers	O
were	O
analyzed	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
.	O
	
RESULTS	O
:	O
Val175Met	O
variant	O
allele	O
of	O
the	O
PEMT	O
gene	O
was	O
significantly	O
more	O
frequent	O
in	O
NASH	B-Disease
patients	O
than	O
in	O
healthy	O
volunteers	O
(	O
p	O
<	O
0	O
.	O
1	O
)","	O
and	O
carriers	O
of	O
Val175Met	O
variant	O
were	O
significantly	O
more	O
frequent	O
in	O
NASH	B-Disease
patients	O
than	O
in	O
healthy	O
volunteers	O
(	O
p	O
<	O
0	O
.	O
1	O
).	O
	
Among	O
NASH	B-Disease
patients	O
","	O
body	O
mass	O
index	O
was	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
5	O
)","	O
and	O
non	O
-	O
obese	B-Disease
patients	O
were	O
significantly	O
more	O
frequent	O
(	O
p	O
<	O
0	O
.	O
1	O
)	O
in	O
carriers	O
of	O
Val175Met	O
variant	O
than	O
in	O
homozygotes	O
of	O
wild	O
type	O
PEMT	O
.	O
	
CONCLUSIONS	O
:	O
Val175Met	O
variant	O
of	O
PEMT	O
could	O
be	O
a	O
candidate	O
molecule	O
that	O
determines	O
the	O
susceptibility	O
to	O
NASH	B-Disease
","	O
because	O
it	O
is	O
more	O
frequently	O
observed	O
in	O
NASH	B-Disease
patients	O
and	O
non	O
-	O
obese	B-Disease
persons	O
with	O
Val175Met	O
variant	O
of	O
PEMT	O
are	O
facilitated	O
to	O
develop	O
NASH	B-Disease
.	O
	
	
Tenomodulin	O
is	O
associated	O
with	O
obesity	B-Disease
and	O
diabetes	B-Disease
risk	O
:	O
the	O
Finnish	O
diabetes	B-Disease
prevention	O
study	O
.	O
	
We	O
recently	O
showed	O
that	O
long	O
-	O
term	O
weight	O
reduction	O
changes	O
the	O
gene	O
expression	O
profile	O
of	O
adipose	O
tissue	O
in	O
overweight	B-Disease
individuals	O
with	O
impaired	B-Disease
glucose	I-Disease
tolerance	I-Disease
(	O
IGT	B-Disease
).	O
	
One	O
of	O
the	O
responding	O
genes	O
was	O
X	O
-	O
chromosomal	O
tenomodulin	O
(	O
TNMD	O
)","	O
a	O
putative	O
angiogenesis	O
inhibitor	O
.	O
	
Our	O
aim	O
was	O
to	O
study	O
the	O
associations	O
of	O
individual	O
single	O
nucleotide	O
polymorphisms	O
and	O
haplotypes	O
with	O
adiposity	B-Disease
","	O
glucose	B-Chemical
metabolism	O
","	O
and	O
the	O
risk	O
of	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
(	O
T2D	B-Disease
).	O
	
Seven	O
single	O
nucleotide	O
polymorphisms	O
from	O
two	O
different	O
haploblocks	O
were	O
genotyped	O
from	O
507	O
participants	O
of	O
the	O
Finnish	O
Diabetes	B-Disease
Prevention	O
Study	O
(	O
DPS	O
).	O
	
Sex	O
-	O
specific	O
genotype	O
effects	O
were	O
observed	O
.	O
	
Three	O
markers	O
of	O
haploblock	O
1	O
were	O
associated	O
with	O
features	O
of	O
adiposity	B-Disease
in	O
women	O
(	O
rs5966709	O
","	O
rs4828037	O
)	O
and	O
men	O
(	O
rs11798018	O
).	O
	
Markers	O
rs2073163	O
and	O
rs1155794	O
from	O
haploblock	O
2	O
were	O
associated	O
with	O
2	O
-	O
hour	O
plasma	O
glucose	B-Chemical
levels	O
in	O
men	O
during	O
the	O
3	O
-	O
year	O
follow	O
-	O
up	O
.	O
	
The	O
same	O
two	O
markers	O
together	O
with	O
rs2073162	O
associated	O
with	O
the	O
conversion	O
of	O
IGT	B-Disease
to	O
T2D	B-Disease
in	O
men	O
.	O
	
The	O
risk	O
of	O
developing	O
T2D	B-Disease
was	O
approximately	O
2	O
-	O
fold	O
in	O
individuals	O
with	O
genotypes	O
associated	O
with	O
higher	O
2	O
-	O
hour	O
plasma	O
glucose	B-Chemical
levels	O
";"	O
the	O
hazard	O
ratios	O
were	O
2	O
.	O
192	O
(	O
p	O
=	O
0	O
.	O
25	O
)	O
for	O
rs2073162	O
-	O
A	O
","	O
2	O
.	O
191	O
(	O
p	O
=	O
0	O
.	O
27	O
)	O
for	O
rs2073163	O
-	O
C	O
","	O
and	O
1	O
.	O
998	O
(	O
p	O
=	O
0	O
.	O
54	O
)	O
for	O
rs1155974	O
-	O
T	O
.	O
	
These	O
results	O
suggest	O
that	O
TNMD	O
polymorphisms	O
are	O
associated	O
with	O
adiposity	B-Disease
and	O
also	O
with	O
glucose	B-Chemical
metabolism	O
and	O
conversion	O
from	O
IGT	B-Disease
to	O
T2D	B-Disease
in	O
men	O
.	O
	
	
Mutations	O
in	O
pattern	O
recognition	O
receptor	O
genes	O
modulate	O
seroreactivity	O
to	O
microbial	O
antigens	O
in	O
patients	O
with	O
inflammatory	B-Disease
bowel	I-Disease
disease	I-Disease
.	O
	
BACKGROUND	O
AND	O
AIMS	O
:	O
A	O
number	O
of	O
antibodies	O
against	O
microbial	O
epitopes	O
or	O
self	O
-	O
antigens	O
have	O
been	O
associated	O
with	O
Crohn	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
	
The	O
development	O
of	O
antibodies	O
reflects	O
a	O
loss	O
of	O
tolerance	O
to	O
intestinal	O
bacteria	O
that	O
underlies	O
Crohn	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
","	O
resulting	O
in	O
an	O
exaggerated	O
adaptive	O
immune	O
response	O
to	O
these	O
bacteria	O
.	O
	
It	O
was	O
hypothesised	O
that	O
the	O
development	O
of	O
antimicrobial	O
antibodies	O
is	O
influenced	O
by	O
the	O
presence	O
of	O
genetic	O
variants	O
in	O
pattern	O
recognition	O
receptor	O
genes	O
.	O
	
The	O
aim	O
of	O
this	O
study	O
was	O
therefore	O
to	O
investigate	O
the	O
influence	O
of	O
mutations	O
in	O
these	O
innate	O
immune	O
receptor	O
genes	O
(	O
nucleotide	O
oligomerisation	O
domain	O
(	O
NOD	O
)	O
2	O
/	O
caspase	O
recruitment	O
domain	O
(	O
CARD	O
)	O
15	O
","	O
NOD1	O
/	O
CARD4	O
","	O
TUCAN	O
/	O
CARDINAL	O
/	O
CARD8	O
","	O
Toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
4	O
","	O
TLR2	O
","	O
TLR1	O
and	O
TLR6	O
)	O
on	O
the	O
development	O
of	O
antimicrobial	O
and	O
antiglycan	O
antibodies	O
in	O
inflammatory	B-Disease
bowel	I-Disease
disease	I-Disease
(	O
IBD	B-Disease
).	O
	
Materials	O
and	O
METHODS	O
:	O
A	O
cohort	O
of	O
1163	O
unrelated	O
patients	O
with	O
IBD	B-Disease
(	O
874	O
Crohn	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
","	O
259	O
ulcerative	B-Disease
colitis	I-Disease
","	O
30	O
indeterminate	O
colitis	B-Disease
)	O
and	O
312	O
controls	O
were	O
analysed	O
for	O
anti	O
-	O
Saccharomyces	O
cerevisiae	O
antibodies	O
(	O
gASCA	O
)	O
IgG	O
","	O
anti	O
-	O
laminaribioside	O
antibodies	O
(	O
ALCA	O
)	O
IgG	O
","	O
anti	O
-	O
chitobioside	O
antibodies	O
(	O
ACCA	O
)	O
IgA	O
","	O
anti	O
-	O
mannobioside	O
antibodies	O
(	O
AMCA	O
)	O
IgG	O
and	O
outer	O
membrane	O
porin	O
(	O
Omp	O
)	O
IgA	O
and	O
were	O
genotyped	O
for	O
variants	O
in	O
NOD2	O
/	O
CARD15	O
","	O
TUCAN	O
/	O
CARDINAL	O
/	O
CARD8	O
","	O
NOD1	O
/	O
CARD4	O
","	O
TLR4	O
","	O
TLR1	O
","	O
TLR2	O
and	O
TLR6	O
.	O
	
RESULTS	O
:	O
When	O
compared	O
with	O
Crohn	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
patients	O
without	O
CARD15	O
mutations	O
","	O
the	O
presence	O
of	O
at	O
least	O
one	O
CARD15	O
variant	O
in	O
Crohn	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
patients	O
more	O
frequently	O
led	O
to	O
gASCA	O
positivity	O
(	O
66	O
.	O
1	O
%	O
versus	O
51	O
.	O
5	O
%","	O
p	O
<	O
0	O
.	O
1	O
)	O
and	O
ALCA	O
positivity	O
(	O
43	O
.	O
3	O
%	O
versus	O
34	O
.	O
9	O
%","	O
p	O
=	O
0	O
.	O
18	O
)	O
and	O
higher	O
gASCA	O
titers	O
(	O
85	O
.	O
7	O
versus	O
51	O
.	O
8	O
ELISA	O
units	O
","	O
p	O
<	O
0	O
.	O
1	O
)","	O
independent	O
of	O
ileal	O
involvement	O
.	O
	
A	O
gene	O
dosage	O
effect	O
","	O
with	O
increasing	O
gASCA	O
and	O
ALCA	O
positivity	O
for	O
patients	O
carrying	O
none	O
","	O
one	O
and	O
two	O
CARD15	O
variants	O
","	O
respectively	O
","	O
was	O
seen	O
for	O
both	O
markers	O
.	O
	
Similarly	O
","	O
Crohn	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
patients	O
carrying	O
NOD1	O
/	O
CARD4	O
indel	O
had	O
a	O
higher	O
prevalence	O
of	O
gASCA	O
antibodies	O
than	O
wild	O
-	O
type	O
patients	O
(	O
63	O
.	O
8	O
%	O
versus	O
55	O
.	O
2	O
%","	O
p	O
=	O
0	O
.	O
14	O
)","	O
also	O
with	O
a	O
gene	O
dosage	O
effect	O
.	O
	
An	O
opposite	O
effect	O
was	O
observed	O
for	O
the	O
TLR4	O
D299G	O
and	O
TLR2	O
P631H	O
variants	O
","	O
with	O
a	O
lower	O
prevalence	O
of	O
ACCA	O
antibodies	O
(	O
23	O
.	O
4	O
%	O
versus	O
35	O
%","	O
p	O
=	O
0	O
.	O
13	O
)	O
and	O
Omp	O
antibodies	O
(	O
20	O
.	O
5	O
%	O
versus	O
34	O
.	O
6	O
%","	O
p	O
=	O
0	O
.	O
9	O
)","	O
respectively	O
.	O
	
CONCLUSION	O
:	O
Variants	O
in	O
innate	O
immune	O
receptor	O
genes	O
were	O
found	O
to	O
influence	O
antibody	O
formation	O
against	O
microbial	O
epitopes	O
.	O
	
In	O
this	O
respect	O
","	O
it	O
is	O
intriguing	O
that	O
an	O
opposite	O
effect	O
of	O
CARD15	O
and	O
TLR4	O
variants	O
was	O
observed	O
.	O
	
These	O
findings	O
may	O
contribute	O
to	O
an	O
understanding	O
of	O
the	O
aetiology	O
of	O
the	O
seroreactivity	O
observed	O
in	O
IBD	B-Disease
.	O
	
	
An	O
improved	O
tetra	O
-	O
primer	O
PCR	O
approach	O
for	O
the	O
detection	O
of	O
the	O
FGFR3	O
G380R	O
mutation	O
responsible	O
for	O
achondroplasia	B-Disease
.	O
	
Achondroplasia	B-Disease
is	O
the	O
most	O
common	O
form	O
of	O
dwarfism	B-Disease
and	O
has	O
an	O
incidence	O
of	O
approximately	O
1	O
/	O
7500	O
.	O
	
In	O
more	O
than	O
98	O
%	O
of	O
cases	O
","	O
the	O
disease	O
is	O
associated	O
with	O
a	O
G	O
to	O
A	O
or	O
G	O
to	O
C	O
substitution	O
at	O
nucleotide	O
position	O
1138	O
(	O
p	O
.	O
G380R	O
)	O
of	O
the	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
(	O
FGFR3	O
)	O
gene	O
.	O
	
We	O
have	O
developed	O
a	O
sensitive	O
single	O
tube	O
tetra	O
-	O
primer	O
PCR	O
assay	O
to	O
detect	O
both	O
the	O
c	O
.	O
1138G	O
>	O
A	O
and	O
c	O
.	O
1138G	O
>	O
C	O
mutations	O
and	O
can	O
successfully	O
distinguish	O
DNA	O
samples	O
that	O
are	O
homozygous	O
and	O
heterozygous	O
for	O
the	O
c	O
.	O
1138G	O
>	O
A	O
mutation	O
.	O
	
Titration	O
studies	O
showed	O
that	O
the	O
assay	O
could	O
reliably	O
detect	O
one	O
copy	O
of	O
the	O
mutant	O
allele	O
in	O
a	O
mix	O
of	O
100	O
wild	O
-	O
type	O
alleles	O
.	O
	
The	O
assay	O
has	O
been	O
tested	O
in	O
50	O
healthy	O
controls	O
","	O
3	O
known	O
patients	O
with	O
achondroplasia	B-Disease
","	O
and	O
5	O
amniotic	O
fluids	O
suspected	O
of	O
having	O
achondroplasia	B-Disease
and	O
for	O
whom	O
we	O
had	O
previously	O
determined	O
the	O
genotypes	O
for	O
the	O
c	O
.	O
1138G	O
>	O
A	O
mutation	O
by	O
PCR	O
-	O
RFLP	O
.	O
	
We	O
have	O
observed	O
complete	O
concordance	O
between	O
methods	O
.	O
	
Our	O
tetra	O
-	O
primer	O
PCR	O
assay	O
is	O
sensitive	O
","	O
low	O
-	O
cost	O
","	O
and	O
easy	O
to	O
use	O
method	O
for	O
FGFR3	O
p	O
.	O
G380R	O
genotyping	O
","	O
which	O
could	O
be	O
used	O
even	O
in	O
low	O
-	O
tech	O
laboratories	O
.	O
	
	
Genetic	O
investigation	O
of	O
four	O
meiotic	O
genes	O
in	O
women	O
with	O
premature	B-Disease
ovarian	I-Disease
failure	I-Disease
.	O
	
OBJECTIVE	O
:	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
mutations	O
of	O
meiotic	O
genes	O
","	O
such	O
as	O
disrupted	O
meiotic	O
cDNA	O
(	O
DMC1	O
)","	O
MutS	O
homolog	O
(	O
MSH4	O
)","	O
MSH5	O
","	O
and	O
S	O
.	O
cerevisiae	O
homolog	O
(	O
SPO11	O
)","	O
were	O
associated	O
with	O
premature	B-Disease
ovarian	I-Disease
failure	I-Disease
(	O
POF	B-Disease
).	O
	
DESIGN	O
:	O
Case	O
-	O
control	O
study	O
.	O
	
METHODS	O
:	O
Blood	O
sampling	O
","	O
karyotype	O
","	O
hormonal	O
dosage	O
","	O
ultrasound	O
","	O
and	O
ovarian	O
biopsy	O
were	O
carried	O
out	O
on	O
most	O
patients	O
.	O
	
However	O
","	O
the	O
main	O
outcome	O
measure	O
was	O
the	O
sequencing	O
of	O
genomic	O
DNA	O
from	O
peripheral	O
blood	O
samples	O
of	O
41	O
women	O
with	O
POF	B-Disease
and	O
36	O
fertile	O
women	O
(	O
controls	O
).	O
	
RESULTS	O
:	O
A	O
single	O
heterozygous	O
missense	O
mutation	O
","	O
substitution	O
of	O
a	O
cytosine	O
residue	O
with	O
thymidine	O
in	O
exon	O
2	O
of	O
MSH5	O
","	O
was	O
found	O
in	O
two	O
Caucasian	O
women	O
in	O
whom	O
POF	B-Disease
developed	O
at	O
18	O
and	O
36	O
years	O
of	O
age	O
.	O
	
This	O
mutation	O
resulted	O
in	O
replacement	O
of	O
a	O
non	O
-	O
polar	O
amino	O
acid	O
(	O
proline	O
)	O
with	O
a	O
polar	O
amino	O
acid	O
(	O
serine	O
)	O
at	O
position	O
29	O
(	O
P29S	O
).	O
	
Neither	O
36	O
control	O
women	O
nor	O
39	O
other	O
patients	O
with	O
POF	B-Disease
possessed	O
this	O
genetic	O
perturbation	O
.	O
	
Another	O
POF	B-Disease
patient	O
of	O
African	O
origin	O
showed	O
a	O
homozygous	O
nucleotide	O
change	O
in	O
the	O
tenth	O
of	O
DMC1	O
gene	O
that	O
led	O
to	O
an	O
alteration	O
of	O
the	O
amino	O
acid	O
composition	O
of	O
the	O
protein	O
(	O
M200V	O
).	O
	
CONCLUSIONS	O
:	O
The	O
symptoms	O
of	O
infertility	B-Disease
observed	O
in	O
the	O
DMC1	O
homozygote	O
mutation	O
carrier	O
and	O
in	O
both	O
patients	O
with	O
a	O
heterozygous	O
substitution	O
in	O
exon	O
2	O
of	O
the	O
MSH5	O
gene	O
provide	O
indirect	O
evidence	O
of	O
the	O
role	O
of	O
genes	O
involved	O
in	O
meiotic	O
recombination	O
in	O
the	O
regulation	O
of	O
ovarian	O
function	O
.	O
	
MSH5	O
and	O
DMC1	O
mutations	O
may	O
be	O
one	O
explanation	O
for	O
POF	B-Disease
","	O
albeit	O
uncommon	O
.	O
	
	
A	O
single	O
nucleotide	O
polymorphism	O
in	O
the	O
IRF5	O
promoter	O
region	O
is	O
associated	O
with	O
susceptibility	O
to	O
rheumatoid	B-Disease
arthritis	I-Disease
in	O
the	O
Japanese	O
population	O
.	O
	
OBJECTIVES	O
:	O
Interferon	O
regulatory	O
factor	O
5	O
(	O
IRF5	O
)	O
is	O
a	O
member	O
of	O
the	O
IRF	O
family	O
of	O
transcription	O
factors	O
","	O
which	O
regulate	O
the	O
production	O
of	O
proinflammatory	O
cytokines	O
.	O
	
Polymorphisms	O
in	O
the	O
IRF5	O
gene	O
have	O
been	O
associated	O
with	O
susceptibility	O
to	O
systemic	B-Disease
lupus	I-Disease
erythaematosus	I-Disease
(	O
SLE	B-Disease
)	O
in	O
Caucasian	O
and	O
Asian	O
populations	O
","	O
but	O
their	O
involvement	O
in	O
other	O
autoimmune	B-Disease
diseases	I-Disease
is	O
still	O
uncertain	O
.	O
	
Here	O
","	O
we	O
assessed	O
the	O
genetic	O
role	O
of	O
IRF5	O
in	O
susceptibility	O
to	O
rheumatoid	B-Disease
arthritis	I-Disease
(	O
RA	B-Disease
)	O
in	O
Japanese	O
subjects	O
.	O
	
METHODS	O
:	O
We	O
selected	O
13	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
and	O
a	O
CGGGG	O
insertion	O
-	O
deletion	O
polymorphism	O
in	O
the	O
IRF5	O
gene	O
.	O
	
We	O
performed	O
2	O
sets	O
of	O
case	O
-	O
control	O
comparisons	O
using	O
Japanese	O
subjects	O
(	O
first	O
set	O
:	O
830	O
patients	O
with	O
RA	B-Disease
and	O
658	O
controls	O
";"	O
second	O
set	O
:	O
1112	O
patients	O
with	O
RA	B-Disease
and	O
940	O
controls	O
)","	O
and	O
then	O
performed	O
a	O
stratified	O
analysis	O
using	O
human	O
leukocyte	O
antigen	O
(	O
HLA	O
)-	O
DRB1	O
shared	O
epitope	O
(	O
SE	O
)	O
status	O
.	O
	
We	O
genotyped	O
the	O
SNPs	O
using	O
TaqMan	O
assays	O
.	O
	
RESULTS	O
:	O
A	O
significant	O
association	O
of	O
the	O
rs729302	O
A	O
allele	O
with	O
RA	B-Disease
susceptibility	O
was	O
found	O
in	O
both	O
sets	O
(	O
odds	O
ratio	O
(	O
OR	O
)	O
1	O
.	O
22	O
","	O
95	O
%	O
CI	O
1	O
.	O
9	O
to	O
1	O
.	O
35	O
","	O
p	O
<	O
0	O
.	O
1	O
in	O
the	O
combined	O
analysis	O
).	O
	
When	O
the	O
patients	O
were	O
stratified	O
by	O
the	O
SE	O
","	O
the	O
rs729302	O
A	O
allele	O
was	O
found	O
to	O
confer	O
increased	O
risk	O
to	O
RA	B-Disease
in	O
patients	O
that	O
were	O
SE	O
negative	O
(	O
OR	O
1	O
.	O
50	O
","	O
95	O
%	O
CI	O
1	O
.	O
17	O
to	O
1	O
.	O
92	O
","	O
p	O
=	O
0	O
.	O
1	O
)	O
as	O
compared	O
with	O
patients	O
carrying	O
the	O
SE	O
(	O
OR	O
1	O
.	O
11	O
","	O
95	O
%	O
CI	O
0	O
.	O
93	O
to	O
1	O
.	O
33	O
","	O
p	O
=	O
0	O
.	O
24	O
).	O
	
In	O
both	O
sets	O
","	O
no	O
genotyped	O
polymorphisms	O
were	O
significantly	O
associated	O
with	O
RA	B-Disease
susceptibility	O
","	O
but	O
rs729302	O
was	O
significantly	O
associated	O
.	O
	
CONCLUSIONS	O
:	O
These	O
findings	O
indicate	O
that	O
the	O
promoter	O
polymorphism	O
of	O
IRF5	O
is	O
a	O
genetic	O
factor	O
conferring	O
predisposition	O
to	O
RA	B-Disease
","	O
and	O
that	O
it	O
contributes	O
considerably	O
to	O
disease	O
pathogenesis	O
in	O
patients	O
that	O
were	O
SE	O
negative	O
.	O
	
	
Association	O
between	O
promoter	O
-	O
1607	O
polymorphism	O
of	O
MMP1	O
and	O
lumbar	B-Disease
disc	I-Disease
disease	I-Disease
in	O
Southern	O
Chinese	O
.	O
	
BACKGROUND	O
:	O
Matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
are	O
involved	O
in	O
the	O
degradation	O
of	O
the	O
extracellular	O
matrix	O
of	O
the	O
intervertebral	O
disc	O
.	O
	
A	O
SNP	O
for	O
guanine	O
insertion	O
/	O
deletion	O
(	O
G	O
/	O
D	O
)","	O
the	O
-	O
1607	O
promoter	O
polymorphism	O
","	O
of	O
the	O
MMP1	O
gene	O
was	O
found	O
significantly	O
affecting	O
promoter	O
activity	O
and	O
corresponding	O
transcription	O
level	O
.	O
	
Hence	O
it	O
is	O
a	O
good	O
candidate	O
for	O
genetic	O
studies	O
in	O
DDD	B-Disease
.	O
	
METHODS	O
:	O
Southern	O
Chinese	O
volunteers	O
between	O
18	O
and	O
55	O
years	O
were	O
recruited	O
from	O
the	O
population	O
.	O
	
DDD	B-Disease
in	O
the	O
lumbar	O
spine	O
was	O
defined	O
by	O
MRI	O
using	O
Schneiderman	O
'	O
s	O
classification	O
.	O
	
Genomic	O
DNA	O
was	O
isolated	O
from	O
the	O
leukocytes	O
and	O
genotyping	O
was	O
performed	O
using	O
the	O
Sequenom	O
platform	O
.	O
	
Association	O
and	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
checking	O
were	O
assessed	O
by	O
Chi	O
-	O
square	O
test	O
and	O
Mann	O
-	O
Whitney	O
U	O
test	O
.	O
	
RESULTS	O
:	O
Our	O
results	O
showed	O
substantial	O
evidence	O
of	O
association	O
between	O
-	O
1607	O
promoter	O
polymorphism	O
of	O
MMP1	O
and	O
DDD	B-Disease
in	O
the	O
Southern	O
Chinese	O
subjects	O
.	O
	
D	O
allelic	O
was	O
significantly	O
associated	O
with	O
DDD	B-Disease
(	O
p	O
value	O
=	O
0	O
.	O
27	O
","	O
odds	O
ratio	O
=	O
1	O
.	O
41	O
with	O
95	O
%	O
CI	O
=	O
1	O
.	O
4	O
-	O
1	O
.	O
90	O
)	O
while	O
Genotypic	O
association	O
on	O
the	O
presence	O
of	O
D	O
allele	O
was	O
also	O
significantly	O
associated	O
with	O
DDD	B-Disease
(	O
p	O
value	O
=	O
0	O
.	O
46	O
","	O
odds	O
ratio	O
=	O
1	O
.	O
50	O
with	O
95	O
%	O
CI	O
=	O
1	O
.	O
1	O
-	O
2	O
.	O
24	O
).	O
	
Further	O
age	O
stratification	O
showed	O
significant	O
genotypic	O
as	O
well	O
as	O
allelic	O
association	O
in	O
the	O
group	O
of	O
over	O
40	O
years	O
(	O
genotypic	O
:	O
p	O
value	O
=	O
0	O
.	O
35	O
","	O
odds	O
ratio	O
=	O
1	O
.	O
617	O
with	O
95	O
%	O
CI	O
=	O
1	O
.	O
33	O
-	O
2	O
.	O
529	O
";"	O
allelic	O
:	O
p	O
value	O
=	O
0	O
.	O
33	O
","	O
odds	O
ratio	O
=	O
1	O
.	O
445	O
with	O
95	O
%	O
CI	O
=	O
1	O
.	O
29	O
-	O
2	O
.	O
29	O
).	O
	
Disc	O
bulge	O
","	O
annular	O
tears	O
and	O
the	O
Schmorl	O
'	O
s	O
nodes	O
were	O
not	O
associated	O
with	O
the	O
D	O
allele	O
.	O
	
CONCLUSION	O
:	O
We	O
demonstrated	O
that	O
individuals	O
with	O
the	O
presence	O
of	O
D	O
allele	O
for	O
the	O
-	O
1607	O
promoter	O
polymorphism	O
of	O
MMP1	O
are	O
about	O
1	O
.	O
5	O
times	O
more	O
susceptible	O
to	O
develop	O
DDD	B-Disease
when	O
compared	O
with	O
those	O
having	O
G	O
allele	O
only	O
.	O
	
Further	O
association	O
was	O
identified	O
in	O
individuals	O
over	O
40	O
years	O
of	O
age	O
.	O
	
Disc	O
bulge	O
","	O
annular	O
tear	O
as	O
well	O
as	O
Schmorl	O
'	O
s	O
nodes	O
were	O
not	O
associated	O
with	O
this	O
polymorphism	O
.	O
	
	
Detailed	O
spectral	O
profile	O
analysis	O
of	O
penicillin	B-Chemical
-	O
induced	O
epileptiform	B-Disease
activity	I-Disease
in	O
anesthetized	O
rats	O
.	O
	
Penicillin	B-Chemical
model	O
is	O
a	O
widely	O
used	O
experimental	O
model	O
for	O
epilepsy	B-Disease
research	O
.	O
	
In	O
the	O
present	O
study	O
we	O
aimed	O
to	O
portray	O
a	O
detailed	O
spectral	O
analysis	O
of	O
penicillin	B-Chemical
-	O
induced	O
epileptiform	B-Disease
activity	I-Disease
in	O
comparison	O
with	O
basal	O
brain	O
activity	O
in	O
anesthetized	O
Wistar	O
rats	O
.	O
	
Male	O
Wistar	O
rats	O
were	O
anesthetized	O
with	O
i	O
.	O
p	O
.	O
	
urethane	B-Chemical
and	O
connected	O
to	O
an	O
electrocorticogram	O
setup	O
.	O
	
After	O
a	O
short	O
period	O
of	O
basal	O
activity	O
recording	O
","	O
epileptic	B-Disease
focus	O
was	O
induced	O
by	O
injecting	O
400IU	O
/	O
2	O
microl	O
penicillin	B-Chemical
-	I-Chemical
G	I-Chemical
potassium	I-Chemical
into	O
the	O
left	O
lateral	O
ventricle	O
while	O
the	O
cortical	O
activity	O
was	O
continuously	O
recorded	O
.	O
	
Basal	O
activity	O
","	O
latent	O
period	O
and	O
the	O
penicillin	B-Chemical
-	O
induced	O
epileptiform	B-Disease
activity	I-Disease
periods	O
were	O
then	O
analyzed	O
using	O
both	O
conventional	O
methods	O
and	O
spectral	O
analysis	O
.	O
	
Spectral	O
analyses	O
were	O
conducted	O
by	O
dividing	O
the	O
whole	O
spectrum	O
into	O
different	O
frequency	O
bands	O
including	O
delta	O
","	O
theta	O
(	O
slow	O
and	O
fast	O
)","	O
alpha	O
-	O
sigma	O
","	O
beta	O
(	O
1	O
and	O
2	O
)	O
and	O
gamma	O
(	O
1	O
and	O
2	O
)	O
bands	O
.	O
	
Our	O
results	O
show	O
that	O
the	O
most	O
affected	O
frequency	O
bands	O
were	O
delta	O
","	O
theta	O
","	O
beta	O
-	O
2	O
and	O
gamma	O
-	O
2	O
bands	O
during	O
the	O
epileptiform	B-Disease
activity	I-Disease
and	O
there	O
were	O
marked	O
differences	O
in	O
terms	O
of	O
spectral	O
densities	O
between	O
three	O
investigated	O
episodes	O
(	O
basal	O
activity	O
","	O
latent	O
period	O
and	O
epileptiform	B-Disease
activity	I-Disease
).	O
	
Our	O
results	O
may	O
help	O
to	O
analyze	O
novel	O
data	O
obtained	O
using	O
similar	O
experimental	O
models	O
and	O
the	O
simple	O
analysis	O
method	O
described	O
here	O
can	O
be	O
used	O
in	O
similar	O
studies	O
to	O
investigate	O
the	O
basic	O
neuronal	O
mechanism	O
of	O
this	O
or	O
other	O
types	O
of	O
experimental	O
epilepsies	B-Disease
.	O
	
	
Expanding	O
clinical	O
spectrum	O
of	O
non	B-Disease
-	I-Disease
autoimmune	I-Disease
hyperthyroidism	I-Disease
due	O
to	O
an	O
activating	O
germline	O
mutation	O
","	O
p	O
.	O
M453T	O
","	O
in	O
the	O
thyrotropin	O
receptor	O
gene	O
.	O
	
OBJECTIVE	O
:	O
To	O
describe	O
clinical	O
and	O
genetic	O
features	O
of	O
a	O
Thai	O
family	O
with	O
non	B-Disease
-	I-Disease
autoimmune	I-Disease
hyperthyroidism	I-Disease
(	O
NAH	B-Disease
)	O
caused	O
by	O
an	O
activating	O
germline	O
mutation	O
in	O
the	O
thyrotropin	O
receptor	O
(	O
TSHR	O
)	O
gene	O
.	O
	
PATIENTS	O
:	O
Three	O
affected	O
individuals	O
from	O
the	O
same	O
family	O
(	O
a	O
father	O
and	O
his	O
two	O
children	O
)	O
were	O
studied	O
.	O
	
Clinical	O
and	O
imaging	O
findings	O
were	O
reviewed	O
and	O
compared	O
.	O
	
GENETIC	O
ANALYSIS	O
:	O
Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
leukocytes	O
and	O
mutation	O
analysis	O
of	O
the	O
entire	O
coding	O
sequence	O
of	O
the	O
TSHR	O
gene	O
was	O
performed	O
in	O
both	O
children	O
and	O
their	O
parents	O
by	O
direct	O
DNA	O
sequencing	O
.	O
	
RESULTS	O
:	O
A	O
heterozygous	O
germline	O
T	O
to	O
C	O
transition	O
in	O
exon	O
10	O
of	O
the	O
TSHR	O
gene	O
(	O
c	O
.	O
1358T	O
-->	O
C	O
)	O
resulting	O
in	O
the	O
substitution	O
of	O
methionine	O
(	O
ATG	O
)	O
by	O
threonine	O
(	O
ACG	O
)	O
at	O
codon	O
453	O
(	O
p	O
.	O
M453T	O
)	O
was	O
identified	O
in	O
the	O
father	O
and	O
his	O
two	O
children	O
.	O
	
They	O
presented	O
with	O
different	O
clinical	O
severity	O
and	O
variable	O
age	O
of	O
onset	O
.	O
	
In	O
addition	O
to	O
hyperthyroidism	B-Disease
","	O
ventriculomegaly	B-Disease
and	O
bilateral	O
shortening	O
of	O
the	O
fifth	O
metacarpal	O
bones	O
and	O
the	O
middle	O
phalanges	O
of	O
the	O
fifth	O
fingers	O
were	O
consistently	O
found	O
in	O
all	O
affected	O
individuals	O
.	O
	
CONCLUSIONS	O
:	O
Ventriculomegaly	B-Disease
and	O
bilateral	O
shortening	O
of	O
the	O
fifth	O
metacarpal	O
bones	O
and	O
the	O
middle	O
phalanges	O
of	O
the	O
fifth	O
fingers	O
might	O
be	O
characteristic	O
features	O
of	O
NAH	B-Disease
because	O
of	O
an	O
activating	O
TSHR	O
germline	O
mutation	O
.	O
	
In	O
addition	O
","	O
the	O
shortening	O
of	O
the	O
middle	O
phalanges	O
of	O
the	O
fifth	O
fingers	O
has	O
never	O
been	O
previously	O
described	O
","	O
expanding	O
the	O
phenotypic	O
spectrum	O
of	O
the	O
disease	O
.	O
	
	
Hemodynamic	O
parameters	O
and	O
heart	O
rate	O
variability	O
during	O
a	O
tilt	O
test	O
in	O
relation	O
to	O
gene	O
polymorphism	O
of	O
renin	O
-	O
angiotensin	O
and	O
serotonin	B-Chemical
system	O
.	O
	
PURPOSE	O
:	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
renin	O
-	O
angiotensin	O
system	O
and	O
serotonin	O
transporter	O
gene	O
polymorphisms	O
in	O
relation	O
to	O
hemodynamic	O
parameters	O
and	O
heart	O
rate	O
variability	O
during	O
a	O
head	O
-	O
up	O
tilt	O
test	O
(	O
HUT	O
)	O
in	O
patients	O
with	O
vasovagal	B-Disease
syncope	I-Disease
.	O
	
METHODS	O
:	O
DNA	O
was	O
collected	O
from	O
191	O
patients	O
(	O
mean	O
age	O
44	O
+/-	O
18	O
years	O
","	O
61	O
men	O
","	O
130	O
women	O
).	O
	
The	O
following	O
gene	O
polymorphisms	O
were	O
determined	O
in	O
genomic	O
DNA	O
:	O
angiotensin	O
-	O
converting	O
enzyme	O
insertion	O
/	O
deletion	O
polymorphism	O
(	O
I	O
/	O
D	O
ACE	O
)","	O
angiotensinogen	O
gene	O
polymorphism	O
(	O
M	O
235	O
)","	O
angiotensin	O
II	O
receptor	O
type	O
1	O
(	O
ATR1	O
)	O
polymorphism	O
(	O
A	O
11666C	O
)","	O
and	O
polymorphism	O
of	O
serotonin	O
transporter	O
gene	O
(	O
5HTTLPR	O
).	O
Heart	O
rate	O
variability	O
during	O
HUT	O
was	O
assessed	O
in	O
5	O
-	O
minute	O
intervals	O
by	O
low	O
frequency	O
","	O
high	O
frequency	O
","	O
standard	O
deviation	O
of	O
the	O
normal	O
-	O
to	O
-	O
normal	O
(	O
SDNN	O
)","	O
and	O
root	O
mean	O
square	O
successive	O
difference	O
parameters	O
.	O
	
RESULTS	O
:	O
AA	O
genotype	O
of	O
A	O
1166C	O
polymorphism	O
was	O
associated	O
with	O
lower	O
minimal	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
and	O
diastolic	O
blood	O
pressure	O
(	O
DBP	O
)	O
during	O
HUT	O
compared	O
with	O
other	O
genotypes	O
(	O
minimal	O
SBP	O
:	O
AA	O
59	O
.	O
6	O
+/-	O
21	O
","	O
8	O
","	O
AC	O
79	O
.	O
9	O
+/-	O
22	O
.	O
7	O
","	O
CC	O
65	O
.	O
4	O
+/-	O
22	O
.	O
7	O
mmHg	O
","	O
P	O
=	O
0	O
.	O
7	O
)","	O
(	O
minimal	O
DBP	O
:	O
AA	O
36	O
.	O
4	O
+/-	O
22	O
.	O
7	O
","	O
AC	O
52	O
.	O
3	O
+/-	O
22	O
.	O
9	O
","	O
CC	O
45	O
.	O
4	O
+/-	O
19	O
.	O
5	O
mmHg	O
","	O
P	O
=	O
0	O
.	O
7	O
).	O
AA	O
genotype	O
was	O
also	O
associated	O
with	O
higher	O
SDNN	O
compared	O
to	O
other	O
genotypes	O
in	O
the	O
early	O
phase	O
of	O
HUT	O
(	O
SDNN	O
in	O
5	O
minutes	O
of	O
tilt	O
:	O
AA	O
59	O
.	O
7	O
+/-	O
24	O
.	O
6	O
","	O
AC	O
50	O
.	O
6	O
+/-	O
20	O
.	O
6	O
","	O
CC	O
46	O
.	O
0	O
+/-	O
13	O
.	O
2	O
","	O
P	O
=	O
0	O
.	O
1	O
)	O
and	O
at	O
syncope	B-Disease
occurrence	O
(	O
SDNN	O
:	O
AA	O
71	O
.	O
0	O
+/-	O
20	O
.	O
9	O
","	O
AC	O
58	O
.	O
2	O
+/-	O
17	O
.	O
9	O
","	O
CC	O
58	O
+/-	O
10	O
","	O
P	O
=	O
0	O
.	O
4	O
)	O
CONCLUSION	O
:	O
AA	O
genotype	O
of	O
A	O
1166C	O
polymorphism	O
in	O
the	O
ATR1	O
gene	O
may	O
be	O
associated	O
with	O
hypotension	B-Disease
and	O
decline	O
in	O
sympathetic	O
tone	O
during	O
HUT	O
.	O
	
Its	O
role	O
in	O
genetic	O
predisposition	O
to	O
vasovagal	B-Disease
syncope	I-Disease
cannot	O
be	O
excluded	O
.	O
	
	
Hypomorphic	O
mutations	O
in	O
meckelin	O
(	O
MKS3	O
/	O
TMEM67	O
)	O
cause	O
nephronophthisis	B-Disease
with	I-Disease
liver	I-Disease
fibrosis	I-Disease
(	O
NPHP11	B-Disease
).	O
	
BACKGROUND	O
:	O
Nephronophthisis	B-Disease
(	O
NPHP	B-Disease
)","	O
a	O
rare	O
recessive	O
cystic	B-Disease
kidney	I-Disease
disease	I-Disease
","	O
is	O
the	O
most	O
frequent	O
genetic	O
cause	O
of	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
in	O
children	O
and	O
young	O
adults	O
.	O
	
Mutations	O
in	O
nine	O
genes	O
(	O
NPHP1	O
-	O
9	O
)	O
have	O
been	O
identified	O
.	O
	
NPHP	B-Disease
can	O
be	O
associated	O
with	O
retinal	B-Disease
degeneration	I-Disease
(	O
Senior	B-Disease
-	I-Disease
Loken	I-Disease
syndrome	I-Disease
)","	O
brainstem	O
and	O
cerebellar	B-Disease
anomalies	I-Disease
(	O
Joubert	B-Disease
syndrome	I-Disease
)","	O
or	O
liver	B-Disease
fibrosis	I-Disease
.	O
	
METHODS	O
:	O
To	O
identify	O
a	O
causative	O
gene	O
for	O
the	O
subset	O
of	O
patients	O
with	O
associated	O
liver	B-Disease
fibrosis	I-Disease
","	O
the	O
authors	O
performed	O
a	O
genome	O
wide	O
linkage	O
search	O
in	O
a	O
consanguineous	O
family	O
with	O
three	O
affected	O
patients	O
using	O
50K	O
SNP	O
microarrays	O
and	O
homozygosity	O
mapping	O
.	O
	
RESULTS	O
:	O
The	O
authors	O
obtained	O
a	O
significant	O
maximum	O
parametric	O
LOD	O
(	O
logarithm	O
of	O
odds	O
)	O
score	O
of	O
Z	O
(	O
max	O
)	O
=	O
3	O
.	O
72	O
on	O
chromosome	O
8q22	O
and	O
identified	O
a	O
homozygous	O
missense	O
mutation	O
in	O
the	O
gene	O
MKS3	O
/	O
TMEM67	O
.	O
	
When	O
examining	O
a	O
worldwide	O
cohort	O
of	O
62	O
independent	O
patients	O
with	O
NPHP	B-Disease
and	O
associated	O
liver	B-Disease
fibrosis	I-Disease
we	O
identified	O
altogether	O
four	O
novel	O
mutations	O
(	O
p	O
.	O
W290L	O
","	O
p	O
.	O
C615R	O
","	O
p	O
.	O
G821S	O
","	O
and	O
p	O
.	O
G821R	O
)	O
in	O
five	O
of	O
them	O
.	O
	
Mutations	O
of	O
MKS3	O
/	O
TMEM67	O
","	O
found	O
recently	O
in	O
Meckel	B-Disease
-	I-Disease
Gruber	I-Disease
syndrome	I-Disease
(	I-Disease
MKS	I-Disease
)	I-Disease
type	I-Disease
3	I-Disease
and	O
Joubert	B-Disease
syndrome	I-Disease
(	I-Disease
JBTS	I-Disease
)	I-Disease
type	I-Disease
6	I-Disease
","	O
are	O
predominantly	O
truncating	O
mutations	O
.	O
	
In	O
contrast	O
","	O
the	O
mutations	O
detected	O
here	O
in	O
patients	O
with	O
NPHP	B-Disease
and	O
associated	O
liver	B-Disease
fibrosis	I-Disease
are	O
exclusively	O
missense	O
mutations	O
.	O
	
This	O
suggests	O
that	O
they	O
may	O
represent	O
hypomorphic	O
alleles	O
","	O
leading	O
to	O
a	O
milder	O
phenotype	O
compared	O
with	O
the	O
more	O
severe	O
MKS	B-Disease
or	O
JBTS	B-Disease
phenotype	O
.	O
	
Additionally	O
","	O
mutation	O
analysis	O
for	O
MKS3	O
/	O
TMEM67	O
in	O
120	O
patients	O
with	O
JBTS	B-Disease
yielded	O
seven	O
different	O
(	O
four	O
novel	O
)	O
mutations	O
in	O
five	O
patients	O
","	O
four	O
of	O
whom	O
also	O
presented	O
with	O
congenital	O
liver	B-Disease
fibrosis	I-Disease
.	O
	
CONCLUSIONS	O
:	O
Hypomorphic	O
MKS3	O
/	O
TMEM67	O
mutations	O
cause	O
NPHP	B-Disease
with	I-Disease
liver	I-Disease
fibrosis	I-Disease
(	O
NPHP11	B-Disease
).	O
	
This	O
is	O
the	O
first	O
report	O
of	O
MKS3	O
mutations	O
in	O
patients	O
with	O
no	O
vermian	O
agenesis	O
and	O
without	O
neurological	O
signs	O
.	O
	
Thus	O
NPHP	B-Disease
","	O
JBTS	B-Disease
","	O
and	O
MKS	B-Disease
represent	O
allelic	B-Disease
disorders	I-Disease
.	O
	
	
Serotonin	O
transporter	O
gene	O
polymorphic	O
element	O
5	O
-	O
HTTLPR	O
increases	O
the	O
risk	O
of	O
sporadic	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
in	O
Italy	O
.	O
	
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
is	O
a	O
neurodegenerative	B-Disease
disorder	I-Disease
causing	O
muscular	B-Disease
rigidity	I-Disease
","	O
resting	B-Disease
tremor	I-Disease
and	O
bradykinesia	B-Disease
.	O
	
We	O
conducted	O
an	O
association	O
study	O
assessing	O
how	O
PD	B-Disease
risk	O
in	O
Italy	O
was	O
influenced	O
by	O
the	O
serotonin	O
transporter	O
gene	O
(	O
SLC6A4	O
)	O
polymorphic	O
region	O
5	O
-	O
HTTLPR	O
","	O
consisting	O
of	O
an	O
insertion	O
/	O
deletion	O
(	O
long	O
allele	O
-	O
L	O
/	O
short	O
allele	O
-	O
S	O
)	O
of	O
43	O
bp	O
in	O
the	O
SLC6A4	O
promoter	O
region	O
.	O
	
The	O
SLC6A4	O
promoter	O
single	O
nucleotide	O
polymorphism	O
rs25531	O
(	O
A	O
-->	O
G	O
)	O
was	O
evaluated	O
too	O
.	O
	
We	O
collected	O
837	O
independent	O
subjects	O
(	O
393	O
PD	B-Disease
","	O
444	O
controls	O
).	O
	
An	O
association	O
between	O
the	O
5	O
-	O
HTTLPR	O
polymorphism	O
and	O
risk	O
of	O
PD	B-Disease
(	O
S	O
/	O
S	O
genotype	O
OR	O
[	O
95	O
%	O
CI	O
]:	O
1	O
.	O
7	O
[	O
1	O
.	O
2	O
-	O
2	O
.	O
5	O
]","	O
p	O
=	O
0	O
.	O
2	O
)	O
was	O
found	O
.	O
	
The	O
rs25531	O
and	O
the	O
haplotype	O
5	O
-	O
HTTLPR	O
/	O
rs25531	O
did	O
not	O
associate	O
with	O
risk	O
of	O
PD	B-Disease
.	O
	
Our	O
data	O
indicate	O
that	O
the	O
5	O
-	O
HTTLPR	O
polymorphic	O
element	O
within	O
the	O
SLC6A4	O
promoter	O
may	O
govern	O
the	O
genetic	O
risk	O
of	O
PD	B-Disease
in	O
Italians	O
.	O
	
	
Prolonged	O
hypothermia	B-Disease
as	O
a	O
bridge	O
to	O
recovery	O
for	O
cerebral	B-Disease
edema	I-Disease
and	O
intracranial	B-Disease
hypertension	I-Disease
associated	O
with	O
fulminant	B-Disease
hepatic	I-Disease
failure	I-Disease
.	O
	
BACKGROUND	O
:	O
To	O
review	O
evidence	O
-	O
based	O
treatment	O
options	O
in	O
patients	O
with	O
cerebral	B-Disease
edema	I-Disease
complicating	O
fulminant	B-Disease
hepatic	I-Disease
failure	I-Disease
(	O
FHF	B-Disease
)	O
and	O
discuss	O
the	O
potential	O
applications	O
of	O
hypothermia	B-Disease
.	O
	
METHOD	O
:	O
Case	O
-	O
based	O
observations	O
from	O
a	O
medical	O
intensive	O
care	O
unit	O
(	O
MICU	O
)	O
in	O
a	O
tertiary	O
care	O
facility	O
in	O
a	O
27	O
-	O
year	O
-	O
old	O
female	O
with	O
FHF	B-Disease
from	O
acetaminophen	B-Chemical
and	O
resultant	O
cerebral	B-Disease
edema	I-Disease
.	O
	
RESULTS	O
:	O
Our	O
patient	O
was	O
admitted	O
to	O
the	O
MICU	O
after	O
being	O
found	O
unresponsive	O
with	O
presumed	O
toxicity	B-Disease
from	O
acetaminophen	B-Chemical
which	O
was	O
ingested	O
over	O
a	O
2	O
-	O
day	O
period	O
.	O
	
The	O
patient	O
had	O
depressed	B-Disease
of	O
mental	O
status	O
lasting	O
at	O
least	O
24	O
h	O
prior	O
to	O
admission	O
.	O
	
Initial	O
evaluation	O
confirmed	O
FHF	B-Disease
from	O
acetaminophen	B-Chemical
and	O
cerebral	B-Disease
edema	I-Disease
.	O
	
The	O
patient	O
was	O
treated	O
with	O
hyperosmolar	O
therapy	O
","	O
hyperventilation	B-Disease
","	O
sedation	O
","	O
and	O
chemical	O
paralysis	B-Disease
.	O
	
Her	O
intracranial	O
pressure	O
remained	O
elevated	O
despite	O
maximal	O
medical	O
therapy	O
.	O
	
We	O
then	O
initiated	O
therapeutic	O
hypothermia	B-Disease
which	O
was	O
continued	O
for	O
5	O
days	O
.	O
	
At	O
re	O
-	O
warming	O
","	O
patient	O
had	O
resolution	O
of	O
her	O
cerebral	B-Disease
edema	I-Disease
and	O
intracranial	B-Disease
hypertension	I-Disease
.	O
	
At	O
discharge	O
","	O
she	O
had	O
complete	O
recovery	O
of	O
neurological	O
and	O
hepatic	O
functions	O
.	O
	
CONCLUSION	O
:	O
In	O
patients	O
with	O
FHF	B-Disease
and	O
cerebral	B-Disease
edema	I-Disease
from	O
acetaminophen	B-Chemical
overdose	O
","	O
prolonged	O
therapeutic	O
hypothermia	B-Disease
could	O
potentially	O
be	O
used	O
as	O
a	O
life	O
saving	O
therapy	O
and	O
a	O
bridge	O
to	O
hepatic	O
and	O
neurological	O
recovery	O
.	O
	
A	O
clinical	O
trial	O
of	O
hypothermia	B-Disease
in	O
patients	O
with	O
this	O
condition	O
is	O
warranted	O
.	O
	
	
hOGG1	O
Ser326Cys	O
polymorphism	O
and	O
risk	O
of	O
lung	B-Disease
cancer	I-Disease
by	O
histological	O
type	O
.	O
	
Human	O
8	O
-	O
oxoguanine	O
DNA	O
glycosylase	O
1	O
(	O
hOGG1	O
)	O
has	O
a	O
major	O
role	O
in	O
the	O
repair	O
of	O
8	B-Chemical
-	I-Chemical
hydroxyguanine	I-Chemical
","	O
a	O
major	O
promutagenic	O
DNA	O
lesion	O
.	O
	
The	O
genetic	O
polymorphism	O
rs1052133	O
","	O
which	O
leads	O
to	O
substitution	O
of	O
the	O
amino	O
acid	O
at	O
codon	O
326	O
from	O
Ser	O
to	O
Cys	O
","	O
shows	O
functional	O
differences	O
","	O
namely	O
a	O
decrease	O
in	O
enzyme	O
activity	O
in	O
hOGG1	O
-	O
Cys326	O
.	O
	
Although	O
several	O
studies	O
have	O
investigated	O
the	O
association	O
between	O
rs1052133	O
and	O
lung	B-Disease
cancer	I-Disease
susceptibility	O
","	O
the	O
effect	O
of	O
this	O
locus	O
on	O
lung	B-Disease
cancer	I-Disease
according	O
to	O
histology	O
remains	O
unclear	O
.	O
	
We	O
therefore	O
conducted	O
a	O
case	O
-	O
control	O
study	O
with	O
515	O
incident	O
lung	B-Disease
cancer	I-Disease
cases	O
and	O
1030	O
age	O
-	O
and	O
sex	O
-	O
matched	O
controls	O
without	O
cancer	B-Disease
","	O
and	O
further	O
conducted	O
a	O
meta	O
-	O
analysis	O
.	O
	
In	O
overall	O
analysis	O
","	O
the	O
homozygous	O
Cys	O
/	O
Cys	O
genotype	O
showed	O
a	O
significant	O
association	O
with	O
lung	B-Disease
cancer	I-Disease
compared	O
to	O
Ser	O
allele	O
carrier	O
status	O
(	O
odds	O
ratio	O
(	O
OR	O
)=	O
1	O
.	O
31	O
","	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)=	O
1	O
.	O
2	O
-	O
1	O
.	O
69	O
).	O
	
By	O
histology	O
-	O
based	O
analysis	O
","	O
the	O
Cys	O
/	O
Cys	O
genotype	O
showed	O
a	O
significantly	O
positive	O
association	O
with	O
small	B-Disease
-	I-Disease
cell	I-Disease
carcinoma	I-Disease
(	O
OR	O
=	O
2	O
.	O
40	O
","	O
95	O
%	O
CI	O
=	O
1	O
.	O
32	O
-	O
4	O
.	O
49	O
)	O
and	O
marginally	O
significant	O
association	O
with	O
adenocarcinoma	B-Disease
(	O
OR	O
=	O
1	O
.	O
32	O
","	O
95	O
%	O
CI	O
=	O
0	O
.	O
98	O
-	O
1	O
.	O
77	O
).	O
	
A	O
meta	O
-	O
analysis	O
of	O
previous	O
and	O
our	O
present	O
study	O
revealed	O
that	O
this	O
polymorphism	O
is	O
positively	O
associated	O
with	O
adenocarcinoma	B-Disease
","	O
although	O
suggestive	O
associations	O
were	O
also	O
found	O
for	O
squamous	B-Disease
-	I-Disease
and	I-Disease
small	I-Disease
-	I-Disease
cell	I-Disease
lung	I-Disease
cancers	I-Disease
.	O
	
These	O
results	O
indicate	O
that	O
rs1052133	O
contributes	O
to	O
the	O
risk	O
of	O
adenocarcinoma	B-Disease
of	I-Disease
lung	I-Disease
.	O
	
	
A	O
potential	O
regulatory	O
single	O
nucleotide	O
polymorphism	O
in	O
the	O
promoter	O
of	O
the	O
Klotho	O
gene	O
may	O
be	O
associated	O
with	O
essential	B-Disease
hypertension	I-Disease
in	O
the	O
Chinese	O
Han	O
population	O
.	O
	
BACKGROUND	O
:	O
Mice	O
with	O
defects	O
in	O
the	O
Klotho	O
gene	O
exhibit	O
multiple	O
aging	O
phenotypes	O
including	O
arteriosclerosis	B-Disease
.	O
	
We	O
hypothesised	O
that	O
the	O
G	O
-	O
395A	O
polymorphism	O
in	O
the	O
promoter	O
region	O
of	O
the	O
human	O
Klotho	O
gene	O
may	O
contribute	O
to	O
the	O
prevalence	O
of	O
Essential	B-Disease
Hypertension	I-Disease
(	O
EH	B-Disease
).	O
	
METHODS	O
:	O
We	O
investigate	O
whether	O
the	O
G	O
-	O
395A	O
polymorphism	O
of	O
Klotho	O
is	O
associated	O
with	O
EH	B-Disease
in	O
a	O
population	O
consisting	O
of	O
215	O
patients	O
with	O
EH	B-Disease
and	O
220	O
non	O
-	O
hypertensive	B-Disease
subjects	O
.	O
	
We	O
also	O
tested	O
whether	O
a	O
G	O
/	O
A	O
substitution	O
at	O
the	O
G	O
-	O
395A	O
site	O
affected	O
the	O
transcription	O
level	O
in	O
vitro	O
through	O
the	O
dual	O
-	O
luciferase	O
reporter	O
assay	O
.	O
	
RESULTS	O
:	O
Differences	O
in	O
the	O
genotype	O
distributions	O
of	O
the	O
G	O
-	O
395A	O
polymorphism	O
between	O
the	O
EH	B-Disease
and	O
non	O
-	O
hypertension	B-Disease
groups	O
are	O
statistically	O
significant	O
(	O
P	O
=	O
0	O
.	O
32	O
).	O
	
There	O
are	O
differential	O
effects	O
of	O
age	O
","	O
gender	O
and	O
smoking	O
status	O
on	O
the	O
association	O
of	O
the	O
G	O
-	O
395A	O
polymorphism	O
with	O
EH	B-Disease
";"	O
the	O
G	O
-	O
395A	O
polymorphism	O
is	O
significantly	O
associated	O
with	O
EH	B-Disease
in	O
subjects	O
over	O
60years	O
old	O
","	O
in	O
females	O
and	O
in	O
nonsmokers	O
.	O
	
A	O
multiple	O
logistic	O
regression	O
analysis	O
indicated	O
that	O
the	O
odds	O
ratio	O
for	O
EH	B-Disease
in	O
the	O
-	O
395A	O
allele	O
carriers	O
as	O
compared	O
with	O
the	O
control	O
group	O
was	O
0	O
.	O
593	O
(	O
P	O
=	O
0	O
.	O
24	O
)	O
after	O
adjusting	O
for	O
current	O
traditional	O
risk	O
factors	O
.	O
	
The	O
dual	O
-	O
luciferase	O
reporter	O
assay	O
revealed	O
that	O
the	O
-	O
395A	O
carrier	O
of	O
a	O
498	O
-	O
bp	O
DNA	O
fragment	O
(	O
containing	O
the	O
G	O
-	O
395A	O
site	O
)	O
upstream	O
of	O
the	O
Klotho	O
gene	O
has	O
higher	O
relative	O
luciferase	O
activity	O
than	O
the	O
-	O
395G	O
carrier	O
.	O
	
CONCLUSIONS	O
:	O
The	O
G	O
-	O
395A	O
polymorphism	O
of	O
the	O
human	O
Klotho	O
gene	O
is	O
associated	O
with	O
EH	B-Disease
and	O
may	O
be	O
a	O
potential	O
regulatory	O
site	O
.	O
	
	
Chemokine	O
CCL2	O
and	O
its	O
receptor	O
CCR2	O
are	O
increased	O
in	O
the	O
hippocampus	O
following	O
pilocarpine	B-Chemical
-	O
induced	O
status	B-Disease
epilepticus	I-Disease
.	O
	
BACKGROUND	O
:	O
Neuroinflammation	B-Disease
occurs	O
after	O
seizures	B-Disease
and	O
is	O
implicated	O
in	O
epileptogenesis	O
.	O
	
CCR2	O
is	O
a	O
chemokine	O
receptor	O
for	O
CCL2	O
and	O
their	O
interaction	O
mediates	O
monocyte	O
infiltration	O
in	O
the	O
neuroinflammatory	B-Disease
cascade	O
triggered	O
in	O
different	O
brain	O
pathologies	O
.	O
	
In	O
this	O
work	O
CCR2	O
and	O
CCL2	O
expression	O
were	O
examined	O
following	O
status	B-Disease
epilepticus	I-Disease
(	O
SE	B-Disease
)	O
induced	O
by	O
pilocarpine	B-Chemical
injection	O
.	O
	
METHODS	O
:	O
SE	B-Disease
was	O
induced	O
by	O
pilocarpine	B-Chemical
injection	O
.	O
	
Control	O
rats	O
were	O
injected	O
with	O
saline	O
instead	O
of	O
pilocarpine	B-Chemical
.	O
	
Five	O
days	O
after	O
SE	B-Disease
","	O
CCR2	O
staining	O
in	O
neurons	O
and	O
glial	O
cells	O
was	O
examined	O
using	O
imunohistochemical	O
analyses	O
.	O
	
The	O
number	O
of	O
CCR2	O
positive	O
cells	O
was	O
determined	O
using	O
stereology	O
probes	O
in	O
the	O
hippocampus	O
.	O
	
CCL2	O
expression	O
in	O
the	O
hippocampus	O
was	O
examined	O
by	O
molecular	O
assay	O
.	O
	
RESULTS	O
:	O
Increased	O
CCR2	O
was	O
observed	O
in	O
the	O
hippocampus	O
after	O
SE	B-Disease
.	O
	
Seizures	B-Disease
also	O
resulted	O
in	O
alterations	O
to	O
the	O
cell	O
types	O
expressing	O
CCR2	O
.	O
	
Increased	O
numbers	O
of	O
neurons	O
that	O
expressed	O
CCR2	O
was	O
observed	O
following	O
SE	B-Disease
.	O
	
Microglial	O
cells	O
were	O
more	O
closely	O
apposed	O
to	O
the	O
CCR2	O
-	O
labeled	O
cells	O
in	O
SE	B-Disease
rats	O
.	O
	
In	O
addition	O
","	O
rats	O
that	O
experienced	O
SE	B-Disease
exhibited	O
CCR2	O
-	O
labeling	O
in	O
populations	O
of	O
hypertrophied	O
astrocytes	O
","	O
especially	O
in	O
CA1	O
and	O
dentate	O
gyrus	O
.	O
	
These	O
CCR2	O
+	O
astroctytes	O
were	O
not	O
observed	O
in	O
control	O
rats	O
.	O
	
Examination	O
of	O
CCL2	O
expression	O
showed	O
that	O
it	O
was	O
elevated	O
in	O
the	O
hippocampus	O
following	O
SE	B-Disease
.	O
	
CONCLUSION	O
:	O
The	O
data	O
show	O
that	O
CCR2	O
and	O
CCL2	O
are	O
up	O
-	O
regulated	O
in	O
the	O
hippocampus	O
after	O
pilocarpine	B-Chemical
-	O
induced	O
SE	B-Disease
.	O
	
Seizures	B-Disease
also	O
result	O
in	O
changes	O
to	O
CCR2	O
receptor	O
expression	O
in	O
neurons	O
and	O
astrocytes	O
.	O
	
These	O
changes	O
might	O
be	O
involved	O
in	O
detrimental	O
neuroplasticity	O
and	O
neuroinflammatory	B-Disease
changes	O
that	O
occur	O
following	O
seizures	B-Disease
.	O
	
	
Association	O
of	O
adipocyte	O
genes	O
with	O
ASP	O
expression	O
:	O
a	O
microarray	O
analysis	O
of	O
subcutaneous	O
and	O
omental	O
adipose	O
tissue	O
in	O
morbidly	O
obese	B-Disease
subjects	O
.	O
	
BACKGROUND	O
:	O
Prevalence	O
of	O
obesity	B-Disease
is	O
increasing	O
to	O
pandemic	O
proportions	O
.	O
	
However	O
","	O
obese	B-Disease
subjects	O
differ	O
in	O
insulin	B-Disease
resistance	I-Disease
","	O
adipokine	O
production	O
and	O
co	O
-	O
morbidities	O
.	O
	
Based	O
on	O
fasting	O
plasma	O
analysis	O
","	O
obese	B-Disease
subjects	O
were	O
grouped	O
as	O
Low	O
Acylation	O
Stimulating	O
protein	O
(	O
ASP	O
)	O
and	O
Triglyceride	B-Chemical
(	O
TG	B-Chemical
)	O
(	O
LAT	O
)	O
vs	O
High	O
ASP	O
and	O
TG	B-Chemical
(	O
HAT	O
).	O
	
Subcutaneous	O
(	O
SC	O
)	O
and	O
omental	O
(	O
OM	O
)	O
adipose	O
tissues	O
(	O
n	O
=	O
21	O
)	O
were	O
analysed	O
by	O
microarray	O
","	O
and	O
biologic	O
pathways	O
in	O
lipid	B-Chemical
metabolism	O
and	O
inflammation	B-Disease
were	O
specifically	O
examined	O
.	O
	
METHODS	O
:	O
LAT	O
and	O
HAT	O
groups	O
were	O
matched	O
in	O
age	O
","	O
obesity	B-Disease
","	O
insulin	O
","	O
and	O
glucose	B-Chemical
","	O
and	O
had	O
similar	O
expression	O
of	O
insulin	O
-	O
related	O
genes	O
(	O
InsR	O
","	O
IRS	O
-	O
1	O
).	O
	
ASP	O
related	O
genes	O
tended	O
to	O
be	O
increased	O
in	O
the	O
HAT	O
group	O
and	O
were	O
correlated	O
(	O
factor	O
B	O
","	O
adipsin	O
","	O
complement	O
C3	O
","	O
p	O
<	O
0	O
.	O
1	O
each	O
).	O
	
Differences	O
between	O
LAT	O
and	O
HAT	O
group	O
were	O
almost	O
exclusively	O
in	O
SC	O
tissue	O
","	O
with	O
little	O
difference	O
in	O
OM	O
tissue	O
.	O
	
Increased	O
C5L2	O
(	O
p	O
<	O
0	O
.	O
1	O
)","	O
an	O
ASP	O
receptor	O
","	O
in	O
HAT	O
suggests	O
a	O
compensatory	O
ASP	O
pathway	O
","	O
associated	O
with	O
increased	O
TG	B-Chemical
storage	O
.	O
	
RESULTS	O
:	O
HAT	O
adipose	O
tissue	O
demonstrated	O
increased	O
lipid	B-Chemical
related	O
genes	O
for	O
storage	O
(	O
CD36	O
","	O
DGAT1	O
","	O
DGAT2	O
","	O
SCD1	O
","	O
FASN	O
","	O
and	O
LPL	O
)","	O
lipolysis	O
(	O
HSL	O
","	O
CES1	O
","	O
perilipin	O
)","	O
fatty	O
acid	O
binding	O
proteins	O
(	O
FABP1	O
","	O
FABP3	O
)	O
and	O
adipocyte	O
differentiation	O
markers	O
(	O
CEBPalpha	O
","	O
CEBPbeta	O
","	O
PPARgamma	O
).	O
	
By	O
contrast	O
","	O
oxidation	O
related	O
genes	O
were	O
decreased	O
(	O
AMPK	O
","	O
UCP1	O
","	O
CPT1	O
","	O
FABP7	O
).	O
	
HAT	O
subjects	O
had	O
increased	O
anti	O
-	O
inflammatory	B-Disease
genes	O
TGFB1	O
","	O
TIMP1	O
","	O
TIMP3	O
","	O
and	O
TIMP4	O
while	O
proinflammatory	B-Disease
PIG7	O
and	O
MMP2	O
were	O
also	O
significantly	O
increased	O
";"	O
all	O
genes	O
","	O
p	O
<	O
0	O
.	O
25	O
.	O
	
CONCLUSION	O
:	O
Taken	O
together	O
","	O
the	O
profile	O
of	O
C5L2	O
receptor	O
","	O
ASP	O
gene	O
expression	O
and	O
metabolic	O
factors	O
in	O
adipose	O
tissue	O
from	O
morbidly	O
obese	B-Disease
HAT	O
subjects	O
suggests	O
a	O
compensatory	O
response	O
associated	O
with	O
the	O
increased	O
plasma	O
ASP	O
and	O
TG	B-Chemical
.	O
	
	
Atypical	O
GH	B-Disease
insensitivity	I-Disease
syndrome	I-Disease
and	O
severe	O
insulin	B-Disease
-	I-Disease
like	I-Disease
growth	I-Disease
factor	I-Disease
-	I-Disease
I	I-Disease
deficiency	I-Disease
resulting	O
from	O
compound	O
heterozygous	O
mutations	O
of	O
the	O
GH	O
receptor	O
","	O
including	O
a	O
novel	O
frameshift	O
mutation	O
affecting	O
the	O
intracellular	O
domain	O
.	O
	
BACKGROUND	O
/	O
AIMS	O
:	O
GH	B-Disease
insensitivity	I-Disease
and	O
IGF	B-Disease
deficiency	I-Disease
may	O
result	O
from	O
aberrations	O
of	O
the	O
GH	O
receptor	O
(	O
GHR	O
).	O
	
We	O
describe	O
a	O
4	O
-	O
year	O
-	O
old	O
child	O
with	O
modest	O
growth	B-Disease
failure	I-Disease
and	O
normal	O
serum	O
concentrations	O
of	O
GH	O
-	O
binding	O
protein	O
(	O
GHBP	O
)","	O
but	O
clinical	O
evidence	O
of	O
GH	B-Disease
insensitivity	I-Disease
.	O
	
METHOD	O
:	O
Serum	O
and	O
DNA	O
samples	O
from	O
the	O
proband	O
and	O
his	O
parents	O
were	O
analyzed	O
.	O
	
RESULTS	O
:	O
The	O
child	O
had	O
a	O
height	O
of	O
-	O
4	O
SD	O
","	O
elevated	O
serum	O
GH	O
concentrations	O
","	O
abnormally	O
low	O
serum	O
IGF	O
-	O
I	O
and	O
IGFBP	O
-	O
3	O
concentrations	O
and	O
normal	O
GHBP	O
concentrations	O
.	O
	
DNA	O
analysis	O
revealed	O
compound	O
heterozygosity	O
for	O
mutations	O
of	O
GHR	O
","	O
including	O
a	O
previously	O
reported	O
R211H	O
mutation	O
and	O
a	O
novel	O
duplication	O
of	O
a	O
nucleotide	O
in	O
exon	O
9	O
(	O
899dupC	O
)","	O
the	O
latter	O
resulting	O
in	O
a	O
frameshift	O
and	O
a	O
premature	O
stop	O
codon	O
.	O
	
Treatment	O
with	O
recombinant	O
DNA	O
-	O
derived	O
IGF	O
-	O
I	O
resulted	O
in	O
growth	O
acceleration	O
.	O
	
CONCLUSION	O
:	O
Mutations	O
affecting	O
the	O
intracellular	O
domain	O
of	O
the	O
GHR	O
can	O
result	O
in	O
GH	B-Disease
insensitivity	I-Disease
and	O
IGF	B-Disease
deficiency	I-Disease
","	O
despite	O
normal	O
serum	O
concentrations	O
of	O
GHBP	O
.	O
	
The	O
presence	O
of	O
clinical	O
and	O
biochemical	O
evidence	O
of	O
GH	O
resistance	O
is	O
sufficient	O
to	O
consider	O
the	O
possibility	O
of	O
aberrations	O
of	O
the	O
GHR	O
","	O
even	O
in	O
the	O
presence	O
of	O
normal	O
serum	O
GHBP	O
concentrations	O
.	O
	
	
Association	O
of	O
DNA	O
polymorphisms	O
within	O
the	O
CYP11B2	O
/	O
CYP11B1	O
locus	O
and	O
postoperative	O
hypertension	B-Disease
risk	O
in	O
the	O
patients	O
with	O
aldosterone	B-Disease
-	I-Disease
producing	I-Disease
adenomas	I-Disease
.	O
	
OBJECTIVES	O
:	O
Hypertension	B-Disease
often	O
persists	O
after	O
adrenalectomy	O
for	O
primary	O
aldosteronism	O
.	O
	
Traditional	O
factors	O
associated	O
with	O
postoperative	O
hypertension	B-Disease
were	O
evaluated	O
","	O
but	O
whether	O
genetic	O
determinants	O
were	O
involved	O
remains	O
poorly	O
understood	O
.	O
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
association	O
of	O
DNA	O
polymorphisms	O
within	O
steroid	O
synthesis	O
genes	O
(	O
CYP11B2	O
","	O
CYP11B1	O
)	O
and	O
the	O
postoperative	O
resolution	O
of	O
hypertension	B-Disease
in	O
Chinese	O
patients	O
undergoing	O
adrenalectomy	O
for	O
aldosterone	B-Disease
-	I-Disease
producing	I-Disease
adenomas	I-Disease
(	O
APA	B-Disease
).	O
	
METHODS	O
:	O
Ninety	O
-	O
three	O
patients	O
with	O
APA	B-Disease
were	O
assessed	O
for	O
postoperative	O
resolution	O
of	O
hypertension	B-Disease
.	O
	
All	O
patients	O
were	O
genotyped	O
for	O
rs1799998	O
(	O
C	O
-	O
344	O
T	O
)","	O
intron	O
2	O
conversion	O
","	O
rs4539	O
(	O
A2718G	O
)	O
within	O
CYP11B2	O
and	O
rs6410	O
(	O
G22	O
5A	O
)","	O
rs6387	O
(	O
A2803G	O
)	O
within	O
CYP11B1	O
.	O
	
The	O
associations	O
between	O
CYPB11B2	O
/	O
CYP11B1	O
polymorphisms	O
and	O
persistent	O
postoperative	O
hypertension	B-Disease
were	O
assessed	O
by	O
multivariate	O
analysis	O
.	O
	
RESULTS	O
:	O
CYP11B2	O
-	O
CYP11B1	O
haplotype	O
was	O
associated	O
with	O
persistent	O
postoperative	O
hypertension	B-Disease
in	O
Chinese	O
patients	O
undergoing	O
adrenalectomy	O
with	O
APA	B-Disease
(	O
P	O
=	O
.	O
6	O
).	O
	
Specifically	O
","	O
the	O
rs4539	O
(	O
AA	O
)	O
polymorphism	O
was	O
associated	O
with	O
persistent	O
postoperative	O
hypertension	B-Disease
(	O
P	O
=	O
.	O
2	O
).	O
	
Multivariate	O
logistic	O
regression	O
revealed	O
the	O
common	O
haplotypes	O
H1	O
(	O
AGACT	O
)","	O
H2	O
(	O
AGAWT	O
)","	O
and	O
H3	O
(	O
AGAWC	O
)	O
were	O
associated	O
with	O
the	O
persistent	O
postoperative	O
hypertension	B-Disease
(	O
P	O
=	O
.	O
1	O
","	O
0	O
.	O
3	O
","	O
0	O
.	O
5	O
after	O
Bonferroni	O
correction	O
).	O
	
Additional	O
predictors	O
of	O
persistent	O
postoperative	O
hypertension	B-Disease
included	O
duration	O
of	O
hypertension	B-Disease
(	O
P	O
<.	O
5	O
)","	O
family	O
history	O
of	O
hypertension	B-Disease
(	O
P	O
=	O
.	O
1	O
)","	O
and	O
elevated	O
systolic	O
blood	O
pressure	O
(	O
P	O
=	O
.	O
15	O
).	O
	
CONCLUSIONS	O
:	O
The	O
rs4539	O
(	O
AA	O
)","	O
H1	O
","	O
H2	O
","	O
and	O
H3	O
are	O
genetic	O
predictors	O
for	O
postoperative	O
persistence	O
of	O
hypertension	B-Disease
for	O
Chinese	O
patients	O
treated	O
by	O
adrenalectomy	O
with	O
APA	B-Disease
.	O
	
DNA	O
polymorphisms	O
at	O
CYP11B2	O
/	O
B1	O
locus	O
may	O
confer	O
susceptibility	O
to	O
postoperative	O
hypertension	B-Disease
of	O
patients	O
with	O
APA	B-Disease
.	O
	
	
A	O
novel	O
mutation	O
in	O
GJA8	O
causing	O
congenital	O
cataract	B-Disease
-	I-Disease
microcornea	I-Disease
syndrome	I-Disease
in	O
a	O
Chinese	O
pedigree	O
.	O
	
PURPOSE	O
:	O
To	O
identify	O
the	O
underlying	O
genetic	B-Disease
defect	I-Disease
in	O
a	O
four	O
-	O
generation	O
family	O
of	O
Chinese	O
origin	O
with	O
autosomal	O
dominant	O
congenital	O
cataract	B-Disease
-	I-Disease
microcornea	I-Disease
syndrome	I-Disease
(	O
CCMC	B-Disease
).	O
	
METHODS	O
:	O
All	O
individuals	O
in	O
the	O
study	O
underwent	O
a	O
full	O
clinical	O
examination	O
and	O
the	O
details	O
of	O
history	O
were	O
collected	O
.	O
	
Genomic	O
DNA	O
extracted	O
from	O
peripheral	O
blood	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
method	O
and	O
the	O
exons	O
of	O
all	O
candidate	O
genes	O
were	O
sequenced	O
.	O
	
RESULTS	O
:	O
Direct	O
sequencing	O
of	O
the	O
encoding	O
regions	O
of	O
the	O
candidate	O
genes	O
revealed	O
a	O
heterozygous	O
mutation	O
c	O
.	O
592C	O
-->	O
T	O
in	O
exon	O
2	O
of	O
the	O
gap	O
junction	O
protein	O
","	O
alpha	O
8	O
(	O
GJA8	O
)	O
gene	O
.	O
	
This	O
mutation	O
was	O
responsible	O
for	O
the	O
familial	O
disorder	O
through	O
the	O
substitution	O
of	O
a	O
highly	O
conserved	O
arginine	O
to	O
tryptophan	O
at	O
codon	O
198	O
(	O
p	O
.	O
R198W	O
).	O
	
This	O
change	O
co	O
-	O
segregated	O
with	O
all	O
affected	O
members	O
of	O
the	O
family	O
","	O
but	O
was	O
not	O
detected	O
either	O
in	O
the	O
non	O
-	O
carrier	O
relatives	O
or	O
in	O
the	O
100	O
normal	O
controls	O
.	O
	
CONCLUSIONS	O
:	O
This	O
report	O
is	O
the	O
first	O
to	O
relate	O
p	O
.	O
R198W	O
mutation	O
in	O
GJA8	O
with	O
CCMC	B-Disease
.	O
	
The	O
result	O
expands	O
the	O
mutation	O
spectrum	O
of	O
GJA8	O
in	O
associated	O
with	O
congenital	O
cataract	B-Disease
and	O
microcornea	B-Disease
","	O
and	O
implies	O
that	O
this	O
gene	O
has	O
direct	O
involvement	O
with	O
the	O
development	O
of	O
the	O
lens	O
as	O
well	O
as	O
the	O
other	O
anterior	O
segment	O
of	O
the	O
eye	O
.	O
	
	
The	O
M235T	O
polymorphism	O
of	O
the	O
angiotensinogen	O
gene	O
in	O
South	O
Indian	O
patients	O
of	O
hypertrophic	B-Disease
cardiomyopathy	I-Disease
.	O
	
INTRODUCTION	O
:	O
Hypertrophic	B-Disease
cardiomyopathy	I-Disease
(	O
HCM	B-Disease
)	O
is	O
a	O
complex	O
disorder	O
and	O
genetically	O
transmitted	O
cardiac	B-Disease
disease	I-Disease
with	O
a	O
diverse	O
clinical	O
course	O
.	O
	
The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
association	O
of	O
the	O
T704C	O
polymorphism	O
of	O
exon	O
2	O
of	O
the	O
angiotensinogen	O
(	O
AGT	O
)	O
gene	O
with	O
HCM	B-Disease
in	O
a	O
South	O
Indian	O
population	O
from	O
Andhra	O
Pradesh	O
.	O
	
Subjects	O
and	O
methods	O
.	O
	
One	O
-	O
hundred	O
and	O
fifty	O
HCM	B-Disease
(	O
90	O
sporadic	B-Disease
hypertrophic	I-Disease
cardiomyopathy	I-Disease
[	O
SHCM	B-Disease
]	O
and	O
60	O
familial	B-Disease
hypertrophic	I-Disease
cardiomyopathy	I-Disease
[	O
FHCM	B-Disease
])	O
patients	O
and	O
165	O
age	O
-	O
and	O
sex	O
-	O
matched	O
normal	O
healthy	O
controls	O
without	O
known	O
hypertension	B-Disease
and	O
left	B-Disease
ventricular	I-Disease
hypertrophy	I-Disease
were	O
included	O
in	O
the	O
study	O
.	O
	
DNA	O
was	O
isolated	O
from	O
peripheral	O
leukocytes	O
and	O
the	O
region	O
of	O
interest	O
in	O
the	O
AGT	O
gene	O
bearing	O
a	O
missense	O
mutation	O
methionine	O
to	O
threonine	O
substitution	O
at	O
codon	O
235	O
(	O
M235T	O
)	O
of	O
exon	O
2	O
","	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
).	O
	
The	O
PCR	O
products	O
were	O
subjected	O
to	O
restriction	O
digestion	O
with	O
the	O
enzyme	O
SfaNI	B-Chemical
.	O
	
RESULTS	O
:	O
Significant	O
differences	O
were	O
detected	O
in	O
genotypic	O
distribution	O
(	O
p	O
=	O
0	O
.	O
4	O
)	O
as	O
well	O
as	O
the	O
allelic	O
frequency	O
(	O
p	O
=	O
0	O
.	O
3	O
)	O
between	O
the	O
SHCM	B-Disease
patients	O
and	O
controls	O
.	O
	
The	O
polymorphism	O
did	O
not	O
show	O
any	O
association	O
with	O
FHCM	B-Disease
.	O
	
CONCLUSION	O
:	O
Our	O
results	O
suggest	O
that	O
the	O
T	O
allele	O
of	O
the	O
AGT	O
gene	O
is	O
significantly	O
associated	O
with	O
SHCM	B-Disease
in	O
a	O
South	O
Indian	O
population	O
from	O
Andhra	O
Pradesh	O
.	O
	
However	O
","	O
we	O
did	O
not	O
find	O
significant	O
association	O
of	O
this	O
polymorphism	O
with	O
FHCM	B-Disease
.	O
	
	
Interleukin	O
-	O
17F	O
gene	O
polymorphism	O
in	O
patients	O
with	O
chronic	B-Disease
immune	I-Disease
thrombocytopenia	I-Disease
.	O
	
INTRODUCTION	O
:	O
IL	O
-	O
17F	O
is	O
a	O
novel	O
inflammatory	O
cytokine	O
and	O
plays	O
an	O
important	O
role	O
in	O
some	O
autoimmune	B-Disease
diseases	I-Disease
.	O
	
We	O
investigated	O
the	O
association	O
between	O
chronic	B-Disease
ITP	I-Disease
and	O
the	O
frequency	O
of	O
the	O
single	O
-	O
nucleotide	O
polymorphism	O
rs763780	O
(	O
7488T	O
/	O
C	O
)","	O
which	O
causes	O
a	O
His	O
-	O
to	O
-	O
Arg	O
substitution	O
at	O
amino	O
acid	O
161	O
.	O
	
PATIENTS	O
AND	O
METHODS	O
:	O
We	O
examined	O
102	O
patients	O
(	O
men	O
/	O
women	O
","	O
40	O
/	O
62	O
";"	O
median	O
age	O
","	O
42	O
)	O
diagnosed	O
with	O
chronic	B-Disease
ITP	I-Disease
and	O
188	O
healthy	O
controls	O
(	O
men	O
/	O
women	O
","	O
78	O
/	O
110	O
";"	O
median	O
age	O
","	O
38	O
).	O
	
Genotyping	O
was	O
determined	O
by	O
the	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
PCR	O
-	O
RFLP	O
)	O
technique	O
.	O
	
RESULTS	O
:	O
Compared	O
with	O
the	O
control	O
group	O
","	O
patients	O
with	O
chronic	B-Disease
ITP	I-Disease
had	O
a	O
significantly	O
lower	O
frequency	O
of	O
the	O
IL	O
-	O
17F	O
7488CC	O
genotype	O
(	O
0	O
%	O
vs	O
.	O
	
4	O
.	O
8	O
%","	O
P	O
<	O
0	O
.	O
5	O
).	O
	
The	O
number	O
of	O
IL	O
-	O
17F	O
7488C	O
alleles	O
among	O
the	O
patients	O
with	O
chronic	B-Disease
ITP	I-Disease
was	O
also	O
significantly	O
lower	O
than	O
in	O
the	O
control	O
group	O
(	O
8	O
.	O
7	O
%	O
vs	O
.	O
	
15	O
.	O
2	O
%	O
OR	O
=	O
0	O
.	O
48	O
","	O
95	O
%	O
CI	O
=	O
0	O
.	O
27	O
-	O
0	O
.	O
84	O
","	O
P	O
=	O
0	O
.	O
16	O
).	O
	
Furthermore	O
","	O
patients	O
with	O
the	O
IL	O
-	O
17F	O
7488TT	O
genotype	O
showed	O
a	O
severe	O
thrombocytopenic	B-Disease
state	O
(	O
platelet	O
count	O
<	O
10	O
10	O
(	O
9	O
)	O
/	O
L	O
)	O
at	O
diagnosis	O
than	O
those	O
with	O
the	O
IL	O
-	O
17F	O
7488TC	O
genotype	O
(	O
20	O
.	O
9	O
%	O
vs	O
.	O
	
0	O
%","	O
P	O
=	O
0	O
.	O
4	O
).	O
	
CONCLUSION	O
:	O
These	O
findings	O
suggest	O
that	O
the	O
IL	O
-	O
17F	O
7488	O
T	O
allele	O
is	O
significantly	O
associated	O
with	O
the	O
development	O
of	O
chronic	B-Disease
ITP	I-Disease
","	O
suggesting	O
a	O
role	O
for	O
IL	O
-	O
17F	O
in	O
the	O
pathogenesis	O
of	O
chronic	B-Disease
ITP	I-Disease
.	O
	
	
XRCC1	O
Arg399Gln	O
gene	O
polymorphism	O
and	O
the	O
risk	O
of	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
in	O
the	O
Polish	O
population	O
.	O
	
It	O
has	O
been	O
shown	O
that	O
DNA	O
repair	O
is	O
reduced	O
in	O
patients	O
with	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
(	O
SLE	B-Disease
)	O
and	O
that	O
the	O
X	O
-	O
ray	O
repair	O
cross	O
-	O
complementing	O
(	O
XRCC1	O
)	O
Arg399Gln	O
(	O
rs25487	O
)	O
polymorphism	O
may	O
contribute	O
to	O
DNA	O
repair	O
.	O
	
We	O
evaluated	O
the	O
frequency	O
of	O
the	O
XRCC1	O
Arg399Gln	O
substitution	O
in	O
patients	O
with	O
SLE	B-Disease
(	O
n	O
=	O
265	O
)	O
and	O
controls	O
(	O
n	O
=	O
360	O
)	O
in	O
a	O
sample	O
of	O
the	O
Polish	O
population	O
.	O
	
The	O
odds	O
ratio	O
(	O
OR	O
)	O
for	O
SLE	B-Disease
patients	O
with	O
the	O
Gln	O
/	O
Gln	O
versus	O
Gln	O
/	O
Arg	O
or	O
Arg	O
/	O
Arg	O
genotypes	O
was	O
1	O
.	O
553	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]=	O
0	O
.	O
9573	O
-	O
2	O
.	O
520	O
";"	O
p	O
=	O
0	O
.	O
729	O
).	O
	
OR	O
for	O
the	O
Gln	O
/	O
Gln	O
or	O
Gln	O
/	O
Arg	O
versus	O
Arg	O
/	O
Arg	O
genotype	O
was	O
1	O
.	O
551	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
122	O
-	O
2	O
.	O
144	O
","	O
p	O
=	O
0	O
.	O
77	O
).	O
	
The	O
OR	O
for	O
the	O
399	O
Gln	O
allele	O
in	O
patients	O
with	O
SLE	B-Disease
was	O
1	O
.	O
406	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
111	O
-	O
1	O
.	O
779	O
","	O
p	O
=	O
0	O
.	O
45	O
).	O
	
There	O
was	O
also	O
a	O
statistically	O
significant	O
p	O
-	O
value	O
of	O
the	O
(	O
2	O
)	O
test	O
for	O
the	O
trend	O
observed	O
in	O
the	O
XRCC1	O
Arg399Gln	O
polymorphism	O
(	O
ptrend	O
=	O
0	O
.	O
48	O
).	O
	
We	O
also	O
found	O
a	O
significant	O
contribution	O
of	O
the	O
Gln	O
/	O
Gln	O
or	O
Arg	O
/	O
Gln	O
versus	O
Arg	O
/	O
Arg	O
genotype	O
to	O
the	O
presence	O
of	O
either	O
the	O
malar	B-Disease
rash	I-Disease
or	O
photosensitivity	O
manifestations	O
of	O
SLE	B-Disease
OR	O
=	O
2	O
.	O
241	O
(	O
1	O
.	O
328	O
-	O
3	O
.	O
781	O
","	O
p	O
=	O
0	O
.	O
23	O
","	O
pcorr	O
=	O
0	O
.	O
414	O
).	O
	
Moreover	O
","	O
the	O
meta	O
-	O
analysis	O
of	O
Taiwanese	O
Han	O
Chinese	O
","	O
Brazilian	O
","	O
and	O
Polish	O
populations	O
showed	O
that	O
the	O
Gln	O
/	O
Gln	O
or	O
Gln	O
/	O
Arg	O
genotype	O
and	O
Gln	O
allele	O
were	O
associated	O
with	O
SLE	B-Disease
incidence	O
.	O
	
OR	O
for	O
the	O
Gln	O
/	O
Gln	O
or	O
Gln	O
/	O
Arg	O
versus	O
Arg	O
/	O
Arg	O
genotype	O
was	O
1	O
.	O
440	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
15	O
-	O
1	O
.	O
80	O
","	O
p	O
=	O
0	O
.	O
19	O
)	O
and	O
OR	O
for	O
the	O
Gln	O
allele	O
was	O
1	O
.	O
27	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
8	O
-	O
1	O
.	O
51	O
","	O
p	O
=	O
0	O
.	O
51	O
).	O
	
Our	O
studies	O
may	O
confirm	O
that	O
the	O
XRCC1	O
Arg399Gln	O
polymorphism	O
may	O
increase	O
the	O
risk	O
of	O
incidence	O
of	O
SLE	B-Disease
and	O
the	O
occurrence	O
of	O
some	O
SLE	B-Disease
manifestations	O
.	O
	
	
Defining	O
an	O
EPOR	O
-	O
regulated	O
transcriptome	O
for	O
primary	O
progenitors	O
","	O
including	O
Tnfr	O
-	O
sf13c	O
as	O
a	O
novel	O
mediator	O
of	O
EPO	O
-	O
dependent	O
erythroblast	O
formation	O
.	O
	
Certain	O
concepts	O
concerning	O
EPO	O
/	O
EPOR	O
action	O
modes	O
have	O
been	O
challenged	O
by	O
in	O
vivo	O
studies	O
:	O
Bcl	O
-	O
x	O
levels	O
are	O
elevated	O
in	O
maturing	O
erythroblasts	O
","	O
but	O
not	O
in	O
their	O
progenitors	O
";"	O
truncated	O
EPOR	O
alleles	O
that	O
lack	O
a	O
major	O
p85	O
/	O
PI3K	O
recruitment	O
site	O
nonetheless	O
promote	O
polycythemia	B-Disease
";"	O
and	O
Erk1	O
disruption	O
unexpectedly	O
bolsters	O
erythropoiesis	O
.	O
	
To	O
discover	O
novel	O
EPO	O
/	O
EPOR	O
action	O
routes	O
","	O
global	O
transcriptome	O
analyses	O
presently	O
are	O
applied	O
to	O
interrogate	O
EPO	O
/	O
EPOR	O
effects	O
on	O
primary	O
bone	O
marrow	O
-	O
derived	O
CFUe	O
-	O
like	O
progenitors	O
.	O
	
Overall	O
","	O
160	O
EPO	O
/	O
EPOR	O
target	O
transcripts	O
were	O
significantly	O
modulated	O
2	O
-	O
to	O
21	O
.	O
8	O
-	O
fold	O
.	O
	
A	O
unique	O
set	O
of	O
EPO	O
-	O
regulated	O
survival	O
factors	O
included	O
Lyl1	O
","	O
Gas5	O
","	O
Pim3	O
","	O
Pim1	O
","	O
Bim	O
","	O
Trib3	O
and	O
Serpina	O
3g	O
.	O
	
EPO	O
/	O
EPOR	O
-	O
modulated	O
cell	O
cycle	O
mediators	O
included	O
Cdc25a	O
","	O
Btg3	O
","	O
Cyclin	O
-	O
d2	O
","	O
p27	O
-	O
kip1	O
","	O
Cyclin	O
-	O
g2	O
and	O
CyclinB1	O
-	O
IP	O
-	O
1	O
.	O
	
EPO	O
regulation	O
of	O
signal	O
transduction	O
factors	O
was	O
also	O
interestingly	O
complex	O
.	O
	
For	O
example	O
","	O
not	O
only	O
Socs3	O
plus	O
Socs2	O
but	O
also	O
Spred2	O
","	O
Spred1	O
and	O
Eaf1	O
were	O
EPO	O
-	O
induced	O
as	O
negative	O
-	O
feedback	O
components	O
.	O
	
Socs2	O
","	O
plus	O
five	O
additional	O
targets	O
","	O
further	O
proved	O
to	O
comprise	O
new	O
EPOR	O
/	O
Jak2	O
/	O
Stat5	O
response	O
genes	O
(	O
which	O
are	O
important	O
for	O
erythropoiesis	O
during	O
anemia	B-Disease
).	O
	
Among	O
receptors	O
","	O
an	O
atypical	O
TNF	O
-	O
receptor	O
Tnfr	O
-	O
sf13c	O
was	O
up	O
-	O
modulated	O
>	O
5	O
-	O
fold	O
by	O
EPO	O
.	O
	
Functionally	O
","	O
Tnfr	O
-	O
sf13c	O
ligation	O
proved	O
to	O
both	O
promote	O
proerythroblast	O
survival	O
","	O
and	O
substantially	O
enhance	O
erythroblast	O
formation	O
.	O
	
The	O
EPOR	O
therefore	O
engages	O
a	O
sophisticated	O
set	O
of	O
transcriptome	O
response	O
circuits	O
","	O
with	O
Tnfr	O
-	O
sf13c	O
deployed	O
as	O
one	O
novel	O
positive	O
regulator	O
of	O
proerythroblast	O
formation	O
.	O
	
	
Association	O
of	O
common	O
genetic	O
variants	O
of	O
HOMER1	O
gene	O
with	O
levodopa	B-Chemical
adverse	O
effects	O
in	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
patients	O
.	O
	
Levodopa	B-Chemical
is	O
the	O
most	O
effective	O
symptomatic	O
therapy	O
for	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
","	O
but	O
its	O
chronic	O
use	O
could	O
lead	O
to	O
chronic	O
adverse	O
outcomes	O
","	O
such	O
as	O
motor	O
fluctuations	O
","	O
dyskinesia	B-Disease
and	O
visual	B-Disease
hallucinations	I-Disease
.	O
	
HOMER1	O
is	O
a	O
protein	O
with	O
pivotal	O
function	O
in	O
glutamate	B-Chemical
transmission	O
","	O
which	O
has	O
been	O
related	O
to	O
the	O
pathogenesis	O
of	O
these	O
complications	O
.	O
	
This	O
study	O
investigates	O
whether	O
polymorphisms	O
in	O
the	O
HOMER1	O
gene	O
promoter	O
region	O
are	O
associated	O
with	O
the	O
occurrence	O
of	O
the	O
chronic	O
complications	O
of	O
levodopa	B-Chemical
therapy	O
.	O
	
A	O
total	O
of	O
205	O
patients	O
with	O
idiopathic	B-Disease
Parkinson	I-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
were	O
investigated	O
.	O
	
Patients	O
were	O
genotyped	O
for	O
rs4704559	O
","	O
rs10942891	O
and	O
rs4704560	O
by	O
allelic	O
discrimination	O
with	O
Taqman	O
assays	O
.	O
	
The	O
rs4704559	O
G	O
allele	O
was	O
associated	O
with	O
a	O
lower	O
prevalence	O
of	O
dyskinesia	B-Disease
(	O
prevalence	O
ratio	O
(	O
PR	O
)=	O
0	O
.	O
615	O
","	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0	O
.	O
426	O
-	O
0	O
.	O
887	O
","	O
P	O
=	O
0	O
.	O
9	O
)	O
and	O
visual	B-Disease
hallucinations	I-Disease
(	O
PR	O
=	O
0	O
.	O
515	O
","	O
95	O
%	O
CI	O
0	O
.	O
295	O
-	O
0	O
.	O
899	O
","	O
P	O
=	O
0	O
.	O
20	O
).	O
	
Our	O
data	O
suggest	O
that	O
HOMER1	O
rs4704559	O
G	O
allele	O
has	O
a	O
protective	O
role	O
for	O
the	O
development	O
of	O
levodopa	B-Chemical
adverse	O
effects	O
.	O
	
	
Midline	O
B3	O
serotonin	B-Chemical
nerves	O
in	O
rat	O
medulla	O
are	O
involved	O
in	O
hypotensive	B-Disease
effect	O
of	O
methyldopa	B-Chemical
.	O
	
Previous	O
experiments	O
in	O
this	O
laboratory	O
have	O
shown	O
that	O
microinjection	O
of	O
methyldopa	B-Chemical
onto	O
the	O
ventrolateral	O
cells	O
of	O
the	O
B3	O
serotonin	B-Chemical
neurons	O
in	O
the	O
medulla	O
elicits	O
a	O
hypotensive	B-Disease
response	O
mediated	O
by	O
a	O
projection	O
descending	O
into	O
the	O
spinal	O
cord	O
.	O
	
The	O
present	O
experiments	O
were	O
designed	O
to	O
investigate	O
the	O
role	O
of	O
the	O
midline	O
cells	O
of	O
the	O
B3	O
serotonin	B-Chemical
neurons	O
in	O
the	O
medulla	O
","	O
coinciding	O
with	O
the	O
raphe	O
magnus	O
.	O
	
In	O
spontaneously	O
hypertensive	B-Disease
","	O
stroke	B-Disease
-	O
prone	O
rats	O
","	O
microinjection	O
of	O
methyldopa	B-Chemical
into	O
the	O
area	O
of	O
the	O
midline	O
B3	O
serotonin	B-Chemical
cell	O
group	O
in	O
the	O
ventral	O
medulla	O
caused	O
a	O
potent	O
hypotension	B-Disease
of	O
30	O
-	O
40	O
mm	O
Hg	O
","	O
which	O
was	O
maximal	O
2	O
-	O
3	O
h	O
after	O
administration	O
and	O
was	O
abolished	O
by	O
the	O
serotonin	B-Chemical
neurotoxin	O
5	B-Chemical
","	I-Chemical
7	I-Chemical
-	I-Chemical
dihydroxytryptamine	I-Chemical
(	O
5	B-Chemical
","	I-Chemical
7	I-Chemical
-	I-Chemical
DHT	I-Chemical
)	O
injected	O
intracerebroventricularly	O
.	O
	
However	O
","	O
intraspinal	O
injection	O
of	O
5	B-Chemical
","	I-Chemical
7	I-Chemical
-	I-Chemical
DHT	I-Chemical
to	O
produce	O
a	O
more	O
selective	O
lesion	O
of	O
only	O
descending	O
serotonin	B-Chemical
projections	O
in	O
the	O
spinal	O
cord	O
did	O
not	O
affect	O
this	O
hypotension	B-Disease
.	O
	
Further	O
","	O
5	B-Chemical
","	I-Chemical
7	I-Chemical
-	I-Chemical
DHT	I-Chemical
lesion	O
of	O
serotonin	B-Chemical
nerves	O
travelling	O
in	O
the	O
median	O
forebrain	O
bundle	O
","	O
one	O
of	O
the	O
main	O
ascending	O
pathways	O
from	O
the	O
B3	O
serotonin	B-Chemical
cells	O
","	O
did	O
not	O
affect	O
the	O
fall	O
in	O
blood	O
pressure	O
associated	O
with	O
a	O
midline	O
B3	O
serotonin	B-Chemical
methyldopa	I-Chemical
injection	O
.	O
	
It	O
is	O
concluded	O
therefore	O
that	O
","	O
unlike	O
the	O
ventrolateral	O
B3	O
cells	O
which	O
mediate	O
a	O
methyldopa	B-Chemical
-	O
induced	O
hypotension	B-Disease
via	O
descending	O
projections	O
","	O
the	O
midline	O
serotonin	B-Chemical
B3	O
cells	O
in	O
the	O
medulla	O
contribute	O
to	O
the	O
hypotensive	B-Disease
action	O
of	O
methyldopa	B-Chemical
","	O
either	O
by	O
way	O
of	O
an	O
ascending	O
projection	O
which	O
does	O
not	O
pass	O
through	O
the	O
median	O
forebrain	O
bundle	O
","	O
or	O
through	O
a	O
projection	O
restricted	O
to	O
the	O
caudal	O
brainstem	O
.	O
	
	
Endothelial	O
NADPH	O
oxidase	O
4	O
mediates	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
-	O
induced	O
intravitreal	O
neovascularization	O
in	O
a	O
rat	O
model	O
of	O
retinopathy	B-Disease
of	I-Disease
prematurity	I-Disease
.	O
	
PURPOSE	O
:	O
NADPH	O
oxidase	O
-	O
generated	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
(	O
ROS	B-Chemical
)	O
are	O
implicated	O
in	O
angiogenesis	O
.	O
	
Isoforms	O
of	O
NADPH	O
oxidase	O
NOX1	O
","	O
NOX2	O
","	O
and	O
NOX4	O
are	O
reported	O
to	O
be	O
expressed	O
in	O
endothelial	O
cells	O
(	O
ECs	O
).	O
	
Of	O
these	O
","	O
NOX1	O
and	O
NOX2	O
have	O
been	O
reported	O
to	O
contribute	O
to	O
intravitreal	O
neovascularization	O
(	O
IVNV	O
)	O
in	O
oxygen	B-Chemical
-	O
induced	O
retinopathy	B-Disease
(	O
OIR	B-Disease
)	O
models	O
.	O
	
In	O
this	O
study	O
","	O
we	O
tested	O
the	O
hypothesis	O
that	O
the	O
isoform	O
NOX4	O
in	O
ECs	O
contributed	O
to	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)-	O
induced	O
angiogenesis	O
and	O
IVNV	O
.	O
	
METHODS	O
:	O
Isoforms	O
of	O
NADPH	O
oxidase	O
MRNA	O
were	O
measured	O
in	O
several	O
types	O
of	O
cultured	O
vascular	O
ecs	O
:	O
human	O
retinal	O
microvascular	O
ECs	O
(	O
hRMVECs	O
)","	O
choroidal	O
ECs	O
(	O
CECs	O
)","	O
and	O
human	O
umbilical	O
vascular	O
ECs	O
(	O
HUVECs	O
)	O
using	O
real	O
-	O
time	O
PCR	O
.	O
	
Newborn	O
rat	O
pups	O
and	O
dams	O
were	O
placed	O
into	O
an	O
OIR	B-Disease
model	O
that	O
cycled	O
oxygen	B-Chemical
concentration	O
between	O
50	O
%	O
and	O
10	O
%	O
every	O
24	O
h	O
for	O
14	O
days	O
","	O
and	O
then	O
were	O
placed	O
in	O
room	O
air	O
(	O
RA	O
)	O
for	O
an	O
additional	O
4	O
days	O
(	O
rat	O
OIR	B-Disease
model	O
).	O
	
NOX4	O
expression	O
in	O
retinal	O
lysates	O
from	O
the	O
RA	O
-	O
raised	O
pups	O
at	O
postnatal	O
day	O
0	O
(	O
P0	O
)","	O
P14	O
","	O
and	O
P18	O
was	O
determined	O
with	O
western	O
blots	O
.	O
	
STAT3	O
activation	O
was	O
determined	O
as	O
the	O
ratio	O
of	O
phosphorylated	O
STAT3	O
to	O
total	O
STAT3	O
with	O
western	O
blot	O
analysis	O
of	O
retinal	O
lysates	O
from	O
pups	O
raised	O
in	O
RA	O
or	O
from	O
the	O
rat	O
OIR	B-Disease
model	O
at	O
P18	O
.	O
	
Semiquantitative	O
assessment	O
of	O
the	O
density	O
of	O
NOX4	O
colabeling	O
with	O
lectin	O
-	O
stained	O
retinal	O
ECs	O
was	O
determined	O
by	O
immunolabeling	O
of	O
retinal	O
cryosections	O
from	O
P18	O
pups	O
in	O
OIR	B-Disease
or	O
in	O
RA	O
.	O
	
In	O
hRMVECs	O
transfected	O
with	O
NOX4	O
siRNA	O
and	O
treated	O
with	O
VEGF	O
or	O
control	O
","	O
1	O
)	O
ROS	B-Chemical
generation	O
was	O
measured	O
using	O
the	O
5	B-Chemical
-(	I-Chemical
and	I-Chemical
-	I-Chemical
6	I-Chemical
)-	I-Chemical
chloromethyl	I-Chemical
-	I-Chemical
2	I-Chemical
'","	I-Chemical
7	I-Chemical
'-	I-Chemical
dichlorodihydrofluorescein	I-Chemical
diacetate	I-Chemical
","	I-Chemical
acetyl	I-Chemical
ester	I-Chemical
fluorescence	O
assay	O
and	O
2	O
)	O
phosphorylated	O
VEGF	O
receptor	O
2	O
and	O
STAT3	O
","	O
and	O
total	O
VEGFR2	O
and	O
STAT3	O
were	O
measured	O
in	O
western	O
blot	O
analyses	O
.	O
	
VEGF	O
-	O
stimulated	O
hRMVEC	O
proliferation	O
was	O
measured	O
following	O
transfection	O
with	O
NOX4	O
siRNA	O
or	O
STAT3	O
siRNA	O
","	O
or	O
respective	O
controls	O
.	O
	
RESULTS	O
:	O
NOX4	O
was	O
the	O
most	O
prevalent	O
isoform	O
of	O
NADPH	O
oxidase	O
in	O
vascular	O
ECs	O
.	O
	
NOX4	O
expression	O
in	O
retinal	O
lysates	O
was	O
significantly	O
decreased	O
during	O
development	O
in	O
RA	O
.	O
	
Compared	O
to	O
RA	O
","	O
the	O
expression	O
of	O
retinal	O
NOX4	O
increased	O
at	O
P18	O
.	O
	
At	O
p18	O
OIR	B-Disease
","	O
semiquantitative	O
assessment	O
of	O
the	O
density	O
of	O
lectin	O
and	O
NOX4	O
colabeling	O
in	O
retinal	O
vascular	O
ECs	O
was	O
greater	O
in	O
retinal	O
cryosections	O
and	O
activated	O
STAT3	O
was	O
greater	O
in	O
retinal	O
lysates	O
when	O
compared	O
to	O
the	O
RA	O
-	O
raised	O
pups	O
.	O
	
In	O
cultured	O
hRMVECs	O
","	O
knockdown	O
of	O
NOX4	O
by	O
siRNA	O
transfection	O
inhibited	O
VEGF	O
-	O
induced	O
ROS	B-Chemical
generation	O
.	O
	
VEGF	O
induced	O
a	O
physical	O
interaction	O
of	O
phosphorylated	O
-	O
VEGFR2	O
and	O
NOX4	O
.	O
	
Knockdown	O
of	O
NOX4	O
:	O
1	O
)	O
reduced	O
VEGFR2	O
activation	O
but	O
did	O
not	O
abolish	O
it	O
and	O
2	O
)	O
abolished	O
STAT3	O
activation	O
in	O
response	O
to	O
VEGF	O
.	O
	
Knockdown	O
of	O
either	O
NOX4	O
or	O
STAT3	O
inhibited	O
VEGF	O
-	O
induced	O
EC	O
proliferation	O
.	O
	
CONCLUSIONS	O
:	O
Our	O
data	O
suggest	O
that	O
in	O
a	O
model	O
representative	O
of	O
human	O
retinopathy	B-Disease
of	I-Disease
prematurity	I-Disease
","	O
NOX4	O
was	O
increased	O
at	O
a	O
time	O
point	O
when	O
IVNV	O
developed	O
.	O
	
VEGF	O
-	O
activated	O
NOX4	O
led	O
to	O
an	O
interaction	O
between	O
VEGF	O
-	O
activated	O
VEGFR2	O
and	O
NOX4	O
that	O
mediated	O
EC	O
proliferation	O
via	O
activation	O
of	O
STAT3	O
.	O
	
Altogether	O
","	O
our	O
results	O
suggest	O
that	O
NOX4	O
may	O
regulate	O
VEGFR2	O
-	O
mediated	O
IVNV	O
through	O
activated	O
STAT3	O
.	O
	
	
Disruption	O
of	O
the	O
temporally	O
regulated	O
cloaca	O
endodermal	O
b	O
-	O
catenin	O
signaling	O
causes	O
anorectal	B-Disease
malformations	I-Disease
.	O
	
The	O
cloaca	O
is	O
temporally	O
formed	O
and	O
eventually	O
divided	O
by	O
the	O
urorectal	O
septum	O
(	O
URS	O
)	O
during	O
urogenital	O
and	O
anorectal	O
organ	O
development	O
.	O
	
Although	O
congenital	B-Disease
malformations	I-Disease
","	O
such	O
as	O
anorectal	B-Disease
malformations	I-Disease
(	O
ARMs	B-Disease
)","	O
are	O
frequently	O
observed	O
during	O
this	O
process	O
","	O
the	O
underlying	O
pathogenic	O
mechanisms	O
remain	O
unclear	O
.	O
	
b	O
-	O
Catenin	O
is	O
a	O
critical	O
component	O
of	O
canonical	O
Wnt	O
signaling	O
and	O
is	O
essential	O
for	O
the	O
regulation	O
of	O
cell	O
differentiation	O
and	O
morphogenesis	O
during	O
embryogenesis	O
.	O
	
The	O
expression	O
of	O
b	O
-	O
catenin	O
is	O
observed	O
in	O
endodermal	O
epithelia	O
","	O
including	O
URS	O
epithelia	O
.	O
	
We	O
modulated	O
the	O
b	O
-	O
catenin	O
gene	O
conditionally	O
in	O
endodermal	O
epithelia	O
by	O
utilizing	O
tamoxifen	B-Chemical
-	O
inducible	O
Cre	O
driver	O
line	O
(	O
Shh	O
(	O
CreERT2	O
)).	O
	
Both	O
b	O
-	O
catenin	O
loss	O
-	O
and	O
gain	O
-	O
of	O
-	O
function	O
(	O
LOF	O
and	O
GOF	O
)	O
mutants	O
displayed	O
abnormal	O
clefts	O
in	O
the	O
perineal	O
region	O
and	O
hypoplastic	B-Disease
elongation	O
of	O
the	O
URS	O
.	O
	
The	O
mutants	O
also	O
displayed	O
reduced	O
cell	O
proliferation	O
in	O
the	O
URS	O
mesenchyme	O
.	O
	
In	O
addition	O
","	O
the	O
b	O
-	O
catenin	O
GOF	O
mutants	O
displayed	O
reduced	O
apoptosis	O
and	O
subsequently	O
increased	O
apoptosis	O
in	O
the	O
URS	O
epithelium	O
.	O
	
This	O
instability	O
possibly	O
resulted	O
in	O
reduced	O
expression	O
levels	O
of	O
differentiation	O
markers	O
","	O
such	O
as	O
keratin	O
1	O
and	O
filaggrin	O
","	O
in	O
the	O
perineal	O
epithelia	O
.	O
	
The	O
expression	O
of	O
bone	O
morphogenetic	O
protein	O
(	O
Bmp	O
)	O
genes	O
","	O
such	O
as	O
Bmp4	O
and	O
Bmp7	O
","	O
was	O
also	O
ectopically	O
induced	O
in	O
the	O
epithelia	O
of	O
the	O
URS	O
in	O
the	O
b	O
-	O
catenin	O
GOF	O
mutants	O
.	O
	
The	O
expression	O
of	O
the	O
Msx2	O
gene	O
and	O
phosphorylated	O
-	O
Smad1	O
/	O
5	O
/	O
8	O
","	O
possible	O
readouts	O
of	O
Bmp	O
signaling	O
","	O
was	O
also	O
increased	O
in	O
the	O
mutants	O
.	O
	
Moreover	O
","	O
we	O
introduced	O
an	O
additional	O
mutation	O
for	O
a	O
Bmp	O
receptor	O
gene	O
:	O
BmprIA	O
.	O
	
The	O
Shh	O
(	O
CreERT2	O
"/+);"	O
b	O
-	O
catenin	O
(	O
flox	O
(	O
ex3	O
")/+);"	O
BmprIA	O
(	O
flox	O
/-)	O
mutants	O
displayed	O
partial	O
restoration	O
of	O
URS	O
elongation	O
compared	O
with	O
the	O
b	O
-	O
catenin	O
GOF	O
mutants	O
.	O
	
These	O
results	O
indicate	O
that	O
some	O
ARM	B-Disease
phenotypes	O
in	O
the	O
b	O
-	O
catenin	O
GOF	O
mutants	O
were	O
caused	O
by	O
abnormal	O
Bmp	O
signaling	O
.	O
	
The	O
current	O
analysis	O
revealed	O
the	O
close	O
relation	O
of	O
endodermal	O
b	O
-	O
catenin	O
signaling	O
to	O
the	O
ARM	B-Disease
phenotypes	O
.	O
	
These	O
results	O
are	O
considered	O
to	O
shed	O
light	O
on	O
the	O
pathogenic	O
mechanisms	O
of	O
human	O
ARMs	B-Disease
.	O
	
	
Behavioral	O
and	O
neurochemical	O
studies	O
in	O
mice	O
pretreated	O
with	O
garcinielliptone	B-Chemical
FC	I-Chemical
in	O
pilocarpine	B-Chemical
-	O
induced	O
seizures	B-Disease
.	O
	
Garcinielliptone	B-Chemical
FC	I-Chemical
(	O
GFC	B-Chemical
)	O
isolated	O
from	O
hexanic	O
fraction	O
seed	O
extract	O
of	O
species	O
Platonia	O
insignis	O
Mart	O
.	O
	
It	O
is	O
widely	O
used	O
in	O
folk	O
medicine	O
to	O
treat	O
skin	B-Disease
diseases	I-Disease
in	O
both	O
humans	O
and	O
animals	O
as	O
well	O
as	O
the	O
seed	O
decoction	O
has	O
been	O
used	O
to	O
treat	O
diarrheas	B-Disease
and	O
inflammatory	B-Disease
diseases	I-Disease
.	O
	
However	O
","	O
there	O
is	O
no	O
research	O
on	O
GFC	B-Chemical
effects	O
in	O
the	O
central	O
nervous	O
system	O
of	O
rodents	O
.	O
	
The	O
present	O
study	O
aimed	O
to	O
evaluate	O
the	O
GFC	B-Chemical
effects	O
at	O
doses	O
of	O
25	O
","	O
50	O
or	O
75	O
mg	O
/	O
kg	O
on	O
seizure	B-Disease
parameters	O
to	O
determine	O
their	O
anticonvulsant	O
activity	O
and	O
its	O
effects	O
on	O
amino	O
acid	O
(	O
r	B-Chemical
-	I-Chemical
aminobutyric	I-Chemical
acid	I-Chemical
(	O
GABA	B-Chemical
)","	O
glutamine	B-Chemical
","	O
aspartate	B-Chemical
and	O
glutathione	B-Chemical
)	O
levels	O
as	O
well	O
as	O
on	O
acetylcholinesterase	O
(	O
AChE	O
)	O
activity	O
in	O
mice	O
hippocampus	O
after	O
seizures	B-Disease
.	O
	
GFC	B-Chemical
produced	O
an	O
increased	O
latency	O
to	O
first	O
seizure	B-Disease
","	O
at	O
doses	O
25mg	O
/	O
kg	O
(	O
20	O
.	O
12	O
+	O
2	O
.	O
20	O
min	O
)","	O
50mg	O
/	O
kg	O
(	O
20	O
.	O
95	O
+	O
2	O
.	O
21	O
min	O
)	O
or	O
75	O
mg	O
/	O
kg	O
(	O
23	O
.	O
43	O
+	O
1	O
.	O
99	O
min	O
)	O
when	O
compared	O
with	O
seized	O
mice	O
.	O
	
In	O
addition	O
","	O
GABA	B-Chemical
content	O
of	O
mice	O
hippocampus	O
treated	O
with	O
GFC75	B-Chemical
plus	O
P400	B-Chemical
showed	O
an	O
increase	O
of	O
46	O
.	O
90	O
%	O
when	O
compared	O
with	O
seized	O
mice	O
.	O
	
In	O
aspartate	B-Chemical
","	O
glutamine	B-Chemical
and	O
glutamate	B-Chemical
levels	O
detected	O
a	O
decrease	O
of	O
5	O
.	O
21	O
%","	O
13	O
.	O
55	O
%	O
and	O
21	O
.	O
80	O
%","	O
respectively	O
in	O
mice	O
hippocampus	O
treated	O
with	O
GFC75	B-Chemical
plus	O
P400	B-Chemical
when	O
compared	O
with	O
seized	O
mice	O
.	O
	
Hippocampus	O
mice	O
treated	O
with	O
GFC75	B-Chemical
plus	O
P400	B-Chemical
showed	O
an	O
increase	O
in	O
AChE	O
activity	O
(	O
63	O
.	O
30	O
%)	O
when	O
compared	O
with	O
seized	O
mice	O
.	O
	
The	O
results	O
indicate	O
that	O
GFC	B-Chemical
can	O
exert	O
anticonvulsant	O
activity	O
and	O
reduce	O
the	O
frequency	O
of	O
installation	O
of	O
pilocarpine	B-Chemical
-	O
induced	O
status	B-Disease
epilepticus	I-Disease
","	O
as	O
demonstrated	O
by	O
increase	O
in	O
latency	O
to	O
first	O
seizure	B-Disease
and	O
decrease	O
in	O
mortality	O
rate	O
of	O
animals	O
.	O
	
In	O
conclusion	O
","	O
our	O
data	O
suggest	O
that	O
GFC	B-Chemical
may	O
influence	O
in	O
epileptogenesis	O
and	O
promote	O
anticonvulsant	O
actions	O
in	O
pilocarpine	B-Chemical
model	O
by	O
modulating	O
the	O
GABA	B-Chemical
and	O
glutamate	B-Chemical
contents	O
and	O
of	O
AChE	O
activity	O
in	O
seized	O
mice	O
hippocampus	O
.	O
	
This	O
compound	O
may	O
be	O
useful	O
to	O
produce	O
neuronal	O
protection	O
and	O
it	O
can	O
be	O
considered	O
as	O
an	O
anticonvulsant	O
agent	O
.	O
	
	
Conversion	O
to	O
sirolimus	B-Chemical
ameliorates	O
cyclosporine	B-Chemical
-	O
induced	O
nephropathy	B-Disease
in	O
the	O
rat	O
:	O
focus	O
on	O
serum	O
","	O
urine	O
","	O
gene	O
","	O
and	O
protein	O
renal	O
expression	O
biomarkers	O
.	O
	
Protocols	O
of	O
conversion	O
from	O
cyclosporin	B-Chemical
A	I-Chemical
(	O
CsA	B-Chemical
)	O
to	O
sirolimus	B-Chemical
(	O
SRL	B-Chemical
)	O
have	O
been	O
widely	O
used	O
in	O
immunotherapy	O
after	O
transplantation	O
to	O
prevent	O
CsA	B-Chemical
-	O
induced	O
nephropathy	B-Disease
","	O
but	O
the	O
molecular	O
mechanisms	O
underlying	O
these	O
protocols	O
remain	O
nuclear	O
.	O
	
This	O
study	O
aimed	O
to	O
identify	O
the	O
molecular	O
pathways	O
and	O
putative	O
biomarkers	O
of	O
CsA	B-Chemical
-	O
to	O
-	O
SRL	B-Chemical
conversion	O
in	O
a	O
rat	O
model	O
.	O
	
Four	O
animal	O
groups	O
(	O
n	O
=	O
6	O
)	O
were	O
tested	O
during	O
9	O
weeks	O
:	O
control	O
","	O
CsA	B-Chemical
","	O
SRL	B-Chemical
","	O
and	O
conversion	O
(	O
CsA	B-Chemical
for	O
3	O
weeks	O
followed	O
by	O
SRL	B-Chemical
for	O
6	O
weeks	O
).	O
	
Classical	O
and	O
emergent	O
serum	O
","	O
urinary	O
","	O
and	O
kidney	O
tissue	O
(	O
gene	O
and	O
protein	O
expression	O
)	O
markers	O
were	O
assessed	O
.	O
	
Renal	B-Disease
lesions	I-Disease
were	O
analyzed	O
in	O
hematoxylin	O
and	O
eosin	O
","	O
periodic	O
acid	O
-	O
Schiff	O
","	O
and	O
Masson	O
'	O
s	O
trichrome	O
stains	O
.	O
	
SRL	B-Chemical
-	O
treated	O
rats	O
presented	O
proteinuria	B-Disease
and	O
NGAL	O
(	O
serum	O
and	O
urinary	O
)	O
as	O
the	O
best	O
markers	O
of	O
renal	B-Disease
impairment	I-Disease
.	O
	
Short	O
CsA	B-Chemical
treatment	O
presented	O
slight	O
or	O
even	O
absent	O
kidney	B-Disease
lesions	I-Disease
and	O
TGF	O
-	O
b	O
","	O
NF	O
-	O
kb	O
","	O
mTOR	O
","	O
PCNA	O
","	O
TP53	O
","	O
KIM	O
-	O
1	O
","	O
and	O
CTGF	O
as	O
relevant	O
gene	O
and	O
protein	O
changes	O
.	O
	
Prolonged	O
CsA	B-Chemical
exposure	O
aggravated	O
renal	B-Disease
damage	I-Disease
","	O
without	O
clear	O
changes	O
on	O
the	O
traditional	O
markers	O
","	O
but	O
with	O
changes	O
in	O
serums	O
TGF	O
-	O
b	O
and	O
IL	O
-	O
7	O
","	O
TBARs	B-Chemical
clearance	O
","	O
and	O
kidney	O
TGF	O
-	O
b	O
and	O
mTOR	O
.	O
	
Conversion	O
to	O
SRL	B-Chemical
prevented	O
CsA	B-Chemical
-	O
induced	O
renal	B-Disease
damage	I-Disease
evolution	O
(	O
absent	O
/	O
mild	O
grade	O
lesions	O
)","	O
while	O
NGAL	O
(	O
serum	O
versus	O
urine	O
)	O
seems	O
to	O
be	O
a	O
feasible	O
biomarker	O
of	O
CsA	B-Chemical
replacement	O
to	O
SRL	B-Chemical
.	O
	
	
Characterization	O
of	O
a	O
novel	O
BCHE	O
silent	O
allele	O
:	O
point	O
mutation	O
(	O
p	O
.	O
Val204Asp	O
)	O
causes	O
loss	O
of	O
activity	O
and	O
prolonged	O
apnea	B-Disease
with	O
suxamethonium	B-Chemical
.	O
	
Butyrylcholinesterase	B-Disease
deficiency	I-Disease
is	O
characterized	O
by	O
prolonged	O
apnea	B-Disease
after	O
the	O
use	O
of	O
muscle	B-Chemical
relaxants	I-Chemical
(	O
suxamethonium	B-Chemical
or	O
mivacurium	B-Chemical
)	O
in	O
patients	O
who	O
have	O
mutations	O
in	O
the	O
BCHE	O
gene	O
.	O
	
Here	O
","	O
we	O
report	O
a	O
case	O
of	O
prolonged	O
neuromuscular	B-Disease
block	I-Disease
after	O
administration	O
of	O
suxamethonium	B-Chemical
leading	O
to	O
the	O
discovery	O
of	O
a	O
novel	O
BCHE	O
variant	O
(	O
c	O
.	O
695T	O
>	O
A	O
","	O
p	O
.	O
Val204Asp	O
).	O
	
Inhibition	O
studies	O
","	O
kinetic	O
analysis	O
and	O
molecular	O
dynamics	O
were	O
undertaken	O
to	O
understand	O
how	O
this	O
mutation	O
disrupts	O
the	O
catalytic	O
triad	O
and	O
determines	O
a	O
silent	O
phenotype	O
.	O
	
Low	O
activity	O
of	O
patient	O
plasma	O
butyrylcholinesterase	O
with	O
butyrylthiocholine	B-Chemical
(	O
BTC	B-Chemical
)	O
and	O
benzoylcholine	B-Chemical
","	O
and	O
values	O
of	O
dibucaine	B-Chemical
and	O
fluoride	B-Chemical
numbers	O
fit	O
with	O
heterozygous	O
atypical	O
silent	O
genotype	O
.	O
	
Electrophoretic	O
analysis	O
of	O
plasma	O
BChE	O
of	O
the	O
proband	O
and	O
his	O
mother	O
showed	O
that	O
patient	O
has	O
a	O
reduced	O
amount	O
of	O
tetrameric	O
enzyme	O
in	O
plasma	O
and	O
that	O
minor	O
fast	O
-	O
moving	O
BChE	O
components	O
:	O
monomer	O
","	O
dimer	O
","	O
and	O
monomer	O
-	O
albumin	O
conjugate	O
are	O
missing	O
.	O
	
Kinetic	O
analysis	O
showed	O
that	O
the	O
p	O
.	O
Val204Asp	O
/	O
p	O
.	O
Asp70Gly	O
-	O
p	O
.	O
Ala539Thr	O
BChE	O
displays	O
a	O
pure	O
Michaelian	O
behavior	O
with	O
BTC	B-Chemical
as	O
the	O
substrate	O
.	O
	
Both	O
catalytic	O
parameters	O
Km	O
=	O
265	O
uM	O
for	O
BTC	B-Chemical
","	O
two	O
times	O
higher	O
than	O
that	O
of	O
the	O
atypical	O
enzyme	O
","	O
and	O
a	O
low	O
Vmax	O
are	O
consistent	O
with	O
the	O
absence	O
of	O
activity	O
against	O
suxamethonium	B-Chemical
.	O
	
Molecular	O
dynamic	O
(	O
MD	O
)	O
simulations	O
showed	O
that	O
the	O
overall	O
effect	O
of	O
the	O
mutation	O
p	O
.	O
Val204Asp	O
is	O
disruption	O
of	O
hydrogen	O
bonding	O
between	O
Gln223	O
and	O
Glu441	O
","	O
leading	O
Ser198	O
and	O
His438	O
to	O
move	O
away	O
from	O
each	O
other	O
with	O
subsequent	O
disruption	O
of	O
the	O
catalytic	O
triad	O
functionality	O
regardless	O
of	O
the	O
type	O
of	O
substrate	O
.	O
	
MD	O
also	O
showed	O
that	O
the	O
enzyme	O
volume	O
is	O
increased	O
","	O
suggesting	O
a	O
pre	O
-	O
denaturation	O
state	O
.	O
	
This	O
fits	O
with	O
the	O
reduced	O
concentration	O
of	O
p	O
.	O
Ala204Asp	O
/	O
p	O
.	O
Asp70Gly	O
-	O
p	O
.	O
Ala539Thr	O
tetrameric	O
enzyme	O
in	O
the	O
plasma	O
and	O
non	O
-	O
detectable	O
fast	O
moving	O
-	O
bands	O
on	O
electrophoresis	O
gels	O
.	O
	
	
Inhibition	O
of	O
LDHA	O
suppresses	O
tumor	B-Disease
progression	O
in	O
prostate	B-Disease
cancer	I-Disease
.	O
	
A	O
key	O
hallmark	O
of	O
cancer	B-Disease
cells	O
is	O
their	O
altered	O
metabolism	O
","	O
known	O
as	O
Warburg	O
effect	O
.	O
	
Lactate	O
dehydrogenase	O
A	O
(	O
LDHA	O
)	O
executes	O
the	O
final	O
step	O
of	O
aerobic	O
glycolysis	O
and	O
has	O
been	O
reported	O
to	O
be	O
involved	O
in	O
the	O
tumor	B-Disease
progression	O
.	O
	
However	O
","	O
the	O
function	O
of	O
LDHA	O
in	O
prostate	B-Disease
cancer	I-Disease
has	O
not	O
been	O
studied	O
.	O
	
In	O
current	O
study	O
","	O
we	O
observed	O
overexpression	O
of	O
LDHA	O
in	O
the	O
clinical	O
prostate	B-Disease
cancer	I-Disease
samples	O
compared	O
with	O
benign	B-Disease
prostate	I-Disease
hyperplasia	I-Disease
tissues	O
as	O
demonstrated	O
by	O
immunohistochemistry	O
and	O
real	O
-	O
time	O
qPCR	O
.	O
	
Attenuated	O
expression	O
of	O
LDHA	O
by	O
siRNA	O
or	O
inhibition	O
of	O
LDHA	O
activities	O
by	O
FX11	B-Chemical
inhibited	O
cell	O
proliferation	O
","	O
migration	O
","	O
invasion	O
","	O
and	O
promoted	O
cell	O
apoptosis	O
of	O
PC	O
-	O
3	O
and	O
DU145	O
cells	O
.	O
	
Mechanistically	O
","	O
decreased	O
Warburg	O
effect	O
as	O
demonstrated	O
by	O
reduced	O
glucose	B-Chemical
consumption	O
and	O
lactate	B-Chemical
secretion	O
and	O
reduced	O
expression	O
of	O
MMP	O
-	O
9	O
","	O
PLAU	O
","	O
and	O
cathepsin	O
B	O
were	O
found	O
after	O
LDHA	O
knockdown	O
or	O
FX11	B-Chemical
treatment	O
in	O
PC	O
-	O
3	O
and	O
DU145	O
cells	O
.	O
	
Taken	O
together	O
","	O
our	O
study	O
revealed	O
the	O
oncogenic	O
role	O
of	O
LDHA	O
in	O
prostate	B-Disease
cancer	I-Disease
and	O
suggested	O
that	O
LDHA	O
might	O
be	O
a	O
potential	O
therapeutic	O
target	O
.	O
	
	
Erythropoietin	O
does	O
not	O
activate	O
erythropoietin	O
receptor	O
signaling	O
or	O
lipolytic	O
pathways	O
in	O
human	O
subcutaneous	O
white	O
adipose	O
tissue	O
in	O
vivo	O
.	O
	
BACKGROUND	O
:	O
Erythropoietin	O
(	O
Epo	O
)	O
exerts	O
direct	O
effects	O
on	O
white	O
adipose	O
tissue	O
(	O
WAT	O
)	O
in	O
mice	O
in	O
addition	O
to	O
its	O
erythropoietic	O
effects	O
","	O
and	O
in	O
humans	O
Epo	O
increases	O
resting	O
energy	O
expenditure	O
and	O
affect	O
serum	O
lipid	B-Chemical
levels	O
","	O
but	O
direct	O
effects	O
of	O
Epo	O
in	O
human	O
WAT	O
have	O
not	O
been	O
documented	O
.	O
	
We	O
therefore	O
investigated	O
the	O
effects	O
of	O
acute	O
and	O
prolonged	O
Epo	O
exposure	O
on	O
human	O
WAT	O
in	O
vivo	O
.	O
	
METHOD	O
:	O
Data	O
were	O
obtained	O
from	O
two	O
clinical	O
trials	O
:	O
1	O
)	O
acute	O
Epo	O
exposure	O
(	O
rHuEpo	O
","	O
400	O
IU	O
/	O
kg	O
)	O
followed	O
by	O
WAT	O
biopsies	O
after	O
1	O
h	O
and	O
2	O
)	O
10	O
weeks	O
treatment	O
with	O
the	O
erythropoiesis	B-Chemical
-	I-Chemical
stimulating	I-Chemical
agent	I-Chemical
(	O
ESA	B-Chemical
)	O
Darbepoietin	B-Chemical
-	I-Chemical
alpha	I-Chemical
.	O
	
Biopsies	O
were	O
analyzed	O
by	O
PCR	O
for	O
Epo	O
receptor	O
(	O
Epo	O
-	O
R	O
)	O
mRNA	O
.	O
	
A	O
new	O
and	O
highly	O
specific	O
antibody	O
(	O
A82	O
","	O
Amgen	O
)	O
was	O
used	O
to	O
evaluate	O
the	O
presence	O
of	O
Epo	O
-	O
R	O
by	O
western	O
blot	O
analysis	O
in	O
addition	O
to	O
Epo	O
-	O
R	O
signaling	O
proteins	O
(	O
Akt	O
","	O
STAT5	O
","	O
p70s6k	O
","	O
LYN	O
","	O
and	O
p38MAPK	O
)","	O
activation	O
of	O
lipolytic	O
pathways	O
(	O
ATGL	O
","	O
HSL	O
","	O
CGI	O
-	O
58	O
","	O
G0S2	O
","	O
Perilipin	O
","	O
Cidea	O
","	O
Cidec	O
","	O
AMPK	O
","	O
and	O
ACC	O
)","	O
and	O
mitochondrial	O
biogenesis	O
(	O
VDAC	O
","	O
HSP90	O
","	O
PDH	O
","	O
and	O
SDHA	O
).	O
	
RESULTS	O
:	O
No	O
evidence	O
of	O
in	O
vivo	O
activation	O
of	O
the	O
Epo	O
-	O
R	O
in	O
WAT	O
could	O
be	O
documented	O
despite	O
detectable	O
levels	O
of	O
Epo	O
-	O
R	O
mRNA	O
.	O
	
CONCLUSION	O
:	O
Thus	O
","	O
in	O
contradiction	O
to	O
animal	O
studies	O
","	O
Epo	O
treatment	O
within	O
a	O
physiological	O
relevant	O
range	O
in	O
humans	O
does	O
not	O
exert	O
direct	O
effects	O
in	O
a	O
subcutaneous	O
WAT	O
.	O
	
	
A	O
Critical	O
Role	O
for	O
the	O
Type	O
I	O
Interferon	O
Receptor	O
in	O
Virus	O
-	O
Induced	O
Autoimmune	B-Disease
Diabetes	I-Disease
in	O
Rats	O
.	O
	
The	O
pathogenesis	O
of	O
human	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
","	O
characterized	O
by	O
immune	O
-	O
mediated	O
damage	O
of	O
insulin	O
-	O
producing	O
b	O
-	O
cells	O
of	O
pancreatic	O
islets	O
","	O
may	O
involve	O
viral	B-Disease
infection	I-Disease
.	O
	
Essential	O
components	O
of	O
the	O
innate	O
immune	O
antiviral	O
response	O
","	O
including	O
type	O
I	O
interferon	O
(	O
IFN	O
)	O
and	O
IFN	O
receptor	O
-	O
mediated	O
signaling	O
pathways	O
","	O
are	O
candidates	O
for	O
determining	O
susceptibility	O
to	O
human	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
.	O
	
Numerous	O
aspects	O
of	O
human	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
pathogenesis	O
are	O
recapitulated	O
in	O
the	O
LEW	O
.	O
1WR1	O
rat	O
model	O
.	O
	
Diabetes	B-Disease
can	O
be	O
induced	O
in	O
LEW	O
.	O
1WR1	O
weanling	O
rats	O
challenged	O
with	O
virus	O
or	O
with	O
the	O
viral	O
mimetic	O
polyinosinic	B-Chemical
:	I-Chemical
polycytidylic	I-Chemical
acid	I-Chemical
(	O
poly	B-Chemical
I	I-Chemical
:	I-Chemical
C	I-Chemical
).	O
	
We	O
hypothesized	O
that	O
disrupting	O
the	O
cognate	O
type	O
I	O
IFN	O
receptor	O
(	O
type	O
I	O
IFN	O
a	O
/	O
b	O
receptor	O
[	O
IFNAR	O
])	O
to	O
interrupt	O
IFN	O
signaling	O
would	O
prevent	O
or	O
delay	O
the	O
development	O
of	O
virus	O
-	O
induced	O
diabetes	B-Disease
.	O
	
We	O
generated	O
IFNAR1	O
subunit	O
-	O
deficient	O
LEW	O
.	O
1WR1	O
rats	O
using	O
CRISPR	O
-	O
Cas9	O
(	O
clustered	O
regularly	O
interspaced	O
short	O
palindromic	O
repeats	O
-	O
associated	O
protein	O
9	O
)	O
genome	O
editing	O
and	O
confirmed	O
functional	O
disruption	O
of	O
the	O
Ifnar1	O
gene	O
.	O
	
IFNAR1	O
deficiency	O
significantly	O
delayed	O
the	O
onset	O
and	O
frequency	O
of	O
diabetes	B-Disease
and	O
greatly	O
reduced	O
the	O
intensity	O
of	O
insulitis	B-Disease
after	O
poly	B-Chemical
I	I-Chemical
:	I-Chemical
C	I-Chemical
treatment	O
.	O
	
The	O
occurrence	O
of	O
Kilham	O
rat	O
virus	O
-	O
induced	O
diabetes	B-Disease
was	O
also	O
diminished	O
in	O
IFNAR1	O
-	O
deficient	O
animals	O
.	O
	
These	O
findings	O
firmly	O
establish	O
that	O
alterations	O
in	O
innate	O
immunity	O
influence	O
the	O
course	O
of	O
autoimmune	B-Disease
diabetes	I-Disease
and	O
support	O
the	O
use	O
of	O
targeted	O
strategies	O
to	O
limit	O
or	O
prevent	O
the	O
development	O
of	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
.	O
	
	
Genetic	O
Variation	O
at	O
the	O
Sulfonylurea	O
Receptor	O
","	O
Type	B-Disease
2	I-Disease
Diabetes	I-Disease
","	O
and	O
Coronary	B-Disease
Heart	I-Disease
Disease	I-Disease
.	O
	
Despite	O
widespread	O
clinical	O
use	O
in	O
the	O
treatment	O
of	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
","	O
the	O
impact	O
of	O
sulfonylurea	B-Chemical
therapy	O
on	O
cardiovascular	O
outcomes	O
remains	O
uncertain	O
.	O
	
Studies	O
of	O
naturally	O
occurring	O
genetic	O
variation	O
can	O
be	O
used	O
to	O
anticipate	O
the	O
expected	O
clinical	O
consequences	O
of	O
a	O
pharmacological	O
therapy	O
.	O
	
A	O
common	O
missense	O
variant	O
in	O
the	O
gene	O
encoding	O
a	O
component	O
of	O
the	O
sulfonylurea	O
receptor	O
(	O
ABCC8	O
p	O
.	O
A1369S	O
)	O
promotes	O
closure	O
of	O
the	O
target	O
channel	O
of	O
sulfonylurea	B-Chemical
therapy	O
and	O
is	O
associated	O
with	O
increased	O
insulin	O
secretion	O
","	O
thus	O
mimicking	O
the	O
effects	O
of	O
sulfonylurea	B-Chemical
therapy	O
.	O
	
Using	O
individual	O
-	O
level	O
data	O
from	O
120	O
","	O
286	O
participants	O
in	O
the	O
UK	O
Biobank	O
and	O
summary	O
association	O
results	O
from	O
four	O
large	O
-	O
scale	O
genome	O
-	O
wide	O
association	O
studies	O
","	O
we	O
examined	O
the	O
impact	O
of	O
this	O
variant	O
on	O
cardiometabolic	O
traits	O
","	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
","	O
and	O
coronary	B-Disease
heart	I-Disease
disease	I-Disease
.	O
	
The	O
p	O
.	O
A1369S	O
variant	O
was	O
associated	O
with	O
a	O
significantly	O
lower	O
risk	O
of	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
(	O
odds	O
ratio	O
[	O
OR	O
]	O
0	O
.	O
93	O
";"	O
95	O
%	O
CI	O
0	O
.	O
91	O
","	O
0	O
.	O
95	O
";"	O
P	O
=	O
1	O
.	O
2	O
x	O
10	O
(-	O
11	O
)).	O
	
The	O
variant	O
was	O
associated	O
with	O
increased	O
BMI	O
(+	O
0	O
.	O
62	O
kg	O
/	O
m	O
(	O
2	O
");"	O
95	O
%	O
CI	O
0	O
.	O
37	O
","	O
0	O
.	O
86	O
";"	O
P	O
=	O
8	O
.	O
1	O
x	O
10	O
(-	O
7	O
))	O
but	O
lower	O
waist	O
-	O
to	O
-	O
hip	O
ratio	O
adjusted	O
for	O
BMI	O
","	O
a	O
marker	O
of	O
abdominal	O
fat	O
distribution	O
.	O
	
Furthermore	O
","	O
p	O
.	O
A1369S	O
was	O
associated	O
with	O
a	O
reduced	O
risk	O
of	O
coronary	B-Disease
heart	I-Disease
disease	I-Disease
(	O
OR	O
0	O
.	O
98	O
";"	O
95	O
%	O
CI	O
0	O
.	O
96	O
","	O
0	O
.	O
99	O
";"	O
P	O
=	O
5	O
.	O
9	O
x	O
10	O
(-	O
4	O
)).	O
	
These	O
results	O
suggest	O
that	O
","	O
despite	O
a	O
known	O
association	O
with	O
increased	O
weight	O
","	O
long	O
-	O
term	O
sulfonylurea	B-Chemical
therapy	O
may	O
reduce	O
the	O
risk	O
of	O
coronary	B-Disease
heart	I-Disease
disease	I-Disease
.	O
	
	
Regulation	O
of	O
lung	O
endothelial	O
permeability	O
and	O
inflammatory	B-Disease
responses	O
by	O
prostaglandin	B-Chemical
A2	I-Chemical
:	O
role	O
of	O
EP4	O
receptor	O
.	O
	
The	O
role	O
of	O
prostaglandin	B-Chemical
A2	I-Chemical
(	O
PGA2	B-Chemical
)	O
in	O
modulation	O
of	O
vascular	O
endothelial	O
function	O
is	O
unknown	O
.	O
	
We	O
investigated	O
effects	O
of	O
PGA2	B-Chemical
on	O
pulmonary	O
endothelial	O
cell	O
(	O
EC	O
)	O
permeability	O
and	O
inflammatory	B-Disease
activation	O
and	O
identified	O
a	O
receptor	O
mediating	O
these	O
effects	O
.	O
	
PGA2	B-Chemical
enhanced	O
the	O
EC	O
barrier	O
and	O
protected	O
against	O
barrier	O
dysfunction	O
caused	O
by	O
vasoactive	O
peptide	O
thrombin	O
and	O
proinflammatory	B-Disease
bacterial	O
wall	O
lipopolysaccharide	B-Chemical
(	O
LPS	B-Chemical
).	O
	
Receptor	O
screening	O
using	O
pharmacological	O
and	O
molecular	O
inhibitory	O
approaches	O
identified	O
EP4	O
as	O
a	O
novel	O
PGA2	O
receptor	O
.	O
	
EP4	O
mediated	O
barrier	O
-	O
protective	O
effects	O
of	O
PGA2	B-Chemical
by	O
activating	O
Rap1	O
/	O
Rac1	O
GTPase	O
and	O
protein	O
kinase	O
A	O
targets	O
at	O
cell	O
adhesions	O
and	O
cytoskeleton	O
:	O
VE	O
-	O
cadherin	O
","	O
p120	O
-	O
catenin	O
","	O
ZO	O
-	O
1	O
","	O
cortactin	O
","	O
and	O
VASP	O
.	O
	
PGA2	B-Chemical
also	O
suppressed	O
LPS	B-Chemical
-	O
induced	O
inflammatory	B-Disease
signaling	O
by	O
inhibiting	O
the	O
NFkB	O
pathway	O
and	O
expression	O
of	O
EC	O
adhesion	O
molecules	O
ICAM1	O
and	O
VCAM1	O
.	O
	
These	O
effects	O
were	O
abolished	O
by	O
pharmacological	O
or	O
molecular	O
inhibition	O
of	O
EP4	O
.	O
	
In	O
vivo	O
","	O
PGA2	B-Chemical
was	O
protective	O
in	O
two	O
distinct	O
models	O
of	O
acute	B-Disease
lung	I-Disease
injury	I-Disease
(	O
ALI	B-Disease
):	O
LPS	B-Chemical
-	O
induced	O
inflammatory	B-Disease
injury	I-Disease
and	O
two	O
-	O
hit	O
ALI	B-Disease
caused	O
by	O
suboptimal	O
mechanical	O
ventilation	O
and	O
injection	O
of	O
thrombin	O
receptor	O
-	O
activating	O
peptide	O
.	O
	
These	O
protective	O
effects	O
were	O
abolished	O
in	O
mice	O
with	O
endothelial	O
-	O
specific	O
EP4	O
knockout	O
.	O
	
The	O
results	O
suggest	O
a	O
novel	O
role	O
for	O
the	O
PGA2	B-Chemical
-	O
EP4	O
axis	O
in	O
vascular	O
EC	O
protection	O
that	O
is	O
critical	O
for	O
improvement	O
of	O
pathological	O
states	O
associated	O
with	O
increased	O
vascular	O
leakage	O
and	O
inflammation	B-Disease
.	O
	
	
Hypoglycemic	O
Effect	O
of	O
Combined	O
Ghrelin	O
and	O
Glucagon	O
Receptor	O
Blockade	O
.	O
	
Glucagon	O
receptor	O
(	O
GcgR	O
)	O
blockade	O
has	O
been	O
proposed	O
as	O
an	O
alternative	O
to	O
insulin	O
monotherapy	O
for	O
treating	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
since	O
deletion	O
or	O
inhibition	O
of	O
GcgRs	O
corrects	O
hyperglycemia	B-Disease
in	O
models	O
of	O
diabetes	B-Disease
.	O
	
The	O
factors	O
regulating	O
glycemia	B-Chemical
in	O
a	O
setting	O
devoid	O
of	O
insulin	O
and	O
glucagon	O
function	O
remain	O
unclear	O
but	O
may	O
include	O
the	O
hormone	O
ghrelin	O
.	O
	
Not	O
only	O
is	O
ghrelin	O
release	O
controlled	O
by	O
glucose	B-Chemical
but	O
also	O
ghrelin	O
has	O
many	O
actions	O
that	O
can	O
raise	O
or	O
reduce	O
falls	O
in	O
blood	B-Chemical
glucose	I-Chemical
level	O
.	O
	
Here	O
","	O
we	O
tested	O
the	O
hypothesis	O
that	O
ghrelin	O
rises	O
to	O
prevent	O
hypoglycemia	B-Disease
in	O
the	O
absence	O
of	O
glucagon	O
function	O
.	O
	
Both	O
GcgR	O
knockout	O
(	O
Gcgr	O
(-/-))	O
mice	O
and	O
db	O
/	O
db	O
mice	O
that	O
were	O
administered	O
GcgR	O
monoclonal	O
antibody	O
displayed	O
lower	O
blood	B-Chemical
glucose	I-Chemical
levels	O
accompanied	O
by	O
elevated	O
plasma	O
ghrelin	O
levels	O
.	O
	
Although	O
treatment	O
with	O
the	O
pancreatic	O
b	O
-	O
cell	O
toxin	O
streptozotocin	B-Chemical
induced	O
hyperglycemia	B-Disease
and	O
raised	O
plasma	O
ghrelin	O
levels	O
in	O
wild	O
-	O
type	O
mice	O
","	O
hyperglycemia	B-Disease
was	O
averted	O
in	O
similarly	O
treated	O
Gcgr	O
(-/-)	O
mice	O
and	O
the	O
plasma	O
ghrelin	O
level	O
was	O
further	O
increased	O
.	O
	
Notably	O
","	O
administration	O
of	O
a	O
ghrelin	O
receptor	O
antagonist	O
further	O
reduced	O
blood	B-Chemical
glucose	I-Chemical
levels	O
into	O
the	O
markedly	O
hypoglycemic	O
range	O
in	O
overnight	O
-	O
fasted	O
","	O
streptozotocin	B-Chemical
-	O
treated	O
Gcgr	O
(-/-)	O
mice	O
.	O
	
A	O
lowered	O
blood	B-Chemical
glucose	I-Chemical
level	O
also	O
was	O
observed	O
in	O
overnight	O
-	O
fasted	O
","	O
streptozotocin	B-Chemical
-	O
treated	O
ghrelin	O
receptor	O
-	O
null	O
mice	O
that	O
were	O
administered	O
GcgR	O
monoclonal	O
antibody	O
.	O
	
These	O
data	O
suggest	O
that	O
when	O
glucagon	O
activity	O
is	O
blocked	O
in	O
the	O
setting	O
of	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
","	O
the	O
plasma	O
ghrelin	O
level	O
rises	O
","	O
preventing	O
hypoglycemia	B-Disease
.	O
	
	
Gankyrin	O
induces	O
STAT3	O
activation	O
in	O
tumor	B-Disease
microenvironment	O
and	O
sorafenib	B-Chemical
resistance	O
in	O
hepatocellular	B-Disease
carcinoma	I-Disease
.	O
	
Most	O
hepatocellular	B-Disease
carcinomas	I-Disease
(	O
HCC	B-Disease
)	O
develop	O
as	O
a	O
result	O
of	O
chronic	B-Disease
liver	I-Disease
inflammation	I-Disease
.	O
	
We	O
have	O
shown	O
that	O
the	O
oncoprotein	O
gankyrin	O
is	O
critical	O
for	O
inflammation	B-Disease
-	O
induced	O
tumorigenesis	B-Disease
in	O
the	O
colon	O
.	O
	
Although	O
the	O
in	O
vitro	O
function	O
of	O
gankyrin	O
is	O
well	O
known	O
","	O
its	O
role	O
in	O
vivo	O
remains	O
to	O
be	O
elucidated	O
.	O
	
We	O
investigated	O
the	O
effect	O
of	O
gankyrin	O
in	O
the	O
tumor	B-Disease
microenvironment	O
of	O
mice	O
with	O
liver	O
parenchymal	O
cell	O
-	O
specific	O
gankyrin	O
ablation	O
(	O
Alb	O
-	O
Cre	O
";"	O
gankyrin	O
(	O
f	O
/	O
f	O
)	O
)	O
and	O
gankyrin	O
deletion	O
both	O
in	O
liver	O
parenchymal	O
and	O
non	O
-	O
parenchymal	O
cells	O
(	O
Mx1	O
-	O
Cre	O
";"	O
gankyrin	O
(	O
f	O
/	O
f	O
)	O
).	O
	
Gankyrin	O
upregulates	O
vascular	O
endothelial	O
growth	O
factor	O
expression	O
in	O
tumor	B-Disease
cells	O
.	O
	
Gankyrin	O
binds	O
to	O
Src	O
homology	O
2	O
domain	O
-	O
containing	O
protein	O
tyrosine	O
phosphatase	O
-	O
1	O
(	O
SHP	O
-	O
1	O
)","	O
mainly	O
expressed	O
in	O
liver	O
non	O
-	O
parenchymal	O
cells	O
","	O
resulting	O
in	O
phosphorylation	O
and	O
activation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
(	O
STAT3	O
).	O
	
Gankyrin	O
deficiency	O
in	O
non	O
-	O
parenchymal	O
cells	O
","	O
but	O
not	O
in	O
parenchymal	O
cells	O
","	O
reduced	O
STAT3	O
activity	O
","	O
interleukin	O
(	O
IL	O
)-	O
6	O
production	O
","	O
and	O
cancer	B-Disease
stem	O
cell	O
marker	O
(	O
Bmi1	O
and	O
epithelial	O
cell	O
adhesion	O
molecule	O
[	O
EpCAM	O
])	O
expression	O
","	O
leading	O
to	O
attenuated	O
tumorigenic	B-Disease
potential	O
.	O
	
Chronic	B-Disease
inflammation	I-Disease
enhances	O
gankyrin	O
expression	O
in	O
the	O
human	O
liver	O
.	O
	
Gankyrin	O
expression	O
in	O
the	O
tumor	B-Disease
microenvironment	O
is	O
negatively	O
correlated	O
with	O
progression	O
-	O
free	O
survival	O
in	O
patients	O
undergoing	O
sorafenib	B-Chemical
treatment	O
for	O
HCC	B-Disease
.	O
	
Thus	O
","	O
gankyrin	O
appears	O
to	O
play	O
a	O
critical	O
oncogenic	O
function	O
in	O
tumor	B-Disease
microenvironment	O
and	O
may	O
be	O
a	O
potential	O
target	O
for	O
developing	O
therapeutic	O
and	O
preventive	O
strategies	O
against	O
HCC	B-Disease
.	O
	
	
Pituitary	O
response	O
to	O
luteinizing	O
hormone	O
-	O
releasing	O
hormone	O
during	O
haloperidol	B-Chemical
-	O
induced	O
hyperprolactinemia	B-Disease
.	O
	
The	O
effects	O
of	O
a	O
6	O
-	O
hour	O
infusion	O
with	O
haloperidol	B-Chemical
on	O
serum	O
prolactin	O
and	O
luteinizing	O
hormone	O
(	O
LH	O
)	O
levels	O
was	O
studied	O
in	O
a	O
group	O
of	O
male	O
subjects	O
.	O
	
Five	O
hours	O
after	O
starting	O
the	O
infusions	O
","	O
a	O
study	O
of	O
the	O
pituitary	O
responses	O
to	O
LH	O
-	O
releasing	O
hormone	O
(	O
LH	O
-	O
RH	O
)	O
was	O
carried	O
out	O
.	O
	
Control	O
patients	O
received	O
infusions	O
of	O
0	O
.	O
9	O
%	O
NaCl	B-Chemical
solution	O
.	O
	
During	O
the	O
course	O
of	O
haloperidol	B-Chemical
infusions	O
","	O
significant	O
hyperprolactinemia	B-Disease
was	O
found	O
","	O
together	O
with	O
an	O
abolished	O
pituitary	O
response	O
to	O
LH	O
-	O
RH	O
","	O
as	O
compared	O
with	O
responses	O
of	O
control	O
subjects	O
.	O
	
	
Cardiovascular	B-Disease
complications	I-Disease
associated	O
with	O
terbutaline	B-Chemical
treatment	O
for	O
preterm	B-Disease
labor	I-Disease
.	O
	
Severe	O
cardiovascular	B-Disease
complications	I-Disease
occurred	O
in	O
eight	O
of	O
160	O
patients	O
treated	O
with	O
terbutaline	B-Chemical
for	O
preterm	B-Disease
labor	I-Disease
.	O
	
Associated	O
corticosteroid	B-Chemical
therapy	O
and	O
twin	O
gestations	O
appear	O
to	O
be	O
predisposing	O
factors	O
.	O
	
Potential	O
mechanisms	O
of	O
the	O
pathophysiology	O
are	O
briefly	O
discussed	O
.	O
	
	
Cloning	O
of	O
human	O
very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
coenzyme	O
A	O
dehydrogenase	O
and	O
molecular	O
characterization	O
of	O
its	O
deficiency	O
in	O
two	O
patients	O
.	O
	
Two	O
overlapping	O
cDNA	O
clones	O
(	O
1	O
","	O
991	O
bp	O
and	O
736	O
bp	O
","	O
respectively	O
)	O
encoding	O
the	O
precursor	O
of	O
human	O
mitochondrial	O
very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
coenzyme	O
A	O
dehydrogenase	O
(	O
VLCAD	O
)	O
were	O
cloned	O
and	O
sequenced	O
.	O
	
The	O
cDNA	O
inserts	O
of	O
these	O
clones	O
together	O
encompass	O
a	O
region	O
of	O
2	O
","	O
177	O
bases	O
","	O
encoding	O
the	O
entire	O
protein	O
of	O
655	O
amino	O
acids	O
","	O
including	O
a	O
40	O
-	O
amino	O
acid	O
leader	O
peptide	O
and	O
a	O
615	O
-	O
amino	O
acid	O
mature	O
polypeptide	O
.	O
	
PCR	O
-	O
amplified	O
VLCAD	O
cDNAs	O
were	O
sequenced	O
in	O
cultured	O
fibroblasts	O
from	O
two	O
VLCAD	B-Disease
-	I-Disease
deficient	I-Disease
patients	O
.	O
	
In	O
both	O
patients	O
","	O
a	O
105	O
-	O
bp	O
deletion	O
encompassing	O
bases	O
1078	O
-	O
1182	O
in	O
VLCAD	O
cDNA	O
was	O
identified	O
.	O
	
The	O
deletion	O
seems	O
to	O
occur	O
due	O
to	O
exon	O
skipping	O
during	O
processing	O
of	O
VLCAD	O
pre	O
-	O
mRNA	O
.	O
	
This	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
mutation	O
causing	O
VLCAD	B-Disease
deficiency	I-Disease
.	O
	
Quantitative	O
cDNA	O
expression	O
of	O
normal	O
human	O
VLCAD	O
was	O
performed	O
in	O
the	O
patients	O
fibroblasts	O
","	O
using	O
vaccinia	O
viral	O
system	O
","	O
which	O
demonstrated	O
that	O
the	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
normal	I-Disease
VLCAD	I-Disease
protein	I-Disease
causes	O
impaired	O
long	B-Chemical
-	I-Chemical
chain	I-Chemical
fatty	I-Chemical
acid	I-Chemical
beta	O
-	O
oxidation	O
activity	O
in	O
the	O
patients	O
fibroblasts	O
.	O
	
In	O
patient	O
fibroblasts	O
","	O
raising	O
VLCAD	O
activity	O
to	O
approximately	O
20	O
%	O
of	O
normal	O
control	O
fibroblast	O
activity	O
raised	O
palmitic	B-Chemical
acid	I-Chemical
beta	O
-	O
oxidation	O
flux	O
to	O
the	O
level	O
found	O
in	O
control	O
fibroblasts	O
","	O
which	O
may	O
offer	O
important	O
information	O
for	O
the	O
rational	O
design	O
of	O
future	O
somatic	O
gene	O
therapy	O
for	O
VLCAD	B-Disease
deficiency	I-Disease
..	O
	
	
Human	O
mu	O
opiate	O
receptor	O
.	O
	
cDNA	O
and	O
genomic	O
clones	O
","	O
pharmacologic	O
characterization	O
and	O
chromosomal	O
assignment	O
.	O
	
A	O
human	O
mu	O
opiate	O
receptor	O
cDNA	O
has	O
been	O
identified	O
from	O
a	O
cerebral	O
cortical	O
cDNA	O
library	O
using	O
sequences	O
from	O
the	O
rat	O
mu	O
opiate	O
receptor	O
cDNA	O
.	O
	
The	O
human	O
mu	O
opiate	O
receptor	O
(	O
h	O
mu	O
OR1	O
)	O
shares	O
95	O
%	O
amino	O
acid	O
identity	O
with	O
the	O
rat	O
sequence	O
.	O
	
The	O
expressed	O
mu	O
OR1	O
recognized	O
tested	O
opiate	B-Chemical
drugs	O
and	O
opioid	B-Chemical
peptides	I-Chemical
in	O
a	O
sodium	B-Chemical
-	O
and	O
GTP	B-Chemical
-	O
sensitive	O
fashion	O
with	O
affinities	O
virtually	O
identical	O
to	O
those	O
displayed	O
by	O
the	O
rat	O
mu	O
opiate	O
receptor	O
.	O
	
Effects	O
on	O
cyclic	B-Chemical
AMP	I-Chemical
are	O
similar	O
to	O
those	O
noted	O
for	O
the	O
rat	O
mu	O
opiate	O
receptor	O
.	O
	
An	O
18	O
kb	O
genomic	O
clone	O
hybridizing	O
with	O
the	O
h	O
mu	O
OR1	O
cDNA	O
contains	O
63	O
and	O
489	O
bp	O
exonic	O
sequences	O
flanked	O
by	O
splice	O
donor	O
/	O
acceptor	O
sequences	O
.	O
	
Analysis	O
of	O
hybridization	O
to	O
DNA	O
prepared	O
from	O
human	O
rodent	O
hybrid	O
cell	O
lines	O
and	O
chromosomal	O
in	O
situ	O
hybridization	O
studies	O
indicate	O
localization	O
to	O
6q24	O
-	O
25	O
.	O
	
An	O
MspI	O
polymorphism	O
","	O
producing	O
a	O
3	O
.	O
7	O
kb	O
band	O
","	O
may	O
prove	O
useful	O
in	O
assessing	O
this	O
gene	O
'	O
s	O
involvement	O
in	O
neuropsychiatric	B-Disease
disorders	I-Disease
involving	O
opiatergic	O
systems	O
.	O
	
	
Adrenoleukodystrophy	O
gene	O
encodes	O
an	O
80	O
kDa	O
membrane	O
protein	O
.	O
	
An	O
antibody	O
against	O
the	O
synthetic	O
C	O
-	O
terminal	O
peptides	O
deduced	O
from	O
the	O
cDNA	O
of	O
the	O
gene	O
responsible	O
for	O
X	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
(	O
ALD	B-Disease
)	O
was	O
produced	O
to	O
characterize	O
the	O
product	O
of	O
the	O
ALD	O
gene	O
.	O
	
The	O
antibody	O
reacted	O
with	O
the	O
80	O
kDa	O
band	O
protein	O
in	O
control	O
fibroblasts	O
","	O
while	O
no	O
bands	O
were	O
detected	O
in	O
the	O
fibroblasts	O
from	O
a	O
patient	O
with	O
ALD	B-Disease
(#	O
163	O
)","	O
in	O
which	O
mRNA	O
of	O
the	O
ALD	O
gene	O
was	O
undetectable	O
based	O
on	O
Northern	O
blot	O
analysis	O
.	O
	
The	O
293T	O
cells	O
transfected	O
with	O
the	O
full	O
-	O
coding	O
cDNA	O
inserted	O
in	O
the	O
expression	O
vector	O
produced	O
a	O
new	O
80	O
kDa	O
protein	O
","	O
as	O
detected	O
by	O
Western	O
blot	O
.	O
	
In	O
an	O
immunocytological	O
study	O
","	O
the	O
staining	O
was	O
in	O
a	O
punctate	O
pattern	O
","	O
in	O
the	O
normal	O
fibroblasts	O
.	O
	
However	O
","	O
there	O
was	O
no	O
punctate	O
staining	O
in	O
the	O
#	O
163	O
cells	O
.	O
	
These	O
data	O
thus	O
indicate	O
that	O
the	O
ALD	O
gene	O
encodes	O
an	O
80	O
kDa	O
membrane	O
protein	O
..	O
	
	
Mutations	O
associated	O
with	O
variant	O
phenotypes	O
in	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
.	O
	
We	O
have	O
identified	O
14	O
families	O
with	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
A	B-Disease
-	I-Disease
T	I-Disease
)	O
in	O
which	O
mutation	O
of	O
the	O
ATM	O
gene	O
is	O
associated	O
with	O
a	O
less	O
severe	O
clinical	O
and	O
cellular	O
phenotype	O
(	O
approximately	O
10	O
%	O
-	O
15	O
%	O
of	O
A	B-Disease
-	I-Disease
T	I-Disease
families	O
identified	O
in	O
the	O
United	O
Kingdom	O
).	O
	
In	O
10	O
of	O
these	O
families	O
","	O
all	O
the	O
homozygotes	O
have	O
a	O
137	O
-	O
bp	O
insertion	O
in	O
their	O
cDNA	O
caused	O
by	O
a	O
point	O
mutation	O
in	O
a	O
sequence	O
resembling	O
a	O
splice	O
-	O
donor	O
site	O
.	O
	
The	O
second	O
A	B-Disease
-	I-Disease
T	I-Disease
allele	O
has	O
a	O
different	O
mutation	O
in	O
each	O
patient	O
.	O
	
We	O
show	O
that	O
the	O
less	O
severe	O
phenotype	O
in	O
these	O
patients	O
is	O
caused	O
by	O
some	O
degree	O
of	O
normal	O
splicing	O
","	O
which	O
occurs	O
as	O
an	O
alternative	O
product	O
from	O
the	O
insertion	O
-	O
containing	O
allele	O
.	O
	
The	O
level	O
of	O
the	O
137	O
-	O
bp	O
PCR	O
product	O
containing	O
the	O
insertion	O
was	O
lowest	O
in	O
two	O
patients	O
who	O
showed	O
a	O
later	O
onset	O
of	O
cerebellar	B-Disease
ataxia	I-Disease
.	O
	
A	O
further	O
four	O
families	O
who	O
do	O
not	O
have	O
this	O
insertion	O
have	O
been	O
identified	O
.	O
	
Mutations	O
detected	O
in	O
two	O
of	O
four	O
of	O
these	O
are	O
missense	O
mutations	O
","	O
normally	O
rare	O
in	O
A	B-Disease
-	I-Disease
T	I-Disease
patients	O
.	O
	
The	O
demonstration	O
of	O
mutations	O
giving	O
rise	O
to	O
a	O
slightly	O
milder	O
phenotype	O
in	O
A	B-Disease
-	I-Disease
T	I-Disease
raises	O
the	O
interesting	O
question	O
of	O
what	O
range	O
of	O
phenotypes	O
might	O
occur	O
in	O
individuals	O
in	O
whom	O
both	O
mutations	O
are	O
milder	O
.	O
	
One	O
possibility	O
might	O
be	O
that	O
individuals	O
who	O
are	O
compound	O
heterozygotes	O
for	O
ATM	O
mutations	O
are	O
more	O
common	O
than	O
we	O
realize	O
..	O
	
	
Myotonic	O
dystrophy	O
protein	O
kinase	O
is	O
involved	O
in	O
the	O
modulation	O
of	O
the	O
Ca2	B-Chemical
+	I-Chemical
homeostasis	O
in	O
skeletal	O
muscle	O
cells	O
.	O
	
Myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)","	O
the	O
most	O
prevalent	O
muscular	B-Disease
disorder	I-Disease
in	O
adults	O
","	O
is	O
caused	O
by	O
(	O
CTG	O
)	O
n	O
-	O
repeat	O
expansion	O
in	O
a	O
gene	O
encoding	O
a	O
protein	O
kinase	O
(	O
DM	O
protein	O
kinase	O
";"	O
DMPK	O
)	O
and	O
involves	O
changes	O
in	O
cytoarchitecture	O
and	O
ion	O
homeostasis	O
.	O
	
To	O
obtain	O
clues	O
to	O
the	O
normal	O
biological	O
role	O
of	O
DMPK	O
in	O
cellular	O
ion	O
homeostasis	O
","	O
we	O
have	O
compared	O
the	O
resting	O
[	O
Ca2	B-Chemical
+]	I-Chemical
i	O
","	O
the	O
amplitude	O
and	O
shape	O
of	O
depolarization	O
-	O
induced	O
Ca2	B-Chemical
+	I-Chemical
transients	O
","	O
and	O
the	O
content	O
of	O
ATP	B-Chemical
-	O
driven	O
ion	O
pumps	O
in	O
cultured	O
skeletal	O
muscle	O
cells	O
of	O
wild	O
-	O
type	O
and	O
DMPK	O
[-/-]	O
knockout	O
mice	O
.	O
	
In	O
vitro	O
-	O
differentiated	O
DMPK	O
[-/-]	O
myotubes	O
exhibit	O
a	O
higher	O
resting	O
[	O
Ca2	B-Chemical
+]	I-Chemical
i	O
than	O
do	O
wild	O
-	O
type	O
myotubes	O
because	O
of	O
an	O
altered	O
open	O
probability	O
of	O
voltage	O
-	O
dependent	O
l	O
-	O
type	O
Ca2	B-Chemical
+	I-Chemical
and	O
Na	B-Chemical
+	I-Chemical
channels	O
.	O
	
The	O
mutant	O
myotubes	O
exhibit	O
smaller	O
and	O
slower	O
Ca2	B-Chemical
+	I-Chemical
responses	O
upon	O
triggering	O
by	O
acetylcholine	B-Chemical
or	O
high	O
external	O
K	B-Chemical
+.	I-Chemical
	
In	O
addition	O
","	O
we	O
observed	O
that	O
these	O
Ca2	B-Chemical
+	I-Chemical
transients	O
partially	O
result	O
from	O
an	O
influx	O
of	O
extracellular	O
Ca2	B-Chemical
+	I-Chemical
through	O
the	O
l	O
-	O
type	O
Ca2	B-Chemical
+	I-Chemical
channel	O
.	O
	
Neither	O
the	O
content	O
nor	O
the	O
activity	O
of	O
Na	B-Chemical
+/	I-Chemical
K	I-Chemical
+	I-Chemical
ATPase	I-Chemical
and	O
sarcoplasmic	B-Chemical
reticulum	I-Chemical
Ca2	I-Chemical
+	I-Chemical
-	I-Chemical
ATPase	I-Chemical
are	O
affected	O
by	O
DMPK	O
absence	O
.	O
	
In	O
conclusion	O
","	O
our	O
data	O
suggest	O
that	O
DMPK	O
is	O
involved	O
in	O
modulating	O
the	O
initial	O
events	O
of	O
excitation	O
-	O
contraction	O
coupling	O
in	O
skeletal	O
muscle	O
..	O
	
	
cDNA	O
sequence	O
and	O
chromosomal	O
localization	O
of	O
the	O
remaining	O
three	O
human	O
nuclear	O
encoded	O
iron	O
sulphur	O
protein	O
(	O
IP	O
)	O
subunits	O
of	O
complex	O
I	O
:	O
the	O
human	O
IP	O
fraction	O
is	O
completed	O
.	O
	
NADH	O
:	O
ubiquinone	O
oxidoreductase	O
(	O
complex	O
I	O
)	O
of	O
the	O
mitochondrial	O
respiratory	O
chain	O
can	O
be	O
fragmented	O
in	O
a	O
flavoprotein	O
(	O
FP	O
)","	O
iron	O
-	O
sulfur	O
protein	O
(	O
IP	O
)","	O
and	O
hydrophobic	O
protein	O
(	O
HP	O
)	O
subfraction	O
.	O
	
The	O
IP	O
subfraction	O
is	O
hypothesized	O
to	O
be	O
significant	O
","	O
since	O
it	O
contains	O
important	O
prosthetic	O
groups	O
highly	O
conserved	O
among	O
species	O
.	O
	
We	O
cloned	O
the	O
cDNA	O
of	O
three	O
remaining	O
human	O
NADH	O
:	O
ubiquinone	O
oxidoreductase	O
subunits	O
of	O
this	O
IP	O
fraction	O
:	O
the	O
NDUFS2	O
(	O
49	O
kDa	O
)","	O
NDUFS3	O
(	O
30	O
kDa	O
)","	O
and	O
NDUFS6	O
(	O
13	O
kDa	O
)	O
subunits	O
.	O
	
All	O
presented	O
cDNAs	O
include	O
the	O
complete	O
open	O
reading	O
frame	O
(	O
ORF	O
)","	O
which	O
consist	O
of	O
1392	O
","	O
795	O
","	O
and	O
375	O
base	O
pairs	O
","	O
coding	O
for	O
463	O
","	O
264	O
","	O
and	O
124	O
amino	O
acids	O
","	O
respectively	O
.	O
	
The	O
latter	O
show	O
96	O
","	O
90	O
","	O
and	O
83	O
%	O
homology	O
with	O
the	O
corresponding	O
bovine	O
translation	O
products	O
.	O
	
The	O
3	O
'	O
untranslated	O
regions	O
(	O
UTR	O
)	O
are	O
complete	O
in	O
all	O
three	O
cDNAs	O
.	O
	
Polymerase	O
chain	O
reaction	O
performed	O
with	O
DNA	O
isolated	O
from	O
somatic	O
human	O
-	O
rodent	O
cell	O
hybrids	O
containing	O
defined	O
human	O
chromosomes	O
as	O
template	O
gave	O
a	O
human	O
-	O
specific	O
signal	O
which	O
mapped	O
the	O
NDUFS2	O
and	O
NDUFS3	O
subunits	O
to	O
chromosomes	O
1	O
and	O
11	O
","	O
respectively	O
.	O
	
In	O
the	O
case	O
of	O
the	O
NDUFS6	O
subunit	O
a	O
pseudogene	O
may	O
be	O
present	O
since	O
signals	O
were	O
seen	O
in	O
the	O
lanes	O
containing	O
chromosomes	O
5	O
and	O
6	O
.	O
	
The	O
NDUFS2	O
contains	O
a	O
highly	O
conserved	O
protein	O
kinase	O
C	O
phosphorylation	O
site	O
and	O
the	O
NDUFS3	O
subunit	O
contains	O
a	O
highly	O
conserved	O
casein	O
kinase	O
II	O
phosphorylation	O
site	O
which	O
make	O
them	O
strong	O
candidates	O
for	O
future	O
mutation	O
detection	O
studies	O
in	O
enzymatic	B-Disease
complex	I-Disease
I	I-Disease
-	I-Disease
deficient	I-Disease
patients	O
.	O
	
	
Inappropriate	O
use	O
of	O
carbamazepine	B-Chemical
and	O
vigabatrin	B-Chemical
in	O
typical	O
absence	B-Disease
seizures	I-Disease
.	O
	
Carbamazepine	B-Chemical
and	O
vigabatrin	B-Chemical
are	O
contraindicated	O
in	O
typical	O
absence	B-Disease
seizures	I-Disease
.	O
	
Of	O
18	O
consecutive	O
referrals	O
of	O
children	O
with	O
resistant	O
typical	O
absences	O
only	O
","	O
eight	O
were	O
erroneously	O
treated	O
with	O
carbamazepine	B-Chemical
either	O
as	O
monotherapy	O
or	O
as	O
an	O
add	O
-	O
on	O
.	O
	
Vigabatrin	B-Chemical
was	O
also	O
used	O
in	O
the	O
treatment	O
of	O
two	O
children	O
.	O
	
Frequency	O
of	O
absences	O
increased	O
in	O
four	O
children	O
treated	O
with	O
carbamazepine	B-Chemical
and	O
two	O
of	O
these	O
developed	O
myoclonic	B-Disease
jerks	I-Disease
","	O
which	O
resolved	O
on	O
withdrawal	O
of	O
carbamazepine	B-Chemical
.	O
	
Absences	O
were	O
aggravated	O
in	O
both	O
cases	O
where	O
vigabatrin	B-Chemical
was	O
added	O
on	O
to	O
concurrent	O
treatment	O
.	O
	
Optimal	O
control	O
of	O
the	O
absences	O
was	O
achieved	O
with	O
sodium	B-Chemical
valproate	I-Chemical
","	O
lamotrigine	B-Chemical
","	O
or	O
ethosuximide	B-Chemical
alone	O
or	O
in	O
combination	O
.	O
	
	
CD72	O
polymorphisms	O
associated	O
with	O
alternative	O
splicing	O
modify	O
susceptibility	O
to	O
human	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
through	O
epistatic	O
interaction	O
with	O
FCGR2B	O
.	O
	
We	O
previously	O
reported	O
association	O
of	O
FCGR2B	O
-	O
Ile232Thr	O
with	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
(	O
SLE	B-Disease
)	O
in	O
three	O
Asian	O
populations	O
.	O
	
Because	O
polymorphism	O
of	O
CD72	O
","	O
another	O
inhibitory	O
receptor	O
of	O
B	O
cells	O
","	O
was	O
associated	O
with	O
murine	O
SLE	B-Disease
","	O
we	O
identified	O
human	O
CD72	O
polymorphisms	O
","	O
tested	O
their	O
association	O
with	O
SLE	B-Disease
and	O
examined	O
genetic	O
interaction	O
with	O
FCGR2B	O
in	O
the	O
Japanese	O
(	O
160	O
SLE	B-Disease
","	O
277	O
controls	O
)","	O
Thais	O
(	O
87	O
SLE	B-Disease
","	O
187	O
controls	O
)	O
and	O
Caucasians	O
(	O
94	O
families	O
containing	O
SLE	B-Disease
members	O
).	O
	
Four	O
polymorphisms	O
and	O
six	O
rare	O
variations	O
were	O
detected	O
.	O
	
The	O
former	O
constituted	O
two	O
major	O
haplotypes	O
that	O
contained	O
one	O
or	O
two	O
repeats	O
of	O
13	O
nucleotides	O
in	O
intron	O
8	O
(	O
designated	O
as	O
*	O
1	O
and	O
*	O
2	O
","	O
respectively	O
).	O
	
Although	O
association	O
with	O
susceptibility	O
to	O
SLE	B-Disease
was	O
not	O
detected	O
","	O
the	O
*	O
1	O
allele	O
was	O
significantly	O
associated	O
with	O
nephritis	B-Disease
among	O
the	O
Japanese	O
patients	O
(	O
P	O
=	O
0	O
.	O
24	O
).	O
	
RT	O
-	O
PCR	O
identified	O
a	O
novel	O
alternatively	O
spliced	O
(	O
AS	O
)	O
transcript	O
that	O
was	O
expressed	O
at	O
the	O
protein	O
level	O
in	O
COS	O
-	O
7	O
transfectants	O
.	O
	
The	O
ratio	O
of	O
AS	O
/	O
common	O
isoforms	O
was	O
strikingly	O
increased	O
in	O
individuals	O
with	O
*	O
2	O
/*	O
2	O
genotype	O
when	O
compared	O
with	O
*	O
1	O
/*	O
1	O
(	O
P	O
=	O
0	O
.	O
38	O
)	O
or	O
*	O
1	O
/*	O
2	O
(	O
P	O
=	O
0	O
.	O
85	O
)	O
genotypes	O
.	O
	
Using	O
the	O
two	O
Asian	O
cohorts	O
","	O
significant	O
association	O
of	O
FCGR2B	O
-	O
232Thr	O
/	O
Thr	O
with	O
SLE	B-Disease
was	O
observed	O
only	O
in	O
the	O
presence	O
of	O
CD72	O
-*	O
1	O
/*	O
1	O
genotype	O
(	O
OR	O
4	O
.	O
63	O
","	O
95	O
%	O
CI	O
1	O
.	O
47	O
-	O
14	O
.	O
6	O
","	O
P	O
=	O
0	O
.	O
9	O
versus	O
FCGR2B	O
-	O
232Ile	O
/	O
Ile	O
plus	O
CD72	O
-*	O
2	O
/*	O
2	O
).	O
	
Minigene	O
assays	O
demonstrated	O
that	O
the	O
13	O
-	O
nucleotide	O
repeat	O
and	O
4	O
bp	O
deletion	O
within	O
the	O
same	O
haplotype	O
of	O
intron	O
8	O
could	O
regulate	O
alternative	O
splicing	O
.	O
	
The	O
AS	O
isoform	O
lacks	O
exon	O
8	O
","	O
and	O
is	O
deduced	O
to	O
contain	O
49	O
amino	O
acid	O
changes	O
in	O
the	O
membrane	O
-	O
distal	O
portion	O
of	O
the	O
extracellular	O
domain	O
","	O
where	O
considerable	O
amino	O
acid	O
changes	O
are	O
known	O
in	O
CD72	O
(	O
c	O
)	O
allele	O
associated	O
with	O
murine	O
SLE	B-Disease
.	O
	
These	O
results	O
indicated	O
that	O
the	O
presence	O
of	O
CD72	O
-*	O
2	O
allele	O
decreases	O
risk	O
for	O
human	O
SLE	B-Disease
conferred	O
by	O
FCGR2B	O
-	O
232Thr	O
","	O
possibly	O
by	O
increasing	O
the	O
AS	O
isoform	O
of	O
CD72	O
.	O
	
	
Polymorphic	O
forms	O
of	O
prostate	O
specific	O
antigen	O
and	O
their	O
interaction	O
with	O
androgen	O
receptor	O
trinucleotide	O
repeats	O
in	O
prostate	B-Disease
cancer	I-Disease
.	O
	
BACKGROUND	O
:	O
Recent	O
data	O
has	O
suggested	O
that	O
polymorphisms	O
in	O
the	O
prostate	O
specific	O
antigen	O
(	O
PSA	O
)	O
may	O
increase	O
prostate	B-Disease
cancer	I-Disease
(	O
PC	B-Disease
)	O
risk	O
.	O
	
The	O
PSA	O
gene	O
contains	O
a	O
G	O
/	O
A	O
substitution	O
in	O
the	O
androgen	B-Chemical
response	O
element	O
(	O
ARE	O
)	O
1	O
region	O
.	O
	
The	O
androgen	O
receptor	O
(	O
AR	O
)	O
gene	O
has	O
polymorphic	O
regions	O
containing	O
variable	O
length	O
glutamine	O
and	O
glycine	O
repeats	O
and	O
these	O
are	O
believed	O
to	O
be	O
associated	O
with	O
PC	B-Disease
risk	O
.	O
	
The	O
effect	O
on	O
PC	B-Disease
risks	O
from	O
PSA	O
polymorphisms	O
alone	O
and	O
synergistically	O
with	O
the	O
AR	O
gene	O
was	O
examined	O
in	O
this	O
report	O
.	O
	
METHODS	O
:	O
One	O
hundred	O
PC	B-Disease
patients	O
and	O
an	O
age	O
matched	O
cohort	O
of	O
79	O
benign	B-Disease
prostate	I-Disease
hyperplasia	I-Disease
and	O
67	O
population	O
controls	O
were	O
entered	O
in	O
this	O
study	O
.	O
	
DNA	O
was	O
extracted	O
from	O
blood	O
and	O
PSA	O
/	O
ARE	O
promoter	O
region	O
amplified	O
by	O
PCR	O
.	O
	
PCR	O
products	O
were	O
cut	O
with	O
Nhe	O
1	O
restriction	O
enzyme	O
to	O
distinguish	O
G	O
/	O
A	O
alleles	O
.	O
	
AR	O
/	O
CAG	O
and	O
GGC	O
repeat	O
length	O
was	O
detected	O
by	O
automated	O
fluorescence	O
from	O
PCR	O
products	O
.	O
	
RESULTS	O
:	O
We	O
found	O
a	O
significantly	O
higher	O
PSA	O
/	O
GG	O
distribution	O
in	O
PC	B-Disease
(	O
30	O
%)	O
than	O
either	O
benign	B-Disease
prostatic	I-Disease
hyperplasia	I-Disease
(	O
BPH	B-Disease
)	O
(	O
18	O
%)	O
or	O
population	O
controls	O
(	O
16	O
%)	O
(	O
P	O
=	O
0	O
.	O
25	O
).	O
	
Furthermore	O
the	O
GG	O
distribution	O
within	O
cases	O
was	O
even	O
greater	O
in	O
younger	O
men	O
(<	O
65	O
years	O
";"	O
42	O
"%;"	O
P	O
=	O
0	O
.	O
12	O
).	O
	
Additionally	O
","	O
when	O
PSA	O
genotype	O
was	O
cross	O
classified	O
with	O
CAG	O
repeat	O
","	O
significantly	O
more	O
cases	O
than	O
both	O
BPH	B-Disease
and	O
population	O
controls	O
were	O
observed	O
to	O
have	O
a	O
short	O
(<	O
22	O
)	O
CAG	O
/	O
GG	O
genotype	O
(	O
P	O
=	O
0	O
.	O
6	O
).	O
	
CONCLUSIONS	O
:	O
Our	O
results	O
indicate	O
that	O
the	O
PSA	O
/	O
ARE	O
GG	O
genotype	O
confers	O
an	O
increased	O
risk	O
of	O
PC	B-Disease
especially	O
among	O
younger	O
men	O
.	O
	
Moreover	O
","	O
we	O
confirm	O
previous	O
results	O
that	O
a	O
short	O
glutamine	O
repeat	O
in	O
conjunction	O
with	O
GG	O
genotype	O
significantly	O
increases	O
the	O
risk	O
of	O
malignant	B-Disease
disease	I-Disease
.	O
	
	
Compound	O
heterozygosity	O
for	O
a	O
novel	O
nine	O
-	O
nucleotide	O
deletion	O
and	O
the	O
Asn45Ser	O
missense	O
mutation	O
in	O
the	O
glycoprotein	O
IX	O
gene	O
in	O
a	O
patient	O
with	O
Bernard	B-Disease
-	I-Disease
Soulier	I-Disease
syndrome	I-Disease
.	O
	
Bernard	B-Disease
-	I-Disease
Soulier	I-Disease
syndrome	I-Disease
(	O
BSS	B-Disease
)	O
is	O
a	O
rare	O
inherited	B-Disease
bleeding	I-Disease
disorder	I-Disease
due	O
to	O
quantitative	O
or	O
qualitative	O
abnormalities	O
in	O
the	O
platelet	O
glycoprotein	O
(	O
GP	O
)	O
Ib	O
/	O
IX	O
/	O
V	O
complex	O
","	O
the	O
major	O
von	O
Willebrand	O
factor	O
receptor	O
.	O
	
The	O
complex	O
comprises	O
four	O
subunits	O
","	O
each	O
encoded	O
by	O
a	O
separate	O
gene	O
.	O
	
Several	O
mutations	O
have	O
been	O
described	O
for	O
each	O
of	O
the	O
subunits	O
","	O
except	O
for	O
GPV	O
","	O
as	O
a	O
cause	O
of	O
BSS	B-Disease
.	O
	
We	O
describe	O
here	O
the	O
genetic	O
basis	O
of	O
the	O
disorder	O
in	O
a	O
child	O
with	O
BSS	B-Disease
.	O
	
Flow	O
-	O
cytometric	O
analysis	O
of	O
the	O
patient	O
'	O
s	O
platelets	O
showed	O
a	O
markedly	O
reduced	O
surface	O
expression	O
of	O
all	O
three	O
glycoproteins	O
of	O
the	O
GPIb	O
/	O
IX	O
/	O
V	O
complex	O
.	O
	
DNA	O
sequencing	O
analysis	O
showed	O
the	O
patient	O
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
two	O
mutations	O
in	O
the	O
GPIX	O
gene	O
","	O
a	O
novel	O
nine	O
-	O
nucleotide	O
deletion	O
starting	O
at	O
position	O
1952	O
of	O
the	O
gene	O
that	O
changes	O
asparagine	O
86	O
for	O
alanine	O
and	O
eliminates	O
amino	O
acids	O
87	O
","	O
88	O
","	O
and	O
89	O
(	O
arginine	O
","	O
threonine	O
","	O
and	O
proline	O
)	O
and	O
a	O
previously	O
reported	O
point	O
mutation	O
that	O
changes	O
the	O
codon	O
asparagine	O
(	O
AAC	O
)	O
for	O
serine	O
(	O
AGC	O
)	O
at	O
residue	O
45	O
.	O
	
Her	O
mother	O
was	O
heterozygous	O
for	O
the	O
Asn45Ser	O
mutation	O
","	O
and	O
her	O
father	O
","	O
for	O
the	O
nine	O
-	O
nucleotide	O
deletion	O
.	O
	
Our	O
findings	O
suggest	O
that	O
the	O
additive	O
effects	O
of	O
both	O
mutations	O
in	O
the	O
GPIX	O
gene	O
are	O
responsible	O
for	O
the	O
BSS	B-Disease
phenotype	O
of	O
the	O
patient	O
.	O
	
	
Genetic	O
homogeneity	O
for	O
inherited	O
congenital	B-Disease
microcoria	I-Disease
loci	O
in	O
an	O
Asian	O
Indian	O
pedigree	O
.	O
	
PURPOSE	O
:	O
Congenital	B-Disease
microcoria	I-Disease
is	O
a	O
rare	O
autosomal	B-Disease
dominant	I-Disease
developmental	I-Disease
disorder	I-Disease
of	I-Disease
the	I-Disease
iris	I-Disease
associated	O
with	O
myopia	B-Disease
and	O
juvenile	B-Disease
open	I-Disease
angle	I-Disease
glaucoma	I-Disease
.	O
	
Linkage	O
to	O
the	O
chromosomal	O
locus	O
13q31	O
-	O
q32	O
has	O
previously	O
been	O
reported	O
in	O
a	O
large	O
French	O
family	O
.	O
	
In	O
the	O
current	O
study	O
","	O
a	O
three	O
generation	O
Asian	O
Indian	O
family	O
with	O
15	O
congenital	B-Disease
microcoria	I-Disease
(	O
pupils	O
with	O
a	O
diameter	O
<	O
2	O
mm	O
)	O
affected	O
members	O
was	O
studied	O
for	O
linkage	O
to	O
candidate	O
microsatellite	O
markers	O
at	O
the	O
13q31	O
-	O
q32	O
locus	O
.	O
	
METHODS	O
:	O
Twenty	O
-	O
four	O
members	O
of	O
the	O
family	O
were	O
clinically	O
examined	O
and	O
genomic	O
DNA	O
was	O
extracted	O
.	O
	
Microsatellite	O
markers	O
at	O
13q31	O
-	O
q32	O
were	O
PCR	O
amplified	O
and	O
run	O
on	O
an	O
ABI	O
Prism	O
310	O
genetic	O
analyzer	O
and	O
genotyped	O
with	O
the	O
GeneScan	O
analysis	O
.	O
	
Two	O
point	O
and	O
multipoint	O
linkage	O
analyses	O
were	O
performed	O
using	O
the	O
MLINK	O
and	O
SUPERLINK	O
programs	O
.	O
	
RESULTS	O
:	O
Peak	O
two	O
point	O
LOD	O
scores	O
of	O
3	O
.	O
5	O
","	O
4	O
.	O
7	O
","	O
and	O
5	O
.	O
3	O
were	O
found	O
co	O
-	O
incident	O
with	O
consecutive	O
markers	O
D13S154	O
","	O
DCT	O
","	O
and	O
D13S1280	O
.	O
	
Multipoint	O
analysis	O
revealed	O
a	O
4	O
cM	O
region	O
encompassing	O
D13S1300	O
to	O
D13S1280	O
where	O
the	O
LOD	O
remains	O
just	O
over	O
6	O
.	O
0	O
Thus	O
we	O
confirm	O
localization	O
of	O
the	O
congenital	B-Disease
microcoria	I-Disease
locus	O
to	O
chromosomal	O
locus	O
13q31	O
-	O
q32	O
.	O
	
In	O
addition	O
","	O
eight	O
individuals	O
who	O
had	O
both	O
microcoria	B-Disease
and	O
glaucoma	B-Disease
were	O
screened	O
for	O
glaucoma	B-Disease
genes	O
:	O
myocilin	O
(	O
MYOC	O
)","	O
optineurin	O
(	O
OPTN	O
)	O
and	O
CYP1B1	O
.	O
	
Using	O
direct	O
sequencing	O
a	O
point	O
mutation	O
(	O
144	O
G	O
>	O
A	O
)	O
resulting	O
in	O
a	O
Q48H	O
substitution	O
in	O
exon	O
1	O
of	O
the	O
MYOC	O
gene	O
was	O
observed	O
in	O
five	O
of	O
the	O
eight	O
glaucoma	B-Disease
patients	O
","	O
but	O
not	O
in	O
unaffected	O
family	O
members	O
and	O
100	O
unrelated	O
controls	O
.	O
	
CONCLUSIONS	O
:	O
We	O
have	O
confirmed	O
the	O
localization	O
of	O
the	O
congenital	B-Disease
microcoria	I-Disease
locus	O
(	O
MCOR	O
)	O
to	O
13q31	O
-	O
q32	O
in	O
a	O
large	O
Asian	O
Indian	O
family	O
and	O
conclude	O
that	O
current	O
information	O
suggests	O
this	O
is	O
a	O
single	O
locus	O
disorder	O
and	O
genetically	O
homogeneous	O
.	O
	
When	O
combined	O
with	O
the	O
initial	O
linkage	O
paper	O
our	O
haplotype	O
and	O
linkage	O
data	O
map	O
the	O
MCOR	O
locus	O
to	O
a	O
6	O
-	O
7	O
cM	O
region	O
between	O
D13S265	O
and	O
D13S1280	O
.	O
	
The	O
DCT	O
locus	O
","	O
a	O
member	O
of	O
the	O
tyrosinase	O
family	O
involved	O
in	O
pigmentation	B-Disease
","	O
maps	O
within	O
this	O
region	O
.	O
	
Data	O
presented	O
here	O
supports	O
the	O
hypothesis	O
that	O
congenital	B-Disease
microcoria	I-Disease
is	O
a	O
potential	O
risk	O
factor	O
for	O
glaucoma	B-Disease
","	O
although	O
this	O
observation	O
is	O
complicated	O
by	O
the	O
partial	O
segregation	O
of	O
MYOC	O
Q48H	O
(	O
1q24	O
.	O
3	O
-	O
q25	O
.	O
2	O
)","	O
a	O
mutation	O
known	O
to	O
be	O
associated	O
with	O
glaucoma	B-Disease
in	O
India	O
.	O
	
Fine	O
mapping	O
and	O
candidate	O
gene	O
analysis	O
continues	O
with	O
the	O
hope	O
that	O
characterizing	O
the	O
micocoria	O
gene	O
will	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
microcoria	B-Disease
and	O
glaucoma	B-Disease
causation	O
.	O
	
The	O
relationship	O
between	O
microcoria	B-Disease
","	O
glaucoma	B-Disease
","	O
and	O
the	O
MYOC	O
Q48H	O
mutation	O
in	O
this	O
family	O
is	O
discussed	O
.	O
	
	
A	O
novel	O
mutation	O
(	O
E333D	O
)	O
in	O
the	O
thyroid	O
hormone	O
beta	O
receptor	O
causing	O
resistance	B-Disease
to	I-Disease
thyroid	I-Disease
hormone	I-Disease
syndrome	I-Disease
.	O
	
Resistance	B-Disease
to	I-Disease
thyroid	I-Disease
hormone	I-Disease
(	O
RTH	B-Disease
)	O
is	O
an	O
inherited	O
syndrome	O
characterized	O
by	O
elevated	O
serum	O
thyroid	B-Chemical
hormones	I-Chemical
(	O
TH	B-Chemical
)","	O
failure	O
to	O
suppress	O
pituitary	O
thyroid	O
stimulating	O
hormone	O
(	O
TSH	O
)	O
secretion	O
","	O
and	O
variable	O
peripheral	O
tissue	O
responsiveness	O
to	O
TH	B-Chemical
.	O
	
The	O
disorder	O
is	O
associated	O
with	O
diverse	O
mutations	O
in	O
the	O
thyroid	O
hormone	O
beta	O
receptor	O
(	O
TRbeta	O
).	O
	
Here	O
","	O
we	O
report	O
a	O
novel	O
natural	O
RTH	B-Disease
mutation	O
(	O
E333D	O
)	O
located	O
in	O
the	O
large	O
carboxy	O
-	O
terminal	O
ligand	O
binding	O
domain	O
of	O
TRbeta	O
.	O
	
The	O
mutation	O
was	O
identified	O
in	O
a	O
22	O
-	O
year	O
-	O
old	O
French	O
woman	O
coming	O
to	O
medical	O
attention	O
because	O
of	O
an	O
increasing	O
overweight	B-Disease
.	O
	
Biochemical	O
tests	O
showed	O
elevated	O
free	O
thyroxine	B-Chemical
(	O
T4	B-Chemical
:	O
20	O
.	O
8	O
pg	O
/	O
ml	O
(	O
normal	O
","	O
8	O
.	O
5	O
-	O
18	O
))	O
and	O
triiodothyronine	B-Chemical
(	O
T3	B-Chemical
:	O
5	O
.	O
7	O
pg	O
/	O
ml	O
(	O
normal	O
","	O
1	O
.	O
4	O
-	O
4	O
))	O
in	O
the	O
serum	O
","	O
together	O
with	O
an	O
inappropriately	O
nonsuppressed	O
TSH	O
level	O
of	O
4	O
.	O
7	O
mU	O
/	O
ml	O
(	O
normal	O
","	O
0	O
.	O
4	O
-	O
4	O
).	O
	
Her	O
father	O
and	O
her	O
brother	O
'	O
s	O
serum	O
tests	O
also	O
showed	O
biochemical	O
abnormalities	O
consistent	O
with	O
RTH	B-Disease
.	O
	
Direct	O
sequencing	O
of	O
the	O
TRbeta	O
gene	O
revealed	O
a	O
heterozygous	O
transition	O
1284A	O
>	O
C	O
in	O
exon	O
9	O
resulting	O
in	O
substitution	O
of	O
glutamic	O
acid	O
333	O
by	O
aspartic	O
acid	O
residue	O
(	O
E333D	O
).	O
	
Further	O
functional	O
analyses	O
of	O
the	O
novel	O
TRbeta	O
mutant	O
were	O
conducted	O
.	O
	
We	O
found	O
that	O
the	O
E333D	O
mutation	O
neither	O
significantly	O
affected	O
the	O
affinity	O
of	O
the	O
receptor	O
for	O
T3	B-Chemical
nor	O
modified	O
heterodimer	O
formation	O
with	O
retinoid	O
X	O
receptor	O
(	O
RXR	O
)	O
when	O
bound	O
to	O
DNA	O
.	O
	
However	O
","	O
in	O
transient	O
transfection	O
assays	O
","	O
the	O
E333D	O
TRbeta	O
mutant	O
exhibited	O
impaired	O
transcriptional	O
regulation	O
on	O
two	O
distinct	O
positively	O
regulated	O
thyroid	O
response	O
elements	O
(	O
F2	O
-	O
and	O
DR4	O
-	O
TREs	O
)	O
as	O
well	O
as	O
on	O
the	O
negatively	O
regulated	O
human	O
TSHalpha	O
promoter	O
.	O
	
Moreover	O
","	O
a	O
dominant	O
inhibition	O
of	O
the	O
wild	O
-	O
type	O
TRbeta	O
counterpart	O
transactivation	O
function	O
was	O
observed	O
on	O
both	O
a	O
positive	O
(	O
F2	O
-	O
TRE	O
)	O
and	O
a	O
negative	O
(	O
TSHalpha	O
)	O
promoter	O
.	O
	
These	O
results	O
strongly	O
suggest	O
that	O
the	O
E333D	O
TRbeta	O
mutation	O
is	O
responsible	O
for	O
the	O
RTH	B-Disease
phenotype	O
in	O
the	O
proposita	O
'	O
s	O
family	O
.	O
	
	
Common	O
germline	O
genetic	O
variation	O
in	O
antioxidant	O
defense	O
genes	O
and	O
survival	O
after	O
diagnosis	O
of	O
breast	B-Disease
cancer	I-Disease
.	O
	
PURPOSE	O
:	O
The	O
prognosis	O
of	O
breast	B-Disease
cancer	I-Disease
varies	O
considerably	O
among	O
individuals	O
","	O
and	O
inherited	O
genetic	O
factors	O
may	O
help	O
explain	O
this	O
variability	O
.	O
	
Of	O
particular	O
interest	O
are	O
genes	O
involved	O
in	O
defense	O
against	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
(	O
ROS	B-Chemical
)	O
because	O
ROS	B-Chemical
are	O
thought	O
to	O
cause	O
DNA	O
damage	O
and	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
cancer	B-Disease
.	O
	
PATIENTS	O
AND	O
METHODS	O
:	O
We	O
examined	O
associations	O
between	O
54	O
polymorphisms	O
that	O
tag	O
the	O
known	O
common	O
variants	O
(	O
minor	O
allele	O
frequency	O
>	O
0	O
.	O
5	O
)	O
in	O
10	O
genes	O
involved	O
in	O
oxidative	O
damage	O
repair	O
(	O
CAT	O
","	O
SOD1	O
","	O
SOD2	O
","	O
GPX1	O
","	O
GPX4	O
","	O
GSR	O
","	O
TXN	O
","	O
TXN2	O
","	O
TXNRD1	O
","	O
and	O
TXNRD2	O
)	O
and	O
survival	O
in	O
4	O
","	O
470	O
women	O
with	O
breast	B-Disease
cancer	I-Disease
.	O
	
RESULTS	O
:	O
Two	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
GPX4	O
(	O
rs713041	O
and	O
rs757229	O
)	O
were	O
associated	O
with	O
all	O
-	O
cause	O
mortality	O
even	O
after	O
adjusting	O
for	O
multiple	O
hypothesis	O
testing	O
(	O
adjusted	O
P	O
=	O
.	O
41	O
and	O
P	O
=	O
.	O
35	O
).	O
	
These	O
SNPs	O
are	O
correlated	O
with	O
each	O
other	O
(	O
r2	O
=	O
0	O
.	O
61	O
).	O
	
GPX4	O
rs713041	O
is	O
located	O
near	O
the	O
selenocysteine	B-Chemical
insertion	O
sequence	O
element	O
in	O
the	O
GPX4	O
3	O
'	O
untranslated	O
region	O
","	O
and	O
the	O
rare	O
allele	O
of	O
this	O
SNP	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
death	B-Disease
","	O
with	O
a	O
hazard	O
ratio	O
of	O
1	O
.	O
27	O
per	O
rare	O
allele	O
carried	O
(	O
95	O
%	O
CI	O
","	O
1	O
.	O
13	O
to	O
11	O
.	O
43	O
).	O
	
This	O
effect	O
was	O
not	O
attenuated	O
after	O
adjusting	O
for	O
tumor	B-Disease
stage	O
","	O
grade	O
","	O
or	O
estrogen	O
receptor	O
status	O
.	O
	
We	O
found	O
that	O
the	O
common	O
allele	O
is	O
preferentially	O
expressed	O
in	O
normal	O
lymphocytes	O
","	O
normal	O
breast	O
","	O
and	O
breast	B-Disease
tumors	I-Disease
compared	O
with	O
the	O
rare	O
allele	O
","	O
but	O
there	O
were	O
no	O
differences	O
in	O
total	O
levels	O
of	O
GPX4	O
mRNA	O
across	O
genotypes	O
.	O
	
CONCLUSION	O
:	O
These	O
data	O
provide	O
strong	O
support	O
for	O
the	O
hypothesis	O
that	O
common	O
variation	O
in	O
GPX4	O
is	O
associated	O
with	O
prognosis	O
after	O
a	O
diagnosis	O
of	O
breast	B-Disease
cancer	I-Disease
.	O
	
	
Integrated	O
genomic	O
and	O
expression	O
profiling	O
in	O
mantle	B-Disease
cell	I-Disease
lymphoma	I-Disease
:	O
identification	O
of	O
gene	O
-	O
dosage	O
regulated	O
candidate	O
genes	O
.	O
	
Mantle	B-Disease
cell	I-Disease
lymphoma	I-Disease
(	O
MCL	B-Disease
)	O
is	O
characterized	O
by	O
the	O
t	O
(	O
11	O
";"	O
14	O
)(	O
q13	O
";"	O
q32	O
)	O
translocation	O
and	O
several	O
other	O
cytogenetic	O
aberrations	O
","	O
including	O
heterozygous	O
loss	O
of	O
chromosomal	O
arms	O
1p	O
","	O
6q	O
","	O
11q	O
and	O
13q	O
and	O
/	O
or	O
gains	O
of	O
3q	O
and	O
8q	O
.	O
	
The	O
common	O
intervals	O
of	O
chromosomal	O
imbalance	O
have	O
been	O
narrowed	O
down	O
using	O
array	O
-	O
comparative	O
genomic	O
hybridization	O
(	O
CGH	O
).	O
	
However	O
","	O
the	O
chromosomal	O
intervals	O
still	O
contain	O
many	O
genes	O
potentially	O
involved	O
in	O
MCL	B-Disease
pathogeny	O
.	O
	
Combined	O
analysis	O
of	O
tiling	O
-	O
resolution	O
array	O
-	O
CGH	O
with	O
gene	O
expression	O
profiling	O
on	O
11	O
MCL	B-Disease
tumours	I-Disease
enabled	O
the	O
identification	O
of	O
genomic	O
alterations	O
and	O
their	O
corresponding	O
gene	O
expression	O
profiles	O
.	O
	
Only	O
subsets	O
of	O
genes	O
located	O
within	O
given	O
cytogenetic	O
anomaly	O
-	O
intervals	O
showed	O
a	O
concomitant	O
change	O
in	O
mRNA	O
expression	O
level	O
.	O
	
The	O
genes	O
that	O
showed	O
consistent	O
correlation	O
between	O
DNA	O
copy	O
number	O
and	O
RNA	O
expression	O
levels	O
are	O
likely	O
to	O
be	O
important	O
in	O
MCL	B-Disease
pathology	O
.	O
	
Besides	O
several	O
'	O
anonymous	O
genes	O
'","	O
we	O
also	O
identified	O
various	O
fully	O
annotated	O
genes	O
","	O
whose	O
gene	O
products	O
are	O
involved	O
in	O
cyclic	B-Chemical
adenosine	I-Chemical
monophosphate	I-Chemical
-	O
regulated	O
pathways	O
(	O
PRKACB	O
)","	O
DNA	O
damage	O
repair	O
","	O
maintenance	O
of	O
chromosome	O
stability	O
and	O
prevention	O
of	O
rereplication	O
(	O
ATM	O
","	O
ERCC5	O
","	O
FBXO5	O
)","	O
energy	O
metabolism	O
(	O
such	O
as	O
genes	O
that	O
are	O
involved	O
in	O
the	O
synthesis	O
of	O
proteins	O
encoded	O
by	O
the	O
mitochondrial	O
genome	O
)	O
and	O
signal	O
transduction	O
(	O
ARHGAP29	O
).	O
	
Deregulation	O
of	O
these	O
gene	O
products	O
may	O
interfere	O
with	O
the	O
signalling	O
pathways	O
that	O
are	O
involved	O
in	O
MCL	B-Disease
tumour	I-Disease
development	O
and	O
maintenance	O
.	O
	
	
The	O
six	O
-	O
nucleotide	O
deletion	O
/	O
insertion	O
variant	O
in	O
the	O
CASP8	O
promoter	O
region	O
is	O
inversely	O
associated	O
with	O
risk	O
of	O
squamous	B-Disease
cell	I-Disease
carcinoma	I-Disease
of	I-Disease
the	I-Disease
head	I-Disease
and	I-Disease
neck	I-Disease
.	O
	
Caspase	O
8	O
(	O
CASP8	O
)	O
is	O
an	O
apoptosis	O
-	O
related	O
cysteine	O
peptidase	O
involved	O
in	O
the	O
death	O
receptor	O
pathway	O
and	O
likely	O
in	O
the	O
mitochondrial	O
pathway	O
.	O
	
A	O
CASP8	O
promoter	O
region	O
six	O
-	O
nucleotide	O
deletion	O
/	O
insertion	O
(-	O
652	O
6N	O
ins	O
/	O
del	O
)	O
variant	O
and	O
a	O
coding	O
region	O
D302H	O
polymorphism	O
are	O
reportedly	O
important	O
in	O
cancer	B-Disease
development	O
","	O
but	O
no	O
reported	O
study	O
has	O
assessed	O
the	O
associations	O
of	O
these	O
genetic	O
variations	O
with	O
risk	O
of	O
head	B-Disease
and	I-Disease
neck	I-Disease
cancer	I-Disease
.	O
	
In	O
a	O
hospital	O
-	O
based	O
study	O
of	O
non	O
-	O
Hispanic	O
whites	O
","	O
we	O
genotyped	O
CASP8	O
-	O
652	O
6N	O
del	O
and	O
302H	O
variants	O
in	O
1	O
","	O
23	O
patients	O
with	O
squamous	B-Disease
cell	I-Disease
carcinoma	I-Disease
of	I-Disease
the	I-Disease
head	I-Disease
and	I-Disease
neck	I-Disease
(	O
SCCHN	B-Disease
)	O
and	O
1	O
","	O
52	O
cancer	O
-	O
free	O
controls	O
.	O
	
Crude	O
and	O
adjusted	O
odds	O
ratios	O
(	O
OR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
were	O
estimated	O
using	O
unconditional	O
logistic	O
regression	O
models	O
.	O
	
The	O
CASP8	O
-	O
652	O
6N	O
del	O
variant	O
genotypes	O
or	O
haplotypes	O
were	O
inversely	O
associated	O
with	O
SCCHN	B-Disease
risk	O
(	O
adjusted	O
OR	O
","	O
0	O
.	O
70	O
";"	O
95	O
%	O
CI	O
","	O
0	O
.	O
57	O
-	O
0	O
.	O
85	O
for	O
the	O
ins	O
/	O
del	O
+	O
del	O
/	O
del	O
genotypes	O
compared	O
with	O
the	O
ins	O
/	O
ins	O
genotype	O
";"	O
adjusted	O
OR	O
","	O
0	O
.	O
73	O
";"	O
95	O
%	O
CI	O
","	O
0	O
.	O
55	O
-	O
0	O
.	O
97	O
for	O
the	O
del	O
-	O
D	O
haplotype	O
compared	O
with	O
the	O
ins	O
-	O
D	O
haplotype	O
).	O
	
Furthermore	O
","	O
the	O
number	O
of	O
the	O
CASP8	O
-	O
652	O
6N	O
del	O
(	O
but	O
not	O
302H	O
)	O
variant	O
allele	O
tended	O
to	O
correlate	O
with	O
increased	O
levels	O
of	O
camptothecin	B-Chemical
-	O
induced	O
p53	O
-	O
mediated	O
apoptosis	O
in	O
T	O
lymphocytes	O
from	O
170	O
cancer	O
-	O
free	O
controls	O
.	O
	
We	O
concluded	O
that	O
the	O
CASP8	O
-	O
652	O
6N	O
del	O
variant	O
allele	O
may	O
contribute	O
to	O
the	O
risk	O
of	O
developing	O
SCCHN	B-Disease
in	O
non	O
-	O
Hispanic	O
white	O
populations	O
.	O
	
Further	O
validation	O
by	O
population	O
-	O
based	O
case	O
-	O
control	O
studies	O
and	O
rigorous	O
mechanistic	O
studies	O
is	O
warranted	O
.	O
	
	
Thyroid	O
hormone	O
receptor	O
a	O
mutation	O
causes	O
a	O
severe	O
and	O
thyroxine	B-Chemical
-	O
resistant	O
skeletal	B-Disease
dysplasia	I-Disease
in	O
female	O
mice	O
.	O
	
A	O
new	O
genetic	O
disorder	O
has	O
been	O
identified	O
that	O
results	O
from	O
mutation	O
of	O
THRA	O
","	O
encoding	O
thyroid	O
hormone	O
receptor	O
a1	O
(	O
TRa1	O
).	O
	
Affected	O
children	O
have	O
a	O
high	O
serum	O
T3	B-Chemical
:	O
T4	B-Chemical
ratio	O
and	O
variable	O
degrees	O
of	O
intellectual	B-Disease
deficit	I-Disease
and	O
constipation	B-Disease
but	O
exhibit	O
a	O
consistently	O
severe	O
skeletal	B-Disease
dysplasia	I-Disease
.	O
	
In	O
an	O
attempt	O
to	O
improve	O
developmental	B-Disease
delay	I-Disease
and	O
alleviate	O
symptoms	O
of	O
hypothyroidism	B-Disease
","	O
patients	O
are	O
receiving	O
varying	O
doses	O
and	O
durations	O
of	O
T4	B-Chemical
treatment	O
","	O
but	O
responses	O
have	O
been	O
inconsistent	O
so	O
far	O
.	O
	
Thra1	O
(	O
PV	O
/+)	O
mice	O
express	O
a	O
similar	O
potent	O
dominant	O
-	O
negative	O
mutant	O
TRa1	O
to	O
affected	O
individuals	O
","	O
and	O
thus	O
represent	O
an	O
excellent	O
disease	O
model	O
.	O
	
We	O
hypothesized	O
that	O
Thra1	O
(	O
PV	O
/+)	O
mice	O
could	O
be	O
used	O
to	O
predict	O
the	O
skeletal	O
outcome	O
of	O
human	O
THRA	O
mutations	O
and	O
determine	O
whether	O
prolonged	O
treatment	O
with	O
a	O
supraphysiological	O
dose	O
of	O
T4	B-Chemical
ameliorates	O
the	O
skeletal	B-Disease
abnormalities	I-Disease
.	O
	
Adult	O
female	O
Thra1	O
(	O
PV	O
/+)	O
mice	O
had	O
short	B-Disease
stature	I-Disease
","	O
grossly	O
abnormal	O
bone	O
morphology	O
but	O
normal	O
bone	O
strength	O
despite	O
high	O
bone	O
mass	O
.	O
	
Although	O
T4	B-Chemical
treatment	O
suppressed	O
TSH	O
secretion	O
","	O
it	O
had	O
no	O
effect	O
on	O
skeletal	O
maturation	O
","	O
linear	O
growth	O
","	O
or	O
bone	O
mineralization	O
","	O
thus	O
demonstrating	O
profound	O
tissue	O
resistance	B-Disease
to	I-Disease
thyroid	I-Disease
hormone	I-Disease
.	O
	
Despite	O
this	O
","	O
prolonged	O
T4	B-Chemical
treatment	O
abnormally	O
increased	O
bone	O
stiffness	O
and	O
strength	O
","	O
suggesting	O
the	O
potential	O
for	O
detrimental	O
consequences	O
in	O
the	O
long	O
term	O
.	O
	
Our	O
studies	O
establish	O
that	O
TRa1	O
has	O
an	O
essential	O
role	O
in	O
the	O
developing	O
and	O
adult	O
skeleton	O
and	O
predict	O
that	O
patients	O
with	O
different	O
THRA	O
mutations	O
will	O
display	O
variable	O
responses	O
to	O
T4	B-Chemical
treatment	O
","	O
which	O
depend	O
on	O
the	O
severity	O
of	O
the	O
causative	O
mutation	O
.	O
	
	
NF	O
-	O
kB	O
functions	O
as	O
a	O
molecular	O
link	O
between	O
tumor	B-Disease
cells	O
and	O
Th1	O
/	O
Tc1	O
T	O
cells	O
in	O
the	O
tumor	B-Disease
microenvironment	O
to	O
exert	O
radiation	O
-	O
mediated	O
tumor	B-Disease
suppression	O
.	O
	
Radiation	O
modulates	O
both	O
tumor	B-Disease
cells	O
and	O
immune	O
cells	O
in	O
the	O
tumor	B-Disease
microenvironment	O
to	O
exert	O
its	O
anti	O
-	O
tumor	B-Disease
activity	O
";"	O
however	O
","	O
the	O
molecular	O
connection	O
between	O
tumor	B-Disease
cells	O
and	O
immune	O
cells	O
that	O
mediates	O
radiation	O
-	O
exerted	O
tumor	B-Disease
suppression	O
activity	O
in	O
the	O
tumor	B-Disease
microenvironment	O
is	O
largely	O
unknown	O
.	O
	
We	O
report	O
here	O
that	O
radiation	O
induces	O
rapid	O
activation	O
of	O
the	O
p65	O
/	O
p50	O
and	O
p50	O
/	O
p50	O
NF	O
-	O
kB	O
complexes	O
in	O
human	O
soft	B-Disease
tissue	I-Disease
sarcoma	I-Disease
(	O
STS	B-Disease
)	O
cells	O
.	O
	
Radiation	O
-	O
activated	O
p65	O
/	O
p50	O
and	O
p50	O
/	O
p50	O
bind	O
to	O
the	O
TNFa	O
promoter	O
to	O
activate	O
its	O
transcription	O
in	O
STS	B-Disease
cells	O
.	O
	
Radiation	O
-	O
induced	O
TNFa	O
induces	O
tumor	B-Disease
cell	O
death	O
in	O
an	O
autocrine	O
manner	O
.	O
	
A	O
sublethal	O
dose	O
of	O
Smac	O
mimetic	O
BV6	B-Chemical
induces	O
cIAP1	O
and	O
cIAP2	O
degradation	O
to	O
increase	O
tumor	B-Disease
cell	O
sensitivity	O
to	O
radiation	O
-	O
induced	O
cell	O
death	O
in	O
vitro	O
and	O
to	O
enhance	O
radiation	O
-	O
mediated	O
suppression	O
of	O
STS	B-Disease
xenografts	O
in	O
vivo	O
.	O
	
Inhibition	O
of	O
caspases	O
","	O
RIP1	O
","	O
or	O
RIP3	O
blocks	O
radiation	O
/	O
TNFa	O
-	O
induced	O
cell	O
death	O
","	O
whereas	O
inhibition	O
of	O
RIP1	O
blocks	O
TNFa	O
-	O
induced	O
caspase	O
activation	O
","	O
suggesting	O
that	O
caspases	O
and	O
RIP1	O
act	O
sequentially	O
to	O
mediate	O
the	O
non	O
-	O
compensatory	O
cell	O
death	O
pathways	O
.	O
	
Furthermore	O
","	O
we	O
determined	O
in	O
a	O
syngeneic	O
sarcoma	B-Disease
mouse	O
model	O
that	O
radiation	O
up	O
-	O
regulates	O
IRF3	O
","	O
IFNb	O
","	O
and	O
the	O
T	O
cell	O
chemokines	O
CCL2	O
and	O
CCL5	O
in	O
the	O
tumor	B-Disease
microenvironment	O
","	O
which	O
are	O
associated	O
with	O
activation	O
and	O
increased	O
infiltration	O
of	O
Th1	O
/	O
Tc1	O
T	O
cells	O
in	O
the	O
tumor	B-Disease
microenvironment	O
.	O
	
Moreover	O
","	O
tumor	B-Disease
-	O
infiltrating	O
T	O
cells	O
are	O
in	O
their	O
active	O
form	O
since	O
both	O
the	O
perforin	O
and	O
FasL	O
pathways	O
are	O
activated	O
in	O
irradiated	O
tumor	B-Disease
tissues	O
.	O
	
Consequently	O
","	O
combined	O
BV6	B-Chemical
and	O
radiation	O
completely	O
suppressed	O
tumor	B-Disease
growth	O
in	O
vivo	O
.	O
	
Therefore	O
","	O
radiation	O
-	O
induced	O
NF	O
-	O
kB	O
functions	O
as	O
a	O
molecular	O
link	O
between	O
tumor	B-Disease
cells	O
and	O
immune	O
cells	O
in	O
the	O
tumor	B-Disease
microenvironment	O
for	O
radiation	O
-	O
mediated	O
tumor	B-Disease
suppression	O
.	O
	
	
Bach1	O
siRNA	O
attenuates	O
bleomycin	B-Chemical
-	O
induced	O
pulmonary	B-Disease
fibrosis	I-Disease
by	O
modulating	O
oxidative	O
stress	O
in	O
mice	O
.	O
	
Oxidative	O
stress	O
plays	O
an	O
essential	O
role	O
in	O
inflammation	B-Disease
and	O
fibrosis	B-Disease
.	O
	
Bach1	O
is	O
an	O
important	O
transcriptional	O
repressor	O
that	O
acts	O
by	O
modulating	O
oxidative	O
stress	O
and	O
represents	O
a	O
potential	O
target	O
in	O
the	O
treatment	O
of	O
pulmonary	B-Disease
fibrosis	I-Disease
(	O
PF	B-Disease
).	O
	
In	O
this	O
study	O
","	O
we	O
knocked	O
down	O
Bach1	O
using	O
adenovirus	O
-	O
mediated	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
to	O
determine	O
whether	O
the	O
use	O
of	O
Bach1	O
siRNA	O
is	O
an	O
effective	O
therapeutic	O
strategy	O
in	O
mice	O
with	O
bleomycin	B-Chemical
(	O
BLM	B-Chemical
)-	O
induced	O
PF	B-Disease
.	O
	
Mouse	O
lung	O
fibroblasts	O
(	O
MLFs	O
)	O
were	O
incubated	O
with	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)-	O
b1	O
(	O
5	O
ng	O
/	O
ml	O
)	O
and	O
subsequently	O
infected	O
with	O
recombined	O
adenovirus	O
-	O
like	O
Bach1	O
siRNA1	O
and	O
Bach1	O
siRNA2	O
","	O
while	O
an	O
empty	O
adenovirus	O
vector	O
was	O
used	O
as	O
the	O
negative	O
control	O
.	O
	
The	O
selected	O
Bach1	O
siRNA	O
with	O
higher	O
interference	O
efficiency	O
was	O
used	O
for	O
the	O
animal	O
experiments	O
.	O
	
A	O
mouse	O
model	O
of	O
BLM	B-Chemical
-	O
induced	O
PF	B-Disease
was	O
established	O
","	O
and	O
Bach1	O
siRNA	O
(	O
1x109	O
pfu	O
)	O
was	O
administered	O
to	O
the	O
mice	O
via	O
the	O
tail	O
vein	O
.	O
	
The	O
results	O
revealed	O
that	O
the	O
Bach1	O
mRNA	O
and	O
protein	O
levels	O
were	O
significantly	O
downregulated	O
by	O
Bach1	O
siRNA	O
.	O
	
Furthermore	O
","	O
the	O
MLFs	O
infected	O
with	O
Bach1	O
siRNA	O
exhibited	O
increased	O
mRNA	O
and	O
protein	O
expression	O
levels	O
of	O
heme	O
oxygenase	O
-	O
1	O
and	O
glutathione	O
peroxidase	O
1	O
","	O
but	O
decreased	O
levels	O
of	O
TGF	O
-	O
b1	O
and	O
interleukin	O
-	O
6	O
in	O
the	O
cell	O
supernatants	O
compared	O
with	O
the	O
cells	O
exposed	O
to	O
TGF	O
-	O
b1	O
alone	O
.	O
	
Bach1	O
knockdown	O
by	O
siRNA	O
also	O
enhanced	O
the	O
expression	O
of	O
antioxidant	O
factors	O
","	O
but	O
suppressed	O
that	O
of	O
fibrosis	B-Disease
-	O
related	O
cytokines	O
in	O
mice	O
compared	O
with	O
the	O
BLM	B-Chemical
group	O
.	O
	
Finally	O
","	O
the	O
inflammatory	B-Disease
infiltration	O
of	O
alveolar	O
and	O
interstitial	O
cells	O
and	O
the	O
destruction	O
of	O
lung	O
structure	O
were	O
significantly	O
attenuated	O
in	O
the	O
mide	O
administered	O
Bach1	O
siRNA	O
compared	O
with	O
those	O
in	O
the	O
BLM	B-Chemical
group	O
.	O
	
On	O
the	O
whole	O
","	O
our	O
findings	O
demonstrate	O
that	O
Bach1	O
siRNA	O
exerts	O
protective	O
effects	O
against	O
BLM	B-Chemical
-	O
induced	O
PF	B-Disease
in	O
mice	O
.	O
	
Our	O
data	O
may	O
provide	O
the	O
basis	O
for	O
the	O
development	O
of	O
novel	O
targeted	O
therapeutic	O
strategies	O
for	O
PF	B-Disease
.	O
	
	
Tissue	O
-	O
Specific	O
Ablation	O
of	O
the	O
LIF	O
Receptor	O
in	O
the	O
Murine	O
Uterine	O
Epithelium	O
Results	O
in	O
Implantation	O
Failure	O
.	O
	
The	O
cytokine	O
leukemia	O
inhibitory	O
factor	O
(	O
LIF	O
)	O
is	O
essential	O
for	O
rendering	O
the	O
uterus	O
receptive	O
for	O
blastocyst	O
implantation	O
.	O
	
In	O
mice	O
","	O
LIF	O
receptor	O
expression	O
(	O
LIFR	O
)	O
is	O
largely	O
restricted	O
to	O
the	O
uterine	O
luminal	O
epithelium	O
(	O
LE	O
).	O
	
LIF	O
","	O
secreted	O
from	O
the	O
endometrial	O
glands	O
(	O
GEs	O
)","	O
binds	O
to	O
the	O
LIFR	O
","	O
activating	O
the	O
Janus	O
kinase	O
-	O
signal	O
transducer	O
and	O
activation	O
of	O
transcription	O
(	O
STAT	O
)	O
3	O
(	O
Jak	O
-	O
Stat3	O
)	O
signaling	O
pathway	O
in	O
the	O
LE	O
.	O
	
JAK	O
-	O
STAT	O
activation	O
converts	O
the	O
LE	O
to	O
a	O
receptive	O
state	O
so	O
that	O
juxtaposed	O
blastocysts	O
begin	O
to	O
implant	O
.	O
	
To	O
specifically	O
delete	O
the	O
LIFR	O
in	O
the	O
LE	O
","	O
we	O
derived	O
a	O
line	O
of	O
mice	O
in	O
which	O
Cre	O
recombinase	O
was	O
inserted	O
into	O
the	O
endogenous	O
lactoferrin	O
gene	O
(	O
Ltf	O
-	O
Cre	O
).	O
	
Lactoferrin	O
expression	O
in	O
the	O
LE	O
is	O
induced	O
by	O
E2	O
","	O
and	O
we	O
demonstrate	O
that	O
Cre	O
recombinase	O
activity	O
is	O
restricted	O
to	O
the	O
LE	O
and	O
GE	O
.	O
	
To	O
determine	O
the	O
requirement	O
of	O
the	O
LIFR	O
in	O
implantation	O
","	O
we	O
derived	O
an	O
additional	O
mouse	O
line	O
carrying	O
a	O
conditional	O
(	O
floxed	O
)	O
Lifr	O
flx	O
/	O
flx	O
gene	O
.	O
	
Crossing	O
Ltf	O
-	O
Cre	O
mice	O
with	O
Lifr	O
flx	O
/	O
flx	O
mice	O
generated	O
Lifr	O
flx	O
/	O
D	O
:	O
Ltf	O
Cre	O
/+	O
females	O
that	O
were	O
overtly	O
normal	O
but	O
infertile	O
.	O
	
Many	O
of	O
these	O
females	O
","	O
despite	O
repeated	O
matings	O
","	O
did	O
not	O
become	O
pregnant	O
.	O
	
Unimplanted	O
blastocysts	O
were	O
recovered	O
from	O
the	O
Lifr	O
flx	O
/	O
D	O
:	O
Ltf	O
Cre	O
/+	O
uteri	O
and	O
","	O
when	O
transferred	O
to	O
wild	O
-	O
type	O
recipients	O
","	O
implanted	O
normally	O
","	O
indicating	O
that	O
uterine	O
receptivity	O
rather	O
than	O
the	O
embryo	O
'	O
s	O
competency	O
is	O
compromised	O
.	O
	
The	O
loss	O
of	O
Lifr	O
results	O
in	O
both	O
the	O
failure	O
for	O
STAT3	O
to	O
translocate	O
to	O
the	O
LE	O
nuclei	O
and	O
a	O
reduction	O
in	O
the	O
expression	O
of	O
the	O
LIF	O
regulated	O
gene	O
Msx1	O
that	O
regulates	O
uterine	O
receptivity	O
.	O
	
These	O
results	O
reveal	O
that	O
uterine	O
expression	O
of	O
the	O
LIFR	O
is	O
essential	O
for	O
embryo	O
implantation	O
and	O
further	O
define	O
the	O
components	O
of	O
the	O
LIF	O
signaling	O
pathway	O
necessary	O
for	O
effective	O
implantation	O
.	O
	
	
Genome	O
-	O
wide	O
loss	O
-	O
of	O
-	O
function	O
genetic	O
screening	O
identifies	O
opioid	O
receptor	O
u1	O
as	O
a	O
key	O
regulator	O
of	O
L	B-Chemical
-	I-Chemical
asparaginase	I-Chemical
resistance	O
in	O
pediatric	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
.	O
	
L	B-Chemical
-	I-Chemical
asparaginase	I-Chemical
is	O
a	O
critical	O
chemotherapeutic	O
agent	O
for	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
(	O
ALL	B-Disease
).	O
	
It	O
hydrolyzes	O
plasma	O
asparagine	B-Chemical
into	O
aspartate	B-Chemical
and	O
NH3	B-Chemical
","	O
causing	O
asparagine	B-Disease
deficit	I-Disease
and	O
inhibition	O
of	O
protein	O
synthesis	O
and	O
eventually	O
","	O
leukemic	B-Disease
cell	O
death	O
.	O
	
However	O
","	O
patient	O
relapse	O
often	O
occurs	O
due	O
to	O
development	O
of	O
resistance	O
.	O
	
The	O
molecular	O
mechanism	O
by	O
which	O
ALL	B-Disease
cells	O
acquire	O
resistance	O
to	O
L	B-Chemical
-	I-Chemical
asparaginase	I-Chemical
is	O
unknown	O
.	O
	
Therefore	O
","	O
we	O
sought	O
to	O
identify	O
genes	O
that	O
are	O
involved	O
in	O
L	B-Chemical
-	I-Chemical
asparaginase	I-Chemical
resistance	O
in	O
primary	O
leukemic	B-Disease
cells	O
.	O
	
By	O
unbiased	O
genome	O
-	O
wide	O
RNAi	O
screening	O
","	O
we	O
found	O
that	O
among	O
10	O
resistant	O
ALL	B-Disease
clones	O
","	O
six	O
hits	O
were	O
for	O
opioid	O
receptor	O
mu	O
1	O
(	O
oprm1	O
)","	O
two	O
hits	O
were	O
for	O
carbonic	O
anhydrase	O
1	O
(	O
ca1	O
)	O
and	O
another	O
two	O
hits	O
were	O
for	O
ubiquitin	O
-	O
conjugating	O
enzyme	O
E2C	O
(	O
ube2c	O
).	O
	
We	O
also	O
found	O
that	O
OPRM1	O
is	O
expressed	O
in	O
all	O
leukemic	B-Disease
cells	O
tested	O
.	O
	
Specific	O
knockdown	O
of	O
OPRM1	O
confers	O
L	B-Chemical
-	I-Chemical
asparaginase	I-Chemical
resistance	O
","	O
validating	O
our	O
genome	O
-	O
wide	O
retroviral	O
shRNA	O
library	O
screening	O
data	O
.	O
	
Methadone	B-Chemical
","	O
an	O
agonist	O
of	O
OPRM1	O
","	O
enhances	O
the	O
sensitivity	O
of	O
parental	O
leukemic	B-Disease
cells	O
","	O
but	O
not	O
OPRM1	O
-	O
depleted	O
cells	O
","	O
to	O
L	B-Chemical
-	I-Chemical
asparaginase	I-Chemical
treatment	O
","	O
indicating	O
that	O
OPRM1	O
is	O
required	O
for	O
the	O
synergistic	O
action	O
of	O
L	B-Chemical
-	I-Chemical
asparaginase	I-Chemical
and	O
methadone	B-Chemical
","	O
and	O
that	O
OPRM1	O
loss	O
promotes	O
leukemic	B-Disease
cell	O
survival	O
likely	O
through	O
downregulation	O
of	O
the	O
OPRM1	O
-	O
mediated	O
apoptotic	O
pathway	O
.	O
	
Consistent	O
with	O
this	O
premise	O
","	O
patient	O
leukemic	B-Disease
cells	O
with	O
relatively	O
high	O
levels	O
of	O
OPRM1	O
are	O
more	O
sensitive	O
to	O
L	B-Chemical
-	I-Chemical
asparaginase	I-Chemical
treatment	O
compared	O
to	O
OPRM1	O
-	O
depleted	O
leukemic	B-Disease
cells	O
","	O
further	O
indicating	O
that	O
OPRM1	O
loss	O
has	O
a	O
crucial	O
role	O
in	O
L	B-Chemical
-	I-Chemical
asparaginase	I-Chemical
resistance	O
in	O
leukemic	B-Disease
patients	O
.	O
	
Thus	O
","	O
our	O
study	O
demonstrates	O
for	O
the	O
first	O
time	O
","	O
a	O
novel	O
OPRM1	O
-	O
mediated	O
mechanism	O
for	O
L	B-Chemical
-	I-Chemical
asparaginase	I-Chemical
resistance	O
in	O
ALL	B-Disease
","	O
and	O
identifies	O
OPRM1	O
as	O
a	O
functional	O
biomarker	O
for	O
defining	O
high	O
-	O
risk	O
subpopulations	O
and	O
for	O
the	O
detection	O
of	O
evolving	O
resistant	O
clones	O
.	O
	
Oprm1	O
may	O
also	O
be	O
utilized	O
for	O
effective	O
treatment	O
of	O
L	B-Chemical
-	I-Chemical
asparaginase	I-Chemical
-	O
resistant	O
ALL	B-Disease
.	O
Oncogene	O
advance	O
online	O
publication	O
","	O
26	O
June	O
2017	O
";"	O
doi	O
:	O
10	O
.	O
1038	O
/	O
onc	O
.	O
2017	O
.	O
211	O
.	O
	
	
Photochemoprevention	O
of	O
ultraviolet	O
B	O
signaling	O
and	O
photocarcinogenesis	O
.	O
	
Exposure	O
to	O
solar	O
radiation	O
","	O
particularly	O
its	O
ultraviolet	O
(	O
UV	O
)	O
B	O
component	O
","	O
has	O
a	O
variety	O
of	O
harmful	O
effects	O
on	O
human	O
health	O
.	O
	
Some	O
of	O
these	O
effects	O
include	O
sunburn	O
cell	O
formation	O
","	O
basal	B-Disease
and	I-Disease
squamous	I-Disease
cell	I-Disease
cancers	I-Disease
","	O
melanoma	B-Disease
","	O
cataracts	B-Disease
","	O
photoaging	O
of	O
the	O
skin	O
","	O
and	O
immune	O
suppression	O
.	O
	
Amongst	O
these	O
various	O
adverse	O
effects	O
of	O
UV	O
radiation	O
","	O
skin	B-Disease
cancer	I-Disease
is	O
of	O
the	O
greatest	O
concern	O
.	O
	
Over	O
the	O
years	O
","	O
changes	O
in	O
lifestyle	O
has	O
led	O
to	O
a	O
significant	O
increase	O
in	O
the	O
amount	O
of	O
UV	O
radiation	O
that	O
people	O
receive	O
","	O
and	O
this	O
consequently	O
has	O
led	O
to	O
a	O
surge	O
in	O
the	O
incidence	O
of	O
skin	B-Disease
cancer	I-Disease
.	O
	
The	O
development	O
of	O
skin	B-Disease
cancer	I-Disease
is	O
a	O
complex	O
multistage	O
phenomenon	O
involving	O
three	O
distinct	O
stages	O
exemplified	O
by	O
initiation	O
","	O
promotion	O
and	O
progression	O
stages	O
.	O
	
Each	O
of	O
these	O
stages	O
is	O
mediated	O
via	O
alterations	O
in	O
various	O
cellular	O
","	O
biochemical	O
","	O
and	O
molecular	O
changes	O
.	O
	
Initiation	O
","	O
the	O
first	O
step	O
in	O
the	O
carcinogenesis	B-Disease
process	O
is	O
essentially	O
an	O
irreversible	O
step	O
in	O
which	O
genetic	O
alterations	O
occur	O
in	O
genes	O
that	O
ultimately	O
leads	O
to	O
DNA	O
modification	O
and	O
fixation	O
of	O
mutation	O
.	O
	
Tumor	B-Disease
promotion	O
is	O
the	O
essential	O
process	O
in	O
cancer	B-Disease
development	O
involving	O
clonal	O
expansion	O
of	O
initiated	O
cells	O
giving	O
rise	O
to	O
pre	O
-	O
malignant	O
and	O
then	O
to	O
malignant	O
lesions	O
","	O
essentially	O
by	O
alterations	O
in	O
signal	O
transduction	O
pathways	O
.	O
	
Tumor	B-Disease
progression	O
involves	O
the	O
conversion	O
of	O
pre	O
-	O
malignant	O
and	O
malignant	O
lesions	O
into	O
an	O
invasive	O
and	O
potentially	O
metastatic	O
malignant	O
tumor	B-Disease
.	O
	
All	O
these	O
processes	O
for	O
skin	B-Disease
cancer	I-Disease
development	O
involve	O
stimulation	O
of	O
DNA	O
synthesis	O
","	O
DNA	O
damage	O
and	O
proliferation	O
","	O
inflammation	B-Disease
","	O
immunosuppression	O
","	O
epidermal	B-Disease
hyperplasia	I-Disease
","	O
cell	O
cycle	O
dysregulation	O
","	O
depletion	O
of	O
antioxidant	B-Chemical
defenses	O
","	O
impairment	O
of	O
signal	O
transduction	O
pathways	O
","	O
induction	O
of	O
cyclooxygenase	O
","	O
increase	O
in	O
prostaglandin	B-Chemical
synthesis	O
","	O
and	O
induction	O
of	O
ornithine	O
decarboxylase	O
.	O
	
Photochemoprevention	O
has	O
been	O
appreciated	O
as	O
a	O
viable	O
approach	O
to	O
reduce	O
the	O
occurrence	O
of	O
skin	B-Disease
cancer	I-Disease
and	O
in	O
recent	O
years	O
","	O
the	O
use	O
of	O
agents	O
","	O
especially	O
botanical	O
antioxidants	B-Chemical
","	O
present	O
in	O
the	O
common	O
diet	O
and	O
beverages	O
consumed	O
by	O
human	O
population	O
have	O
gained	O
considerable	O
attention	O
as	O
photochemopreventive	O
agents	O
for	O
human	O
use	O
.	O
	
Many	O
such	O
agents	O
have	O
also	O
found	O
a	O
place	O
in	O
skin	O
care	O
products	O
.	O
	
Although	O
this	O
is	O
more	O
common	O
in	O
oriental	O
countries	O
","	O
its	O
popularity	O
is	O
significantly	O
growing	O
in	O
western	O
countries	O
.	O
	
In	O
this	O
article	O
","	O
we	O
have	O
summarized	O
the	O
available	O
information	O
of	O
laboratory	O
studies	O
on	O
UVB	O
-	O
mediated	O
signaling	O
that	O
can	O
be	O
exploited	O
as	O
targets	O
for	O
photochemoprevention	O
.	O
	
We	O
suggest	O
that	O
the	O
use	O
of	O
skin	O
care	O
products	O
supplemented	O
with	O
proven	O
chemopreventive	O
agents	O
in	O
conjunction	O
with	O
the	O
use	O
of	O
sunscreens	O
along	O
with	O
educational	O
efforts	O
may	O
be	O
an	O
effective	O
strategy	O
for	O
reducing	O
UV	O
-	O
induced	O
photodamage	O
and	O
skin	B-Disease
cancer	I-Disease
in	O
humans	O
.	O
	
The	O
mechanistic	O
basis	O
for	O
the	O
use	O
of	O
such	O
products	O
is	O
discussed	O
.	O
	
	
A	O
G1103R	O
mutation	O
in	O
CRB1	O
is	O
co	O
-	O
inherited	O
with	O
high	O
hyperopia	B-Disease
and	O
Leber	B-Disease
congenital	I-Disease
amaurosis	I-Disease
.	O
	
PURPOSE	O
:	O
To	O
identify	O
the	O
genetic	O
basis	O
of	O
recessive	O
inheritance	O
of	O
high	B-Disease
hyperopia	I-Disease
and	O
Leber	B-Disease
congenital	I-Disease
amaurosis	I-Disease
(	O
LCA	B-Disease
)	O
in	O
a	O
family	O
of	O
Middle	O
Eastern	O
origin	O
.	O
	
MATERIALS	O
AND	O
METHODS	O
:	O
The	O
patients	O
were	O
examined	O
using	O
standard	O
ophthalmic	O
techniques	O
.	O
	
DNA	O
samples	O
were	O
obtained	O
and	O
genetic	O
linkage	O
was	O
carried	O
out	O
using	O
polymorphic	O
markers	O
flanking	O
the	O
known	O
genes	O
and	O
loci	O
for	O
LCA	B-Disease
.	O
	
Exons	O
were	O
amplified	O
and	O
sequenced	O
.	O
	
RESULTS	O
:	O
All	O
four	O
members	O
of	O
this	O
family	O
affected	O
by	O
LCA	B-Disease
showed	O
high	O
to	O
extreme	O
hyperopia	B-Disease
","	O
with	O
average	O
spherical	O
refractive	O
errors	O
ranging	O
from	O
+	O
5	O
.	O
0	O
to	O
+	O
10	O
.	O
0	O
.	O
	
Linkage	O
was	O
obtained	O
to	O
1q31	O
.	O
3	O
with	O
a	O
maximal	O
LOD	O
score	O
of	O
5	O
.	O
20	O
and	O
a	O
mutation	O
found	O
in	O
exon	O
9	O
of	O
the	O
CRB1	O
gene	O
","	O
causing	O
a	O
G1103R	O
substitution	O
at	O
a	O
highly	O
conserved	O
site	O
in	O
the	O
protein	O
.	O
	
CRB1	O
is	O
a	O
vertebrate	O
homolog	O
of	O
the	O
Drosophila	O
crumbs	O
gene	O
","	O
which	O
is	O
required	O
for	O
photoreceptor	O
morphogenesis	O
","	O
and	O
has	O
been	O
associated	O
with	O
either	O
retinitis	B-Disease
pigmentosa	I-Disease
(	O
RP	B-Disease
)	O
or	O
LCA	B-Disease
.	O
	
This	O
sequence	O
variant	O
has	O
previously	O
been	O
reported	O
as	O
a	O
compound	O
heterozygote	O
in	O
one	O
sporadic	O
LCA	B-Disease
patient	O
.	O
	
CONCLUSION	O
:	O
Although	O
hyperopia	B-Disease
has	O
been	O
associated	O
with	O
LCA	B-Disease
","	O
it	O
is	O
typically	O
moderate	O
and	O
variable	O
between	O
patients	O
with	O
the	O
same	O
mutation	O
.	O
	
In	O
addition	O
","	O
some	O
CRB1	O
mutations	O
can	O
be	O
associated	O
with	O
either	O
RP	B-Disease
or	O
LCA	B-Disease
.	O
	
We	O
have	O
shown	O
that	O
hyperopia	B-Disease
and	O
LCA	B-Disease
are	O
linked	O
to	O
the	O
mutant	O
CRB1	O
gene	O
itself	O
and	O
are	O
not	O
dependent	O
on	O
unlinked	O
modifiers	O
.	O
	
	
MDMA	B-Chemical
polydrug	O
users	O
show	O
process	O
-	O
specific	O
central	O
executive	O
impairments	O
coupled	O
with	O
impaired	B-Disease
social	I-Disease
and	I-Disease
emotional	I-Disease
judgement	I-Disease
processes	I-Disease
.	O
	
In	O
recent	O
years	O
working	O
memory	B-Disease
deficits	I-Disease
have	O
been	O
reported	O
in	O
users	O
of	O
MDMA	B-Chemical
(	O
3	B-Chemical
","	I-Chemical
4	I-Chemical
-	I-Chemical
methylenedioxymethamphetamine	I-Chemical
","	O
ecstasy	B-Chemical
).	O
	
The	O
current	O
study	O
aimed	O
to	O
assess	O
the	O
impact	O
of	O
MDMA	B-Chemical
use	O
on	O
three	O
separate	O
central	O
executive	O
processes	O
(	O
set	O
shifting	O
","	O
inhibition	O
and	O
memory	O
updating	O
)	O
and	O
also	O
on	O
prefrontal	O
mediated	O
social	O
and	O
emotional	O
judgement	O
processes	O
.	O
	
Fifteen	O
polydrug	O
ecstasy	B-Chemical
users	O
and	O
15	O
polydrug	O
non	O
-	O
ecstasy	B-Chemical
user	O
controls	O
completed	O
a	O
general	O
drug	O
use	O
questionnaire	O
","	O
the	O
Brixton	O
Spatial	O
Anticipation	O
task	O
(	O
set	O
shifting	O
)","	O
Backward	O
Digit	O
Span	O
procedure	O
(	O
memory	O
updating	O
)","	O
Inhibition	O
of	O
Return	O
(	O
inhibition	O
)","	O
an	O
emotional	O
intelligence	O
scale	O
","	O
the	O
Tromso	O
Social	O
Intelligence	O
Scale	O
and	O
the	O
Dysexecutive	O
Questionnaire	O
(	O
DEX	O
).	O
	
Compared	O
with	O
MDMA	B-Chemical
-	O
free	O
polydrug	O
controls	O
","	O
MDMA	B-Chemical
polydrug	O
users	O
showed	O
impairments	O
in	O
set	O
shifting	O
and	O
memory	O
updating	O
","	O
and	O
also	O
in	O
social	O
and	O
emotional	O
judgement	O
processes	O
.	O
	
The	O
latter	O
two	O
deficits	O
remained	O
significant	O
after	O
controlling	O
for	O
other	O
drug	O
use	O
.	O
	
These	O
data	O
lend	O
further	O
support	O
to	O
the	O
proposal	O
that	O
cognitive	O
processes	O
mediated	O
by	O
the	O
prefrontal	O
cortex	O
may	O
be	O
impaired	O
by	O
recreational	O
ecstasy	B-Chemical
use	O
.	O
	
	
Tumor	B-Disease
thymidylate	O
synthase	O
1494del6	O
genotype	O
as	O
a	O
prognostic	O
factor	O
in	O
colorectal	B-Disease
cancer	I-Disease
patients	O
receiving	O
fluorouracil	B-Chemical
-	O
based	O
adjuvant	O
treatment	O
.	O
	
PURPOSE	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
value	O
of	O
germline	O
and	O
tumor	B-Disease
thymidylate	O
synthase	O
(	O
TS	O
)	O
genotyping	O
as	O
a	O
prognostic	O
marker	O
in	O
a	O
series	O
of	O
colorectal	B-Disease
cancer	I-Disease
patients	O
receiving	O
adjuvant	O
fluorouracil	B-Chemical
(	O
FU	B-Chemical
)	O
-	O
based	O
treatment	O
.	O
	
PATIENTS	O
AND	O
METHODS	O
:	O
One	O
hundred	O
twenty	O
-	O
nine	O
colorectal	B-Disease
cancer	I-Disease
patients	O
homogeneously	O
treated	O
with	O
FU	B-Chemical
plus	O
levamisole	B-Chemical
or	O
leucovorin	B-Chemical
in	O
the	O
adjuvant	O
setting	O
were	O
included	O
.	O
	
TS	O
enhancer	O
region	O
","	O
3R	O
G	O
>	O
C	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)","	O
and	O
TS	O
1494del6	O
polymorphisms	O
were	O
assessed	O
in	O
both	O
fresh	O
-	O
frozen	O
normal	O
mucosa	O
and	O
tumor	B-Disease
.	O
	
Mutational	O
analyses	O
of	O
TS	O
and	O
allelic	O
imbalances	O
were	O
studied	O
in	O
all	O
primary	O
tumors	B-Disease
and	O
in	O
18	O
additional	O
metachronic	O
metastases	B-Disease
.	O
	
TS	O
protein	O
immunostaining	O
was	O
assessed	O
in	O
an	O
expanded	O
series	O
of	O
214	O
tumors	B-Disease
.	O
	
Multivariate	O
Cox	O
models	O
were	O
adjusted	O
for	O
stage	O
","	O
differentiation	O
","	O
and	O
location	O
.	O
	
RESULTS	O
:	O
Tumor	B-Disease
genotyping	O
(	O
frequency	O
of	O
allelic	O
loss	O
","	O
26	O
%)	O
showed	O
that	O
the	O
3R	O
/	O
3R	O
genotype	O
was	O
associated	O
with	O
a	O
better	O
outcome	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
=	O
0	O
.	O
38	O
";"	O
95	O
%	O
CI	O
","	O
0	O
.	O
16	O
to	O
0	O
.	O
93	O
";"	O
P	O
=	O
.	O
20	O
for	O
the	O
recessive	O
model	O
).	O
	
3R	O
G	O
>	O
C	O
SNP	O
genotyping	O
did	O
not	O
add	O
prognostic	O
information	O
.	O
	
Tumor	B-Disease
TS	O
1494del6	O
allele	O
(	O
frequency	O
of	O
allelic	O
loss	O
","	O
36	O
%)	O
was	O
protective	O
(	O
for	O
each	O
allele	O
with	O
the	O
deletion	O
","	O
based	O
on	O
an	O
additive	O
model	O
","	O
HR	O
=	O
0	O
.	O
42	O
";"	O
95	O
%	O
CI	O
","	O
0	O
.	O
22	O
to	O
0	O
.	O
82	O
";"	O
P	O
=	O
.	O
34	O
).	O
	
Both	O
polymorphisms	O
were	O
in	O
strong	O
linkage	O
disequilibrium	O
(	O
D	O
'	O
=	O
0	O
.	O
71	O
","	O
P	O
<	O
.	O
1	O
)","	O
and	O
the	O
3R	O
/-	O
6	O
base	O
pair	O
(	O
bp	O
)	O
haplotype	O
showed	O
a	O
significant	O
overall	O
survival	O
benefit	O
compared	O
with	O
the	O
most	O
prevalent	O
haplotype	O
2R	O
/+	O
6bp	O
(	O
HR	O
=	O
0	O
.	O
42	O
";"	O
95	O
%	O
CI	O
","	O
0	O
.	O
20	O
to	O
0	O
.	O
85	O
";"	O
P	O
=	O
.	O
17	O
).	O
	
No	O
TS	O
point	O
mutation	O
was	O
detected	O
in	O
primary	O
tumors	B-Disease
or	O
metastases	B-Disease
.	O
	
TS	O
protein	O
immunostaining	O
was	O
not	O
associated	O
with	O
survival	O
or	O
any	O
of	O
the	O
genotypes	O
analyzed	O
.	O
	
CONCLUSION	O
:	O
Tumor	B-Disease
TS	O
1494del6	O
genotype	O
may	O
be	O
a	O
prognostic	O
factor	O
in	O
FU	B-Chemical
-	O
based	O
adjuvant	O
treatment	O
of	O
colorectal	B-Disease
cancer	I-Disease
patients	O
.	O
	
	
Valproate	B-Chemical
-	O
induced	O
chorea	B-Disease
and	O
encephalopathy	B-Disease
in	O
atypical	O
nonketotic	B-Disease
hyperglycinemia	I-Disease
.	O
	
Nonketotic	B-Disease
hyperglycinemia	I-Disease
is	O
a	O
disorder	B-Disease
of	I-Disease
amino	I-Disease
acid	I-Disease
metabolism	I-Disease
in	O
which	O
a	O
defect	O
in	O
the	O
glycine	B-Chemical
cleavage	O
system	O
leads	O
to	O
an	O
accumulation	O
of	O
glycine	B-Chemical
in	O
the	O
brain	O
and	O
other	O
body	O
compartments	O
.	O
	
In	O
the	O
classical	O
form	O
it	O
presents	O
as	O
neonatal	O
apnea	B-Disease
","	O
intractable	O
seizures	B-Disease
","	O
and	O
hypotonia	B-Disease
","	O
followed	O
by	O
significant	O
psychomotor	B-Disease
retardation	I-Disease
.	O
	
An	O
important	O
subset	O
of	O
children	O
with	O
nonketotic	B-Disease
hyperglycinemia	I-Disease
are	O
atypical	O
variants	O
who	O
present	O
in	O
a	O
heterogeneous	O
manner	O
.	O
	
This	O
report	O
describes	O
a	O
patient	O
with	O
mild	O
language	B-Disease
delay	I-Disease
and	O
mental	B-Disease
retardation	I-Disease
","	O
who	O
was	O
found	O
to	O
have	O
nonketotic	B-Disease
hyperglycinemia	I-Disease
following	O
her	O
presentation	O
with	O
acute	O
encephalopathy	B-Disease
and	O
chorea	B-Disease
shortly	O
after	O
initiation	O
of	O
valproate	B-Chemical
therapy	O
.	O
	
	
Bone	O
morphogenetic	O
protein	O
-	O
4	O
interacts	O
with	O
activin	O
and	O
GnRH	O
to	O
modulate	O
gonadotrophin	O
secretion	O
in	O
LbetaT2	O
gonadotrophs	O
.	O
	
We	O
have	O
shown	O
previously	O
that	O
","	O
in	O
sheep	O
primary	O
pituitary	O
cells	O
","	O
bone	O
morphogenetic	O
proteins	O
(	O
BMP	O
)-	O
4	O
inhibits	O
FSHbeta	O
mRNA	O
expression	O
and	O
FSH	O
release	O
.	O
	
In	O
contrast	O
","	O
in	O
mouse	O
LbetaT2	O
gonadotrophs	O
","	O
others	O
have	O
shown	O
a	O
stimulatory	O
effect	O
of	O
BMPs	O
on	O
basal	O
or	O
activin	O
-	O
stimulated	O
FSHbeta	O
promoter	O
-	O
driven	O
transcription	O
.	O
	
As	O
a	O
species	O
comparison	O
with	O
our	O
previous	O
results	O
","	O
we	O
used	O
LbetaT2	O
cells	O
to	O
investigate	O
the	O
effects	O
of	O
BMP	O
-	O
4	O
on	O
gonadotrophin	O
mRNA	O
and	O
secretion	O
modulated	O
by	O
activin	O
and	O
GnRH	O
.	O
	
BMP	O
-	O
4	O
alone	O
had	O
no	O
effect	O
on	O
FSH	O
production	O
","	O
but	O
enhanced	O
the	O
activin	O
+	O
GnRH	O
-	O
induced	O
stimulation	O
of	O
FSHbeta	O
mRNA	O
and	O
FSH	O
secretion	O
","	O
without	O
any	O
effect	O
on	O
follistatin	O
mRNA	O
.	O
	
BMP	O
-	O
4	O
reduced	O
LHbeta	O
mRNA	O
up	O
-	O
regulation	O
in	O
response	O
to	O
GnRH	O
(+/-	O
activin	O
)	O
and	O
decreased	O
GnRH	O
receptor	O
expression	O
","	O
which	O
would	O
favour	O
FSH	O
","	O
rather	O
than	O
LH	O
","	O
synthesis	O
and	O
secretion	O
.	O
	
In	O
contrast	O
to	O
sheep	O
pituitary	O
gonadotrophs	O
","	O
which	O
express	O
only	O
BMP	O
receptor	O
types	O
IA	O
(	O
BMPRIA	O
)	O
and	O
II	O
(	O
BMPRII	O
)","	O
LbetaT2	O
cells	O
also	O
express	O
BMPRIB	O
.	O
	
Smad1	O
/	O
5	O
phosphorylation	O
induced	O
by	O
BMP	O
-	O
4	O
","	O
indicating	O
activation	O
of	O
BMP	O
signalling	O
","	O
was	O
the	O
same	O
whether	O
BMP	O
-	O
4	O
was	O
used	O
alone	O
or	O
combined	O
with	O
activin	O
+/-	O
GnRH	O
.	O
	
We	O
hypothesized	O
that	O
activin	O
and	O
/	O
or	O
GnRH	O
pathways	O
may	O
be	O
modulated	O
by	O
BMP	O
-	O
4	O
","	O
but	O
neither	O
the	O
activin	O
-	O
stimulated	O
phosphorylation	O
of	O
Smad2	O
/	O
3	O
nor	O
the	O
GnRH	O
-	O
induced	O
ERK1	O
/	O
2	O
or	O
cAMP	O
response	O
element	O
-	O
binding	O
phosphorylation	O
were	O
modified	O
.	O
	
However	O
","	O
the	O
GnRH	O
-	O
induced	O
activation	O
of	O
p38	O
MAPK	O
was	O
decreased	O
by	O
BMP	O
-	O
4	O
.	O
	
This	O
was	O
associated	O
with	O
increased	O
FSHbeta	O
mRNA	O
levels	O
and	O
FSH	O
secretion	O
","	O
but	O
decreased	O
LHbeta	O
mRNA	O
levels	O
.	O
	
These	O
results	O
confirm	O
1	O
.	O
	
BMPs	O
as	O
important	O
modulators	O
of	O
activin	O
and	O
/	O
or	O
GnRH	O
-	O
stimulated	O
gonadotrophin	O
synthesis	O
and	O
release	O
and	O
2	O
.	O
important	O
species	O
differences	O
in	O
these	O
effects	O
","	O
which	O
could	O
relate	O
to	O
differences	O
in	O
BMP	O
receptor	O
expression	O
in	O
gonadotrophs	O
.	O
	
	
Combination	O
of	O
polymorphisms	O
within	O
5	O
'	O
and	O
3	O
'	O
untranslated	O
regions	O
of	O
thymidylate	O
synthase	O
gene	O
modulates	O
survival	O
in	O
5	B-Chemical
fluorouracil	I-Chemical
-	O
treated	O
colorectal	B-Disease
cancer	I-Disease
patients	O
.	O
	
In	O
the	O
present	O
study	O
we	O
explored	O
the	O
effect	O
of	O
three	O
polymorphisms	O
of	O
the	O
TS	O
gene	O
on	O
overall	O
and	O
progression	O
-	O
free	O
survival	O
of	O
colorectal	B-Disease
cancer	I-Disease
(	O
CRC	B-Disease
)	O
patients	O
subjected	O
to	O
5FU	B-Chemical
chemotherapy	O
.	O
	
A	O
28	O
bp	O
variable	O
number	O
of	O
tandem	O
repeats	O
(	O
VNTR	O
)","	O
a	O
G	O
/	O
C	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)","	O
and	O
a	O
deletion	O
of	O
6	O
bp	O
at	O
position	O
1494	O
were	O
studied	O
.	O
	
The	O
possible	O
combined	O
effect	O
of	O
these	O
DNA	O
polymorphisms	O
on	O
the	O
clinical	O
outcome	O
of	O
patients	O
was	O
also	O
evaluated	O
.	O
	
A	O
retrospective	O
study	O
was	O
carried	O
out	O
on	O
paraffin	B-Chemical
-	O
embedded	O
sections	O
from	O
113	O
patients	O
diagnosed	O
of	O
advanced	O
CRC	B-Disease
.	O
	
TS	O
genotyping	O
methods	O
were	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
for	O
VNTR	O
and	O
PCR	O
","	O
followed	O
by	O
restriction	O
length	O
fragment	O
polymorphism	O
(	O
PCR	O
-	O
RFLP	O
)	O
for	O
SNP	O
and	O
ins	O
/	O
del	O
6	O
bp	O
.	O
	
To	O
study	O
the	O
combined	O
effect	O
of	O
TS	O
polymorphisms	O
","	O
four	O
categories	O
were	O
defined	O
accordingly	O
to	O
the	O
level	O
of	O
expression	O
attributed	O
to	O
SNP	O
and	O
ins	O
/	O
del	O
6	O
bp	O
genotypes	O
:	O
C_allele	O
6	O
-","	O
C_6	O
+/	O
6	O
+","	O
G_allele6	O
-	O
and	O
G_6	O
+/	O
6	O
+.	O
	
VNTR	O
and	O
ins	O
/	O
del	O
6	O
bp	O
genotypes	O
varied	O
with	O
tumour	B-Disease
anatomical	O
site	O
:	O
2R	O
/	O
2R	O
genotype	O
was	O
rare	O
in	O
left	O
-	O
sided	O
tumours	B-Disease
(	O
7	O
.	O
0	O
%	O
vs	O
.	O
	
26	O
.	O
3	O
%	O
of	O
right	O
-	O
sided	O
and	O
24	O
.	O
1	O
%	O
of	O
rectal	B-Disease
cancers	I-Disease
";"	O
P	O
<	O
0	O
.	O
1	O
)","	O
where	O
the	O
variant	O
allele	O
6	O
-	O
was	O
very	O
frequent	O
(	O
69	O
.	O
0	O
%).	O
	
Instead	O
","	O
most	O
patients	O
with	O
right	O
-	O
sided	O
tumours	B-Disease
were	O
wild	O
-	O
type	O
homozygous	O
6	O
+/	O
6	O
+	O
(	O
63	O
.	O
9	O
%)	O
(	O
P	O
<	O
0	O
.	O
1	O
).	O
	
Heterozygous	O
6	O
+/	O
6	O
-	O
genotype	O
was	O
more	O
frequent	O
among	O
tumours	B-Disease
classified	O
as	O
C	O
(	O
50	O
.	O
0	O
%)	O
and	O
D	O
(	O
76	O
.	O
5	O
%)	O
Dukes	O
stages	O
(	O
P	O
=	O
0	O
.	O
5	O
).	O
	
None	O
of	O
the	O
studied	O
polymorphisms	O
alone	O
affected	O
overall	O
or	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
).	O
	
C_6	O
+/	O
6	O
+	O
and	O
G_6	O
+/	O
6	O
+	O
combined	O
genotypes	O
were	O
respectively	O
associated	O
to	O
the	O
best	O
and	O
worst	O
PFS	O
(	O
P	O
=	O
0	O
.	O
3	O
when	O
compared	O
with	O
each	O
other	O
)","	O
while	O
combinations	O
carrying	O
the	O
allele	O
6	O
-	O
determined	O
an	O
intermediate	O
evolution	O
that	O
might	O
be	O
indicative	O
of	O
a	O
variable	O
response	O
to	O
chemotherapy	O
.	O
	
The	O
rate	O
of	O
Dukes	O
B	O
stage	O
tumours	B-Disease
was	O
unexpectedly	O
high	O
(	O
59	O
.	O
1	O
%)	O
among	O
patients	O
with	O
the	O
unfavourable	O
G_6	O
+/	O
6	O
+	O
combination	O
.	O
	
In	O
our	O
study	O
the	O
combination	O
of	O
high	O
TS	O
expression	O
genotypes	O
G_6	O
+/	O
6	O
+	O
identifies	O
a	O
group	O
of	O
high	O
risk	O
within	O
CRC	B-Disease
patients	O
treated	O
with	O
5FU	B-Chemical
.	O
	
	
Phosphatidylinositol	O
3	O
-	O
kinase	O
p85alpha	O
regulatory	O
subunit	O
gene	O
Met326Ile	O
polymorphism	O
in	O
women	O
with	O
polycystic	B-Disease
ovary	I-Disease
syndrome	I-Disease
.	O
	
BACKGROUND	O
:	O
Insulin	B-Disease
resistance	I-Disease
is	O
a	O
core	O
feature	O
of	O
polycystic	B-Disease
ovary	I-Disease
syndrome	I-Disease
(	O
PCOS	B-Disease
).	O
	
Phosphatidylinositol	O
(	O
PI	O
)	O
3	O
-	O
kinase	O
is	O
an	O
important	O
enzyme	O
in	O
the	O
early	O
insulin	O
signaling	O
cascade	O
and	O
plays	O
a	O
key	O
role	O
in	O
insulin	O
-	O
mediated	O
glucose	B-Chemical
transport	O
.	O
	
In	O
its	O
regulatory	O
subunit	O
","	O
p85alpha	O
","	O
there	O
is	O
a	O
common	O
amino	O
acid	O
substitution	O
(	O
the	O
Met326Ile	O
polymorphism	O
)","	O
and	O
this	O
amino	O
acid	O
may	O
be	O
crucial	O
for	O
the	O
function	O
of	O
the	O
p85alpha	O
regulatory	O
subunit	O
and	O
PI3	O
-	O
kinase	O
.	O
	
METHODS	O
:	O
Analysis	O
of	O
the	O
Met326Ile	O
polymorphism	O
was	O
carried	O
out	O
on	O
DNA	O
samples	O
from	O
256	O
PCOS	B-Disease
patients	O
and	O
283	O
controls	O
.	O
	
Clinical	O
and	O
biochemical	O
profiles	O
of	O
participants	O
were	O
also	O
compared	O
.	O
	
RESULTS	O
:	O
The	O
genotype	O
distribution	O
of	O
the	O
Met326Ile	O
polymorphism	O
in	O
the	O
PCOS	B-Disease
group	O
was	O
not	O
different	O
from	O
that	O
of	O
the	O
controls	O
(	O
Met326Met	O
/	O
Met326Ile	O
/	O
Ile326Ile	O
rates	O
were	O
73	O
.	O
4	O
%/	O
23	O
.	O
4	O
%/	O
3	O
.	O
2	O
%	O
and	O
70	O
.	O
3	O
%/	O
26	O
.	O
1	O
%/	O
3	O
.	O
6	O
%	O
for	O
the	O
PCOS	B-Disease
and	O
control	O
groups	O
","	O
respectively	O
","	O
P	O
=	O
0	O
.	O
72	O
).	O
	
The	O
PCOS	B-Disease
group	O
was	O
divided	O
into	O
two	O
subgroups	O
according	O
to	O
the	O
presence	O
of	O
the	O
variant	O
326Ile	O
allele	O
.	O
	
Compared	O
with	O
those	O
carrying	O
at	O
least	O
one	O
variant	O
326Ile	O
allele	O
","	O
carriers	O
with	O
the	O
Met326Met	O
genotype	O
had	O
higher	O
serum	O
17	B-Chemical
-	I-Chemical
hydroxyprogesterone	I-Chemical
(	O
17	B-Chemical
-	I-Chemical
OHP	I-Chemical
)	O
{	O
1	O
.	O
1	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1	O
.	O
1	O
-	O
1	O
.	O
3	O
]	O
ng	O
/	O
ml	O
in	O
those	O
with	O
the	O
Met326Met	O
genotype	O
versus	O
0	O
.	O
8	O
(	O
95	O
%	O
CI	O
0	O
.	O
7	O
-	O
1	O
.	O
0	O
)	O
ng	O
/	O
ml	O
in	O
those	O
with	O
Ile326Ile	O
and	O
Met326Ile	O
genotypes	O
","	O
P	O
=	O
0	O
.	O
73	O
}	O
and	O
free	O
testosterone	B-Chemical
levels	O
[	O
1	O
.	O
2	O
(	O
95	O
%	O
CI	O
1	O
.	O
1	O
-	O
1	O
.	O
4	O
)	O
pg	O
/	O
ml	O
for	O
Met326Met	O
genotype	O
versus	O
0	O
.	O
9	O
(	O
95	O
%	O
CI	O
0	O
.	O
6	O
-	O
1	O
.	O
3	O
)	O
pg	O
/	O
ml	O
for	O
Ile326Ile	O
and	O
Met326Ile	O
genotypes	O
","	O
P	O
=	O
0	O
.	O
38	O
].	O
	
CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
the	O
PI3	O
-	O
kinase	O
gene	O
Met326Ile	O
polymorphism	O
may	O
not	O
be	O
a	O
major	O
determinant	O
for	O
the	O
development	O
of	O
PCOS	B-Disease
","	O
but	O
it	O
may	O
modulate	O
the	O
concentrations	O
of	O
serum	O
17	B-Chemical
-	I-Chemical
OHP	I-Chemical
or	O
free	O
testosterone	B-Chemical
in	O
PCOS	B-Disease
patients	O
.	O
	
	
High	O
-	O
dose	O
tranexamic	B-Chemical
Acid	I-Chemical
is	O
associated	O
with	O
nonischemic	O
clinical	O
seizures	B-Disease
in	O
cardiac	O
surgical	O
patients	O
.	O
	
BACKGROUND	O
:	O
In	O
2	O
separate	O
centers	O
","	O
we	O
observed	O
a	O
notable	O
increase	O
in	O
the	O
incidence	O
of	O
postoperative	O
convulsive	B-Disease
seizures	I-Disease
from	O
1	O
.	O
3	O
%	O
to	O
3	O
.	O
8	O
%	O
in	O
patients	O
having	O
undergone	O
major	O
cardiac	O
surgical	O
procedures	O
.	O
	
These	O
events	O
were	O
temporally	O
coincident	O
with	O
the	O
initial	O
use	O
of	O
high	O
-	O
dose	O
tranexamic	B-Chemical
acid	I-Chemical
(	O
TXA	B-Chemical
)	O
therapy	O
after	O
withdrawal	O
of	O
aprotinin	O
from	O
general	O
clinical	O
usage	O
.	O
	
The	O
purpose	O
of	O
this	O
review	O
was	O
to	O
perform	O
a	O
retrospective	O
analysis	O
to	O
examine	O
whether	O
there	O
was	O
a	O
relation	O
between	O
TXA	B-Chemical
usage	O
and	O
seizures	B-Disease
after	O
cardiac	O
surgery	O
.	O
	
METHODS	O
:	O
An	O
in	O
-	O
depth	O
chart	O
review	O
was	O
undertaken	O
in	O
all	O
24	O
patients	O
who	O
developed	O
perioperative	O
seizures	B-Disease
.	O
	
Electroencephalographic	O
activity	O
was	O
recorded	O
in	O
11	O
of	O
these	O
patients	O
","	O
and	O
all	O
patients	O
had	O
a	O
formal	O
neurological	O
evaluation	O
and	O
brain	O
imaging	O
studies	O
.	O
	
RESULTS	O
:	O
Twenty	O
-	O
one	O
of	O
the	O
24	O
patients	O
did	O
not	O
have	O
evidence	O
of	O
new	O
cerebral	B-Disease
ischemic	I-Disease
injury	I-Disease
","	O
but	O
seizures	B-Disease
were	O
likely	O
due	O
to	O
ischemic	B-Disease
brain	I-Disease
injury	I-Disease
in	O
3	O
patients	O
.	O
	
All	O
patients	O
with	O
seizures	B-Disease
did	O
not	O
have	O
permanent	O
neurological	B-Disease
abnormalities	I-Disease
.	O
	
All	O
24	O
patients	O
with	O
seizures	B-Disease
received	O
high	O
doses	O
of	O
TXA	B-Chemical
intraoperatively	O
ranging	O
from	O
61	O
to	O
259	O
mg	O
/	O
kg	O
","	O
had	O
a	O
mean	O
age	O
of	O
69	O
.	O
9	O
years	O
","	O
and	O
21	O
of	O
24	O
had	O
undergone	O
open	O
chamber	O
rather	O
than	O
coronary	O
bypass	O
procedures	O
.	O
	
All	O
but	O
one	O
patient	O
were	O
managed	O
using	O
cardiopulmonary	O
bypass	O
.	O
	
No	O
evidence	O
of	O
brain	B-Disease
ischemic	I-Disease
","	O
metabolic	O
","	O
or	O
hyperthermia	B-Disease
-	O
induced	O
causes	O
for	O
their	O
seizures	B-Disease
was	O
apparent	O
.	O
	
CONCLUSION	O
:	O
Our	O
results	O
suggest	O
that	O
use	O
of	O
high	O
-	O
dose	O
TXA	B-Chemical
in	O
older	O
patients	O
in	O
conjunction	O
with	O
cardiopulmonary	O
bypass	O
and	O
open	O
-	O
chamber	O
cardiac	O
surgery	O
is	O
associated	O
with	O
clinical	O
seizures	B-Disease
in	O
susceptible	O
patients	O
.	O
	
	
Cocaine	B-Chemical
causes	O
memory	B-Disease
and	I-Disease
learning	I-Disease
impairments	I-Disease
in	O
rats	O
:	O
involvement	O
of	O
nuclear	O
factor	O
kappa	O
B	O
and	O
oxidative	O
stress	O
","	O
and	O
prevention	O
by	O
topiramate	B-Chemical
.	O
	
Different	O
mechanisms	O
have	O
been	O
suggested	O
for	O
cocaine	B-Chemical
toxicity	B-Disease
including	O
an	O
increase	O
in	O
oxidative	O
stress	O
but	O
the	O
association	O
between	O
oxidative	O
status	O
in	O
the	O
brain	O
and	O
cocaine	B-Chemical
induced	O
-	O
behaviour	O
is	O
poorly	O
understood	O
.	O
	
Nuclear	O
factor	O
kappa	O
B	O
(	O
NFkappaB	O
)	O
is	O
a	O
sensor	O
of	O
oxidative	O
stress	O
and	O
participates	O
in	O
memory	O
formation	O
that	O
could	O
be	O
involved	O
in	O
drug	O
toxicity	B-Disease
and	O
addiction	O
mechanisms	O
.	O
	
Therefore	O
NFkappaB	O
activity	O
","	O
oxidative	O
stress	O
","	O
neuronal	O
nitric	O
oxide	O
synthase	O
(	O
nNOS	O
)	O
activity	O
","	O
spatial	O
learning	O
and	O
memory	O
as	O
well	O
as	O
the	O
effect	O
of	O
topiramate	B-Chemical
","	O
a	O
previously	O
proposed	O
therapy	O
for	O
cocaine	B-Disease
addiction	I-Disease
","	O
were	O
evaluated	O
in	O
an	O
experimental	O
model	O
of	O
cocaine	B-Chemical
administration	O
in	O
rats	O
.	O
	
NFkappaB	O
activity	O
was	O
decreased	O
in	O
the	O
frontal	O
cortex	O
of	O
cocaine	B-Chemical
treated	O
rats	O
","	O
as	O
well	O
as	O
GSH	B-Chemical
concentration	O
and	O
glutathione	O
peroxidase	O
activity	O
in	O
the	O
hippocampus	O
","	O
whereas	O
nNOS	O
activity	O
in	O
the	O
hippocampus	O
was	O
increased	O
.	O
	
Memory	O
retrieval	O
of	O
experiences	O
acquired	O
prior	O
to	O
cocaine	B-Chemical
administration	O
was	O
impaired	O
and	O
negatively	O
correlated	O
with	O
NFkappaB	O
activity	O
in	O
the	O
frontal	O
cortex	O
.	O
	
In	O
contrast	O
","	O
learning	O
of	O
new	O
tasks	O
was	O
enhanced	O
and	O
correlated	O
with	O
the	O
increase	O
of	O
nNOS	O
activity	O
and	O
the	O
decrease	O
of	O
glutathione	O
peroxidase	O
.	O
	
These	O
results	O
provide	O
evidence	O
for	O
a	O
possible	O
mechanistic	O
role	O
of	O
oxidative	O
and	O
nitrosative	O
stress	O
and	O
NFkappaB	O
in	O
the	O
alterations	O
induced	O
by	O
cocaine	B-Chemical
.	O
	
Topiramate	B-Chemical
prevented	O
all	O
the	O
alterations	O
observed	O
","	O
showing	O
novel	O
neuroprotective	O
properties	O
.	O
	
	
Antioxidant	B-Chemical
effects	O
of	O
bovine	O
lactoferrin	O
on	O
dexamethasone	B-Chemical
-	O
induced	O
hypertension	B-Disease
in	O
rat	O
.	O
	
Dexamethasone	B-Chemical
-	O
(	O
Dex	B-Chemical
-)	O
induced	O
hypertension	B-Disease
is	O
associated	O
with	O
enhanced	O
oxidative	O
stress	O
.	O
	
Lactoferrin	O
(	O
LF	O
)	O
is	O
an	O
iron	B-Chemical
-	O
binding	O
glycoprotein	O
with	O
antihypertensive	O
properties	O
.	O
	
In	O
this	O
study	O
","	O
we	O
investigated	O
the	O
effect	O
of	O
chronic	O
administration	O
of	O
LF	O
on	O
oxidative	O
stress	O
and	O
hypertension	B-Disease
upon	O
Dex	B-Chemical
administration	O
.	O
	
Male	O
Wistar	O
rats	O
were	O
treated	O
by	O
Dex	B-Chemical
(	O
30	O
u	O
g	O
/	O
kg	O
/	O
day	O
subcutaneously	O
)	O
or	O
saline	O
for	O
14	O
days	O
.	O
	
Oral	O
bovine	O
LF	O
(	O
30	O
","	O
100	O
","	O
300	O
mg	O
/	O
kg	O
)	O
was	O
given	O
from	O
day	O
8	O
to	O
14	O
in	O
a	O
reversal	O
study	O
.	O
	
In	O
a	O
prevention	O
study	O
","	O
rats	O
received	O
4	O
days	O
of	O
LF	O
treatment	O
followed	O
by	O
Dex	B-Chemical
and	O
continued	O
during	O
the	O
test	O
period	O
.	O
	
Systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
was	O
measured	O
using	O
tail	O
-	O
cuff	O
method	O
.	O
	
Thymus	O
weight	O
was	O
used	O
as	O
a	O
marker	O
of	O
glucocorticoid	B-Chemical
activity	O
.	O
	
Plasma	O
hydrogen	B-Chemical
peroxide	I-Chemical
(	O
H2O2	B-Chemical
)	O
concentration	O
and	O
ferric	B-Chemical
reducing	O
antioxidant	O
power	O
(	O
FRAP	O
)	O
value	O
were	O
determined	O
.	O
	
Dexamethasone	B-Chemical
significantly	O
increased	O
SBP	O
and	O
plasma	O
H2O2	B-Chemical
level	O
and	O
decreased	O
thymus	O
and	O
body	O
weights	O
.	O
	
LF	O
lowered	O
(	O
P	O
<	O
0	O
.	O
1	O
)	O
and	O
dose	O
dependently	O
prevented	O
(	O
P	O
<	O
0	O
.	O
1	O
)	O
Dex	B-Chemical
-	O
induced	O
hypertension	B-Disease
.	O
	
LF	O
prevented	O
body	O
weight	B-Disease
loss	I-Disease
and	O
significantly	O
reduced	O
the	O
elevated	O
plasma	O
H2O2	B-Chemical
and	O
increased	O
FRAP	O
values	O
.	O
	
Chronic	O
administration	O
of	O
LF	O
strongly	O
reduced	O
the	O
blood	O
pressure	O
and	O
production	O
of	O
ROS	B-Chemical
and	O
improved	O
antioxidant	O
capacity	O
in	O
Dex	B-Chemical
-	O
induced	O
hypertension	B-Disease
","	O
suggesting	O
the	O
role	O
of	O
inhibition	O
of	O
oxidative	O
stress	O
as	O
another	O
mechanism	O
of	O
antihypertensive	O
action	O
of	O
LF	O
.	O
	
	
IL	O
-	O
3	O
and	O
CSF	O
-	O
1	O
interact	O
to	O
promote	O
generation	O
of	O
CD11c	O
+	O
IL	O
-	O
10	O
-	O
producing	O
macrophages	O
.	O
	
Unraveling	O
the	O
mechanisms	O
of	O
hematopoiesis	O
regulated	O
by	O
multiple	O
cytokines	O
remains	O
a	O
challenge	O
in	O
hematology	O
.	O
	
IL	O
-	O
3	O
is	O
an	O
allergic	O
cytokine	O
with	O
the	O
multilineage	O
potential	O
","	O
while	O
CSF	O
-	O
1	O
is	O
produced	O
in	O
the	O
steady	O
state	O
with	O
restricted	O
lineage	O
coverage	O
.	O
	
Here	O
","	O
we	O
uncovered	O
an	O
instructive	O
role	O
of	O
CSF	O
-	O
1	O
in	O
IL	O
-	O
3	O
-	O
mediated	O
hematopoiesis	O
.	O
	
CSF	O
-	O
1	O
significantly	O
promoted	O
IL	O
-	O
3	O
-	O
driven	O
CD11c	O
+	O
cell	O
expansion	O
and	O
dampened	O
basophil	O
and	O
mast	O
cell	O
generation	O
from	O
C57BL	O
/	O
6	O
bone	O
marrow	O
.	O
	
Further	O
studies	O
indicated	O
that	O
the	O
CSF	O
-	O
1	O
/	O
CSF	O
-	O
1R	O
axis	O
contributed	O
significantly	O
to	O
IL	O
-	O
3	O
-	O
induced	O
CD11c	O
+	O
cell	O
generation	O
through	O
enhancing	O
c	O
-	O
Fos	O
-	O
associated	O
monopoiesis	O
.	O
	
CD11c	O
+	O
cells	O
induced	O
by	O
IL	O
-	O
3	O
or	O
IL	O
-	O
3	O
/	O
CSF	O
-	O
1	O
were	O
competent	O
in	O
cellular	O
maturation	O
and	O
endocytosis	O
.	O
	
Both	O
IL	O
-	O
3	O
and	O
IL	O
-	O
3	O
/	O
CSF	O
-	O
1	O
cells	O
lacked	O
classical	O
dendritic	O
cell	O
appearance	O
and	O
resembled	O
macrophages	O
in	O
morphology	O
.	O
	
Both	O
populations	O
produced	O
a	O
high	O
level	O
of	O
IL	O
-	O
10	O
","	O
in	O
addition	O
to	O
IL	O
-	O
1	O
","	O
IL	O
-	O
6	O
and	O
TNFa	O
","	O
in	O
response	O
to	O
LPS	B-Chemical
","	O
and	O
were	O
relatively	O
poor	O
T	O
cell	O
stimulators	O
.	O
	
Collectively	O
","	O
these	O
findings	O
reveal	O
a	O
role	O
for	O
CSF	O
-	O
1	O
in	O
mediating	O
the	O
IL	O
-	O
3	O
hematopoietic	O
pathway	O
through	O
monopoiesis	O
","	O
which	O
regulates	O
expansion	O
of	O
CD11c	O
+	O
macrophages	O
.	O
	
	
FGFR2	O
is	O
required	O
for	O
airway	O
basal	O
cell	O
self	O
-	O
renewal	O
and	O
terminal	O
differentiation	O
.	O
	
Airway	O
stem	O
cells	O
slowly	O
self	O
-	O
renew	O
and	O
produce	O
differentiated	O
progeny	O
to	O
maintain	O
homeostasis	O
throughout	O
the	O
lifespan	O
of	O
an	O
individual	O
.	O
	
Mutations	O
in	O
the	O
molecular	O
regulators	O
of	O
these	O
processes	O
may	O
drive	O
cancer	B-Disease
or	O
degenerative	B-Disease
disease	I-Disease
","	O
but	O
are	O
also	O
potential	O
therapeutic	O
targets	O
.	O
	
Conditionally	O
deleting	O
one	O
copy	O
of	O
FGF	O
receptor	O
2	O
(	O
FGFR2	O
)	O
in	O
adult	O
mouse	O
airway	O
basal	O
cells	O
results	O
in	O
self	O
-	O
renewal	O
and	O
differentiation	O
phenotypes	O
.	O
	
We	O
show	O
that	O
FGFR2	O
signalling	O
correlates	O
with	O
maintenance	O
of	O
expression	O
of	O
a	O
key	O
transcription	O
factor	O
for	O
basal	O
cell	O
self	O
-	O
renewal	O
and	O
differentiation	O
:	O
SOX2	O
.	O
	
This	O
heterozygous	O
phenotype	O
illustrates	O
that	O
subtle	O
changes	O
in	O
receptor	O
tyrosine	O
kinase	O
signalling	O
can	O
have	O
significant	O
effects	O
","	O
perhaps	O
providing	O
an	O
explanation	O
for	O
the	O
numerous	O
changes	O
seen	O
in	O
cancer	B-Disease
.	O
	
	
Biophysical	O
and	O
functional	O
characterization	O
of	O
hippocalcin	O
mutants	O
responsible	O
for	O
human	O
dystonia	B-Disease
.	O
	
Dystonia	B-Disease
is	O
a	O
neurological	B-Disease
movement	I-Disease
disorder	I-Disease
that	O
forces	O
the	O
body	O
into	O
twisting	O
","	O
repetitive	O
movements	O
or	O
sometimes	O
painful	O
abnormal	O
postures	O
.	O
	
With	O
the	O
advent	O
of	O
next	O
-	O
generation	O
sequencing	O
technologies	O
","	O
the	O
homozygous	O
mutations	O
T71N	O
and	O
A190T	O
in	O
the	O
neuronal	O
calcium	O
sensor	O
(	O
NCS	O
)	O
hippocalcin	O
were	O
identified	O
as	O
the	O
genetic	O
cause	O
of	O
primary	B-Disease
isolated	I-Disease
dystonia	I-Disease
(	O
DYT2	O
dystonia	B-Disease
).	O
	
However	O
","	O
the	O
effect	O
of	O
these	O
mutations	O
on	O
the	O
physiological	O
role	O
of	O
hippocalcin	O
has	O
not	O
yet	O
been	O
elucidated	O
.	O
	
Using	O
a	O
multidisciplinary	O
approach	O
","	O
we	O
demonstrated	O
that	O
hippocalcin	O
oligomerises	O
in	O
a	O
calcium	B-Chemical
-	O
dependent	O
manner	O
and	O
binds	O
to	O
voltage	O
-	O
gated	O
calcium	O
channels	O
.	O
	
Mutations	O
T71N	O
and	O
A190T	O
in	O
hippocalcin	O
did	O
not	O
affect	O
stability	O
","	O
calcium	B-Chemical
-	O
binding	O
affinity	O
or	O
translocation	O
to	O
cellular	O
membranes	O
(	O
Ca2	B-Chemical
+/	I-Chemical
myristoyl	O
switch	O
).	O
	
We	O
obtained	O
the	O
first	O
crystal	O
structure	O
of	O
hippocalcin	O
and	O
alignment	O
with	O
other	O
NCS	O
proteins	O
showed	O
significant	O
variability	O
in	O
the	O
orientation	O
of	O
the	O
C	O
-	O
terminal	O
part	O
of	O
the	O
molecule	O
","	O
the	O
region	O
expected	O
to	O
be	O
important	O
for	O
target	O
binding	O
.	O
	
We	O
demonstrated	O
that	O
the	O
disease	O
-	O
causing	O
mutations	O
did	O
not	O
affect	O
the	O
structure	O
of	O
the	O
protein	O
","	O
however	O
both	O
mutants	O
showed	O
a	O
defect	O
in	O
oligomerisation	O
.	O
	
In	O
addition	O
","	O
we	O
observed	O
an	O
increased	O
calcium	B-Chemical
influx	O
in	O
KCl	B-Chemical
-	O
depolarised	O
cells	O
expressing	O
mutated	O
hippocalcin	O
","	O
mostly	O
driven	O
by	O
N	O
-	O
type	O
voltage	O
-	O
gated	O
calcium	O
channels	O
.	O
	
Our	O
data	O
demonstrate	O
that	O
the	O
dystonia	B-Disease
-	O
causing	O
mutations	O
strongly	O
affect	O
hippocalcin	O
cellular	O
functions	O
which	O
suggest	O
a	O
central	O
role	O
for	O
perturbed	O
calcium	B-Chemical
signalling	O
in	O
DYT2	O
dystonia	B-Disease
.	O
	
	
Ca2	B-Chemical
+-	I-Chemical
dependent	O
endoplasmic	O
reticulum	O
stress	O
correlation	O
with	O
astrogliosis	B-Disease
involves	O
upregulation	O
of	O
KCa3	O
.	O
1	O
and	O
inhibition	O
of	O
AKT	O
/	O
mTOR	O
signaling	O
.	O
	
BACKGROUND	O
:	O
The	O
intermediate	O
-	O
conductance	O
Ca2	O
+-	O
activated	O
K	O
+	O
channel	O
KCa3	O
.	O
1	O
was	O
recently	O
shown	O
to	O
control	O
the	O
phenotype	O
switch	O
of	O
reactive	B-Disease
astrogliosis	I-Disease
(	O
RA	B-Disease
)	O
in	O
Alzheimer	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
AD	B-Disease
).	O
	
METHODS	O
:	O
KCa3	O
.	O
1	O
channels	O
expression	O
and	O
cell	O
localization	O
in	O
the	O
brains	O
of	O
AD	B-Disease
patients	O
and	O
APP	O
/	O
PS1	O
mice	O
model	O
were	O
measured	O
by	O
immunoblotting	O
and	O
immunostaining	O
.	O
	
APP	O
/	O
PS1	O
mice	O
and	O
KCa3	O
.	O
1	O
-/-/	O
APP	O
/	O
PS1	O
mice	O
were	O
subjected	O
to	O
Morris	O
water	O
maze	O
test	O
to	O
evaluate	O
the	O
spatial	O
memory	B-Disease
deficits	I-Disease
.	O
	
Glia	O
activation	O
and	O
neuron	B-Disease
loss	I-Disease
was	O
measured	O
by	O
immunostaining	O
.	O
	
Fluo	B-Chemical
-	I-Chemical
4AM	I-Chemical
was	O
used	O
to	O
measure	O
cytosolic	O
Ca2	B-Chemical
+	I-Chemical
level	O
in	O
beta	O
-	O
amyloid	O
(	O
Abeta	O
)	O
induced	O
reactive	O
astrocytes	O
in	O
vitro	O
.	O
	
RESULTS	O
:	O
KCa3	O
.	O
1	O
expression	O
was	O
markedly	O
associated	O
with	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
and	O
unfolded	O
protein	O
response	O
(	O
UPR	O
)	O
in	O
both	O
Abeta	O
-	O
stimulated	O
primary	O
astrocytes	O
and	O
brain	O
lysates	O
of	O
AD	B-Disease
patients	O
and	O
APP	O
/	O
PS1	O
AD	B-Disease
mice	O
.	O
	
The	O
KCa3	O
.	O
1	O
channel	O
was	O
shown	O
to	O
regulate	O
store	O
-	O
operated	O
Ca2	B-Chemical
+	I-Chemical
entry	O
(	O
SOCE	O
)	O
through	O
an	O
interaction	O
with	O
the	O
Ca2	B-Chemical
+	I-Chemical
channel	O
Orai1	O
in	O
primary	O
astrocytes	O
.	O
	
Gene	O
deletion	O
or	O
pharmacological	O
blockade	O
of	O
KCa3	O
.	O
1	O
protected	O
against	O
SOCE	O
-	O
induced	O
Ca2	B-Chemical
+	I-Chemical
overload	O
and	O
ER	O
stress	O
via	O
the	O
protein	O
kinase	O
B	O
(	O
AKT	O
)	O
signaling	O
pathway	O
in	O
astrocytes	O
.	O
	
Importantly	O
","	O
gene	O
deletion	O
or	O
blockade	O
of	O
KCa3	O
.	O
1	O
restored	O
AKT	O
/	O
mechanistic	O
target	O
of	O
rapamycin	O
signaling	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O
	
Consistent	O
with	O
these	O
in	O
vitro	O
data	O
","	O
expression	O
levels	O
of	O
the	O
ER	O
stress	O
markers	O
78	O
-	O
kDa	O
glucose	O
-	O
regulated	O
protein	O
and	O
CCAAT	O
/	O
enhancer	O
-	O
binding	O
protein	O
homologous	O
protein	O
","	O
as	O
well	O
as	O
that	O
of	O
the	O
RA	B-Disease
marker	O
glial	O
fibrillary	O
acidic	O
protein	O
were	O
increased	O
in	O
APP	O
/	O
PS1	O
AD	B-Disease
mouse	O
model	O
.	O
	
Elimination	O
of	O
KCa3	O
.	O
1	O
in	O
KCa3	O
.	O
1	O
-/-/	O
APP	O
/	O
PS1	O
mice	O
corrected	O
these	O
abnormal	O
responses	O
.	O
	
Moreover	O
","	O
glial	O
activation	O
and	O
neuroinflammation	B-Disease
were	O
attenuated	O
in	O
the	O
hippocampi	O
of	O
KCa3	O
.	O
1	O
-/-/	O
APP	O
/	O
PS1	O
mice	O
","	O
as	O
compared	O
with	O
APP	O
/	O
PS1	O
mice	O
.	O
	
In	O
addition	O
","	O
memory	B-Disease
deficits	I-Disease
and	O
neuronal	B-Disease
loss	I-Disease
in	O
APP	O
/	O
PS1	O
mice	O
were	O
reversed	O
in	O
KCa3	O
.	O
1	O
-/-/	O
APP	O
/	O
PS1	O
mice	O
.	O
	
CONCLUSIONS	O
:	O
Overall	O
","	O
these	O
results	O
suggest	O
that	O
KCa3	O
.	O
1	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
Ca2	B-Chemical
+	I-Chemical
homeostasis	O
in	O
astrocytes	O
and	O
attenuation	O
of	O
the	O
UPR	O
and	O
ER	O
stress	O
","	O
thus	O
contributing	O
to	O
memory	B-Disease
deficits	I-Disease
and	O
neuronal	B-Disease
loss	I-Disease
.	O
	
	
Vaccine	O
candidates	O
derived	O
from	O
a	O
novel	O
infectious	O
cDNA	O
clone	O
of	O
an	O
American	O
genotype	O
dengue	O
virus	O
type	O
2	O
.	O
	
BACKGROUND	O
:	O
A	O
dengue	O
virus	O
type	O
2	O
(	O
DEN	O
-	O
2	O
Tonga	O
/	O
74	O
)	O
isolated	O
from	O
a	O
1974	O
epidemic	O
was	O
characterized	O
by	O
mild	O
illness	O
and	O
belongs	O
to	O
the	O
American	O
genotype	O
of	O
DEN	O
-	O
2	O
viruses	O
.	O
	
To	O
prepare	O
a	O
vaccine	O
candidate	O
","	O
a	O
previously	O
described	O
30	O
nucleotide	O
deletion	O
(	O
Delta30	O
)	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
DEN	O
-	O
4	O
has	O
been	O
engineered	O
into	O
the	O
DEN	O
-	O
2	O
isolate	O
.	O
	
METHODS	O
:	O
A	O
full	O
-	O
length	O
cDNA	O
clone	O
was	O
generated	O
from	O
the	O
DEN	O
-	O
2	O
virus	O
and	O
used	O
to	O
produce	O
recombinant	O
DEN	O
-	O
2	O
(	O
rDEN	O
-	O
2	O
)	O
and	O
	
.	O
	
Viruses	O
were	O
evaluated	O
for	O
replication	O
in	O
SCID	O
mice	O
transplanted	O
with	O
human	O
hepatoma	B-Disease
cells	O
(	O
SCID	O
-	O
HuH	O
-	O
7	O
mice	O
)","	O
in	O
mosquitoes	O
","	O
and	O
in	O
rhesus	O
monkeys	O
.	O
	
Neutralizing	O
antibody	O
induction	O
and	O
protective	O
efficacy	O
were	O
also	O
assessed	O
in	O
rhesus	O
monkeys	O
.	O
	
RESULTS	O
:	O
The	O
	
virus	O
was	O
ten	O
-	O
fold	O
reduced	O
in	O
replication	O
in	O
SCID	O
-	O
HuH	O
-	O
7	O
mice	O
when	O
compared	O
to	O
the	O
parent	O
virus	O
.	O
	
The	O
rDEN	O
-	O
2	O
viruses	O
were	O
not	O
infectious	O
for	O
Aedes	O
mosquitoes	O
","	O
but	O
both	O
readily	O
infected	O
Toxorynchites	O
mosquitoes	O
.	O
	
In	O
rhesus	O
monkeys	O
","	O
	
appeared	O
to	O
be	O
slightly	O
attenuated	O
when	O
compared	O
to	O
the	O
parent	O
virus	O
as	O
measured	O
by	O
duration	O
and	O
peak	O
of	O
viremia	B-Disease
and	O
neutralizing	O
antibody	O
induction	O
.	O
	
A	O
derivative	O
of	O
	
","	O
designated	O
	
-	O
4995	O
","	O
was	O
generated	O
by	O
incorporation	O
of	O
a	O
point	O
mutation	O
previously	O
identified	O
in	O
the	O
NS3	O
gene	O
of	O
DEN	O
-	O
4	O
and	O
was	O
found	O
to	O
be	O
more	O
attenuated	O
than	O
	
in	O
SCID	O
-	O
HuH	O
-	O
7	O
mice	O
.	O
	
CONCLUSIONS	O
:	O
The	O
	
and	O
	
-	O
4995	O
viruses	O
can	O
be	O
considered	O
for	O
evaluation	O
in	O
humans	O
and	O
for	O
inclusion	O
in	O
a	O
tetravalent	O
dengue	B-Disease
vaccine	O
.	O
	
	
Genetic	O
investigation	O
of	O
the	O
TSPYL1	O
gene	O
in	O
sudden	B-Disease
infant	I-Disease
death	I-Disease
syndrome	I-Disease
.	O
	
BACKGROUND	O
:	O
Sudden	B-Disease
infant	I-Disease
death	I-Disease
syndrome	I-Disease
(	O
SIDS	B-Disease
)	O
constitutes	O
the	O
most	O
frequent	O
cause	O
of	O
death	B-Disease
in	O
the	O
postperinatal	O
period	O
in	O
Germany	O
.	O
	
Recently	O
","	O
a	O
lethal	O
phenotype	O
characterized	O
by	O
sudden	B-Disease
infant	I-Disease
death	I-Disease
with	I-Disease
dysgenesis	I-Disease
of	I-Disease
the	I-Disease
testes	I-Disease
syndrome	I-Disease
(	O
SIDDT	B-Disease
)	O
was	O
identified	O
to	O
be	O
caused	O
by	O
loss	O
of	O
function	O
mutations	O
in	O
the	O
TSPYL1	O
gene	O
.	O
	
PURPOSE	O
:	O
The	O
study	O
'	O
s	O
purpose	O
was	O
to	O
reveal	O
a	O
possible	O
role	O
of	O
TSPYL1	O
in	O
SIDS	B-Disease
.	O
	
METHODS	O
:	O
DNA	O
samples	O
of	O
126	O
SIDS	B-Disease
cases	O
and	O
261	O
controls	O
were	O
investigated	O
.	O
	
RESULTS	O
:	O
We	O
found	O
five	O
sequence	O
variations	O
","	O
each	O
of	O
them	O
causing	O
an	O
amino	O
acid	O
substitution	O
.	O
	
No	O
Hardy	O
Weinberg	O
disequilibrium	O
and	O
no	O
significant	O
difference	O
in	O
allele	O
frequencies	O
between	O
patients	O
and	O
controls	O
were	O
observed	O
for	O
any	O
variation	O
.	O
	
In	O
one	O
female	O
patient	O
a	O
p	O
.	O
F366L	O
amino	O
acid	O
polymorphism	O
was	O
found	O
heterozygous	O
","	O
which	O
could	O
not	O
be	O
displayed	O
in	O
controls	O
.	O
	
A	O
pathogenic	O
implication	O
of	O
this	O
substitution	O
","	O
which	O
is	O
conserved	O
in	O
primates	O
and	O
rodents	O
","	O
cannot	O
be	O
ruled	O
out	O
completely	O
.	O
	
Because	O
SIDDT	B-Disease
is	O
the	O
result	O
of	O
homozygous	O
TSPYL1	O
mutations	O
","	O
this	O
heterozygous	O
exchange	O
cannot	O
solely	O
explain	O
the	O
sudden	B-Disease
death	I-Disease
in	O
this	O
child	O
.	O
	
The	O
reported	O
mutation	O
associated	O
with	O
SIDDT	B-Disease
(	O
457_458insG	O
)	O
was	O
not	O
detectable	O
in	O
our	O
cohort	O
.	O
	
CONCLUSION	O
:	O
No	O
association	O
of	O
sequence	O
variations	O
in	O
the	O
TSPYL1	O
gene	O
and	O
SIDS	B-Disease
has	O
been	O
found	O
in	O
a	O
German	O
cohort	O
.	O
	
Genetic	O
analysis	O
of	O
TSPYL1	O
seems	O
to	O
be	O
of	O
limited	O
significance	O
in	O
the	O
differential	O
diagnosis	O
of	O
SIDS	B-Disease
without	O
dysgenesis	B-Disease
of	I-Disease
the	I-Disease
testes	I-Disease
.	O
	
	
Possible	O
neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
related	O
to	O
concomitant	O
treatment	O
with	O
paroxetine	B-Chemical
and	O
alprazolam	B-Chemical
.	O
	
A	O
74	O
-	O
year	O
-	O
old	O
man	O
with	O
depressive	B-Disease
symptoms	I-Disease
was	O
admitted	O
to	O
a	O
psychiatric	B-Disease
hospital	O
due	O
to	O
insomnia	B-Disease
","	O
loss	B-Disease
of	I-Disease
appetite	I-Disease
","	O
exhaustion	O
","	O
and	O
agitation	B-Disease
.	O
	
Medical	O
treatment	O
was	O
initiated	O
at	O
a	O
daily	O
dose	O
of	O
20	O
mg	O
paroxetine	B-Chemical
and	O
1	O
.	O
2	O
mg	O
alprazolam	B-Chemical
.	O
	
On	O
the	O
10th	O
day	O
of	O
paroxetine	B-Chemical
and	O
alprazolam	B-Chemical
treatment	O
","	O
the	O
patient	O
exhibited	O
marked	O
psychomotor	B-Disease
retardation	I-Disease
","	O
disorientation	O
","	O
and	O
severe	O
muscle	B-Disease
rigidity	I-Disease
with	O
tremors	B-Disease
.	O
	
The	O
patient	O
had	O
a	O
fever	B-Disease
(	O
38	O
.	O
2	O
degrees	O
C	O
)","	O
fluctuating	O
blood	O
pressure	O
(	O
between	O
165	O
/	O
90	O
and	O
130	O
/	O
70	O
mg	O
mm	O
Hg	O
)","	O
and	O
severe	O
extrapyramidal	B-Disease
symptoms	I-Disease
.	O
	
Laboratory	O
tests	O
showed	O
an	O
elevation	O
of	O
creatine	B-Chemical
phosphokinase	I-Chemical
(	O
2218	O
IU	O
/	O
L	O
)","	O
aspartate	B-Chemical
aminotransferase	I-Chemical
(	O
134	O
IU	O
/	O
L	O
)","	O
alanine	B-Chemical
aminotransferase	I-Chemical
(	O
78	O
IU	O
/	O
L	O
)","	O
and	O
BUN	O
(	O
27	O
.	O
9	O
mg	O
/	O
ml	O
)	O
levels	O
.	O
	
The	O
patient	O
received	O
bromocriptine	B-Chemical
and	O
diazepam	B-Chemical
to	O
treat	O
his	O
symptoms	O
.	O
	
7	O
days	O
later	O
","	O
the	O
fever	B-Disease
disappeared	O
and	O
the	O
patient	O
'	O
s	O
serum	O
CPK	B-Chemical
levels	O
were	O
normalized	O
(	O
175	O
IU	O
/	O
L	O
).	O
	
This	O
patient	O
presented	O
with	O
symptoms	O
of	O
neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
(	O
NMS	B-Disease
)","	O
thus	O
demonstrating	O
that	O
NMS	B-Disease
-	O
like	O
symptoms	O
can	O
occur	O
after	O
combined	O
paroxetine	B-Chemical
and	O
alprazolam	B-Chemical
treatment	O
.	O
	
The	O
adverse	O
drug	O
reaction	O
score	O
obtained	O
by	O
the	O
Naranjo	O
algorithm	O
was	O
6	O
in	O
our	O
case	O
","	O
indicating	O
a	O
probable	O
relationship	O
between	O
the	O
patient	O
'	O
s	O
NMS	B-Disease
-	O
like	O
adverse	O
symptoms	O
and	O
the	O
combined	O
treatment	O
used	O
in	O
this	O
case	O
.	O
	
The	O
involvement	O
of	O
physiologic	O
and	O
environmental	O
aspects	O
specific	O
to	O
this	O
patient	O
was	O
suspected	O
.	O
	
Several	O
risk	O
factors	O
for	O
NMS	B-Disease
should	O
be	O
noted	O
in	O
elderly	O
depressive	B-Disease
patients	O
whose	O
symptoms	O
often	O
include	O
dehydration	B-Disease
","	O
agitation	B-Disease
","	O
malnutrition	B-Disease
","	O
and	O
exhaustion	O
.	O
	
Careful	O
therapeutic	O
intervention	O
is	O
necessary	O
in	O
cases	O
involving	O
elderly	O
patients	O
who	O
suffer	O
from	O
depression	B-Disease
.	O
	
	
Cauda	B-Disease
equina	I-Disease
syndrome	I-Disease
after	O
epidural	O
steroid	B-Chemical
injection	O
:	O
a	O
case	O
report	O
.	O
	
OBJECTIVE	O
:	O
Conventional	O
treatment	O
methods	O
of	O
lumbusacral	O
radiculopathy	B-Disease
are	O
physical	O
therapy	O
","	O
epidural	O
steroid	B-Chemical
injections	O
","	O
oral	O
medications	O
","	O
and	O
spinal	O
manipulative	O
therapy	O
.	O
	
Cauda	B-Disease
equina	I-Disease
syndrome	I-Disease
is	O
a	O
rare	O
complication	O
of	O
epidural	O
anesthesia	O
.	O
	
The	O
following	O
case	O
is	O
a	O
report	O
of	O
cauda	B-Disease
equina	I-Disease
syndrome	I-Disease
possibly	O
caused	O
by	O
epidural	O
injection	O
of	O
triamcinolone	B-Chemical
and	O
bupivacaine	B-Chemical
.	O
	
CLINICAL	O
FEATURES	O
:	O
A	O
50	O
-	O
year	O
-	O
old	O
woman	O
with	O
low	B-Disease
back	I-Disease
and	I-Disease
right	I-Disease
leg	I-Disease
pain	I-Disease
was	O
scheduled	O
for	O
epidural	O
steroid	B-Chemical
injection	O
.	O
	
INTERVENTION	O
AND	O
OUTCOME	O
:	O
An	O
18	O
-	O
gauge	O
Touhy	O
needle	O
was	O
inserted	O
until	O
loss	O
of	O
resistance	O
occurred	O
at	O
the	O
L4	O
-	O
5	O
level	O
.	O
	
Spread	O
of	O
the	O
contrast	O
medium	O
within	O
the	O
epidural	O
space	O
was	O
determined	O
by	O
radiographic	O
imaging	O
.	O
	
After	O
verifying	O
the	O
epidural	O
space	O
","	O
bupivacaine	B-Chemical
and	O
triamcinolone	B-Chemical
diacetate	I-Chemical
were	O
injected	O
.	O
	
After	O
the	O
injection	O
","	O
there	O
was	O
a	O
reduction	O
in	O
radicular	O
symptoms	O
.	O
	
Three	O
hours	O
later	O
","	O
she	O
complained	O
of	O
perineal	O
numbness	B-Disease
and	O
lower	B-Disease
extremity	I-Disease
weakness	I-Disease
.	O
	
The	O
neurologic	O
evaluation	O
revealed	O
loss	B-Disease
of	I-Disease
sensation	I-Disease
in	O
the	O
saddle	O
area	O
and	O
medial	O
aspect	O
of	O
her	O
right	O
leg	O
.	O
	
There	O
was	O
a	O
decrease	O
in	O
the	O
perception	O
of	O
pinprick	O
test	O
.	O
	
Deep	O
-	O
tendon	O
reflexes	O
were	O
decreased	O
especially	O
in	O
the	O
right	O
leg	O
.	O
	
She	O
was	O
unable	O
to	O
urinate	O
.	O
	
The	O
patient	O
'	O
s	O
symptoms	O
improved	O
slightly	O
over	O
the	O
next	O
few	O
hours	O
.	O
	
She	O
had	O
a	O
gradual	O
return	O
of	O
motor	O
function	O
and	O
ability	O
of	O
feeling	O
Foley	O
catheter	O
.	O
	
All	O
of	O
the	O
symptoms	O
were	O
completely	O
resolved	O
over	O
the	O
next	O
8	O
hours	O
.	O
	
CONCLUSION	O
:	O
Complications	O
associated	O
with	O
epidural	O
steroid	B-Chemical
injections	O
are	O
rare	O
.	O
	
Clinical	O
examination	O
and	O
continued	O
vigilance	O
for	O
neurologic	B-Disease
deterioration	I-Disease
after	O
epidural	O
steroid	B-Chemical
injections	O
is	O
important	O
.	O
	
	
Genetic	O
polymorphism	O
of	O
the	O
binding	O
domain	O
of	O
surfactant	O
protein	O
-	O
A2	O
increases	O
susceptibility	O
to	O
meningococcal	B-Disease
disease	I-Disease
.	O
	
BACKGROUND	O
:	O
Meningococcal	B-Disease
disease	I-Disease
occurs	O
after	O
colonization	O
of	O
the	O
nasopharynx	O
with	O
Neisseria	B-Disease
meningitidis	I-Disease
.	O
	
Surfactant	O
protein	O
(	O
SP	O
)-	O
A	O
and	O
SP	O
-	O
D	O
are	O
pattern	O
-	O
recognition	O
molecules	O
of	O
the	O
respiratory	O
tract	O
that	O
activate	O
inflammatory	B-Disease
and	O
phagocytic	O
defences	O
after	O
binding	O
to	O
microbial	O
sugars	B-Chemical
.	O
	
Variation	O
in	O
the	O
genes	O
of	O
the	O
surfactant	O
proteins	O
affects	O
the	O
expression	O
and	O
function	O
of	O
these	O
molecules	O
.	O
	
METHODS	O
:	O
Allele	O
frequencies	O
of	O
SP	O
-	O
A1	O
","	O
SP	O
-	O
A2	O
","	O
and	O
SP	O
-	O
D	O
were	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
in	O
303	O
patients	O
with	O
microbiologically	O
proven	O
meningococcal	B-Disease
disease	I-Disease
","	O
including	O
18	O
patients	O
who	O
died	B-Disease
","	O
and	O
222	O
healthy	O
control	O
subjects	O
.	O
	
RESULTS	O
:	O
Homozygosity	O
of	O
allele	O
1A1	O
of	O
SP	O
-	O
A2	O
increased	O
the	O
risk	O
of	O
meningococcal	B-Disease
disease	I-Disease
(	O
odds	O
ratio	O
[	O
OR	O
]","	O
7	O
.	O
4	O
";"	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]","	O
1	O
.	O
3	O
-	O
42	O
.	O
4	O
");"	O
carriage	O
of	O
1A5	O
reduced	O
the	O
risk	O
(	O
OR	O
","	O
0	O
.	O
3	O
";"	O
95	O
%	O
CI	O
","	O
0	O
.	O
1	O
-	O
0	O
.	O
97	O
).	O
	
An	O
analysis	O
of	O
the	O
multiple	O
single	O
-	O
nucleotide	O
polymorphisms	O
in	O
SP	O
-	O
A	O
demonstrated	O
that	O
homozygosity	O
for	O
alleles	O
encoding	O
lysine	O
(	O
in	O
1A1	O
)	O
rather	O
than	O
glutamine	O
(	O
in	O
1A5	O
)	O
at	O
amino	O
acid	O
223	O
in	O
the	O
carbohydrate	B-Chemical
recognition	O
domain	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
meningococcal	B-Disease
disease	I-Disease
(	O
OR	O
","	O
6	O
.	O
7	O
";"	O
95	O
%	O
CI	O
","	O
1	O
.	O
4	O
-	O
31	O
.	O
5	O
).	O
	
Carriage	O
of	O
alleles	O
encoding	O
lysine	O
at	O
residue	O
223	O
was	O
found	O
in	O
61	O
%	O
of	O
patients	O
who	O
died	B-Disease
","	O
compared	O
with	O
35	O
%	O
of	O
those	O
who	O
survived	O
(	O
OR	O
adjusted	O
for	O
age	O
","	O
2	O
.	O
9	O
";"	O
95	O
%	O
CI	O
","	O
1	O
.	O
1	O
-	O
7	O
.	O
7	O
).	O
	
Genetic	O
variation	O
of	O
SP	O
-	O
A1	O
and	O
SP	O
-	O
D	O
was	O
not	O
associated	O
with	O
meningococcal	B-Disease
disease	I-Disease
.	O
	
CONCLUSIONS	O
:	O
Gene	O
polymorphism	O
resulting	O
in	O
the	O
substitution	O
of	O
glutamine	O
with	O
lysine	O
at	O
residue	O
223	O
in	O
the	O
carbohydrate	B-Chemical
recognition	O
domain	O
of	O
SP	O
-	O
A2	O
increases	O
susceptibility	O
to	O
meningococcal	B-Disease
disease	I-Disease
","	O
as	O
well	O
as	O
the	O
risk	O
of	O
death	B-Disease
.	O
	
	
A	O
novel	O
missense	O
mutation	O
in	O
the	O
paired	O
domain	O
of	O
human	O
PAX9	O
causes	O
oligodontia	B-Disease
.	O
	
PAX9	O
and	O
MSX1	O
are	O
transcription	O
factors	O
that	O
play	O
essential	O
roles	O
in	O
craniofacial	O
and	O
limb	O
development	O
.	O
	
In	O
humans	O
","	O
mutations	O
in	O
both	O
genes	O
are	O
associated	O
with	O
nonsyndromic	B-Disease
and	I-Disease
syndromic	I-Disease
oligodontia	I-Disease
","	O
respectively	O
.	O
	
We	O
screened	O
one	O
family	O
with	O
nonsyndromic	B-Disease
oligodontia	I-Disease
for	O
mutations	O
in	O
PAX9	O
and	O
MSX1	O
.	O
	
Single	O
stranded	O
conformational	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
and	O
sequencing	O
revealed	O
a	O
novel	O
heterozygous	O
C139T	O
transition	O
in	O
PAX9	O
in	O
the	O
affected	O
members	O
of	O
the	O
family	O
.	O
	
There	O
were	O
no	O
mutations	O
detected	O
in	O
the	O
entire	O
coding	O
sequence	O
of	O
MSX1	O
.	O
	
The	O
C139T	O
mutation	O
","	O
predicted	O
to	O
result	O
in	O
the	O
substitution	O
of	O
an	O
arginine	O
by	O
a	O
tryptophan	O
(	O
R47W	O
)	O
in	O
the	O
N	O
-	O
terminal	O
subdomain	O
","	O
affected	O
conserved	O
residues	O
in	O
the	O
PAX9	O
paired	O
domain	O
.	O
	
To	O
elucidate	O
the	O
pathogenic	O
mechanism	O
producing	O
oligodontia	B-Disease
phenotype	I-Disease
caused	O
by	O
this	O
mutation	O
","	O
we	O
analyzed	O
the	O
binding	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
PAX9	O
paired	O
domain	O
protein	O
to	O
double	O
-	O
stranded	O
DNA	O
targets	O
.	O
	
The	O
R47W	O
mutation	O
dramatically	O
reduced	O
DNA	O
binding	O
suggesting	O
that	O
the	O
mutant	O
protein	O
with	O
consequent	O
haploinsufficiency	O
results	O
in	O
a	O
clinical	O
phenotype	O
.	O
	
	
The	O
FH	O
mutation	O
database	O
:	O
an	O
online	O
database	O
of	O
fumarate	O
hydratase	O
mutations	O
involved	O
in	O
the	O
MCUL	B-Disease
(	O
HLRCC	B-Disease
)	O
tumor	B-Disease
syndrome	I-Disease
and	O
congenital	O
fumarase	B-Disease
deficiency	I-Disease
.	O
	
BACKGROUND	O
:	O
Fumarate	O
hydratase	O
(	O
HGNC	O
approved	O
gene	O
symbol	O
-	O
FH	O
)","	O
also	O
known	O
as	O
fumarase	O
","	O
is	O
an	O
enzyme	O
of	O
the	O
tricarboxylic	B-Chemical
acid	I-Chemical
(	O
TCA	B-Chemical
)	O
cycle	O
","	O
involved	O
in	O
fundamental	O
cellular	O
energy	O
production	O
.	O
	
First	O
described	O
by	O
Zinn	O
et	O
al	O
in	O
1986	O
","	O
deficiency	B-Disease
of	I-Disease
FH	I-Disease
results	O
in	O
early	O
onset	O
","	O
severe	O
encephalopathy	B-Disease
.	O
	
In	O
2002	O
","	O
the	O
Multiple	O
Leiomyoma	B-Disease
Consortium	O
identified	O
heterozygous	O
germline	O
mutations	O
of	O
FH	O
in	O
patients	O
with	O
multiple	B-Disease
cutaneous	I-Disease
and	I-Disease
uterine	I-Disease
leiomyomas	I-Disease
","	O
(	O
MCUL	B-Disease
:	O
OMIM	B-Disease
150800	I-Disease
).	O
	
In	O
some	O
families	O
renal	B-Disease
cell	I-Disease
cancer	I-Disease
also	O
forms	O
a	O
component	O
of	O
the	O
complex	O
and	O
as	O
such	O
has	O
been	O
described	O
as	O
hereditary	B-Disease
leiomyomatosis	I-Disease
and	I-Disease
renal	I-Disease
cell	I-Disease
cancer	I-Disease
(	O
HLRCC	B-Disease
:	O
OMIM	B-Disease
605839	I-Disease
).	O
	
The	O
identification	O
of	O
FH	O
as	O
a	O
tumor	B-Disease
suppressor	O
was	O
an	O
unexpected	O
finding	O
and	O
following	O
the	O
identification	O
of	O
subunits	O
of	O
succinate	O
dehydrogenase	O
in	O
2000	O
and	O
2001	O
","	O
was	O
only	O
the	O
second	O
description	O
of	O
the	O
involvement	O
of	O
an	O
enzyme	O
of	O
intermediary	O
metabolism	O
in	O
tumorigenesis	B-Disease
.	O
	
DESCRIPTION	O
:	O
The	O
FH	O
mutation	O
database	O
is	O
a	O
part	O
of	O
the	O
TCA	B-Chemical
cycle	O
gene	O
mutation	O
database	O
(	O
formerly	O
the	O
succinate	O
dehydrogenase	O
gene	O
mutation	O
database	O
)	O
and	O
is	O
based	O
on	O
the	O
Leiden	O
Open	O
(	O
source	O
)	O
Variation	O
Database	O
(	O
LOVD	O
)	O
system	O
.	O
	
The	O
variants	O
included	O
in	O
the	O
database	O
were	O
derived	O
from	O
the	O
published	O
literature	O
and	O
annotated	O
to	O
conform	O
to	O
current	O
mutation	O
nomenclature	O
.	O
	
The	O
FH	O
database	O
applies	O
HGVS	O
nomenclature	O
guidelines	O
","	O
and	O
will	O
assist	O
researchers	O
in	O
applying	O
these	O
guidelines	O
when	O
directly	O
submitting	O
new	O
sequence	O
variants	O
online	O
.	O
	
Since	O
the	O
first	O
molecular	O
characterization	O
of	O
an	O
FH	O
mutation	O
by	O
Bourgeron	O
et	O
al	O
in	O
1994	O
","	O
a	O
series	O
of	O
reports	O
of	O
both	O
FH	B-Disease
deficiency	I-Disease
patients	O
and	O
patients	O
with	O
MCUL	B-Disease
/	O
HLRRC	B-Disease
have	O
described	O
107	O
variants	O
","	O
of	O
which	O
93	O
are	O
thought	O
to	O
be	O
pathogenic	O
.	O
	
The	O
most	O
common	O
type	O
of	O
mutation	O
is	O
missense	O
(	O
57	O
%)","	O
followed	O
by	O
frameshifts	O
&	O
nonsense	O
(	O
27	O
%)","	O
and	O
diverse	O
deletions	O
","	O
insertions	O
and	O
duplications	O
.	O
	
Here	O
we	O
introduce	O
an	O
online	O
database	O
detailing	O
all	O
reported	O
FH	O
sequence	O
variants	O
.	O
	
CONCLUSION	O
:	O
The	O
FH	O
mutation	O
database	O
strives	O
to	O
systematically	O
unify	O
all	O
current	O
genetic	O
knowledge	O
of	O
FH	O
variants	O
.	O
	
We	O
believe	O
that	O
this	O
knowledge	O
will	O
assist	O
clinical	O
geneticists	O
and	O
treating	O
physicians	O
when	O
advising	O
patients	O
and	O
their	O
families	O
","	O
will	O
provide	O
a	O
rapid	O
and	O
convenient	O
resource	O
for	O
research	O
scientists	O
","	O
and	O
may	O
eventually	O
assist	O
in	O
gaining	O
novel	O
insights	O
into	O
FH	O
and	O
its	O
related	O
clinical	O
syndromes	O
.	O
	
	
A	O
novel	O
point	O
mutation	O
in	O
the	O
amino	O
terminal	O
domain	O
of	O
the	O
human	O
glucocorticoid	O
receptor	O
(	O
hGR	O
)	O
gene	O
enhancing	O
hGR	O
-	O
mediated	O
gene	O
expression	O
.	O
	
CONTEXT	O
:	O
Interindividual	O
variations	O
in	O
glucocorticoid	B-Chemical
sensitivity	O
have	O
been	O
associated	O
with	O
manifestations	O
of	O
cortisol	B-Chemical
excess	O
or	O
deficiency	O
and	O
may	O
be	O
partly	O
explained	O
by	O
polymorphisms	O
in	O
the	O
human	O
glucocorticoid	O
receptor	O
(	O
hGR	O
)	O
gene	O
.	O
	
We	O
studied	O
a	O
43	O
-	O
yr	O
-	O
old	O
female	O
","	O
who	O
presented	O
with	O
manifestations	O
consistent	O
with	O
tissue	O
-	O
selective	O
glucocorticoid	B-Chemical
hypersensitivity	B-Disease
.	O
	
We	O
detected	O
a	O
novel	O
","	O
single	O
","	O
heterozygous	O
nucleotide	O
(	O
G	O
-->	O
C	O
)	O
substitution	O
at	O
position	O
1201	O
(	O
exon	O
2	O
)	O
of	O
the	O
hGR	O
gene	O
","	O
which	O
resulted	O
in	O
aspartic	O
acid	O
to	O
histidine	O
substitution	O
at	O
amino	O
acid	O
position	O
401	O
in	O
the	O
amino	O
-	O
terminal	O
domain	O
of	O
the	O
hGRalpha	O
.	O
	
We	O
investigated	O
the	O
molecular	O
mechanisms	O
of	O
action	O
of	O
the	O
natural	O
mutant	O
receptor	O
	
.	O
	
METHODS	O
-	O
RESULTS	O
:	O
Compared	O
with	O
the	O
wild	O
-	O
type	O
hGRalpha	O
","	O
the	O
mutant	O
receptor	O
	
demonstrated	O
a	O
2	O
.	O
4	O
-	O
fold	O
increase	O
in	O
its	O
ability	O
to	O
transactivate	O
the	O
glucocorticoid	B-Chemical
-	O
inducible	O
mouse	O
mammary	O
tumor	O
virus	O
promoter	O
in	O
response	O
to	O
dexamethasone	B-Chemical
but	O
had	O
similar	O
affinity	O
for	O
the	O
ligand	O
(	O
dissociation	O
constant	O
=	O
6	O
.	O
2	O
+/-	O
0	O
.	O
6	O
vs	O
.	O
	
6	O
.	O
1	O
+/-	O
0	O
.	O
6	O
nm	O
)	O
and	O
time	O
to	O
nuclear	O
translocation	O
(	O
14	O
.	O
75	O
+/-	O
0	O
.	O
25	O
vs	O
.	O
	
14	O
.	O
25	O
+/-	O
1	O
.	O
13	O
min	O
).	O
	
The	O
mutant	O
receptor	O
	
did	O
not	O
exert	O
a	O
dominant	O
positive	O
or	O
negative	O
effect	O
upon	O
the	O
wild	O
-	O
type	O
receptor	O
","	O
it	O
preserved	O
its	O
ability	O
to	O
bind	O
to	O
glucocorticoid	B-Chemical
response	O
elements	O
","	O
and	O
displayed	O
a	O
normal	O
interaction	O
with	O
the	O
glucocorticoid	O
receptor	O
-	O
interacting	O
protein	O
1	O
coactivator	O
.	O
	
CONCLUSIONS	O
:	O
The	O
mutant	O
receptor	O
	
enhances	O
the	O
transcriptional	O
activity	O
of	O
glucocorticoid	O
-	O
responsive	O
genes	O
.	O
	
The	O
presence	O
of	O
the	O
D401H	O
mutation	O
may	O
predispose	O
subjects	O
to	O
obesity	B-Disease
","	O
hypertension	B-Disease
","	O
and	O
other	O
manifestations	O
of	O
the	O
metabolic	B-Disease
syndrome	I-Disease
.	O
	
	
Activated	O
Ras	O
alters	O
lens	O
and	O
corneal	O
development	O
through	O
induction	O
of	O
distinct	O
downstream	O
targets	O
.	O
	
BACKGROUND	O
:	O
Mammalian	O
Ras	O
genes	O
regulate	O
diverse	O
cellular	O
processes	O
including	O
proliferation	O
and	O
differentiation	O
and	O
are	O
frequently	O
mutated	O
in	O
human	O
cancers	B-Disease
.	O
	
Tumor	B-Disease
development	O
in	O
response	O
to	O
Ras	O
activation	O
varies	O
between	O
different	O
tissues	O
and	O
the	O
molecular	O
basis	O
for	O
these	O
variations	O
are	O
poorly	O
understood	O
.	O
	
The	O
murine	O
lens	O
and	O
cornea	O
have	O
a	O
common	O
embryonic	O
origin	O
and	O
arise	O
from	O
adjacent	O
regions	O
of	O
the	O
surface	O
ectoderm	O
.	O
	
Activation	O
of	O
the	O
fibroblast	O
growth	O
factor	O
(	O
FGF	O
)	O
signaling	O
pathway	O
induces	O
the	O
corneal	O
epithelial	O
cells	O
to	O
proliferate	O
and	O
the	O
lens	O
epithelial	O
cells	O
to	O
exit	O
the	O
cell	O
cycle	O
.	O
	
The	O
molecular	O
mechanisms	O
that	O
regulate	O
the	O
differential	O
responses	O
of	O
these	O
two	O
related	O
tissues	O
have	O
not	O
been	O
defined	O
.	O
	
We	O
have	O
generated	O
transgenic	O
mice	O
that	O
express	O
a	O
constitutively	O
active	O
version	O
of	O
human	O
H	O
-	O
Ras	O
in	O
their	O
lenses	O
and	O
corneas	O
.	O
	
RESULTS	O
:	O
Ras	O
transgenic	O
lenses	O
and	O
corneal	O
epithelial	O
cells	O
showed	O
increased	O
proliferation	O
with	O
concomitant	O
increases	O
in	O
cyclin	O
D1	O
and	O
D2	O
expression	O
.	O
	
This	O
initial	O
increase	O
in	O
proliferation	O
is	O
sustained	O
in	O
the	O
cornea	O
but	O
not	O
in	O
the	O
lens	O
epithelial	O
cells	O
.	O
	
Coincidentally	O
","	O
cdk	O
inhibitors	O
p27Kip1	O
and	O
p57Kip2	O
were	O
upregulated	O
in	O
the	O
Ras	O
transgenic	O
lenses	O
but	O
not	O
in	O
the	O
corneas	O
.	O
	
Phospho	O
-	O
Erk1	O
and	O
Erk2	O
levels	O
were	O
elevated	O
in	O
the	O
lens	O
but	O
not	O
in	O
the	O
cornea	O
and	O
Spry	O
1	O
and	O
Spry	O
2	O
","	O
negative	O
regulators	O
of	O
Ras	O
-	O
Raf	O
-	O
Erk	O
signaling	O
","	O
were	O
upregulated	O
more	O
in	O
the	O
corneal	O
than	O
in	O
the	O
lens	O
epithelial	O
cells	O
.	O
	
Both	O
lens	O
and	O
corneal	O
differentiation	O
programs	O
were	O
sensitive	O
to	O
Ras	O
activation	O
.	O
	
Ras	O
transgenic	O
embryos	O
showed	O
a	O
distinctive	O
alteration	O
in	O
the	O
architecture	O
of	O
the	O
lens	O
pit	O
.	O
	
Ras	O
activation	O
","	O
though	O
sufficient	O
for	O
upregulation	O
of	O
Prox1	O
","	O
a	O
transcription	O
factor	O
critical	O
for	O
cell	O
cycle	O
exit	O
and	O
initiation	O
of	O
fiber	O
differentiation	O
","	O
is	O
not	O
sufficient	O
for	O
induction	O
of	O
terminal	O
fiber	O
differentiation	O
.	O
	
Expression	O
of	O
Keratin	O
12	O
","	O
a	O
marker	O
of	O
corneal	O
epithelial	O
differentiation	O
","	O
was	O
reduced	O
in	O
the	O
Ras	O
transgenic	O
corneas	O
.	O
	
CONCLUSIONS	O
:	O
Collectively	O
","	O
these	O
results	O
suggest	O
that	O
Ras	O
activation	O
a	O
)	O
induces	O
distinct	O
sets	O
of	O
downstream	O
targets	O
in	O
the	O
lens	O
and	O
cornea	O
resulting	O
in	O
distinct	O
cellular	O
responses	O
and	O
b	O
)	O
is	O
sufficient	O
for	O
initiation	O
but	O
not	O
completion	O
of	O
lens	O
fiber	O
differentiation	O
.	O
	
	
A	O
novel	O
mutation	O
in	O
the	O
connexin	O
26	O
gene	O
(	O
GJB2	O
)	O
in	O
a	O
child	O
with	O
clinical	O
and	O
histological	O
features	O
of	O
keratitis	B-Disease
-	I-Disease
ichthyosis	I-Disease
-	I-Disease
deafness	I-Disease
(	I-Disease
KID	I-Disease
)	I-Disease
syndrome	I-Disease
.	O
	
BACKGROUND	O
:	O
Keratitis	B-Disease
-	I-Disease
ichthyosis	I-Disease
-	I-Disease
deafness	I-Disease
(	I-Disease
KID	I-Disease
)	I-Disease
syndrome	I-Disease
is	O
a	O
rare	O
congenital	B-Disease
ectodermal	I-Disease
disorder	I-Disease
","	O
caused	O
by	O
heterozygous	O
missense	O
mutation	O
in	O
GJB2	O
","	O
encoding	O
the	O
gap	O
junction	O
protein	O
connexin	O
26	O
.	O
	
The	O
commonest	O
mutation	O
is	O
the	O
p	O
.	O
Asp50Asn	O
mutation	O
","	O
and	O
only	O
a	O
few	O
other	O
mutations	O
have	O
been	O
described	O
to	O
date	O
.	O
	
AIM	O
:	O
To	O
report	O
the	O
fatal	O
clinical	O
course	O
and	O
characterize	O
the	O
genetic	O
background	O
of	O
a	O
premature	O
male	O
neonate	O
with	O
the	O
clinical	O
and	O
histological	O
features	O
of	O
KID	B-Disease
syndrome	I-Disease
.	O
	
METHODS	O
:	O
Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
and	O
used	O
for	O
PCR	O
amplification	O
of	O
the	O
GJB2	O
gene	O
.	O
	
Direct	O
sequencing	O
was	O
used	O
for	O
mutation	O
analysis	O
.	O
	
RESULTS	O
:	O
The	O
clinical	O
features	O
included	O
hearing	B-Disease
impairment	I-Disease
","	O
ichthyosiform	B-Disease
erythroderma	I-Disease
with	O
hyperkeratotic	O
plaques	O
","	O
palmoplantar	B-Disease
keratoderma	I-Disease
","	O
alopecia	B-Disease
of	I-Disease
the	I-Disease
scalp	I-Disease
and	I-Disease
eyelashes	I-Disease
","	O
and	O
a	O
thick	O
vernix	O
caseosa	O
-	O
like	O
covering	O
of	O
the	O
scalp	O
.	O
	
On	O
histological	O
analysis	O
","	O
features	O
characteristic	O
of	O
KID	B-Disease
syndrome	I-Disease
","	O
such	O
as	O
acanthosis	B-Disease
and	O
papillomatosis	B-Disease
of	O
the	O
epidermis	O
with	O
basket	O
-	O
weave	O
hyperkeratosis	B-Disease
","	O
were	O
seen	O
.	O
	
The	O
skin	O
symptoms	O
were	O
treated	O
successfully	O
with	O
acitretin	B-Chemical
0	O
.	O
5	O
mg	O
/	O
kg	O
.	O
	
The	O
boy	O
developed	O
intraventricular	B-Disease
and	I-Disease
intracerebral	I-Disease
haemorrhage	I-Disease
","	O
leading	O
to	O
hydrocephalus	B-Disease
.	O
	
His	O
condition	O
was	O
further	O
complicated	O
by	O
septicaemia	B-Disease
and	O
meningitis	B-Disease
caused	O
by	O
infection	B-Disease
with	O
extended	O
-	O
spectrum	O
beta	O
-	O
lactamase	O
-	O
producing	O
Klebsiella	B-Disease
pneumoniae	I-Disease
.	O
	
Severe	O
respiratory	B-Disease
failure	I-Disease
followed	O
","	O
and	O
the	O
child	O
died	O
at	O
46	O
weeks	O
of	O
gestational	O
age	O
(	O
13	O
weeks	O
postnatally	O
).	O
	
Sequencing	O
of	O
the	O
GJB2	O
gene	O
showed	O
that	O
the	O
child	O
was	O
heterozygous	O
for	O
a	O
novel	O
nucleotide	O
change	O
","	O
c	O
.	O
263C	O
>	O
T	O
","	O
in	O
exon	O
2	O
","	O
leading	O
to	O
a	O
substitution	O
of	O
alanine	O
for	O
valine	O
at	O
position	O
88	O
(	O
p	O
.	O
Ala88Val	O
).	O
	
CONCLUSIONS	O
:	O
This	O
study	O
has	O
identified	O
a	O
new	O
heterozygous	O
de	O
novo	O
mutation	O
in	O
the	O
Cx26	O
gene	O
(	O
c	O
.	O
263C	O
>	O
T	O
";"	O
p	O
.	O
Ala88Val	O
)	O
leading	O
to	O
KID	B-Disease
syndrome	I-Disease
.	O
	
	
Inactivation	O
of	O
Sag	O
/	O
Rbx2	O
/	O
Roc2	O
e3	O
ubiquitin	O
ligase	O
triggers	O
senescence	O
and	O
inhibits	O
kras	O
-	O
induced	O
immortalization	O
.	O
	
Our	O
recent	O
study	O
showed	O
that	O
SAG	O
/	O
RBX2	O
E3	O
ubiquitin	O
ligase	O
regulates	O
apoptosis	O
and	O
vasculogenesis	O
by	O
promoting	O
degradation	O
of	O
NOXA	O
and	O
NF1	O
","	O
and	O
co	O
-	O
operates	O
with	O
Kras	O
to	O
promote	O
lung	B-Disease
tumorigenesis	I-Disease
by	O
activating	O
NFkappaB	O
and	O
mTOR	O
pathways	O
via	O
targeted	O
degradation	O
of	O
tumor	B-Disease
suppressive	O
substrates	O
including	O
IkappaB	O
","	O
DEPTOR	O
","	O
p21	O
and	O
p27	O
.	O
	
Here	O
we	O
investigated	O
the	O
role	O
of	O
Sag	O
/	O
Rbx2	O
E3	O
ligase	O
in	O
cellular	O
senescence	O
and	O
immortalization	O
of	O
mouse	O
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
and	O
report	O
that	O
Sag	O
is	O
required	O
for	O
proper	O
cell	O
proliferation	O
and	O
Kras	O
(	O
G12D	O
)-	O
induced	O
immortalization	O
.	O
	
Sag	O
inactivation	O
by	O
genetic	O
deletion	O
remarkably	O
suppresses	O
cell	O
proliferation	O
by	O
inducing	O
senescence	O
","	O
which	O
is	O
associated	O
with	O
accumulation	O
of	O
p16	O
","	O
but	O
not	O
p53	O
.	O
	
Mechanistically	O
","	O
Sag	O
deletion	O
caused	O
accumulation	O
of	O
Jun	O
-	O
B	O
","	O
a	O
substrate	O
of	O
Sag	O
-	O
Fbxw7	O
E3	O
ligase	O
and	O
a	O
transcription	O
factor	O
that	O
drives	O
p16	O
transcription	O
.	O
	
Importantly	O
","	O
senescence	O
triggered	O
by	O
Sag	O
deletion	O
can	O
be	O
largely	O
rescued	O
by	O
simultaneous	O
deletion	O
of	O
Cdkn2a	O
","	O
the	O
p16	O
encoding	O
gene	O
","	O
indicating	O
its	O
causal	O
role	O
.	O
	
Furthermore	O
","	O
Kras	O
(	O
G12D	O
)-	O
induced	O
immortalization	O
can	O
also	O
be	O
abrogated	O
by	O
Sag	O
deletion	O
via	O
senescence	O
induction	O
","	O
which	O
is	O
again	O
rescued	O
by	O
simultaneous	O
deletion	O
of	O
Cdkn2a	O
.	O
	
Finally	O
","	O
we	O
found	O
that	O
Sag	O
deletion	O
inactivates	O
Kras	O
(	O
G12D	O
)	O
activity	O
and	O
block	O
the	O
MAPK	O
signaling	O
pathway	O
","	O
together	O
with	O
accumulated	O
p16	O
","	O
to	O
induce	O
senescence	O
.	O
	
Taken	O
together	O
","	O
our	O
results	O
demonstrated	O
that	O
Sag	O
is	O
a	O
Kras	O
(	O
G12D	O
)-	O
cooperating	O
oncogene	O
required	O
for	O
Kras	O
(	O
G12D	O
)-	O
induced	O
immortalization	O
and	O
transformation	O
","	O
and	O
targeting	O
SAG	O
-	O
SCF	O
E3	O
ligase	O
may	O
","	O
therefore	O
","	O
have	O
therapeutic	O
value	O
for	O
senescence	O
-	O
based	O
cancer	B-Disease
treatment	O
.	O
	
	
Mechanisms	O
Underlying	O
Latent	O
Disease	O
Risk	O
Associated	O
with	O
Early	O
-	O
Life	O
Arsenic	B-Chemical
Exposure	O
:	O
Current	O
Research	O
Trends	O
and	O
Scientific	O
Gaps	O
.	O
	
BACKGROUND	O
:	O
Millions	O
of	O
individuals	O
worldwide	O
","	O
particularly	O
those	O
living	O
in	O
rural	O
and	O
developing	O
areas	O
","	O
are	O
exposed	O
to	O
harmful	O
levels	O
of	O
inorganic	B-Chemical
arsenic	I-Chemical
(	O
iAs	B-Chemical
)	O
in	O
their	O
drinking	O
water	O
.	O
	
Inorganic	B-Chemical
As	I-Chemical
exposure	O
during	O
key	O
developmental	O
periods	O
is	O
associated	O
with	O
a	O
variety	O
of	O
adverse	O
health	O
effects	O
including	O
those	O
that	O
are	O
evident	O
in	O
adulthood	O
.	O
	
There	O
is	O
considerable	O
interest	O
in	O
identifying	O
the	O
molecular	O
mechanisms	O
that	O
relate	O
early	O
-	O
life	O
iAs	B-Chemical
exposure	O
to	O
the	O
development	O
of	O
these	O
latent	O
diseases	O
","	O
particularly	O
in	O
relationship	O
to	O
cancer	B-Disease
.	O
	
OBJECTIVES	O
:	O
This	O
work	O
summarizes	O
research	O
on	O
the	O
molecular	O
mechanisms	O
that	O
underlie	O
the	O
increased	O
risk	O
of	O
cancer	B-Disease
development	O
in	O
adulthood	O
that	O
is	O
associated	O
with	O
early	O
-	O
life	O
iAs	B-Chemical
exposure	O
.	O
	
DISCUSSION	O
:	O
Epigenetic	O
reprogramming	O
that	O
imparts	O
functional	O
changes	O
in	O
gene	O
expression	O
","	O
the	O
development	O
of	O
cancer	B-Disease
stem	O
cells	O
","	O
and	O
immunomodulation	O
are	O
plausible	O
underlying	O
mechanisms	O
by	O
which	O
early	O
-	O
life	O
iAs	B-Chemical
exposure	O
elicits	O
latent	O
carcinogenic	B-Disease
effects	O
.	O
	
CONCLUSIONS	O
:	O
Evidence	O
is	O
mounting	O
that	O
relates	O
early	O
-	O
life	O
iAs	B-Chemical
exposure	O
and	O
cancer	B-Disease
development	O
later	O
in	O
life	O
.	O
	
Future	O
research	O
should	O
include	O
animal	O
studies	O
that	O
address	O
mechanistic	O
hypotheses	O
and	O
studies	O
of	O
human	O
populations	O
that	O
integrate	O
early	O
-	O
life	O
exposure	O
","	O
molecular	O
alterations	O
","	O
and	O
latent	O
disease	O
outcomes	O
.	O
	
	
Brain	O
-	O
derived	O
neurotrophic	O
factor	O
attenuates	O
doxorubicin	B-Chemical
-	O
induced	O
cardiac	B-Disease
dysfunction	I-Disease
through	O
activating	O
Akt	O
signalling	O
in	O
rats	O
.	O
	
The	O
clinical	O
application	O
of	O
doxorubicin	B-Chemical
(	O
Dox	B-Chemical
)	O
is	O
limited	O
by	O
its	O
adverse	O
effect	O
of	O
cardiotoxicity	B-Disease
.	O
	
Previous	O
studies	O
have	O
suggested	O
the	O
cardioprotective	O
effect	O
of	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
(	O
BDNF	O
).	O
	
We	O
hypothesize	O
that	O
BDNF	O
could	O
protect	O
against	O
Dox	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O
	
Sprague	O
Dawley	O
rats	O
were	O
injected	O
with	O
Dox	B-Chemical
(	O
2	O
.	O
5	O
mg	O
/	O
kg	O
","	O
3	O
times	O
/	O
week	O
","	O
i	O
.	O
p	O
.	O
	
)","	O
in	O
the	O
presence	O
or	O
absence	O
of	O
recombinant	O
BDNF	O
(	O
0	O
.	O
4	O
ug	O
/	O
kg	O
","	O
i	O
.	O
v	O
.)	O
	
for	O
2	O
weeks	O
.	O
	
H9c2	O
cells	O
were	O
treated	O
with	O
Dox	B-Chemical
(	O
1	O
uM	O
)	O
and	O
/	O
or	O
BDNF	O
(	O
400	O
ng	O
/	O
ml	O
)	O
for	O
24	O
hrs	O
.	O
	
Functional	O
roles	O
of	O
BDNF	O
against	O
Dox	B-Chemical
-	O
induced	O
cardiac	B-Disease
injury	I-Disease
were	O
examined	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O
	
Protein	O
level	O
of	O
BDNF	O
was	O
reduced	O
in	O
Dox	B-Chemical
-	O
treated	O
rat	O
ventricles	O
","	O
whereas	O
BDNF	O
and	O
its	O
receptor	O
tropomyosin	O
-	O
related	O
kinase	O
B	O
(	O
TrkB	O
)	O
were	O
markedly	O
up	O
-	O
regulated	O
after	O
BDNF	O
administration	O
.	O
	
Brain	O
-	O
derived	O
neurotrophic	O
factor	O
significantly	O
inhibited	O
Dox	B-Chemical
-	O
induced	O
cardiomyocyte	O
apoptosis	O
","	O
oxidative	O
stress	O
and	O
cardiac	B-Disease
dysfunction	I-Disease
in	O
rats	O
.	O
	
Meanwhile	O
","	O
BDNF	O
increased	O
cell	O
viability	O
","	O
inhibited	O
apoptosis	O
and	O
DNA	O
damage	O
of	O
Dox	B-Chemical
-	O
treated	O
H9c2	O
cells	O
.	O
	
Investigations	O
of	O
the	O
underlying	O
mechanisms	O
revealed	O
that	O
BDNF	O
activated	O
Akt	O
and	O
preserved	O
phosphorylation	O
of	O
mammalian	O
target	O
of	O
rapamycin	O
and	O
Bad	O
without	O
affecting	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
and	O
extracellular	O
regulated	O
protein	O
kinase	O
pathways	O
.	O
	
Furthermore	O
","	O
the	O
beneficial	O
effect	O
of	O
BDNF	O
was	O
abolished	O
by	O
BDNF	O
scavenger	O
TrkB	O
-	O
Fc	O
or	O
Akt	O
inhibitor	O
.	O
	
In	O
conclusion	O
","	O
our	O
findings	O
reveal	O
a	O
potent	O
protective	O
role	O
of	O
BDNF	O
against	O
Dox	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
by	O
activating	O
Akt	O
signalling	O
","	O
which	O
may	O
facilitate	O
the	O
safe	O
use	O
of	O
Dox	B-Chemical
in	O
cancer	B-Disease
treatment	O
.	O
	
	
Atrial	B-Disease
fibrillation	I-Disease
following	O
chemotherapy	O
for	O
stage	O
IIIE	O
diffuse	O
large	O
B	O
-	O
cell	O
gastric	B-Disease
lymphoma	I-Disease
in	O
a	O
patient	O
with	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
Steinert	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
).	O
	
The	O
authors	O
describe	O
the	O
unusual	O
association	O
between	O
diffuse	O
B	O
-	O
cell	O
gastric	B-Disease
lymphoma	I-Disease
and	O
myotonic	B-Disease
dystrophy	I-Disease
","	O
the	O
most	O
common	O
form	O
of	O
adult	O
muscular	B-Disease
dystrophy	I-Disease
","	O
and	O
sudden	O
atrial	B-Disease
fibrillation	I-Disease
following	O
one	O
cycle	O
of	O
doxorubicin	B-Chemical
-	O
based	O
chemotherapy	O
in	O
the	O
same	O
patient	O
.	O
	
Atrial	B-Disease
fibrillation	I-Disease
or	O
other	O
cardiac	B-Disease
arrhythmias	I-Disease
are	O
unusual	O
complications	O
in	O
patients	O
treated	O
with	O
chemotherapy	O
.	O
	
The	O
cardiac	B-Disease
toxicity	I-Disease
intrinsically	O
associated	O
with	O
the	O
aggressive	O
chemotherapy	O
employed	O
could	O
function	O
as	O
a	O
triggering	O
factor	O
for	O
the	O
arrhythmia	B-Disease
in	O
the	O
predisposed	O
myocardium	O
of	O
this	O
patient	O
.	O
	
	
Ca2	B-Chemical
+	I-Chemical
dependence	O
of	O
the	O
Ca2	B-Chemical
+-	I-Chemical
selective	O
TRPV6	O
channel	O
.	O
	
Microfluorimetry	O
and	O
patch	O
-	O
clamp	O
experiments	O
were	O
performed	O
on	O
TRPV6	O
-	O
expressing	O
HEK	O
cells	O
to	O
determine	O
whether	O
this	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+)-	I-Chemical
sensing	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+)	I-Chemical
channel	O
is	O
constitutively	O
active	O
.	O
	
Intact	O
cells	O
loaded	O
with	O
fura	B-Chemical
-	I-Chemical
2	I-Chemical
had	O
an	O
elevated	O
intracellular	O
free	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+)	I-Chemical
concentration	O
((	O
i	O
))","	O
which	O
decreased	O
to	O
the	O
same	O
level	O
such	O
as	O
in	O
non	O
-	O
transfected	O
cells	O
if	O
external	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+)	I-Chemical
was	O
chelated	O
by	O
EGTA	B-Chemical
.	O
	
Whole	O
cell	O
recordings	O
from	O
non	O
-	O
transfected	O
HEK	O
cells	O
and	O
cells	O
expressing	O
human	O
TRPV6	O
revealed	O
the	O
presence	O
of	O
a	O
basal	O
inward	O
current	O
in	O
both	O
types	O
of	O
cells	O
when	O
the	O
internal	O
solution	O
contained	O
0	O
.	O
1	O
mm	O
EGTA	B-Chemical
and	O
100	O
nm	O
(	O
i	O
)	O
or	O
if	O
the	O
cytosolic	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+)	I-Chemical
buffering	O
remained	O
undisturbed	O
in	O
perforated	O
patch	O
-	O
clamp	O
experiments	O
.	O
	
If	O
recombinantly	O
expressed	O
TRPV6	O
forms	O
open	O
channels	O
","	O
one	O
would	O
expect	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+)-	I-Chemical
induced	O
current	O
inhibition	O
","	O
because	O
TRPV6	O
is	O
negatively	O
regulated	O
by	O
internal	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+).	I-Chemical
	
However	O
","	O
dialyzing	O
solutions	O
with	O
high	O
such	O
as	O
1	O
microm	O
into	O
TRPV6	O
-	O
expressing	O
cells	O
did	O
not	O
block	O
the	O
basal	O
inward	O
current	O
","	O
which	O
was	O
not	O
different	O
from	O
the	O
recordings	O
from	O
non	O
-	O
transfected	O
cells	O
.	O
	
In	O
contrast	O
","	O
dialyzing	O
0	O
.	O
5	O
mm	O
EGTA	B-Chemical
into	O
TRPV6	O
-	O
expressing	O
cells	O
readily	O
activated	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+)	I-Chemical
inward	O
currents	O
","	O
which	O
were	O
undetectable	O
in	O
non	O
-	O
transfected	O
cells	O
.	O
	
Interestingly	O
","	O
monovalent	O
cations	O
permeated	O
the	O
TRPV6	O
channels	O
under	O
conditions	O
where	O
no	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+)	I-Chemical
permeation	O
was	O
detectable	O
","	O
indicating	O
that	O
divalent	O
cations	O
block	O
TRPV6	O
channels	O
from	O
the	O
extracellular	O
side	O
.	O
	
Like	O
human	O
TRPV6	O
","	O
the	O
truncated	O
human	O
TRPV6	O
(	O
Delta695	O
-	O
725	O
)","	O
which	O
lacks	O
the	O
C	O
-	O
terminal	O
domain	O
required	O
for	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+)-	I-Chemical
calmodulin	O
binding	O
","	O
does	O
not	O
form	O
constitutive	O
active	O
channels	O
","	O
whereas	O
the	O
human	O
TRPV6	O
(	O
D542A	O
)","	O
carrying	O
a	O
point	O
mutation	O
in	O
the	O
presumed	O
pore	O
region	O
","	O
does	O
not	O
function	O
as	O
a	O
channel	O
.	O
	
In	O
summary	O
","	O
no	O
constitutive	O
open	O
TRPV6	O
channels	O
were	O
detected	O
in	O
patch	O
-	O
clamp	O
experiments	O
from	O
transfected	O
HEK	O
cells	O
.	O
	
However	O
","	O
channel	O
activity	O
is	O
highly	O
regulated	O
by	O
intracellular	O
and	O
extracellular	O
divalent	O
cations	O
.	O
	
	
Identification	O
of	O
novel	O
type	O
VII	O
collagen	O
gene	O
mutations	O
resulting	O
in	O
severe	O
recessive	B-Disease
dystrophic	I-Disease
epidermolysis	I-Disease
bullosa	I-Disease
.	O
	
In	O
this	O
work	O
","	O
we	O
studied	O
the	O
proband	O
in	O
a	O
small	O
nuclear	O
family	O
of	O
Chinese	O
and	O
Dutch	O
/	O
German	O
descent	O
and	O
identified	O
two	O
novel	O
mutations	O
in	O
the	O
type	O
VII	O
collagen	O
gene	O
leading	O
to	O
recessive	B-Disease
dystrophic	I-Disease
epidermolysis	I-Disease
bullosa	I-Disease
","	O
Hallopeau	B-Disease
-	I-Disease
Siemens	I-Disease
variant	O
(	O
HS	B-Disease
-	I-Disease
RDEB	I-Disease
).	O
	
The	O
maternal	O
mutation	O
is	O
a	O
single	O
base	O
pair	O
deletion	O
of	O
a	O
cytosine	O
nucleotide	O
in	O
exon	O
26	O
","	O
designated	O
3472delC	O
","	O
resulting	O
in	O
a	O
frameshift	O
and	O
a	O
premature	O
termination	O
codon	O
(	O
PTC	O
)	O
within	O
the	O
same	O
exon	O
","	O
7	O
bp	O
downstream	O
of	O
the	O
site	O
of	O
the	O
mutation	O
.	O
	
The	O
paternal	O
mutation	O
is	O
a	O
G	O
-->	O
A	O
transition	O
located	O
at	O
the	O
5	O
'	O
donor	O
splice	O
site	O
within	O
intron	O
51	O
","	O
designated	O
IVS51	O
+	O
1G	O
-->	O
A	O
.	O
	
This	O
mutation	O
leads	O
to	O
the	O
activation	O
of	O
a	O
cryptic	O
splice	O
site	O
","	O
32	O
bp	O
downstream	O
of	O
the	O
mutation	O
site	O
and	O
to	O
subsequent	O
aberrant	O
out	O
-	O
of	O
-	O
frame	O
splicing	O
","	O
resulting	O
in	O
two	O
alternative	O
mRNA	O
transcripts	O
and	O
a	O
downstream	O
PTC	O
.	O
	
To	O
our	O
knowledge	O
","	O
these	O
two	O
mutations	O
have	O
not	O
been	O
previously	O
reported	O
.	O
	
These	O
findings	O
extend	O
the	O
body	O
of	O
evidence	O
for	O
compound	O
heterozygous	O
mutations	O
leading	O
to	O
HS	B-Disease
-	I-Disease
RDEB	I-Disease
and	O
provide	O
the	O
basis	O
for	O
prenatal	O
diagnosis	O
in	O
this	O
family	O
.	O
	
	
A	O
Cys	O
23	O
-	O
Ser	O
23	O
substitution	O
in	O
the	O
5	O
-	O
HT	O
(	O
2C	O
)	O
receptor	O
gene	O
influences	O
body	O
weight	O
regulation	O
in	O
females	O
with	O
seasonal	B-Disease
affective	I-Disease
disorder	I-Disease
:	O
an	O
Austrian	O
-	O
Canadian	O
collaborative	O
study	O
.	O
	
Most	O
females	O
with	O
seasonal	B-Disease
affective	I-Disease
disorder	I-Disease
(	O
SAD	B-Disease
)	O
exhibit	O
atypical	O
vegetative	O
symptoms	O
such	O
as	O
overeating	O
","	O
and	O
weight	B-Disease
gain	I-Disease
when	I-Disease
depressed	I-Disease
.	O
	
The	O
serotonin	O
2C	O
receptor	O
(	O
5	O
-	O
HT	O
(	O
2C	O
))	O
plays	O
a	O
key	O
role	O
in	O
control	O
of	O
appetite	O
and	O
satiety	O
.	O
	
A	O
5	O
-	O
HT	O
(	O
2C	O
)	O
Cys	O
23	O
Ser	O
substitution	O
","	O
coded	O
for	O
by	O
a	O
single	O
nucleotide	O
polymorphism	O
(	O
Cys	O
23	O
Ser	O
)	O
within	O
the	O
5	O
-	O
HT	O
(	O
2C	O
)	O
gene	O
","	O
has	O
been	O
shown	O
to	O
influence	O
5	O
-	O
HT	O
(	O
2C	O
)	O
function	O
.	O
	
We	O
hypothesized	O
that	O
Cys	O
23	O
Ser	O
influences	O
weight	O
regulation	O
in	O
females	O
with	O
SAD	B-Disease
.	O
	
Two	O
independent	O
samples	O
from	O
Austria	O
(	O
162	O
females	O
with	O
SAD	B-Disease
","	O
119	O
controls	O
)","	O
and	O
Canada	O
(	O
90	O
females	O
with	O
SAD	B-Disease
","	O
42	O
controls	O
)	O
were	O
genotyped	O
for	O
Cys	O
23	O
Ser	O
.	O
	
Influence	O
on	O
weight	O
regulation	O
was	O
analyzed	O
within	O
patients	O
with	O
atypical	O
features	O
.	O
	
In	O
Austrians	O
","	O
genotype	O
distribution	O
differed	O
between	O
patients	O
and	O
controls	O
(	O
p	O
=	O
0	O
.	O
44	O
)	O
and	O
Cys	O
23	O
Ser	O
was	O
associated	O
with	O
weight	O
(	O
p	O
=	O
0	O
.	O
39	O
)","	O
body	O
mass	O
index	O
(	O
BMI	O
";"	O
p	O
=	O
0	O
.	O
38	O
)","	O
and	O
seasonal	O
appetite	O
change	O
(	O
p	O
=	O
0	O
.	O
31	O
).	O
	
All	O
values	O
were	O
highest	O
in	O
Cys	O
/	O
Cys	O
","	O
intermediate	O
in	O
Cys	O
/	O
Ser	O
","	O
and	O
lowest	O
in	O
Ser	O
/	O
Ser	O
carriers	O
.	O
	
In	O
Canadian	O
patients	O
","	O
Cys	O
23	O
Ser	O
was	O
associated	O
with	O
minimum	O
lifetime	O
BMI	O
(	O
p	O
=	O
0	O
.	O
46	O
)","	O
with	O
lowest	O
values	O
in	O
Ser	O
/	O
Ser	O
carriers	O
.	O
	
Our	O
data	O
provide	O
evidence	O
that	O
Cys	O
23	O
Ser	O
mediates	O
severity	O
of	O
weight	O
regulation	O
disturbances	O
in	O
females	O
with	O
SAD	B-Disease
","	O
and	O
the	O
gene	O
-	O
dose	O
effect	O
-	O
like	O
differences	O
suggest	O
a	O
direct	O
functional	O
role	O
of	O
Cys	O
23	O
Ser	O
in	O
the	O
behavioral	O
regulation	O
of	O
body	O
weight	O
.	O
	
	
Cytochrome	O
p4501A1	O
gene	O
variants	O
as	O
susceptibility	O
marker	O
for	O
prostate	B-Disease
cancer	I-Disease
.	O
	
CYP1A1	O
activates	O
environmental	O
procarcinogens	O
and	O
catalyzes	O
oxidative	O
metabolism	O
of	O
estrogens	O
and	O
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
etiology	O
of	O
prostate	B-Disease
cancer	I-Disease
.	O
	
To	O
evaluate	O
this	O
phenomenon	O
","	O
the	O
association	O
between	O
two	O
single	O
nucleotide	O
polymorphisms	O
(	O
A	O
to	O
G	O
transition	O
in	O
exon7	O
leading	O
to	O
amino	O
acid	O
substitution	O
Ile462Val	O
and	O
T3801C	O
at	O
3	O
'	O
UTR	O
)	O
of	O
CYP1A1	O
gene	O
in	O
prostate	B-Disease
cancer	I-Disease
were	O
analyzed	O
in	O
a	O
case	O
-	O
control	O
study	O
of	O
100	O
individuals	O
in	O
South	O
Indian	O
population	O
.	O
	
The	O
estimated	O
relative	O
risk	O
was	O
significantly	O
high	O
for	O
individuals	O
with	O
w1	O
/	O
m1	O
genotype	O
at	O
3	O
'	O
UTR	O
of	O
CYP1A1	O
gene	O
(	O
OR	O
-	O
4	O
.	O
64	O
";"	O
95	O
%	O
CI	O
=	O
1	O
.	O
51	O
-	O
14	O
.	O
86	O
";"	O
P	O
<	O
0	O
.	O
1	O
)	O
whereas	O
the	O
CYP1A1	O
Ile	O
/	O
Val	O
genotype	O
(	O
w2	O
/	O
m2	O
)	O
on	O
exon	O
7	O
was	O
found	O
to	O
be	O
associated	O
with	O
a	O
decreased	O
risk	O
for	O
prostate	B-Disease
cancer	I-Disease
(	O
OR	O
-	O
0	O
.	O
17	O
";"	O
95	O
%	O
CI	O
=	O
0	O
.	O
2	O
-	O
0	O
.	O
89	O
";"	O
P	O
=	O
0	O
.	O
3	O
).	O
	
A	O
Stratified	O
analysis	O
of	O
the	O
genotypes	O
with	O
age	O
of	O
onset	O
and	O
tumor	B-Disease
grade	O
showed	O
the	O
w1	O
/	O
m1	O
genotype	O
to	O
be	O
significantly	O
associated	O
with	O
an	O
early	O
age	O
of	O
onset	O
";"	O
however	O
the	O
tumor	B-Disease
grades	O
did	O
not	O
have	O
significant	O
association	O
with	O
the	O
variant	O
genotypes	O
.	O
	
Thus	O
the	O
present	O
study	O
indicates	O
that	O
individuals	O
with	O
the	O
variant	O
w1	O
/	O
m1	O
genotype	O
exhibit	O
an	O
increased	O
risk	O
while	O
those	O
with	O
w2	O
/	O
m2	O
genotype	O
exhibit	O
a	O
decreased	O
risk	O
for	O
prostate	B-Disease
cancer	I-Disease
.	O
	
	
An	O
evaluation	O
of	O
amikacin	B-Chemical
nephrotoxicity	B-Disease
in	O
the	O
hematology	O
/	O
oncology	O
population	O
.	O
	
Amikacin	B-Chemical
is	O
an	O
aminoglycoside	B-Chemical
commonly	O
used	O
to	O
provide	O
empirical	O
double	O
gram	O
-	O
negative	O
treatment	O
for	O
febrile	B-Disease
neutropenia	I-Disease
and	O
other	O
suspected	O
infections	B-Disease
.	O
	
Strategies	O
of	O
extended	O
-	O
interval	O
and	O
conventional	O
dosing	O
have	O
been	O
utilized	O
extensively	O
in	O
the	O
general	O
medical	O
population	O
";"	O
however	O
","	O
data	O
are	O
lacking	O
to	O
support	O
a	O
dosing	O
strategy	O
in	O
the	O
hematology	O
/	O
oncology	O
population	O
.	O
	
To	O
evaluate	O
amikacin	B-Chemical
-	O
associated	O
nephrotoxicity	B-Disease
in	O
an	O
adult	O
hematology	O
/	O
oncology	O
population	O
","	O
a	O
prospective	O
","	O
randomized	O
","	O
open	O
-	O
label	O
trial	O
was	O
conducted	O
at	O
a	O
university	O
-	O
affiliated	O
medical	O
center	O
.	O
	
Forty	O
patients	O
with	O
a	O
diagnosis	O
consistent	O
with	O
a	O
hematologic	B-Disease
/	I-Disease
oncologic	I-Disease
disorder	I-Disease
that	O
required	O
treatment	O
with	O
an	O
aminoglycoside	B-Chemical
were	O
randomized	O
to	O
either	O
conventional	O
or	O
extended	O
-	O
interval	O
amikacin	B-Chemical
.	O
	
The	O
occurrence	O
of	O
nephrotoxicity	B-Disease
by	O
means	O
of	O
an	O
increase	O
in	O
serum	O
creatinine	B-Chemical
and	O
evaluation	O
of	O
efficacy	O
via	O
amikacin	B-Chemical
serum	O
concentrations	O
with	O
respective	O
pathogens	O
were	O
assessed	O
.	O
	
The	O
occurrence	O
of	O
nephrotoxicity	B-Disease
was	O
similar	O
between	O
the	O
conventional	O
and	O
extended	O
-	O
interval	O
groups	O
","	O
at	O
10	O
%	O
and	O
5	O
%","	O
respectively	O
(	O
P	O
=	O
1	O
.	O
0	O
).	O
	
Six	O
patients	O
in	O
the	O
conventional	O
group	O
had	O
a	O
positive	O
culture	O
","	O
compared	O
with	O
none	O
in	O
the	O
extended	O
-	O
interval	O
group	O
(	O
P	O
=	O
0	O
.	O
2	O
).	O
	
The	O
occurrence	O
of	O
nephrotoxicity	B-Disease
was	O
similar	O
between	O
the	O
two	O
dosing	O
regimens	O
","	O
but	O
the	O
distribution	O
of	O
risk	O
factors	O
was	O
variable	O
between	O
the	O
two	O
groups	O
.	O
	
Efficacy	O
could	O
not	O
be	O
assessed	O
.	O
	
	
Single	O
nucleotide	O
polymorphism	O
in	O
ABCG2	O
is	O
associated	O
with	O
irinotecan	B-Chemical
-	O
induced	O
severe	O
myelosuppression	B-Disease
.	O
	
Irinotecan	B-Chemical
is	O
an	O
anti	O
-	O
neoplastic	O
agent	O
that	O
is	O
widely	O
used	O
for	O
treating	O
colorectal	B-Disease
and	I-Disease
lung	I-Disease
cancers	I-Disease
","	O
but	O
often	O
causes	O
toxicities	B-Disease
such	O
as	O
severe	O
myelosuppression	B-Disease
and	O
diarrhea	B-Disease
.	O
	
In	O
this	O
study	O
","	O
we	O
performed	O
a	O
two	O
-	O
stage	O
case	O
-	O
control	O
association	O
study	O
for	O
irinotecan	B-Chemical
-	O
induced	O
severe	O
myelosuppression	B-Disease
(	O
grades	O
3	O
and	O
4	O
).	O
	
In	O
the	O
first	O
stage	O
","	O
23	O
patients	O
who	O
developed	O
severe	O
myelosuppression	B-Disease
and	O
58	O
patients	O
who	O
did	O
not	O
develop	O
any	O
toxicity	B-Disease
were	O
examined	O
for	O
170	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
14	O
genes	O
involved	O
in	O
the	O
metabolism	O
and	O
transport	O
of	O
irinotecan	B-Chemical
.	O
	
A	O
total	O
of	O
five	O
SNPs	O
were	O
identified	O
to	O
show	O
the	O
possible	O
association	O
with	O
severe	O
myelosuppression	B-Disease
(	O
P	O
(	O
Fisher	O
)<	O
0	O
.	O
1	O
)	O
and	O
were	O
further	O
examined	O
in	O
7	O
cases	O
and	O
20	O
controls	O
in	O
the	O
second	O
stage	O
of	O
the	O
study	O
.	O
	
An	O
intronic	O
SNP	O
","	O
rs2622604	O
","	O
in	O
ABCG2	O
showed	O
P	O
(	O
Fisher	O
)=	O
0	O
.	O
419	O
in	O
the	O
second	O
stage	O
and	O
indicated	O
a	O
significant	O
association	O
with	O
severe	O
myelosuppression	B-Disease
in	O
the	O
combined	O
study	O
(	O
P	O
(	O
Fisher	O
)=	O
0	O
.	O
237	O
";"	O
P	O
(	O
Corrected	O
)=	O
0	O
.	O
36	O
).	O
	
Although	O
only	O
limited	O
subjects	O
were	O
investigated	O
","	O
our	O
results	O
suggested	O
that	O
a	O
genetic	O
polymorphism	O
in	O
ABCG2	O
might	O
alter	O
the	O
transport	O
activity	O
for	O
the	O
drug	O
and	O
elevate	O
the	O
systemic	O
circulation	O
level	O
of	O
irinotecan	B-Chemical
","	O
leading	O
to	O
severe	O
myelosuppression	B-Disease
.	O
	
	
Zebrafish	O
chordin	O
-	O
like	O
and	O
chordin	O
are	O
functionally	O
redundant	O
in	O
regulating	O
patterning	O
of	O
the	O
dorsoventral	O
axis	O
.	O
	
Chordin	O
is	O
the	O
prototype	O
of	O
a	O
group	O
of	O
cysteine	O
-	O
rich	O
domain	O
-	O
containing	O
proteins	O
that	O
bind	O
and	O
modulate	O
signaling	O
of	O
various	O
TGFbeta	O
-	O
like	O
ligands	O
.	O
	
Chordin	O
-	O
like	O
1	O
and	O
2	O
(	O
CHL1	O
and	O
2	O
)	O
are	O
two	O
members	O
of	O
this	O
group	O
that	O
have	O
been	O
described	O
in	O
human	O
","	O
mouse	O
","	O
and	O
chick	O
.	O
	
However	O
","	O
in	O
vivo	O
roles	O
for	O
CHL1	O
and	O
2	O
in	O
early	O
development	O
are	O
unknown	O
due	O
to	O
lack	O
of	O
loss	O
-	O
of	O
-	O
function	O
analysis	O
.	O
	
Here	O
we	O
identify	O
and	O
characterize	O
zebrafish	O
","	O
Danio	O
rerio	O
","	O
CHL	O
(	O
Chl	O
).	O
	
The	O
chl	O
gene	O
is	O
on	O
a	O
region	O
of	O
chromosome	O
21	O
syntenic	O
with	O
the	O
area	O
of	O
murine	O
chromosome	O
7	O
bearing	O
the	O
CHL2	O
gene	O
.	O
	
Inability	O
to	O
identify	O
a	O
separate	O
zebrafish	O
gene	O
corresponding	O
to	O
the	O
mammalian	O
CHL1	O
gene	O
suggests	O
that	O
Chl	O
may	O
serve	O
roles	O
in	O
zebrafish	O
distributed	O
between	O
CHL1	O
and	O
CHL2	O
in	O
other	O
species	O
.	O
	
Chl	O
is	O
a	O
maternal	O
factor	O
that	O
is	O
also	O
zygotically	O
expressed	O
later	O
in	O
development	O
and	O
has	O
spatiotemporal	O
expression	O
patterns	O
that	O
differ	O
from	O
but	O
overlap	O
those	O
of	O
zebrafish	O
chordin	O
(	O
Chd	O
)","	O
suggesting	O
differences	O
but	O
also	O
possible	O
overlap	O
in	O
developmental	O
roles	O
of	O
the	O
two	O
proteins	O
.	O
	
Chl	O
","	O
like	O
Chd	O
","	O
dorsalizes	O
embryos	O
upon	O
overexpression	O
and	O
is	O
cleaved	O
by	O
BMP1	O
","	O
which	O
antagonizes	O
this	O
activity	O
.	O
	
Loss	O
-	O
of	O
-	O
function	O
experiments	O
demonstrate	O
that	O
Chl	O
serves	O
as	O
a	O
BMP	O
antagonist	O
with	O
functions	O
that	O
overlap	O
and	O
are	O
redundant	O
with	O
those	O
of	O
Chd	O
in	O
forming	O
the	O
dorsoventral	O
axis	O
.	O
	
	
Identification	O
of	O
a	O
frameshift	O
mutation	O
in	O
Osterix	O
in	O
a	O
patient	O
with	O
recessive	B-Disease
osteogenesis	I-Disease
imperfecta	I-Disease
.	O
	
Osteogenesis	B-Disease
imperfecta	I-Disease
","	O
or	O
brittle	B-Disease
bone	I-Disease
disease	I-Disease
","	O
is	O
a	O
type	O
I	O
collagen	O
-	O
related	O
condition	O
associated	O
with	O
osteoporosis	B-Disease
and	O
increased	O
risk	O
of	O
bone	B-Disease
fractures	I-Disease
.	O
	
Using	O
a	O
combination	O
of	O
homozygosity	O
mapping	O
and	O
candidate	O
gene	O
approach	O
","	O
we	O
have	O
identified	O
a	O
homozygous	O
single	O
base	O
pair	O
deletion	O
(	O
c	O
.	O
1052delA	O
)	O
in	O
SP7	O
/	O
Osterix	O
(	O
OSX	O
)	O
in	O
an	O
Egyptian	O
child	O
with	O
recessive	B-Disease
osteogenesis	I-Disease
imperfecta	I-Disease
.	O
	
The	O
clinical	O
findings	O
from	O
this	O
patient	O
include	O
recurrent	O
fractures	B-Disease
","	O
mild	O
bone	B-Disease
deformities	I-Disease
","	O
delayed	O
tooth	B-Disease
eruption	I-Disease
","	O
normal	O
hearing	O
","	O
and	O
white	O
sclera	O
.	O
	
OSX	O
encodes	O
a	O
transcription	O
factor	O
containing	O
three	O
Cys2	O
-	O
His2	O
zinc	O
-	O
finger	O
DNA	O
-	O
binding	O
domains	O
at	O
its	O
C	O
terminus	O
","	O
which	O
","	O
in	O
mice	O
","	O
has	O
been	O
shown	O
to	O
be	O
essential	O
for	O
bone	O
formation	O
.	O
	
The	O
frameshift	O
caused	O
by	O
the	O
c	O
.	O
1052delA	O
deletion	O
removes	O
the	O
last	O
81	O
amino	O
acids	O
of	O
the	O
protein	O
","	O
including	O
the	O
third	O
zinc	O
-	O
finger	O
motif	O
.	O
	
This	O
finding	O
adds	O
another	O
locus	O
to	O
the	O
spectrum	O
of	O
genes	O
associated	O
with	O
osteogenesis	B-Disease
imperfecta	I-Disease
and	O
reveals	O
that	O
SP7	O
/	O
OSX	O
also	O
plays	O
a	O
key	O
role	O
in	O
human	O
bone	O
development	O
.	O
	
	
Variation	O
in	O
the	O
CXCR1	O
gene	O
(	O
IL8RA	O
)	O
is	O
not	O
associated	O
with	O
susceptibility	O
to	O
chronic	B-Disease
periodontitis	I-Disease
.	O
	
BACKGROUND	O
:	O
The	O
chemokine	O
receptor	O
1	O
CXCR	O
-	O
1	O
(	O
or	O
IL8R	O
-	O
alpha	O
)	O
is	O
a	O
specific	O
receptor	O
for	O
the	O
interleukin	O
8	O
(	O
IL	O
-	O
8	O
)","	O
which	O
is	O
chemoattractant	O
for	O
neutrophils	O
and	O
has	O
an	O
important	O
role	O
in	O
the	O
inflammatory	B-Disease
response	O
.	O
	
The	O
polymorphism	O
rs2234671	O
at	O
position	O
Ex2	O
+	O
860G	O
>	O
C	O
of	O
the	O
CXCR1	O
gene	O
causes	O
a	O
conservative	O
amino	O
acid	O
substitution	O
(	O
S276T	O
).	O
	
This	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
seemed	O
to	O
be	O
functional	O
as	O
it	O
was	O
associated	O
with	O
decreased	O
lung	B-Disease
cancer	I-Disease
risk	O
.	O
	
Previous	O
studies	O
of	O
our	O
group	O
found	O
association	O
of	O
haplotypes	O
in	O
the	O
IL8	O
and	O
in	O
the	O
CXCR2	O
genes	O
with	O
the	O
multifactorial	O
disease	O
chronic	B-Disease
periodontitis	I-Disease
.	O
	
In	O
this	O
study	O
we	O
investigated	O
the	O
polymorphism	O
rs2234671	O
in	O
395	O
Brazilian	O
subjects	O
with	O
and	O
without	O
chronic	B-Disease
periodontitis	I-Disease
.	O
	
FINDINGS	O
:	O
Similar	O
distribution	O
of	O
the	O
allelic	O
and	O
genotypic	O
frequencies	O
were	O
observed	O
between	O
the	O
groups	O
(	O
p	O
>	O
0	O
.	O
5	O
).	O
	
CONCLUSIONS	O
:	O
The	O
polymorphism	O
rs2234671	O
in	O
the	O
CXCR1	O
gene	O
was	O
not	O
associated	O
with	O
the	O
susceptibility	O
to	O
chronic	B-Disease
periodontitis	I-Disease
in	O
the	O
studied	O
Brazilian	O
population	O
.	O
	
	
TBX21	O
and	O
HLX1	O
polymorphisms	O
influence	O
cytokine	O
secretion	O
at	O
birth	O
.	O
	
BACKGROUND	O
:	O
TBX21	O
(	O
T	O
cell	O
specific	O
T	O
-	O
box	O
transcription	O
factor	O
)	O
and	O
HLX1	O
(	O
H	O
.	O
20	O
-	O
like	O
homeobox	O
1	O
)	O
are	O
crucial	O
transcription	O
factors	O
of	O
T	O
(	O
H	O
)	O
1	O
-	O
cells	O
","	O
inducing	O
their	O
differentiation	O
and	O
suppressing	O
T	O
(	O
H	O
)	O
2	O
commitment	O
","	O
particularly	O
important	O
for	O
early	O
life	O
immune	O
development	O
.	O
	
This	O
study	O
investigated	O
the	O
influence	O
of	O
TBX21	O
and	O
HLX1	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)","	O
which	O
have	O
previously	O
been	O
shown	O
to	O
be	O
associated	O
with	O
asthma	B-Disease
","	O
on	O
T	O
(	O
H	O
)	O
1	O
/	O
T	O
(	O
H	O
)	O
2	O
lineage	O
cytokines	O
at	O
birth	O
.	O
	
METHODS	O
AND	O
FINDINGS	O
:	O
Cord	O
blood	O
mononuclear	O
cells	O
(	O
CBMCs	O
)	O
of	O
200	O
neonates	O
were	O
genotyped	O
for	O
two	O
TBX21	O
and	O
three	O
HLX1	O
SNPs	O
.	O
	
CBMCs	O
were	O
stimulated	O
with	O
innate	O
(	O
Lipid	B-Chemical
A	I-Chemical
","	O
LpA	B-Chemical
";"	O
Peptidoglycan	B-Chemical
","	O
Ppg	B-Chemical
)","	O
adaptive	O
stimuli	O
(	O
house	O
dust	O
mite	O
Dermatophagoides	O
pteronyssinus	O
1	O
","	O
Derp1	O
)	O
or	O
mitogen	O
(	O
phytohemagglutinin	B-Chemical
","	O
PHA	B-Chemical
).	O
	
Cytokines	O
","	O
T	O
-	O
cells	O
and	O
mRNA	O
expression	O
of	O
T	O
(	O
H	O
)	O
1	O
/	O
T	O
(	O
H	O
)	O
2	O
-	O
related	O
genes	O
were	O
assessed	O
.	O
	
Atopic	O
diseases	O
during	O
the	O
first	O
3	O
years	O
of	O
life	O
were	O
assessed	O
by	O
questionnaire	O
answered	O
by	O
the	O
parents	O
.	O
	
Carriers	O
of	O
TBX21	O
promoter	O
SNP	O
rs17250932	O
and	O
HLX1	O
promoter	O
SNP	O
rs2738751	O
showed	O
reduced	O
or	O
trendwise	O
reduced	O
(	O
p	O
<	O
0	O
.	O
7	O
)	O
IL	O
-	O
5	O
","	O
IL	O
-	O
13	O
and	O
TNF	O
-	O
a	O
secretion	O
after	O
LpA	B-Chemical
-	O
stimulation	O
.	O
	
Carriers	O
of	O
HLX1	O
SNP	O
rs2738751	O
had	O
lower	O
IL	O
-	O
13	O
levels	O
following	O
Ppg	B-Chemical
-	O
stimulation	O
(	O
p	O
=	O
0	O
.	O
8	O
).	O
	
Carriers	O
of	O
HLX1	O
exon	O
1	O
SNP	O
rs12141189	O
showed	O
increased	O
IL	O
-	O
5	O
(	O
LpA	B-Chemical
","	O
p	O
=	O
0	O
.	O
7	O
";"	O
Ppg	B-Chemical
","	O
p	O
=	O
0	O
.	O
10	O
)","	O
trendwise	O
increased	O
IL	O
-	O
13	O
(	O
LpA	B-Chemical
)","	O
higher	O
GM	O
-	O
CSF	O
(	O
LpA	B-Chemical
/	O
Ppg	B-Chemical
","	O
p	O
<	O
0	O
.	O
5	O
)	O
and	O
trendwise	O
decreased	O
IFN	O
-	O
g	O
secretion	O
(	O
Derp1	O
+	O
LpA	B-Chemical
-	O
stimulation	O
","	O
p	O
=	O
0	O
.	O
1	O
).	O
	
Homozygous	O
carriers	O
of	O
HLX1	O
promoter	O
SNP	O
rs3806325	O
showed	O
increased	O
IL	O
-	O
13	O
and	O
IL	O
-	O
6	O
(	O
unstimulated	O
","	O
p	O
<	O
0	O
.	O
3	O
).	O
	
In	O
carriers	O
of	O
TBX21	O
intron	O
3	O
SNP	O
rs11079788	O
no	O
differences	O
in	O
cytokine	O
secretion	O
were	O
observed	O
.	O
	
mRNA	O
expression	O
of	O
T	O
(	O
H	O
)	O
1	O
/	O
T	O
(	O
H	O
)	O
2	O
-	O
related	O
genes	O
partly	O
correlated	O
with	O
cytokines	O
at	O
protein	O
level	O
.	O
	
TBX21	O
SNP	O
rs11079788	O
carriers	O
developed	O
less	O
symptoms	O
of	O
atopic	B-Disease
dermatitis	I-Disease
at	O
3	O
years	O
of	O
age	O
(	O
p	O
=	O
0	O
.	O
3	O
).	O
	
CONCLUSIONS	O
:	O
Polymorphisms	O
in	O
TBX21	O
and	O
HLX1	O
influenced	O
primarily	O
IL	O
-	O
5	O
and	O
IL	O
-	O
13	O
secretion	O
after	O
LpA	B-Chemical
-	O
stimulation	O
in	O
cord	O
blood	O
suggesting	O
that	O
genetic	O
variations	O
in	O
the	O
transcription	O
factors	O
essential	O
for	O
the	O
T	O
(	O
H	O
)	O
1	O
-	O
pathway	O
may	O
contribute	O
to	O
modified	O
T	O
(	O
H	O
)	O
2	O
-	O
immune	O
responses	O
already	O
early	O
in	O
life	O
.	O
	
Further	O
follow	O
-	O
up	O
of	O
the	O
cohort	O
is	O
required	O
to	O
study	O
the	O
polymorphisms	O
'	O
relevance	O
for	O
immune	B-Disease
-	I-Disease
mediated	I-Disease
diseases	I-Disease
such	O
as	O
childhood	O
asthma	B-Disease
.	O
	
	
Superoxide	O
dismutase	O
1	O
overexpression	O
in	O
mice	O
abolishes	O
maternal	B-Disease
diabetes	I-Disease
-	O
induced	O
endoplasmic	O
reticulum	O
stress	O
in	O
diabetic	B-Disease
embryopathy	I-Disease
.	O
	
OBJECTIVE	O
:	O
Both	O
oxidative	O
stress	O
and	O
endoplasmic	O
reticulum	O
stress	O
(	O
ER	O
stress	O
)	O
are	O
causal	O
events	O
in	O
diabetic	B-Disease
embryopathy	I-Disease
.	O
	
We	O
tested	O
whether	O
oxidative	O
stress	O
causes	O
ER	O
stress	O
.	O
	
STUDY	O
DESIGN	O
:	O
Wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
superoxide	O
dismutase	O
1	O
(	O
SOD1	O
)-	O
overexpressing	O
day	O
8	O
.	O
75	O
embryos	O
from	O
nondiabetic	O
WT	O
control	O
with	O
SOD1	O
transgenic	O
male	O
and	O
diabetic	B-Disease
WT	O
female	O
with	O
SOD1	O
transgenic	O
male	O
were	O
analyzed	O
for	O
ER	O
stress	O
markers	O
:	O
C	O
/	O
EBP	O
-	O
homologous	O
protein	O
(	O
CHOP	O
)","	O
calnexin	O
","	O
eukaryotic	O
initiation	O
factor	O
2a	O
(	O
eIF2a	O
)","	O
protein	O
kinase	O
ribonucleic	O
acid	O
(	O
RNA	O
)-	O
like	O
ER	O
kinase	O
(	O
PERK	O
)","	O
binding	O
immunoglobulin	O
protein	O
","	O
protein	O
disulfide	O
isomerase	O
family	O
A	O
member	O
3	O
","	O
kinases	O
inositol	O
-	O
requiring	O
protein	O
-	O
1a	O
(	O
IRE1a	O
)","	O
and	O
the	O
X	O
-	O
box	O
binding	O
protein	O
(	O
XBP1	O
)	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
splicing	O
.	O
	
RESULTS	O
:	O
Maternal	B-Disease
diabetes	I-Disease
significantly	O
increased	O
the	O
levels	O
of	O
CHOP	O
","	O
calnexin	O
","	O
phosphorylated	O
(	O
p	O
)-	O
eIF2a	O
","	O
p	O
-	O
PERK	O
","	O
and	O
p	O
-	O
IRE1a	O
";"	O
triggered	O
XBP1	O
mRNA	O
splicing	O
";"	O
and	O
enhanced	O
ER	O
chaperone	O
gene	O
expression	O
in	O
WT	O
embryos	O
.	O
	
SOD1	O
overexpression	O
blocked	O
these	O
diabetes	B-Disease
-	O
induced	O
ER	O
stress	O
markers	O
.	O
	
CONCLUSION	O
:	O
Mitigating	O
oxidative	O
stress	O
via	O
SOD1	O
overexpression	O
blocks	O
maternal	B-Disease
diabetes	I-Disease
-	O
induced	O
ER	O
stress	O
in	O
vivo	O
.	O
	
	
The	O
autotaxin	O
-	O
LPA2	O
GPCR	O
axis	O
is	O
modulated	O
by	O
gamma	O
-	O
irradiation	O
and	O
facilitates	O
DNA	O
damage	O
repair	O
.	O
	
In	O
this	O
study	O
we	O
characterized	O
the	O
effects	O
of	O
radiation	B-Disease
injury	I-Disease
on	O
the	O
expression	O
and	O
function	O
of	O
the	O
autotaxin	O
(	O
ATX	O
)-	O
LPA2	O
GPCR	O
axis	O
.	O
	
In	O
IEC	O
-	O
6	O
crypt	O
cells	O
and	O
jejunum	O
enteroids	O
quantitative	O
RT	O
-	O
PCR	O
showed	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
upregulation	O
of	O
lpa2	O
in	O
response	O
to	O
gamma	O
-	O
irradiation	O
that	O
was	O
abolished	O
by	O
mutation	O
of	O
the	O
NF	O
-	O
kappaB	O
site	O
in	O
the	O
lpa2	O
promoter	O
or	O
by	O
inhibition	O
of	O
ATM	O
/	O
ATR	O
kinases	O
with	O
CGK	B-Chemical
-	I-Chemical
733	I-Chemical
","	O
suggesting	O
that	O
lpa2	O
is	O
a	O
DNA	O
damage	O
response	O
gene	O
upregulated	O
by	O
ATM	O
via	O
NF	O
-	O
kappaB	O
.	O
	
The	O
resolution	O
kinetics	O
of	O
the	O
DNA	O
damage	O
marker	O
gamma	O
-	O
H2AX	O
in	O
LPA	O
-	O
treated	O
IEC	O
-	O
6	O
cells	O
exposed	O
to	O
gamma	O
-	O
irradiation	O
was	O
accelerated	O
compared	O
to	O
vehicle	O
","	O
whereas	O
pharmacological	O
inhibition	O
of	O
LPA2	O
delayed	O
the	O
resolution	O
of	O
gamma	O
-	O
H2AX	O
.	O
	
In	O
LPA2	O
-	O
reconstituted	O
MEF	O
cells	O
lacking	O
LPA1	O
'	O
3	O
the	O
levels	O
of	O
gamma	O
-	O
H2AX	O
decreased	O
rapidly	O
","	O
whereas	O
in	O
Vector	O
MEF	O
were	O
high	O
and	O
remained	O
sustained	O
.	O
	
Inhibition	O
of	O
ERK1	O
'	O
2	O
or	O
PI3K	O
/	O
AKT	O
signaling	O
axis	O
by	O
pertussis	O
toxin	O
or	O
the	O
C311A	O
/	O
C314A	O
/	O
L351A	O
mutation	O
in	O
the	O
C	O
-	O
terminus	O
of	O
LPA2	O
abrogated	O
the	O
effect	O
of	O
LPA	O
on	O
DNA	O
repair	O
.	O
	
LPA2	O
transcripts	O
in	O
Lin	O
(-)	O
Sca	O
-	O
1	O
(+)	O
c	O
-	O
Kit	O
(+)	O
enriched	O
for	O
bone	O
marrow	O
stem	O
cells	O
were	O
27	O
-	O
and	O
5	O
-	O
fold	O
higher	O
than	O
in	O
common	O
myeloid	O
or	O
lymphoid	O
progenitors	O
","	O
respectively	O
.	O
	
Furthermore	O
","	O
after	O
irradiation	O
higher	O
residual	O
gamma	O
-	O
H2AX	O
levels	O
were	O
detected	O
in	O
the	O
bone	O
marrow	O
or	O
jejunum	O
of	O
irradiated	O
LPA2	O
-	O
KO	O
mice	O
compared	O
to	O
WT	O
mice	O
.	O
	
We	O
found	O
that	O
gamma	O
-	O
irradiation	O
increases	O
plasma	O
ATX	O
activity	O
and	O
LPA	O
level	O
that	O
is	O
in	O
part	O
due	O
to	O
the	O
previously	O
established	O
radiation	O
-	O
induced	O
upregulation	O
of	O
TNFalpha	O
.	O
	
These	O
findings	O
identify	O
ATX	O
and	O
LPA2	O
as	O
radiation	O
-	O
regulated	O
genes	O
that	O
appear	O
to	O
play	O
a	O
physiological	O
role	O
in	O
DNA	O
repair	O
.	O
	
	
NEK2	O
serves	O
as	O
a	O
prognostic	O
biomarker	O
for	O
hepatocellular	B-Disease
carcinoma	I-Disease
.	O
	
Never	O
in	O
mitosis	O
gene	O
A	O
(	O
NIMA	O
)-	O
related	O
kinase	O
2	O
(	O
NEK2	O
)	O
is	O
a	O
microtubule	O
-	O
associated	O
protein	O
that	O
regulates	O
spindle	O
assembly	O
in	O
human	O
cells	O
and	O
is	O
overexpressed	O
in	O
various	O
malignancies	B-Disease
.	O
	
However	O
","	O
the	O
role	O
of	O
NEK2	O
in	O
hepatocellular	B-Disease
carcinoma	I-Disease
(	O
HCC	B-Disease
)	O
remains	O
undetermined	O
.	O
	
We	O
performed	O
RNA	O
-	O
seq	O
of	O
the	O
HCC	B-Disease
cell	O
line	O
SMMC	O
-	O
7721	O
and	O
the	O
normal	O
liver	O
cell	O
line	O
HL	O
-	O
7702	O
using	O
the	O
Ion	O
Proton	O
System	O
.	O
	
NEK2	O
expression	O
was	O
detected	O
using	O
quantitative	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
in	O
two	O
cell	O
lines	O
and	O
5	O
matched	O
HCC	B-Disease
and	O
adjacent	O
non	O
-	O
tumorous	O
liver	O
tissues	O
.	O
	
The	O
correlation	O
between	O
survival	O
and	O
NEK2	O
expression	O
was	O
analyzed	O
in	O
359	O
patients	O
with	O
HCC	B-Disease
using	O
RNASeqV2	O
data	O
available	O
from	O
The	O
Cancer	B-Disease
Genome	O
Atlas	O
(	O
TCGA	O
)	O
website	O
(	O
https	O
://	O
tcga	O
-	O
data	O
.	O
nci	O
.	O
nih	O
.	O
gov	O
/	O
tcga	O
/).	O
	
The	O
expression	O
of	O
NEK2	O
","	O
phospho	O
-	O
AKT	O
and	O
MMP	O
-	O
2	O
was	O
evaluated	O
by	O
immunohistochemistry	O
in	O
63	O
cases	O
of	O
HCC	B-Disease
and	O
matched	O
adjacent	O
non	O
-	O
tumorous	O
liver	O
tissues	O
.	O
	
Relationships	O
between	O
protein	O
expression	O
and	O
clinicopathological	O
parameters	O
were	O
assessed	O
","	O
and	O
the	O
correlations	O
between	O
NEK2	O
with	O
phospho	O
-	O
AKT	O
and	O
MMP	O
-	O
2	O
expressions	O
were	O
evaluated	O
.	O
	
A	O
total	O
of	O
610	O
differentially	O
expressed	O
genes	O
(	O
DEGs	O
)	O
were	O
revealed	O
in	O
the	O
transcriptome	O
comparison	O
","	O
297	O
of	O
which	O
were	O
upregulated	O
and	O
313	O
were	O
downregulated	O
in	O
HCC	B-Disease
.	O
	
NEK2	O
","	O
as	O
the	O
most	O
obviously	O
different	O
DEG	O
in	O
cells	O
and	O
tissues	O
from	O
the	O
RNA	O
-	O
seq	O
data	O
","	O
was	O
listed	O
as	O
an	O
HCC	B-Disease
candidate	O
biomarker	O
for	O
further	O
verification	O
.	O
	
NEK2	O
was	O
overexpressed	O
in	O
HCC	B-Disease
cells	O
and	O
tissues	O
(	O
P	O
=	O
0	O
.	O
2	O
","	O
P	O
=	O
0	O
.	O
13	O
)	O
and	O
HCC	B-Disease
patients	O
with	O
a	O
high	O
expression	O
of	O
NEK2	O
had	O
a	O
poor	O
prognosis	O
(	O
P	O
=	O
0	O
.	O
145	O
).	O
	
Clinical	O
analysis	O
indicated	O
that	O
the	O
overexpression	O
of	O
NEK2	O
in	O
HCC	B-Disease
was	O
significantly	O
correlated	O
with	O
diolame	O
complete	O
(	O
P	O
<	O
0	O
.	O
1	O
)","	O
tumor	B-Disease
nodule	O
number	O
(	O
P	O
=	O
0	O
.	O
12	O
)	O
and	O
recurrence	O
(	O
P	O
=	O
0	O
.	O
4	O
).	O
	
NEK2	O
expression	O
was	O
positively	O
correlated	O
with	O
the	O
expression	O
of	O
phospho	O
-	O
AKT	O
(	O
r	O
=	O
0	O
.	O
883	O
","	O
P	O
<	O
0	O
.	O
1	O
)	O
and	O
MMP	O
-	O
2	O
(	O
r	O
=	O
0	O
.	O
781	O
","	O
P	O
<	O
0	O
.	O
1	O
).	O
	
Overexpression	O
of	O
NEK2	O
was	O
associated	O
with	O
clinicopathological	O
characteristics	O
and	O
poor	O
patient	O
outcomes	O
","	O
suggesting	O
that	O
NEK2	O
serves	O
as	O
a	O
prognostic	O
biomarker	O
for	O
HCC	B-Disease
.	O
	
Alteration	O
of	O
NEK2	O
protein	O
levels	O
may	O
contribute	O
to	O
invasion	O
and	O
metastasis	B-Disease
of	I-Disease
HCC	I-Disease
","	O
which	O
may	O
occur	O
through	O
activation	O
of	O
AKT	O
signaling	O
and	O
promotion	O
of	O
MMP	O
-	O
2	O
expression	O
.	O
	
	
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
in	O
13	O
%	O
of	O
age	O
-	O
matched	O
Czech	O
children	O
with	O
primary	B-Disease
microcephaly	I-Disease
.	O
	
The	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
is	O
a	O
rare	O
autosomal	B-Disease
recessive	I-Disease
chromosomal	I-Disease
instability	I-Disease
disorder	I-Disease
characterized	O
by	O
early	O
growth	B-Disease
retardation	I-Disease
","	O
congenital	B-Disease
microcephaly	I-Disease
","	O
immunodeficiency	B-Disease
","	O
borderline	O
mental	O
development	O
","	O
and	O
a	O
high	O
tendency	O
to	O
lymphoreticular	B-Disease
malignancies	I-Disease
.	O
	
Most	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
patients	O
are	O
of	O
Slavonic	O
origin	O
","	O
and	O
all	O
of	O
them	O
known	O
so	O
far	O
carry	O
a	O
founder	O
homozygous	O
5	O
nucleotide	O
deletion	O
in	O
the	O
NBS1	O
gene	O
.	O
	
Microcephaly	B-Disease
was	O
present	O
in	O
100	O
%	O
of	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
patients	O
in	O
a	O
recent	O
large	O
international	O
cooperative	O
study	O
.	O
	
The	O
frequency	O
of	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
among	O
children	O
with	O
primary	B-Disease
microcephaly	I-Disease
was	O
not	O
known	O
.	O
	
Early	O
correct	O
diagnosis	O
of	O
the	O
syndrome	O
is	O
crucial	O
for	O
appropriate	O
preventive	O
care	O
and	O
therapy	O
.	O
	
We	O
tested	O
67	O
Czech	O
patients	O
of	O
different	O
ages	O
with	O
simple	O
microcephaly	O
for	O
the	O
presence	O
of	O
the	O
most	O
common	O
mutation	O
in	O
the	O
NBS1	O
gene	O
.	O
	
Three	O
new	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
cases	O
were	O
detected	O
in	O
this	O
cohort	O
","	O
representing	O
4	O
.	O
5	O
%	O
of	O
the	O
cohort	O
.	O
	
All	O
these	O
newly	O
diagnosed	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
patients	O
were	O
younger	O
than	O
10	O
months	O
at	O
the	O
time	O
of	O
diagnosis	O
.	O
	
They	O
were	O
all	O
born	O
within	O
a	O
2	O
.	O
5	O
-	O
year	O
period	O
.	O
	
Twenty	O
-	O
three	O
of	O
the	O
67	O
children	O
in	O
the	O
cohort	O
were	O
born	O
within	O
this	O
2	O
.	O
5	O
-	O
year	O
period	O
","	O
representing	O
a	O
13	O
%	O
incidence	O
of	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
.	O
	
Frequency	O
of	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
heterozygotes	O
among	O
infants	O
in	O
the	O
Czech	O
Republic	O
is	O
1	O
:	O
130	O
-	O
158	O
and	O
the	O
birth	O
rate	O
is	O
90	O
","	O
0	O
per	O
year	O
","	O
therefore	O
in	O
the	O
time	O
span	O
of	O
2	O
.	O
5	O
years	O
","	O
three	O
new	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
homozygotes	O
are	O
expected	O
to	O
be	O
born	O
.	O
	
Therefore	O
we	O
assume	O
that	O
by	O
DNA	O
testing	O
of	O
Czech	O
primary	O
microcephalic	O
children	O
it	O
is	O
possible	O
to	O
detect	O
all	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
patients	O
to	O
be	O
expected	O
.	O
	
The	O
age	O
at	O
correct	O
diagnosis	O
was	O
lowered	O
from	O
7	O
.	O
1	O
years	O
at	O
the	O
time	O
before	O
DNA	O
testing	O
","	O
to	O
well	O
under	O
1	O
year	O
of	O
age	O
.	O
	
All	O
new	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
patients	O
could	O
receive	O
appropriate	O
preventive	O
care	O
","	O
which	O
should	O
significantly	O
improve	O
their	O
life	O
expectancy	O
and	O
prognosis	O
.	O
	
	
Evaluation	O
of	O
the	O
Lys198Asn	O
and	O
-	O
134delA	O
genetic	O
polymorphisms	O
of	O
the	O
endothelin	O
-	O
1	O
gene	O
.	O
	
Endothelin	O
-	O
1	O
(	O
ET	O
-	O
1	O
)	O
is	O
a	O
potent	O
vasoconstrictor	O
and	O
shows	O
various	O
pharmacological	O
responses	O
.	O
	
Two	O
single	O
nucleotide	O
polymorphisms	O
in	O
the	O
ET	O
-	O
1	O
gene	O
(	O
EDN1	O
)	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
blood	O
pressure	O
(	O
BP	O
).	O
	
One	O
is	O
the	O
Lys198Asn	O
polymorphism	O
","	O
which	O
showed	O
a	O
positive	O
association	O
with	O
BP	O
in	O
overweight	B-Disease
people	O
.	O
	
Another	O
is	O
the	O
3A	O
/	O
4A	O
polymorphism	O
(-	O
134delA	O
)	O
located	O
in	O
the	O
5	O
'-	O
untranslated	O
region	O
.	O
	
In	O
this	O
study	O
","	O
we	O
investigated	O
the	O
expression	O
of	O
the	O
Lys198Asn	O
polymorphism	O
in	O
ET	O
-	O
1	O
in	O
vitro	O
","	O
as	O
well	O
as	O
the	O
association	O
between	O
either	O
of	O
the	O
two	O
polymorphisms	O
and	O
the	O
plasma	O
ET	O
-	O
1	O
level	O
.	O
	
We	O
expressed	O
both	O
the	O
major	O
(	O
Lys	O
-	O
type	O
)	O
and	O
minor	O
type	O
(	O
Asn	O
-	O
type	O
)	O
preproET	O
-	O
1	O
in	O
three	O
different	O
cell	O
lines	O
","	O
and	O
measured	O
the	O
levels	O
of	O
ET	O
-	O
1	O
and	O
big	O
ET	O
-	O
1	O
in	O
the	O
culture	O
supernatant	O
.	O
	
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
levels	O
of	O
ET	O
-	O
1	O
or	O
big	O
ET	O
-	O
1	O
between	O
the	O
Asn	O
-	O
type	O
and	O
Lys	O
-	O
type	O
transfectant	O
.	O
	
In	O
the	O
association	O
study	O
","	O
the	O
plasma	O
levels	O
of	O
ET	O
-	O
1	O
in	O
54	O
hypertensive	B-Disease
patients	O
having	O
an	O
amino	O
acid	O
substitution	O
from	O
Lys	O
to	O
Asn	O
at	O
position	O
198	O
were	O
not	O
different	O
from	O
those	O
of	O
hypertensives	B-Disease
without	O
the	O
substitution	O
.	O
	
However	O
","	O
we	O
found	O
a	O
significant	O
difference	O
in	O
ET	O
-	O
1	O
levels	O
between	O
individuals	O
with	O
the	O
3A	O
/	O
3A	O
and	O
3A	O
/	O
4A	O
genotypes	O
.	O
	
Our	O
transient	O
expression	O
study	O
indicates	O
that	O
the	O
Lys198Asn	O
polymorphism	O
may	O
not	O
directly	O
affect	O
ET	O
-	O
1	O
and	O
big	O
ET	O
-	O
1	O
production	O
.	O
	
Another	O
variant	O
in	O
the	O
EDN1	O
gene	O
in	O
linkage	O
disequilibrium	O
with	O
the	O
Lys198Asn	O
polymorphism	O
may	O
be	O
responsible	O
for	O
the	O
association	O
with	O
BP	O
","	O
or	O
the	O
interaction	O
between	O
the	O
EDN1	O
Lys198Asn	O
polymorphism	O
and	O
other	O
factors	O
such	O
as	O
obesity	B-Disease
may	O
be	O
involved	O
in	O
the	O
mechanisms	O
elevating	O
BP	O
in	O
vivo	O
.	O
	
	
A	O
single	O
-	O
nucleotide	O
polymorphism	O
in	O
the	O
5	O
'-	O
untranslated	O
region	O
of	O
the	O
hPER2	O
gene	O
is	O
associated	O
with	O
diurnal	O
preference	O
.	O
	
The	O
PERIOD2	O
(	O
PER2	O
)	O
gene	O
is	O
a	O
key	O
component	O
of	O
the	O
molecular	O
mechanism	O
that	O
generates	O
circadian	O
rhythms	O
in	O
mammals	O
.	O
	
A	O
missense	O
mutation	O
in	O
the	O
human	O
PER2	O
gene	O
has	O
previously	O
been	O
linked	O
to	O
advanced	B-Disease
sleep	I-Disease
phase	I-Disease
syndrome	I-Disease
(	O
ASPS	B-Disease
).	O
	
We	O
have	O
investigated	O
three	O
other	O
single	O
-	O
nucleotide	O
polymorphisms	O
in	O
the	O
hPER2	O
gene	O
","	O
one	O
downstream	O
of	O
the	O
transcription	O
start	O
site	O
(	O
C	O
-	O
1228T	O
)","	O
one	O
in	O
exon	O
2	O
in	O
the	O
5	O
'-	O
untranslated	O
region	O
(	O
5	O
'-	O
UTR	O
)	O
(	O
C111G	O
)","	O
and	O
one	O
missense	O
mutation	O
(	O
G3853A	O
)	O
causing	O
a	O
glycine	O
to	O
glutamine	O
substitution	O
in	O
the	O
predicted	O
protein	O
.	O
	
Subjects	O
selected	O
from	O
a	O
group	O
of	O
484	O
volunteers	O
for	O
extreme	O
morning	O
or	O
evening	O
preference	O
","	O
or	O
intermediate	O
diurnal	O
preference	O
were	O
genotyped	O
with	O
regard	O
to	O
the	O
three	O
polymorphisms	O
(	O
n	O
=	O
35	O
for	O
each	O
group	O
).	O
	
Whereas	O
allele	O
frequencies	O
for	O
the	O
other	O
two	O
polymorphisms	O
did	O
not	O
differ	O
significantly	O
between	O
any	O
of	O
the	O
groups	O
","	O
the	O
111G	O
allele	O
frequency	O
was	O
significantly	O
higher	O
in	O
subjects	O
with	O
extreme	O
morning	O
preference	O
(	O
0	O
.	O
14	O
)	O
than	O
in	O
subjects	O
with	O
extreme	O
evening	O
preference	O
(	O
0	O
.	O
3	O
)	O
(	O
Fisher	O
'	O
s	O
exact	O
test	O
","	O
two	O
-	O
sided	O
P	O
value	O
=	O
0	O
.	O
31	O
","	O
odds	O
ratio	O
=	O
5	O
.	O
67	O
).	O
	
No	O
significant	O
difference	O
in	O
111G	O
allele	O
frequency	O
was	O
observed	O
between	O
either	O
of	O
these	O
groups	O
and	O
subjects	O
with	O
intermediate	O
diurnal	O
preference	O
.	O
	
Computer	O
prediction	O
indicated	O
that	O
the	O
C111G	O
polymorphism	O
","	O
which	O
occurs	O
12	O
bases	O
upstream	O
from	O
the	O
translation	O
start	O
codon	O
","	O
might	O
alter	O
the	O
secondary	O
structure	O
of	O
the	O
transcript	O
.	O
	
The	O
PER2	O
111G	O
allele	O
associates	O
with	O
morning	O
preference	O
and	O
is	O
a	O
potential	O
candidate	O
allele	O
for	O
ASPS	B-Disease
.	O
	
	
A	O
haplotype	O
-	O
based	O
analysis	O
of	O
the	O
PTPN22	O
locus	O
in	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
.	O
	
A	O
recent	O
addition	O
to	O
the	O
list	O
of	O
widely	O
confirmed	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
risk	O
loci	O
is	O
the	O
PTPN22	O
gene	O
encoding	O
a	O
lymphoid	O
-	O
specific	O
phosphatase	O
(	O
Lyp	O
).	O
	
However	O
","	O
evidence	O
supporting	O
a	O
role	O
for	O
PTPN22	O
in	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
derives	O
entirely	O
from	O
the	O
study	O
of	O
just	O
one	O
coding	O
single	O
nucleotide	O
polymorphism	O
","	O
1858C	O
/	O
T	O
.	O
	
In	O
the	O
current	O
study	O
","	O
the	O
haplotype	O
structure	O
of	O
the	O
PTPN22	O
region	O
was	O
determined	O
","	O
and	O
individual	O
haplotypes	O
were	O
tested	O
for	O
association	O
with	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
in	O
family	O
-	O
based	O
tests	O
.	O
	
The	O
1858T	O
risk	O
allele	O
occurred	O
on	O
only	O
a	O
single	O
haplotype	O
that	O
was	O
strongly	O
associated	O
with	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
(	O
P	O
=	O
7	O
.	O
9	O
x	O
10	O
(-	O
5	O
)).	O
	
After	O
controlling	O
for	O
the	O
effects	O
of	O
this	O
allele	O
","	O
two	O
other	O
haplotypes	O
were	O
observed	O
to	O
be	O
weakly	O
associated	O
with	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
(	O
P	O
<	O
0	O
.	O
5	O
).	O
	
Sequencing	O
of	O
the	O
coding	O
region	O
of	O
PTPN22	O
on	O
these	O
haplotypes	O
revealed	O
a	O
novel	O
variant	O
(	O
2250G	O
/	O
C	O
)	O
predicted	O
to	O
result	O
in	O
a	O
nonsynonymous	O
amino	O
acid	O
substitution	O
.	O
	
Analysis	O
of	O
PTPN22	O
transcripts	O
from	O
a	O
subject	O
heterozygous	O
for	O
this	O
variant	O
indicated	O
that	O
it	O
interfered	O
with	O
normal	O
mRNA	O
splicing	O
","	O
resulting	O
in	O
a	O
premature	O
termination	O
codon	O
after	O
exon	O
17	O
.	O
	
These	O
results	O
support	O
the	O
conclusion	O
that	O
the	O
1858C	O
/	O
T	O
allele	O
is	O
the	O
major	O
risk	O
variant	O
for	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
in	O
the	O
PTPN22	O
locus	O
","	O
but	O
they	O
suggest	O
that	O
additional	O
infrequent	O
coding	O
variants	O
at	O
PTPN22	O
may	O
also	O
contribute	O
to	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
risk	O
.	O
	
	
Polymorphic	O
Alu	O
insertions	O
and	O
the	O
genetic	O
structure	O
of	O
Iberian	O
Basques	O
.	O
	
Eight	O
Alu	O
sequences	O
(	O
ACE	O
","	O
TPA25	O
","	O
PV92	O
","	O
APO	O
","	O
FXIIIB	O
","	O
D1	O
","	O
A25	O
and	O
B65	O
)	O
were	O
analyzed	O
in	O
two	O
samples	O
from	O
Navarre	O
and	O
Guipuzcoa	O
provinces	O
(	O
Basque	O
Country	O
","	O
Spain	O
).	O
	
Alu	O
data	O
for	O
other	O
European	O
","	O
Caucasus	O
and	O
North	O
African	O
populations	O
were	O
compiled	O
from	O
the	O
literature	O
for	O
comparison	O
purposes	O
to	O
assess	O
the	O
genetic	O
relationships	O
of	O
the	O
Basques	O
in	O
a	O
broader	O
geographic	O
context	O
.	O
	
Results	O
of	O
both	O
MDS	O
plot	O
and	O
AMOVA	O
revealed	O
spatial	O
heterogeneity	O
among	O
these	O
three	O
population	O
clusters	O
clearly	O
defined	O
by	O
geography	O
.	O
	
On	O
the	O
contrary	O
","	O
no	O
substantial	O
genetic	O
heterogeneity	O
was	O
found	O
between	O
the	O
Basque	O
samples	O
","	O
or	O
between	O
Basques	O
and	O
other	O
Europeans	O
(	O
excluding	O
Caucasus	O
populations	O
).	O
	
Moreover	O
","	O
the	O
genetic	O
information	O
obtained	O
from	O
Alu	O
data	O
conflicts	O
with	O
hypotheses	O
linking	O
the	O
origin	O
of	O
Basques	O
with	O
populations	O
from	O
North	O
Africa	O
(	O
Berbers	O
)	O
or	O
from	O
the	O
Caucasus	O
region	O
(	O
Georgia	O
).	O
	
In	O
order	O
to	O
explain	O
the	O
reduced	O
genetic	O
heterogeneity	O
detected	O
by	O
Alu	O
insertions	O
among	O
Basque	O
subpopulations	O
","	O
values	O
of	O
the	O
Wright	O
'	O
s	O
F	O
(	O
ST	O
)	O
statistic	O
were	O
estimated	O
for	O
both	O
Alu	O
markers	O
and	O
a	O
set	O
of	O
short	O
tandem	O
repeats	O
(	O
STRs	O
)	O
in	O
terms	O
of	O
two	O
geographical	O
scales	O
:	O
(	O
1	O
)	O
the	O
Basque	O
Country	O
","	O
(	O
2	O
)	O
Europe	O
(	O
including	O
Basques	O
).	O
	
In	O
the	O
Basque	O
area	O
","	O
estimates	O
of	O
Wahlund	O
'	O
s	O
effect	O
for	O
both	O
genetic	O
markers	O
showed	O
no	O
statistical	O
difference	O
between	O
Basque	O
subpopulations	O
.	O
	
However	O
","	O
when	O
this	O
analysis	O
was	O
performed	O
on	O
a	O
European	O
scale	O
","	O
F	O
(	O
ST	O
)	O
values	O
were	O
significantly	O
higher	O
for	O
Alu	O
insertions	O
than	O
for	O
STR	O
alleles	O
.	O
	
From	O
these	O
results	O
","	O
we	O
suggest	O
that	O
the	O
spatial	O
heterogeneity	O
of	O
the	O
Basque	O
gene	O
pool	O
identified	O
in	O
previous	O
polymorphism	O
studies	O
is	O
relatively	O
recent	O
and	O
probably	O
caused	O
by	O
a	O
differential	O
process	O
of	O
genetic	O
admixture	O
with	O
non	O
-	O
Basque	O
neighboring	O
populations	O
modulated	O
by	O
the	O
effect	O
of	O
a	O
linguistic	O
barrier	O
to	O
random	O
mating	O
.	O
	
	
Manganese	O
superoxide	O
dismutase	O
(	O
Mn	O
-	O
SOD	O
)	O
gene	O
polymorphisms	O
in	O
urolithiasis	B-Disease
.	O
	
Polymorphism	O
in	O
manganese	O
superoxide	O
dismutase	O
gene	O
(	O
Mn	O
-	O
SOD	O
)	O
is	O
a	O
new	O
approach	O
to	O
identify	O
its	O
probable	O
association	O
with	O
urolithiasis	B-Disease
.	O
	
Oxidative	O
stress	O
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
stone	B-Disease
formation	I-Disease
in	O
the	O
renal	O
system	O
.	O
	
MnSOD	O
is	O
one	O
of	O
the	O
primary	O
enzymes	O
that	O
directly	O
scavenges	O
potential	O
harmful	O
oxidizing	O
species	O
.	O
	
A	O
valine	O
(	O
Val	O
)	O
to	O
alanine	O
(	O
Ala	O
)	O
substitution	O
at	O
amino	O
acid	O
16	O
","	O
occurring	O
in	O
the	O
mitochondrial	O
targeting	O
sequence	O
of	O
the	O
MnSOD	O
gene	O
","	O
has	O
been	O
associated	O
with	O
an	O
increase	O
in	O
urolithiasis	B-Disease
risk	O
.	O
	
This	O
study	O
was	O
conducted	O
to	O
investigate	O
the	O
association	O
of	O
MnSOD	O
gene	O
polymorphism	O
with	O
the	O
risk	O
of	O
urolithiasis	B-Disease
.	O
	
We	O
investigated	O
the	O
MnSOD	O
in	O
66	O
stone	B-Disease
-	I-Disease
forming	I-Disease
adults	O
and	O
72	O
healthy	O
volunteers	O
.	O
	
DNA	O
was	O
isolated	O
from	O
peripheral	O
blood	O
and	O
genotyping	O
was	O
performed	O
with	O
PCR	O
-	O
based	O
methods	O
.	O
	
Then	O
PCR	O
products	O
were	O
cut	O
by	O
BsaW1	O
.	O
	
Products	O
were	O
run	O
on	O
3	O
%	O
agarose	B-Chemical
gel	O
","	O
246	O
bp	O
regions	O
were	O
1	O
-	O
Ala	O
-	O
9	O
","	O
164	O
and	O
82	O
bp	O
products	O
were	O
determined	O
as	O
2	O
Val	O
-	O
9	O
.	O
	
Chi	O
-	O
square	O
test	O
was	O
used	O
for	O
comparison	O
between	O
patients	O
and	O
controls	O
.	O
	
In	O
the	O
control	O
group	O
the	O
homozygote	O
Ala	O
allele	O
was	O
significantly	O
higher	O
than	O
in	O
the	O
patient	O
group	O
(	O
P	O
<	O
0	O
.	O
1	O
).	O
	
The	O
distribution	O
of	O
Ala	O
/	O
Val	O
and	O
homozygote	O
Val	O
alleles	O
in	O
the	O
patient	O
group	O
was	O
significantly	O
higher	O
than	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
5	O
).	O
	
MnSOD	O
genotype	O
determination	O
may	O
provide	O
a	O
tool	O
to	O
identify	O
individuals	O
who	O
are	O
at	O
risk	O
of	O
urolithiasis	B-Disease
.	O
	
This	O
experiment	O
also	O
provides	O
data	O
about	O
antioxidant	O
status	O
and	O
stone	B-Disease
formation	I-Disease
.	O
	
	
P2RX7	O
:	O
A	O
bipolar	B-Disease
and	I-Disease
unipolar	I-Disease
disorder	I-Disease
candidate	O
susceptibility	O
gene	O
?	O
	
The	O
chromosomal	O
region	O
12q24	O
has	O
been	O
previously	O
implicated	O
by	O
linkage	O
studies	O
of	O
both	O
bipolar	B-Disease
disorder	I-Disease
and	O
unipolar	B-Disease
mood	I-Disease
disorder	I-Disease
and	O
we	O
have	O
reported	O
two	O
pedigrees	O
segregating	O
both	O
bipolar	B-Disease
disorder	I-Disease
and	O
Darier	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
that	O
show	O
linkage	O
across	O
this	O
region	O
.	O
	
The	O
gene	O
P2RX7	O
is	O
located	O
in	O
this	O
chromosomal	O
region	O
and	O
has	O
been	O
recently	O
reported	O
as	O
a	O
susceptibility	O
gene	O
for	O
bipolar	B-Disease
disorder	I-Disease
and	O
unipolar	B-Disease
depression	I-Disease
.	O
	
The	O
non	O
-	O
synonymous	O
SNP	O
rs2230912	O
(	O
resulting	O
in	O
amino	O
-	O
acid	O
polymorphism	O
Q460R	O
)	O
showed	O
the	O
strongest	O
association	O
and	O
has	O
been	O
postulated	O
to	O
be	O
pathogenically	O
relevant	O
.	O
	
We	O
have	O
investigated	O
this	O
gene	O
in	O
a	O
large	O
UK	O
case	O
-	O
control	O
sample	O
(	O
bipolar	B-Disease
I	I-Disease
disorder	I-Disease
N	O
=	O
687	O
","	O
unipolar	B-Disease
recurrent	I-Disease
major	I-Disease
depression	I-Disease
N	O
=	O
1	O
","	O
36	O
","	O
controls	O
N	O
=	O
1	O
","	O
204	O
).	O
	
Neither	O
rs2230912	O
nor	O
any	O
of	O
8	O
other	O
SNPs	O
genotyped	O
across	O
P2RX7	O
was	O
found	O
to	O
be	O
associated	O
with	O
mood	B-Disease
disorder	I-Disease
in	O
general	O
","	O
nor	O
specifically	O
with	O
bipolar	B-Disease
or	I-Disease
unipolar	I-Disease
disorder	I-Disease
.	O
	
Further	O
","	O
sequencing	O
of	O
our	O
two	O
chromosome	O
12	O
-	O
linked	O
bipolar	O
-	O
Darier	O
families	O
showed	O
no	O
evidence	O
of	O
rare	O
variants	O
at	O
P2RX7	O
that	O
could	O
explain	O
the	O
linkage	O
.	O
	
Our	O
data	O
do	O
not	O
provide	O
support	O
for	O
rs2230912	O
or	O
the	O
other	O
polymorphisms	O
studied	O
within	O
the	O
P2RX7	O
locus	O
","	O
being	O
involved	O
in	O
susceptibility	O
to	O
mood	B-Disease
disorders	I-Disease
.	O
	
	
Efficacy	O
of	O
everolimus	B-Chemical
(	O
RAD001	B-Chemical
)	O
in	O
patients	O
with	O
advanced	O
NSCLC	B-Disease
previously	O
treated	O
with	O
chemotherapy	O
alone	O
or	O
with	O
chemotherapy	O
and	O
EGFR	O
inhibitors	O
.	O
	
BACKGROUND	O
:	O
Treatment	O
options	O
are	O
scarce	O
in	O
pretreated	O
advanced	O
non	B-Disease
-	I-Disease
small	I-Disease
-	I-Disease
cell	I-Disease
lung	I-Disease
cancer	I-Disease
(	O
NSCLC	B-Disease
)	O
patients	O
.	O
	
RAD001	B-Chemical
","	O
an	O
oral	O
inhibitor	O
of	O
the	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)","	O
has	O
shown	O
phase	O
I	O
efficacy	O
in	O
NSCLC	B-Disease
.	O
	
METHODS	O
:	O
Stage	O
IIIb	O
or	O
IV	O
NSCLC	B-Disease
patients	O
","	O
with	O
two	O
or	O
fewer	O
prior	O
chemotherapy	O
regimens	O
","	O
one	O
platinum	B-Chemical
based	O
(	O
stratum	O
1	O
)	O
or	O
both	O
chemotherapy	O
and	O
epidermal	O
growth	O
factor	O
receptor	O
tyrosine	O
kinase	O
inhibitors	O
(	O
stratum	O
2	O
)","	O
received	O
RAD001	B-Chemical
10	O
mg	O
/	O
day	O
until	O
progression	O
or	O
unacceptable	O
toxicity	B-Disease
.	O
	
Primary	O
objective	O
was	O
overall	O
response	O
rate	O
(	O
ORR	O
).	O
	
Analyses	O
of	O
markers	O
associated	O
with	O
the	O
mTOR	O
pathway	O
were	O
carried	O
out	O
on	O
archival	O
tumor	B-Disease
from	O
a	O
subgroup	O
using	O
immunohistochemistry	O
(	O
IHC	O
)	O
and	O
direct	O
mutation	O
sequencing	O
.	O
	
RESULTS	O
:	O
Eighty	O
-	O
five	O
patients	O
were	O
enrolled	O
","	O
42	O
in	O
stratum	O
1	O
and	O
43	O
in	O
stratum	O
.	O
	
ORR	O
was	O
4	O
.	O
7	O
%	O
(	O
7	O
.	O
1	O
%	O
stratum	O
1	O
";"	O
2	O
.	O
3	O
%	O
stratum	O
2	O
).	O
	
Overall	O
disease	O
control	O
rate	O
was	O
47	O
.	O
1	O
%.	O
	
Median	O
progression	O
-	O
free	O
survivals	O
(	O
PFSs	O
)	O
were	O
2	O
.	O
6	O
(	O
stratum	O
1	O
)	O
and	O
2	O
.	O
7	O
months	O
(	O
stratum	O
2	O
).	O
	
Common	O
>	O
or	O
=	O
grade	O
3	O
events	O
were	O
fatigue	B-Disease
","	O
dyspnea	B-Disease
","	O
stomatitis	B-Disease
","	O
anemia	B-Disease
","	O
and	O
thrombocytopenia	B-Disease
.	O
	
Pneumonitis	B-Disease
","	O
probably	O
or	O
possibly	O
related	O
","	O
mainly	O
grade	O
1	O
/	O
2	O
","	O
occurred	O
in	O
25	O
%.	O
	
Cox	O
regression	O
analysis	O
of	O
IHC	O
scores	O
found	O
that	O
only	O
phospho	O
AKT	O
(	O
pAKT	O
)	O
was	O
a	O
significant	O
independent	O
predictor	O
of	O
worse	O
PFS	O
.	O
	
CONCLUSIONS	O
:	O
RAD001	B-Chemical
10	O
mg	O
/	O
day	O
was	O
well	O
tolerated	O
","	O
showing	O
modest	O
clinical	O
activity	O
in	O
pretreated	O
NSCLC	B-Disease
.	O
	
Evaluation	O
of	O
RAD001	B-Chemical
plus	O
standard	O
therapy	O
for	O
metastatic	O
NSCLC	B-Disease
continues	O
.	O
	
	
Clopidogrel	B-Chemical
pharmacogenomics	O
and	O
risk	O
of	O
inadequate	O
platelet	O
inhibition	O
:	O
US	O
FDA	O
recommendations	O
.	O
	
Antiplatelet	O
therapy	O
with	O
clopidogrel	B-Chemical
is	O
the	O
current	O
standard	O
of	O
care	O
for	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
patients	O
undergoing	O
a	O
percutaneous	O
coronary	O
intervention	O
.	O
	
However	O
","	O
approximately	O
25	O
%	O
of	O
patients	O
experience	O
a	O
subtherapeutic	O
antiplatelet	O
response	O
.	O
	
Clopidogrel	B-Chemical
is	O
a	O
prodrug	O
that	O
undergoes	O
hepatic	O
biotransformation	O
by	O
CYP2C19	O
into	O
its	O
active	O
metabolite	O
.	O
	
Several	O
studies	O
have	O
reported	O
that	O
","	O
compared	O
with	O
wild	O
-	O
type	O
individuals	O
","	O
CYP2C19	O
variant	O
allele	O
carriers	O
exhibit	O
a	O
significantly	O
lower	O
capacity	O
to	O
metabolize	O
clopidogrel	B-Chemical
into	O
its	O
active	O
metabolite	O
and	O
inhibit	O
platelet	O
activation	O
","	O
and	O
are	O
therefore	O
at	O
significantly	O
higher	O
risk	O
of	O
adverse	O
cardiovascular	O
events	O
.	O
	
Consequently	O
","	O
the	O
US	O
FDA	O
has	O
recently	O
changed	O
clopidogrel	B-Chemical
'	O
s	O
prescribing	O
information	O
to	O
highlight	O
the	O
impact	O
of	O
CYP2C19	O
genotype	O
on	O
clopidogrel	B-Chemical
pharmacokinetics	O
","	O
pharmacodynamics	O
and	O
clinical	O
response	O
.	O
	
Future	O
studies	O
remain	O
necessary	O
to	O
develop	O
effective	O
personalized	O
therapeutic	O
strategies	O
for	O
CYP2C19	O
variant	O
allele	O
carriers	O
and	O
other	O
individuals	O
at	O
risk	O
for	O
clopidogrel	B-Chemical
nonresponsiveness	O
.	O
	
	
Mutation	O
analysis	O
in	O
a	O
Chinese	O
family	O
with	O
multiple	B-Disease
endocrine	I-Disease
neoplasia	I-Disease
type	I-Disease
1	I-Disease
.	O
	
BACKGROUND	O
:	O
Multiple	B-Disease
endocrine	I-Disease
neoplasia	I-Disease
type	I-Disease
1	I-Disease
(	O
MEN1	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
cancer	I-Disease
syndrome	I-Disease
which	O
is	O
caused	O
by	O
germline	O
mutations	O
of	O
the	O
tumor	B-Disease
suppressor	O
gene	O
MEN1	O
.	O
	
This	O
study	O
aimed	O
to	O
identify	O
mutations	O
in	O
a	O
Chinese	O
pedigree	O
with	O
MEN1	B-Disease
.	O
	
METHODS	O
:	O
A	O
large	O
Chinese	O
family	O
with	O
MEN1	B-Disease
was	O
collected	O
.	O
	
All	O
of	O
the	O
coded	O
regions	O
and	O
their	O
adjacent	O
sequences	O
of	O
the	O
MEN1	O
gene	O
were	O
amplified	O
and	O
sequenced	O
.	O
	
RESULTS	O
:	O
In	O
this	O
family	O
","	O
a	O
heterozygous	O
cytosine	O
insertion	O
in	O
exon	O
10	O
(	O
c	O
.	O
1546_1547insC	O
)	O
inducing	O
a	O
frame	O
shift	O
mutation	O
of	O
MEN1	O
was	O
found	O
in	O
the	O
proband	O
and	O
the	O
other	O
two	O
suffering	O
members	O
of	O
his	O
family	O
.	O
	
This	O
mutation	O
was	O
linked	O
to	O
a	O
novel	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
in	O
intron	O
3	O
(	O
IVS3	O
+	O
18C	O
>	O
T	O
).	O
	
CONCLUSIONS	O
:	O
The	O
mutation	O
in	O
exon	O
10	O
of	O
MEN1	O
gene	O
might	O
induce	O
development	O
of	O
parathyroid	B-Disease
hyperplasia	I-Disease
and	O
pituitary	B-Disease
adenoma	I-Disease
and	O
cosegregate	O
with	O
MEN1	B-Disease
syndrome	I-Disease
.	O
	
The	O
significance	O
of	O
the	O
new	O
found	O
IVS3	O
+	O
18C	O
>	O
T	O
of	O
MEN1	O
needs	O
a	O
further	O
investigation	O
.	O
	
	
Genetic	O
polymorphism	O
of	O
the	O
glutathione	O
-	O
S	O
-	O
transferase	O
P1	O
gene	O
(	O
GSTP1	O
)	O
and	O
susceptibility	O
to	O
prostate	B-Disease
cancer	I-Disease
in	O
the	O
Kashmiri	O
population	O
.	O
	
Glutathione	O
-	O
S	O
-	O
transferase	O
P1	O
(	O
GSTP1	O
)	O
is	O
a	O
critical	O
enzyme	O
of	O
the	O
phase	O
II	O
detoxification	O
pathway	O
.	O
	
One	O
of	O
the	O
common	O
functional	O
polymorphisms	O
of	O
GSTP1	O
is	O
A	O
>	O
G	O
at	O
nucleotide	O
313	O
","	O
which	O
results	O
in	O
an	O
amino	O
acid	O
substitution	O
(	O
Ile105Val	O
)	O
at	O
the	O
substrate	O
binding	O
site	O
of	O
GSTP1	O
and	O
reduces	O
catalytic	O
activity	O
of	O
GSTP1	O
.	O
	
To	O
investigate	O
the	O
GSTP1	O
Ile105Val	O
genotype	O
frequency	O
in	O
prostate	B-Disease
cancer	I-Disease
cases	O
in	O
the	O
Kashmiri	O
population	O
","	O
we	O
designed	O
a	O
case	O
-	O
control	O
study	O
","	O
in	O
which	O
50	O
prostate	B-Disease
cancer	I-Disease
cases	O
and	O
45	O
benign	B-Disease
prostate	I-Disease
hyperplasia	I-Disease
cases	O
were	O
studied	O
for	O
GSTP1	O
Ile105Val	O
polymorphism	O
","	O
compared	O
to	O
80	O
controls	O
taken	O
from	O
the	O
general	O
population	O
","	O
employing	O
the	O
PCR	O
-	O
RFLP	O
technique	O
.	O
	
We	O
found	O
the	O
frequency	O
of	O
the	O
three	O
different	O
genotypes	O
of	O
GSTP1	O
Ile105Val	O
in	O
our	O
ethnic	O
Kashmir	O
population	O
","	O
i	O
.	O
e	O
.","	O
Ile	O
/	O
Ile	O
","	O
Ile	O
/	O
Val	O
and	O
Val	O
/	O
Val	O
","	O
to	O
be	O
52	O
.	O
4	O
","	O
33	O
.	O
3	O
and	O
14	O
.	O
3	O
%	O
among	O
prostate	B-Disease
cancer	I-Disease
cases	O
","	O
48	O
.	O
5	O
","	O
37	O
.	O
5	O
and	O
14	O
%	O
among	O
benign	B-Disease
prostate	I-Disease
hyperplasia	I-Disease
cases	O
and	O
73	O
.	O
8	O
","	O
21	O
.	O
3	O
and	O
5	O
%	O
in	O
the	O
control	O
population	O
","	O
respectively	O
.	O
	
There	O
was	O
a	O
significant	O
association	O
between	O
the	O
GSTP1	O
Ile	O
/	O
Val	O
genotype	O
and	O
the	O
advanced	O
age	O
group	O
among	O
the	O
cases	O
.	O
	
We	O
conclude	O
that	O
GSTP1	O
Ile	O
/	O
Val	O
polymorphism	O
is	O
involved	O
in	O
the	O
risk	O
of	O
prostate	B-Disease
cancer	I-Disease
development	O
in	O
our	O
population	O
.	O
	
	
Availability	O
of	O
human	O
induced	O
pluripotent	O
stem	O
cell	O
-	O
derived	O
cardiomyocytes	O
in	O
assessment	O
of	O
drug	O
potential	O
for	O
QT	B-Disease
prolongation	I-Disease
.	O
	
Field	O
potential	O
duration	O
(	O
FPD	O
)	O
in	O
human	O
-	O
induced	O
pluripotent	O
stem	O
cell	O
-	O
derived	O
cardiomyocytes	O
(	O
hiPS	O
-	O
CMs	O
)","	O
which	O
can	O
express	O
QT	O
interval	O
in	O
an	O
electrocardiogram	O
","	O
is	O
reported	O
to	O
be	O
a	O
useful	O
tool	O
to	O
predict	O
K	B-Chemical
(+)	I-Chemical
channel	I-Chemical
and	I-Chemical
Ca	I-Chemical
(	I-Chemical
2	I-Chemical
+)	I-Chemical
channel	I-Chemical
blocker	I-Chemical
effects	O
on	O
QT	O
interval	O
.	O
	
However	O
","	O
there	O
is	O
no	O
report	O
showing	O
that	O
this	O
technique	O
can	O
be	O
used	O
to	O
predict	O
multichannel	O
blocker	O
potential	O
for	O
QT	B-Disease
prolongation	I-Disease
.	O
	
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
show	O
that	O
FPD	O
from	O
MEA	O
(	O
Multielectrode	O
array	O
)	O
of	O
hiPS	O
-	O
CMs	O
can	O
detect	O
QT	B-Disease
prolongation	I-Disease
induced	O
by	O
multichannel	O
blockers	O
.	O
	
hiPS	O
-	O
CMs	O
were	O
seeded	O
onto	O
MEA	O
and	O
FPD	O
was	O
measured	O
for	O
2min	O
every	O
10min	O
for	O
30min	O
after	O
drug	O
exposure	O
for	O
the	O
vehicle	O
and	O
each	O
drug	O
concentration	O
.	O
	
IKr	O
and	O
IKs	O
blockers	O
concentration	O
-	O
dependently	O
prolonged	O
corrected	O
FPD	O
(	O
FPDc	O
)","	O
whereas	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+)	I-Chemical
channel	I-Chemical
blockers	I-Chemical
concentration	O
-	O
dependently	O
shortened	O
FPDc	O
.	O
	
Also	O
","	O
the	O
multichannel	O
blockers	O
Amiodarone	B-Chemical
","	O
Paroxetine	B-Chemical
","	O
Terfenadine	B-Chemical
and	O
Citalopram	B-Chemical
prolonged	O
FPDc	O
in	O
a	O
concentration	O
dependent	O
manner	O
.	O
	
Finally	O
","	O
the	O
IKr	O
blockers	O
","	O
Terfenadine	B-Chemical
and	O
Citalopram	B-Chemical
","	O
which	O
are	O
reported	O
to	O
cause	O
Torsade	B-Disease
de	I-Disease
Pointes	I-Disease
(	O
TdP	B-Disease
)	O
in	O
clinical	O
practice	O
","	O
produced	O
early	O
afterdepolarization	O
(	O
EAD	O
).	O
	
hiPS	O
-	O
CMs	O
using	O
MEA	O
system	O
and	O
FPDc	O
can	O
predict	O
the	O
effects	O
of	O
drug	O
candidates	O
on	O
QT	O
interval	O
.	O
	
This	O
study	O
also	O
shows	O
that	O
this	O
assay	O
can	O
help	O
detect	O
EAD	O
for	O
drugs	O
with	O
TdP	B-Disease
potential	O
.	O
	
	
Serum	O
levels	O
of	O
chemokines	O
CCL4	O
and	O
CCL5	O
in	O
cirrhotic	B-Disease
patients	O
indicate	O
the	O
presence	O
of	O
hepatocellular	B-Disease
carcinoma	I-Disease
.	O
	
BACKGROUND	O
:	O
Most	O
hepatocellular	B-Disease
carcinomas	I-Disease
(	O
HCCs	B-Disease
)	O
are	O
diagnosed	O
at	O
an	O
advanced	O
stage	O
.	O
	
The	O
prognostic	O
value	O
of	O
serum	O
tumour	B-Disease
markers	O
alpha	O
-	O
fetoprotein	O
(	O
AFP	O
)	O
and	O
des	O
-	O
gamma	O
-	O
carboxy	O
prothrombin	O
(	O
DCP	O
)	O
is	O
limited	O
.	O
	
The	O
aim	O
of	O
our	O
study	O
is	O
to	O
evaluate	O
the	O
diagnostic	O
value	O
of	O
serum	O
growth	O
factors	O
","	O
apoptotic	O
and	O
inflammatory	B-Disease
mediators	O
of	O
cirrhotic	B-Disease
patients	O
with	O
and	O
without	O
HCC	B-Disease
.	O
	
METHODS	O
:	O
Serum	O
samples	O
were	O
collected	O
from	O
cirrhotic	B-Disease
potential	O
liver	O
transplant	O
patients	O
(	O
LTx	O
)	O
with	O
(	O
n	O
=	O
61	O
)	O
and	O
without	O
HCC	B-Disease
(	O
n	O
=	O
78	O
)	O
as	O
well	O
as	O
from	O
healthy	O
controls	O
(	O
HCs	O
";"	O
n	O
=	O
39	O
).	O
	
Serum	O
concentrations	O
of	O
CRP	O
","	O
neopterin	B-Chemical
and	O
IL	O
-	O
6	O
as	O
markers	O
of	O
inflammation	B-Disease
and	O
thrombopoietin	O
(	O
TPO	O
)","	O
GCSF	O
","	O
FGF	O
basic	O
and	O
VEGF	O
","	O
HMGB1	O
","	O
CK	O
-	O
18	O
(	O
M65	O
)	O
and	O
CK18	O
fragment	O
(	O
M30	O
)	O
and	O
a	O
panel	O
of	O
proinflammatory	O
chemokines	O
(	O
CCL2	O
","	O
CCL3	O
","	O
CCL4	O
","	O
CCL5	O
","	O
CXCL5	O
and	O
IL	O
-	O
8	O
)	O
were	O
measured	O
.	O
	
Chi	O
square	O
","	O
Fisher	O
exact	O
","	O
Mann	O
-	O
Whitney	O
U	O
-	O
tests	O
","	O
ROC	O
curve	O
analysis	O
and	O
forward	O
stepwise	O
logistic	O
regression	O
analyses	O
were	O
applied	O
.	O
	
RESULTS	O
:	O
Patients	O
with	O
HCC	B-Disease
had	O
higher	O
serum	O
TPO	O
and	O
chemokines	O
(	O
P	O
<	O
0	O
.	O
1	O
for	O
TPO	O
","	O
CCL4	O
","	O
CCL5	O
and	O
CXCL5	O
)	O
and	O
lower	O
CCL2	O
(	O
P	O
=	O
0	O
.	O
8	O
)	O
levels	O
than	O
cirrhotic	B-Disease
patients	O
without	O
HCC	B-Disease
.	O
	
Multivariate	O
forward	O
stepwise	O
regression	O
analysis	O
for	O
significant	O
parameters	O
showed	O
that	O
among	O
the	O
studied	O
parameters	O
CCL4	O
and	O
CCL5	O
(	O
P	O
=	O
0	O
.	O
1	O
)	O
are	O
diagnostic	O
markers	O
of	O
HCC	B-Disease
.	O
	
Serum	O
levels	O
of	O
TPO	O
and	O
chemokines	O
were	O
lower	O
","	O
whereas	O
M30	O
was	O
significantly	O
higher	O
in	O
cirrhotic	B-Disease
patients	O
than	O
in	O
HCs	O
.	O
	
CONCLUSIONS	O
:	O
High	O
serum	O
levels	O
of	O
inflammatory	B-Disease
chemokines	O
such	O
as	O
CCL4	O
and	O
CCL5	O
in	O
the	O
serum	O
of	O
cirrhotic	B-Disease
patients	O
indicate	O
the	O
presence	O
of	O
HCC	B-Disease
.	O
	
	
Disease	O
-	O
associated	O
mutations	O
in	O
human	O
BICD2	O
hyperactivate	O
motility	O
of	O
dynein	O
-	O
dynactin	O
.	O
	
Bicaudal	O
D2	O
(	O
BICD2	O
)	O
joins	O
dynein	O
with	O
dynactin	O
into	O
a	O
ternary	O
complex	O
(	O
termed	O
DDB	O
)	O
capable	O
of	O
processive	O
movement	O
.	O
	
Point	O
mutations	O
in	O
the	O
BICD2	O
gene	O
have	O
been	O
identified	O
in	O
patients	O
with	O
a	O
dominant	O
form	O
of	O
spinal	B-Disease
muscular	I-Disease
atrophy	I-Disease
","	O
but	O
how	O
these	O
mutations	O
cause	O
disease	O
is	O
unknown	O
.	O
	
To	O
investigate	O
this	O
question	O
","	O
we	O
have	O
developed	O
in	O
vitro	O
motility	O
assays	O
with	O
purified	O
DDB	O
and	O
BICD2	O
'	O
s	O
membrane	O
vesicle	O
partner	O
","	O
the	O
GTPase	O
Rab6a	O
.	O
	
Rab6a	O
-	O
GTP	O
","	O
either	O
in	O
solution	O
or	O
bound	O
to	O
artificial	O
liposomes	O
","	O
released	O
BICD2	O
from	O
an	O
autoinhibited	O
state	O
and	O
promoted	O
robust	O
dynein	O
-	O
dynactin	O
transport	O
.	O
	
In	O
these	O
assays	O
","	O
BICD2	O
mutants	O
showed	O
an	O
enhanced	O
ability	O
to	O
form	O
motile	O
DDB	O
complexes	O
.	O
	
Increased	O
retrograde	O
transport	O
by	O
BICD2	O
mutants	O
also	O
was	O
observed	O
in	O
cells	O
using	O
an	O
inducible	O
organelle	O
transport	O
assay	O
.	O
	
When	O
overexpressed	O
in	O
rat	O
hippocampal	O
neurons	O
","	O
the	O
hyperactive	O
BICD2	O
mutants	O
decreased	O
neurite	O
growth	O
.	O
	
Our	O
results	O
reveal	O
that	O
dominant	O
mutations	O
in	O
BICD2	O
hyperactivate	O
DDB	O
motility	O
and	O
suggest	O
that	O
an	O
imbalance	O
of	O
minus	O
versus	O
plus	O
end	O
-	O
directed	O
microtubule	O
motility	O
in	O
neurons	O
may	O
underlie	O
spinal	B-Disease
muscular	I-Disease
atrophy	I-Disease
.	O
	
	
Thiamine	B-Disease
deficiency	I-Disease
activates	O
hypoxia	O
inducible	O
factor	O
-	O
1a	O
to	O
facilitate	O
pro	O
-	O
apoptotic	O
responses	O
in	O
mouse	O
primary	O
astrocytes	O
.	O
	
Thiamine	B-Chemical
is	O
an	O
essential	O
enzyme	O
cofactor	O
required	O
for	O
proper	O
metabolic	O
function	O
and	O
maintenance	O
of	O
metabolism	O
and	O
energy	O
production	O
in	O
the	O
brain	O
.	O
	
In	O
developed	O
countries	O
","	O
thiamine	B-Disease
deficiency	I-Disease
(	O
TD	B-Disease
)	O
is	O
most	O
often	O
manifested	O
following	O
chronic	O
alcohol	B-Chemical
consumption	O
leading	O
to	O
impaired	B-Disease
mitochondrial	I-Disease
function	I-Disease
","	O
oxidative	O
stress	O
","	O
inflammation	B-Disease
and	O
excitotoxicity	B-Disease
.	O
	
These	O
biochemical	O
lesions	O
result	O
in	O
apoptotic	O
cell	O
death	O
in	O
both	O
neurons	O
and	O
astrocytes	O
.	O
	
Comparable	O
histological	O
injuries	O
in	O
patients	O
with	O
hypoxia	B-Disease
/	O
ischemia	B-Disease
and	O
TD	B-Disease
have	O
been	O
described	O
in	O
the	O
thalamus	O
and	O
mammillary	O
bodies	O
","	O
suggesting	O
a	O
congruency	O
between	O
the	O
cellular	O
responses	O
to	O
these	O
stresses	O
.	O
	
Consistent	O
with	O
hypoxia	B-Disease
/	O
ischemia	B-Disease
","	O
TD	B-Disease
stabilizes	O
and	O
activates	O
Hypoxia	O
Inducible	O
Factor	O
-	O
1a	O
(	O
HIF	O
-	O
1a	O
)	O
under	O
physiological	O
oxygen	B-Chemical
levels	O
.	O
	
However	O
","	O
the	O
role	O
of	O
TD	B-Disease
-	O
induced	O
HIF	O
-	O
1a	O
in	O
neurological	B-Disease
injury	I-Disease
is	O
currently	O
unknown	O
.	O
	
Using	O
Western	O
blot	O
analysis	O
and	O
RT	O
-	O
PCR	O
","	O
we	O
have	O
demonstrated	O
that	O
TD	B-Disease
induces	O
HIF	O
-	O
1a	O
expression	O
and	O
activity	O
in	O
primary	O
mouse	O
astrocytes	O
.	O
	
We	O
observed	O
a	O
time	O
-	O
dependent	O
increase	O
in	O
mRNA	O
and	O
protein	O
expression	O
of	O
the	O
pro	O
-	O
apoptotic	O
and	O
pro	O
-	O
inflammatory	B-Disease
HIF	O
-	O
1a	O
target	O
genes	O
MCP1	O
","	O
BNIP3	O
","	O
Nix	O
and	O
Noxa	O
during	O
TD	B-Disease
.	O
	
We	O
also	O
observed	O
apoptotic	O
cell	O
death	O
in	O
TD	B-Disease
as	O
demonstrated	O
by	O
PI	O
/	O
Annexin	O
V	O
staining	O
","	O
TUNEL	O
assay	O
","	O
and	O
Cell	O
Death	O
ELISA	O
.	O
	
Pharmacological	O
inhibition	O
of	O
HIF	O
-	O
1a	O
activity	O
using	O
YC1	O
and	O
thiamine	B-Chemical
repletion	O
both	O
reduced	O
expression	O
of	O
pro	O
-	O
apoptotic	O
HIF	O
-	O
1a	O
target	O
genes	O
and	O
apoptotic	O
cell	O
death	O
in	O
TD	B-Disease
.	O
	
These	O
results	O
demonstrate	O
that	O
induction	O
of	O
HIF	O
-	O
1a	O
mediated	O
transcriptional	O
up	O
-	O
regulation	O
of	O
pro	O
-	O
apoptotic	O
/	O
inflammatory	B-Disease
signaling	O
contributes	O
to	O
astrocyte	O
cell	O
death	O
during	O
thiamine	B-Disease
deficiency	I-Disease
.	O
	
	
Recurrent	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
induced	O
by	O
azithromycin	B-Chemical
.	O
	
A	O
14	O
-	O
year	O
-	O
old	O
girl	O
is	O
reported	O
with	O
recurrent	O
","	O
azithromycin	B-Chemical
-	O
induced	O
","	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
.	O
	
The	O
second	O
episode	O
was	O
more	O
severe	O
than	O
the	O
first	O
";"	O
and	O
although	O
both	O
were	O
treated	O
with	O
intensive	O
corticosteroid	B-Chemical
therapy	O
","	O
renal	O
function	O
remained	O
impaired	O
.	O
	
Although	O
most	O
cases	O
of	O
antibiotic	B-Chemical
induced	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
are	O
benign	O
and	O
self	O
-	O
limited	O
","	O
some	O
patients	O
are	O
at	O
risk	O
for	O
permanent	O
renal	B-Disease
injury	I-Disease
.	O
	
	
Behavioral	O
effects	O
of	O
urotensin	O
-	O
II	O
centrally	O
administered	O
in	O
mice	O
.	O
	
Urotensin	O
-	O
II	O
(	O
U	O
-	O
II	O
)	O
receptors	O
are	O
widely	O
distributed	O
in	O
the	O
central	O
nervous	O
system	O
.	O
	
Intracerebroventricular	O
(	O
i	O
.	O
c	O
.	O
v	O
.)	O
	
injection	O
of	O
U	O
-	O
II	O
causes	O
hypertension	B-Disease
and	O
bradycardia	B-Disease
and	O
stimulates	O
prolactin	O
and	O
thyrotropin	O
secretion	O
.	O
	
However	O
","	O
the	O
behavioral	O
effects	O
of	O
centrally	O
administered	O
U	O
-	O
II	O
have	O
received	O
little	O
attention	O
.	O
	
In	O
the	O
present	O
study	O
","	O
we	O
tested	O
the	O
effects	O
of	O
i	O
.	O
c	O
.	O
v	O
.	O
	
injections	O
of	O
U	O
-	O
II	O
on	O
behavioral	O
","	O
metabolic	O
","	O
and	O
endocrine	O
responses	O
in	O
mice	O
.	O
	
Administration	O
of	O
graded	O
doses	O
of	O
U	O
-	O
II	O
(	O
1	O
-	O
10	O
","	O
0	O
ng	O
/	O
mouse	O
)	O
provoked	O
:	O
(	O
1	O
)	O
a	O
dose	O
-	O
dependent	O
reduction	O
in	O
the	O
number	O
of	O
head	O
dips	O
in	O
the	O
hole	O
-	O
board	O
test	O
";"	O
(	O
2	O
)	O
a	O
dose	O
-	O
dependent	O
reduction	O
in	O
the	O
number	O
of	O
entries	O
in	O
the	O
white	O
chamber	O
in	O
the	O
black	O
-	O
and	O
-	O
white	O
compartment	O
test	O
","	O
and	O
in	O
the	O
number	O
of	O
entries	O
in	O
the	O
central	O
platform	O
and	O
open	O
arms	O
in	O
the	O
plus	O
-	O
maze	O
test	O
";"	O
and	O
(	O
3	O
)	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
the	O
duration	O
of	O
immobility	O
in	O
the	O
forced	O
-	O
swimming	O
test	O
and	O
tail	O
suspension	O
test	O
.	O
	
Intracerebroventricular	O
injection	O
of	O
U	O
-	O
II	O
also	O
caused	O
an	O
increase	O
in	O
:	O
food	O
intake	O
at	O
doses	O
of	O
100	O
and	O
1	O
","	O
0	O
ng	O
/	O
mouse	O
","	O
water	O
intake	O
at	O
doses	O
of	O
100	O
-	O
10	O
","	O
0	O
ng	O
/	O
mouse	O
","	O
and	O
horizontal	O
locomotion	O
activity	O
at	O
a	O
dose	O
of	O
10	O
","	O
0	O
ng	O
/	O
mouse	O
.	O
	
Whatever	O
was	O
the	O
dose	O
","	O
the	O
central	O
administration	O
of	O
U	O
-	O
II	O
had	O
no	O
effect	O
on	O
body	O
temperature	O
","	O
nociception	O
","	O
apomorphine	B-Chemical
-	O
induced	O
penile	O
erection	O
and	O
climbing	O
behavior	O
","	O
and	O
stress	O
-	O
induced	O
plasma	O
corticosterone	B-Chemical
level	O
.	O
	
Taken	O
together	O
","	O
the	O
present	O
study	O
demonstrates	O
that	O
the	O
central	O
injection	O
of	O
U	O
-	O
II	O
at	O
doses	O
of	O
1	O
-	O
10	O
","	O
0	O
ng	O
/	O
mouse	O
induces	O
anxiogenic	B-Disease
-	O
and	O
depressant	B-Disease
-	O
like	O
effects	O
in	O
mouse	O
.	O
	
These	O
data	O
suggest	O
that	O
U	O
-	O
II	O
may	O
be	O
involved	O
in	O
some	O
aspects	O
of	O
psychiatric	B-Disease
disorders	I-Disease
.	O
	
	
The	O
promoter	O
of	O
inducible	O
nitric	O
oxide	O
synthase	O
implicated	O
in	O
glaucoma	B-Disease
based	O
on	O
genetic	O
analysis	O
and	O
nuclear	O
factor	O
binding	O
.	O
	
PURPOSE	O
:	O
Nitric	B-Chemical
oxide	I-Chemical
has	O
many	O
beneficial	O
functions	O
in	O
the	O
human	O
body	O
at	O
the	O
right	O
amounts	O
","	O
but	O
it	O
can	O
also	O
be	O
hazardous	O
if	O
it	O
is	O
produced	O
in	O
amounts	O
more	O
than	O
needed	O
and	O
has	O
therefore	O
been	O
studied	O
in	O
relation	O
to	O
several	O
neurological	B-Disease
and	I-Disease
non	I-Disease
-	I-Disease
neurological	I-Disease
disorders	I-Disease
.	O
	
In	O
vitro	O
and	O
in	O
vivo	O
studies	O
demonstrate	O
a	O
connection	O
between	O
the	O
inducible	O
form	O
of	O
Nitric	O
Oxide	O
Synthase	O
","	O
iNOS	O
","	O
and	O
the	O
neuropathological	B-Disease
disorder	I-Disease
glaucoma	I-Disease
","	O
one	O
of	O
the	O
major	O
causes	O
of	O
blindness	B-Disease
in	O
the	O
world	O
.	O
	
In	O
this	O
study	O
","	O
we	O
sought	O
to	O
establish	O
the	O
genetic	O
association	O
between	O
iNOS	O
and	O
primary	B-Disease
open	I-Disease
angle	I-Disease
glaucoma	I-Disease
","	O
POAG	B-Disease
","	O
and	O
to	O
find	O
the	O
functional	O
element	O
(	O
s	O
)	O
connected	O
with	O
the	O
pathogenesis	O
of	O
the	O
disease	O
.	O
	
METHODS	O
:	O
Two	O
microsatellites	O
","	O
1	O
insertion	O
/	O
deletion	O
","	O
and	O
8	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
the	O
regulatory	O
region	O
of	O
iNOS	O
were	O
genotyped	O
in	O
200	O
POAG	B-Disease
patients	O
and	O
200	O
age	O
-	O
matched	O
controls	O
.	O
	
Also	O
","	O
the	O
CCTTT	O
-	O
microsatellite	O
was	O
examined	O
for	O
its	O
protein	O
-	O
binding	O
capability	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
","	O
EMSA	O
.	O
	
RESULTS	O
:	O
There	O
was	O
a	O
significant	O
difference	O
in	O
allele	O
distribution	O
of	O
the	O
CCTTT	O
-	O
microsatellite	O
","	O
between	O
patients	O
and	O
controls	O
.	O
	
(	O
CCTTT	O
)	O
14	O
","	O
which	O
has	O
been	O
reported	O
to	O
have	O
a	O
higher	O
activity	O
in	O
a	O
reporter	O
-	O
construct	O
","	O
was	O
significantly	O
more	O
abundant	O
in	O
POAG	B-Disease
patients	O
","	O
while	O
(	O
CCTTT	O
)	O
10	O
and	O
(	O
CCTTT	O
)	O
13	O
were	O
less	O
common	O
.	O
	
In	O
EMSA	O
","	O
the	O
(	O
CCTTT	O
)	O
14	O
allele	O
exhibited	O
specific	O
binding	O
of	O
nuclear	O
proteins	O
.	O
	
CONCLUSIONS	O
:	O
These	O
results	O
","	O
together	O
with	O
other	O
studies	O
on	O
this	O
gene	O
and	O
the	O
CCTTT	O
-	O
microsatellite	O
","	O
establish	O
","	O
for	O
the	O
first	O
time	O
","	O
a	O
genetic	O
association	O
of	O
iNOS	O
with	O
POAG	B-Disease
and	O
suggest	O
a	O
regulatory	O
function	O
for	O
the	O
microsatellite	O
.	O
	
	
Homozygous	O
deletion	O
and	O
reduced	O
expression	O
of	O
the	O
DOCK8	O
gene	O
in	O
human	O
lung	B-Disease
cancer	I-Disease
.	O
	
A	O
homozygous	O
deletion	O
of	O
the	O
DOCK8	O
(	O
dedicator	O
of	O
cytokinesis	O
8	O
)	O
locus	O
at	O
chromosome	O
9p24	O
was	O
found	O
in	O
a	O
lung	B-Disease
cancer	I-Disease
cell	O
line	O
by	O
array	O
-	O
CGH	O
analysis	O
.	O
	
Cloning	O
of	O
the	O
full	O
-	O
length	O
DOCK8	O
cDNA	O
led	O
us	O
to	O
define	O
that	O
the	O
DOCK8	O
gene	O
encodes	O
a	O
protein	O
consisting	O
of	O
2	O
","	O
99	O
amino	O
acids	O
.	O
	
DOCK8	O
was	O
expressed	O
in	O
a	O
variety	O
of	O
human	O
organs	O
","	O
including	O
the	O
lungs	O
","	O
and	O
was	O
also	O
expressed	O
in	O
type	O
II	O
alveolar	O
","	O
bronchiolar	O
epithelial	O
and	O
bronchial	O
epithelial	O
cells	O
","	O
which	O
are	O
considered	O
as	O
being	O
progenitors	O
for	O
lung	B-Disease
cancer	I-Disease
cells	O
.	O
	
DOCK8	O
expression	O
was	O
reduced	O
in	O
62	O
/	O
71	O
(	O
87	O
%)	O
primary	O
lung	B-Disease
cancers	I-Disease
compared	O
with	O
normal	O
lung	O
tissue	O
","	O
and	O
the	O
reduction	O
occurred	O
irrespective	O
of	O
the	O
histological	O
type	O
of	O
lung	B-Disease
cancer	I-Disease
.	O
	
5	B-Chemical
-	I-Chemical
Aza	I-Chemical
-	I-Chemical
2	I-Chemical
'-	I-Chemical
deoxy	I-Chemical
-	I-Chemical
cytidine	I-Chemical
and	O
/	O
or	O
Trichostatin	B-Chemical
A	I-Chemical
treatments	O
induced	O
DOCK8	O
expression	O
in	O
lung	B-Disease
cancer	I-Disease
cell	O
lines	O
with	O
reduced	O
DOCK8	O
expression	O
.	O
	
Therefore	O
","	O
epigenetic	O
mechanisms	O
","	O
including	O
DNA	O
methylation	O
and	O
histone	O
deacetylation	O
","	O
were	O
indicated	O
to	O
be	O
involved	O
in	O
DOCK8	O
down	O
-	O
regulation	O
in	O
lung	B-Disease
cancer	I-Disease
cells	O
.	O
	
Further	O
screening	O
revealed	O
homozygous	O
deletions	O
of	O
the	O
DOCK8	O
gene	O
in	O
a	O
gastric	O
and	O
a	O
breast	B-Disease
cancer	I-Disease
cell	O
line	O
.	O
	
DOCK	O
family	O
proteins	O
have	O
been	O
shown	O
to	O
play	O
roles	O
in	O
regulation	O
of	O
migration	O
","	O
morphology	O
","	O
adhesion	O
and	O
growth	O
of	O
cells	O
.	O
	
Thus	O
","	O
the	O
present	O
results	O
suggest	O
that	O
genetic	O
and	O
epigenetic	O
inactivation	O
of	O
DOCK8	O
is	O
involved	O
in	O
the	O
development	O
and	O
/	O
or	O
progression	O
of	O
lung	B-Disease
and	I-Disease
other	I-Disease
cancers	I-Disease
by	O
disturbing	O
such	O
regulations	O
.	O
	
	
A	O
novel	O
mutation	O
at	O
the	O
DFNA36	O
hearing	B-Disease
loss	I-Disease
locus	O
reveals	O
a	O
critical	O
function	O
and	O
potential	O
genotype	O
-	O
phenotype	O
correlation	O
for	O
amino	O
acid	O
-	O
572	O
of	O
TMC1	O
.	O
	
We	O
ascertained	O
a	O
North	O
American	O
Caucasian	O
family	O
(	O
LMG248	O
)	O
segregating	O
autosomal	O
dominant	O
","	O
non	O
-	O
syndromic	O
","	O
post	O
-	O
lingual	O
","	O
progressive	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
.	O
	
The	O
hearing	B-Disease
loss	I-Disease
begins	O
in	O
the	O
second	O
decade	O
of	O
life	O
and	O
initially	O
affects	O
high	O
frequencies	O
.	O
	
It	O
progresses	O
to	O
profound	O
deafness	B-Disease
at	O
all	O
frequencies	O
by	O
the	O
fourth	O
or	O
fifth	O
decade	O
.	O
	
The	O
phenotype	O
co	O
-	O
segregates	O
with	O
short	O
-	O
tandem	O
repeat	O
markers	O
flanking	O
the	O
TMC1	O
gene	O
at	O
the	O
DFNA36	O
locus	O
on	O
chromosome	O
9q31	O
-	O
q21	O
.	O
	
The	O
affected	O
individuals	O
carry	O
a	O
novel	O
missense	O
substitution	O
","	O
p	O
.	O
D572H	O
(	O
c	O
.	O
G1714C	O
)","	O
of	O
the	O
TMC1	O
gene	O
.	O
	
This	O
mutation	O
is	O
at	O
the	O
same	O
nucleotide	O
and	O
amino	O
acid	O
position	O
as	O
the	O
only	O
other	O
reported	O
DFNA36	O
mutation	O
","	O
p	O
.	O
D572N	O
(	O
c	O
.	O
G1714A	O
).	O
	
Our	O
observations	O
implicate	O
a	O
critical	O
function	O
for	O
amino	O
acid	O
-	O
572	O
for	O
wild	O
-	O
type	O
TMC1	O
function	O
or	O
the	O
pathogenesis	O
of	O
DFNA36	O
hearing	B-Disease
loss	I-Disease
.	O
	
The	O
slower	O
progression	O
of	O
hearing	B-Disease
loss	I-Disease
associated	O
with	O
p	O
.	O
D572H	O
","	O
in	O
comparison	O
with	O
that	O
caused	O
by	O
p	O
.	O
D572N	O
","	O
may	O
reflect	O
a	O
correlation	O
of	O
DFNA36	O
phenotype	O
with	O
TMC1	O
genotype	O
.	O
	
	
Interferon	O
regulatory	O
factor	O
6	O
(	O
IRF6	O
)	O
and	O
fibroblast	O
growth	O
factor	O
receptor	O
1	O
(	O
FGFR1	O
)	O
contribute	O
to	O
human	O
tooth	B-Disease
agenesis	I-Disease
.	O
	
Phenotypic	O
characteristics	O
expressed	O
in	O
syndromes	O
give	O
clues	O
to	O
the	O
factors	O
involved	O
in	O
the	O
cause	O
of	O
isolated	O
forms	O
of	O
the	O
same	O
defects	O
.	O
	
We	O
investigated	O
two	O
genes	O
responsible	O
for	O
craniofacial	B-Disease
syndromes	I-Disease
","	O
FGFR1	O
and	O
IRF6	O
","	O
in	O
a	O
collection	O
of	O
families	O
with	O
isolated	O
tooth	B-Disease
agenesis	I-Disease
.	O
	
Cheek	O
swab	O
samples	O
were	O
obtained	O
for	O
DNA	O
analysis	O
from	O
116	O
case	O
/	O
parent	O
trios	O
.	O
	
Probands	O
had	O
at	O
least	O
one	O
developmentally	O
missing	O
tooth	O
","	O
excluding	O
third	O
molars	O
.	O
	
In	O
addition	O
","	O
we	O
studied	O
89	O
cases	O
and	O
50	O
controls	O
from	O
Ohio	O
to	O
replicate	O
any	O
positive	O
findings	O
.	O
	
Genotyping	O
was	O
performed	O
by	O
kinetic	O
polymerase	O
chain	O
-	O
reaction	O
or	O
TaqMan	O
assays	O
.	O
	
Linkage	O
disequilibrium	O
analysis	O
and	O
transmission	O
distortion	O
of	O
the	O
marker	O
alleles	O
were	O
performed	O
.	O
	
The	O
same	O
variants	O
in	O
the	O
IRF6	O
gene	O
that	O
are	O
associated	O
with	O
isolated	O
orofacial	B-Disease
clefts	I-Disease
are	O
also	O
associated	O
with	O
human	O
tooth	B-Disease
agenesis	I-Disease
(	O
rs861019	O
","	O
P	O
=	O
0	O
.	O
58	O
";"	O
rs17015215	O
-	O
V274I	O
","	O
P	O
=	O
0	O
.	O
6	O
";"	O
rs7802	O
","	O
P	O
=	O
0	O
.	O
4	O
).	O
	
Mutations	O
in	O
IRF6	O
cause	O
Van	B-Disease
der	I-Disease
Woude	I-Disease
and	I-Disease
popliteal	I-Disease
pterygium	I-Disease
syndromes	I-Disease
.	O
	
The	O
craniofacial	O
phenotypic	O
characteristics	O
of	O
these	O
syndromes	O
include	O
oral	B-Disease
clefts	I-Disease
and	O
preferential	O
tooth	B-Disease
agenesis	I-Disease
of	O
incisors	O
and	O
premolars	O
","	O
besides	O
pits	B-Disease
on	I-Disease
the	I-Disease
lower	I-Disease
lips	I-Disease
.	O
	
Also	O
it	O
appears	O
that	O
preferential	O
premolar	O
agenesis	O
is	O
associated	O
with	O
FGFR1	O
(	O
P	O
=	O
0	O
.	O
14	O
)	O
and	O
IRF6	O
(	O
P	O
=	O
0	O
.	O
2	O
)	O
markers	O
.	O
	
There	O
were	O
statistically	O
significant	O
data	O
suggesting	O
that	O
IRF6	O
interacts	O
not	O
only	O
with	O
MSX1	O
(	O
P	O
=	O
0	O
.	O
1	O
)","	O
but	O
also	O
with	O
TGFA	O
(	O
P	O
=	O
0	O
.	O
3	O
).	O
	
	
Focal	B-Disease
dermal	I-Disease
hypoplasia	I-Disease
resulting	O
from	O
a	O
new	O
nonsense	O
mutation	O
","	O
p	O
.	O
E300X	O
","	O
in	O
the	O
PORCN	O
gene	O
.	O
	
BACKGROUND	O
:	O
Focal	B-Disease
dermal	I-Disease
hypoplasia	I-Disease
(	O
FDH	B-Disease
)	O
(	O
OMIM	B-Disease
305600	I-Disease
)	O
is	O
an	O
X	B-Disease
-	I-Disease
linked	I-Disease
dominant	I-Disease
disorder	I-Disease
of	O
ecto	O
-	O
mesodermal	O
development	O
.	O
	
Also	O
known	O
as	O
Goltz	B-Disease
syndrome	I-Disease
","	O
FDH	B-Disease
presents	O
with	O
characteristic	O
linear	O
streaks	O
of	O
hypoplastic	B-Disease
dermis	I-Disease
and	O
variable	O
abnormalities	O
of	O
bone	O
","	O
nails	O
","	O
hair	O
","	O
limbs	O
","	O
teeth	O
and	O
eyes	O
.	O
	
The	O
molecular	O
basis	O
of	O
FDH	B-Disease
involves	O
mutations	O
in	O
the	O
PORCN	O
gene	O
","	O
which	O
encodes	O
an	O
enzyme	O
that	O
allows	O
membrane	O
targeting	O
and	O
secretion	O
of	O
several	O
Wnt	O
proteins	O
critical	O
for	O
normal	O
tissue	O
development	O
.	O
	
OBJECTIVES	O
:	O
To	O
investigate	O
the	O
molecular	O
basis	O
of	O
FDH	B-Disease
in	O
a	O
2	O
-	O
year	O
-	O
old	O
Thai	O
girl	O
who	O
presented	O
at	O
birth	O
with	O
depressed	B-Disease
","	O
pale	O
linear	O
scars	O
on	O
the	O
trunk	O
and	O
limbs	O
","	O
sparse	O
brittle	O
hair	O
","	O
syndactyly	O
of	O
the	O
right	O
middle	O
and	O
ring	O
fingers	O
","	O
dental	B-Disease
caries	I-Disease
and	O
radiological	O
features	O
of	O
osteopathia	O
striata	O
.	O
	
METHODS	O
:	O
Sequencing	O
of	O
genomic	O
DNA	O
from	O
the	O
affected	O
individual	O
and	O
both	O
parents	O
to	O
search	O
for	O
pathogenic	O
mutations	O
in	O
PORCN	O
gene	O
.	O
	
RESULTS	O
:	O
DNA	O
sequencing	O
disclosed	O
a	O
heterozygous	O
G	O
>	O
T	O
substitution	O
at	O
nucleotide	O
c	O
.	O
898	O
within	O
exon	O
10	O
(	O
NM_203475	O
.	O
1	O
)","	O
converting	O
a	O
glutamic	O
acid	O
residue	O
(	O
GAA	O
)	O
to	O
a	O
premature	O
termination	O
codon	O
(	O
TAA	O
).	O
	
This	O
mutation	O
","	O
designated	O
p	O
.	O
E300X	O
","	O
was	O
not	O
detected	O
in	O
DNA	O
from	O
either	O
parent	O
or	O
in	O
100	O
control	O
chromosomes	O
.	O
	
CONCLUSION	O
:	O
Identification	O
of	O
this	O
new	O
de	O
novo	O
nonsense	O
mutation	O
confirms	O
the	O
diagnosis	O
of	O
FDH	B-Disease
in	O
this	O
child	O
and	O
highlights	O
the	O
clinical	O
importance	O
of	O
PORCN	O
and	O
Wnt	O
signalling	O
pathways	O
in	O
embryogenesis	O
.	O
	
	
A	O
recessive	B-Disease
skeletal	I-Disease
dysplasia	I-Disease
","	O
SEMD	B-Disease
aggrecan	O
type	O
","	O
results	O
from	O
a	O
missense	O
mutation	O
affecting	O
the	O
C	O
-	O
type	O
lectin	O
domain	O
of	O
aggrecan	O
.	O
	
Analysis	O
of	O
a	O
nuclear	O
family	O
with	O
three	O
affected	O
offspring	O
identified	O
an	O
autosomal	O
-	O
recessive	O
form	O
of	O
spondyloepimetaphyseal	B-Disease
dysplasia	I-Disease
characterized	O
by	O
severe	O
short	B-Disease
stature	I-Disease
and	O
a	O
unique	O
constellation	O
of	O
radiographic	O
findings	O
.	O
	
Homozygosity	O
for	O
a	O
haplotype	O
that	O
was	O
identical	O
by	O
descent	O
between	O
two	O
of	O
the	O
affected	O
individuals	O
identified	O
a	O
locus	O
for	O
the	O
disease	O
gene	O
within	O
a	O
17	O
.	O
4	O
Mb	O
interval	O
on	O
chromosome	O
15	O
","	O
a	O
region	O
containing	O
296	O
genes	O
.	O
	
These	O
genes	O
were	O
assessed	O
and	O
ranked	O
by	O
cartilage	O
selectivity	O
with	O
whole	O
-	O
genome	O
microarray	O
data	O
","	O
revealing	O
only	O
two	O
genes	O
","	O
encoding	O
aggrecan	O
and	O
chondroitin	O
sulfate	O
proteoglycan	O
4	O
","	O
that	O
were	O
selectively	O
expressed	O
in	O
cartilage	O
.	O
	
Sequence	O
analysis	O
of	O
aggrecan	O
complementary	O
DNA	O
from	O
an	O
affected	O
individual	O
revealed	O
homozygosity	O
for	O
a	O
missense	O
mutation	O
(	O
c	O
.	O
6799G	O
-->	O
A	O
)	O
that	O
predicts	O
a	O
p	O
.	O
D2267N	O
amino	O
acid	O
substitution	O
in	O
the	O
C	O
-	O
type	O
lectin	O
domain	O
within	O
the	O
G3	O
domain	O
of	O
aggrecan	O
.	O
	
The	O
D2267	O
residue	O
is	O
predicted	O
to	O
coordinate	O
binding	O
of	O
a	O
calcium	B-Chemical
ion	O
","	O
which	O
influences	O
the	O
conformational	O
binding	O
loops	O
of	O
the	O
C	O
-	O
type	O
lectin	O
domain	O
that	O
mediate	O
interactions	O
with	O
tenascins	O
and	O
other	O
extracellular	O
-	O
matrix	O
proteins	O
.	O
	
Expression	O
of	O
the	O
normal	O
and	O
mutant	O
G3	O
domains	O
in	O
mammalian	O
cells	O
showed	O
that	O
the	O
mutation	O
created	O
a	O
functional	O
N	O
-	O
glycosylation	O
site	O
but	O
did	O
not	O
adversely	O
affect	O
protein	O
trafficking	O
and	O
secretion	O
.	O
	
Surface	O
-	O
plasmon	O
-	O
resonance	O
studies	O
showed	O
that	O
the	O
mutation	O
influenced	O
the	O
binding	O
and	O
kinetics	O
of	O
the	O
interactions	O
between	O
the	O
aggrecan	O
G3	O
domain	O
and	O
tenascin	O
-	O
C	O
.	O
	
These	O
findings	O
identify	O
an	O
autosomal	B-Disease
-	I-Disease
recessive	I-Disease
skeletal	I-Disease
dysplasia	I-Disease
and	O
a	O
significant	O
role	O
for	O
the	O
aggrecan	O
C	O
-	O
type	O
lectin	O
domain	O
in	O
regulating	O
endochondral	O
ossification	O
and	O
","	O
thereby	O
","	O
height	O
.	O
	
	
Matriptase	O
-	O
2	O
mutations	O
in	O
iron	B-Chemical
-	O
refractory	O
iron	B-Disease
deficiency	I-Disease
anemia	I-Disease
patients	O
provide	O
new	O
insights	O
into	O
protease	O
activation	O
mechanisms	O
.	O
	
Mutations	O
leading	O
to	O
abrogation	O
of	O
matriptase	O
-	O
2	O
proteolytic	O
activity	O
in	O
humans	O
are	O
associated	O
with	O
an	O
iron	B-Disease
-	I-Disease
refractory	I-Disease
iron	I-Disease
deficiency	I-Disease
anemia	I-Disease
(	O
IRIDA	B-Disease
)	O
due	O
to	O
elevated	O
hepcidin	O
levels	O
.	O
	
Here	O
we	O
describe	O
two	O
novel	O
heterozygous	O
mutations	O
within	O
the	O
matriptase	O
-	O
2	O
(	O
TMPRSS6	O
)	O
gene	O
of	O
monozygotic	O
twin	O
girls	O
exhibiting	O
an	O
IRIDA	B-Disease
phenotype	O
.	O
	
The	O
first	O
is	O
the	O
frameshift	O
mutation	O
(	O
P686fs	O
)	O
caused	O
by	O
the	O
insertion	O
of	O
the	O
four	O
nucleotides	O
CCCC	O
in	O
exon	O
16	O
(	O
2172_2173insCCCC	O
)	O
that	O
is	O
predicted	O
to	O
terminate	O
translation	O
before	O
the	O
catalytic	O
serine	O
.	O
	
The	O
second	O
mutation	O
is	O
the	O
di	O
-	O
nucleotide	O
substitution	O
c	O
.	O
467C	O
>	O
A	O
and	O
c	O
.	O
468C	O
>	O
T	O
in	O
exon	O
3	O
that	O
causes	O
the	O
missense	O
mutation	O
A118D	O
in	O
the	O
SEA	O
domain	O
of	O
the	O
extracellular	O
stem	O
region	O
of	O
matriptase	O
-	O
2	O
.	O
	
Functional	O
analysis	O
of	O
both	O
variant	O
matriptase	O
-	O
2	O
proteases	O
has	O
revealed	O
that	O
they	O
lead	O
to	O
ineffective	O
suppression	O
of	O
hepcidin	O
transcription	O
.	O
	
We	O
also	O
demonstrate	O
that	O
the	O
A118D	O
SEA	O
domain	O
mutation	O
causes	O
an	O
intra	O
-	O
molecular	O
structural	O
imbalance	O
that	O
impairs	O
matriptase	O
-	O
2	O
activation	O
.	O
	
Collectively	O
","	O
these	O
results	O
extend	O
the	O
pattern	O
of	O
TMPRSS6	O
mutations	O
associated	O
with	O
IRIDA	B-Disease
and	O
functionally	O
demonstrate	O
that	O
mutations	O
affecting	O
protease	O
regions	O
other	O
than	O
the	O
catalytic	O
domain	O
may	O
have	O
a	O
profound	O
impact	O
in	O
the	O
regulatory	O
role	O
of	O
matriptase	O
-	O
2	O
during	O
iron	B-Disease
deficiency	I-Disease
.	O
	
	
Smoking	O
of	O
crack	B-Chemical
cocaine	I-Chemical
as	O
a	O
risk	O
factor	O
for	O
HIV	B-Disease
infection	I-Disease
among	O
people	O
who	O
use	O
injection	O
drugs	O
.	O
	
BACKGROUND	O
:	O
Little	O
is	O
known	O
about	O
the	O
possible	O
role	O
that	O
smoking	O
crack	B-Chemical
cocaine	I-Chemical
has	O
on	O
the	O
incidence	O
of	O
HIV	B-Disease
infection	I-Disease
.	O
	
Given	O
the	O
increasing	O
use	O
of	O
crack	B-Chemical
cocaine	I-Chemical
","	O
we	O
sought	O
to	O
examine	O
whether	O
use	O
of	O
this	O
illicit	O
drug	O
has	O
become	O
a	O
risk	O
factor	O
for	O
HIV	B-Disease
infection	I-Disease
.	O
	
METHODS	O
:	O
We	O
included	O
data	O
from	O
people	O
participating	O
in	O
the	O
Vancouver	O
Injection	O
Drug	O
Users	O
Study	O
who	O
reported	O
injecting	O
illicit	O
drugs	O
at	O
least	O
once	O
in	O
the	O
month	O
before	O
enrolment	O
","	O
lived	O
in	O
the	O
greater	O
Vancouver	O
area	O
","	O
were	O
HIV	B-Disease
-	O
negative	O
at	O
enrolment	O
and	O
completed	O
at	O
least	O
1	O
follow	O
-	O
up	O
study	O
visit	O
.	O
	
To	O
determine	O
whether	O
the	O
risk	O
of	O
HIV	B-Disease
seroconversion	I-Disease
among	O
daily	O
smokers	O
of	O
crack	B-Chemical
cocaine	I-Chemical
changed	O
over	O
time	O
","	O
we	O
used	O
Cox	O
proportional	O
hazards	O
regression	O
and	O
divided	O
the	O
study	O
into	O
3	O
periods	O
:	O
May	O
1	O
","	O
1996	O
-	O
Nov	O
.	O
	
30	O
","	O
1999	O
(	O
period	O
1	O
)","	O
Dec	O
.	O
	
1	O
","	O
1999	O
-	O
Nov	O
.	O
	
30	O
","	O
2002	O
(	O
period	O
2	O
)","	O
and	O
Dec	O
.	O
	
1	O
","	O
2002	O
-	O
Dec	O
.	O
	
30	O
","	O
2005	O
(	O
period	O
3	O
).	O
	
RESULTS	O
:	O
Overall	O
","	O
1048	O
eligible	O
injection	O
drug	O
users	O
were	O
included	O
in	O
our	O
study	O
.	O
	
Of	O
these	O
","	O
137	O
acquired	O
HIV	B-Disease
infection	I-Disease
during	O
follow	O
-	O
up	O
.	O
	
The	O
mean	O
proportion	O
of	O
participants	O
who	O
reported	O
daily	O
smoking	O
of	O
crack	B-Chemical
cocaine	I-Chemical
increased	O
from	O
11	O
.	O
6	O
%	O
in	O
period	O
1	O
to	O
39	O
.	O
7	O
%	O
in	O
period	O
3	O
.	O
	
After	O
adjusting	O
for	O
potential	O
confounders	O
","	O
we	O
found	O
that	O
the	O
risk	O
of	O
HIV	B-Disease
seroconversion	I-Disease
among	O
participants	O
who	O
were	O
daily	O
smokers	O
of	O
crack	B-Chemical
cocaine	I-Chemical
increased	O
over	O
time	O
(	O
period	O
1	O
:	O
hazard	O
ratio	O
[	O
HR	O
]	O
1	O
.	O
3	O
","	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
0	O
.	O
57	O
-	O
1	O
.	O
85	O
";"	O
period	O
2	O
:	O
HR	O
1	O
.	O
68	O
","	O
95	O
%	O
CI	O
1	O
.	O
1	O
-	O
2	O
.	O
80	O
";"	O
and	O
period	O
3	O
:	O
HR	O
2	O
.	O
74	O
","	O
95	O
%	O
CI	O
1	O
.	O
6	O
-	O
7	O
.	O
11	O
).	O
	
INTERPRETATION	O
:	O
Smoking	O
of	O
crack	B-Chemical
cocaine	I-Chemical
was	O
found	O
to	O
be	O
an	O
independent	O
risk	O
factor	O
for	O
HIV	B-Disease
seroconversion	I-Disease
among	O
people	O
who	O
were	O
injection	O
drug	O
users	O
.	O
	
This	O
finding	O
points	O
to	O
the	O
urgent	O
need	O
for	O
evidence	O
-	O
based	O
public	O
health	O
initiatives	O
targeted	O
at	O
people	O
who	O
smoke	O
crack	B-Chemical
cocaine	I-Chemical
.	O
	
	
Roles	O
of	O
G1359A	O
polymorphism	O
of	O
the	O
cannabinoid	O
receptor	O
gene	O
(	O
CNR1	O
)	O
on	O
weight	B-Disease
loss	I-Disease
and	O
adipocytokines	O
after	O
a	O
hypocaloric	O
diet	O
.	O
	
BACKGROUND	O
:	O
A	O
intragenic	O
biallelic	O
polymorphism	O
(	O
1359	O
G	O
/	O
A	O
)	O
of	O
the	O
CB1	O
gene	O
resulting	O
in	O
the	O
substitution	O
of	O
the	O
G	O
to	O
A	O
at	O
nucleotide	O
position	O
1359	O
in	O
codon	O
435	O
(	O
Thr	O
)","	O
was	O
reported	O
as	O
a	O
common	O
polymorphism	O
in	O
Caucasian	O
populations	O
.	O
	
Intervention	O
studies	O
with	O
this	O
polymorphism	O
have	O
not	O
been	O
realized	O
.	O
	
OBJECTIVE	O
:	O
We	O
decided	O
to	O
investigate	O
the	O
role	O
of	O
the	O
polymorphism	O
(	O
G1359A	O
)	O
of	O
CB1	O
receptor	O
gene	O
on	O
adipocytokines	O
response	O
and	O
weight	B-Disease
loss	I-Disease
secondary	O
to	O
a	O
lifestyle	O
modification	O
(	O
Mediterranean	O
hypocaloric	O
diet	O
and	O
exercise	O
)	O
in	O
obese	B-Disease
patients	O
.	O
	
DESIGN	O
:	O
A	O
population	O
of	O
94	O
patients	O
with	O
obesity	B-Disease
was	O
analyzed	O
.	O
	
Before	O
and	O
after	O
3	O
months	O
on	O
a	O
hypocaloric	O
diet	O
","	O
an	O
anthropometric	O
evaluation	O
","	O
an	O
assessment	O
of	O
nutritional	O
intake	O
and	O
a	O
biochemical	O
analysis	O
were	O
performed	O
.	O
	
The	O
statistical	O
analysis	O
was	O
performed	O
for	O
the	O
combined	O
G1359A	O
and	O
A1359A	O
as	O
a	O
group	O
and	O
wild	O
type	O
G1359G	O
as	O
second	O
group	O
","	O
with	O
a	O
dominant	O
model	O
.	O
	
Results	O
:	O
Forty	O
seven	O
patients	O
(	O
50	O
%)	O
had	O
the	O
genotype	O
G1359G	O
(	O
wild	O
type	O
group	O
)	O
and	O
47	O
(	O
50	O
%)	O
patients	O
G1359A	O
(	O
41	O
patients	O
","	O
43	O
.	O
6	O
%)	O
or	O
A1359A	O
(	O
6	O
patients	O
","	O
6	O
.	O
4	O
%)	O
(	O
mutant	O
type	O
group	O
)	O
had	O
the	O
genotype	O
.	O
	
In	O
wild	O
and	O
mutant	O
type	O
groups	O
","	O
weight	O
","	O
body	O
mass	O
index	O
","	O
fat	O
mass	O
","	O
waist	O
circumference	O
and	O
systolic	O
blood	O
pressure	O
decreased	O
.	O
	
In	O
mutant	O
type	O
group	O
","	O
resistin	O
(	O
4	O
.	O
15	O
1	O
.	O
7	O
ng	O
/	O
ml	O
vs	O
.	O
	
3	O
.	O
90	O
2	O
.	O
1	O
ng	O
/	O
ml	O
:	O
P	O
<	O
0	O
.	O
5	O
)","	O
leptin	O
(	O
78	O
.	O
4	O
69	O
ng	O
/	O
ml	O
vs	O
66	O
.	O
2	O
32	O
ng	O
/	O
ml	O
:	O
P	O
<	O
0	O
.	O
5	O
)	O
and	O
IL	O
-	O
6	O
(	O
1	O
.	O
40	O
1	O
.	O
9	O
pg	O
/	O
ml	O
vs	O
0	O
.	O
81	O
1	O
.	O
5	O
pg	O
/	O
ml	O
:	O
P	O
<	O
0	O
.	O
5	O
)	O
levels	O
decreased	O
after	O
dietary	O
treatment	O
.	O
	
CONCLUSION	O
:	O
The	O
novel	O
finding	O
of	O
this	O
study	O
is	O
the	O
association	O
of	O
the	O
mutant	O
allele	O
(	O
A1359	O
)	O
with	O
a	O
decrease	O
of	O
resistin	O
","	O
leptin	O
and	O
interleukin	O
-	O
6	O
secondary	O
to	O
weight	B-Disease
loss	I-Disease
.	O
	
	
HIV	O
-	O
1	O
Tat	O
activates	O
indoleamine	O
2	O
","	O
3	O
dioxygenase	O
in	O
murine	O
organotypic	O
hippocampal	O
slice	O
cultures	O
in	O
a	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
-	O
dependent	O
manner	O
.	O
	
BACKGROUND	O
:	O
We	O
have	O
established	O
that	O
activation	O
of	O
the	O
tryptophan	B-Chemical
degrading	O
enzyme	O
indoleamine	O
2	O
","	O
3	O
dioxygenase	O
(	O
IDO	O
)	O
mediates	O
the	O
switch	O
from	O
cytokine	O
-	O
induced	O
sickness	O
behavior	O
to	O
depressive	B-Disease
-	O
like	O
behavior	O
.	O
	
Because	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
Tat	O
protein	O
causes	O
depressive	B-Disease
-	O
like	O
behavior	O
in	O
mice	O
","	O
we	O
investigated	O
its	O
ability	O
to	O
activate	O
IDO	O
in	O
organotypic	O
hippocampal	O
slice	O
cultures	O
(	O
OHSCs	O
)	O
derived	O
from	O
neonatal	O
C57BL	O
/	O
6	O
mice	O
.	O
	
METHODS	O
:	O
Depressive	B-Disease
-	O
like	O
behavior	O
in	O
C57BL	O
/	O
6J	O
mice	O
was	O
assessed	O
by	O
the	O
forced	O
swim	O
test	O
.	O
	
Expression	O
of	O
cytokines	O
and	O
IDO	O
mRNA	O
in	O
OHSCs	O
was	O
measured	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
and	O
cytokine	O
protein	O
was	O
measured	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
(	O
ELISAs	O
).	O
	
p38	O
MAPK	O
phosphorylation	O
was	O
analyzed	O
by	O
western	O
blot	O
.	O
	
RESULTS	O
:	O
Intracerebroventricular	O
(	O
i	O
.	O
c	O
.	O
v	O
.)	O
	
administration	O
of	O
Tat	O
(	O
40	O
ng	O
)	O
induced	O
depressive	B-Disease
-	O
like	O
behavior	O
in	O
the	O
absence	O
of	O
sickness	O
.	O
	
Addition	O
of	O
Tat	O
(	O
40	O
ng	O
/	O
slice	O
)	O
to	O
the	O
medium	O
of	O
OHSCs	O
induced	O
IDO	O
steady	O
-	O
state	O
mRNA	O
that	O
peaked	O
at	O
6	O
h	O
.	O
This	O
effect	O
was	O
potentiated	O
by	O
pretreatment	O
with	O
IFNg	O
.	O
	
Tat	O
also	O
induced	O
the	O
synthesis	O
and	O
release	O
of	O
TNFa	O
and	O
IL	O
-	O
6	O
protein	O
in	O
the	O
supernatant	O
of	O
the	O
slices	O
and	O
increased	O
expression	O
of	O
the	O
inducible	O
isoform	O
of	O
nitric	O
oxide	O
synthase	O
(	O
iNOS	O
)	O
and	O
the	O
serotonin	O
transporter	O
(	O
SERT	O
).	O
	
Tat	O
had	O
no	O
effect	O
on	O
endogenous	O
synthesis	O
of	O
IFNg	O
.	O
	
To	O
explore	O
the	O
mechanisms	O
of	O
Tat	O
-	O
induced	O
IDO	O
expression	O
","	O
slices	O
were	O
pretreated	O
with	O
the	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
inhibitor	O
SB	B-Chemical
202190	I-Chemical
for	O
30	O
min	O
before	O
Tat	O
treatment	O
.	O
	
SB	B-Chemical
202190	I-Chemical
significantly	O
decreased	O
IDO	O
expression	O
induced	O
by	O
Tat	O
","	O
and	O
this	O
effect	O
was	O
accompanied	O
by	O
a	O
reduction	O
of	O
Tat	O
-	O
induced	O
expression	O
of	O
TNFa	O
","	O
IL	O
-	O
6	O
","	O
iNOS	O
and	O
SERT	O
.	O
	
CONCLUSION	O
:	O
These	O
data	O
establish	O
that	O
Tat	O
induces	O
IDO	O
expression	O
via	O
an	O
IFNg	O
-	O
independent	O
mechanism	O
that	O
depends	O
upon	O
activation	O
of	O
p38	O
MAPK	O
.	O
	
Targeting	O
IDO	O
itself	O
or	O
the	O
p38	O
MAPK	O
signaling	O
pathway	O
could	O
provide	O
a	O
novel	O
therapy	O
for	O
comorbid	O
depressive	B-Disease
disorders	I-Disease
in	O
HIV	B-Disease
-	I-Disease
1	I-Disease
-	I-Disease
infected	I-Disease
patients	O
.	O
	
	
Gastrointestinal	B-Chemical
hormones	I-Chemical
/	O
neurotransmitters	B-Chemical
and	O
growth	O
factors	O
can	O
activate	O
P21	O
activated	O
kinase	O
2	O
in	O
pancreatic	O
acinar	O
cells	O
by	O
novel	O
mechanisms	O
.	O
	
P	O
-	O
21	O
-	O
activated	O
kinases	O
(	O
PAKs	O
)	O
are	O
serine	O
/	O
threonine	O
kinases	O
comprising	O
six	O
isoforms	O
divided	O
in	O
two	O
groups	O
","	O
group	O
-	O
I	O
(	O
PAK1	O
-	O
3	O
)/	O
group	O
-	O
II	O
(	O
PAK4	O
-	O
6	O
)	O
which	O
play	O
important	O
roles	O
in	O
cell	O
cytoskeletal	O
dynamics	O
","	O
survival	O
","	O
secretion	O
and	O
proliferation	O
and	O
are	O
activated	O
by	O
diverse	O
stimuli	O
.	O
	
However	O
","	O
little	O
is	O
known	O
about	O
PAKs	O
ability	O
to	O
be	O
activated	O
by	O
gastrointestinal	B-Chemical
(	I-Chemical
GI	I-Chemical
)	I-Chemical
hormones	I-Chemical
/	O
neurotransmitters	B-Chemical
/	O
growth	O
-	O
factors	O
.	O
	
We	O
used	O
rat	O
pancreatic	O
acini	O
to	O
explore	O
the	O
ability	O
of	O
GI	B-Chemical
-	I-Chemical
hormones	I-Chemical
/	O
neurotransmitters	B-Chemical
/	O
growth	O
-	O
factors	O
to	O
activate	O
Group	O
-	O
I	O
-	O
PAKs	O
and	O
the	O
signaling	O
cascades	O
involved	O
.	O
	
Only	O
PAK2	O
was	O
present	O
in	O
acini	O
.	O
	
PAK2	O
was	O
activated	O
by	O
some	O
pancreatic	O
growth	O
-	O
factors	O
[	O
EGF	O
","	O
PDGF	O
","	O
bFGF	O
]","	O
by	O
secretagogues	O
activating	O
phospholipase	O
-	O
C	O
(	O
PLC	O
)	O
[	O
CCK	O
","	O
carbachol	B-Chemical
","	O
bombesin	B-Chemical
]	O
and	O
by	O
post	O
-	O
receptor	O
stimulants	O
activating	O
PKC	O
[	O
TPA	B-Chemical
]","	O
but	O
not	O
agents	O
only	O
mobilizing	O
cellular	O
calcium	B-Chemical
or	O
increasing	O
cyclic	B-Chemical
AMP	I-Chemical
.	O
	
CCK	O
-	O
activation	O
of	O
PAK2	O
required	O
both	O
high	O
-	O
and	O
low	O
-	O
affinity	O
-	O
CCK1	O
-	O
receptor	O
-	O
state	O
activation	O
.	O
	
It	O
was	O
partially	O
reduced	O
by	O
PKC	O
-	O
or	O
Src	O
-	O
inhibition	O
","	O
but	O
not	O
with	O
PI3K	O
-	O
inhibitors	O
(	O
wortmannin	B-Chemical
","	O
LY294002	B-Chemical
)	O
or	O
thapsigargin	B-Chemical
.	O
	
IPA	B-Chemical
-	I-Chemical
3	I-Chemical
","	O
which	O
prevents	O
PAK2	O
binding	O
to	O
small	O
-	O
GTPases	O
partially	O
inhibited	O
PAK2	O
-	O
activation	O
","	O
as	O
well	O
as	O
reduced	O
CCK	O
-	O
induced	O
ERK1	O
/	O
2	O
activation	O
and	O
amylase	O
release	O
induced	O
by	O
CCK	O
or	O
bombesin	B-Chemical
.	O
	
This	O
study	O
demonstrates	O
pancreatic	O
acini	O
","	O
possess	O
only	O
one	O
Group	O
-	O
I	O
-	O
PAK	O
","	O
PAK2	O
.	O
	
CCK	O
and	O
other	O
GI	B-Chemical
-	I-Chemical
hormones	I-Chemical
/	O
neurotransmitters	B-Chemical
/	O
growth	O
-	O
factors	O
activate	O
PAK2	O
via	O
small	O
GTPases	O
(	O
CDC42	O
/	O
Rac1	O
)","	O
PKC	O
and	O
SFK	O
but	O
not	O
cytosolic	O
calcium	B-Chemical
or	O
PI3K	O
.	O
	
CCK	O
-	O
activation	O
of	O
PAK2	O
showed	O
several	O
novel	O
features	O
being	O
dependent	O
on	O
both	O
receptor	O
-	O
activation	O
states	O
","	O
having	O
PLC	O
-	O
and	O
PKC	O
-	O
dependent	O
/	O
independent	O
components	O
and	O
small	O
-	O
GTPase	O
-	O
dependent	O
/	O
independent	O
components	O
.	O
	
These	O
results	O
show	O
that	O
PAK2	O
is	O
important	O
in	O
signaling	O
cascades	O
activated	O
by	O
numerous	O
pancreatic	O
stimuli	O
which	O
mediate	O
their	O
various	O
physiological	O
/	O
pathophysiological	O
responses	O
and	O
thus	O
could	O
be	O
a	O
promising	O
target	O
for	O
the	O
development	O
of	O
therapies	O
in	O
some	O
pancreatic	B-Disease
disorders	I-Disease
such	O
as	O
pancreatitis	B-Disease
.	O
	
	
Whole	O
-	O
Organism	O
Developmental	O
Expression	O
Profiling	O
Identifies	O
RAB	O
-	O
28	O
as	O
a	O
Novel	O
Ciliary	O
GTPase	O
Associated	O
with	O
the	O
BBSome	O
and	O
Intraflagellar	O
Transport	O
.	O
	
Primary	O
cilia	O
are	O
specialised	O
sensory	O
and	O
developmental	O
signalling	O
devices	O
extending	O
from	O
the	O
surface	O
of	O
most	O
eukaryotic	O
cells	O
.	O
	
Defects	O
in	O
these	O
organelles	O
cause	O
inherited	B-Disease
human	I-Disease
disorders	I-Disease
(	O
ciliopathies	B-Disease
)	O
such	O
as	O
retinitis	B-Disease
pigmentosa	I-Disease
and	O
Bardet	B-Disease
-	I-Disease
Biedl	I-Disease
syndrome	I-Disease
(	O
BBS	B-Disease
)","	O
frequently	O
affecting	O
many	O
physiological	O
and	O
developmental	O
processes	O
across	O
multiple	O
organs	O
.	O
	
Cilium	O
formation	O
","	O
maintenance	O
and	O
function	O
depend	O
on	O
intracellular	O
transport	O
systems	O
such	O
as	O
intraflagellar	O
transport	O
(	O
IFT	O
)","	O
which	O
is	O
driven	O
by	O
kinesin	O
-	O
2	O
and	O
IFT	O
-	O
dynein	O
motors	O
and	O
regulated	O
by	O
the	O
Bardet	O
-	O
Biedl	O
syndrome	O
(	O
BBS	O
)	O
cargo	O
-	O
adaptor	O
protein	O
complex	O
","	O
or	O
BBSome	O
.	O
	
To	O
identify	O
new	O
cilium	O
-	O
associated	O
genes	O
","	O
we	O
employed	O
the	O
nematode	O
C	O
.	O
elegans	O
","	O
where	O
ciliogenesis	O
occurs	O
within	O
a	O
short	O
timespan	O
during	O
late	O
embryogenesis	O
when	O
most	O
sensory	O
neurons	O
differentiate	O
.	O
	
Using	O
whole	O
-	O
organism	O
RNA	O
-	O
Seq	O
libraries	O
","	O
we	O
discovered	O
a	O
signature	O
expression	O
profile	O
highly	O
enriched	O
for	O
transcripts	O
of	O
known	O
ciliary	O
proteins	O
","	O
including	O
FAM	O
-	O
161	O
(	O
FAM161A	O
orthologue	O
)","	O
CCDC	O
-	O
104	O
(	O
CCDC104	O
)","	O
and	O
RPI	O
-	O
1	O
(	O
RP1	O
/	O
RP1L1	O
)","	O
which	O
we	O
confirm	O
are	O
cilium	O
-	O
localised	O
in	O
worms	O
.	O
	
From	O
a	O
list	O
of	O
185	O
candidate	O
ciliary	O
genes	O
","	O
we	O
uncover	O
orthologues	O
of	O
human	O
MAP9	O
","	O
YAP	O
","	O
CCDC149	O
","	O
and	O
RAB28	O
as	O
conserved	O
cilium	O
-	O
associated	O
components	O
.	O
	
Further	O
analyses	O
of	O
C	O
.	O
elegans	O
RAB	O
-	O
28	O
","	O
recently	O
associated	O
with	O
autosomal	O
-	O
recessive	O
cone	B-Disease
-	I-Disease
rod	I-Disease
dystrophy	I-Disease
","	O
reveal	O
that	O
this	O
small	O
GTPase	O
is	O
exclusively	O
expressed	O
in	O
ciliated	O
neurons	O
where	O
it	O
dynamically	O
associates	O
with	O
IFT	O
trains	O
.	O
	
Whereas	O
inactive	O
GDP	B-Chemical
-	O
bound	O
RAB	O
-	O
28	O
displays	O
no	O
IFT	O
movement	O
and	O
diffuse	O
localisation	O
","	O
GTP	B-Chemical
-	O
bound	O
(	O
activated	O
)	O
RAB	O
-	O
28	O
concentrates	O
at	O
the	O
periciliary	O
membrane	O
in	O
a	O
BBSome	O
-	O
dependent	O
manner	O
and	O
undergoes	O
bidirectional	O
IFT	O
.	O
	
Functional	O
analyses	O
reveal	O
that	O
whilst	O
cilium	O
structure	O
","	O
sensory	O
function	O
and	O
IFT	O
are	O
seemingly	O
normal	O
in	O
a	O
rab	O
-	O
28	O
null	O
allele	O
","	O
overexpression	O
of	O
predicted	O
GDP	B-Chemical
or	O
GTP	B-Chemical
locked	O
variants	O
of	O
RAB	O
-	O
28	O
perturbs	O
cilium	O
and	O
sensory	O
pore	O
morphogenesis	O
and	O
function	O
.	O
	
Collectively	O
","	O
our	O
findings	O
present	O
a	O
new	O
approach	O
for	O
identifying	O
ciliary	O
proteins	O
","	O
and	O
unveil	O
RAB28	O
","	O
a	O
GTPase	O
most	O
closely	O
related	O
to	O
the	O
BBS	B-Disease
protein	O
RABL4	O
/	O
IFT27	O
","	O
as	O
an	O
IFT	O
-	O
associated	O
cargo	O
with	O
BBSome	O
-	O
dependent	O
cell	O
autonomous	O
and	O
non	O
-	O
autonomous	O
functions	O
at	O
the	O
ciliary	O
base	O
.	O
	
	
Dynamic	O
subunit	O
turnover	O
in	O
ESCRT	O
-	O
III	O
assemblies	O
is	O
regulated	O
by	O
Vps4	O
to	O
mediate	O
membrane	O
remodelling	O
during	O
cytokinesis	O
.	O
	
The	O
endosomal	O
sorting	O
complex	O
required	O
for	O
transport	O
(	O
ESCRT	O
)-	O
III	O
mediates	O
membrane	O
fission	O
in	O
fundamental	O
cellular	O
processes	O
","	O
including	O
cytokinesis	O
.	O
	
ESCRT	O
-	O
III	O
is	O
thought	O
to	O
form	O
persistent	O
filaments	O
that	O
over	O
time	O
increase	O
their	O
curvature	O
to	O
constrict	O
membranes	O
.	O
	
Unexpectedly	O
","	O
we	O
found	O
that	O
ESCRT	O
-	O
III	O
at	O
the	O
midbody	O
of	O
human	O
cells	O
rapidly	O
turns	O
over	O
subunits	O
with	O
cytoplasmic	O
pools	O
while	O
gradually	O
forming	O
larger	O
assemblies	O
.	O
	
ESCRT	O
-	O
III	O
turnover	O
depended	O
on	O
the	O
ATPase	O
VPS4	O
","	O
which	O
accumulated	O
at	O
the	O
midbody	O
simultaneously	O
with	O
ESCRT	O
-	O
III	O
subunits	O
","	O
and	O
was	O
required	O
for	O
assembly	O
of	O
functional	O
ESCRT	O
-	O
III	O
structures	O
.	O
	
In	O
vitro	O
","	O
the	O
Vps2	O
/	O
Vps24	O
subunits	O
of	O
ESCRT	O
-	O
III	O
formed	O
side	O
-	O
by	O
-	O
side	O
filaments	O
with	O
Snf7	O
and	O
inhibited	O
further	O
polymerization	O
","	O
but	O
the	O
growth	O
inhibition	O
was	O
alleviated	O
by	O
the	O
addition	O
of	O
Vps4	O
and	O
ATP	B-Chemical
.	O
	
High	O
-	O
speed	O
atomic	O
force	O
microscopy	O
further	O
revealed	O
highly	O
dynamic	O
arrays	O
of	O
growing	O
and	O
shrinking	O
ESCRT	O
-	O
III	O
spirals	O
in	O
the	O
presence	O
of	O
Vps4	O
.	O
	
Continuous	O
ESCRT	O
-	O
III	O
remodelling	O
by	O
subunit	O
turnover	O
might	O
facilitate	O
shape	O
adaptions	O
to	O
variable	O
membrane	O
geometries	O
","	O
with	O
broad	O
implications	O
for	O
diverse	O
cellular	O
processes	O
.	O
	
	
The	O
effects	O
of	O
short	O
-	O
term	O
raloxifene	B-Chemical
therapy	O
on	O
fibrinolysis	O
markers	O
:	O
TAFI	O
","	O
tPA	O
","	O
and	O
PAI	O
-	O
1	O
.	O
	
BACKGROUND	O
:	O
Markers	O
of	O
fibrinolysis	O
","	O
thrombin	O
-	O
activatable	O
fibrinolysis	O
inhibitor	O
(	O
TAFI	O
)","	O
tissue	O
-	O
type	O
plasminogen	O
activator	O
(	O
tPA	O
)","	O
and	O
plasminogen	O
activator	O
inhibitor	O
-	O
1	O
(	O
PAI	O
-	O
1	O
)	O
levels	O
were	O
studied	O
for	O
the	O
evaluation	O
of	O
short	O
-	O
term	O
effects	O
of	O
raloxifene	B-Chemical
administration	O
in	O
postmenopausal	O
women	O
.	O
	
METHODS	O
:	O
Thirty	O
-	O
nine	O
postmenopausal	O
women	O
with	O
osteopenia	B-Disease
or	O
osteoporosis	B-Disease
were	O
included	O
in	O
this	O
prospective	O
","	O
controlled	O
clinical	O
study	O
.	O
	
Twenty	O
-	O
five	O
women	O
were	O
given	O
raloxifene	B-Chemical
hydrochloride	I-Chemical
(	O
60	O
mg	O
/	O
day	O
)	O
plus	O
calcium	B-Chemical
(	O
500	O
mg	O
/	O
day	O
).	O
	
Age	O
-	O
matched	O
controls	O
(	O
n	O
=	O
14	O
)	O
were	O
given	O
only	O
calcium	B-Chemical
.	O
	
Plasma	O
TAFI	O
","	O
tPA	O
","	O
and	O
PAI	O
-	O
1	O
antigen	O
levels	O
were	O
measured	O
at	O
baseline	O
and	O
after	O
3	O
months	O
of	O
treatment	O
by	O
commercially	O
available	O
ELISA	O
kits	O
.	O
	
Variations	O
of	O
individuals	O
were	O
assessed	O
by	O
Wilcoxon	O
'	O
s	O
test	O
.	O
	
Relationship	O
between	O
those	O
markers	O
and	O
demographic	O
characteristics	O
were	O
investigated	O
.	O
	
RESULTS	O
:	O
Three	O
months	O
of	O
raloxifene	B-Chemical
treatment	O
was	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
the	O
plasma	O
TAFI	O
antigen	O
concentrations	O
(	O
16	O
%	O
change	O
","	O
P	O
<	O
0	O
.	O
1	O
)","	O
and	O
a	O
significant	O
increase	O
in	O
tPA	O
antigen	O
concentrations	O
(	O
25	O
%	O
change	O
","	O
P	O
<	O
0	O
.	O
5	O
).	O
	
A	O
significant	O
correlation	O
was	O
found	O
between	O
baseline	O
TAFI	O
antigen	O
concentrations	O
and	O
the	O
duration	O
of	O
amenorrhea	O
(	O
P	O
<	O
0	O
.	O
5	O
";"	O
r	O
=	O
0	O
.	O
33	O
).	O
	
CONCLUSION	O
:	O
We	O
suggest	O
that	O
the	O
increased	O
risk	O
of	O
venous	B-Disease
thromboembolism	I-Disease
due	O
to	O
raloxifene	B-Chemical
treatment	O
may	O
be	O
related	O
to	O
increased	O
tPA	O
levels	O
","	O
but	O
not	O
TAFI	O
levels	O
.	O
	
	
Ectodermal	B-Disease
dysplasia	I-Disease
-	I-Disease
skin	I-Disease
fragility	I-Disease
syndrome	I-Disease
resulting	O
from	O
a	O
new	O
homozygous	O
mutation	O
","	O
888delC	O
","	O
in	O
the	O
desmosomal	O
protein	O
plakophilin	O
1	O
.	O
	
We	O
report	O
an	O
unusual	O
case	O
of	O
an	O
inherited	B-Disease
disorder	I-Disease
of	O
the	O
desmosomal	O
protein	O
plakophilin	O
1	O
","	O
resulting	O
in	O
ectodermal	B-Disease
dysplasia	I-Disease
-	I-Disease
skin	I-Disease
fragility	I-Disease
syndrome	I-Disease
.	O
	
The	O
affected	O
6	O
-	O
year	O
-	O
old	O
boy	O
had	O
red	O
skin	O
at	O
birth	O
and	O
subsequently	O
developed	O
skin	B-Disease
fragility	I-Disease
","	O
progressive	O
plantar	B-Disease
keratoderma	I-Disease
","	O
nail	B-Disease
dystrophy	I-Disease
","	O
and	O
alopecia	B-Disease
.	O
	
Skin	O
biopsy	O
revealed	O
widening	O
of	O
intercellular	O
spaces	O
in	O
the	O
epidermis	O
and	O
a	O
reduced	O
number	O
of	O
small	O
","	O
poorly	O
formed	O
desmosomes	O
.	O
	
Mutation	O
analysis	O
of	O
the	O
plakophilin	O
1	O
gene	O
PKP1	O
revealed	O
a	O
homozygous	O
deletion	O
of	O
C	O
at	O
nucleotide	O
888	O
within	O
exon	O
5	O
.	O
	
This	O
mutation	O
differs	O
from	O
the	O
PKP1	O
gene	O
pathology	O
reported	O
in	O
8	O
previously	O
published	O
individuals	O
with	O
this	O
rare	O
genodermatosis	B-Disease
.	O
	
However	O
","	O
all	O
cases	O
show	O
similar	O
clinical	O
features	O
","	O
highlighting	O
the	O
importance	O
of	O
functional	O
plakophilin	O
1	O
in	O
maintaining	O
desmosomal	O
adhesion	O
in	O
skin	O
","	O
as	O
well	O
as	O
the	O
role	O
of	O
this	O
protein	O
in	O
aspects	O
of	O
ectodermal	O
development	O
.	O
	
	
DNA	O
damage	O
and	O
repair	O
in	O
gastric	B-Disease
cancer	I-Disease
--	O
a	O
correlation	O
with	O
the	O
hOGG1	O
and	O
RAD51	O
genes	O
polymorphisms	O
.	O
	
The	O
cell	O
'	O
s	O
susceptibility	O
to	O
mutagens	O
and	O
its	O
ability	O
to	O
repair	O
DNA	O
lesions	O
are	O
important	O
for	O
cancer	B-Disease
induction	O
","	O
promotion	O
and	O
progression	O
.	O
	
Both	O
the	O
mutagens	O
'	O
sensitivity	O
and	O
the	O
efficacy	O
of	O
DNA	O
repair	O
may	O
be	O
affected	O
by	O
variation	O
in	O
several	O
genes	O
","	O
including	O
DNA	O
repair	O
genes	O
.	O
	
The	O
hOGG1	O
gene	O
encodes	O
glycosylase	O
of	O
base	O
excision	O
repair	O
and	O
RAD51	O
specifies	O
a	O
key	O
protein	O
in	O
homologues	O
recombination	O
repair	O
.	O
	
Both	O
can	O
be	O
involved	O
in	O
the	O
repair	O
of	O
oxidative	O
DNA	O
lesions	O
","	O
which	O
can	O
contribute	O
to	O
stomach	B-Disease
cancer	I-Disease
.	O
	
In	O
the	O
present	O
work	O
we	O
determined	O
the	O
level	O
of	O
basal	O
and	O
oxidative	O
DNA	O
damage	O
and	O
the	O
kinetics	O
of	O
removal	O
of	O
DNA	O
damage	O
induced	O
by	O
hydrogen	B-Chemical
peroxide	I-Chemical
in	O
peripheral	O
blood	O
lymphocytes	O
of	O
30	O
gastric	B-Disease
cancer	I-Disease
patients	O
and	O
30	O
healthy	O
individuals	O
.	O
	
The	O
metrics	O
from	O
DNA	O
damage	O
and	O
repair	O
study	O
were	O
correlated	O
with	O
the	O
genotypes	O
of	O
common	O
polymorphisms	O
of	O
the	O
hOGG1	O
and	O
RAD51	O
genes	O
:	O
a	O
G	O
-->	O
C	O
transversion	O
at	O
1245	O
position	O
of	O
the	O
hOGG1	O
gene	O
producing	O
a	O
Ser	O
-->	O
Cys	O
substitution	O
at	O
the	O
codon	O
326	O
(	O
the	O
Ser326Cys	O
polymorphism	O
)	O
and	O
a	O
G	O
-->	O
C	O
substitution	O
at	O
position	O
135	O
(	O
5	O
'-	O
untranslated	O
region	O
)	O
of	O
the	O
RAD51	O
gene	O
(	O
the	O
G135C	O
polymorphism	O
).	O
	
DNA	O
damage	O
and	O
repair	O
were	O
evaluated	O
by	O
alkaline	O
single	O
cell	O
gel	O
electrophoresis	O
(	O
comet	O
assay	O
)	O
assisted	O
by	O
DNA	O
repair	O
enzymes	O
:	O
endonuclease	O
III	O
(	O
Nth	O
)	O
and	O
formamidopyrimidine	O
-	O
DNA	O
glycosylase	O
(	O
Fpg	O
)","	O
preferentially	O
recognizing	O
oxidized	O
DNA	O
bases	O
.	O
	
The	O
genotypes	O
of	O
the	O
polymorphism	O
were	O
determined	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
PCR	O
.	O
	
We	O
observed	O
a	O
strong	O
association	O
between	O
gastric	B-Disease
cancer	I-Disease
occurrence	O
","	O
impaired	O
DNA	O
repair	O
in	O
human	O
lymphocytes	O
and	O
the	O
G	O
/	O
C	O
genotype	O
of	O
the	O
G135C	O
polymorphism	O
of	O
the	O
RAD51	O
gene	O
.	O
	
Moreover	O
","	O
there	O
was	O
a	O
strong	O
correlation	O
between	O
that	O
genotype	O
and	O
stomach	B-Disease
cancer	I-Disease
occurrence	O
in	O
subjects	O
with	O
high	O
level	O
of	O
oxidatively	O
damaged	O
DNA	O
.	O
	
We	O
did	O
not	O
observe	O
any	O
correlation	O
between	O
the	O
Ser1245Cys	O
polymorphism	O
of	O
the	O
hOGG1	O
gene	O
and	O
gastric	B-Disease
cancer	I-Disease
","	O
including	O
subjects	O
with	O
impaired	O
DNA	O
repair	O
and	O
/	O
or	O
high	O
levels	O
of	O
endogenous	O
oxidative	O
DNA	O
lesions	O
.	O
	
Therefore	O
","	O
our	O
result	O
suggest	O
that	O
the	O
G135C	O
polymorphism	O
of	O
the	O
RAD51	O
gene	O
may	O
be	O
linked	O
with	O
gastric	B-Disease
cancer	I-Disease
by	O
the	O
modulation	O
of	O
the	O
cellular	O
response	O
to	O
oxidative	O
stress	O
and	O
this	O
polymorphism	O
may	O
be	O
a	O
useful	O
additional	O
marker	O
in	O
this	O
disease	O
along	O
with	O
the	O
genetic	O
or	O
/	O
and	O
environmental	O
indicators	O
of	O
oxidative	O
stress	O
.	O
	
	
The	O
G51S	O
purine	O
nucleoside	O
phosphorylase	O
polymorphism	O
is	O
associated	O
with	O
cognitive	B-Disease
decline	I-Disease
in	O
Alzheimer	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
patients	O
.	O
	
Alzheimer	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
AD	B-Disease
)	O
is	O
a	O
polygenic	O
and	O
multifactorial	O
complex	O
disease	O
","	O
whose	O
etiopathology	O
is	O
still	O
unclear	O
","	O
however	O
several	O
genetic	O
factors	O
have	O
shown	O
to	O
increase	O
the	O
risk	O
of	O
developing	O
the	O
disease	O
.	O
	
Purine	O
nucleotides	O
and	O
nucleosides	O
play	O
an	O
important	O
role	O
in	O
the	O
brain	O
.	O
	
Besides	O
their	O
role	O
in	O
neurotransmission	O
and	O
neuromodulation	O
","	O
they	O
are	O
involved	O
in	O
trophic	O
factor	O
release	O
","	O
apoptosis	O
","	O
and	O
inflammatory	B-Disease
responses	O
.	O
	
These	O
mediators	O
may	O
also	O
have	O
a	O
pivotal	O
role	O
in	O
the	O
control	O
of	O
neurodegenerative	O
processes	O
associated	O
with	O
AD	B-Disease
.	O
	
In	O
this	O
report	O
the	O
distribution	O
of	O
the	O
exonic	O
G	O
/	O
A	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
in	O
purine	O
nucleoside	O
phosphorylase	O
(	O
PNP	O
)	O
gene	O
","	O
resulting	O
in	O
the	O
amino	O
acid	O
substitution	O
serine	O
to	O
glycine	O
at	O
position	O
51	O
(	O
G51S	O
)","	O
was	O
investigated	O
in	O
a	O
large	O
population	O
of	O
AD	B-Disease
patients	O
(	O
n	O
=	O
321	O
)	O
and	O
non	O
-	O
demented	O
control	O
(	O
n	O
=	O
208	O
).	O
	
The	O
PNP	O
polymorphism	O
distribution	O
was	O
not	O
different	O
between	O
patients	O
and	O
controls	O
.	O
	
The	O
polymorphism	O
distribution	O
was	O
also	O
analyzed	O
in	O
AD	B-Disease
patients	O
stratified	O
according	O
to	O
differential	O
progressive	O
rate	O
of	O
cognitive	B-Disease
decline	I-Disease
during	O
a	O
2	O
-	O
year	O
follow	O
-	O
up	O
.	O
	
An	O
increased	O
representation	O
of	O
the	O
PNP	O
AA	O
genotype	O
was	O
observed	O
in	O
AD	B-Disease
patients	O
with	O
fast	O
cognitive	B-Disease
deterioration	I-Disease
in	O
comparison	O
with	O
that	O
from	O
patients	O
with	O
slow	O
deterioration	O
rate	O
.	O
	
Our	O
findings	O
suggest	O
that	O
the	O
G51S	O
PNP	O
polymorphism	O
is	O
associated	O
with	O
a	O
faster	O
rate	O
of	O
cognitive	B-Disease
decline	I-Disease
in	O
AD	B-Disease
patients	O
","	O
highlighting	O
the	O
important	O
role	O
of	O
purine	O
metabolism	O
in	O
the	O
progression	O
of	O
this	O
neurodegenerative	B-Disease
disorder	I-Disease
.	O
	
	
Retinoblastoma	B-Disease
in	O
India	O
:	O
microsatellite	O
analysis	O
and	O
its	O
application	O
in	O
genetic	O
counseling	O
.	O
	
OBJECTIVES	O
:	O
This	O
study	O
was	O
conducted	O
with	O
two	O
objectives	O
.	O
	
The	O
first	O
was	O
to	O
estimate	O
the	O
frequency	O
of	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
of	O
the	O
RB1	O
gene	O
as	O
a	O
mechanism	O
in	O
disease	O
causation	O
in	O
tumors	B-Disease
of	O
patients	O
from	O
India	O
.	O
	
The	O
second	O
objective	O
was	O
to	O
employ	O
RB1	O
molecular	O
deletion	O
and	O
microsatellite	O
-	O
based	O
linkage	O
analysis	O
as	O
laboratory	O
tools	O
","	O
while	O
counseling	O
families	O
with	O
a	O
history	O
of	O
retinoblastoma	B-Disease
(	O
RB	B-Disease
).	O
	
METHODS	O
:	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
and	O
tumors	B-Disease
of	O
54	O
RB	B-Disease
patients	O
and	O
their	O
relatives	O
.	O
	
Eight	O
fluorescent	O
microsatellite	O
markers	O
","	O
both	O
intragenic	O
and	O
flanking	O
the	O
RB1	O
gene	O
","	O
were	O
used	O
.	O
	
After	O
PCR	O
amplification	O
","	O
samples	O
were	O
run	O
on	O
an	O
ABI	O
PRISM	O
310	O
genetic	O
analyzer	O
for	O
LOH	O
","	O
deletion	O
detection	O
","	O
and	O
haplotype	O
generation	O
.	O
	
RESULTS	O
:	O
LOH	O
was	O
found	O
in	O
conjunction	O
with	O
tumor	B-Disease
formation	O
in	O
72	O
.	O
9	O
%	O
of	O
RB	B-Disease
patients	O
(	O
39	O
/	O
54	O
patients	O
";"	O
p	O
=	O
0	O
.	O
1	O
";"	O
95	O
%	O
CI	O
0	O
.	O
6028	O
","	O
0	O
.	O
8417	O
");"	O
however	O
","	O
we	O
could	O
not	O
associate	O
various	O
other	O
clinical	O
parameters	O
of	O
RB	B-Disease
patients	O
with	O
the	O
presence	O
or	O
absence	O
of	O
RB1	O
LOH	O
.	O
	
Seven	O
germline	O
deletions	O
(	O
13	O
%	O
of	O
RB	B-Disease
patients	O
)	O
were	O
identified	O
","	O
and	O
the	O
maternal	O
allele	O
was	O
more	O
frequently	O
lost	O
(	O
p	O
=	O
0	O
.	O
1	O
).	O
	
A	O
disease	O
co	O
-	O
segregating	O
haplotype	O
was	O
detected	O
in	O
two	O
hereditary	O
autosomal	O
dominant	O
cases	O
.	O
	
CONCLUSION	O
:	O
LOH	O
of	O
the	O
RB1	O
gene	O
could	O
play	O
an	O
important	O
role	O
in	O
tumor	B-Disease
formation	O
.	O
	
Large	O
deletions	O
involving	O
RB1	O
were	O
observed	O
","	O
and	O
a	O
disease	O
co	O
-	O
segregating	O
haplotype	O
was	O
used	O
for	O
indirect	O
genetic	O
testing	O
.	O
	
This	O
is	O
the	O
first	O
report	O
from	O
India	O
where	O
molecular	O
testing	O
has	O
been	O
applied	O
for	O
RB	B-Disease
families	O
in	O
conjunction	O
with	O
genetic	O
counseling	O
.	O
	
In	O
tertiary	O
ophthalmic	O
practice	O
in	O
India	O
","	O
there	O
is	O
an	O
emerging	O
trend	O
towards	O
the	O
application	O
of	O
genetical	O
knowledge	O
in	O
clinical	O
practice	O
.	O
	
	
Molecular	O
analysis	O
of	O
the	O
CYP2F1	O
gene	O
:	O
identification	O
of	O
a	O
frequent	O
non	O
-	O
functional	O
allelic	O
variant	O
.	O
	
The	O
CYP2F1	O
is	O
a	O
human	O
cytochrome	O
P450	O
that	O
is	O
selectively	O
expressed	O
in	O
lung	O
tissue	O
and	O
involved	O
in	O
the	O
metabolism	O
of	O
various	O
pneumotoxicants	O
with	O
potential	O
carcinogenic	B-Disease
effects	O
.	O
	
In	O
the	O
present	O
study	O
","	O
we	O
report	O
the	O
first	O
systematic	O
investigation	O
of	O
the	O
genetic	O
polymorphism	O
of	O
this	O
enzyme	O
.	O
	
We	O
analyzed	O
the	O
nucleotidic	O
sequence	O
of	O
the	O
CYP2F1	O
gene	O
in	O
DNA	O
samples	O
from	O
90	O
French	O
Caucasians	O
consisting	O
in	O
44	O
patients	O
with	O
lung	B-Disease
cancer	I-Disease
and	O
46	O
control	O
individuals	O
","	O
using	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
of	O
PCR	O
products	O
(	O
PCR	O
-	O
SSCP	O
).	O
	
We	O
identified	O
24	O
novel	O
mutations	O
distributed	O
in	O
the	O
promoter	O
region	O
of	O
the	O
gene	O
","	O
as	O
well	O
as	O
in	O
the	O
coding	O
regions	O
and	O
their	O
flanking	O
intronic	O
sequences	O
.	O
	
In	O
addition	O
to	O
the	O
wild	O
-	O
type	O
CYP2F1	O
*	O
1	O
allele	O
","	O
seven	O
allelic	O
variant	O
","	O
CYP2F1	O
*	O
2A	O
","	O
*	O
2B	O
","	O
*	O
3	O
","	O
*	O
4	O
","	O
*	O
5A	O
","	O
*	O
5B	O
and	O
*	O
6	O
","	O
were	O
characterized	O
.	O
	
The	O
most	O
frequent	O
allelic	O
variant	O
","	O
CYP2F1	O
*	O
2A	O
(	O
25	O
.	O
6	O
%)","	O
harbors	O
a	O
combination	O
of	O
9	O
mutations	O
","	O
including	O
2	O
missense	O
mutations	O
(	O
Asp218Asn	O
and	O
Gln266His	O
)	O
and	O
a	O
1	O
-	O
bp	O
insertion	O
(	O
c	O
.	O
14_15insC	O
)	O
that	O
creates	O
a	O
premature	O
stop	O
codon	O
in	O
exon	O
2	O
","	O
probably	O
leading	O
to	O
the	O
synthesis	O
of	O
a	O
severely	O
truncated	O
protein	O
with	O
no	O
catalytic	O
activity	O
.	O
	
The	O
identification	O
of	O
around	O
7	O
%	O
of	O
homozygotes	O
for	O
the	O
frameshift	O
mutation	O
in	O
our	O
Caucasian	O
population	O
suggests	O
the	O
existence	O
of	O
an	O
interindividual	O
variation	O
of	O
the	O
CYP2F1	O
activity	O
and	O
","	O
consequently	O
","	O
the	O
possibility	O
of	O
interindividual	O
differences	O
in	O
the	O
toxic	O
response	O
to	O
some	O
pneumotoxicants	O
and	O
in	O
the	O
susceptibility	O
to	O
certain	O
chemically	O
induced	O
diseases	O
.	O
	
However	O
","	O
our	O
preliminary	O
results	O
did	O
not	O
show	O
any	O
evidence	O
that	O
the	O
CYP2F1	O
genetic	O
polymorphism	O
has	O
implications	O
in	O
the	O
pathogenesis	O
of	O
lung	B-Disease
cancer	I-Disease
.	O
	
	
Comparison	O
of	O
unilateral	O
pallidotomy	O
and	O
subthalamotomy	O
findings	O
in	O
advanced	O
idiopathic	B-Disease
Parkinson	I-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
	
A	O
prospective	O
","	O
randomized	O
","	O
double	O
-	O
blind	O
pilot	O
study	O
to	O
compare	O
the	O
results	O
of	O
stereotactic	O
unilateral	O
pallidotomy	O
and	O
subthalamotomy	O
in	O
advanced	O
idiopathic	B-Disease
Parkinson	I-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
refractory	O
to	O
medical	O
treatment	O
was	O
designed	O
.	O
	
Ten	O
consecutive	O
patients	O
(	O
mean	O
age	O
","	O
58	O
.	O
4	O
+/-	O
6	O
.	O
8	O
years	O
";"	O
7	O
men	O
","	O
3	O
women	O
)	O
with	O
similar	O
characteristics	O
at	O
the	O
duration	O
of	O
disease	O
(	O
mean	O
disease	O
time	O
","	O
8	O
.	O
4	O
+/-	O
3	O
.	O
5	O
years	O
)","	O
disabling	O
motor	O
fluctuations	O
(	O
Hoehn	O
_	O
Yahr	O
stage	O
3	O
-	O
5	O
in	O
off	O
-	O
drug	O
phases	O
)	O
and	O
levodopa	B-Chemical
-	O
induced	O
dyskinesias	B-Disease
were	O
selected	O
.	O
	
All	O
patients	O
had	O
bilateral	O
symptoms	O
and	O
their	O
levodopa	B-Chemical
equivalent	O
dosing	O
were	O
analysed	O
.	O
	
Six	O
patients	O
were	O
operated	O
on	O
in	O
the	O
globus	O
pallidus	O
interna	O
(	O
GPi	O
)	O
and	O
four	O
in	O
the	O
subthalamic	O
nucleus	O
(	O
STN	O
).	O
	
Clinical	O
evaluation	O
included	O
the	O
use	O
of	O
the	O
Unified	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
Disease	I-Disease
Rating	O
Scale	O
(	O
UPDRS	O
)","	O
Hoehn_Yahr	O
score	O
and	O
Schwab	O
England	O
activities	O
of	O
daily	O
living	O
(	O
ADL	O
)	O
score	O
in	O
'	O
on	O
'-	O
and	O
'	O
off	O
'-	O
drug	O
conditions	O
before	O
surgery	O
and	O
6	O
months	O
after	O
surgery	O
.	O
	
There	O
was	O
statistically	O
significant	O
improvement	O
in	O
all	O
contralateral	O
major	O
parkinsonian	B-Disease
motor	O
signs	O
in	O
all	O
patients	O
followed	O
for	O
6	O
months	O
.	O
	
Levodopa	B-Chemical
equivalent	O
daily	O
intake	O
was	O
significantly	O
reduced	O
in	O
the	O
STN	O
group	O
.	O
	
Changes	O
in	O
UPDRS	O
","	O
Hoehn	O
_	O
Yahr	O
and	O
Schwab	O
England	O
ADL	O
scores	O
were	O
similar	O
in	O
both	O
groups	O
.	O
	
Cognitive	O
functions	O
were	O
unchanged	O
in	O
both	O
groups	O
.	O
	
Complications	O
were	O
observed	O
in	O
two	O
patients	O
:	O
one	O
had	O
a	O
left	O
homonymous	B-Disease
hemianopsia	I-Disease
after	O
pallidotomy	O
and	O
another	O
one	O
developed	O
left	O
hemiballistic	O
movements	O
3	O
days	O
after	O
subthalamotomy	O
which	O
partly	O
improved	O
within	O
1	O
month	O
with	O
Valproate	B-Chemical
1000	O
mg	O
/	O
day	O
.	O
	
The	O
findings	O
of	O
this	O
study	O
suggest	O
that	O
lesions	O
of	O
the	O
unilateral	O
STN	O
and	O
GPi	O
are	O
equally	O
effective	O
treatment	O
for	O
patients	O
with	O
advanced	O
PD	B-Disease
refractory	O
to	O
medical	O
treatment	O
.	O
	
	
Macular	B-Disease
corneal	I-Disease
dystrophy	I-Disease
in	O
a	O
Chinese	O
family	O
related	O
with	O
novel	O
mutations	O
of	O
CHST6	O
.	O
	
PURPOSE	O
:	O
To	O
identify	O
mutations	O
in	O
the	O
carbohydrate	O
sulfotransferase	O
gene	O
(	O
CHST6	O
)	O
for	O
a	O
Chinese	O
family	O
with	O
macular	B-Disease
corneal	I-Disease
dystrophy	I-Disease
(	O
MCD	B-Disease
)	O
and	O
to	O
investigate	O
the	O
histopathological	O
changes	O
in	O
the	O
affected	O
cornea	O
.	O
	
METHODS	O
:	O
A	O
corneal	O
button	O
of	O
the	O
proband	O
was	O
obtained	O
by	O
penetrating	O
keratoplasty	O
.	O
	
The	O
half	O
button	O
and	O
ultrathin	O
sections	O
from	O
the	O
other	O
half	O
button	O
were	O
examined	O
with	O
special	O
stains	O
under	O
a	O
light	O
microscope	O
(	O
LM	O
)	O
and	O
an	O
electron	O
microscope	O
(	O
EM	O
)	O
separately	O
.	O
	
Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
of	O
11	O
family	O
members	O
","	O
and	O
the	O
coding	O
region	O
of	O
CHST6	O
was	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
method	O
.	O
	
The	O
PCR	O
products	O
were	O
analyzed	O
by	O
direct	O
sequencing	O
and	O
restriction	O
enzyme	O
digestion	O
.	O
	
RESULTS	O
:	O
The	O
positive	O
reaction	O
to	O
colloidal	O
iron	B-Chemical
stain	O
(	O
extracellular	O
blue	O
accumulations	O
in	O
the	O
stroma	O
)	O
was	O
detected	O
under	O
light	O
microscopy	O
.	O
	
Transmission	O
electron	O
microscopy	O
revealed	O
the	O
enlargement	O
of	O
smooth	O
endoplasmic	O
reticulum	O
and	O
the	O
presence	O
of	O
intracytoplasmic	O
vacuoles	O
.	O
	
The	O
compound	O
heterozygous	O
mutations	O
","	O
c	O
.	O
892C	O
>	O
T	O
and	O
c	O
.	O
1072T	O
>	O
C	O
","	O
were	O
identified	O
in	O
exon	O
3	O
of	O
CHST6	O
in	O
three	O
patients	O
.	O
	
The	O
two	O
transversions	O
resulted	O
in	O
the	O
substitution	O
of	O
a	O
stop	O
codon	O
for	O
glutamine	O
at	O
codon	O
298	O
(	O
p	O
.	O
Q298X	O
)	O
and	O
a	O
missense	O
mutation	O
at	O
codon	O
358	O
","	O
tyrosine	O
to	O
histidine	O
(	O
p	O
.	O
Y358H	O
).	O
	
The	O
six	O
unaffected	O
family	O
individuals	O
carried	O
alternative	O
heterozygous	O
mutations	O
.	O
	
These	O
two	O
mutations	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
100	O
control	O
subjects	O
.	O
	
CONCLUSIONS	O
:	O
Those	O
novel	O
compound	O
heterozygous	O
mutations	O
were	O
thought	O
to	O
contribute	O
to	O
the	O
loss	O
of	O
CHST6	O
function	O
","	O
which	O
induced	O
the	O
abnormal	O
metabolism	O
of	O
keratan	B-Chemical
sulfate	I-Chemical
(	O
KS	B-Chemical
)	O
that	O
deposited	O
in	O
the	O
corneal	O
stroma	O
.	O
	
It	O
could	O
be	O
proved	O
by	O
the	O
observation	O
of	O
a	O
positive	O
stain	O
reaction	O
and	O
the	O
enlarged	O
collagen	O
fibers	O
as	O
well	O
as	O
hyperplastic	O
fibroblasts	O
under	O
microscopes	O
.	O
	
	
Acute	B-Disease
renal	I-Disease
failure	I-Disease
in	O
patients	O
with	O
AIDS	B-Disease
on	O
tenofovir	B-Chemical
while	O
receiving	O
prolonged	O
vancomycin	B-Chemical
course	O
for	O
osteomyelitis	B-Disease
.	O
	
Renal	B-Disease
failure	I-Disease
developed	O
after	O
a	O
prolonged	O
course	O
of	O
vancomycin	B-Chemical
therapy	O
in	O
2	O
patients	O
who	O
were	O
receiving	O
tenofovir	B-Chemical
disoproxil	I-Chemical
fumarate	I-Chemical
as	O
part	O
of	O
an	O
antiretroviral	O
regimen	O
.	O
	
Tenofovir	B-Chemical
has	O
been	O
implicated	O
in	O
the	O
development	O
of	O
Fanconi	B-Disease
syndrome	I-Disease
and	O
renal	B-Disease
insufficiency	I-Disease
because	O
of	O
its	O
effects	O
on	O
the	O
proximal	O
renal	O
tubule	O
.	O
	
Vancomycin	B-Chemical
nephrotoxicity	B-Disease
is	O
infrequent	O
but	O
may	O
result	O
from	O
coadministration	O
with	O
a	O
nephrotoxic	B-Disease
agent	O
.	O
	
Clinicians	O
should	O
be	O
aware	O
that	O
tenofovir	B-Chemical
may	O
raise	O
the	O
risk	O
of	O
renal	B-Disease
failure	I-Disease
during	O
prolonged	O
administration	O
of	O
vancomycin	B-Chemical
.	O
	
	
Protein	O
kinase	O
C	O
alpha	O
-	O
dependent	O
signaling	O
mediates	O
endometrial	B-Disease
cancer	I-Disease
cell	O
growth	O
and	O
tumorigenesis	B-Disease
.	O
	
Endometrial	B-Disease
cancer	I-Disease
is	O
the	O
most	O
common	O
invasive	O
gynecologic	B-Disease
malignancy	I-Disease
","	O
yet	O
molecular	O
mechanisms	O
and	O
signaling	O
pathways	O
underlying	O
its	O
etiology	O
and	O
pathophysiology	O
remain	O
poorly	O
characterized	O
.	O
	
We	O
sought	O
to	O
define	O
a	O
functional	O
role	O
for	O
the	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
isoform	O
","	O
PKCalpha	O
","	O
in	O
an	O
established	O
cell	O
model	O
of	O
endometrial	B-Disease
adenocarcinoma	I-Disease
.	O
	
Ishikawa	O
cells	O
depleted	O
of	O
PKCalpha	O
protein	O
grew	O
slower	O
","	O
formed	O
fewer	O
colonies	O
in	O
anchorage	O
-	O
independent	O
growth	O
assays	O
and	O
exhibited	O
impaired	O
xenograft	O
tumor	B-Disease
formation	O
in	O
nude	O
mice	O
.	O
	
Consistent	O
with	O
impaired	O
growth	O
","	O
PKCalpha	O
knockdown	O
increased	O
levels	O
of	O
the	O
cyclin	O
-	O
dependent	O
kinase	O
(	O
CDK	O
)	O
inhibitors	O
p21	O
(	O
Cip1	O
/	O
WAF1	O
)	O
(	O
p21	O
)	O
and	O
p27	O
(	O
Kip1	O
)	O
(	O
p27	O
).	O
	
Despite	O
the	O
absence	O
of	O
functional	O
phosphatase	O
and	O
tensin	O
homolog	O
(	O
PTEN	O
)	O
protein	O
in	O
Ishikawa	O
cells	O
","	O
PKCalpha	O
knockdown	O
reduced	O
Akt	O
phosphorylation	O
at	O
serine	O
473	O
and	O
concomitantly	O
inhibited	O
phosphorylation	O
of	O
the	O
Akt	O
target	O
","	O
glycogen	O
synthase	O
kinase	O
-	O
3beta	O
(	O
GSK	O
-	O
3beta	O
).	O
	
PKCalpha	O
knockdown	O
also	O
resulted	O
in	O
decreased	O
basal	O
ERK	O
phosphorylation	O
and	O
attenuated	O
ERK	O
activation	O
following	O
EGF	O
stimulation	O
.	O
	
p21	O
and	O
p27	O
expression	O
was	O
not	O
increased	O
by	O
treatment	O
of	O
Ishikawa	O
cells	O
with	O
ERK	O
and	O
Akt	O
inhibitors	O
","	O
suggesting	O
that	O
PKCalpha	O
regulates	O
CDK	O
expression	O
independently	O
of	O
Akt	O
and	O
ERK	O
.	O
	
Immunohistochemical	O
analysis	O
of	O
Grade	O
1	O
endometrioid	B-Disease
adenocarcinoma	I-Disease
revealed	O
aberrant	O
PKCalpha	O
expression	O
","	O
with	O
foci	O
of	O
elevated	O
PKCalpha	O
staining	O
","	O
not	O
observed	O
in	O
normal	O
endometrium	O
.	O
	
These	O
studies	O
demonstrate	O
a	O
critical	O
role	O
for	O
PKCalpha	O
signaling	O
in	O
endometrial	O
tumorigenesis	B-Disease
by	O
regulating	O
expression	O
of	O
CDK	O
inhibitors	O
p21	O
and	O
p27	O
and	O
activation	O
of	O
Akt	O
and	O
ERK	O
-	O
dependent	O
proliferative	O
pathways	O
.	O
	
Thus	O
","	O
targeting	O
PKCalpha	O
may	O
provide	O
novel	O
therapeutic	O
options	O
in	O
endometrial	B-Disease
tumors	I-Disease
.	O
	
	
Metallothionein	B-Chemical
induction	O
reduces	O
caspase	O
-	O
3	O
activity	O
and	O
TNFalpha	O
levels	O
with	O
preservation	O
of	O
cognitive	O
function	O
and	O
intact	O
hippocampal	O
neurons	O
in	O
carmustine	B-Chemical
-	O
treated	O
rats	O
.	O
	
Hippocampal	O
integrity	O
is	O
essential	O
for	O
cognitive	O
functions	O
.	O
	
On	O
the	O
other	O
hand	O
","	O
induction	O
of	O
metallothionein	B-Chemical
(	O
MT	B-Chemical
)	O
by	O
ZnSO	B-Chemical
(	I-Chemical
4	I-Chemical
)	I-Chemical
and	O
its	O
role	O
in	O
neuroprotection	O
has	O
been	O
documented	O
.	O
	
The	O
present	O
study	O
aimed	O
to	O
explore	O
the	O
effect	O
of	O
MT	B-Chemical
induction	O
on	O
carmustine	B-Chemical
(	O
BCNU	B-Chemical
)-	O
induced	O
hippocampal	O
cognitive	B-Disease
dysfunction	I-Disease
in	O
rats	O
.	O
	
A	O
total	O
of	O
60	O
male	O
Wistar	O
albino	O
rats	O
were	O
randomly	O
divided	O
into	O
four	O
groups	O
(	O
15	O
/	O
group	O
):	O
The	O
control	O
group	O
injected	O
with	O
single	O
doses	O
of	O
normal	O
saline	O
(	O
i	O
.	O
c	O
.	O
v	O
)	O
followed	O
24	O
h	O
later	O
by	O
BCNU	B-Chemical
solvent	O
(	O
i	O
.	O
v	O
).	O
	
The	O
second	O
group	O
administered	O
ZnSO	B-Chemical
(	I-Chemical
4	I-Chemical
)	I-Chemical
(	O
0	O
.	O
1	O
micromol	O
/	O
10	O
microl	O
normal	O
saline	O
","	O
i	O
.	O
c	O
.	O
v	O
","	O
once	O
)	O
then	O
BCNU	B-Chemical
solvent	O
(	O
i	O
.	O
v	O
)	O
after	O
24	O
h	O
.	O
Third	O
group	O
received	O
BCNU	B-Chemical
(	O
20	O
mg	O
/	O
kg	O
","	O
i	O
.	O
v	O
","	O
once	O
)	O
24	O
h	O
after	O
injection	O
with	O
normal	O
saline	O
(	O
i	O
.	O
c	O
.	O
v	O
).	O
	
Fourth	O
group	O
received	O
a	O
single	O
dose	O
of	O
ZnSO	B-Chemical
(	I-Chemical
4	I-Chemical
)	I-Chemical
(	O
0	O
.	O
1	O
micromol	O
/	O
10	O
microl	O
normal	O
saline	O
","	O
i	O
.	O
c	O
.	O
v	O
)	O
then	O
BCNU	B-Chemical
(	O
20	O
mg	O
/	O
kg	O
","	O
i	O
.	O
v	O
","	O
once	O
)	O
after	O
24	O
h	O
.	O
The	O
obtained	O
data	O
revealed	O
that	O
BCNU	B-Chemical
administration	O
resulted	O
in	O
deterioration	B-Disease
of	I-Disease
learning	I-Disease
and	I-Disease
short	I-Disease
-	I-Disease
term	I-Disease
memory	I-Disease
(	O
STM	O
)","	O
as	O
measured	O
by	O
using	O
radial	O
arm	O
water	O
maze	O
","	O
accompanied	O
with	O
decreased	O
hippocampal	O
glutathione	O
reductase	O
(	O
GR	O
)	O
activity	O
and	O
reduced	O
glutathione	B-Chemical
(	O
GSH	B-Chemical
)	O
content	O
.	O
	
Also	O
","	O
BCNU	B-Chemical
administration	O
increased	O
serum	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNFalpha	O
)","	O
hippocampal	O
MT	B-Chemical
and	O
malondialdehyde	B-Chemical
(	O
MDA	B-Chemical
)	O
contents	O
as	O
well	O
as	O
caspase	O
-	O
3	O
activity	O
in	O
addition	O
to	O
histological	O
alterations	O
.	O
	
ZnSO	B-Chemical
(	I-Chemical
4	I-Chemical
)	I-Chemical
pretreatment	O
counteracted	O
BCNU	B-Chemical
-	O
induced	O
inhibition	O
of	O
GR	O
and	O
depletion	O
of	O
GSH	B-Chemical
and	O
resulted	O
in	O
significant	O
reduction	O
in	O
the	O
levels	O
of	O
MDA	B-Chemical
and	O
TNFalpha	O
as	O
well	O
as	O
the	O
activity	O
of	O
caspase	O
-	O
3	O
.	O
	
The	O
histological	O
features	O
were	O
improved	O
in	O
hippocampus	O
of	O
rats	O
treated	O
with	O
ZnSO	B-Chemical
(	I-Chemical
4	I-Chemical
)	I-Chemical
+	O
BCNU	B-Chemical
compared	O
to	O
only	O
BCNU	B-Chemical
-	O
treated	O
animals	O
.	O
	
In	O
conclusion	O
","	O
MT	B-Chemical
induction	O
halts	O
BCNU	B-Chemical
-	O
induced	O
hippocampal	O
toxicity	B-Disease
as	O
it	O
prevented	O
GR	O
inhibition	O
and	O
GSH	B-Chemical
depletion	O
and	O
counteracted	O
the	O
increased	O
levels	O
of	O
TNFalpha	O
","	O
MDA	B-Chemical
and	O
caspase	O
-	O
3	O
activity	O
with	O
subsequent	O
preservation	O
of	O
cognition	O
.	O
	
	
Association	O
of	O
obesity	B-Disease
risk	O
SNPs	O
in	O
PCSK1	O
with	O
insulin	O
sensitivity	O
and	O
proinsulin	B-Chemical
conversion	O
.	O
	
BACKGROUND	O
:	O
Prohormone	O
convertase	O
1	O
is	O
involved	O
in	O
maturation	O
of	O
peptides	O
.	O
	
Rare	O
mutations	O
in	O
gene	O
PCSK1	O
","	O
encoding	O
this	O
enzyme	O
","	O
cause	O
childhood	O
obesity	B-Disease
and	O
abnormal	B-Disease
glucose	I-Disease
homeostasis	I-Disease
with	O
elevated	O
proinsulin	B-Chemical
concentrations	O
.	O
	
Common	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
within	O
this	O
gene	O
","	O
rs6232	O
and	O
rs6235	O
","	O
are	O
associated	O
with	O
obesity	B-Disease
.	O
	
We	O
studied	O
whether	O
these	O
SNPs	O
influence	O
the	O
prediabetic	O
traits	O
insulin	B-Disease
resistance	I-Disease
","	O
beta	B-Disease
-	I-Disease
cell	I-Disease
dysfunction	I-Disease
","	O
or	O
glucose	B-Disease
intolerance	I-Disease
.	O
	
METHODS	O
:	O
We	O
genotyped	O
1498	O
German	O
subjects	O
for	O
SNPs	O
rs6232	O
and	O
rs6235	O
within	O
PCSK1	O
.	O
	
The	O
subjects	O
were	O
metabolically	O
characterized	O
by	O
oral	O
glucose	B-Chemical
tolerance	O
test	O
with	O
glucose	B-Chemical
","	O
insulin	O
","	O
proinsulin	B-Chemical
","	O
and	O
C	B-Chemical
-	I-Chemical
peptide	I-Chemical
measurements	O
.	O
	
A	O
subgroup	O
of	O
512	O
subjects	O
underwent	O
a	O
hyperinsulinemic	B-Disease
-	I-Disease
euglycemic	I-Disease
clamp	O
.	O
	
RESULTS	O
:	O
The	O
minor	O
allele	O
frequencies	O
were	O
25	O
.	O
8	O
%	O
for	O
SNP	O
rs6235	O
and	O
6	O
.	O
0	O
%	O
for	O
rs6232	O
.	O
	
After	O
adjustment	O
for	O
sex	O
and	O
age	O
","	O
we	O
found	O
no	O
association	O
of	O
SNPs	O
rs6235	O
and	O
rs6232	O
with	O
BMI	O
or	O
other	O
weight	O
-	O
related	O
traits	O
(	O
all	O
p	O
>	O
or	O
=	O
0	O
.	O
7	O
).	O
	
Both	O
minor	O
alleles	O
","	O
adjusted	O
for	O
sex	O
","	O
age	O
","	O
BMI	O
and	O
insulin	O
sensitivity	O
were	O
associated	O
with	O
elevated	O
AUCproinsulin	B-Chemical
and	O
AUCproinsulin	B-Chemical
/	O
AUCinsulin	O
(	O
rs6235	O
:	O
p	O
(	O
additive	O
)	O
model	O
<	O
or	O
=	O
0	O
.	O
9	O
","	O
effect	O
sizes	O
8	O
/	O
8	O
%","	O
rs6232	O
:	O
pdominant	O
model	O
<	O
or	O
=	O
0	O
.	O
1	O
","	O
effect	O
sizes	O
10	O
/	O
21	O
%).	O
	
Insulin	O
secretion	O
was	O
not	O
affected	O
by	O
the	O
variants	O
(	O
different	O
secretion	O
parameters	O
","	O
all	O
p	O
>	O
or	O
=	O
0	O
.	O
8	O
).	O
	
The	O
minor	O
allele	O
of	O
SNP	O
rs6232	O
was	O
additionally	O
associated	O
with	O
15	O
%	O
higher	O
OGTT	O
-	O
derived	O
and	O
19	O
%	O
higher	O
clamp	O
-	O
derived	O
insulin	O
sensitivity	O
(	O
pdom	O
<	O
or	O
=	O
0	O
.	O
47	O
)","	O
4	O
.	O
5	O
%	O
lower	O
HOMAIR	O
(	O
pdom	O
=	O
0	O
.	O
2	O
)	O
and	O
3	O
.	O
5	O
%	O
lower	O
120	O
-	O
min	O
glucose	B-Chemical
(	O
pdom	O
=	O
0	O
.	O
3	O
)	O
independently	O
of	O
BMI	O
and	O
proinsulin	B-Chemical
conversion	O
.	O
	
SNP	O
rs6235	O
was	O
not	O
associated	O
with	O
parameters	O
of	O
glucose	O
metabolism	O
.	O
	
CONCLUSIONS	O
:	O
Like	O
rare	O
mutations	O
in	O
PCSK1	O
","	O
the	O
more	O
common	O
variants	O
tested	O
determine	O
glucose	B-Chemical
-	O
stimulated	O
proinsulin	B-Chemical
conversion	O
","	O
but	O
not	O
insulin	O
secretion	O
.	O
	
In	O
addition	O
","	O
rs6232	O
","	O
encoding	O
the	O
amino	O
acid	O
exchange	O
N221D	O
","	O
influences	O
insulin	O
sensitivity	O
and	O
glucose	B-Chemical
homeostasis	O
.	O
	
	
Inhibitory	O
effect	O
of	O
emodin	B-Chemical
on	O
fatty	O
acid	O
synthase	O
","	O
colon	B-Disease
cancer	I-Disease
proliferation	O
and	O
apoptosis	O
.	O
	
Fatty	O
acid	O
synthase	O
(	O
FASN	O
)	O
is	O
a	O
key	O
anabolic	O
enzyme	O
for	O
de	O
novo	O
fatty	B-Chemical
acid	I-Chemical
synthesis	O
","	O
which	O
is	O
important	O
in	O
the	O
development	O
of	O
colon	B-Disease
carcinoma	I-Disease
.	O
	
The	O
high	O
expression	O
of	O
FASN	O
is	O
considered	O
a	O
promising	O
molecular	O
target	O
for	O
colon	B-Disease
cancer	I-Disease
therapy	O
.	O
	
Emodin	B-Chemical
","	O
a	O
naturally	O
occurring	O
anthraquinone	B-Chemical
","	O
exhibits	O
an	O
anticancer	O
effect	O
in	O
various	O
types	O
of	O
human	O
cancer	B-Disease
","	O
including	O
colon	B-Disease
cancer	I-Disease
";"	O
however	O
","	O
the	O
molecular	O
mechanisms	O
remain	O
to	O
be	O
fully	O
elucidated	O
.	O
	
Cell	O
viability	O
was	O
evaluated	O
using	O
a	O
Cell	O
Counting	O
Kit	O
-	O
8	O
assay	O
.	O
	
The	O
apoptosis	O
rate	O
of	O
cells	O
was	O
quantified	O
via	O
flow	O
cytometry	O
following	O
Annexin	O
V	O
/	O
propidium	B-Chemical
iodide	I-Chemical
staining	O
.	O
	
FASN	O
activity	O
was	O
measured	O
by	O
monitoring	O
oxidation	O
of	O
nicotinamide	B-Chemical
adenine	I-Chemical
dinucleotide	I-Chemical
phosphate	I-Chemical
at	O
a	O
wavelength	O
of	O
340	O
nm	O
","	O
and	O
intracellular	O
free	B-Chemical
fatty	I-Chemical
acid	I-Chemical
levels	O
were	O
detected	O
using	O
a	O
Free	B-Chemical
Fatty	I-Chemical
Acid	I-Chemical
Quantification	O
kit	O
.	O
	
Western	O
blot	O
analysis	O
and	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
were	O
used	O
to	O
detect	O
target	O
gene	O
and	O
protein	O
expression	O
.	O
	
The	O
present	O
study	O
was	O
performed	O
to	O
investigate	O
whether	O
the	O
gene	O
expression	O
of	O
FASN	O
and	O
its	O
enzymatic	O
activity	O
are	O
regulated	O
by	O
emodin	B-Chemical
in	O
a	O
human	O
colon	B-Disease
cancer	I-Disease
cell	O
line	O
.	O
	
Emodin	B-Chemical
markedly	O
inhibited	O
the	O
proliferation	O
of	O
HCT116	O
cells	O
and	O
a	O
higher	O
protein	O
level	O
of	O
FASN	O
was	O
expressed	O
","	O
compared	O
with	O
that	O
in	O
SW480	O
","	O
SNU	O
-	O
C2A	O
or	O
SNU	O
-	O
C5	O
cells	O
.	O
	
Emodin	B-Chemical
significantly	O
downregulated	O
the	O
protein	O
expression	O
of	O
FASN	O
in	O
HCT116	O
cells	O
","	O
which	O
was	O
caused	O
by	O
protein	O
degradation	O
due	O
to	O
elevated	O
protein	O
ubiquitination	O
.	O
	
Emodin	B-Chemical
also	O
inhibited	O
intracellular	O
FASN	O
enzymatic	O
activity	O
and	O
reduced	O
the	O
levels	O
of	O
intracellular	O
free	B-Chemical
fatty	I-Chemical
acids	I-Chemical
.	O
	
Emodin	B-Chemical
enhanced	O
antiproliferation	O
and	O
apoptosis	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O
	
The	O
combined	O
treatment	O
of	O
emodin	B-Chemical
and	O
cerulenin	B-Chemical
","	O
a	O
commercial	O
FASN	O
inhibitor	O
","	O
had	O
an	O
additive	O
effect	O
on	O
these	O
activities	O
.	O
	
Palmitate	B-Chemical
","	O
the	O
final	O
product	O
of	O
the	O
FASN	O
reaction	O
","	O
rescued	O
emodin	B-Chemical
-	O
induced	O
viability	O
and	O
apoptosis	O
.	O
	
In	O
addition	O
","	O
emodin	B-Chemical
altered	O
FASN	O
-	O
involved	O
signaling	O
pathways	O
","	O
including	O
phosphatidylinositol	O
3	O
-	O
kinase	O
/	O
Akt	O
and	O
mitogen	O
-	O
activated	O
protein	O
kinases	O
/	O
extracellular	O
signal	O
-	O
regulated	O
kinases	O
1	O
/	O
2	O
.	O
	
These	O
results	O
suggested	O
that	O
emodin	B-Chemical
-	O
regulated	O
cell	O
growth	O
and	O
apoptosis	O
were	O
mediated	O
by	O
inhibiting	O
FASN	O
and	O
provide	O
a	O
molecular	O
basis	O
for	O
colon	B-Disease
cancer	I-Disease
therapy	O
.	O
	
	
A	O
single	O
amino	O
acid	O
substitution	O
confers	O
B	O
-	O
cell	O
clonogenic	O
activity	O
to	O
the	O
HIV	O
-	O
1	O
matrix	O
protein	O
p17	O
.	O
	
Recent	O
data	O
highlight	O
the	O
presence	O
","	O
in	O
HIV	B-Disease
-	I-Disease
1	I-Disease
-	I-Disease
seropositive	I-Disease
patients	O
with	O
lymphoma	B-Disease
","	O
of	O
p17	O
variants	O
(	O
vp17s	O
)	O
endowed	O
with	O
B	O
-	O
cell	O
clonogenicity	O
","	O
suggesting	O
a	O
role	O
of	O
vp17s	O
in	O
lymphomagenesis	B-Disease
.	O
	
We	O
investigated	O
the	O
mechanisms	O
responsible	O
for	O
the	O
functional	O
disparity	O
on	O
B	O
cells	O
between	O
a	O
wild	O
-	O
type	O
p17	O
(	O
refp17	O
)	O
and	O
a	O
vp17	O
named	O
S75X	O
.	O
	
Here	O
","	O
we	O
show	O
that	O
a	O
single	O
Arginine	O
(	O
R	O
)	O
to	O
Glycine	O
(	O
G	O
)	O
mutation	O
at	O
position	O
76	O
in	O
the	O
refp17	O
backbone	O
(	O
	
)","	O
as	O
in	O
the	O
S75X	O
variant	O
","	O
is	O
per	O
se	O
sufficient	O
to	O
confer	O
a	O
B	O
-	O
cell	O
clonogenic	O
potential	O
to	O
the	O
viral	O
protein	O
and	O
modulate	O
","	O
through	O
activation	O
of	O
the	O
PTEN	O
/	O
PI3K	O
/	O
Akt	O
signaling	O
pathway	O
","	O
different	O
molecules	O
involved	O
in	O
apoptosis	O
inhibition	O
(	O
CASP	O
-	O
9	O
","	O
CASP	O
-	O
7	O
","	O
DFF	O
-	O
45	O
","	O
NPM	O
","	O
YWHAZ	O
","	O
Src	O
","	O
PAX2	O
","	O
MAPK8	O
)","	O
cell	O
cycle	O
promotion	O
and	O
cancer	B-Disease
progression	O
(	O
CDK1	O
","	O
CDK2	O
","	O
CDK8	O
","	O
CHEK1	O
","	O
CHEK2	O
","	O
GSK	O
-	O
3	O
beta	O
","	O
NPM	O
","	O
PAK1	O
","	O
PP2C	O
-	O
alpha	O
).	O
	
Moreover	O
","	O
the	O
only	O
R	O
to	O
G	O
mutation	O
at	O
position	O
76	O
was	O
found	O
to	O
strongly	O
impact	O
on	O
protein	O
folding	O
and	O
oligomerization	O
by	O
altering	O
the	O
hydrogen	O
bond	O
network	O
.	O
	
This	O
generates	O
a	O
conformational	O
shift	O
in	O
the	O
p17	O
R76G	O
mutant	O
which	O
enables	O
a	O
functional	O
epitope	O
(	O
s	O
)","	O
masked	O
in	O
refp17	O
","	O
to	O
elicit	O
B	O
-	O
cell	O
growth	O
-	O
promoting	O
signals	O
after	O
its	O
interaction	O
with	O
a	O
still	O
unknown	O
receptor	O
(	O
s	O
).	O
	
Our	O
findings	O
offer	O
new	O
opportunities	O
to	O
understand	O
the	O
molecular	O
mechanisms	O
accounting	O
for	O
the	O
B	O
-	O
cell	O
growth	O
-	O
promoting	O
activity	O
of	O
vp17s	O
.	O
	
	
Genetic	O
alterations	O
in	O
primary	O
glioblastomas	B-Disease
in	O
Japan	O
.	O
	
Current	O
knowledge	O
of	O
genetic	O
alterations	O
in	O
glioblastomas	B-Disease
is	O
based	O
largely	O
on	O
genetic	O
analyses	O
of	O
tumors	B-Disease
from	O
mainly	O
caucasian	O
patients	O
in	O
the	O
United	O
States	O
and	O
Europe	O
.	O
	
In	O
the	O
present	O
study	O
","	O
screening	O
for	O
several	O
key	O
genetic	O
alterations	O
was	O
performed	O
on	O
77	O
primary	O
(	O
de	O
novo	O
)	O
glioblastomas	B-Disease
in	O
Japanese	O
patients	O
.	O
	
SSCP	O
followed	O
by	O
DNA	O
sequencing	O
revealed	O
TP53	O
mutations	O
in	O
16	O
of	O
73	O
(	O
22	O
%)	O
glioblastomas	B-Disease
and	O
PTEN	O
mutations	O
in	O
13	O
of	O
63	O
(	O
21	O
%)	O
cases	O
analyzed	O
.	O
	
Polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
showed	O
EGFR	O
amplification	O
in	O
25	O
of	O
77	O
(	O
32	O
%)	O
cases	O
and	O
p16	O
homozygous	O
deletion	O
in	O
32	O
of	O
77	O
(	O
42	O
%)	O
cases	O
.	O
	
Quantitative	O
microsatellite	O
analysis	O
revealed	O
LOH	O
10q	O
in	O
41	O
of	O
59	O
(	O
69	O
%)	O
glioblastomas	B-Disease
.	O
	
The	O
frequencies	O
of	O
these	O
genetic	O
alterations	O
were	O
similar	O
to	O
those	O
reported	O
for	O
primary	O
glioblastomas	B-Disease
at	O
the	O
population	O
level	O
in	O
Switzerland	O
.	O
	
As	O
previously	O
observed	O
for	O
glioblastomas	B-Disease
in	O
Europe	O
","	O
there	O
was	O
a	O
positive	O
association	O
between	O
EGFR	O
amplification	O
and	O
p16	O
deletion	O
(	O
p	O
=	O
0	O
.	O
9	O
)","	O
whereas	O
there	O
was	O
an	O
inverse	O
association	O
between	O
TP53	O
mutations	O
and	O
p16	O
deletion	O
(	O
p	O
=	O
0	O
.	O
49	O
)	O
in	O
glioblastomas	B-Disease
in	O
Japan	O
.	O
	
Multivariate	O
analyses	O
showed	O
that	O
radiotherapy	O
was	O
significantly	O
predictive	O
for	O
longer	O
survival	O
of	O
glioblastoma	B-Disease
patients	O
(	O
p	O
=	O
0	O
.	O
2	O
).	O
	
SSCP	O
followed	O
by	O
DNA	O
sequencing	O
of	O
the	O
kinase	O
domain	O
(	O
exons	O
18	O
-	O
21	O
)	O
of	O
the	O
EGFR	O
gene	O
revealed	O
mutations	O
in	O
2	O
ou	O
of	O
69	O
(	O
3	O
%)	O
glioblastomas	B-Disease
in	O
Japan	O
and	O
in	O
4	O
of	O
81	O
(	O
5	O
%)	O
glioblastomas	B-Disease
in	O
Switzerland	O
.	O
	
The	O
allele	O
frequencies	O
of	O
polymorphisms	O
at	O
codon	O
787	O
CAG	O
/	O
CAA	O
(	O
Gln	O
/	O
Gln	O
)	O
in	O
glioblastomas	B-Disease
in	O
Japan	O
were	O
G	O
/	O
G	O
(	O
82	O
.	O
4	O
%)","	O
G	O
/	O
A	O
(	O
10	O
.	O
8	O
%)","	O
A	O
/	O
A	O
(	O
6	O
.	O
8	O
%)","	O
corresponding	O
to	O
G	O
0	O
.	O
878	O
versus	O
A	O
0	O
.	O
122	O
","	O
significantly	O
different	O
from	O
those	O
in	O
glioblastomas	B-Disease
in	O
Switzerland	O
:	O
G	O
/	O
G	O
(	O
27	O
.	O
2	O
%)","	O
G	O
/	O
A	O
(	O
28	O
.	O
4	O
%)","	O
A	O
/	O
A	O
(	O
44	O
.	O
4	O
%)","	O
corresponding	O
to	O
G	O
0	O
.	O
414	O
versus	O
A	O
0	O
.	O
586	O
(	O
p	O
<	O
0	O
.	O
1	O
).	O
	
These	O
results	O
suggest	O
that	O
primary	O
glioblastomas	B-Disease
in	O
Japan	O
show	O
genetic	O
alterations	O
similar	O
to	O
those	O
in	O
Switzerland	O
","	O
suggesting	O
a	O
similar	O
molecular	O
basis	O
in	O
caucasians	O
and	O
Asians	O
","	O
despite	O
different	O
genetic	O
backgrounds	O
","	O
including	O
different	O
status	O
of	O
a	O
polymorphism	O
in	O
the	O
EGFR	O
gene	O
.	O
	
	
Evaluation	O
of	O
RGS4	O
as	O
a	O
candidate	O
gene	O
for	O
schizophrenia	B-Disease
.	O
	
Several	O
studies	O
have	O
suggested	O
that	O
the	O
regulator	O
of	O
G	O
-	O
protein	O
signaling	O
4	O
(	O
RGS4	O
)	O
may	O
be	O
a	O
positional	O
and	O
functional	O
candidate	O
gene	O
for	O
schizophrenia	B-Disease
.	O
	
Three	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNP	O
)	O
located	O
at	O
the	O
promoter	O
region	O
(	O
SNP4	O
and	O
SNP7	O
)	O
and	O
the	O
intron	O
1	O
(	O
SNP18	O
)	O
of	O
RGS4	O
have	O
been	O
verified	O
in	O
different	O
ethnic	O
groups	O
.	O
	
Positive	O
results	O
have	O
been	O
reported	O
in	O
these	O
SNPs	O
with	O
different	O
numbers	O
of	O
SNP	O
combinatory	O
haplotypes	O
.	O
	
In	O
this	O
study	O
","	O
these	O
three	O
SNP	O
markers	O
were	O
genotyped	O
in	O
218	O
schizophrenia	B-Disease
pedigrees	O
of	O
Taiwan	O
(	O
864	O
individuals	O
)	O
for	O
association	O
analysis	O
.	O
	
Among	O
these	O
three	O
SNPs	O
","	O
neither	O
SNP4	O
","	O
SNP7	O
","	O
SNP18	O
has	O
shown	O
significant	O
association	O
with	O
schizophrenia	B-Disease
in	O
single	O
locus	O
association	O
analysis	O
","	O
nor	O
any	O
compositions	O
of	O
the	O
three	O
SNP	O
haplotypes	O
has	O
shown	O
significantly	O
associations	O
with	O
the	O
DSM	O
-	O
IV	O
diagnosed	O
schizophrenia	B-Disease
.	O
	
Our	O
results	O
fail	O
to	O
support	O
the	O
RGS4	O
as	O
a	O
candidate	O
gene	O
for	O
schizophrenia	B-Disease
when	O
evaluated	O
from	O
these	O
three	O
SNP	O
markers	O
.	O
	
	
Analysis	O
of	O
skin	B-Disease
cancer	I-Disease
risk	O
factors	O
in	O
immunosuppressed	O
renal	O
transplant	O
patients	O
shows	O
high	O
levels	O
of	O
UV	O
-	O
specific	O
tandem	O
CC	O
to	O
TT	O
mutations	O
of	O
the	O
p53	O
gene	O
.	O
	
Immunosuppressed	O
renal	O
transplant	O
recipients	O
(	O
RTRs	O
)	O
are	O
predisposed	O
to	O
non	B-Disease
-	I-Disease
melanoma	I-Disease
skin	I-Disease
cancers	I-Disease
(	O
NMSCs	B-Disease
)","	O
predominantly	O
squamous	B-Disease
cell	I-Disease
carcinomas	I-Disease
(	O
SCCs	B-Disease
).	O
	
We	O
have	O
analyzed	O
skin	B-Disease
lesions	I-Disease
from	O
RTRs	O
with	O
aggressive	O
tumors	B-Disease
for	O
p53	O
gene	O
modifications	O
","	O
the	O
presence	O
of	O
Human	O
Papillomas	O
Virus	O
(	O
HPV	O
)	O
DNA	O
in	O
relation	O
to	O
the	O
p53	O
codon	O
72	O
genotype	O
and	O
polymorphisms	O
of	O
the	O
XPD	O
repair	O
gene	O
.	O
	
We	O
detected	O
24	O
p53	O
mutations	O
in	O
15	O
/	O
25	O
(	O
60	O
%)	O
NMSCs	B-Disease
","	O
1	O
deletion	O
and	O
23	O
base	O
substitutions	O
","	O
the	O
majority	O
(	O
78	O
%)	O
being	O
UV	O
-	O
specific	O
C	O
to	O
T	O
transitions	O
at	O
bipyrimidine	O
sites	O
.	O
	
Importantly	O
","	O
35	O
%	O
(	O
6	O
/	O
17	O
)	O
are	O
tandem	O
mutations	O
","	O
including	O
4	O
UV	O
signature	O
CC	O
to	O
TT	O
transitions	O
possibly	O
linked	O
to	O
modulated	O
DNA	O
repair	O
caused	O
by	O
the	O
immunosuppressive	O
drug	O
cyclosporin	B-Chemical
A	I-Chemical
(	O
CsA	B-Chemical
).	O
	
We	O
found	O
8	O
p53	O
mutations	O
in	O
7	O
/	O
17	O
(	O
41	O
%)	O
precancerous	B-Disease
actinic	I-Disease
keratosis	I-Disease
(	O
AK	B-Disease
)","	O
suggesting	O
that	O
p53	O
mutations	O
are	O
early	O
events	O
in	O
RTR	O
skin	B-Disease
carcinogenesis	I-Disease
.	O
	
Immunohistochemical	O
analysis	O
shows	O
a	O
good	O
correlation	O
between	O
p53	O
accumulation	O
and	O
mutations	O
.	O
	
HPV	O
DNA	O
was	O
detected	O
in	O
78	O
%	O
of	O
skin	B-Disease
lesions	I-Disease
(	O
60	O
%	O
Basal	B-Disease
Cell	I-Disease
Carcinomas	I-Disease
","	O
82	O
%	O
AK	B-Disease
and	O
79	O
%	O
SCCs	B-Disease
).	O
	
Thus	O
","	O
immunosuppression	O
has	O
increased	O
the	O
risk	O
of	O
infections	B-Disease
by	O
HPVs	O
","	O
predominantly	O
epidermodysplasia	B-Disease
verruciformis	I-Disease
","	O
speculated	O
to	O
play	O
a	O
role	O
in	O
skin	B-Disease
cancer	I-Disease
development	O
.	O
	
No	O
association	O
is	O
found	O
between	O
HPV	O
status	O
and	O
p53	O
mutation	O
.	O
	
Moreover	O
","	O
p53	O
codon	O
72	O
or	O
frequencies	O
of	O
three	O
XPD	O
genotypes	O
of	O
RTRs	O
are	O
comparable	O
with	O
control	O
populations	O
.	O
	
The	O
p53	O
mutation	O
spectrum	O
","	O
presenting	O
a	O
high	O
level	O
of	O
CC	O
to	O
TT	O
mutations	O
","	O
shows	O
that	O
the	O
UV	O
component	O
of	O
sunlight	O
is	O
the	O
major	O
risk	O
factor	O
and	O
modulated	O
DNA	O
repair	O
by	O
immunosuppressive	O
drug	O
treatment	O
may	O
be	O
significant	O
in	O
the	O
skin	B-Disease
carcinogenesis	I-Disease
of	O
RTRs	O
.	O
	
	
Syncope	B-Disease
and	O
QT	B-Disease
prolongation	I-Disease
among	O
patients	O
treated	O
with	O
methadone	B-Chemical
for	O
heroin	B-Disease
dependence	I-Disease
in	O
the	O
city	O
of	O
Copenhagen	O
.	O
	
BACKGROUND	O
:	O
Methadone	B-Chemical
is	O
prescribed	O
to	O
heroin	B-Disease
addicts	I-Disease
to	O
decrease	O
illicit	O
opioid	B-Chemical
use	O
.	O
	
Prolongation	B-Disease
of	I-Disease
the	I-Disease
QT	I-Disease
interval	I-Disease
in	O
the	O
ECG	O
of	O
patients	O
with	O
torsade	B-Disease
de	I-Disease
pointes	I-Disease
(	O
TdP	B-Disease
)	O
has	O
been	O
reported	O
in	O
methadone	B-Chemical
users	O
.	O
	
As	O
heroin	B-Disease
addicts	I-Disease
sometimes	O
faint	O
while	O
using	O
illicit	O
drugs	O
","	O
doctors	O
might	O
attribute	O
too	O
many	O
episodes	O
of	O
syncope	B-Disease
to	O
illicit	O
drug	O
use	O
and	O
thereby	O
underestimate	O
the	O
incidence	O
of	O
TdP	B-Disease
in	O
this	O
special	O
population	O
","	O
and	O
the	O
high	O
mortality	O
in	O
this	O
population	O
may	O
","	O
in	O
part	O
","	O
be	O
caused	O
by	O
the	O
proarrhythmic	O
effect	O
of	O
methadone	B-Chemical
.	O
	
METHODS	O
:	O
In	O
this	O
cross	O
-	O
sectional	O
study	O
interview	O
","	O
ECGs	O
and	O
blood	O
samples	O
were	O
collected	O
in	O
a	O
population	O
of	O
adult	O
heroin	B-Disease
addicts	I-Disease
treated	O
with	O
methadone	B-Chemical
or	O
buprenorphine	B-Chemical
on	O
a	O
daily	O
basis	O
.	O
	
Of	O
the	O
patients	O
at	O
the	O
Drug	O
Addiction	O
Service	O
in	O
the	O
municipal	O
of	O
Copenhagen	O
","	O
450	O
(	O
approximately	O
52	O
%)	O
were	O
included	O
.	O
	
The	O
QT	O
interval	O
was	O
estimated	O
from	O
12	O
lead	O
ECGs	O
.	O
	
All	O
participants	O
were	O
interviewed	O
about	O
any	O
experience	O
of	O
syncope	B-Disease
.	O
	
The	O
association	O
between	O
opioid	B-Chemical
dose	O
and	O
QT	O
","	O
and	O
methadone	B-Chemical
dose	O
and	O
reporting	O
of	O
syncope	B-Disease
was	O
assessed	O
using	O
multivariate	O
linear	O
regression	O
and	O
logistic	O
regression	O
","	O
respectively	O
.	O
	
RESULTS	O
:	O
Methadone	B-Chemical
dose	O
was	O
associated	O
with	O
longer	B-Disease
QT	I-Disease
interval	I-Disease
of	O
0	O
.	O
140	O
ms	O
/	O
mg	O
(	O
p	O
=	O
0	O
.	O
2	O
).	O
	
No	O
association	O
between	O
buprenorphine	B-Chemical
and	O
QTc	O
was	O
found	O
.	O
	
Among	O
the	O
subjects	O
treated	O
with	O
methadone	B-Chemical
","	O
28	O
%	O
men	O
and	O
32	O
%	O
women	O
had	O
prolonged	B-Disease
QTc	I-Disease
interval	I-Disease
.	O
	
None	O
of	O
the	O
subjects	O
treated	O
with	O
buprenorphine	B-Chemical
had	O
QTc	O
interval	O
>	O
0	O
.	O
440	O
s	O
((	O
1	O
/	O
2	O
)).	O
	
A	O
50	O
mg	O
higher	O
methadone	B-Chemical
dose	O
was	O
associated	O
with	O
a	O
1	O
.	O
2	O
(	O
95	O
%	O
CI	O
1	O
.	O
1	O
to	O
1	O
.	O
4	O
)	O
times	O
higher	O
odds	O
for	O
syncope	B-Disease
.	O
	
CONCLUSIONS	O
:	O
Methadone	B-Chemical
is	O
associated	O
with	O
QT	B-Disease
prolongation	I-Disease
and	O
higher	O
reporting	O
of	O
syncope	B-Disease
in	O
a	O
population	O
of	O
heroin	B-Disease
addicts	I-Disease
.	O
	
	
R58fs	O
mutation	O
in	O
the	O
HGD	O
gene	O
in	O
a	O
family	O
with	O
alkaptonuria	B-Disease
in	O
the	O
UAE	O
.	O
	
This	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
prevalence	O
of	O
alkaptonuria	B-Disease
in	O
the	O
UAE	O
population	O
and	O
to	O
identify	O
the	O
genotype	O
of	O
affected	O
individuals	O
.	O
	
In	O
a	O
3	O
stage	O
sampling	O
technique	O
2981	O
pupils	O
from	O
Government	O
schools	O
in	O
Al	O
Ain	O
and	O
private	O
schools	O
in	O
Dubai	O
were	O
selected	O
to	O
take	O
part	O
in	O
the	O
study	O
","	O
of	O
whom	O
2857	O
provided	O
urine	O
samples	O
.	O
	
Urine	O
collected	O
was	O
analysed	O
for	O
homogentisic	B-Chemical
acid	I-Chemical
by	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
.	O
	
Genomic	O
DNA	O
was	O
isolated	O
from	O
the	O
white	O
blood	O
cells	O
of	O
all	O
family	O
members	O
of	O
the	O
affected	O
case	O
following	O
standard	O
established	O
protocols	O
.	O
	
Specific	O
PRC	O
primers	O
were	O
designed	O
to	O
amplify	O
all	O
14	O
exons	O
of	O
the	O
HGD	O
gene	O
with	O
the	O
flanking	O
intronic	O
sequences	O
including	O
the	O
splice	O
site	O
sequences	O
.	O
	
2857	O
children	O
returned	O
a	O
viable	O
urine	O
sample	O
","	O
of	O
which	O
one	O
was	O
highly	O
positive	O
for	O
homogentisic	B-Chemical
acid	I-Chemical
.	O
	
All	O
12	O
members	O
of	O
this	O
girl	O
'	O
s	O
family	O
were	O
studied	O
and	O
one	O
","	O
a	O
22	O
year	O
old	O
brother	O
","	O
was	O
found	O
to	O
excrete	O
HGA	B-Chemical
.	O
	
Another	O
","	O
a	O
sister	O
who	O
had	O
not	O
provided	O
a	O
urine	O
sample	O
","	O
was	O
discovered	O
by	O
genetic	O
testing	O
.	O
	
There	O
were	O
no	O
complaints	O
of	O
joint	B-Disease
pain	I-Disease
or	O
other	O
symptoms	O
in	O
any	O
member	O
of	O
this	O
family	O
.	O
	
Parents	O
were	O
first	O
cousins	O
.	O
	
We	O
found	O
a	O
single	O
nucleotide	O
deletion	O
c	O
.	O
342delA	O
","	O
located	O
in	O
exon	O
3	O
","	O
which	O
resulted	O
in	O
a	O
frameshift	O
at	O
amino	O
acid	O
position	O
58	O
(	O
p	O
.	O
Arg58fs	O
or	O
p	O
.	O
R58fs	O
).	O
	
Alkaptonuria	B-Disease
may	O
be	O
more	O
common	O
than	O
it	O
is	O
thought	O
to	O
be	O
with	O
an	O
allele	O
prevalence	O
estimated	O
at	O
0	O
.	O
107	O
(	O
95	O
%	O
CI	O
0	O
.	O
392	O
-	O
0	O
.	O
3473	O
).	O
	
The	O
R58fs	O
mutation	O
is	O
old	O
","	O
perhaps	O
having	O
occurred	O
several	O
thousand	O
years	O
ago	O
","	O
and	O
has	O
spread	O
over	O
a	O
large	O
geographical	O
area	O
.	O
	
	
Neuregulin	O
-	O
1	O
beta	O
and	O
neuregulin	O
-	O
1	O
alpha	O
differentially	O
affect	O
the	O
migration	O
and	O
invasion	O
of	O
malignant	B-Disease
peripheral	I-Disease
nerve	I-Disease
sheath	I-Disease
tumor	I-Disease
cells	O
.	O
	
Malignant	B-Disease
peripheral	I-Disease
nerve	I-Disease
sheath	I-Disease
tumors	I-Disease
(	O
MPNSTs	B-Disease
)	O
are	O
the	O
most	O
common	O
malignancy	B-Disease
associated	O
with	O
neurofibromatosis	O
Type	O
1	O
(	O
NF1	O
).	O
	
These	O
Schwann	O
cell	O
lineage	O
-	O
derived	O
sarcomas	B-Disease
aggressively	O
invade	O
adjacent	O
nerve	O
and	O
soft	O
tissue	O
","	O
frequently	O
precluding	O
surgical	O
resection	O
.	O
	
Little	O
is	O
known	O
regarding	O
the	O
mechanisms	O
underlying	O
this	O
invasive	O
behavior	O
.	O
	
We	O
have	O
shown	O
that	O
MPNSTs	B-Disease
express	O
neuregulin	O
-	O
1	O
(	O
NRG	O
-	O
1	O
)	O
beta	O
isoforms	O
","	O
which	O
promote	O
Schwann	O
cell	O
migration	O
during	O
development	O
","	O
and	O
NRG	O
-	O
1	O
alpha	O
isoforms	O
","	O
whose	O
effects	O
on	O
Schwann	O
cells	O
are	O
poorly	O
understood	O
.	O
	
Hypothesizing	O
that	O
NRG	O
-	O
1	O
beta	O
and	O
/	O
or	O
NRG	O
-	O
1	O
alpha	O
promote	O
MPNST	B-Disease
invasion	O
","	O
we	O
found	O
that	O
NRG	O
-	O
1	O
beta	O
promoted	O
MPNST	B-Disease
migration	O
in	O
a	O
substrate	O
-	O
specific	O
manner	O
","	O
markedly	O
enhancing	O
migration	O
on	O
laminin	O
but	O
not	O
on	O
collagen	O
type	O
I	O
or	O
fibronectin	O
.	O
	
The	O
NRG	O
-	O
1	O
receptors	O
erbB3	O
and	O
erbB4	O
were	O
present	O
in	O
MPNST	B-Disease
invadopodia	O
(	O
processes	O
mediating	O
invasion	O
)","	O
partially	O
colocalized	O
with	O
focal	O
adhesion	O
kinase	O
and	O
the	O
laminin	O
receptor	O
beta	O
(	O
1	O
)-	O
integrin	O
and	O
coimmunoprecipitated	O
with	O
beta	O
(	O
1	O
)-	O
integrin	O
.	O
	
NRG	O
-	O
1	O
beta	O
stimulated	O
human	O
and	O
murine	O
MPNST	B-Disease
cell	O
migration	O
and	O
invasion	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
in	O
three	O
-	O
dimensional	O
migration	O
assays	O
","	O
acting	O
as	O
a	O
chemotactic	O
factor	O
.	O
	
Both	O
baseline	O
and	O
NRG	O
-	O
1	O
beta	O
-	O
induced	O
migration	O
were	O
erbB	O
-	O
dependent	O
and	O
required	O
the	O
action	O
of	O
MEK	O
1	O
/	O
2	O
","	O
SAPK	O
/	O
JNK	O
","	O
PI	O
-	O
3	O
kinase	O
","	O
Src	O
family	O
kinases	O
and	O
ROCK	O
-	O
I	O
/	O
II	O
.	O
	
In	O
contrast	O
","	O
NRG	O
-	O
1	O
alpha	O
had	O
no	O
effect	O
on	O
the	O
migration	O
and	O
invasion	O
of	O
some	O
MPNST	B-Disease
lines	O
and	O
inhibited	O
the	O
migration	O
of	O
others	O
.	O
	
While	O
NRG	O
-	O
1	O
beta	O
potently	O
and	O
persistently	O
activated	O
Erk	O
1	O
/	O
2	O
","	O
SAPK	O
/	O
JNK	O
","	O
Akt	O
and	O
Src	O
family	O
kinases	O
","	O
NRG	O
-	O
1	O
alpha	O
did	O
not	O
activate	O
Akt	O
and	O
activated	O
these	O
other	O
kinases	O
with	O
kinetics	O
distinct	O
from	O
those	O
evident	O
in	O
NRG	O
-	O
1	O
beta	O
-	O
stimulated	O
cells	O
.	O
	
These	O
findings	O
suggest	O
that	O
NRG	O
-	O
1	O
beta	O
enhances	O
MPNST	B-Disease
migration	O
and	O
that	O
NRG	O
-	O
1	O
beta	O
and	O
NRG	O
-	O
1	O
alpha	O
differentially	O
modulate	O
this	O
process	O
.	O
	
	
Exploratory	O
investigation	O
on	O
functional	O
significance	O
of	O
ETS2	O
and	O
SIM2	O
genes	O
in	O
Down	B-Disease
syndrome	I-Disease
.	O
	
Trisomy	O
of	O
the	O
21	O
{	O
st	O
}	O
chromosome	O
leads	O
to	O
an	O
over	O
dosage	O
of	O
several	O
regulatory	O
genes	O
in	O
Down	B-Disease
syndrome	I-Disease
(	O
DS	B-Disease
).	O
	
Though	O
allelic	O
and	O
genotypic	O
combinations	O
formed	O
between	O
genes	O
are	O
interesting	O
","	O
till	O
date	O
","	O
this	O
particular	O
area	O
has	O
never	O
been	O
explored	O
in	O
DS	B-Disease
.	O
	
In	O
the	O
present	O
investigation	O
four	O
SNPs	O
in	O
two	O
transcription	O
factors	O
","	O
Single	O
minded	O
2	O
(	O
SIM2	O
)	O
and	O
V	O
-	O
ets	O
erythroblastosis	O
virus	O
E26	O
oncogene	O
homolog2	O
(	O
ETS2	O
)","	O
located	O
in	O
the	O
21	O
{	O
st	O
}	O
chromosome	O
were	O
genotyped	O
to	O
understand	O
their	O
role	O
in	O
DS	B-Disease
.	O
	
Genomic	O
DNA	O
of	O
eastern	O
Indian	O
probands	O
with	O
DS	B-Disease
(	O
N	O
=	O
132	O
)","	O
their	O
parents	O
(	O
N	O
=	O
209	O
)	O
and	O
ethnically	O
matched	O
controls	O
(	O
N	O
=	O
149	O
)	O
was	O
subjected	O
to	O
PCR	O
-	O
based	O
analyses	O
of	O
functionally	O
important	O
SNPs	O
followed	O
by	O
statistical	O
analyses	O
.	O
	
ETS2	O
rs461155	O
showed	O
high	O
heterozygosity	O
in	O
DS	B-Disease
.	O
	
Significantly	O
lower	O
frequency	O
of	O
SIM2	O
C	O
-	O
G	O
haplotype	O
(	O
rs2073601	O
-	O
rs2073416	O
)	O
was	O
noticed	O
in	O
individuals	O
with	O
DS	B-Disease
(	O
P	O
value	O
=	O
0	O
.	O
1669	O
)	O
and	O
their	O
fathers	O
(	O
P	O
value	O
=	O
0	O
.	O
1185	O
).	O
	
Significantly	O
lower	O
frequency	O
of	O
the	O
A	O
-	O
C	O
-	O
C	O
-	O
G	O
with	O
higher	O
frequency	O
of	O
A	O
-	O
C	O
-	O
A	O
-	O
G	O
haplotypes	O
was	O
also	O
noticed	O
in	O
subjects	O
with	O
DS	B-Disease
(	O
P	O
value	O
=	O
0	O
.	O
2089	O
and	O
0	O
.	O
588	O
respectively	O
).	O
	
Data	O
obtained	O
indicate	O
that	O
the	O
rs2073601	O
'	O
A	O
'	O
allele	O
","	O
responsible	O
for	O
nonsynonymous	O
substitution	O
of	O
leucine	O
to	O
methionine	O
","	O
may	O
have	O
some	O
role	O
in	O
DS	B-Disease
in	O
this	O
population	O
.	O
	
	
Crucial	O
role	O
of	O
calbindin	O
-	O
D28k	O
in	O
the	O
pathogenesis	O
of	O
Alzheimer	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
mouse	O
model	O
.	O
	
Calbindin	O
-	O
D28k	O
(	O
CB	O
)","	O
one	O
of	O
the	O
major	O
calcium	B-Chemical
-	O
binding	O
and	O
buffering	O
proteins	O
","	O
has	O
a	O
critical	O
role	O
in	O
preventing	O
a	O
neuronal	B-Disease
death	I-Disease
as	O
well	O
as	O
maintaining	O
calcium	B-Chemical
homeostasis	O
.	O
	
Although	O
marked	O
reductions	O
of	O
CB	O
expression	O
have	O
been	O
observed	O
in	O
the	O
brains	O
of	O
mice	O
and	O
humans	O
with	O
Alzheimer	B-Disease
disease	I-Disease
(	O
AD	B-Disease
)","	O
it	O
is	O
unknown	O
whether	O
these	O
changes	O
contribute	O
to	O
AD	B-Disease
-	O
related	O
dysfunction	O
.	O
	
To	O
determine	O
the	O
pathogenic	O
importance	O
of	O
CB	O
depletions	O
in	O
AD	B-Disease
models	O
","	O
we	O
crossed	O
5	O
familial	O
AD	B-Disease
mutations	O
(	O
5XFAD	B-Disease
";"	O
Tg	O
)	O
mice	O
with	O
CB	O
knock	O
-	O
out	O
(	O
CBKO	O
)	O
mice	O
and	O
generated	O
a	O
novel	O
line	O
CBKO	O
.	O
5XFAD	B-Disease
(	O
CBKOTg	O
)	O
mice	O
.	O
	
We	O
first	O
identified	O
the	O
change	O
of	O
signaling	O
pathways	O
and	O
differentially	O
expressed	O
proteins	O
globally	O
by	O
removing	O
CB	O
in	O
Tg	O
mice	O
using	O
mass	O
spectrometry	O
and	O
antibody	O
microarray	O
.	O
	
Immunohistochemistry	O
showed	O
that	O
CBKOTg	O
mice	O
had	O
significant	O
neuronal	B-Disease
loss	I-Disease
in	O
the	O
subiculum	O
area	O
without	O
changing	O
the	O
magnitude	O
(	O
number	O
)	O
of	O
amyloid	O
b	O
-	O
peptide	O
(	O
Ab	O
)	O
plaques	O
deposition	O
and	O
elicited	O
significant	O
apoptotic	O
features	O
and	O
mitochondrial	B-Disease
dysfunction	I-Disease
compared	O
with	O
Tg	O
mice	O
.	O
	
Moreover	O
","	O
CBKOTg	O
mice	O
reduced	O
levels	O
of	O
phosphorylated	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
)	O
1	O
/	O
2	O
and	O
cAMP	O
response	O
element	O
-	O
binding	O
protein	O
at	O
Ser	O
-	O
133	O
and	O
synaptic	O
molecules	O
such	O
as	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
receptor	O
1	O
(	O
NMDA	O
receptor	O
1	O
)","	O
NMDA	O
receptor	O
2A	O
","	O
PSD	O
-	O
95	O
and	O
synaptophysin	O
in	O
the	O
subiculum	O
compared	O
with	O
Tg	O
mice	O
.	O
	
Importantly	O
","	O
this	O
is	O
the	O
first	O
experimental	O
evidence	O
that	O
removal	O
of	O
CB	O
from	O
amyloid	O
precursor	O
protein	O
/	O
presenilin	O
transgenic	O
mice	O
aggravates	O
AD	B-Disease
pathogenesis	O
","	O
suggesting	O
that	O
CB	O
has	O
a	O
critical	O
role	O
in	O
AD	B-Disease
pathogenesis	O
.	O
	
	
Role	O
of	O
stress	O
-	O
activated	O
OCT4A	O
in	O
the	O
cell	O
fate	O
decisions	O
of	O
embryonal	B-Disease
carcinoma	I-Disease
cells	O
treated	O
with	O
etoposide	B-Chemical
.	O
	
Tumor	O
cellular	O
senescence	O
induced	O
by	O
genotoxic	O
treatments	O
has	O
recently	O
been	O
found	O
to	O
be	O
paradoxically	O
linked	O
to	O
the	O
induction	O
of	O
stemness	O
"."	O
	
This	O
observation	O
is	O
critical	O
as	O
it	O
directly	O
impinges	O
upon	O
the	O
response	O
of	O
tumors	B-Disease
to	O
current	O
chemo	O
-	O
radio	O
-	O
therapy	O
treatment	O
regimens	O
.	O
	
Previously	O
","	O
we	O
showed	O
that	O
following	O
etoposide	B-Chemical
(	O
ETO	B-Chemical
)	O
treatment	O
embryonal	B-Disease
carcinoma	I-Disease
PA	O
-	O
1	O
cells	O
undergo	O
a	O
p53	O
-	O
dependent	O
upregulation	O
of	O
OCT4A	O
and	O
p21Cip1	O
(	O
governing	O
self	O
-	O
renewal	O
and	O
regulating	O
cell	O
cycle	O
inhibition	O
and	O
senescence	O
","	O
respectively	O
).	O
	
Here	O
we	O
report	O
further	O
detail	O
on	O
the	O
relationship	O
between	O
these	O
and	O
other	O
critical	O
cell	O
-	O
fate	O
regulators	O
.	O
	
PA	O
-	O
1	O
cells	O
treated	O
with	O
ETO	B-Chemical
display	O
highly	O
heterogeneous	O
increases	O
in	O
OCT4A	O
and	O
p21Cip1	O
indicative	O
of	O
dis	O
-	O
adaptation	O
catastrophe	O
.	O
	
Silencing	O
OCT4A	O
suppresses	O
p21Cip1	O
","	O
changes	O
cell	O
cycle	O
regulation	O
and	O
subsequently	O
suppresses	O
terminal	O
senescence	O
";"	O
p21Cip1	O
-	O
silencing	O
did	O
not	O
affect	O
OCT4A	O
expression	O
or	O
cellular	O
phenotype	O
.	O
	
SOX2	O
and	O
NANOG	O
expression	O
did	O
not	O
change	O
following	O
ETO	B-Chemical
treatment	O
suggesting	O
a	O
dissociation	O
of	O
OCT4A	O
from	O
its	O
pluripotency	O
function	O
.	O
	
Instead	O
","	O
ETO	B-Chemical
-	O
induced	O
OCT4A	O
was	O
concomitant	O
with	O
activation	O
of	O
AMPK	O
","	O
a	O
key	O
component	O
of	O
metabolic	O
stress	O
and	O
autophagy	O
regulation	O
.	O
	
p16ink4a	O
","	O
the	O
inducer	O
of	O
terminal	O
senescence	O
","	O
underwent	O
autophagic	O
sequestration	O
in	O
the	O
cytoplasm	O
of	O
ETO	B-Chemical
-	O
treated	O
cells	O
","	O
allowing	O
alternative	O
cell	O
fates	O
.	O
	
Accordingly	O
","	O
failure	O
of	O
autophagy	O
was	O
accompanied	O
by	O
an	O
accumulation	O
of	O
p16ink4a	O
","	O
nuclear	O
disintegration	O
","	O
and	O
loss	O
of	O
cell	O
recovery	O
.	O
	
Together	O
","	O
these	O
findings	O
imply	O
that	O
OCT4A	O
induction	O
following	O
DNA	O
damage	O
in	O
PA	O
-	O
1	O
cells	O
","	O
performs	O
a	O
cell	O
stress	O
","	O
rather	O
than	O
self	O
-	O
renewal	O
","	O
function	O
by	O
moderating	O
the	O
expression	O
of	O
p21Cip1	O
","	O
which	O
alongside	O
AMPK	O
helps	O
to	O
then	O
regulate	O
autophagy	O
.	O
	
Moreover	O
","	O
this	O
data	O
indicates	O
that	O
exhaustion	O
of	O
autophagy	O
","	O
through	O
persistent	O
DNA	O
damage	O
","	O
is	O
the	O
cause	O
of	O
terminal	O
cellular	O
senescence	O
.	O
	
	
Putative	O
Prostate	B-Disease
Cancer	I-Disease
Risk	O
SNP	O
in	O
an	O
Androgen	O
Receptor	O
-	O
Binding	O
Site	O
of	O
the	O
Melanophilin	O
Gene	O
Illustrates	O
Enrichment	O
of	O
Risk	O
SNPs	O
in	O
Androgen	O
Receptor	O
Target	O
Sites	O
.	O
	
Genome	O
-	O
wide	O
association	O
studies	O
have	O
identified	O
genomic	O
loci	O
","	O
whose	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
predispose	O
to	O
prostate	B-Disease
cancer	I-Disease
(	O
PCa	B-Disease
).	O
	
However	O
","	O
the	O
mechanisms	O
of	O
most	O
of	O
these	O
variants	O
are	O
largely	O
unknown	O
.	O
	
We	O
integrated	O
chromatin	O
-	O
immunoprecipitation	O
-	O
coupled	O
sequencing	O
and	O
microarray	O
expression	O
profiling	O
in	O
TMPRSS2	O
-	O
ERG	O
gene	O
rearrangement	O
positive	O
DUCaP	O
cells	O
with	O
the	O
GWAS	O
PCa	B-Disease
risk	O
SNPs	O
catalog	O
to	O
identify	O
disease	O
susceptibility	O
SNPs	O
localized	O
within	O
functional	O
androgen	O
receptor	O
-	O
binding	O
sites	O
(	O
ARBSs	O
).	O
	
Among	O
the	O
48	O
GWAS	O
index	O
risk	O
SNPs	O
and	O
3	O
","	O
917	O
linked	O
SNPs	O
","	O
80	O
were	O
found	O
located	O
in	O
ARBSs	O
.	O
	
Of	O
these	O
","	O
rs11891426	O
:	O
T	O
>	O
G	O
in	O
an	O
intron	O
of	O
the	O
melanophilin	O
gene	O
(	O
MLPH	O
)	O
was	O
within	O
a	O
novel	O
putative	O
auxiliary	O
AR	O
-	O
binding	O
motif	O
","	O
which	O
is	O
enriched	O
in	O
the	O
neighborhood	O
of	O
canonical	O
androgen	B-Chemical
-	O
responsive	O
elements	O
.	O
	
T	O
>	O
G	O
exchange	O
attenuated	O
the	O
transcriptional	O
activity	O
of	O
the	O
ARBS	O
in	O
an	O
AR	O
reporter	O
gene	O
assay	O
.	O
	
The	O
expression	O
of	O
MLPH	O
in	O
primary	O
prostate	B-Disease
tumors	I-Disease
was	O
significantly	O
lower	O
in	O
those	O
with	O
the	O
G	O
compared	O
with	O
the	O
T	O
allele	O
and	O
correlated	O
significantly	O
with	O
AR	O
protein	O
.	O
	
Higher	O
melanophilin	O
level	O
in	O
prostate	O
tissue	O
of	O
patients	O
with	O
a	O
favorable	O
PCa	B-Disease
risk	O
profile	O
points	O
out	O
a	O
tumor	B-Disease
-	O
suppressive	O
effect	O
.	O
	
These	O
results	O
unravel	O
a	O
hidden	O
link	O
between	O
AR	O
and	O
a	O
functional	O
putative	O
PCa	B-Disease
risk	O
SNP	O
","	O
whose	O
allele	O
alteration	O
affects	O
androgen	B-Chemical
regulation	O
of	O
its	O
host	O
gene	O
MLPH	O
.	O
	
	
Voltage	O
-	O
Dependent	O
Anion	O
Channel	O
1	O
(	O
VDAC1	O
)	O
Participates	O
the	O
Apoptosis	O
of	O
the	O
Mitochondrial	B-Disease
Dysfunction	I-Disease
in	O
Desminopathy	B-Disease
.	O
	
Desminopathies	B-Disease
caused	O
by	O
the	O
mutation	O
in	O
the	O
gene	O
coding	O
for	O
desmin	O
are	O
genetically	O
protein	O
aggregation	O
myopathies	B-Disease
.	O
	
Mitochondrial	B-Disease
dysfunction	I-Disease
is	O
one	O
of	O
pathological	O
changes	O
in	O
the	O
desminopathies	B-Disease
at	O
the	O
earliest	O
stage	O
.	O
	
The	O
molecular	O
mechanisms	O
of	O
mitochondria	B-Disease
dysfunction	I-Disease
in	O
desminopathies	B-Disease
remain	O
exclusive	O
.	O
	
VDAC1	O
regulates	O
mitochondrial	O
uptake	O
across	O
the	O
outer	O
membrane	O
and	O
mitochondrial	O
outer	O
membrane	O
permeabilization	O
(	O
MOMP	O
).	O
	
Relationships	O
between	O
desminopathies	B-Disease
and	O
Voltage	O
-	O
dependent	O
anion	O
channel	O
1	O
(	O
VDAC1	O
)	O
remain	O
unclear	O
.	O
	
Here	O
we	O
successfully	O
constructed	O
the	O
desminopathy	B-Disease
rat	O
model	O
","	O
evaluated	O
with	O
conventional	O
stains	O
","	O
containing	O
hematoxylin	O
and	O
eosin	O
(	O
HE	O
)","	O
Gomori	O
Trichrome	O
(	O
MGT	O
)","	O
(	O
PAS	O
)","	O
red	O
oil	O
(	O
ORO	O
)","	O
NADH	O
-	O
TR	O
","	O
SDH	O
staining	O
and	O
immunohistochemistry	O
.	O
	
Immunofluorescence	O
results	O
showed	O
that	O
VDAC1	O
was	O
accumulated	O
in	O
the	O
desmin	O
highly	O
stained	O
area	O
of	O
muscle	O
fibers	O
of	O
desminopathy	B-Disease
patients	O
or	O
desminopathy	B-Disease
rat	O
model	O
compared	O
to	O
the	O
normal	O
ones	O
.	O
	
Meanwhile	O
apoptosis	O
related	O
proteins	O
bax	O
and	O
ATF2	O
were	O
involved	O
in	O
desminopathy	B-Disease
patients	O
and	O
desminopathy	B-Disease
rat	O
model	O
","	O
but	O
not	O
bcl	O
-	O
2	O
","	O
bcl	O
-	O
xl	O
or	O
HK2	O
.	O
VDAC1	O
and	O
desmin	O
are	O
closely	O
relevant	O
in	O
the	O
tissue	O
splices	O
of	O
deminopathies	O
patients	O
and	O
rats	O
with	O
desminopathy	B-Disease
at	O
protein	O
lever	O
.	O
	
Moreover	O
","	O
apoptotic	O
proteins	O
are	O
also	O
involved	O
in	O
the	O
desminopathies	B-Disease
","	O
like	O
bax	O
","	O
ATF2	O
","	O
but	O
not	O
bcl	O
-	O
2	O
","	O
bcl	O
-	O
xl	O
or	O
HK2	O
.	O
	
This	O
pathological	O
analysis	O
presents	O
the	O
correlation	O
between	O
VDAC1	O
and	O
desmin	O
","	O
and	O
apoptosis	O
related	O
proteins	O
are	O
correlated	O
in	O
the	O
desminopathy	B-Disease
.	O
	
Furthermore	O
","	O
we	O
provide	O
a	O
rat	O
model	O
of	O
desminopathy	B-Disease
for	O
the	O
investigation	O
of	O
desmin	O
related	O
myopathy	B-Disease
.	O
	
	
Salidroside	B-Chemical
Ameliorates	O
Renal	B-Disease
Interstitial	I-Disease
Fibrosis	I-Disease
by	O
Inhibiting	O
the	O
TLR4	O
/	O
NF	O
-	O
kappaB	O
and	O
MAPK	O
Signaling	O
Pathways	O
.	O
	
Salidroside	B-Chemical
(	O
Sal	B-Chemical
)	O
is	O
an	O
active	O
ingredient	O
that	O
is	O
isolated	O
from	O
Rhodiola	O
rosea	O
","	O
which	O
has	O
been	O
reported	O
to	O
have	O
anti	O
-	O
inflammatory	B-Disease
activities	O
and	O
a	O
renal	O
protective	O
effect	O
.	O
	
However	O
","	O
the	O
role	O
of	O
Sal	B-Chemical
on	O
renal	B-Disease
fibrosis	I-Disease
has	O
not	O
yet	O
been	O
elucidated	O
.	O
	
Here	O
","	O
the	O
purpose	O
of	O
the	O
current	O
study	O
is	O
to	O
test	O
the	O
protective	O
effects	O
of	O
Sal	B-Chemical
against	O
renal	B-Disease
interstitial	I-Disease
fibrosis	I-Disease
(	O
RIF	B-Disease
)","	O
and	O
to	O
explore	O
the	O
underlying	O
mechanisms	O
using	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
models	O
.	O
	
In	O
this	O
study	O
","	O
we	O
establish	O
the	O
unilateral	B-Disease
ureteric	I-Disease
obstruction	I-Disease
(	O
UUO	B-Disease
)	O
or	O
folic	B-Chemical
acid	I-Chemical
(	O
FA	B-Chemical
)-	O
induced	O
mice	O
renal	B-Disease
interstitial	I-Disease
fibrosis	I-Disease
in	O
vivo	O
and	O
the	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)-	O
beta1	O
-	O
stimulated	O
human	O
proximal	O
tubular	O
epithelial	O
cell	O
(	O
HK	O
-	O
2	O
)	O
model	O
in	O
vitro	O
.	O
	
The	O
levels	O
of	O
kidney	O
functional	O
parameters	O
and	O
inflammatory	B-Disease
cytokines	O
in	O
serum	O
are	O
examined	O
.	O
	
The	O
degree	O
of	O
renal	B-Disease
damage	I-Disease
and	O
fibrosis	B-Disease
is	O
determined	O
by	O
histological	O
assessment	O
.	O
	
Immunohistochemistry	O
and	O
western	O
blotting	O
are	O
used	O
to	O
determine	O
the	O
mechanisms	O
of	O
Sal	B-Chemical
against	O
RIF	B-Disease
.	O
	
Our	O
results	O
show	O
that	O
treatment	O
with	O
Sal	B-Chemical
can	O
ameliorate	O
tubular	B-Disease
injury	I-Disease
and	O
deposition	O
of	O
the	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
components	O
(	O
including	O
collagen	O
SH	O
and	O
collagen	O
I	O
).	O
	
Furthermore	O
","	O
Sal	B-Chemical
administration	O
significantly	O
suppresses	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)","	O
as	O
evidenced	O
by	O
a	O
decreased	O
expression	O
of	O
alpha	O
-	O
SMA	O
","	O
vimentin	O
","	O
TGF	O
-	O
beta1	O
","	O
snail	O
","	O
slug	O
","	O
and	O
a	O
largely	O
restored	O
expression	O
of	O
E	O
-	O
cadherin	O
.	O
	
Additionally	O
","	O
Sal	B-Chemical
also	O
reduces	O
the	O
levels	O
of	O
serum	O
biochemical	O
markers	O
(	O
serum	O
creatinine	B-Chemical
","	O
Scr	O
";"	O
blood	O
urea	B-Chemical
nitrogen	I-Chemical
","	O
BUN	O
";"	O
and	O
uric	B-Chemical
acid	I-Chemical
","	O
UA	B-Chemical
)	O
and	O
decreases	O
the	O
release	O
of	O
inflammatory	B-Disease
cytokines	O
(	O
IL	O
-	O
1beta	O
","	O
IL	O
-	O
6	O
","	O
TNF	O
-	O
alpha	O
).	O
	
Further	O
study	O
revealed	O
that	O
the	O
effect	O
of	O
Sal	B-Chemical
on	O
renal	B-Disease
interstitial	I-Disease
fibrosis	I-Disease
is	O
associated	O
with	O
the	O
lower	O
expression	O
of	O
TLR4	O
","	O
p	O
-	O
IkappaBalpha	O
","	O
p	O
-	O
NF	O
-	O
kappaB	O
and	O
mitogen	O
-	O
activated	O
protein	O
kinases	O
(	O
MAPK	O
)","	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O
	
In	O
conclusion	O
","	O
Sal	B-Chemical
treatment	O
improves	O
kidney	O
function	O
","	O
ameliorates	O
the	O
deposition	O
of	O
the	O
ECM	O
components	O
and	O
relieves	O
the	O
protein	O
levels	O
of	O
EMT	O
markers	O
in	O
mouse	O
kidneys	O
and	O
HK	O
-	O
2	O
cells	O
.	O
	
Furthermore	O
","	O
Sal	B-Chemical
treatment	O
significantly	O
decreases	O
the	O
release	O
of	O
inflammatory	B-Disease
cytokines	O
and	O
inhibits	O
the	O
TLR4	O
/	O
NF	O
-	O
kappaB	O
and	O
MAPK	O
signaling	O
pathways	O
.	O
	
Collectively	O
","	O
these	O
results	O
suggest	O
that	O
the	O
administration	O
of	O
Sal	B-Chemical
could	O
be	O
a	O
novel	O
therapeutic	O
strategy	O
in	O
treating	O
renal	B-Disease
fibrosis	I-Disease
.	O
	
	
Two	O
novel	O
mutations	O
","	O
L490R	O
and	O
V561X	O
","	O
of	O
the	O
transferrin	O
receptor	O
2	O
gene	O
in	O
Japanese	O
patients	O
with	O
hemochromatosis	B-Disease
.	O
	
BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
The	O
low	O
prevalence	O
of	O
the	O
C282Y	O
mutation	O
of	O
the	O
HFE	O
gene	O
in	O
Japan	O
means	O
that	O
the	O
genetic	O
background	O
of	O
hemochromatosis	B-Disease
in	O
Japanese	O
patients	O
remains	O
unclear	O
.	O
	
In	O
a	O
previous	O
report	O
","	O
we	O
showed	O
that	O
3	O
patients	O
from	O
one	O
family	O
had	O
an	O
AVAQ	O
594	O
-	O
597	O
deletion	O
of	O
the	O
transferrin	O
receptor	O
(	O
TfR2	O
)	O
gene	O
.	O
	
This	O
suggests	O
that	O
the	O
TfR2	O
gene	O
is	O
involved	O
in	O
hemochromatosis	B-Disease
in	O
Japanese	O
patients	O
.	O
	
DESIGN	O
AND	O
METHODS	O
:	O
Nine	O
patients	O
clinically	O
diagnosed	O
with	O
hemochromatosis	B-Disease
were	O
included	O
in	O
the	O
study	O
.	O
	
DNA	O
was	O
extracted	O
from	O
whole	O
blood	O
samples	O
collected	O
with	O
informed	O
consent	O
.	O
	
The	O
HFE	O
and	O
TfR2	O
genes	O
were	O
analyzed	O
by	O
sequencing	O
the	O
coding	O
region	O
and	O
splicing	O
sites	O
.	O
	
RESULTS	O
:	O
There	O
were	O
no	O
mutations	O
in	O
the	O
HFE	O
gene	O
.	O
	
In	O
the	O
TfR2	O
gene	O
","	O
2	O
novel	O
mutations	O
","	O
1469T	O
->	O
G	O
(	O
L490R	O
)	O
and	O
1665delC	O
(	O
V561X	O
)","	O
were	O
found	O
in	O
2	O
patients	O
.	O
	
A	O
known	O
variation	O
","	O
714C	O
->	O
(	O
I238M	O
)","	O
was	O
also	O
found	O
in	O
the	O
patient	O
with	O
L490R	O
.	O
	
The	O
patient	O
homozygous	O
for	O
both	O
L490R	O
and	O
I238M	O
presented	O
with	O
a	O
mild	O
manifestation	O
of	O
hemochromatosis	B-Disease
at	O
the	O
age	O
of	O
41	O
years	O
.	O
	
His	O
liver	O
was	O
cirrhotic	B-Disease
with	O
parenchymal	O
iron	B-Chemical
deposits	O
and	O
the	O
result	O
of	O
a	O
glucose	B-Chemical
tolerance	O
test	O
was	O
compatible	O
with	O
diabetes	B-Disease
mellitus	I-Disease
.	O
	
The	O
patient	O
homozygous	O
for	O
V561X	O
had	O
severe	O
iron	B-Disease
overload	I-Disease
with	O
the	O
triad	O
of	O
cirrhosis	B-Disease
","	O
diabetes	B-Disease
mellitus	I-Disease
and	O
skin	B-Disease
pigmentation	I-Disease
at	O
the	O
age	O
of	O
58	O
years	O
.	O
	
INTERPRETATION	O
AND	O
CONCLUSIONS	O
:	O
Taken	O
together	O
with	O
the	O
previous	O
report	O
","	O
5	O
of	O
our	O
12	O
patients	O
with	O
hemochromatosis	B-Disease
manifesting	O
in	O
middle	O
age	O
had	O
mutations	O
in	O
the	O
TfR2	O
gene	O
.	O
	
Thus	O
","	O
TfR2	O
plays	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
hemochromatosis	B-Disease
in	O
Japan	O
.	O
	
	
Succinylcholine	B-Chemical
-	O
induced	O
masseter	B-Disease
muscle	I-Disease
rigidity	I-Disease
during	O
bronchoscopic	O
removal	O
of	O
a	O
tracheal	O
foreign	O
body	O
.	O
	
Masseter	B-Disease
muscle	I-Disease
rigidity	I-Disease
during	O
general	O
anesthesia	O
is	O
considered	O
an	O
early	O
warning	O
sign	O
of	O
a	O
possible	O
episode	O
of	O
malignant	B-Disease
hyperthermia	I-Disease
.	O
	
The	O
decision	O
whether	O
to	O
continue	O
or	O
discontinue	O
the	O
procedure	O
depends	O
on	O
the	O
urgency	O
of	O
the	O
surgery	O
and	O
severity	O
of	O
masseter	B-Disease
muscle	I-Disease
rigidity	I-Disease
.	O
	
Here	O
","	O
we	O
describe	O
a	O
case	O
of	O
severe	O
masseter	B-Disease
muscle	I-Disease
rigidity	I-Disease
(	O
jaw	B-Disease
of	I-Disease
steel	I-Disease
)	O
after	O
succinylcholine	B-Chemical
(	O
Sch	B-Chemical
)	O
administration	O
during	O
general	O
anesthetic	O
management	O
for	O
rigid	O
bronchoscopic	O
removal	O
of	O
a	O
tracheal	O
foreign	O
body	O
.	O
	
Anesthesia	O
was	O
continued	O
uneventfully	O
with	O
propofol	B-Chemical
infusion	O
while	O
all	O
facilities	O
were	O
available	O
to	O
detect	O
and	O
treat	O
malignant	B-Disease
hyperthermia	I-Disease
.	O
	
	
Identities	O
","	O
frequencies	O
and	O
origins	O
of	O
TMC1	O
mutations	O
causing	O
DFNB7	B-Disease
/	I-Disease
B11	I-Disease
deafness	I-Disease
in	O
Pakistan	O
.	O
	
Non	B-Disease
-	I-Disease
syndromic	I-Disease
deafness	I-Disease
is	O
genetically	O
heterogeneous	O
.	O
	
We	O
previously	O
reported	O
that	O
mutations	O
of	O
transmembrane	O
channel	O
-	O
like	O
gene	O
1	O
(	O
TMC1	O
)	O
cause	O
non	B-Disease
-	I-Disease
syndromic	I-Disease
recessive	I-Disease
deafness	I-Disease
at	O
the	O
DFNB7	O
/	O
B11	O
locus	O
on	O
chromosome	O
9q13	O
-	O
q21	O
in	O
nine	O
Pakistani	O
families	O
.	O
	
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
define	O
the	O
identities	O
","	O
origins	O
and	O
frequencies	O
of	O
TMC1	O
mutations	O
in	O
an	O
expanded	O
cohort	O
of	O
557	O
large	O
Pakistani	O
families	O
segregating	O
recessive	B-Disease
deafness	I-Disease
.	O
	
We	O
screened	O
affected	O
family	O
members	O
for	O
homozygosity	O
at	O
short	O
-	O
tandem	O
repeats	O
flanking	O
known	O
autosomal	B-Disease
recessive	I-Disease
(	I-Disease
DFNB	I-Disease
)	I-Disease
deafness	I-Disease
loci	O
","	O
followed	O
by	O
TMC1	O
sequence	O
analysis	O
in	O
families	O
segregating	O
deafness	B-Disease
linked	O
to	O
DFNB7	O
/	O
B11	O
.	O
	
We	O
identified	O
10	O
new	O
families	O
segregating	O
DFNB7	B-Disease
/	I-Disease
B11	I-Disease
deafness	I-Disease
and	O
TMC1	O
mutations	O
","	O
including	O
three	O
novel	O
alleles	O
.	O
	
Overall	O
","	O
9	O
different	O
TMC1	O
mutations	O
account	O
for	O
deafness	B-Disease
in	O
19	O
(	O
3	O
.	O
4	O
%)	O
of	O
the	O
557	O
Pakistani	O
families	O
.	O
	
A	O
single	O
mutation	O
","	O
p	O
.	O
R34X	O
","	O
causes	O
deafness	B-Disease
in	O
10	O
(	O
1	O
.	O
8	O
%)	O
of	O
the	O
families	O
.	O
	
Genotype	O
analysis	O
of	O
p	O
.	O
R34X	O
-	O
linked	O
markers	O
indicates	O
that	O
it	O
arose	O
from	O
a	O
common	O
founder	O
.	O
	
We	O
also	O
detected	O
p	O
.	O
R34X	O
among	O
normal	O
control	O
samples	O
of	O
African	O
-	O
American	O
and	O
northern	O
European	O
origins	O
","	O
raising	O
the	O
possibility	O
that	O
p	O
.	O
R34X	O
and	O
other	O
mutations	O
of	O
TMC1	O
are	O
prevalent	O
contributors	O
to	O
the	O
genetic	O
load	O
of	O
deafness	B-Disease
across	O
a	O
variety	O
of	O
populations	O
and	O
continents	O
.	O
	
	
Aryl	O
hydrocarbon	O
receptor	O
interacting	O
protein	O
(	O
AIP	O
)	O
gene	O
mutation	O
analysis	O
in	O
children	O
and	O
adolescents	O
with	O
sporadic	O
pituitary	B-Disease
adenomas	I-Disease
.	O
	
OBJECTIVE	O
:	O
Pituitary	B-Disease
adenomas	I-Disease
occur	O
rarely	O
in	O
childhood	O
and	O
adolescence	O
.	O
	
Pituitary	B-Disease
adenoma	I-Disease
predisposition	O
(	O
PAP	O
)	O
has	O
been	O
recently	O
associated	O
with	O
germline	O
mutations	O
in	O
the	O
aryl	O
hydrocarbon	O
receptor	O
interacting	O
protein	O
(	O
AIP	O
)	O
gene	O
.	O
	
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
examine	O
the	O
proportion	O
of	O
germline	O
AIP	O
mutations	O
in	O
apparently	O
sporadic	O
paediatric	O
pituitary	B-Disease
adenomas	I-Disease
.	O
	
DESIGN	O
:	O
Genomic	O
DNA	O
was	O
analysed	O
for	O
mutations	O
in	O
the	O
AIP	O
gene	O
","	O
by	O
PCR	O
amplification	O
and	O
direct	O
sequencing	O
.	O
	
PATIENTS	O
:	O
A	O
population	O
-	O
based	O
cohort	O
consisting	O
of	O
36	O
apparently	O
sporadic	O
paediatric	O
pituitary	B-Disease
adenoma	I-Disease
patients	O
","	O
referred	O
to	O
two	O
medical	O
centres	O
in	O
Italy	O
","	O
was	O
included	O
in	O
the	O
study	O
.	O
	
Patients	O
were	O
either	O
less	O
than	O
18	O
years	O
at	O
diagnosis	O
","	O
or	O
showed	O
clinical	O
evidence	O
of	O
adenoma	B-Disease
development	O
before	O
the	O
age	O
of	O
18	O
years	O
.	O
	
RESULTS	O
:	O
A	O
heterozygous	O
in	O
-	O
frame	O
deletion	O
Y248del	O
(	O
c	O
.	O
742_744delTAC	O
)	O
was	O
identified	O
in	O
one	O
GH	B-Disease
-	I-Disease
secreting	I-Disease
adenoma	I-Disease
patient	O
.	O
	
Loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
analysis	O
of	O
tumour	B-Disease
DNA	O
revealed	O
the	O
loss	O
of	O
the	O
wild	O
-	O
type	O
allele	O
.	O
	
First	O
degree	O
relatives	O
carrying	O
the	O
mutation	O
were	O
clinically	O
unaffected	O
.	O
	
CONCLUSIONS	O
:	O
While	O
mutations	O
were	O
absent	O
in	O
non	O
-	O
GH	B-Disease
-	I-Disease
secreting	I-Disease
adenoma	I-Disease
patients	O
","	O
germline	O
AIP	O
mutations	O
can	O
be	O
found	O
in	O
children	O
and	O
adolescents	O
with	O
GH	B-Disease
-	I-Disease
secreting	I-Disease
tumours	I-Disease
","	O
even	O
in	O
the	O
absence	O
of	O
family	O
history	O
.	O
	
The	O
present	O
study	O
reports	O
the	O
AIP	O
mutation	O
analysis	O
results	O
on	O
patients	O
of	O
a	O
single	O
ethnic	O
origin	O
.	O
	
Clearly	O
","	O
further	O
studies	O
are	O
needed	O
to	O
improve	O
our	O
knowledge	O
on	O
the	O
role	O
of	O
AIP	O
in	O
paediatric	O
pituitary	B-Disease
adenomas	I-Disease
.	O
	
	
Curcumin	B-Chemical
decreases	O
specificity	O
protein	O
expression	O
in	O
bladder	B-Disease
cancer	I-Disease
cells	O
.	O
	
Curcumin	B-Chemical
is	O
the	O
active	O
component	O
of	O
tumeric	O
","	O
and	O
this	O
polyphenolic	O
compound	O
has	O
been	O
extensively	O
investigated	O
as	O
an	O
anticancer	O
drug	O
that	O
modulates	O
multiple	O
pathways	O
and	O
genes	O
.	O
	
In	O
this	O
study	O
","	O
10	O
to	O
25	O
micromol	O
/	O
L	O
curcumin	B-Chemical
inhibited	O
253JB	O
-	O
V	O
and	O
KU7	O
bladder	B-Disease
cancer	I-Disease
cell	O
growth	O
","	O
and	O
this	O
was	O
accompanied	O
by	O
induction	O
of	O
apoptosis	O
and	O
decreased	O
expression	O
of	O
the	O
proapoptotic	O
protein	O
survivin	O
and	O
the	O
angiogenic	O
proteins	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
VEGF	O
receptor	O
1	O
(	O
VEGFR1	O
).	O
	
Because	O
expression	O
of	O
survivin	O
","	O
VEGF	O
","	O
and	O
VEGFR1	O
are	O
dependent	O
on	O
specificity	O
protein	O
(	O
Sp	O
)	O
transcription	O
factors	O
","	O
we	O
also	O
investigated	O
the	O
effects	O
of	O
curcumin	B-Chemical
on	O
Sp	O
protein	O
expression	O
as	O
an	O
underlying	O
mechanism	O
for	O
the	O
apoptotic	O
and	O
antiangiogenic	O
activity	O
of	O
this	O
compound	O
.	O
	
The	O
results	O
show	O
that	O
curcumin	B-Chemical
induced	O
proteasome	O
-	O
dependent	O
down	O
-	O
regulation	O
of	O
Sp1	O
","	O
Sp3	O
","	O
and	O
Sp4	O
in	O
253JB	O
-	O
V	O
and	O
KU7	O
cells	O
.	O
	
Moreover	O
","	O
using	O
RNA	O
interference	O
with	O
small	O
inhibitory	O
RNAs	O
for	O
Sp1	O
","	O
Sp3	O
","	O
and	O
Sp4	O
","	O
we	O
observed	O
that	O
curcumin	B-Chemical
-	O
dependent	O
inhibition	O
of	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)-	O
dependent	O
genes	O
","	O
such	O
as	O
bcl	O
-	O
2	O
","	O
survivin	O
","	O
and	O
cyclin	O
D1	O
","	O
was	O
also	O
due	O
","	O
in	O
part	O
","	O
to	O
loss	O
of	O
Sp	O
proteins	O
.	O
	
Curcumin	B-Chemical
also	O
decreased	O
bladder	B-Disease
tumor	I-Disease
growth	O
in	O
athymic	O
nude	O
mice	O
bearing	O
KU7	O
cells	O
as	O
xenografts	O
and	O
this	O
was	O
accompanied	O
by	O
decreased	O
Sp1	O
","	O
Sp3	O
","	O
and	O
Sp4	O
protein	O
levels	O
in	O
tumors	B-Disease
.	O
	
These	O
results	O
show	O
for	O
the	O
first	O
time	O
that	O
one	O
of	O
the	O
underlying	O
mechanisms	O
of	O
action	O
of	O
curcumin	B-Chemical
as	O
a	O
cancer	B-Disease
chemotherapeutic	O
agent	O
is	O
due	O
","	O
in	O
part	O
","	O
to	O
decreased	O
expression	O
of	O
Sp	O
transcription	O
factors	O
in	O
bladder	B-Disease
cancer	I-Disease
cells	O
.	O
	
	
H3	O
histamine	O
receptor	O
-	O
mediated	O
activation	O
of	O
protein	O
kinase	O
Calpha	O
inhibits	O
the	O
growth	O
of	O
cholangiocarcinoma	B-Disease
in	O
vitro	O
and	O
in	O
vivo	O
.	O
	
Histamine	B-Chemical
regulates	O
functions	O
via	O
four	O
receptors	O
(	O
HRH1	O
","	O
HRH2	O
","	O
HRH3	O
","	O
and	O
HRH4	O
).	O
	
The	O
d	B-Chemical
-	I-Chemical
myo	I-Chemical
-	I-Chemical
inositol	I-Chemical
1	I-Chemical
","	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
trisphosphate	I-Chemical
(	O
IP	B-Chemical
(	I-Chemical
3	I-Chemical
))/	I-Chemical
Ca	I-Chemical
(	I-Chemical
2	I-Chemical
+)/	I-Chemical
protein	O
kinase	O
C	O
(	O
PKC	O
)/	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
pathway	O
regulates	O
cholangiocarcinoma	B-Disease
growth	O
.	O
	
We	O
evaluated	O
the	O
role	O
of	O
HRH3	O
in	O
the	O
regulation	O
of	O
cholangiocarcinoma	B-Disease
growth	O
.	O
	
Expression	O
of	O
HRH3	O
in	O
intrahepatic	O
and	O
extrahepatic	O
cell	O
lines	O
","	O
normal	O
cholangiocytes	O
","	O
and	O
human	O
tissue	O
arrays	O
was	O
measured	O
.	O
	
In	O
Mz	O
-	O
ChA	O
-	O
1	O
cells	O
stimulated	O
with	O
(	B-Chemical
R	I-Chemical
)-(	I-Chemical
alpha	I-Chemical
)-(-)-	I-Chemical
methylhistamine	I-Chemical
dihydrobromide	I-Chemical
(	O
RAMH	B-Chemical
)","	O
we	O
measured	O
(	O
a	O
)	O
cell	O
growth	O
","	O
(	O
b	O
)	O
IP	B-Chemical
(	I-Chemical
3	I-Chemical
)	I-Chemical
and	O
cyclic	B-Chemical
AMP	I-Chemical
levels	O
","	O
and	O
(	O
c	O
)	O
phosphorylation	O
of	O
PKC	O
and	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
isoforms	O
.	O
	
Localization	O
of	O
PKCalpha	O
was	O
visualized	O
by	O
immunofluorescence	O
in	O
cell	O
smears	O
and	O
immunoblotting	O
for	O
PKCalpha	O
in	O
cytosol	O
and	O
membrane	O
fractions	O
.	O
	
Following	O
knockdown	O
of	O
PKCalpha	O
","	O
Mz	O
-	O
ChA	O
-	O
1	O
cells	O
were	O
stimulated	O
with	O
RAMH	B-Chemical
before	O
evaluating	O
cell	O
growth	O
and	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)-	O
1	O
/	O
2	O
phosphorylation	O
.	O
	
In	O
vivo	O
experiments	O
were	O
done	O
in	O
BALB	O
/	O
c	O
nude	O
mice	O
.	O
	
Mice	O
were	O
treated	O
with	O
saline	O
or	O
RAMH	B-Chemical
for	O
44	O
days	O
and	O
tumor	B-Disease
volume	O
was	O
measured	O
.	O
	
Tumors	B-Disease
were	O
excised	O
and	O
evaluated	O
for	O
proliferation	O
","	O
apoptosis	O
","	O
and	O
expression	O
of	O
PKCalpha	O
","	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)-	O
A	O
","	O
VEGF	O
-	O
C	O
","	O
VEGF	O
receptor	O
2	O
","	O
and	O
VEGF	O
receptor	O
3	O
.	O
	
HRH3	O
expression	O
was	O
found	O
in	O
all	O
cells	O
.	O
	
RAMH	B-Chemical
inhibited	O
the	O
growth	O
of	O
cholangiocarcinoma	B-Disease
cells	O
.	O
	
RAMH	B-Chemical
increased	O
IP	B-Chemical
(	I-Chemical
3	I-Chemical
)	I-Chemical
levels	O
and	O
PKCalpha	O
phosphorylation	O
and	O
decreased	O
ERK1	O
/	O
2	O
phosphorylation	O
.	O
	
RAMH	B-Chemical
induced	O
a	O
shift	O
in	O
the	O
localization	O
of	O
PKCalpha	O
expression	O
from	O
the	O
cytosolic	O
domain	O
into	O
the	O
membrane	O
region	O
of	O
Mz	O
-	O
ChA	O
-	O
1	O
cells	O
.	O
	
Silencing	O
of	O
PKCalpha	O
prevented	O
RAMH	B-Chemical
inhibition	O
of	O
Mz	O
-	O
ChA	O
-	O
1	O
cell	O
growth	O
and	O
ablated	O
RAMH	B-Chemical
effects	O
on	O
ERK1	O
/	O
2	O
phosphorylation	O
.	O
	
In	O
vivo	O
","	O
RAMH	B-Chemical
decreased	O
tumor	B-Disease
growth	O
and	O
expression	O
of	O
VEGF	O
and	O
its	O
receptors	O
";"	O
PKCalpha	O
expression	O
was	O
increased	O
.	O
	
RAMH	B-Chemical
inhibits	O
cholangiocarcinoma	B-Disease
growth	O
by	O
PKCalpha	O
-	O
dependent	O
ERK1	O
/	O
2	O
dephosphorylation	O
.	O
	
Modulation	O
of	O
PKCalpha	O
by	O
histamine	O
receptors	O
may	O
be	O
important	O
in	O
regulating	O
cholangiocarcinoma	B-Disease
growth	O
.	O
	
	
Promoter	O
insertion	O
/	O
deletion	O
in	O
the	O
IRF5	O
gene	O
is	O
highly	O
associated	O
with	O
susceptibility	O
to	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
in	O
distinct	O
populations	O
","	O
but	O
exerts	O
a	O
modest	O
effect	O
on	O
gene	O
expression	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O
	
OBJECTIVE	O
:	O
We	O
examined	O
the	O
genetic	O
association	O
of	O
the	O
promoter	O
insertion	O
/	O
deletion	O
(	O
indel	O
)	O
in	O
IRF5	O
gene	O
with	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
(	O
SLE	B-Disease
)	O
in	O
distinct	O
populations	O
and	O
assessed	O
its	O
role	O
in	O
gene	O
expression	O
.	O
	
METHODS	O
:	O
Four	O
IRF5	O
polymorphisms	O
were	O
genotyped	O
in	O
1488	O
SLE	B-Disease
patients	O
and	O
1466	O
controls	O
.	O
	
Gene	O
expression	O
was	O
analyzed	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
using	O
RNA	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
).	O
	
RESULTS	O
:	O
The	O
promoter	O
indel	O
and	O
rs2070197	O
had	O
independent	O
genetic	O
effects	O
","	O
which	O
accounted	O
for	O
the	O
association	O
of	O
rs2004640	O
and	O
rs10954213	O
.	O
	
Gene	O
expression	O
analysis	O
revealed	O
that	O
rs10954213	O
exerted	O
the	O
greatest	O
influence	O
on	O
IRF5	O
transcript	O
levels	O
.	O
	
CONCLUSION	O
:	O
We	O
corroborated	O
the	O
association	O
of	O
the	O
promoter	O
indel	O
with	O
SLE	B-Disease
in	O
5	O
different	O
populations	O
and	O
revealed	O
that	O
rs10954213	O
is	O
the	O
main	O
single	O
-	O
nucleotide	O
polymorphism	O
responsible	O
for	O
altered	O
IRF5	O
expression	O
in	O
PBMC	O
.	O
	
	
Screening	O
and	O
cell	O
-	O
based	O
assessment	O
of	O
mutations	O
in	O
the	O
Aristaless	O
-	O
related	O
homeobox	O
(	O
ARX	O
)	O
gene	O
.	O
	
ARX	O
mutations	O
cause	O
a	O
diverse	O
spectrum	O
of	O
human	O
disorders	O
","	O
ranging	O
from	O
severe	O
brain	B-Disease
and	I-Disease
genital	I-Disease
malformations	I-Disease
to	O
non	O
-	O
syndromic	O
intellectual	B-Disease
disability	I-Disease
(	O
ID	B-Disease
).	O
	
ARX	O
is	O
a	O
transcription	O
factor	O
with	O
multiple	O
domains	O
that	O
include	O
four	O
polyalanine	B-Chemical
(	O
pA	B-Chemical
)	O
tracts	O
","	O
the	O
first	O
two	O
of	O
which	O
are	O
frequently	O
expanded	O
by	O
mutations	O
.	O
	
We	O
progressively	O
screened	O
DNA	O
samples	O
from	O
613	O
individuals	O
with	O
ID	B-Disease
initially	O
for	O
the	O
most	O
frequent	O
ARX	O
mutations	O
(	O
c	O
.	O
304ins	O
(	O
GCG	O
)(	O
7	O
)'	O
expansion	O
'	O
of	O
pA1	O
and	O
c	O
.	O
429_452dup	O
'	O
dup24bp	O
'	O
of	O
pA2	O
).	O
	
Five	O
hundred	O
samples	O
without	O
pA1	O
or	O
pA2	O
mutations	O
had	O
the	O
entire	O
ARX	O
ORF	O
screened	O
by	O
single	O
stranded	O
polymorphism	O
conformation	O
(	O
SSCP	O
)	O
and	O
/	O
or	O
denaturing	O
high	O
pressure	O
liquid	O
chromatography	O
(	O
dHPLC	O
)	O
analysis	O
.	O
	
Overall	O
","	O
eight	O
families	O
with	O
six	O
mutations	O
in	O
ARX	O
were	O
identified	O
(	O
1	O
.	O
31	O
%):	O
five	O
duplication	O
mutations	O
in	O
pA2	O
(	O
0	O
.	O
82	O
%)	O
with	O
three	O
new	O
clinical	O
reports	O
of	O
families	O
with	O
the	O
dup24bp	O
and	O
two	O
duplications	O
larger	O
than	O
the	O
dup24bp	O
mutation	O
discovered	O
(	O
dup27bp	O
","	O
dup33bp	O
");"	O
and	O
three	O
point	O
mutations	O
(	O
0	O
.	O
6	O
%)","	O
including	O
one	O
novel	O
mutation	O
in	O
the	O
homeodomain	O
(	O
c	O
.	O
1074G	O
>	O
T	O
).	O
	
Four	O
ultraconserved	O
regions	O
distal	O
to	O
ARX	O
(	O
uc466	O
-	O
469	O
)	O
were	O
also	O
screened	O
in	O
a	O
subset	O
of	O
94	O
patients	O
","	O
with	O
three	O
unique	O
nucleotide	O
changes	O
identified	O
in	O
two	O
(	O
uc466	O
","	O
uc467	O
).	O
	
The	O
subcellular	O
localization	O
of	O
full	O
length	O
ARX	O
proteins	O
was	O
assessed	O
for	O
11	O
variants	O
.	O
	
Protein	O
mislocalization	O
increased	O
as	O
a	O
function	O
of	O
pA2	O
tract	O
length	O
and	O
phenotypic	O
severity	O
","	O
as	O
has	O
been	O
previously	O
suggested	O
for	O
pA1	O
.	O
	
Similarly	O
","	O
protein	O
mislocalization	O
of	O
the	O
homeodomain	O
mutations	O
also	O
correlated	O
with	O
clinical	O
severity	O
","	O
suggesting	O
an	O
emerging	O
genotype	O
vs	O
cellular	O
phenotype	O
correlation	O
.	O
	
	
Structural	O
mechanisms	O
determining	O
inhibition	O
of	O
the	O
collagen	O
receptor	O
DDR1	O
by	O
selective	O
and	O
multi	O
-	O
targeted	O
type	O
II	O
kinase	O
inhibitors	O
.	O
	
The	O
discoidin	O
domain	O
receptors	O
(	O
DDRs	O
)","	O
DDR1	O
and	O
DDR2	O
","	O
form	O
a	O
unique	O
subfamily	O
of	O
receptor	O
tyrosine	O
kinases	O
that	O
are	O
activated	O
by	O
the	O
binding	O
of	O
triple	O
-	O
helical	O
collagen	O
.	O
	
Excessive	O
signaling	O
by	O
DDR1	O
and	O
DDR2	O
has	O
been	O
linked	O
to	O
the	O
progression	O
of	O
various	O
human	O
diseases	O
","	O
including	O
fibrosis	B-Disease
","	O
atherosclerosis	B-Disease
and	O
cancer	B-Disease
.	O
	
We	O
report	O
the	O
inhibition	O
of	O
these	O
unusual	O
receptor	O
tyrosine	O
kinases	O
by	O
the	O
multi	O
-	O
targeted	O
cancer	B-Disease
drugs	O
imatinib	B-Chemical
and	O
ponatinib	B-Chemical
","	O
as	O
well	O
as	O
the	O
selective	O
type	O
II	O
inhibitor	O
DDR1	B-Chemical
-	I-Chemical
IN	I-Chemical
-	I-Chemical
1	I-Chemical
.	O
	
Ponatinib	B-Chemical
is	O
identified	O
as	O
the	O
more	O
potent	O
molecule	O
","	O
which	O
inhibits	O
DDR1	O
and	O
DDR2	O
with	O
an	O
IC50	O
of	O
9nM	O
.	O
	
Co	O
-	O
crystal	O
structures	O
of	O
human	O
DDR1	O
reveal	O
a	O
DFG	B-Chemical
-	O
out	O
conformation	O
(	O
DFG	B-Chemical
","	O
Asp	B-Chemical
-	I-Chemical
Phe	I-Chemical
-	I-Chemical
Gly	I-Chemical
)	O
of	O
the	O
kinase	O
domain	O
that	O
is	O
stabilized	O
by	O
an	O
unusual	O
salt	O
bridge	O
between	O
the	O
activation	O
loop	O
and	O
aD	O
helix	O
.	O
	
Differences	O
to	O
Abelson	O
kinase	O
(	O
ABL	O
)	O
are	O
observed	O
in	O
the	O
DDR1	O
P	O
-	O
loop	O
","	O
where	O
a	O
b	O
-	O
hairpin	O
replaces	O
the	O
cage	O
-	O
like	O
structure	O
of	O
ABL	O
.	O
	
P	O
-	O
loop	O
residues	O
in	O
DDR1	O
that	O
confer	O
drug	O
resistance	O
in	O
ABL	O
are	O
therefore	O
accommodated	O
outside	O
the	O
ATP	B-Chemical
pocket	O
.	O
	
Whereas	O
imatinib	B-Chemical
and	O
ponatinib	B-Chemical
bind	O
potently	O
to	O
both	O
the	O
DDR	O
and	O
ABL	O
kinases	O
","	O
the	O
hydrophobic	O
interactions	O
of	O
the	O
ABL	O
P	O
-	O
loop	O
appear	O
poorly	O
satisfied	O
by	O
DDR1	B-Chemical
-	I-Chemical
IN	I-Chemical
-	I-Chemical
1	I-Chemical
suggesting	O
a	O
structural	O
basis	O
for	O
its	O
DDR1	O
selectivity	O
.	O
	
Such	O
inhibitors	O
may	O
have	O
applications	O
in	O
clinical	O
indications	O
of	O
DDR1	O
and	O
DDR2	O
overexpression	O
or	O
mutation	O
","	O
including	O
lung	B-Disease
cancer	I-Disease
.	O
	
	
Low	O
functional	O
programming	O
of	O
renal	O
AT2R	O
mediates	O
the	O
developmental	O
origin	O
of	O
glomerulosclerosis	B-Disease
in	O
adult	O
offspring	O
induced	O
by	O
prenatal	O
caffeine	B-Chemical
exposure	O
.	O
	
UNASSIGNED	O
:	O
Our	O
previous	O
study	O
has	O
indicated	O
that	O
prenatal	O
caffeine	B-Chemical
exposure	O
(	O
PCE	O
)	O
could	O
induce	O
intrauterine	B-Disease
growth	I-Disease
retardation	I-Disease
(	O
IUGR	B-Disease
)	O
of	O
offspring	O
.	O
	
Recent	O
research	O
suggested	O
that	O
IUGR	B-Disease
is	O
a	O
risk	O
factor	O
for	O
glomerulosclerosis	B-Disease
.	O
	
However	O
","	O
whether	O
PCE	O
could	O
induce	O
glomerulosclerosis	B-Disease
and	O
its	O
underlying	O
mechanisms	O
remain	O
unknown	O
.	O
	
This	O
study	O
aimed	O
to	O
demonstrate	O
the	O
induction	O
to	O
glomerulosclerosis	B-Disease
in	O
adult	O
offspring	O
by	O
PCE	O
and	O
its	O
intrauterine	O
programming	O
mechanisms	O
.	O
	
A	O
rat	O
model	O
of	O
IUGR	B-Disease
was	O
established	O
by	O
PCE	O
","	O
male	O
fetuses	O
and	O
adult	O
offspring	O
at	O
the	O
age	O
of	O
postnatal	O
week	O
24	O
were	O
euthanized	O
.	O
	
The	O
results	O
revealed	O
that	O
the	O
adult	O
offspring	O
kidneys	O
in	O
the	O
PCE	O
group	O
exhibited	O
glomerulosclerosis	B-Disease
as	O
well	O
as	O
interstitial	B-Disease
fibrosis	I-Disease
","	O
accompanied	O
by	O
elevated	O
levels	O
of	O
serum	O
creatinine	B-Chemical
and	O
urine	O
protein	O
.	O
	
Renal	O
angiotensin	O
II	O
receptor	O
type	O
2	O
(	O
AT2R	O
)	O
gene	O
expression	O
in	O
adult	O
offspring	O
was	O
reduced	O
by	O
PCE	O
","	O
whereas	O
the	O
renal	O
angiotensin	O
II	O
receptor	O
type	O
1a	O
(	O
AT1aR	O
)/	O
AT2R	O
expression	O
ratio	O
was	O
increased	O
.	O
	
The	O
fetal	O
kidneys	O
in	O
the	O
PCE	O
group	O
displayed	O
an	O
enlarged	O
Bowman	O
'	O
s	O
space	O
and	O
a	O
shrunken	O
glomerular	O
tuft	O
","	O
accompanied	O
by	O
a	O
reduced	O
cortex	O
width	O
and	O
an	O
increase	O
in	O
the	O
nephrogenic	O
zone	O
/	O
cortical	O
zone	O
ratio	O
.	O
	
Observation	O
by	O
electronic	O
microscope	O
revealed	O
structural	O
damage	O
of	O
podocytes	O
";"	O
the	O
reduced	O
expression	O
level	O
of	O
podocyte	O
marker	O
genes	O
","	O
nephrin	O
and	O
podocin	O
","	O
was	O
also	O
detected	O
by	O
q	O
-	O
PCR	O
.	O
	
Moreover	O
","	O
AT2R	O
gene	O
and	O
protein	O
expressions	O
in	O
fetal	O
kidneys	O
were	O
inhibited	O
by	O
PCE	O
","	O
associated	O
with	O
the	O
repression	O
of	O
the	O
gene	O
expression	O
of	O
glial	O
-	O
cell	O
-	O
line	O
-	O
derived	O
neurotrophic	O
factor	O
(	O
GDNF	O
)/	O
tyrosine	O
kinase	O
receptor	O
(	O
c	O
-	O
Ret	O
)	O
signaling	O
pathway	O
.	O
	
These	O
results	O
demonstrated	O
that	O
PCE	O
could	O
induce	O
dysplasia	B-Disease
of	I-Disease
fetal	I-Disease
kidneys	I-Disease
as	O
well	O
as	O
glomerulosclerosis	B-Disease
of	O
adult	O
offspring	O
","	O
and	O
the	O
low	O
functional	O
programming	O
of	O
renal	O
AT2R	O
might	O
mediate	O
the	O
developmental	O
origin	O
of	O
adult	O
glomerulosclerosis	B-Disease
.	O
	
	
Myc	O
enhances	O
B	O
-	O
cell	O
receptor	O
signaling	O
in	O
precancerous	B-Disease
B	O
cells	O
and	O
confers	O
resistance	O
to	O
Btk	O
inhibition	O
.	O
	
Dysregulation	O
of	O
the	O
oncogenic	O
transcription	O
factor	O
MYC	O
induces	O
B	O
-	O
cell	O
transformation	O
and	O
is	O
a	O
driver	O
for	O
B	B-Disease
-	I-Disease
cell	I-Disease
non	I-Disease
-	I-Disease
Hodgkin	I-Disease
lymphoma	I-Disease
(	O
B	B-Disease
-	I-Disease
NHL	I-Disease
).	O
	
MYC	O
overexpression	O
in	O
B	B-Disease
-	I-Disease
NHL	I-Disease
is	O
associated	O
with	O
more	O
aggressive	O
phenotypes	O
and	O
poor	O
prognosis	O
.	O
	
Although	O
genomic	O
studies	O
suggest	O
a	O
link	O
between	O
MYC	O
overexpression	O
and	O
B	O
-	O
cell	O
receptor	O
(	O
BCR	O
)	O
signaling	O
molecules	O
in	O
B	B-Disease
-	I-Disease
NHL	I-Disease
","	O
signaling	O
pathways	O
essential	O
to	O
Myc	O
-	O
mediated	O
B	O
-	O
cell	O
transformation	O
have	O
not	O
been	O
fully	O
elucidated	O
.	O
	
We	O
utilized	O
intracellular	O
phospho	O
-	O
flow	O
cytometry	O
to	O
investigate	O
the	O
relationship	O
between	O
Myc	O
and	O
BCR	O
signaling	O
in	O
pre	O
-	O
malignant	O
B	O
cells	O
.	O
	
Utilizing	O
the	O
Eu	O
-	O
myc	O
mouse	O
model	O
","	O
where	O
Myc	O
is	O
overexpressed	O
specifically	O
in	O
B	O
cells	O
","	O
both	O
basal	O
and	O
stimulated	O
BCR	O
signaling	O
were	O
increased	O
in	O
precancerous	B-Disease
B	O
lymphocytes	O
from	O
Eu	O
-	O
myc	O
mice	O
compared	O
with	O
wild	O
-	O
type	O
littermates	O
.	O
	
B	O
cells	O
overexpressing	O
Myc	O
displayed	O
constitutively	O
higher	O
levels	O
of	O
activated	O
CD79a	O
","	O
Btk	O
","	O
Plcg2	O
and	O
Erk1	O
/	O
2	O
.	O
	
Notably	O
","	O
Myc	O
-	O
overexpressing	O
B	O
cells	O
maintained	O
elevated	O
BCR	O
signaling	O
despite	O
treatment	O
with	O
ibrutinib	B-Chemical
","	O
a	O
Bruton	O
'	O
s	O
tyrosine	O
kinase	O
inhibitor	O
.	O
	
Furthermore	O
","	O
PI3K	O
/	O
Akt	O
pathway	O
signaling	O
was	O
also	O
increased	O
in	O
Eu	O
-	O
myc	O
B	O
cells	O
","	O
and	O
this	O
increase	O
was	O
partially	O
suppressed	O
with	O
ibrutinib	B-Chemical
.	O
	
In	O
addition	O
","	O
experiments	O
with	O
Btk	O
-	O
null	O
B	O
cells	O
revealed	O
off	O
-	O
target	O
effects	O
of	O
ibrutinib	B-Chemical
on	O
BCR	O
signaling	O
.	O
	
Our	O
data	O
show	O
that	O
in	O
pre	O
-	O
malignant	O
B	O
cells	O
","	O
Myc	O
overexpression	O
is	O
sufficient	O
to	O
activate	O
BCR	O
and	O
PI3K	O
/	O
Akt	O
signaling	O
pathways	O
and	O
further	O
enhances	O
signaling	O
following	O
BCR	O
ligation	O
.	O
	
Therefore	O
","	O
our	O
results	O
indicate	O
that	O
precancerous	B-Disease
B	O
cells	O
have	O
already	O
acquired	O
enhanced	O
survival	O
and	O
growth	O
capabilities	O
before	O
transformation	O
","	O
and	O
that	O
elevated	O
MYC	O
levels	O
confer	O
resistance	O
to	O
pharmacologic	O
inhibitors	O
of	O
BCR	O
signaling	O
","	O
which	O
has	O
significant	O
implications	O
for	O
B	B-Disease
-	I-Disease
NHL	I-Disease
treatment	O
.	O
	
	
A	O
TSPO	O
ligand	O
attenuates	O
brain	B-Disease
injury	I-Disease
after	O
intracerebral	B-Disease
hemorrhage	I-Disease
.	O
	
Intracerebral	B-Disease
hemorrhage	I-Disease
(	O
ICH	B-Disease
)	O
is	O
a	O
devastating	O
disease	O
without	O
effective	O
treatment	O
.	O
	
After	O
ICH	B-Disease
","	O
the	O
immediate	O
infiltration	O
of	O
leukocytes	O
and	O
activation	O
of	O
microglia	O
are	O
accompanied	O
by	O
a	O
rapid	O
up	O
-	O
regulation	O
of	O
the	O
18	O
-	O
kDa	O
translocator	O
protein	O
(	O
TSPO	O
).	O
	
TSPO	O
ligands	O
have	O
shown	O
anti	O
-	O
inflammatory	B-Disease
and	O
neuroprotective	O
properties	O
in	O
models	O
of	O
CNS	B-Disease
injury	I-Disease
.	O
	
In	O
this	O
study	O
","	O
we	O
determined	O
the	O
impact	O
of	O
a	O
TSPO	O
ligand	O
","	O
etifoxine	B-Chemical
","	O
on	O
brain	B-Disease
injury	I-Disease
and	O
inflammation	B-Disease
in	O
2	O
mouse	O
models	O
of	O
ICH	B-Disease
.	O
	
TSPO	O
was	O
up	O
-	O
regulated	O
in	O
Iba1	O
(+)	O
cells	O
from	O
brains	O
of	O
patients	O
with	O
ICH	B-Disease
and	O
in	O
CD11b	O
(+)	O
CD45	O
(	O
int	O
)	O
cells	O
from	O
mice	O
subjected	O
to	O
collagenase	B-Chemical
-	O
induced	O
ICH	B-Disease
.	O
	
Etifoxine	B-Chemical
significantly	O
reduced	O
neurodeficits	B-Disease
and	O
perihematomal	O
brain	B-Disease
edema	I-Disease
after	O
ICH	B-Disease
induction	O
by	O
injection	O
of	O
either	O
autologous	O
blood	O
or	O
collagenase	B-Chemical
.	O
	
In	O
collagenase	B-Chemical
-	O
induced	O
ICH	B-Disease
mice	O
","	O
the	O
protection	O
of	O
etifoxine	B-Chemical
was	O
associated	O
with	O
reduced	O
leukocyte	O
infiltration	O
into	O
the	O
brain	O
and	O
microglial	O
production	O
of	O
IL	O
-	O
6	O
and	O
TNF	O
-	O
a	O
.	O
	
Etifoxine	B-Chemical
improved	O
blood	O
-	O
brain	O
barrier	O
integrity	O
and	O
diminished	O
cell	O
death	O
.	O
	
Notably	O
","	O
the	O
protective	O
effect	O
of	O
etifoxine	B-Chemical
was	O
abolished	O
in	O
mice	O
depleted	O
of	O
microglia	O
by	O
using	O
a	O
colony	O
-	O
stimulating	O
factor	O
1	O
receptor	O
inhibitor	O
.	O
	
These	O
results	O
indicate	O
that	O
the	O
TSPO	O
ligand	O
etifoxine	B-Chemical
attenuates	O
brain	B-Disease
injury	I-Disease
and	O
inflammation	B-Disease
after	O
ICH	B-Disease
.	O
	
TSPO	O
may	O
be	O
a	O
viable	O
therapeutic	O
target	O
that	O
requires	O
further	O
investigations	O
in	O
ICH	B-Disease
.-	O
Li	O
","	O
M	O
.","	O
Ren	O
","	O
H	O
.","	O
Sheth	O
","	O
K	O
.	O
N	O
.","	O
Shi	O
","	O
F	O
.-	O
D	O
.","	O
Liu	O
","	O
Q	O
.	O
A	O
TSPO	O
ligand	O
attenuates	O
brain	B-Disease
injury	I-Disease
after	O
intracerebral	B-Disease
hemorrhage	I-Disease
.	O
	
	
Mutation	O
of	O
the	O
a	O
-	O
tubulin	O
Tuba1a	O
leads	O
to	O
straighter	O
microtubules	O
and	O
perturbs	O
neuronal	O
migration	O
.	O
	
Brain	O
development	O
involves	O
extensive	O
migration	O
of	O
neurons	O
.	O
	
Microtubules	O
(	O
MTs	O
)	O
are	O
key	O
cellular	O
effectors	O
of	O
neuronal	O
displacement	O
that	O
are	O
assembled	O
from	O
a	O
/	O
b	O
-	O
tubulin	O
heterodimers	O
.	O
	
Mutation	O
of	O
the	O
a	O
-	O
tubulin	O
isotype	O
TUBA1A	O
is	O
associated	O
with	O
cortical	B-Disease
malformations	I-Disease
in	O
humans	O
.	O
	
In	O
this	O
study	O
","	O
we	O
provide	O
detailed	O
in	O
vivo	O
and	O
in	O
vitro	O
analyses	O
of	O
Tuba1a	O
mutants	O
.	O
	
In	O
mice	O
carrying	O
a	O
Tuba1a	O
missense	O
mutation	O
(	O
S140G	O
)","	O
neurons	O
accumulate	O
","	O
and	O
glial	O
cells	O
are	O
dispersed	O
along	O
the	O
rostral	O
migratory	O
stream	O
in	O
postnatal	O
and	O
adult	O
brains	O
.	O
	
Live	O
imaging	O
of	O
Tuba1a	O
-	O
mutant	O
neurons	O
revealed	O
slowed	O
migration	O
and	O
increased	O
neuronal	O
branching	O
","	O
which	O
correlated	O
with	O
directionality	O
alterations	O
and	O
perturbed	O
nucleus	O
-	O
centrosome	O
(	O
N	O
-	O
C	O
)	O
coupling	O
.	O
	
Tuba1a	O
mutation	O
led	O
to	O
increased	O
straightness	O
of	O
newly	O
polymerized	O
MTs	O
","	O
and	O
structural	O
modeling	O
data	O
suggest	O
a	O
conformational	O
change	O
in	O
the	O
a	O
/	O
b	O
-	O
tubulin	O
heterodimer	O
.	O
	
We	O
show	O
that	O
Tuba8	O
","	O
another	O
a	O
-	O
tubulin	O
isotype	O
previously	O
associated	O
with	O
cortical	B-Disease
malformations	I-Disease
","	O
has	O
altered	O
function	O
compared	O
with	O
Tuba1a	O
.	O
	
Our	O
work	O
shows	O
that	O
Tuba1a	O
plays	O
an	O
essential	O
","	O
noncompensated	O
role	O
in	O
neuronal	O
saltatory	O
migration	O
in	O
vivo	O
and	O
highlights	O
the	O
importance	O
of	O
MT	O
flexibility	O
in	O
N	O
-	O
C	O
coupling	O
and	O
neuronal	O
-	O
branching	O
regulation	O
during	O
neuronal	O
migration	O
.	O
	
	
HEB	O
is	O
required	O
for	O
the	O
specification	O
of	O
fetal	O
IL	O
-	O
17	O
-	O
producing	O
gd	O
T	O
cells	O
.	O
	
IL	O
-	O
17	O
-	O
producing	O
gd	O
T	O
(	O
gdT17	O
)	O
cells	O
are	O
critical	O
components	O
of	O
the	O
innate	O
immune	O
system	O
.	O
	
However	O
","	O
the	O
gene	O
networks	O
that	O
control	O
their	O
development	O
are	O
unclear	O
.	O
	
Here	O
we	O
show	O
that	O
HEB	O
(	O
HeLa	O
E	O
-	O
box	O
binding	O
protein	O
","	O
encoded	O
by	O
Tcf12	O
)	O
is	O
required	O
for	O
the	O
generation	O
of	O
a	O
newly	O
defined	O
subset	O
of	O
fetal	O
-	O
derived	O
CD73	O
-	O
gdT17	O
cells	O
.	O
	
HEB	O
is	O
required	O
in	O
immature	O
CD24	O
+	O
CD73	O
-	O
gd	O
T	O
cells	O
for	O
the	O
expression	O
of	O
Sox4	O
","	O
Sox13	O
","	O
and	O
Rorc	O
","	O
and	O
these	O
genes	O
are	O
repressed	O
by	O
acute	O
expression	O
of	O
the	O
HEB	O
antagonist	O
Id3	O
.	O
	
HEB	O
-	O
deficiency	O
also	O
affects	O
mature	O
CD73	O
+	O
gd	O
T	O
cells	O
","	O
which	O
are	O
defective	O
in	O
RORgt	O
expression	O
and	O
IL	O
-	O
17	O
production	O
.	O
	
Additionally	O
","	O
the	O
fetal	O
TCRg	O
chain	O
repertoire	O
is	O
altered	O
","	O
and	O
peripheral	O
Vg4	O
gd	O
T	O
cells	O
are	O
mostly	O
restricted	O
to	O
the	O
IFNg	O
-	O
producing	O
phenotype	O
in	O
HEB	O
-	O
deficient	O
mice	O
.	O
	
Therefore	O
","	O
our	O
work	O
identifies	O
HEB	O
-	O
dependent	O
pathways	O
for	O
the	O
development	O
of	O
CD73	O
+	O
and	O
CD73	O
-	O
gdT17	O
cells	O
","	O
and	O
provides	O
mechanistic	O
evidence	O
for	O
control	O
of	O
the	O
gdT17	O
gene	O
network	O
by	O
HEB	O
.	O
	
	
Primary	B-Disease
malignant	I-Disease
lymphoma	I-Disease
of	I-Disease
the	I-Disease
brain	I-Disease
:	O
frequent	O
abnormalities	O
and	O
inactivation	O
of	O
p14	O
tumor	B-Disease
suppressor	O
gene	O
.	O
	
Ten	O
primary	B-Disease
central	I-Disease
nervous	I-Disease
system	I-Disease
lymphomas	I-Disease
(	O
PCNSL	B-Disease
","	O
brain	B-Disease
lymphomas	I-Disease
)	O
were	O
examined	O
for	O
p14	O
gene	O
exon	O
1beta	O
deletion	O
","	O
mutation	O
and	O
methylation	O
by	O
Southern	O
blot	O
analysis	O
","	O
nucleotide	O
analysis	O
of	O
polymerase	O
chain	O
reaction	O
clones	O
and	O
Southern	O
blot	O
-	O
based	O
methylation	O
assay	O
.	O
	
In	O
Southern	O
blot	O
analysis	O
","	O
from	O
the	O
signal	O
densities	O
of	O
the	O
hybridized	O
bands	O
and	O
their	O
similarities	O
to	O
those	O
of	O
exons	O
2	O
and	O
3	O
in	O
our	O
previous	O
quantitative	O
study	O
","	O
we	O
found	O
that	O
exon	O
1beta	O
was	O
homozygously	O
deleted	O
in	O
four	O
cases	O
","	O
hemizygously	O
deleted	O
in	O
five	O
cases	O
and	O
not	O
deleted	O
in	O
one	O
case	O
.	O
	
Thus	O
","	O
the	O
same	O
deletion	O
patterns	O
covered	O
the	O
entire	O
p14	O
gene	O
for	O
all	O
cases	O
except	O
for	O
one	O
case	O
","	O
which	O
suggested	O
the	O
hemizygous	O
deletion	O
of	O
exons	O
1beta	O
and	O
2	O
and	O
homozygous	O
deletion	O
of	O
exon	O
3	O
.	O
	
In	O
addition	O
","	O
although	O
exon	O
1beta	O
mutation	O
is	O
rare	O
in	O
various	O
tumors	B-Disease
","	O
we	O
detected	O
a	O
missense	O
mutation	O
(	O
L50R	O
)	O
in	O
one	O
case	O
with	O
a	O
hemizygous	O
deletion	O
.	O
	
Methylation	O
of	O
the	O
5	O
'	O
CpG	O
island	O
of	O
the	O
p14	O
gene	O
was	O
not	O
suggested	O
for	O
any	O
case	O
without	O
homozygous	O
deletion	O
.	O
	
Our	O
observation	O
of	O
frequent	O
p14	O
gene	O
abnormalities	O
(	O
90	O
%)	O
and	O
inactivation	O
(	O
40	O
-	O
60	O
%)	O
was	O
in	O
striking	O
contrast	O
to	O
the	O
same	O
pathological	O
subtype	O
of	O
systemic	B-Disease
lymphoma	I-Disease
in	O
which	O
p14	O
gene	O
abnormalities	O
and	O
inactivation	O
were	O
infrequent	O
","	O
suggesting	O
a	O
difference	O
in	O
carcinogenesis	B-Disease
between	O
PCNSL	B-Disease
and	O
systemic	B-Disease
lymphoma	I-Disease
.	O
	
	
Congenital	B-Disease
disorder	I-Disease
of	I-Disease
glycosylation	I-Disease
Ic	I-Disease
due	O
to	O
a	O
de	O
novo	O
deletion	O
and	O
an	O
hALG	O
-	O
6	O
mutation	O
.	O
	
We	O
describe	O
a	O
new	O
cause	O
of	O
congenital	B-Disease
disorder	I-Disease
of	I-Disease
glycosylation	I-Disease
-	I-Disease
Ic	I-Disease
(	O
CDG	B-Disease
-	I-Disease
Ic	I-Disease
)	O
in	O
a	O
young	O
girl	O
with	O
a	O
rather	O
mild	O
CDG	B-Disease
phenotype	O
.	O
	
Her	O
cells	O
accumulated	O
lipid	B-Chemical
-	I-Chemical
linked	I-Chemical
oligosaccharides	I-Chemical
lacking	O
three	O
glucose	B-Chemical
residues	O
","	O
and	O
sequencing	O
of	O
the	O
ALG6	O
gene	O
showed	O
what	O
initially	O
appeared	O
to	O
be	O
a	O
homozygous	O
novel	O
point	O
mutation	O
(	O
338G	O
>	O
A	O
).	O
	
However	O
","	O
haplotype	O
analysis	O
showed	O
that	O
the	O
patient	O
does	O
not	O
carry	O
any	O
paternal	O
DNA	O
markers	O
extending	O
33kb	O
in	O
the	O
telomeric	O
direction	O
from	O
the	O
ALG6	O
region	O
","	O
and	O
microsatellite	O
analysis	O
extended	O
the	O
abnormal	O
region	O
to	O
at	O
least	O
2	O
.	O
5Mb	O
.	O
	
We	O
used	O
high	O
-	O
resolution	O
karyotyping	O
to	O
confirm	O
a	O
deletion	O
(	O
10	O
-	O
12Mb	O
)	O
[	O
del	O
(	O
1	O
)(	O
p31	O
.	O
2p32	O
.	O
3	O
)]	O
and	O
found	O
no	O
structural	O
abnormalities	O
in	O
the	O
father	O
","	O
suggesting	O
a	O
de	O
novo	O
event	O
.	O
	
Our	O
findings	O
extend	O
the	O
causes	O
of	O
CDG	B-Disease
to	O
larger	O
DNA	O
deletions	O
and	O
identify	O
the	O
first	O
Japanese	O
CDG	B-Disease
-	I-Disease
Ic	I-Disease
mutation	O
.	O
	
	
Genetic	O
variation	O
in	O
the	O
COX	O
-	O
2	O
gene	O
and	O
the	O
association	O
with	O
prostate	B-Disease
cancer	I-Disease
risk	O
.	O
	
COX	O
-	O
2	O
is	O
a	O
key	O
enzyme	O
in	O
the	O
conversion	O
of	O
arachidonic	B-Chemical
acid	I-Chemical
to	O
prostaglandins	B-Chemical
.	O
	
The	O
prostaglandins	B-Chemical
produced	O
by	O
COX	O
-	O
2	O
are	O
involved	O
in	O
inflammation	B-Disease
and	O
pain	B-Disease
response	O
in	O
different	O
tissues	O
in	O
the	O
body	O
.	O
	
Accumulating	O
evidence	O
from	O
epidemiologic	O
studies	O
","	O
chemical	O
carcinogen	O
-	O
induced	O
rodent	O
models	O
and	O
clinical	O
trials	O
indicate	O
that	O
COX	O
-	O
2	O
plays	O
a	O
role	O
in	O
human	O
carcinogenesis	B-Disease
and	O
is	O
overexpressed	O
in	O
prostate	B-Disease
cancer	I-Disease
tissue	O
.	O
	
We	O
examined	O
whether	O
sequence	O
variants	O
in	O
the	O
COX	O
-	O
2	O
gene	O
are	O
associated	O
with	O
prostate	B-Disease
cancer	I-Disease
risk	O
.	O
	
We	O
analyzed	O
a	O
large	O
population	O
-	O
based	O
case	O
-	O
control	O
study	O
","	O
cancer	B-Disease
prostate	I-Disease
in	O
Sweden	O
(	O
CAPS	O
)	O
consisting	O
of	O
1	O
","	O
378	O
cases	O
and	O
782	O
controls	O
.	O
	
We	O
evaluated	O
16	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
spanning	O
the	O
entire	O
COX	O
-	O
2	O
gene	O
in	O
94	O
subjects	O
of	O
the	O
control	O
group	O
.	O
	
Five	O
SNPs	O
had	O
a	O
minor	O
allele	O
frequency	O
of	O
more	O
than	O
5	O
%	O
in	O
our	O
study	O
population	O
and	O
these	O
were	O
genotyped	O
in	O
all	O
case	O
patients	O
and	O
control	O
subjects	O
and	O
gene	O
-	O
specific	O
haplotypes	O
were	O
constructed	O
.	O
	
A	O
statistically	O
significant	O
difference	O
in	O
allele	O
frequency	O
between	O
cases	O
and	O
controls	O
was	O
observed	O
for	O
2	O
of	O
the	O
SNPs	O
(+	O
3100	O
T	O
/	O
G	O
and	O
+	O
8365	O
C	O
/	O
T	O
)","	O
with	O
an	O
odds	O
ratio	O
of	O
0	O
.	O
78	O
(	O
95	O
%	O
CI	O
=	O
0	O
.	O
64	O
-	O
0	O
.	O
96	O
)	O
and	O
0	O
.	O
65	O
(	O
95	O
%	O
CI	O
=	O
0	O
.	O
45	O
-	O
0	O
.	O
94	O
)	O
respectively	O
.	O
	
In	O
the	O
haplotype	O
analysis	O
","	O
1	O
haplotype	O
carrying	O
the	O
variant	O
allele	O
from	O
both	O
+	O
3100	O
T	O
/	O
G	O
and	O
+	O
8365	O
C	O
/	O
T	O
","	O
with	O
a	O
population	O
frequency	O
of	O
3	O
%","	O
was	O
also	O
significantly	O
associated	O
with	O
decreased	O
risk	O
of	O
prostate	B-Disease
cancer	I-Disease
(	O
p	O
=	O
0	O
.	O
36	O
","	O
global	O
simulated	O
p	O
-	O
value	O
=	O
0	O
.	O
46	O
).	O
	
This	O
study	O
supports	O
the	O
hypothesis	O
that	O
inflammation	B-Disease
is	O
involved	O
in	O
prostate	B-Disease
carcinogenesis	I-Disease
and	O
that	O
sequence	O
variation	O
within	O
the	O
COX	O
-	O
2	O
gene	O
influence	O
the	O
risk	O
of	O
prostate	B-Disease
cancer	I-Disease
.	O
	
	
Drug	O
-	O
induced	O
long	B-Disease
QT	I-Disease
syndrome	I-Disease
in	O
injection	O
drug	O
users	O
receiving	O
methadone	B-Chemical
:	O
high	O
frequency	O
in	O
hospitalized	O
patients	O
and	O
risk	O
factors	O
.	O
	
BACKGROUND	O
:	O
Drug	O
-	O
induced	O
long	B-Disease
QT	I-Disease
syndrome	I-Disease
is	O
a	O
serious	O
adverse	O
drug	O
reaction	O
.	O
	
Methadone	B-Chemical
prolongs	O
the	O
QT	O
interval	O
in	O
vitro	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
	
In	O
the	O
inpatient	O
setting	O
","	O
the	O
frequency	O
of	O
QT	B-Disease
interval	I-Disease
prolongation	I-Disease
with	O
methadone	B-Chemical
treatment	O
","	O
its	O
dose	O
dependence	O
","	O
and	O
the	O
importance	O
of	O
cofactors	O
such	O
as	O
drug	O
-	O
drug	O
interactions	O
remain	O
unknown	O
.	O
	
METHODS	O
:	O
We	O
performed	O
a	O
systematic	O
","	O
retrospective	O
study	O
comparing	O
active	O
or	O
former	O
intravenous	O
drug	O
users	O
receiving	O
methadone	B-Chemical
and	O
those	O
not	O
receiving	O
methadone	B-Chemical
among	O
all	O
patients	O
hospitalized	O
over	O
a	O
5	O
-	O
year	O
period	O
in	O
a	O
tertiary	O
care	O
hospital	O
.	O
	
A	O
total	O
of	O
167	O
patients	O
receiving	O
methadone	B-Chemical
fulfilled	O
the	O
inclusion	O
criteria	O
and	O
were	O
compared	O
with	O
a	O
control	O
group	O
of	O
80	O
injection	O
drug	O
users	O
not	O
receiving	O
methadone	B-Chemical
.	O
	
In	O
addition	O
to	O
methadone	B-Chemical
dose	O
","	O
15	O
demographic	O
","	O
biological	O
","	O
and	O
pharmacological	O
variables	O
were	O
considered	O
as	O
potential	O
risk	O
factors	O
for	O
QT	B-Disease
prolongation	I-Disease
.	O
	
RESULTS	O
:	O
Among	O
167	O
methadone	B-Chemical
maintenance	O
patients	O
","	O
the	O
prevalence	O
of	O
QTc	B-Disease
prolongation	I-Disease
to	O
0	O
.	O
50	O
second	O
((	O
1	O
/	O
2	O
))	O
or	O
longer	O
was	O
16	O
.	O
2	O
%	O
compared	O
with	O
0	O
%	O
in	O
80	O
control	O
subjects	O
.	O
	
Six	O
patients	O
(	O
3	O
.	O
6	O
%)	O
in	O
the	O
methadone	B-Chemical
group	O
presented	O
torsades	B-Disease
de	I-Disease
pointes	I-Disease
.	O
	
QTc	O
length	O
was	O
weakly	O
but	O
significantly	O
associated	O
with	O
methadone	B-Chemical
daily	O
dose	O
(	O
Spearman	O
rank	O
correlation	O
coefficient	O
","	O
0	O
.	O
20	O
";"	O
P	O
<.	O
1	O
).	O
	
Multivariate	O
regression	O
analysis	O
allowed	O
attribution	O
of	O
31	O
.	O
8	O
%	O
of	O
QTc	O
variability	O
to	O
methadone	B-Chemical
dose	O
","	O
cytochrome	O
P	O
-	O
450	O
3A4	O
drug	O
-	O
drug	O
interactions	O
","	O
hypokalemia	B-Disease
","	O
and	O
altered	O
liver	O
function	O
.	O
	
CONCLUSIONS	O
:	O
QT	B-Disease
interval	I-Disease
prolongation	I-Disease
in	O
methadone	B-Chemical
maintenance	O
patients	O
hospitalized	O
in	O
a	O
tertiary	O
care	O
center	O
is	O
a	O
frequent	O
finding	O
.	O
	
Methadone	B-Chemical
dose	O
","	O
presence	O
of	O
cytochrome	B-Chemical
P	I-Chemical
-	I-Chemical
450	I-Chemical
3A4	I-Chemical
inhibitors	I-Chemical
","	O
potassium	B-Chemical
level	O
","	O
and	O
liver	O
function	O
contribute	O
to	O
QT	B-Disease
prolongation	I-Disease
.	O
	
Long	B-Disease
QT	I-Disease
syndrome	I-Disease
can	O
occur	O
with	O
low	O
doses	O
of	O
methadone	B-Chemical
.	O
	
	
Alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
prevents	O
mitochondrial	B-Disease
damage	I-Disease
and	O
neurotoxicity	B-Disease
in	O
experimental	O
chemotherapy	O
neuropathy	B-Disease
.	O
	
The	O
study	O
investigates	O
if	O
alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
is	O
neuroprotective	O
against	O
chemotherapy	O
induced	O
neurotoxicity	B-Disease
","	O
if	O
mitochondrial	B-Disease
damage	I-Disease
plays	O
a	O
critical	O
role	O
in	O
toxic	B-Disease
neurodegenerative	I-Disease
cascade	I-Disease
","	O
and	O
if	O
neuroprotective	O
effects	O
of	O
alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
depend	O
on	O
mitochondria	O
protection	O
.	O
	
We	O
used	O
an	O
in	O
vitro	O
model	O
of	O
chemotherapy	O
induced	O
peripheral	B-Disease
neuropathy	I-Disease
that	O
closely	O
mimic	O
the	O
in	O
vivo	O
condition	O
by	O
exposing	O
primary	O
cultures	O
of	O
dorsal	O
root	O
ganglion	O
(	O
DRG	O
)	O
sensory	O
neurons	O
to	O
paclitaxel	B-Chemical
and	O
cisplatin	B-Chemical
","	O
two	O
widely	O
used	O
and	O
highly	O
effective	O
chemotherapeutic	O
drugs	O
.	O
	
This	O
approach	O
allowed	O
investigating	O
the	O
efficacy	O
of	O
alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
in	O
preventing	O
axonal	B-Disease
damage	I-Disease
and	O
apoptosis	O
and	O
the	O
function	O
and	O
ultrastructural	O
morphology	O
of	O
mitochondria	O
after	O
exposure	O
to	O
toxic	O
agents	O
and	O
alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
.	O
	
Our	O
results	O
demonstrate	O
that	O
both	O
cisplatin	B-Chemical
and	O
paclitaxel	B-Chemical
cause	O
early	O
mitochondrial	B-Disease
impairment	I-Disease
with	O
loss	O
of	O
membrane	O
potential	O
and	O
induction	O
of	O
autophagic	O
vacuoles	O
in	O
neurons	O
.	O
	
Alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
exerts	O
neuroprotective	O
effects	O
against	O
chemotherapy	O
induced	O
neurotoxicity	B-Disease
in	O
sensory	O
neurons	O
:	O
it	O
rescues	O
the	O
mitochondrial	B-Disease
toxicity	I-Disease
and	O
induces	O
the	O
expression	O
of	O
frataxin	O
","	O
an	O
essential	O
mitochondrial	O
protein	O
with	O
anti	O
-	O
oxidant	O
and	O
chaperone	O
properties	O
.	O
	
In	O
conclusion	O
mitochondrial	B-Disease
toxicity	I-Disease
is	O
an	O
early	O
common	O
event	O
both	O
in	O
paclitaxel	B-Chemical
and	O
cisplatin	B-Chemical
induced	O
neurotoxicity	B-Disease
.	O
	
Alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
protects	O
sensory	O
neurons	O
through	O
its	O
anti	O
-	O
oxidant	O
and	O
mitochondrial	O
regulatory	O
functions	O
","	O
possibly	O
inducing	O
the	O
expression	O
of	O
frataxin	O
.	O
	
These	O
findings	O
suggest	O
that	O
alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
might	O
reduce	O
the	O
risk	O
of	O
developing	O
peripheral	B-Disease
nerve	I-Disease
toxicity	I-Disease
in	O
patients	O
undergoing	O
chemotherapy	O
and	O
encourage	O
further	O
confirmatory	O
clinical	O
trials	O
.	O
	
	
Bortezomib	B-Chemical
and	O
dexamethasone	B-Chemical
as	O
salvage	O
therapy	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	B-Disease
myeloma	I-Disease
:	O
analysis	O
of	O
long	O
-	O
term	O
clinical	O
outcomes	O
.	O
	
Bortezomib	B-Chemical
(	O
bort	B-Chemical
)-	O
dexamethasone	B-Chemical
(	O
dex	B-Chemical
)	O
is	O
an	O
effective	O
therapy	O
for	O
relapsed	O
/	O
refractory	O
(	O
R	O
/	O
R	O
)	O
multiple	B-Disease
myeloma	I-Disease
(	O
MM	B-Disease
).	O
	
This	O
retrospective	O
study	O
investigated	O
the	O
combination	O
of	O
bort	B-Chemical
(	O
1	O
.	O
3	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
","	O
4	O
","	O
8	O
","	O
and	O
11	O
every	O
3	O
weeks	O
)	O
and	O
dex	B-Chemical
(	O
20	O
mg	O
on	O
the	O
day	O
of	O
and	O
the	O
day	O
after	O
bort	B-Chemical
)	O
as	O
salvage	O
treatment	O
in	O
85	O
patients	O
with	O
R	O
/	O
R	O
MM	B-Disease
after	O
prior	O
autologous	O
stem	O
cell	O
transplantation	O
or	O
conventional	O
chemotherapy	O
.	O
	
The	O
median	O
number	O
of	O
prior	O
lines	O
of	O
therapy	O
was	O
2	O
.	O
	
Eighty	O
-	O
seven	O
percent	O
of	O
the	O
patients	O
had	O
received	O
immunomodulatory	O
drugs	O
included	O
in	O
some	O
line	O
of	O
therapy	O
before	O
bort	B-Chemical
-	O
dex	B-Chemical
.	O
	
The	O
median	O
number	O
of	O
bort	B-Chemical
-	O
dex	B-Chemical
cycles	O
was	O
6	O
","	O
up	O
to	O
a	O
maximum	O
of	O
12	O
cycles	O
.	O
	
On	O
an	O
intention	O
-	O
to	O
-	O
treat	O
basis	O
","	O
55	O
%	O
of	O
the	O
patients	O
achieved	O
at	O
least	O
partial	O
response	O
","	O
including	O
19	O
%	O
CR	O
and	O
35	O
%	O
achieved	O
at	O
least	O
very	O
good	O
partial	O
response	O
.	O
	
Median	O
durations	O
of	O
response	O
","	O
time	O
to	O
next	O
therapy	O
and	O
treatment	O
-	O
free	O
interval	O
were	O
8	O
","	O
11	O
.	O
2	O
","	O
and	O
5	O
.	O
1	O
months	O
","	O
respectively	O
.	O
	
The	O
most	O
relevant	O
adverse	O
event	O
was	O
peripheral	B-Disease
neuropathy	I-Disease
","	O
which	O
occurred	O
in	O
78	O
%	O
of	O
the	O
patients	O
(	O
grade	O
II	O
","	O
38	O
"%;"	O
grade	O
III	O
","	O
21	O
%)	O
and	O
led	O
to	O
treatment	O
discontinuation	O
in	O
6	O
%.	O
	
With	O
a	O
median	O
follow	O
up	O
of	O
22	O
months	O
","	O
median	O
time	O
to	O
progression	O
","	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
were	O
8	O
.	O
9	O
","	O
8	O
.	O
7	O
","	O
and	O
22	O
months	O
","	O
respectively	O
.	O
	
Prolonged	O
PFS	O
and	O
OS	O
were	O
observed	O
in	O
patients	O
achieving	O
CR	O
and	O
receiving	O
bort	B-Chemical
-	O
dex	B-Chemical
a	O
single	O
line	O
of	O
prior	O
therapy	O
.	O
	
Bort	B-Chemical
-	O
dex	B-Chemical
was	O
an	O
effective	O
salvage	O
treatment	O
for	O
MM	B-Disease
patients	O
","	O
particularly	O
for	O
those	O
in	O
first	O
relapse	O
.	O
	
	
Chronic	O
treatment	O
with	O
metformin	B-Chemical
suppresses	O
toll	O
-	O
like	O
receptor	O
4	O
signaling	O
and	O
attenuates	O
left	B-Disease
ventricular	I-Disease
dysfunction	I-Disease
following	O
myocardial	B-Disease
infarction	I-Disease
.	O
	
Acute	O
treatment	O
with	O
metformin	B-Chemical
has	O
a	O
protective	O
effect	O
in	O
myocardial	B-Disease
infarction	I-Disease
by	O
suppression	O
of	O
inflammatory	B-Disease
responses	O
due	O
to	O
activation	O
of	O
AMP	O
-	O
activated	O
protein	O
kinase	O
(	O
AMPK	O
).	O
	
In	O
the	O
present	O
study	O
","	O
the	O
effect	O
of	O
chronic	O
pre	O
-	O
treatment	O
with	O
metformin	B-Chemical
on	O
cardiac	B-Disease
dysfunction	I-Disease
and	O
toll	O
-	O
like	O
receptor	O
4	O
(	O
TLR4	O
)	O
activities	O
following	O
myocardial	B-Disease
infarction	I-Disease
and	O
their	O
relation	O
with	O
AMPK	O
were	O
assessed	O
.	O
	
Male	O
Wistar	O
rats	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
5	O
groups	O
(	O
n	O
=	O
6	O
):	O
normal	O
control	O
and	O
groups	O
were	O
injected	O
isoproterenol	B-Chemical
after	O
chronic	O
pre	O
-	O
treatment	O
with	O
0	O
","	O
25	O
","	O
50	O
","	O
or	O
100mg	O
/	O
kg	O
of	O
metformin	B-Chemical
twice	O
daily	O
for	O
14	O
days	O
.	O
	
Isoproterenol	B-Chemical
(	O
100mg	O
/	O
kg	O
)	O
was	O
injected	O
subcutaneously	O
on	O
the	O
13th	O
and	O
14th	O
days	O
to	O
induce	O
acute	B-Disease
myocardial	I-Disease
infarction	I-Disease
.	O
	
Isoproterenol	B-Chemical
alone	O
decreased	O
left	O
ventricular	O
systolic	O
pressure	O
and	O
myocardial	O
contractility	O
indexed	O
as	O
LVdp	O
/	O
dtmax	O
and	O
LVdp	O
/	O
dtmin	O
.	O
	
The	O
left	B-Disease
ventricular	I-Disease
dysfunction	I-Disease
was	O
significantly	O
lower	O
in	O
the	O
groups	O
treated	O
with	O
25	O
and	O
50mg	O
/	O
kg	O
of	O
metformin	B-Chemical
.	O
	
Metfromin	B-Chemical
markedly	O
lowered	O
isoproterenol	B-Chemical
-	O
induced	O
elevation	O
in	O
the	O
levels	O
of	O
TLR4	O
mRNA	O
","	O
myeloid	O
differentiation	O
protein	O
88	O
(	O
MyD88	O
)","	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
a	O
)","	O
and	O
interleukin	O
6	O
(	O
IL	O
-	O
6	O
)	O
in	O
the	O
heart	O
tissues	O
.	O
	
Similar	O
changes	O
were	O
also	O
seen	O
in	O
the	O
serum	O
levels	O
of	O
TNF	O
-	O
a	O
and	O
IL	O
-	O
6	O
.	O
	
However	O
","	O
the	O
lower	O
doses	O
of	O
25	O
and	O
50mg	O
/	O
kg	O
were	O
more	O
effective	O
than	O
100mg	O
/	O
kg	O
.	O
	
Phosphorylated	O
AMPKa	O
(	O
p	O
-	O
AMPK	O
)	O
in	O
the	O
myocardium	O
was	O
significantly	O
elevated	O
by	O
25mg	O
/	O
kg	O
of	O
metformin	B-Chemical
","	O
slightly	O
by	O
50mg	O
/	O
kg	O
","	O
but	O
not	O
by	O
100mg	O
/	O
kg	O
.	O
	
Chronic	O
pre	O
-	O
treatment	O
with	O
metformin	B-Chemical
reduces	O
post	O
-	O
myocardial	B-Disease
infarction	I-Disease
cardiac	I-Disease
dysfunction	I-Disease
and	O
suppresses	O
inflammatory	B-Disease
responses	O
","	O
possibly	O
through	O
inhibition	O
of	O
TLR4	O
activities	O
.	O
	
This	O
mechanism	O
can	O
be	O
considered	O
as	O
a	O
target	O
to	O
protect	O
infarcted	B-Disease
myocardium	I-Disease
.	O
	
	
High	O
glucose	B-Chemical
repatterns	O
human	O
podocyte	O
energy	O
metabolism	O
during	O
differentiation	O
and	O
diabetic	B-Disease
nephropathy	I-Disease
.	O
	
Podocytes	O
play	O
a	O
key	O
role	O
in	O
diabetic	B-Disease
nephropathy	I-Disease
pathogenesis	O
","	O
but	O
alteration	O
of	O
their	O
metabolism	O
remains	O
unknown	O
in	O
human	O
kidney	O
.	O
	
By	O
using	O
a	O
conditionally	O
differentiating	O
human	O
podocyte	O
cell	O
line	O
","	O
we	O
addressed	O
the	O
functional	O
and	O
molecular	O
changes	O
in	O
podocyte	O
energetics	O
during	O
in	O
vitro	O
development	O
or	O
under	O
high	O
glucose	B-Chemical
conditions	O
.	O
	
In	O
5	O
mM	O
glucose	B-Chemical
medium	O
","	O
we	O
observed	O
a	O
stepwise	O
activation	O
of	O
oxidative	O
metabolism	O
during	O
cell	O
differentiation	O
that	O
was	O
characterized	O
by	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
-	O
g	O
coactivator	O
1a	O
(	O
PGC	O
-	O
1a	O
)-	O
dependent	O
stimulation	O
of	O
mitochondrial	O
biogenesis	O
and	O
function	O
","	O
with	O
concomitant	O
reduction	O
of	O
the	O
glycolytic	O
enzyme	O
content	O
.	O
	
Conversely	O
","	O
when	O
podocytes	O
were	O
cultured	O
in	O
high	O
glucose	B-Chemical
(	O
20	O
mM	O
)","	O
stepwise	O
oxidative	O
phosphorylation	O
biogenesis	O
was	O
aborted	O
","	O
and	O
a	O
glycolytic	O
switch	O
occurred	O
","	O
with	O
consecutive	O
lactic	B-Disease
acidosis	I-Disease
.	O
	
Expression	O
of	O
the	O
master	O
regulators	O
of	O
oxidative	O
metabolism	O
transcription	O
factor	O
A	O
mitochondrial	O
","	O
PGC	O
-	O
1a	O
","	O
AMPK	O
","	O
and	O
serine	O
-	O
threonine	O
liver	O
kinase	O
B1	O
was	O
altered	O
by	O
high	O
glucose	B-Chemical
","	O
as	O
well	O
as	O
their	O
downstream	O
signaling	O
networks	O
.	O
	
Focused	O
transcriptomics	O
revealed	O
that	O
myocyte	O
-	O
specific	O
enhancer	O
factor	O
2C	O
(	O
MEF2C	O
)	O
and	O
myogenic	O
factor	O
5	O
(	O
MYF5	O
)	O
expression	O
was	O
inhibited	O
by	O
high	O
glucose	B-Chemical
levels	O
","	O
and	O
endoribonuclease	O
-	O
prepared	O
small	O
interfering	O
RNA	O
-	O
mediated	O
combined	O
inhibition	O
of	O
those	O
transcription	O
factors	O
phenocopied	O
the	O
glycolytic	O
shift	O
that	O
was	O
observed	O
in	O
high	O
glucose	B-Chemical
conditions	O
.	O
	
Accordingly	O
","	O
a	O
reduced	O
expression	O
of	O
MEF2C	O
","	O
MYF5	O
","	O
and	O
PGC	O
-	O
1a	O
was	O
found	O
in	O
kidney	O
tissue	O
sections	O
that	O
were	O
obtained	O
from	O
patients	O
with	O
diabetic	B-Disease
nephropathy	I-Disease
.	O
	
These	O
findings	O
obtained	O
in	O
human	O
samples	O
demonstrate	O
that	O
MEF2C	O
-	O
MYF5	O
-	O
dependent	O
bioenergetic	O
dedifferentiation	O
occurs	O
in	O
podocytes	O
that	O
are	O
confronted	O
with	O
a	O
high	O
-	O
glucose	B-Chemical
milieu	O
.-	O
Imasawa	O
","	O
T	O
.","	O
Obre	O
","	O
E	O
.","	O
Bellance	O
","	O
N	O
.","	O
Lavie	O
","	O
J	O
.","	O
Imasawa	O
","	O
T	O
.","	O
Rigothier	O
","	O
C	O
.","	O
Delmas	O
","	O
Y	O
.","	O
Combe	O
","	O
C	O
.","	O
Lacombe	O
","	O
D	O
.","	O
Benard	O
","	O
G	O
.","	O
Claverol	O
","	O
S	O
.","	O
Bonneu	O
","	O
M	O
.","	O
Rossignol	O
","	O
R	O
.	O
High	O
glucose	B-Chemical
repatterns	O
human	O
podocyte	O
energy	O
metabolism	O
during	O
differentiation	O
and	O
diabetic	B-Disease
nephropathy	I-Disease
.	O
	
	
Role	O
of	O
protein	O
arginine	O
methyltransferase	O
5	O
in	O
inflammation	B-Disease
and	O
migration	O
of	O
fibroblast	O
-	O
like	O
synoviocytes	O
in	O
rheumatoid	B-Disease
arthritis	I-Disease
.	O
	
To	O
probe	O
the	O
role	O
of	O
protein	O
arginine	O
methyltransferase	O
5	O
(	O
PRMT5	O
)	O
in	O
regulating	O
inflammation	B-Disease
","	O
cell	O
proliferation	O
","	O
migration	O
and	O
invasion	O
of	O
fibroblast	O
-	O
like	O
synoviocytes	O
(	O
FLSs	O
)	O
from	O
patients	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
(	O
RA	B-Disease
).	O
	
FLSs	O
were	O
separated	O
from	O
synovial	O
tissues	O
(	O
STs	O
)	O
from	O
patients	O
with	O
RA	B-Disease
and	O
osteoarthritis	B-Disease
(	O
OA	B-Disease
).	O
	
An	O
inhibitor	O
of	O
PRMT5	O
(	O
EPZ015666	B-Chemical
)	O
and	O
short	O
interference	O
RNA	O
(	O
siRNA	O
)	O
against	O
PRMT5	O
were	O
used	O
to	O
inhibit	O
PRMT5	O
expression	O
.	O
	
The	O
standard	O
of	O
protein	O
was	O
measured	O
by	O
Western	O
blot	O
or	O
immunofluorescence	O
.	O
	
The	O
excretion	O
and	O
genetic	O
expression	O
of	O
inflammatory	B-Disease
factors	O
were	O
","	O
respectively	O
","	O
estimated	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
).	O
	
Migration	O
and	O
invasion	O
in	O
vitro	O
were	O
detected	O
by	O
Boyden	O
chamber	O
assay	O
.	O
	
FLSs	O
proliferation	O
was	O
detected	O
by	O
BrdU	O
incorporation	O
.	O
	
Increased	O
PRMT5	O
was	O
discovered	O
in	O
STs	O
and	O
FLSs	O
from	O
patients	O
with	O
RA	B-Disease
.	O
	
In	O
RA	B-Disease
FLSs	O
","	O
the	O
level	O
of	O
PRMT5	O
was	O
up	O
-	O
regulated	O
by	O
stimulation	O
with	O
IL	O
-	O
1b	O
and	O
TNF	O
-	O
a	O
.	O
	
Inhibition	O
of	O
PRMT5	O
by	O
EPZ015666	B-Chemical
and	O
siRNA	O
-	O
mediated	O
knockdown	O
reduced	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
production	O
","	O
and	O
proliferation	O
of	O
RA	B-Disease
FLSs	O
.	O
	
In	O
addition	O
","	O
inhibition	O
of	O
PRMT5	O
decreased	O
in	O
vitro	O
migration	O
and	O
invasion	O
of	O
RA	B-Disease
FLSs	O
.	O
	
Furthermore	O
","	O
EPZ015666	B-Chemical
restrained	O
the	O
phosphorylation	O
of	O
IkB	O
kinaseb	O
and	O
IkBa	O
","	O
as	O
well	O
as	O
nucleus	O
transsituation	O
of	O
p65	O
as	O
well	O
as	O
AKT	O
in	O
FLSs	O
.	O
	
PRMT5	O
regulated	O
the	O
production	O
of	O
inflammatory	B-Disease
factors	O
","	O
cell	O
proliferation	O
","	O
migration	O
and	O
invasion	O
of	O
RA	B-Disease
FLS	O
","	O
which	O
was	O
mediated	O
by	O
the	O
NF	O
-	O
kB	O
and	O
AKT	O
pathways	O
.	O
	
Our	O
data	O
suggested	O
that	O
targeting	O
PRMT5	O
to	O
prevent	O
synovial	B-Disease
inflammation	I-Disease
and	O
destruction	O
might	O
be	O
a	O
promising	O
therapy	O
for	O
RA	B-Disease
.	O
	
	
Metalloprotease	O
-	O
disintegrin	O
ADAM12	O
actively	O
promotes	O
the	O
stem	O
cell	O
-	O
like	O
phenotype	O
in	O
claudin	O
-	O
low	O
breast	B-Disease
cancer	I-Disease
.	O
	
BACKGROUND	O
:	O
ADAM12	O
is	O
upregulated	O
in	O
human	O
breast	B-Disease
cancers	I-Disease
and	O
is	O
a	O
predictor	O
of	O
chemoresistance	O
in	O
estrogen	O
receptor	O
-	O
negative	O
tumors	B-Disease
.	O
	
ADAM12	O
is	O
induced	O
during	O
epithelial	O
-	O
to	O
-	O
mesenchymal	O
transition	O
","	O
a	O
feature	O
associated	O
with	O
claudin	O
-	O
low	O
breast	B-Disease
tumors	I-Disease
","	O
which	O
are	O
enriched	O
in	O
cancer	B-Disease
stem	O
cell	O
(	O
CSC	O
)	O
markers	O
.	O
	
It	O
is	O
currently	O
unknown	O
whether	O
ADAM12	O
plays	O
an	O
active	O
role	O
in	O
promoting	O
the	O
CSC	O
phenotype	O
in	O
breast	B-Disease
cancer	I-Disease
cells	O
.	O
	
METHODS	O
:	O
ADAM12	O
expression	O
was	O
downregulated	O
in	O
representative	O
claudin	O
-	O
low	O
breast	B-Disease
cancer	I-Disease
cell	O
lines	O
","	O
SUM159PT	O
and	O
Hs578T	O
","	O
using	O
siRNA	O
transfection	O
or	O
inducible	O
shRNA	O
expression	O
.	O
	
Cell	O
characteristics	O
commonly	O
associated	O
with	O
the	O
CSC	O
phenotype	O
in	O
vitro	O
(	O
cell	O
migration	O
","	O
invasion	O
","	O
anoikis	O
resistance	O
","	O
mammosphere	O
formation	O
","	O
ALDH	O
activity	O
","	O
and	O
expression	O
of	O
the	O
CD44	O
and	O
CD24	O
cell	O
surface	O
markers	O
)	O
and	O
in	O
vivo	O
(	O
tumor	B-Disease
formation	O
in	O
mice	O
using	O
limiting	O
dilution	O
transplantation	O
assays	O
)	O
were	O
evaluated	O
.	O
	
RNA	O
sequencing	O
was	O
performed	O
to	O
identify	O
global	O
gene	O
expression	O
changes	O
after	O
ADAM12	O
knockdown	O
.	O
	
RESULTS	O
:	O
We	O
found	O
that	O
sorted	O
SUM159PT	O
cell	O
populations	O
with	O
high	O
ADAM12	O
levels	O
had	O
elevated	O
expression	O
of	O
CSC	O
markers	O
and	O
an	O
increased	O
ability	O
to	O
form	O
mammospheres	O
.	O
	
ADAM12	O
knockdown	O
reduced	O
cell	O
migration	O
and	O
invasion	O
","	O
decreased	O
anoikis	O
resistance	O
","	O
and	O
compromised	O
mammosphere	O
formation	O
.	O
	
ADAM12	O
knockdown	O
also	O
diminished	O
ALDEFLUOR	O
(+)	O
and	O
CD44	O
(	O
hi	O
)/	O
CD24	O
(-/	O
lo	O
)	O
CSC	O
-	O
enriched	O
populations	O
in	O
vitro	O
and	O
reduced	O
tumorigenesis	B-Disease
in	O
mice	O
in	O
vivo	O
.	O
	
RNA	O
sequencing	O
identified	O
a	O
significant	O
overlap	O
between	O
ADAM12	O
-	O
and	O
Epidermal	O
Growth	O
Factor	O
Receptor	O
(	O
EGFR	O
)-	O
regulated	O
genes	O
.	O
	
Consequently	O
","	O
ADAM12	O
knockdown	O
lowered	O
the	O
basal	O
activation	O
level	O
of	O
EGFR	O
","	O
and	O
this	O
effect	O
was	O
abolished	O
by	O
batimastat	B-Chemical
","	O
a	O
metalloproteinase	O
inhibitor	O
.	O
	
Furthermore	O
","	O
incubation	O
of	O
cells	O
with	O
exogenously	O
added	O
EGF	O
prevented	O
the	O
downregulation	O
of	O
CD44	O
(	O
hi	O
)/	O
CD24	O
(-/	O
lo	O
)	O
cell	O
population	O
by	O
ADAM12	O
knockdown	O
.	O
	
CONCLUSIONS	O
:	O
These	O
results	O
indicate	O
that	O
ADAM12	O
actively	O
supports	O
the	O
CSC	O
phenotype	O
in	O
claudin	O
-	O
low	O
breast	B-Disease
cancer	I-Disease
cells	O
via	O
modulation	O
of	O
the	O
EGFR	O
pathway	O
.	O
	
	
Compound	O
heterozygous	O
mutations	O
in	O
the	O
SRD5A2	O
gene	O
exon	O
4	O
in	O
a	O
male	B-Disease
pseudohermaphrodite	I-Disease
patient	O
of	O
Chinese	O
origin	O
.	O
	
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
perform	O
5	O
-	O
alpha	O
-	O
reductase	O
type	O
2	O
gene	O
(	O
SRD5A2	O
)	O
analysis	O
in	O
a	O
male	B-Disease
pseudohermaphrodite	I-Disease
(	O
MPH	B-Disease
)	O
patient	O
with	O
normal	O
testosterone	B-Chemical
(	O
T	B-Chemical
)	O
production	O
and	O
normal	O
androgen	O
receptor	O
(	O
AR	O
)	O
gene	O
coding	O
sequences	O
.	O
	
A	O
patient	O
of	O
Chinese	O
origin	O
with	O
ambiguous	O
genitalia	O
at	O
14	O
months	O
","	O
a	O
46	O
","	O
XY	O
karyotype	O
","	O
and	O
normal	O
T	B-Chemical
secretion	O
under	O
human	B-Chemical
chorionic	I-Chemical
gonadotropin	I-Chemical
(	O
hCG	B-Chemical
)	O
stimulation	O
underwent	O
a	O
gonadectomy	O
at	O
20	O
months	O
.	O
	
Exons	O
1	O
-	O
8	O
of	O
the	O
AR	O
gene	O
and	O
exons	O
1	O
-	O
5	O
of	O
the	O
SRD5A2	O
gene	O
were	O
sequenced	O
from	O
peripheral	O
blood	O
DNA	O
.	O
	
AR	O
gene	O
coding	O
sequences	O
were	O
normal	O
.	O
	
SRD5A2	O
gene	O
analysis	O
revealed	O
2	O
consecutive	O
mutations	O
in	O
exon	O
4	O
","	O
each	O
located	O
in	O
a	O
different	O
allele	O
:	O
1	O
)	O
a	O
T	O
nucleotide	O
deletion	O
","	O
which	O
predicts	O
a	O
frameshift	O
mutation	O
from	O
codon	O
219	O
","	O
and	O
2	O
)	O
a	O
missense	O
mutation	O
at	O
codon	O
227	O
","	O
where	O
the	O
substitution	O
of	O
guanine	O
(	O
CGA	O
)	O
by	O
adenine	O
(	O
CAA	O
)	O
predicts	O
a	O
glutamine	O
replacement	O
of	O
arginine	O
(	O
R227Q	O
).	O
	
Testes	O
located	O
in	O
the	O
inguinal	O
canal	O
showed	O
a	O
normal	O
morphology	O
for	O
age	O
.	O
	
The	O
patient	O
was	O
a	O
compound	O
heterozygote	O
for	O
SRD5A2	O
mutations	O
","	O
carrying	O
2	O
mutations	O
in	O
exon	O
4	O
.	O
	
The	O
patient	O
showed	O
an	O
R227Q	O
mutation	O
that	O
has	O
been	O
described	O
in	O
an	O
Asian	O
population	O
and	O
MPH	B-Disease
patients	O
","	O
along	O
with	O
a	O
novel	O
frameshift	O
mutation	O
","	O
Tdel219	O
.	O
	
Testis	O
morphology	O
showed	O
that	O
","	O
during	O
early	O
infancy	O
","	O
the	O
5	O
-	O
alpha	O
-	O
reductase	O
enzyme	O
deficiency	O
may	O
not	O
have	O
affected	O
interstitial	O
or	O
tubular	O
development	O
.	O
	
	
Tumor	B-Disease
associated	O
antigen	O
recognition	O
by	O
autologous	O
serum	O
in	O
patients	O
with	O
breast	B-Disease
cancer	I-Disease
.	O
	
Breast	B-Disease
cancer	I-Disease
accounts	O
for	O
30	O
-	O
40	O
%	O
of	O
all	O
deaths	O
from	O
cancers	B-Disease
in	O
females	O
.	O
	
In	O
an	O
effort	O
to	O
identify	O
tumor	B-Disease
associated	O
antigens	O
that	O
may	O
be	O
useful	O
for	O
immunotherapy	O
","	O
we	O
utilized	O
serological	O
analysis	O
of	O
recombinant	O
cDNA	O
expression	O
libraries	O
(	O
SEREX	O
)	O
technique	O
to	O
identify	O
breast	B-Disease
cancer	I-Disease
-	O
associated	O
antigens	O
.	O
	
SEREX	O
screening	O
of	O
cDNA	O
expression	O
libraries	O
derived	O
from	O
3	O
breast	B-Disease
cancer	I-Disease
patients	O
identified	O
a	O
total	O
of	O
88	O
positive	O
clones	O
(	O
bcg	O
-	O
1	O
to	O
bcg	O
-	O
88	O
)","	O
including	O
27	O
hitherto	O
unknown	O
sequences	O
.	O
	
The	O
cDNA	O
sequences	O
and	O
mRNA	O
expression	O
patterns	O
were	O
characterized	O
.	O
	
Seroreactivity	O
of	O
the	O
SEREX	O
clones	O
were	O
determined	O
in	O
sera	O
from	O
75	O
breast	B-Disease
cancer	I-Disease
patients	O
","	O
75	O
colon	B-Disease
cancer	I-Disease
patients	O
","	O
and	O
25	O
healthy	O
donors	O
.	O
	
Expression	O
analysis	O
on	O
a	O
cDNA	O
panel	O
from	O
17	O
different	O
normal	O
tissues	O
by	O
reverse	O
transcription	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
revealed	O
tissue	O
restricted	O
mRNA	O
expression	O
of	O
2	O
of	O
the	O
27	O
unknown	O
antigens	O
.	O
	
Bcg	O
-	O
72	O
is	O
expressed	O
only	O
in	O
breast	O
","	O
prostate	O
and	O
thymus	O
","	O
while	O
bcg	O
-	O
84	O
is	O
expressed	O
at	O
moderate	O
levels	O
in	O
testis	O
","	O
spleen	O
and	O
breast	O
.	O
	
The	O
other	O
25	O
unknown	O
antigens	O
were	O
expressed	O
in	O
most	O
other	O
tissues	O
.	O
	
Serologic	O
assay	O
revealed	O
that	O
7	O
out	O
of	O
the	O
88	O
clones	O
showed	O
reactivity	O
to	O
at	O
least	O
one	O
serum	O
from	O
either	O
75	O
breast	O
or	O
75	O
colon	B-Disease
cancer	I-Disease
patients	O
.	O
	
These	O
clones	O
did	O
not	O
react	O
with	O
sera	O
from	O
a	O
panel	O
of	O
25	O
healthy	O
adult	O
individuals	O
.	O
	
Our	O
results	O
demonstrate	O
the	O
utility	O
of	O
the	O
SEREX	O
approach	O
for	O
the	O
identification	O
of	O
potential	O
tumor	B-Disease
associated	O
antigens	O
in	O
human	O
breast	B-Disease
cancer	I-Disease
.	O
	
	
TGFBI	O
gene	O
mutations	O
causing	O
lattice	B-Disease
and	I-Disease
granular	I-Disease
corneal	I-Disease
dystrophies	I-Disease
in	O
Indian	O
patients	O
.	O
	
PURPOSE	O
:	O
To	O
identify	O
mutations	O
in	O
the	O
TGFBI	O
gene	O
in	O
Indian	O
patients	O
with	O
lattice	B-Disease
corneal	I-Disease
dystrophy	I-Disease
(	O
LCD	B-Disease
)	O
or	O
granular	B-Disease
corneal	I-Disease
dystrophy	I-Disease
(	O
GCD	B-Disease
)	O
and	O
to	O
look	O
for	O
genotype	O
-	O
phenotype	O
correlations	O
.	O
	
METHODS	O
:	O
Thirty	O
-	O
seven	O
unrelated	O
patients	O
were	O
studied	O
","	O
18	O
with	O
LCD	B-Disease
and	O
19	O
with	O
GCD	B-Disease
.	O
	
The	O
diagnosis	O
of	O
LCD	B-Disease
or	O
GCD	B-Disease
was	O
made	O
on	O
the	O
basis	O
of	O
clinical	O
and	O
/	O
or	O
histopathological	O
evaluation	O
.	O
	
Exons	O
and	O
flanking	O
intron	O
sequences	O
of	O
the	O
TGFBI	O
gene	O
were	O
amplified	O
by	O
PCR	O
with	O
specific	O
primers	O
.	O
	
PCR	O
products	O
were	O
screened	O
by	O
the	O
method	O
of	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
followed	O
by	O
sequencing	O
.	O
	
Mutations	O
were	O
confirmed	O
by	O
screening	O
at	O
least	O
100	O
unrelated	O
normal	O
control	O
subjects	O
.	O
	
RESULTS	O
:	O
Mutations	O
were	O
identified	O
in	O
14	O
of	O
18	O
patients	O
with	O
LCD	B-Disease
and	O
in	O
all	O
19	O
patients	O
with	O
GCD	B-Disease
.	O
	
In	O
LCD	B-Disease
","	O
three	O
novel	O
heterozygous	O
mutations	O
found	O
were	O
glycine	O
-	O
594	O
-	O
valine	O
(	O
Gly594Val	O
)	O
in	O
2	O
of	O
18	O
patients	O
","	O
valine	O
-	O
539	O
-	O
aspartic	O
acid	O
(	O
Val539Asp	O
)	O
in	O
1	O
patient	O
","	O
and	O
deletion	O
of	O
valine	O
624	O
","	O
valine	O
625	O
(	O
Val624	O
-	O
Val625del	O
)	O
in	O
1	O
patient	O
.	O
	
In	O
addition	O
","	O
mutation	O
of	O
arginine	O
124	O
-	O
to	O
-	O
cysteine	O
(	O
Arg124Cys	O
)	O
was	O
found	O
in	O
8	O
of	O
18	O
patients	O
and	O
histidine	O
626	O
-	O
to	O
-	O
arginine	O
(	O
His626Arg	O
)	O
in	O
2	O
of	O
18	O
patients	O
.	O
	
Atypical	O
clinical	O
features	O
for	O
LCD	B-Disease
were	O
noted	O
in	O
patients	O
with	O
the	O
Gly594Val	O
and	O
Val624	O
-	O
Val625del	O
mutations	O
.	O
	
In	O
GCD	B-Disease
","	O
18	O
patients	O
with	O
GCD	B-Disease
type	I-Disease
I	I-Disease
had	O
a	O
mutation	O
of	O
arginine	O
555	O
-	O
to	O
-	O
tryptophan	O
(	O
Arg555Trp	O
)	O
and	O
1	O
patient	O
with	O
GCD	B-Disease
type	I-Disease
III	I-Disease
(	O
Reis	B-Disease
-	I-Disease
Bucklers	I-Disease
dystrophy	I-Disease
)","	O
had	O
the	O
Arg124Leu	O
mutation	O
.	O
	
Seven	O
novel	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
were	O
also	O
found	O
","	O
of	O
which	O
a	O
change	O
of	O
leucine	O
269	O
to	O
phenylalanine	O
(	O
Leu269Phe	O
)	O
was	O
found	O
in	O
12	O
of	O
18	O
patients	O
with	O
the	O
Arg555Trp	O
mutation	O
.	O
	
CONCLUSIONS	O
:	O
Arg124Cys	O
and	O
Arg555Trp	O
appear	O
to	O
be	O
the	O
predominant	O
mutations	O
causing	O
LCD	B-Disease
and	O
GCD	B-Disease
","	O
respectively	O
","	O
in	O
the	O
population	O
studied	O
.	O
	
The	O
novel	O
mutations	O
identified	O
in	O
this	O
study	O
are	O
associated	O
with	O
distinct	O
phenotypes	O
.	O
	
	
A	O
two	O
base	O
pair	O
deletion	O
in	O
the	O
PQBP1	O
gene	O
is	O
associated	O
with	O
microphthalmia	B-Disease
","	O
microcephaly	B-Disease
","	O
and	O
mental	B-Disease
retardation	I-Disease
.	O
	
X	B-Disease
-	I-Disease
linked	I-Disease
mental	I-Disease
retardation	I-Disease
has	O
been	O
traditionally	O
divided	O
into	O
syndromic	O
(	O
S	O
-	O
XLMR	B-Disease
)	O
and	O
non	O
-	O
syndromic	O
forms	O
(	O
NS	O
-	O
XLMR	B-Disease
)","	O
although	O
the	O
borderlines	O
between	O
these	O
phenotypes	O
begin	O
to	O
vanish	O
and	O
mutations	O
in	O
a	O
single	O
gene	O
","	O
for	O
example	O
PQBP1	O
","	O
can	O
cause	O
S	O
-	O
XLMR	B-Disease
as	O
well	O
as	O
NS	O
-	O
XLMR	B-Disease
.	O
	
Here	O
","	O
we	O
report	O
two	O
maternal	O
cousins	O
with	O
an	O
apparently	O
X	B-Disease
-	I-Disease
linked	I-Disease
phenotype	I-Disease
of	I-Disease
mental	I-Disease
retardation	I-Disease
(	O
MR	B-Disease
)","	O
microphthalmia	B-Disease
","	O
choroid	B-Disease
coloboma	I-Disease
","	O
microcephaly	B-Disease
","	O
renal	B-Disease
hypoplasia	I-Disease
","	O
and	O
spastic	B-Disease
paraplegia	I-Disease
.	O
	
By	O
multipoint	O
linkage	O
analysis	O
with	O
markers	O
spanning	O
the	O
entire	O
X	O
-	O
chromosome	O
we	O
mapped	O
the	O
disease	O
locus	O
to	O
a	O
28	O
-	O
Mb	O
interval	O
between	O
Xp11	O
.	O
4	O
and	O
Xq12	O
","	O
including	O
the	O
BCOR	O
gene	O
.	O
	
A	O
missense	O
mutation	O
in	O
BCOR	O
was	O
described	O
in	O
a	O
family	O
with	O
Lenz	B-Disease
microphthalmia	I-Disease
syndrome	I-Disease
","	O
a	O
phenotype	O
showing	O
substantial	O
overlapping	O
features	O
with	O
that	O
described	O
in	O
the	O
two	O
cousins	O
.	O
	
However	O
","	O
no	O
mutation	O
in	O
the	O
BCOR	O
gene	O
was	O
found	O
in	O
both	O
patients	O
.	O
	
Subsequent	O
mutation	O
analysis	O
of	O
PQBP1	O
","	O
located	O
within	O
the	O
delineated	O
linkage	O
interval	O
in	O
Xp11	O
.	O
23	O
","	O
revealed	O
a	O
2	O
-	O
bp	O
deletion	O
","	O
c	O
.	O
461_462delAG	O
","	O
that	O
cosegregated	O
with	O
the	O
disease	O
.	O
	
Notably	O
","	O
the	O
same	O
mutation	O
is	O
associated	O
with	O
the	O
Hamel	B-Disease
cerebropalatocardiac	I-Disease
syndrome	I-Disease
","	O
another	O
form	O
of	O
S	O
-	O
XLMR	B-Disease
.	O
	
Haplotype	O
analysis	O
suggests	O
a	O
germline	O
mosaicism	O
of	O
the	O
2	O
-	O
bp	O
deletion	O
in	O
the	O
maternal	O
grandmother	O
of	O
both	O
affected	O
individuals	O
.	O
	
In	O
summary	O
","	O
our	O
findings	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
mutations	O
in	O
PQBP1	O
are	O
associated	O
with	O
an	O
S	O
-	O
XLMR	B-Disease
phenotype	O
including	O
microphthalmia	B-Disease
","	O
thereby	O
further	O
extending	O
the	O
clinical	O
spectrum	O
of	O
phenotypes	O
associated	O
with	O
PQBP1	O
mutations	O
.	O
	
	
Interaction	O
between	O
warfarin	B-Chemical
and	O
levofloxacin	B-Chemical
:	O
case	O
series	O
.	O
	
Warfarin	B-Chemical
is	O
the	O
most	O
widely	O
used	O
oral	O
anticoagulant	O
and	O
is	O
indicated	O
for	O
many	O
clinical	O
conditions	O
.	O
	
Levofloxacin	B-Chemical
","	O
a	O
fluoroquinolone	B-Chemical
","	O
is	O
one	O
of	O
the	O
most	O
commonly	O
prescribed	O
antibiotics	O
in	O
clinical	O
practice	O
and	O
is	O
effective	O
against	O
Gram	O
-	O
positive	O
","	O
Gram	O
-	O
negative	O
","	O
and	O
atypical	O
bacteria	O
.	O
	
While	O
small	O
prospective	O
studies	O
have	O
not	O
revealed	O
any	O
significant	O
drug	O
-	O
drug	O
interaction	O
between	O
warfarin	B-Chemical
and	O
levofloxacin	B-Chemical
","	O
several	O
case	O
reports	O
have	O
indicated	O
that	O
levofloxacin	B-Chemical
may	O
significantly	O
potentiate	O
the	O
anticoagulation	O
effect	O
of	O
warfarin	B-Chemical
.	O
	
We	O
report	O
3	O
cases	O
of	O
serious	O
bleeding	B-Disease
complications	O
that	O
appear	O
to	O
be	O
the	O
result	O
of	O
the	O
interaction	O
between	O
warfarin	B-Chemical
and	O
levofloxacin	B-Chemical
.	O
	
Physicians	O
should	O
be	O
aware	O
of	O
this	O
potential	O
interaction	O
and	O
use	O
caution	O
when	O
prescribing	O
levofloxacin	B-Chemical
to	O
patients	O
taking	O
warfarin	B-Chemical
.	O
	
	
Rapid	O
reversal	O
of	O
anticoagulation	O
reduces	O
hemorrhage	B-Disease
volume	O
in	O
a	O
mouse	O
model	O
of	O
warfarin	B-Chemical
-	O
associated	O
intracerebral	B-Disease
hemorrhage	I-Disease
.	O
	
Warfarin	B-Chemical
-	O
associated	O
intracerebral	B-Disease
hemorrhage	I-Disease
(	O
W	B-Chemical
-	O
ICH	B-Disease
)	O
is	O
a	O
severe	O
type	O
of	O
stroke	B-Disease
.	O
	
There	O
is	O
no	O
consensus	O
on	O
the	O
optimal	O
treatment	O
for	O
W	B-Chemical
-	O
ICH	B-Disease
.	O
	
Using	O
a	O
mouse	O
model	O
","	O
we	O
tested	O
whether	O
the	O
rapid	O
reversal	O
of	O
anticoagulation	O
using	O
human	O
prothrombin	B-Chemical
complex	I-Chemical
concentrate	I-Chemical
(	O
PCC	B-Chemical
)	O
can	O
reduce	O
hemorrhagic	O
blood	O
volume	O
.	O
	
Male	O
CD	O
-	O
1	O
mice	O
were	O
treated	O
with	O
warfarin	B-Chemical
(	O
2	O
mg	O
/	O
kg	O
over	O
24	O
h	O
)","	O
resulting	O
in	O
a	O
mean	O
(+/-	O
s	O
.	O
d	O
.)	O
	
International	O
Normalized	O
Ratio	O
of	O
3	O
.	O
5	O
+/-	O
0	O
.	O
9	O
.	O
	
First	O
","	O
we	O
showed	O
that	O
an	O
intravenous	O
administration	O
of	O
human	O
PCC	B-Chemical
rapidly	O
reversed	O
anticoagulation	O
in	O
mice	O
.	O
	
Second	O
","	O
a	O
stereotactic	O
injection	O
of	O
collagenase	B-Chemical
was	O
administered	O
to	O
induce	O
hemorrhage	B-Disease
in	O
the	O
right	O
striatum	O
.	O
	
Forty	O
-	O
five	O
minutes	O
later	O
","	O
the	O
animals	O
were	O
randomly	O
treated	O
with	O
PCC	B-Chemical
(	O
100	O
U	O
/	O
kg	O
)	O
or	O
saline	O
i	O
.	O
v	O
.	O
	
(	O
n	O
=	O
12	O
per	O
group	O
).	O
	
Twenty	O
-	O
four	O
hours	O
after	O
hemorrhage	B-Disease
induction	O
","	O
hemorrhagic	O
blood	O
volume	O
was	O
quantified	O
using	O
a	O
photometric	O
hemoglobin	O
assay	O
.	O
	
The	O
mean	O
hemorrhagic	O
blood	O
volume	O
was	O
reduced	O
in	O
PCC	B-Chemical
-	O
treated	O
animals	O
(	O
6	O
.	O
5	O
+/-	O
3	O
.	O
1	O
microL	O
)	O
compared	O
with	O
saline	O
controls	O
(	O
15	O
.	O
3	O
+/-	O
11	O
.	O
2	O
microL	O
","	O
P	O
=	O
0	O
.	O
15	O
).	O
	
In	O
the	O
saline	O
group	O
","	O
45	O
%	O
of	O
the	O
mice	O
developed	O
large	O
hematomas	B-Disease
(	O
i	O
.	O
e	O
.","	O
>	O
15	O
microL	O
).	O
	
In	O
contrast	O
","	O
such	O
extensive	O
lesions	O
were	O
never	O
found	O
in	O
the	O
PCC	B-Chemical
group	O
.	O
	
We	O
provide	O
experimental	O
data	O
suggesting	O
PCC	B-Chemical
to	O
be	O
an	O
effective	O
acute	O
treatment	O
for	O
W	B-Chemical
-	O
ICH	B-Disease
in	O
terms	O
of	O
reducing	O
hemorrhagic	O
blood	O
volume	O
.	O
	
Future	O
studies	O
are	O
needed	O
to	O
assess	O
the	O
therapeutic	O
potential	O
emerging	O
from	O
our	O
finding	O
for	O
human	O
W	B-Chemical
-	O
ICH	B-Disease
.	O
	
	
FGFR4	O
Gly388Arg	O
polymorphism	O
and	O
prostate	B-Disease
cancer	I-Disease
risk	O
in	O
Scottish	O
men	O
.	O
	
Fibroblast	O
growth	O
factor	O
receptor	O
4	O
(	O
FGFR4	O
)","	O
a	O
member	O
of	O
the	O
fibroblast	O
growth	O
receptor	O
family	O
","	O
was	O
recently	O
reported	O
to	O
be	O
more	O
abundantly	O
expressed	O
in	O
malignant	O
than	O
benign	O
prostate	O
cells	O
.	O
	
A	O
single	O
nucleotide	O
polymorphism	O
at	O
position	O
388	O
of	O
the	O
FGFR4	O
amino	O
-	O
acid	O
sequence	O
results	O
in	O
the	O
substitution	O
of	O
glycine	O
(	O
Gly	O
)	O
with	O
arginine	O
(	O
Arg	O
)	O
and	O
higher	O
frequency	O
of	O
the	O
ArgArg	O
genotype	O
was	O
previously	O
found	O
in	O
prostate	B-Disease
cancer	I-Disease
patients	O
.	O
	
DNA	O
was	O
extracted	O
from	O
the	O
blood	O
drawn	O
from	O
399	O
prostate	B-Disease
cancer	I-Disease
patients	O
","	O
150	O
BPH	B-Disease
patients	O
and	O
294	O
healthy	O
community	O
controls	O
.	O
	
Polymerase	O
chain	O
reaction	O
was	O
carried	O
out	O
and	O
single	O
nucleotide	O
polymorphisms	O
of	O
FGFR4	O
were	O
identified	O
by	O
restriction	O
enzyme	O
digestion	O
.	O
	
No	O
overall	O
association	O
is	O
detectable	O
between	O
the	O
Arg	O
allele	O
and	O
increased	O
prostate	B-Disease
cancer	I-Disease
risk	O
.	O
	
Subgroup	O
analysis	O
shows	O
a	O
higher	O
incidence	O
of	O
the	O
heterozygous	O
ArgGly	O
genotype	O
in	O
cancer	B-Disease
cases	O
than	O
in	O
the	O
combined	O
group	O
of	O
BPH	B-Disease
and	O
controls	O
(	O
P	O
<	O
0	O
.	O
5	O
");"	O
this	O
difference	O
is	O
statistically	O
significant	O
between	O
cancer	B-Disease
and	O
BPH	B-Disease
patients	O
but	O
not	O
between	O
cancer	B-Disease
cases	O
and	O
community	O
controls	O
.	O
	
The	O
single	O
nucleotide	O
polymorphism	O
Gly	O
(	O
388	O
)	O
Arg	O
in	O
FGFR4	O
is	O
not	O
associated	O
with	O
increased	O
risk	O
of	O
prostate	B-Disease
cancer	I-Disease
in	O
Scottish	O
men	O
.	O
	
This	O
observation	O
is	O
in	O
contrast	O
with	O
results	O
from	O
two	O
previous	O
studies	O
conducted	O
in	O
the	O
USA	O
and	O
Japan	O
.	O
	
	
A	O
novel	O
point	O
mutation	O
in	O
helix	O
10	O
of	O
the	O
human	O
glucocorticoid	O
receptor	O
causes	O
generalized	O
glucocorticoid	B-Disease
resistance	I-Disease
by	O
disrupting	O
the	O
structure	O
of	O
the	O
ligand	O
-	O
binding	O
domain	O
.	O
	
CONTEXT	O
:	O
Generalized	O
glucocorticoid	B-Disease
resistance	I-Disease
syndrome	O
is	O
a	O
rare	O
familial	O
or	O
sporadic	O
condition	O
characterized	O
by	O
partial	O
insensitivity	O
to	O
glucocorticoids	B-Chemical
","	O
caused	O
by	O
mutations	O
in	O
the	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
gene	O
.	O
	
Most	O
of	O
the	O
reported	O
cases	O
are	O
adults	O
","	O
demonstrating	O
symptoms	O
associated	O
with	O
mineralocorticoid	B-Chemical
and	O
/	O
or	O
adrenal	O
androgen	B-Chemical
excess	O
caused	O
by	O
compensatively	O
increased	O
secretion	O
of	O
the	O
adrenocorticotropic	O
hormone	O
.	O
	
PATIENT	O
:	O
We	O
identified	O
a	O
new	O
2	O
-	O
yr	O
-	O
old	O
female	O
case	O
of	O
generalized	O
glucocorticoid	B-Disease
resistance	I-Disease
syndrome	O
.	O
	
The	O
patient	O
(	O
TJ	O
)	O
presented	O
with	O
a	O
generalized	O
seizure	B-Disease
associated	O
with	O
hypoglycemia	B-Disease
and	O
hypokalemia	B-Disease
.	O
	
She	O
also	O
had	O
hypertension	B-Disease
and	O
premature	B-Disease
pubarche	I-Disease
","	O
whereas	O
dexamethasone	B-Chemical
effectively	O
suppressed	O
these	O
clinical	O
manifestations	O
.	O
	
RESULTS	O
:	O
The	O
patient	O
'	O
s	O
GR	O
gene	O
had	O
a	O
heterozygotic	O
mutation	O
(	O
G	O
-->	O
A	O
)	O
at	O
nucleotide	O
position	O
2141	O
(	O
exon	O
8	O
)","	O
which	O
resulted	O
in	O
substitution	O
of	O
arginine	O
by	O
glutamine	O
at	O
amino	O
acid	O
position	O
714	O
in	O
the	O
ligand	O
-	O
binding	O
domain	O
(	O
LBD	O
)	O
of	O
the	O
GR	O
alpha	O
.	O
	
Molecular	O
analysis	O
revealed	O
that	O
the	O
mutant	O
receptor	O
had	O
significantly	O
impaired	O
transactivation	O
activity	O
with	O
a	O
2	O
-	O
fold	O
reduction	O
in	O
affinity	O
to	O
ligand	O
.	O
	
It	O
showed	O
attenuated	O
transactivation	O
of	O
the	O
activation	O
function	O
(	O
AF	O
)-	O
2	O
and	O
reduced	O
binding	O
to	O
a	O
p160	O
nuclear	O
receptor	O
coactivator	O
.	O
	
Computer	O
-	O
based	O
structural	O
analysis	O
revealed	O
that	O
replacement	O
of	O
arginine	O
by	O
glutamine	O
at	O
position	O
714	O
transmitted	O
a	O
conformational	O
change	O
to	O
the	O
LBD	O
and	O
the	O
AF	O
-	O
2	O
transactivation	O
surface	O
","	O
resulting	O
in	O
a	O
decreased	O
binding	O
affinity	O
to	O
ligand	O
and	O
to	O
the	O
LXXLL	O
coactivator	O
motif	O
.	O
	
CONCLUSIONS	O
:	O
Dexamethasone	B-Chemical
treatment	O
is	O
effective	O
in	O
controlling	O
the	O
premature	B-Disease
pubarche	I-Disease
","	O
hypoglycemia	B-Disease
","	O
hypertension	B-Disease
","	O
and	O
hypokalemia	B-Disease
in	O
this	O
child	O
case	O
","	O
wherein	O
arginine	O
714	O
plays	O
a	O
key	O
role	O
in	O
the	O
proper	O
formation	O
of	O
the	O
ligand	O
-	O
binding	O
pocket	O
and	O
the	O
AF	O
-	O
2	O
surface	O
of	O
the	O
GR	O
alpha	O
LBD	O
.	O
	
	
MHC	O
region	O
and	O
risk	O
of	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
in	O
African	O
American	O
women	O
.	O
	
The	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
on	O
chromosome	O
6p21	O
is	O
a	O
key	O
contributor	O
to	O
the	O
genetic	O
basis	O
of	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
(	O
SLE	B-Disease
).	O
	
Although	O
SLE	B-Disease
affects	O
African	O
Americans	O
disproportionately	O
compared	O
to	O
European	O
Americans	O
","	O
there	O
has	O
been	O
no	O
comprehensive	O
analysis	O
of	O
the	O
MHC	O
region	O
in	O
relationship	O
to	O
SLE	B-Disease
in	O
African	O
Americans	O
.	O
	
We	O
conducted	O
a	O
screening	O
of	O
the	O
MHC	O
region	O
for	O
1	O
","	O
536	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
and	O
the	O
deletion	O
of	O
the	O
C4A	O
gene	O
in	O
a	O
SLE	B-Disease
case	O
-	O
control	O
study	O
(	O
380	O
cases	O
","	O
765	O
age	O
-	O
matched	O
controls	O
)	O
nested	O
within	O
the	O
prospective	O
Black	O
Women	O
'	O
s	O
Health	O
Study	O
.	O
	
We	O
also	O
genotyped	O
1	O
","	O
509	O
ancestral	O
informative	O
markers	O
throughout	O
the	O
genome	O
to	O
estimate	O
European	O
ancestry	O
to	O
control	O
for	O
population	O
stratification	O
due	O
to	O
population	O
admixture	O
.	O
	
The	O
most	O
strongly	O
associated	O
SNP	O
with	O
SLE	B-Disease
was	O
the	O
rs9271366	O
(	O
odds	O
ratio	O
","	O
OR	O
=	O
1	O
.	O
70	O
","	O
p	O
=	O
5	O
.	O
6	O
10	O
(-	O
5	O
))	O
near	O
the	O
HLA	O
-	O
DRB1	O
gene	O
.	O
	
Conditional	O
haplotype	O
analysis	O
revealed	O
three	O
other	O
SNPs	O
","	O
rs204890	O
(	O
OR	O
=	O
1	O
.	O
86	O
","	O
p	O
=	O
1	O
.	O
2	O
10	O
(-	O
4	O
))","	O
rs2071349	O
(	O
OR	O
=	O
1	O
.	O
53	O
","	O
p	O
=	O
1	O
.	O
0	O
10	O
(-	O
3	O
))","	O
and	O
rs2844580	O
(	O
OR	O
=	O
1	O
.	O
43	O
","	O
p	O
=	O
1	O
.	O
3	O
10	O
(-	O
3	O
))","	O
to	O
be	O
associated	O
with	O
SLE	B-Disease
independent	O
of	O
the	O
rs9271366	O
SNP	O
.	O
	
In	O
univariate	O
analysis	O
","	O
the	O
OR	O
for	O
the	O
C4A	O
deletion	O
was	O
1	O
.	O
38	O
","	O
p	O
=	O
0	O
.	O
75	O
","	O
but	O
after	O
simultaneous	O
adjustment	O
for	O
the	O
other	O
four	O
SNPs	O
the	O
odds	O
ratio	O
was	O
1	O
.	O
1	O
","	O
p	O
=	O
0	O
.	O
98	O
.	O
	
A	O
genotype	O
score	O
combining	O
the	O
four	O
newly	O
identified	O
SNPs	O
showed	O
an	O
additive	O
risk	O
according	O
to	O
the	O
number	O
of	O
high	O
-	O
risk	O
alleles	O
(	O
OR	O
=	O
1	O
.	O
67	O
per	O
high	O
-	O
risk	O
allele	O
","	O
p	O
<	O
0	O
.	O
1	O
).	O
	
Our	O
strongest	O
signal	O
","	O
the	O
rs9271366	O
SNP	O
","	O
was	O
also	O
associated	O
with	O
higher	O
risk	O
of	O
SLE	B-Disease
in	O
a	O
previous	O
Chinese	O
genome	O
-	O
wide	O
association	O
study	O
(	O
GWAS	O
).	O
	
In	O
addition	O
","	O
two	O
SNPs	O
found	O
in	O
a	O
GWAS	O
of	O
European	O
ancestry	O
women	O
were	O
confirmed	O
in	O
our	O
study	O
","	O
indicating	O
that	O
African	O
Americans	O
share	O
some	O
genetic	O
risk	O
factors	O
for	O
SLE	B-Disease
with	O
European	O
and	O
Chinese	O
subjects	O
.	O
	
In	O
summary	O
","	O
we	O
found	O
four	O
independent	O
signals	O
in	O
the	O
MHC	O
region	O
associated	O
with	O
risk	O
of	O
SLE	B-Disease
in	O
African	O
American	O
women	O
.	O
	
	
Plasminogen	O
activator	O
inhibitor	O
type	O
1	O
serum	O
levels	O
and	O
4G	O
/	O
5G	O
gene	O
polymorphism	O
in	O
morbidly	O
obese	B-Disease
Hispanic	O
patients	O
with	O
non	B-Disease
-	I-Disease
alcoholic	I-Disease
fatty	I-Disease
liver	I-Disease
disease	I-Disease
.	O
	
BACKGROUND	O
:	O
The	O
plasminogen	O
activator	O
inhibitor	O
type	O
-	O
1	O
(	O
PAI	O
-	O
1	O
)	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
fibrinolysis	O
and	O
extracellular	O
matrix	O
components	O
.	O
	
The	O
single	O
base	O
pair	O
guanine	O
insertion	O
/	O
deletion	O
polymorphism	O
(	O
4G	O
/	O
5G	O
)	O
within	O
the	O
promoter	O
region	O
of	O
the	O
PAI	O
-	O
1	O
gene	O
influences	O
PAI	O
-	O
1	O
synthesis	O
and	O
may	O
modulate	O
hepatic	B-Disease
fibrogenesis	I-Disease
.	O
	
AIM	O
:	O
To	O
evaluate	O
the	O
influence	O
of	O
PAI	O
-	O
1	O
serum	O
levels	O
and	O
4G	O
/	O
5G	O
polymorphism	O
on	O
the	O
risk	O
of	O
liver	B-Disease
fibrosis	I-Disease
associated	O
to	O
non	B-Disease
-	I-Disease
alcoholic	I-Disease
fatty	I-Disease
liver	I-Disease
disease	I-Disease
(	O
NAFLD	B-Disease
)	O
in	O
morbidly	O
obese	B-Disease
patients	O
.	O
	
MATERIAL	O
AND	O
METHODS	O
:	O
Case	O
-	O
control	O
study	O
of	O
50	O
obese	B-Disease
patients	O
undergoing	O
bariatric	O
surgery	O
and	O
71	O
non	O
-	O
obese	B-Disease
subjects	O
matched	O
by	O
age	O
and	O
sex	O
.	O
	
Anthropometric	O
and	O
biochemical	O
measurements	O
were	O
performed	O
","	O
including	O
PAI	O
-	O
1	O
serum	O
levels	O
.	O
	
Genomic	O
DNA	O
was	O
obtained	O
to	O
assess	O
the	O
presence	O
of	O
4G	O
/	O
5G	O
polymorphism	O
.	O
	
RESULTS	O
:	O
BMI	O
","	O
insulinemia	O
","	O
triglycerides	B-Chemical
","	O
HOMA	O
-	O
IR	O
","	O
hypertension	B-Disease
and	O
diabetes	B-Disease
were	O
significantly	O
higher	O
in	O
obese	B-Disease
patients	O
compared	O
to	O
control	O
subjects	O
.	O
	
PAI	O
-	O
1	O
serum	O
levels	O
observed	O
in	O
obese	B-Disease
patients	O
were	O
significantly	O
lower	O
(	O
10	O
.	O
63	O
4	O
.	O
82	O
)	O
compared	O
to	O
controls	O
(	O
14	O
.	O
26	O
11	O
.	O
4	O
";"	O
p	O
<	O
0	O
.	O
5	O
).	O
	
No	O
differences	O
were	O
observed	O
in	O
the	O
PAI	O
-	O
1	O
4G	O
/	O
5G	O
promoter	O
genotypes	O
frequencies	O
(	O
p	O
=	O
0	O
.	O
12	O
).	O
	
No	O
differences	O
were	O
observed	O
in	O
PAI	O
-	O
1	O
plasma	O
levels	O
among	O
obese	B-Disease
patients	O
with	O
liver	B-Disease
fibrosis	I-Disease
(	O
10	O
.	O
64	O
4	O
.	O
35	O
)	O
compared	O
to	O
patients	O
without	O
liver	B-Disease
fibrosis	I-Disease
(	O
10	O
.	O
61	O
5	O
.	O
2	O
";"	O
p	O
=	O
0	O
.	O
985	O
).	O
	
PAI	O
-	O
1	O
4G	O
/	O
5G	O
promoter	O
genotypes	O
frequencies	O
were	O
similar	O
in	O
patients	O
with	O
or	O
without	O
liver	B-Disease
fibrosis	I-Disease
associated	O
to	O
NASH	B-Disease
(	O
p	O
=	O
0	O
.	O
6	O
).	O
	
CONCLUSIONS	O
:	O
Morbidly	O
obese	B-Disease
patients	O
had	O
significantly	O
lower	O
PAI	O
-	O
1	O
serum	O
levels	O
with	O
similar	O
PAI	O
-	O
1	O
4G	O
/	O
5G	O
genotypes	O
frequencies	O
compared	O
to	O
non	O
-	O
obese	B-Disease
subjects	O
.	O
	
The	O
frequency	O
of	O
4G	O
/	O
5G	O
genotypes	O
in	O
Chilean	O
Hispanic	O
healthy	O
subjects	O
was	O
similar	O
to	O
that	O
described	O
in	O
other	O
populations	O
.	O
	
No	O
association	O
was	O
found	O
between	O
PAI	O
-	O
1	O
serum	O
levels	O
or	O
4G	O
/	O
5G	O
genotype	O
with	O
liver	B-Disease
fibrosis	I-Disease
in	O
obese	B-Disease
patients	O
.	O
	
	
Aberrant	O
caveolin	O
-	O
1	O
-	O
mediated	O
Smad	O
signaling	O
and	O
proliferation	O
identified	O
by	O
analysis	O
of	O
adenine	O
474	O
deletion	O
mutation	O
(	O
c	O
.	O
474delA	O
)	O
in	O
patient	O
fibroblasts	O
:	O
a	O
new	O
perspective	O
on	O
the	O
mechanism	O
of	O
pulmonary	B-Disease
hypertension	I-Disease
.	O
	
A	O
heterozygous	O
caveolin	O
-	O
1	O
c	O
.	O
474delA	O
mutation	O
has	O
been	O
identified	O
in	O
a	O
family	O
with	O
heritable	O
pulmonary	B-Disease
arterial	I-Disease
hypertension	I-Disease
(	O
PAH	B-Disease
).	O
	
This	O
frameshift	O
mutation	O
leads	O
to	O
a	O
caveolin	O
-	O
1	O
protein	O
that	O
contains	O
all	O
known	O
functional	O
domains	O
but	O
has	O
a	O
change	O
in	O
only	O
the	O
final	O
20	O
amino	O
acids	O
of	O
the	O
C	O
-	O
terminus	O
.	O
	
Here	O
we	O
studied	O
how	O
this	O
mutation	O
alters	O
caveolin	O
-	O
1	O
function	O
","	O
using	O
patient	O
-	O
derived	O
fibroblasts	O
.	O
	
Transmission	O
electron	O
microscopy	O
showed	O
that	O
fibroblasts	O
carrying	O
the	O
c	O
.	O
474delA	O
mutation	O
form	O
typical	O
caveolae	O
.	O
	
Expression	O
of	O
mutated	O
caveolin	O
-	O
1	O
in	O
caveolin	O
-	O
1	O
-	O
null	O
mouse	O
fibroblasts	O
failed	O
to	O
induce	O
formation	O
of	O
caveolae	O
due	O
to	O
retention	O
of	O
the	O
mutated	O
protein	O
in	O
the	O
endoplasmic	O
reticulum	O
.	O
	
However	O
","	O
coexpression	O
of	O
wild	O
-	O
type	O
caveolin	O
-	O
1	O
with	O
mutated	O
caveolin	O
-	O
1	O
restored	O
the	O
ability	O
to	O
form	O
caveolae	O
.	O
	
Importantly	O
","	O
fibroblasts	O
carrying	O
the	O
mutation	O
showed	O
twofold	O
increase	O
in	O
proliferation	O
rate	O
associated	O
with	O
hyperphosphorylation	O
of	O
Smad1	O
/	O
5	O
/	O
8	O
.	O
	
This	O
mutation	O
impaired	O
the	O
antiproliferative	O
function	O
of	O
caveolin	O
-	O
1	O
.	O
	
Inhibition	O
of	O
type	O
I	O
TGFb	O
receptors	O
ALK1	O
/	O
2	O
/	O
3	O
/	O
6	O
responsible	O
for	O
phosphorylation	O
of	O
Smad1	O
/	O
5	O
/	O
8	O
reduced	O
the	O
hyperproliferation	O
seen	O
in	O
c	O
.	O
474delA	O
fibroblasts	O
.	O
	
These	O
results	O
demonstrate	O
the	O
critical	O
role	O
of	O
the	O
final	O
20	O
amino	O
acids	O
of	O
caveolin	O
-	O
1	O
in	O
modulating	O
fibroblast	O
proliferation	O
by	O
dampening	O
Smad	O
signaling	O
and	O
suggest	O
that	O
augmented	O
Smad	O
signaling	O
and	O
fibroblast	O
hyperproliferation	O
are	O
contributing	O
factors	O
in	O
the	O
pathogenesis	O
of	O
PAH	B-Disease
in	O
patients	O
with	O
caveolin	O
-	O
1	O
c	O
.	O
474delA	O
mutation	O
.	O
	
	
Severe	O
form	O
of	O
thyroid	B-Disease
hormone	I-Disease
resistance	I-Disease
in	O
a	O
patient	O
with	O
homozygous	O
/	O
hemizygous	O
mutation	O
of	O
T3	O
receptor	O
gene	O
.	O
	
Resistance	B-Disease
to	I-Disease
thyroid	I-Disease
hormone	I-Disease
syndrome	I-Disease
(	O
RTH	B-Disease
)	O
is	O
a	O
rare	O
disorder	O
","	O
usually	O
inherited	O
as	O
an	O
autosomal	O
dominant	O
trait	O
.	O
	
Patients	O
with	O
RTH	B-Disease
are	O
usually	O
euthyroid	O
but	O
can	O
occasionally	O
present	O
with	O
signs	O
and	O
symptoms	O
of	O
thyrotoxicosis	B-Disease
or	O
rarely	O
with	O
hypothyroidism	B-Disease
.	O
	
Affected	O
individuals	O
are	O
usually	O
heterozygous	O
for	O
mutations	O
in	O
the	O
thyroid	O
hormone	O
receptor	O
beta	O
gene	O
(	O
TR	O
-	O
beta	O
).	O
	
We	O
present	O
a	O
patient	O
with	O
RTH	B-Disease
found	O
to	O
be	O
homo	O
-/	O
hemizygous	O
for	O
a	O
mutation	O
in	O
the	O
TR	O
-	O
beta	O
gene	O
.	O
	
The	O
single	O
nucleotide	O
substitution	O
I280S	O
(	O
1123T	O
-->	O
G	O
)	O
was	O
present	O
either	O
on	O
both	O
alleles	O
or	O
in	O
a	O
hemizygous	O
form	O
with	O
complete	O
deletion	O
of	O
the	O
second	O
allele	O
.	O
	
The	O
I280S	O
mutation	O
was	O
recently	O
reported	O
in	O
a	O
heterozygous	O
patient	O
.	O
	
The	O
severe	O
phenotype	O
with	O
seriously	O
impaired	B-Disease
intellectual	I-Disease
development	I-Disease
","	O
hyperkinetic	B-Disease
behaviour	O
","	O
tachycardia	B-Disease
","	O
hearing	B-Disease
and	I-Disease
visual	I-Disease
impairment	I-Disease
is	O
probably	O
due	O
to	O
the	O
dominant	O
negative	O
effect	O
of	O
the	O
I280S	O
mutant	O
protein	O
and	O
the	O
absence	O
of	O
any	O
functional	O
TR	O
-	O
beta	O
.	O
	
	
The	O
number	O
of	O
lymph	B-Disease
node	I-Disease
metastases	I-Disease
in	O
gastric	B-Disease
cancer	I-Disease
correlates	O
with	O
the	O
angiotensin	O
I	O
-	O
converting	O
enzyme	O
gene	O
insertion	O
/	O
deletion	O
polymorphism	O
.	O
	
PURPOSE	O
:	O
In	O
the	O
present	O
study	O
","	O
we	O
aimed	O
to	O
substantiate	O
the	O
putative	O
significance	O
of	O
angiotensin	O
I	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
on	O
gastric	B-Disease
cancer	I-Disease
biology	O
by	O
investigating	O
the	O
influence	O
of	O
its	O
gene	O
polymorphism	O
on	O
gastric	B-Disease
cancer	I-Disease
progression	O
.	O
	
EXPERIMENTAL	O
DESIGN	O
:	O
Genomic	O
DNA	O
was	O
purified	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
or	O
tissue	O
specimens	O
.	O
	
Amplified	O
ACE	O
gene	O
fragments	O
were	O
separated	O
on	O
agarose	B-Chemical
gels	O
.	O
	
D	O
or	O
I	O
alleles	O
were	O
identified	O
by	O
the	O
presence	O
of	O
190	O
-	O
or	O
490	O
-	O
bp	O
fragments	O
","	O
respectively	O
.	O
	
Local	O
expression	O
of	O
ACE	O
was	O
investigated	O
by	O
immunohistochemistry	O
.	O
	
RESULTS	O
:	O
Twenty	O
-	O
four	O
of	O
113	O
(	O
21	O
%)	O
gastric	B-Disease
cancer	I-Disease
patients	O
had	O
the	O
II	O
","	O
57	O
(	O
51	O
%)	O
the	O
ID	O
","	O
and	O
32	O
(	O
28	O
%)	O
the	O
DD	O
genotype	O
.	O
	
The	O
distribution	O
of	O
the	O
ACE	O
genotypes	O
did	O
not	O
differ	O
significantly	O
from	O
the	O
control	O
group	O
of	O
189	O
patients	O
without	O
gastric	B-Disease
cancer	I-Disease
.	O
	
However	O
","	O
the	O
ACE	O
genotypes	O
correlated	O
with	O
the	O
number	O
of	O
lymph	B-Disease
node	I-Disease
metastases	I-Disease
and	O
the	O
Unio	O
Internationale	O
Contra	O
Cancrum	O
(	O
UICC	O
)	O
tumor	B-Disease
stage	O
.	O
	
Patients	O
with	O
the	O
II	O
genotype	O
had	O
a	O
highly	O
significantly	O
smaller	O
number	O
of	O
lymph	B-Disease
node	I-Disease
metastases	I-Disease
(	O
P	O
<	O
0	O
.	O
1	O
)	O
and	O
a	O
significantly	O
lower	O
UICC	O
tumor	B-Disease
stage	O
(	O
P	O
=	O
0	O
.	O
1	O
)	O
than	O
patients	O
with	O
the	O
DD	O
genotype	O
.	O
	
No	O
correlation	O
was	O
found	O
between	O
tumor	B-Disease
type	O
","	O
tumor	B-Disease
location	O
","	O
local	O
tumor	B-Disease
growth	O
","	O
distant	O
metastases	B-Disease
","	O
and	O
the	O
ACE	O
genotype	O
.	O
	
The	O
expression	O
of	O
ACE	O
in	O
gastric	B-Disease
cancer	I-Disease
was	O
investigated	O
by	O
immunohistochemistry	O
in	O
100	O
of	O
113	O
patients	O
.	O
	
ACE	O
was	O
expressed	O
by	O
endothelial	O
cells	O
in	O
all	O
(	O
100	O
%)	O
specimens	O
and	O
by	O
tumor	B-Disease
cells	O
in	O
56	O
(	O
56	O
%)	O
specimens	O
.	O
	
CONCLUSIONS	O
:	O
Our	O
study	O
shows	O
that	O
ACE	O
is	O
expressed	O
locally	O
in	O
gastric	B-Disease
cancer	I-Disease
and	O
that	O
the	O
gene	O
polymorphism	O
influences	O
metastatic	O
behavior	O
.	O
	
	
Distinct	O
patterns	O
of	O
germ	O
-	O
line	O
deletions	O
in	O
MLH1	O
and	O
MSH2	O
:	O
the	O
implication	O
of	O
Alu	O
repetitive	O
element	O
in	O
the	O
genetic	O
etiology	O
of	O
Lynch	B-Disease
syndrome	I-Disease
(	O
HNPCC	B-Disease
).	O
	
A	O
relatively	O
high	O
frequency	O
of	O
germ	O
-	O
line	O
genomic	O
rearrangements	O
in	O
MLH1	O
and	O
MSH2	O
has	O
been	O
reported	O
among	O
Lynch	B-Disease
Syndrome	I-Disease
(	O
HNPCC	B-Disease
)	O
patients	O
from	O
different	O
ethnic	O
populations	O
.	O
	
To	O
investigate	O
the	O
underlying	O
molecular	O
mechanisms	O
","	O
we	O
characterized	O
the	O
DNA	O
breakpoints	O
of	O
11	O
germ	O
-	O
line	O
deletions	O
","	O
six	O
for	O
MLH1	O
and	O
five	O
for	O
MSH2	O
.	O
	
Distinct	O
deletion	O
patterns	O
were	O
found	O
for	O
the	O
two	O
genes	O
.	O
	
The	O
five	O
cases	O
of	O
MSH2	O
deletions	O
result	O
exclusively	O
from	O
intragenic	O
unequal	O
recombination	O
mediated	O
by	O
repetitive	O
Alu	O
sequences	O
.	O
	
In	O
contrast	O
","	O
five	O
out	O
of	O
the	O
six	O
MLH1	O
deletions	O
are	O
due	O
to	O
recombinations	O
involving	O
sequences	O
of	O
no	O
significant	O
homology	O
(	O
P	O
=	O
0	O
.	O
15	O
).	O
	
A	O
detailed	O
analysis	O
of	O
the	O
DNA	O
breakpoints	O
in	O
the	O
two	O
genes	O
","	O
previously	O
characterized	O
by	O
other	O
groups	O
","	O
validated	O
the	O
observation	O
that	O
Alu	O
-	O
mediated	O
unequal	O
recombination	O
is	O
the	O
main	O
type	O
of	O
deletion	O
in	O
MSH2	O
(	O
n	O
=	O
34	O
)","	O
but	O
not	O
in	O
MLH1	O
(	O
n	O
=	O
21	O
)	O
(	O
P	O
<	O
0	O
.	O
1	O
).	O
	
Plotting	O
the	O
distribution	O
of	O
known	O
DNA	O
breakpoints	O
among	O
the	O
introns	O
of	O
the	O
two	O
genes	O
showed	O
that	O
","	O
the	O
highest	O
breakpoint	O
density	O
is	O
co	O
-	O
localized	O
with	O
the	O
highest	O
Alu	O
density	O
.	O
	
Our	O
study	O
suggests	O
that	O
Alu	O
is	O
a	O
promoting	O
factor	O
for	O
the	O
genomic	O
recombinations	O
in	O
both	O
MLH1	O
and	O
MSH2	O
","	O
and	O
the	O
local	O
Alu	O
density	O
may	O
be	O
involved	O
in	O
shaping	O
the	O
deletion	O
pattern	O
.	O
	
	
Families	O
with	O
the	O
risk	O
allele	O
of	O
DISC1	O
reveal	O
a	O
link	O
between	O
schizophrenia	B-Disease
and	O
another	O
component	O
of	O
the	O
same	O
molecular	O
pathway	O
","	O
NDE1	O
.	O
	
We	O
have	O
previously	O
reported	O
a	O
robust	O
association	O
between	O
an	O
allelic	O
haplotype	O
of	O
'	O
Disrupted	O
in	O
Schizophrenia	O
1	O
'	O
(	O
DISC1	O
)	O
and	O
schizophrenia	B-Disease
in	O
a	O
nationwide	O
collection	O
of	O
Finnish	O
schizophrenia	B-Disease
families	O
.	O
	
This	O
specific	O
DISC1	O
allele	O
was	O
later	O
identified	O
to	O
associate	O
with	O
visual	O
working	O
memory	O
","	O
selectively	O
in	O
males	O
.	O
	
DISC1	O
association	O
to	O
schizophrenia	B-Disease
has	O
since	O
been	O
replicated	O
in	O
multiple	O
independent	O
study	O
samples	O
from	O
different	O
populations	O
.	O
	
In	O
this	O
study	O
","	O
we	O
conditioned	O
our	O
sample	O
of	O
Finnish	O
families	O
for	O
the	O
presence	O
of	O
the	O
Finnish	O
tentative	O
risk	O
allele	O
for	O
DISC1	O
and	O
re	O
-	O
analyzed	O
our	O
genome	O
-	O
wide	O
scan	O
data	O
of	O
443	O
markers	O
on	O
the	O
basis	O
of	O
this	O
stratification	O
.	O
	
Two	O
additional	O
loci	O
displayed	O
an	O
evidence	O
of	O
linkage	O
(	O
LOD	O
>	O
3	O
)	O
and	O
included	O
a	O
locus	O
on	O
16p13	O
","	O
proximal	O
to	O
the	O
gene	O
encoding	O
NDE1	O
","	O
which	O
has	O
been	O
shown	O
to	O
biologically	O
interact	O
with	O
DISC1	O
.	O
	
Although	O
none	O
of	O
the	O
observed	O
linkages	O
remained	O
significant	O
after	O
multiple	O
test	O
correction	O
through	O
simulation	O
","	O
further	O
analysis	O
of	O
NDE1	O
revealed	O
an	O
association	O
between	O
a	O
tag	O
-	O
haplotype	O
and	O
schizophrenia	B-Disease
(	O
P	O
=	O
0	O
.	O
46	O
)	O
specific	O
to	O
females	O
","	O
which	O
proved	O
to	O
be	O
significant	O
(	O
P	O
=	O
0	O
.	O
11	O
)	O
after	O
multiple	O
test	O
correction	O
.	O
	
Our	O
finding	O
would	O
support	O
the	O
concept	O
that	O
initial	O
gene	O
findings	O
in	O
multifactorial	O
diseases	O
will	O
assist	O
in	O
the	O
identification	O
of	O
other	O
components	O
of	O
complex	O
genetic	O
etiology	O
.	O
	
Notably	O
","	O
this	O
and	O
other	O
converging	O
lines	O
of	O
evidence	O
underline	O
the	O
importance	O
of	O
DISC1	O
-	O
related	O
functional	O
pathways	O
in	O
the	O
etiology	O
of	O
schizophrenia	B-Disease
.	O
	
	
Identification	O
of	O
a	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
of	O
the	O
prolactin	O
receptor	O
in	O
women	O
with	O
benign	B-Disease
breast	I-Disease
tumors	I-Disease
.	O
	
There	O
is	O
currently	O
no	O
known	O
genetic	B-Disease
disease	I-Disease
linked	O
to	O
prolactin	O
(	O
Prl	O
)	O
or	O
its	O
receptor	O
(	O
PrlR	O
)	O
in	O
humans	O
.	O
	
Given	O
the	O
essential	O
role	O
of	O
this	O
hormonal	O
system	O
in	O
breast	O
physiology	O
","	O
we	O
reasoned	O
that	O
genetic	O
anomalies	O
of	O
Prl	O
/	O
PrlR	O
genes	O
may	O
be	O
related	O
to	O
the	O
occurrence	O
of	O
breast	B-Disease
diseases	I-Disease
with	O
high	O
proliferative	O
potential	O
.	O
	
Multiple	B-Disease
fibroadenomas	I-Disease
(	O
MFA	B-Disease
)	O
are	O
benign	B-Disease
breast	I-Disease
tumors	I-Disease
which	O
appear	O
most	O
frequently	O
in	O
young	O
women	O
","	O
including	O
at	O
puberty	O
","	O
when	O
Prl	O
has	O
well	O
-	O
recognized	O
proliferative	O
actions	O
on	O
the	O
breast	O
.	O
	
In	O
a	O
prospective	O
study	O
involving	O
74	O
MFA	B-Disease
patients	O
and	O
170	O
control	O
subjects	O
","	O
we	O
identified	O
four	O
patients	O
harboring	O
a	O
heterozygous	O
single	O
nucleotide	O
polymorphism	O
in	O
exon	O
6	O
of	O
the	O
PrlR	O
gene	O
","	O
encoding	O
Ile	O
(	O
146	O
)-->	O
Leu	O
substitution	O
in	O
its	O
extracellular	O
domain	O
.	O
	
This	O
sole	O
substitution	O
was	O
sufficient	O
to	O
confer	O
constitutive	O
activity	O
to	O
the	O
receptor	O
variant	O
(	O
PrlR	O
(	O
I146L	O
))","	O
as	O
assessed	O
in	O
three	O
reconstituted	O
cell	O
models	O
(	O
Ba	O
/	O
F3	O
","	O
HEK293	O
and	O
MCF	O
-	O
7	O
cells	O
)	O
by	O
Prl	O
-	O
independent	O
(	O
i	O
)	O
PrlR	O
tyrosine	O
phosphorylation	O
","	O
(	O
ii	O
)	O
activation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
5	O
(	O
STAT5	O
)	O
signaling	O
","	O
(	O
iii	O
)	O
transcriptional	O
activity	O
toward	O
a	O
Prl	O
-	O
responsive	O
reporter	O
gene	O
","	O
and	O
(	O
iv	O
)	O
cell	O
proliferation	O
and	O
protection	O
from	O
cell	O
death	O
.	O
	
Constitutive	O
activity	O
of	O
PrlR	O
(	O
I146L	O
)	O
in	O
the	O
breast	O
sample	O
from	O
a	O
patient	O
was	O
supported	O
by	O
increased	O
STAT5	O
signaling	O
.	O
	
This	O
is	O
a	O
unique	O
description	O
of	O
a	O
functional	O
mutation	O
of	O
the	O
PrlR	O
associated	O
with	O
a	O
human	O
disease	O
.	O
	
Hallmarks	O
of	O
constitutive	O
activity	O
were	O
all	O
reversed	O
by	O
a	O
specific	O
PrlR	B-Chemical
antagonist	I-Chemical
","	O
which	O
opens	O
potential	O
therapeutic	O
approaches	O
for	O
MFA	B-Disease
","	O
or	O
any	O
other	O
disease	O
that	O
could	O
be	O
associated	O
with	O
this	O
mutation	O
in	O
future	O
.	O
	
	
Reversible	O
inferior	B-Disease
colliculus	I-Disease
lesion	I-Disease
in	O
metronidazole	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
:	O
magnetic	O
resonance	O
findings	O
on	O
diffusion	O
-	O
weighted	O
and	O
fluid	O
attenuated	O
inversion	O
recovery	O
imaging	O
.	O
	
OBJECTIVE	O
:	O
This	O
is	O
to	O
present	O
reversible	O
inferior	B-Disease
colliculus	I-Disease
lesions	I-Disease
in	O
metronidazole	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
","	O
to	O
focus	O
on	O
the	O
diffusion	O
-	O
weighted	O
imaging	O
(	O
DWI	O
)	O
and	O
fluid	O
attenuated	O
inversion	O
recovery	O
(	O
FLAIR	O
)	O
imaging	O
.	O
	
MATERIALS	O
AND	O
METHODS	O
:	O
From	O
November	O
2005	O
to	O
September	O
2007	O
","	O
8	O
patients	O
(	O
5	O
men	O
and	O
3	O
women	O
)	O
were	O
diagnosed	O
as	O
having	O
metronidazole	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
(	O
age	O
range	O
";"	O
43	O
-	O
78	O
years	O
).	O
	
They	O
had	O
been	O
taking	O
metronidazole	B-Chemical
(	O
total	O
dosage	O
","	O
45	O
-	O
120	O
g	O
";"	O
duration	O
","	O
30	O
days	O
to	O
2	O
months	O
)	O
to	O
treat	O
the	O
infection	B-Disease
in	O
various	O
organs	O
.	O
	
Initial	O
brain	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
were	O
obtained	O
after	O
the	O
hospitalization	O
","	O
including	O
DWI	O
(	O
8	O
/	O
8	O
)","	O
apparent	O
diffusion	O
coefficient	O
(	O
ADC	O
)	O
map	O
(	O
4	O
/	O
8	O
)","	O
FLAIR	O
(	O
7	O
/	O
8	O
)","	O
and	O
T2	O
-	O
weighted	O
image	O
(	O
8	O
/	O
8	O
).	O
	
Follow	O
-	O
up	O
MRIs	O
were	O
performed	O
on	O
5	O
patients	O
from	O
third	O
to	O
14th	O
days	O
after	O
discontinuation	O
of	O
metronidazole	B-Chemical
administration	O
.	O
	
Findings	O
of	O
initial	O
and	O
follow	O
-	O
up	O
MRIs	O
were	O
retrospectively	O
evaluated	O
by	O
2	O
neuroradiologists	O
by	O
consensus	O
","	O
to	O
analyze	O
the	O
presence	O
of	O
abnormal	O
signal	O
intensities	O
","	O
their	O
locations	O
","	O
and	O
signal	O
changes	O
on	O
follow	O
-	O
up	O
images	O
.	O
	
RESULTS	O
:	O
Initial	O
MRIs	O
showed	O
abnormal	O
high	O
signal	O
intensities	O
on	O
DWI	O
and	O
FLAIR	O
(	O
or	O
T2	O
-	O
weighted	O
image	O
)	O
at	O
the	O
dentate	O
nucleus	O
(	O
8	O
/	O
8	O
)","	O
inferior	O
colliculus	O
(	O
6	O
/	O
8	O
)","	O
corpus	O
callosum	O
(	O
2	O
/	O
8	O
)","	O
pons	O
(	O
2	O
/	O
8	O
)","	O
medulla	O
(	O
1	O
/	O
8	O
)","	O
and	O
bilateral	O
cerebral	O
white	O
matter	O
(	O
1	O
/	O
8	O
).	O
	
High	O
-	O
signal	O
intensity	O
lesions	O
on	O
DWI	O
tended	O
to	O
show	O
low	O
signal	O
intensity	O
on	O
ADC	O
map	O
(	O
3	O
/	O
4	O
)","	O
but	O
in	O
one	O
patient	O
","	O
high	O
signal	O
intensity	O
was	O
shown	O
at	O
bilateral	O
dentate	O
nuclei	O
on	O
not	O
only	O
DWI	O
but	O
also	O
ADC	O
map	O
.	O
	
All	O
the	O
lesions	O
in	O
dentate	O
","	O
inferior	O
colliculus	O
","	O
pons	O
","	O
and	O
medullas	O
had	O
been	O
resolved	O
completely	O
on	O
follow	O
-	O
up	O
MRIs	O
in	O
5	O
patients	O
","	O
but	O
in	O
1	O
patient	O
of	O
them	O
","	O
corpus	O
callosal	B-Disease
lesion	I-Disease
persisted	O
.	O
	
CONCLUSIONS	O
:	O
Reversible	O
inferior	B-Disease
colliculus	I-Disease
lesions	I-Disease
could	O
be	O
considered	O
as	O
the	O
characteristic	O
for	O
metronidazole	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
","	O
next	O
to	O
the	O
dentate	O
nucleus	O
involvement	O
.	O
	
	
Differential	O
impact	O
of	O
immune	O
escape	O
mutations	O
G145R	O
and	O
P120T	O
on	O
the	O
replication	O
of	O
lamivudine	B-Chemical
-	O
resistant	O
hepatitis	B-Chemical
B	I-Chemical
virus	I-Chemical
e	I-Chemical
antigen	I-Chemical
-	O
positive	O
and	O
-	O
negative	O
strains	O
.	O
	
Immune	O
escape	O
variants	O
of	O
the	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
represent	O
an	O
emerging	O
clinical	O
challenge	O
","	O
because	O
they	O
can	O
be	O
associated	O
with	O
vaccine	O
escape	O
","	O
HBV	O
reactivation	O
","	O
and	O
failure	O
of	O
diagnostic	O
tests	O
.	O
	
Recent	O
data	O
suggest	O
a	O
preferential	O
selection	O
of	O
immune	O
escape	O
mutants	O
in	O
distinct	O
peripheral	O
blood	O
leukocyte	O
compartments	O
of	O
infected	O
individuals	O
.	O
	
We	O
therefore	O
systematically	O
analyzed	O
the	O
functional	O
impact	O
of	O
the	O
most	O
prevalent	O
immune	O
escape	O
variants	O
","	O
the	O
sG145R	O
and	O
sP120T	O
mutants	O
","	O
on	O
the	O
viral	O
replication	O
efficacy	O
and	O
antiviral	O
drug	O
susceptibility	O
of	O
common	O
treatment	O
-	O
associated	O
mutants	O
with	O
resistance	O
to	O
lamivudine	B-Chemical
(	O
LAM	B-Chemical
)	O
and	O
/	O
or	O
HBeAg	B-Chemical
negativity	O
.	O
	
Replication	O
-	O
competent	O
HBV	O
strains	O
with	O
sG145R	O
or	O
sP120T	O
and	O
LAM	B-Chemical
resistance	O
(	O
rtM204I	O
or	O
rtL180M	O
/	O
rtM204V	O
)	O
were	O
generated	O
on	O
an	O
HBeAg	B-Chemical
-	O
positive	O
and	O
an	O
HBeAg	B-Chemical
-	O
negative	O
background	O
with	O
precore	O
(	O
PC	O
)	O
and	O
basal	O
core	O
promoter	O
(	O
BCP	O
)	O
mutants	O
.	O
	
The	O
sG145R	O
mutation	O
strongly	O
reduced	O
HBsAg	B-Chemical
levels	O
and	O
was	O
able	O
to	O
fully	O
restore	O
the	O
impaired	O
replication	O
of	O
LAM	B-Chemical
-	O
resistant	O
HBV	O
mutants	O
to	O
the	O
levels	O
of	O
wild	O
-	O
type	O
HBV	O
","	O
and	O
PC	O
or	O
BCP	O
mutations	O
further	O
enhanced	O
viral	O
replication	O
.	O
	
Although	O
the	O
sP120T	O
substitution	O
also	O
impaired	O
HBsAg	B-Chemical
secretion	O
","	O
it	O
did	O
not	O
enhance	O
the	O
replication	O
of	O
LAM	B-Chemical
-	O
resistant	O
clones	O
.	O
	
However	O
","	O
the	O
concomitant	O
occurrence	O
of	O
HBeAg	B-Chemical
negativity	O
(	O
PC	O
/	O
BCP	O
)","	O
sP120T	O
","	O
and	O
LAM	B-Chemical
resistance	O
resulted	O
in	O
the	O
restoration	O
of	O
replication	O
to	O
levels	O
of	O
wild	O
-	O
type	O
HBV	O
.	O
	
In	O
all	O
clones	O
with	O
combined	O
immune	O
escape	O
and	O
LAM	B-Chemical
resistance	O
mutations	O
","	O
the	O
nucleotide	O
analogues	O
adefovir	B-Chemical
and	O
tenofovir	B-Chemical
remained	O
effective	O
in	O
suppressing	O
viral	O
replication	O
in	O
vitro	O
.	O
	
These	O
findings	O
reveal	O
the	O
differential	O
impact	O
of	O
immune	O
escape	O
variants	O
on	O
the	O
replication	O
and	O
drug	O
susceptibility	O
of	O
complex	O
HBV	O
mutants	O
","	O
supporting	O
the	O
need	O
of	O
close	O
surveillance	O
and	O
treatment	O
adjustment	O
in	O
response	O
to	O
the	O
selection	O
of	O
distinct	O
mutational	O
patterns	O
.	O
	
	
Molecular	O
diagnosis	O
of	O
46	B-Disease
","	I-Disease
XY	I-Disease
DSD	I-Disease
and	O
identification	O
of	O
a	O
novel	O
8	O
nucleotide	O
deletion	O
in	O
exon	O
1	O
of	O
the	O
SRD5A2	O
gene	O
.	O
	
Phenotypic	O
presentation	O
of	O
46	B-Disease
","	I-Disease
XY	I-Disease
DSD	I-Disease
depends	O
on	O
the	O
underlying	O
defects	O
.	O
	
Defect	O
in	O
androgen	O
action	O
on	O
the	O
target	O
tissues	O
or	O
production	O
of	O
active	O
metabolite	O
share	O
common	O
morphological	O
features	O
.	O
	
Molecular	O
study	O
may	O
help	O
differentiating	O
these	O
abnormalities	O
with	O
precision	O
.	O
	
Mutational	O
analysis	O
of	O
androgen	O
receptor	O
(	O
AR	O
)	O
and	O
SRD5A2	O
genes	O
was	O
performed	O
in	O
29	O
patients	O
with	O
46	B-Disease
","	I-Disease
XY	I-Disease
DSD	I-Disease
","	O
by	O
PCR	O
-	O
SSCP	O
.	O
	
The	O
amplicons	O
that	O
showed	O
an	O
aberrant	O
migration	O
in	O
SSCP	O
were	O
subjected	O
to	O
sequencing	O
.	O
	
Interestingly	O
","	O
six	O
patients	O
from	O
4	O
unrelated	O
families	O
(	O
a	O
pair	O
of	O
sibs	O
","	O
uncle	O
/	O
nephew	O
and	O
other	O
two	O
isolated	O
)	O
were	O
identified	O
with	O
mutations	O
in	O
SRD5A2	O
gene	O
.	O
	
In	O
five	O
patients	O
p	O
.	O
R246Q	O
missense	O
mutation	O
was	O
detected	O
","	O
of	O
which	O
four	O
were	O
homozygous	O
and	O
one	O
was	O
compound	O
heterozygous	O
:	O
g	O
.	O
80_87delT	O
CGCGAAG	O
(	O
p	O
.	O
A27fsX132	O
)	O
and	O
p	O
.	O
R246Q	O
.	O
	
Another	O
patient	O
with	O
isolated	B-Disease
micropenis	I-Disease
harbored	O
a	O
heterozygous	O
p	O
.	O
G196S	O
missense	O
mutation	O
.	O
	
No	O
AR	O
gene	O
mutation	O
was	O
detected	O
.	O
	
In	O
conclusion	O
","	O
our	O
study	O
suggests	O
that	O
p	O
.	O
R246Q	O
mutation	O
is	O
common	O
amongst	O
patients	O
with	O
SRD5A2	O
gene	O
defect	O
from	O
the	O
Northern	O
states	O
of	O
India	O
.	O
	
Also	O
","	O
it	O
records	O
a	O
novel	O
deletion	O
in	O
exon	O
1	O
of	O
SRD5A2	O
gene	O
in	O
a	O
patient	O
with	O
severe	O
hypospadias	B-Disease
.	O
	
	
Safety	O
of	O
capecitabine	B-Chemical
:	O
a	O
review	O
.	O
	
IMPORTANCE	O
OF	O
THE	O
FIELD	O
:	O
Fluoropyrimidines	B-Chemical
","	O
in	O
particular	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)","	O
have	O
been	O
the	O
mainstay	O
of	O
treatment	O
for	O
several	O
solid	O
tumors	B-Disease
","	O
including	O
colorectal	B-Disease
","	I-Disease
breast	I-Disease
and	I-Disease
head	I-Disease
and	I-Disease
neck	I-Disease
cancers	I-Disease
","	O
for	O
>	O
40	O
years	O
.	O
	
AREAS	O
COVERED	O
IN	O
THIS	O
REVIEW	O
:	O
This	O
article	O
reviews	O
the	O
pharmacology	O
and	O
efficacy	O
of	O
capecitabine	B-Chemical
with	O
a	O
special	O
emphasis	O
on	O
its	O
safety	O
.	O
	
WHAT	O
THE	O
READER	O
WILL	O
GAIN	O
:	O
The	O
reader	O
will	O
gain	O
better	O
insight	O
into	O
the	O
safety	O
of	O
capecitabine	B-Chemical
in	O
special	O
populations	O
such	O
as	O
patients	O
with	O
advanced	O
age	O
","	O
renal	B-Disease
and	I-Disease
kidney	I-Disease
disease	I-Disease
.	O
	
We	O
also	O
explore	O
different	O
dosing	O
and	O
schedules	O
of	O
capecitabine	B-Chemical
administration	O
.	O
	
TAKE	O
HOME	O
MESSAGE	O
:	O
Capecitabine	B-Chemical
is	O
an	O
oral	O
prodrug	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
was	O
developed	O
to	O
fulfill	O
the	O
need	O
for	O
a	O
more	O
convenient	O
therapy	O
and	O
provide	O
an	O
improved	O
safety	O
/	O
efficacy	O
profile	O
.	O
	
It	O
has	O
shown	O
promising	O
results	O
alone	O
or	O
in	O
combination	O
with	O
other	O
chemotherapeutic	O
agents	O
in	O
colorectal	B-Disease
","	I-Disease
breast	I-Disease
","	I-Disease
pancreaticobiliary	I-Disease
","	I-Disease
gastric	I-Disease
","	I-Disease
renal	I-Disease
cell	I-Disease
and	I-Disease
head	I-Disease
and	I-Disease
neck	I-Disease
cancers	I-Disease
.	O
	
The	O
most	O
commonly	O
reported	O
toxic	O
effects	O
of	O
capecitabine	B-Chemical
are	O
diarrhea	B-Disease
","	O
nausea	B-Disease
","	O
vomiting	B-Disease
","	O
stomatitis	B-Disease
and	O
hand	B-Disease
-	I-Disease
foot	I-Disease
syndrome	I-Disease
.	O
	
Capecitabine	B-Chemical
has	O
a	O
well	O
-	O
established	O
safety	O
profile	O
and	O
can	O
be	O
given	O
safely	O
to	O
patients	O
with	O
advanced	O
age	O
","	O
hepatic	B-Disease
and	I-Disease
renal	I-Disease
dysfunctions	I-Disease
.	O
	
	
Cytostatic	O
and	O
anti	O
-	O
angiogenic	O
effects	O
of	O
temsirolimus	B-Chemical
in	O
refractory	O
mantle	B-Disease
cell	I-Disease
lymphoma	I-Disease
.	O
	
Mantle	B-Disease
cell	I-Disease
lymphoma	I-Disease
(	O
MCL	B-Disease
)	O
is	O
a	O
rare	O
and	O
aggressive	O
type	O
of	O
B	B-Disease
-	I-Disease
cell	I-Disease
non	I-Disease
-	I-Disease
Hodgkin	I-Disease
'	I-Disease
s	I-Disease
lymphoma	I-Disease
.	O
	
Patients	O
become	O
progressively	O
refractory	O
to	O
conventional	O
chemotherapy	O
","	O
and	O
their	O
prognosis	O
is	O
poor	O
.	O
	
However	O
","	O
a	O
38	O
%	O
remission	O
rate	O
has	O
been	O
recently	O
reported	O
in	O
refractory	O
MCL	B-Disease
treated	O
with	O
temsirolimus	B-Chemical
","	O
a	O
mTOR	O
inhibitor	O
.	O
Here	O
we	O
had	O
the	O
opportunity	O
to	O
study	O
a	O
case	O
of	O
refractory	O
MCL	B-Disease
who	O
had	O
tumor	B-Disease
regression	O
two	O
months	O
after	O
temsirolimus	B-Chemical
treatment	O
","	O
and	O
a	O
progression	O
-	O
free	O
survival	O
of	O
10	O
months	O
.	O
	
In	O
this	O
case	O
","	O
lymph	O
node	O
biopsies	O
were	O
performed	O
before	O
and	O
six	O
months	O
after	O
temsirolimus	B-Chemical
therapy	O
.	O
	
Comparison	O
of	O
the	O
two	O
biopsies	O
showed	O
that	O
temsirolimus	B-Chemical
inhibited	O
tumor	B-Disease
cell	O
proliferation	O
through	O
cell	O
cycle	O
arrest	O
","	O
but	O
did	O
not	O
induce	O
any	O
change	O
in	O
the	O
number	O
of	O
apoptotic	O
tumor	B-Disease
cells	O
.	O
	
Apart	O
from	O
this	O
cytostatic	O
effect	O
","	O
temsirolimus	B-Chemical
had	O
an	O
antiangiogenic	O
effect	O
with	O
decrease	O
of	O
tumor	B-Disease
microvessel	O
density	O
and	O
of	O
VEGF	O
expression	O
.	O
	
Moreover	O
","	O
numerous	O
patchy	O
","	O
well	O
-	O
limited	O
fibrotic	O
areas	O
","	O
compatible	O
with	O
post	O
-	O
necrotic	B-Disease
tissue	O
repair	O
","	O
were	O
found	O
after	O
6	O
-	O
month	O
temsirolimus	B-Chemical
therapy	O
.	O
	
Thus	O
","	O
temsirolimus	B-Chemical
reduced	O
tumor	B-Disease
burden	O
through	O
associated	O
cytostatic	O
and	O
anti	O
-	O
angiogenic	O
effects	O
.	O
This	O
dual	O
effect	O
of	O
temsirolimus	B-Chemical
on	O
tumor	B-Disease
tissue	O
could	O
contribute	O
to	O
its	O
recently	O
reported	O
efficiency	O
in	O
refractory	O
MCL	B-Disease
resistant	O
to	O
conventional	O
chemotherapy	O
.	O
	
	
The	O
-	O
930A	O
>	O
G	O
polymorphism	O
of	O
the	O
CYBA	O
gene	O
is	O
associated	O
with	O
premature	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
.	O
	
A	O
case	O
-	O
control	O
study	O
and	O
gene	O
-	O
risk	O
factors	O
interactions	O
.	O
	
Reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
(	O
ROS	B-Chemical
)	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
atherosclerosis	B-Disease
and	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
(	O
CAD	B-Disease
).	O
	
NADPH	O
oxidases	O
are	O
the	O
main	O
source	O
of	O
ROS	B-Chemical
in	O
the	O
vasculature	O
.	O
	
p22phox	O
is	O
a	O
critical	O
component	O
of	O
vascular	O
NADPH	O
oxidases	O
and	O
is	O
encoded	O
by	O
the	O
CYBA	O
(	O
cytochrome	O
b245	O
alpha	O
)	O
gene	O
.	O
	
The	O
-	O
930A	O
>	O
G	O
CYBA	O
polymorphism	O
(	O
rs9932581	O
:	O
A	O
>	O
G	O
)	O
modulates	O
the	O
activity	O
of	O
the	O
CYBA	O
promoter	O
","	O
and	O
influences	O
CYBA	O
transcriptional	O
activity	O
.	O
	
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
analyze	O
a	O
possible	O
association	O
between	O
the	O
-	O
930A	O
>	O
G	O
polymorphism	O
and	O
CAD	B-Disease
and	O
to	O
search	O
for	O
gene	O
-	O
traditional	O
risk	O
factors	O
interactions	O
.	O
	
480	O
subjects	O
were	O
studied	O
:	O
240	O
patients	O
with	O
premature	O
CAD	B-Disease
","	O
240	O
age	O
and	O
sex	O
matched	O
blood	O
donors	O
.	O
	
The	O
-	O
930A	O
>	O
G	O
polymorphism	O
was	O
genotyped	O
using	O
the	O
TaqMan	O
-	O
Pre	O
-	O
designed	O
SNP	O
Genotyping	O
Assay	O
(	O
Applied	O
Biosystems	O
).	O
	
The	O
-	O
930G	O
allele	O
carrier	O
state	O
was	O
a	O
risk	O
factor	O
for	O
CAD	B-Disease
(	O
OR	O
2	O
.	O
3	O
","	O
95	O
%	O
CI	O
1	O
.	O
21	O
-	O
3	O
.	O
44	O
","	O
P	O
=	O
0	O
.	O
7	O
).	O
	
A	O
synergistic	O
effect	O
of	O
the	O
-	O
930G	O
allele	O
with	O
overweight	B-Disease
/	O
obesity	B-Disease
(	O
BMI	O
--	O
25	O
)	O
and	O
cigarette	O
smoking	O
was	O
found	O
.	O
	
The	O
estimated	O
CAD	B-Disease
risk	O
for	O
BMI	O
--	O
25	O
and	O
the	O
-	O
930G	O
allele	O
interaction	O
was	O
about	O
160	O
%	O
greater	O
than	O
that	O
predicted	O
by	O
assuming	O
additivity	O
of	O
the	O
effects	O
","	O
and	O
about	O
40	O
%	O
greater	O
for	O
interaction	O
of	O
cigarette	O
smoking	O
and	O
the	O
-	O
930G	O
allele	O
.	O
	
Overweight	B-Disease
/	O
obesity	B-Disease
was	O
a	O
risk	O
factor	O
for	O
CAD	B-Disease
only	O
in	O
the	O
-	O
930G	O
allele	O
carriers	O
(	O
P	O
<	O
10	O
(-	O
10	O
))	O
but	O
not	O
in	O
the	O
AA	O
homozygotes	O
(	O
P	O
=	O
1	O
.	O
0	O
).	O
	
In	O
conclusion	O
the	O
-	O
930A	O
>	O
G	O
CYBA	O
polymorphism	O
is	O
associated	O
with	O
CAD	B-Disease
in	O
the	O
Polish	O
population	O
.	O
	
The	O
-	O
930G	O
allele	O
carriers	O
are	O
particularly	O
at	O
risk	O
of	O
consequences	O
of	O
obesity	B-Disease
and	O
tobacco	O
smoke	O
exposure	O
.	O
	
	
GLUT4	O
Is	O
Not	O
Necessary	O
for	O
Overload	O
-	O
Induced	O
Glucose	B-Chemical
Uptake	O
or	O
Hypertrophic	O
Growth	O
in	O
Mouse	O
Skeletal	O
Muscle	O
.	O
	
GLUT4	O
is	O
necessary	O
for	O
acute	O
insulin	O
-	O
and	O
contraction	O
-	O
induced	O
skeletal	O
muscle	O
glucose	B-Chemical
uptake	O
","	O
but	O
its	O
role	O
in	O
chronic	O
muscle	O
loading	O
(	O
overload	O
)-	O
induced	O
glucose	B-Chemical
uptake	O
is	O
unknown	O
.	O
	
Our	O
goal	O
was	O
to	O
determine	O
whether	O
GLUT4	O
is	O
required	O
for	O
overload	O
-	O
induced	O
glucose	B-Chemical
uptake	O
.	O
	
Overload	O
was	O
induced	O
in	O
mouse	O
plantaris	O
muscle	O
by	O
unilateral	O
synergist	O
ablation	O
.	O
	
After	O
5	O
days	O
","	O
muscle	O
weights	O
and	O
ex	O
vivo	O
[(	B-Chemical
3	I-Chemical
)	I-Chemical
H	I-Chemical
]-	I-Chemical
2	I-Chemical
-	I-Chemical
deoxy	I-Chemical
-	I-Chemical
d	I-Chemical
-	I-Chemical
glucose	I-Chemical
uptake	O
were	O
assessed	O
.	O
	
Overload	O
-	O
induced	O
muscle	O
glucose	B-Chemical
uptake	O
and	O
hypertrophic	O
growth	O
were	O
not	O
impaired	O
in	O
muscle	O
-	O
specific	O
GLUT4	O
knockout	O
mice	O
","	O
demonstrating	O
that	O
GLUT4	O
is	O
not	O
necessary	O
for	O
these	O
processes	O
.	O
	
To	O
assess	O
which	O
transporters	O
mediate	O
overload	O
-	O
induced	O
glucose	B-Chemical
uptake	O
","	O
chemical	O
inhibitors	O
were	O
used	O
.	O
	
The	O
facilitative	O
GLUT	O
inhibitor	O
cytochalasin	B-Chemical
B	I-Chemical
","	O
but	O
not	O
the	O
sodium	B-Chemical
-	O
dependent	O
glucose	B-Chemical
cotransport	O
inhibitor	O
phloridzin	B-Chemical
","	O
prevented	O
overload	O
-	O
induced	O
uptake	O
demonstrating	O
that	O
GLUTs	O
mediate	O
this	O
effect	O
.	O
	
To	O
assess	O
which	O
GLUT	O
","	O
hexose	B-Chemical
competition	O
experiments	O
were	O
performed	O
.	O
	
Overload	O
-	O
induced	O
[(	B-Chemical
3	I-Chemical
)	I-Chemical
H	I-Chemical
]-	I-Chemical
2	I-Chemical
-	I-Chemical
deoxy	I-Chemical
-	I-Chemical
d	I-Chemical
-	I-Chemical
glucose	I-Chemical
uptake	O
was	O
not	O
inhibited	O
by	O
d	B-Chemical
-	I-Chemical
fructose	I-Chemical
","	O
demonstrating	O
that	O
the	O
fructose	O
-	O
transporting	O
GLUT2	O
","	O
GLUT5	O
","	O
GLUT8	O
","	O
and	O
GLUT12	O
do	O
not	O
mediate	O
this	O
effect	O
.	O
	
To	O
assess	O
additional	O
GLUTs	O
","	O
immunoblots	O
were	O
performed	O
.	O
	
Overload	O
increased	O
GLUT1	O
","	O
GLUT3	O
","	O
GLUT6	O
","	O
and	O
GLUT10	O
protein	O
levels	O
twofold	O
to	O
fivefold	O
.	O
	
Collectively	O
","	O
these	O
results	O
demonstrate	O
that	O
GLUT4	O
is	O
not	O
necessary	O
for	O
overload	O
-	O
induced	O
muscle	O
glucose	B-Chemical
uptake	O
or	O
hypertrophic	O
growth	O
and	O
suggest	O
that	O
GLUT1	O
","	O
GLUT3	O
","	O
GLUT6	O
","	O
and	O
/	O
or	O
GLUT10	O
mediate	O
overload	O
-	O
induced	O
glucose	B-Chemical
uptake	O
.	O
	
	
Ubiquitin	O
carboxyl	O
-	O
terminal	O
esterase	O
L1	O
(	O
UCHL1	O
)	O
is	O
associated	O
with	O
stem	O
-	O
like	O
cancer	B-Disease
cell	O
functions	O
in	O
pediatric	O
high	O
-	O
grade	O
glioma	B-Disease
.	O
	
Pediatric	O
high	O
-	O
grade	O
gliomas	B-Disease
represent	O
8	O
-	O
12	O
%	O
of	O
all	O
primary	O
tumors	B-Disease
of	O
the	O
nervous	O
system	O
in	O
children	O
.	O
	
Five	O
-	O
year	O
survival	O
for	O
these	O
pediatric	O
aggressive	O
tumors	B-Disease
is	O
poor	O
(	O
15	O
-	O
35	O
%)	O
indicating	O
the	O
need	O
to	O
develop	O
better	O
treatments	O
for	O
pediatric	O
high	O
-	O
grade	O
gliomas	B-Disease
.	O
	
In	O
this	O
work	O
we	O
used	O
SF188	O
and	O
SJ	O
-	O
GBM2	O
cell	O
lines	O
to	O
study	O
the	O
function	O
of	O
the	O
ubiquitin	O
carboxyl	O
-	O
terminal	O
esterase	O
L1	O
(	O
UCHL1	O
)","	O
a	O
deubiquitinase	O
de	O
-	O
regulated	O
in	O
several	O
cancers	B-Disease
","	O
in	O
pediatric	O
high	O
-	O
grade	O
gliomas	B-Disease
.	O
	
UCHL1	O
depletion	O
in	O
SF188	O
and	O
SJ	O
-	O
GBM2	O
glioma	B-Disease
cells	O
was	O
associated	O
with	O
decreased	O
cell	O
proliferation	O
and	O
invasion	O
","	O
along	O
with	O
a	O
reduced	O
ability	O
to	O
grow	O
in	O
soft	O
agar	B-Chemical
and	O
to	O
form	O
spheres	O
(	O
i	O
.	O
e	O
.	O
	
self	O
-	O
renewal	O
measure	O
).	O
	
A	O
70	O
%	O
reduction	O
in	O
Wnt	O
signaling	O
was	O
also	O
observed	O
in	O
the	O
SF188	O
and	O
SJ	O
-	O
GBM2	O
UCHL1	O
knockdowns	O
(	O
KDs	O
)	O
using	O
a	O
TCF	O
-	O
dependent	O
TOPflash	O
reporter	O
assay	O
.	O
	
Transcriptome	O
comparisons	O
of	O
UCHL1	O
KDs	O
versus	O
vector	O
control	O
identified	O
a	O
list	O
of	O
306	O
differentially	O
expressed	O
genes	O
(	O
at	O
least	O
2	O
-	O
fold	O
change	O
";"	O
p	O
<	O
0	O
.	O
5	O
)	O
which	O
included	O
genes	O
known	O
to	O
be	O
involved	O
in	O
cancer	B-Disease
like	O
ACTA2	O
","	O
POSTN	O
","	O
LIF	O
","	O
FBXL7	O
","	O
FBXW11	O
","	O
GDF15	O
","	O
HEY2	O
","	O
but	O
also	O
potential	O
novel	O
genes	O
such	O
us	O
IGLL5	O
","	O
ABCA4	O
","	O
AQP3	O
","	O
AQP4	O
","	O
CALB1	O
","	O
and	O
ALK	O
.	O
	
Bioinformatics	O
gene	O
ontology	O
(	O
GO	O
)	O
analysis	O
of	O
these	O
306	O
genes	O
revealed	O
significant	O
enrichment	O
in	O
signal	O
peptides	O
","	O
extracellular	O
matrix	O
and	O
secreted	O
proteins	O
GO	O
Terms	O
.	O

Angiogenesis	O
and	O
blood	O
vessel	O
development	O
","	O
neuron	O
differentiation	O
/	O
development	O
cell	O
adhesion	O
and	O
cell	O
migration	O
also	O
showed	O
significant	O
enrichment	O
in	O
our	O
GO	O
analysis	O
.	O
	
Top	O
canonical	O
pathways	O
identified	O
by	O
Ingenuity	O
Pathway	O
Analysis	O
(	O
IPA	O
)	O
included	O
Clathrin	O
-	O
mediated	O
Endocytosis	O
Signaling	O
(	O
p	O
=	O
5	O
.	O
14x10	O
-	O
4	O
)","	O
Virus	O
Entry	O
via	O
Endocytic	O
Pathways	O
(	O
p	O
=	O
6	O
.	O
15x	O
10	O
-	O
4	O
)","	O
and	O
High	O
Mobility	O
Group	O
-	O
Box	O
1	O
(	O
HMGB1	O
)	O
Signaling	O
(	O
p	O
=	O
6	O
.	O
15x10	O
-	O
4	O
).	O
	
While	O
FGF2	O
","	O
IL1B	O
","	O
TNF	O
and	O
PDGFB	O
were	O
predicted	O
as	O
top	O
upstream	O
regulators	O
(	O
p	O
<	O
2x10	O
-	O
16	O
)	O
of	O
the	O
UCHL1	O
KD	O
-	O
associated	O
transcriptome	O
.	O
	
Aberrant	O
expression	O
of	O
UCHL1	O
in	O
pediatric	O
high	O
-	O
grade	O
gliomas	B-Disease
may	O
promote	O
cell	O
invasion	O
","	O
transformation	O
","	O
and	O
self	O
-	O
renewal	O
properties	O
","	O
at	O
least	O
in	O
part	O
","	O
by	O
modulating	O
Wnt	O
/	O
Beta	O
catenin	O
activity	O
.	O
	
UCHL1	O
might	O
act	O
as	O
an	O
oncogene	O
in	O
glioma	B-Disease
within	O
the	O
gene	O
network	O
that	O
imparts	O
stem	O
-	O
like	O
characteristics	O
to	O
these	O
cancer	B-Disease
cells	O
.	O
	
	
Mutations	O
in	O
N	O
-	O
acetylglucosamine	O
(	O
O	O
-	O
GlcNAc	O
)	O
transferase	O
in	O
patients	O
with	O
X	B-Disease
-	I-Disease
linked	I-Disease
intellectual	I-Disease
disability	I-Disease
.	O
	
N	O
-	O
Acetylglucosamine	O
(	O
O	O
-	O
GlcNAc	O
)	O
transferase	O
(	O
OGT	O
)	O
regulates	O
protein	O
O	O
-	O
GlcNAcylation	O
","	O
an	O
essential	O
and	O
dynamic	O
post	O
-	O
translational	O
modification	O
.	O
	
The	O
O	O
-	O
GlcNAc	O
modification	O
is	O
present	O
on	O
numerous	O
nuclear	O
and	O
cytosolic	O
proteins	O
and	O
has	O
been	O
implicated	O
in	O
essential	O
cellular	O
functions	O
such	O
as	O
signaling	O
and	O
gene	O
expression	O
.	O
	
Accordingly	O
","	O
altered	O
levels	O
of	O
protein	O
O	O
-	O
GlcNAcylation	O
have	O
been	O
associated	O
with	O
developmental	B-Disease
defects	I-Disease
and	O
neurodegeneration	B-Disease
.	O
	
However	O
","	O
mutations	O
in	O
the	O
OGT	O
gene	O
have	O
not	O
yet	O
been	O
functionally	O
confirmed	O
in	O
humans	O
.	O
	
Here	O
","	O
we	O
report	O
on	O
two	O
hemizygous	O
mutations	O
in	O
OGT	O
in	O
individuals	O
with	O
X	B-Disease
-	I-Disease
linked	I-Disease
intellectual	I-Disease
disability	I-Disease
(	O
XLID	B-Disease
)	O
and	O
dysmorphic	O
features	O
:	O
one	O
missense	O
mutation	O
(	O
p	O
.	O
Arg284Pro	O
)	O
and	O
one	O
mutation	O
leading	O
to	O
a	O
splicing	O
defect	O
(	O
c	O
.	O
463	O
-	O
6T	O
>	O
G	O
).	O
	
Both	O
mutations	O
reside	O
in	O
the	O
tetratricopeptide	O
repeats	O
of	O
OGT	O
that	O
are	O
essential	O
for	O
substrate	O
recognition	O
.	O
	
We	O
observed	O
slightly	O
reduced	O
levels	O
of	O
OGT	O
protein	O
and	O
reduced	O
levels	O
of	O
its	O
opposing	O
enzyme	O
O	O
-	O
GlcNAcase	O
in	O
both	O
patient	O
-	O
derived	O
fibroblasts	O
","	O
but	O
global	O
O	O
-	O
GlcNAc	O
levels	O
appeared	O
to	O
be	O
unaffected	O
.	O
	
Our	O
data	O
suggest	O
that	O
mutant	O
cells	O
attempt	O
to	O
maintain	O
global	O
O	O
-	O
GlcNAcylation	O
by	O
down	O
-	O
regulating	O
O	O
-	O
GlcNAcase	O
expression	O
.	O
	
We	O
also	O
found	O
that	O
the	O
c	O
.	O
463	O
-	O
6T	O
>	O
G	O
mutation	O
leads	O
to	O
aberrant	O
mRNA	O
splicing	O
","	O
but	O
no	O
stable	O
truncated	O
protein	O
was	O
detected	O
in	O
the	O
corresponding	O
patient	O
-	O
derived	O
fibroblasts	O
.	O
	
Recombinant	O
OGT	O
bearing	O
the	O
p	O
.	O
Arg284Pro	O
mutation	O
was	O
prone	O
to	O
unfolding	O
and	O
exhibited	O
reduced	O
glycosylation	O
activity	O
against	O
a	O
complex	O
array	O
of	O
glycosylation	O
substrates	O
and	O
proteolytic	O
processing	O
of	O
the	O
transcription	O
factor	O
host	O
cell	O
factor	O
1	O
","	O
which	O
is	O
also	O
encoded	O
by	O
an	O
XLID	B-Disease
-	O
associated	O
gene	O
.	O
	
We	O
conclude	O
that	O
defects	O
in	O
O	O
-	O
GlcNAc	O
homeostasis	O
and	O
host	O
cell	O
factor	O
1	O
proteolysis	O
may	O
play	O
roles	O
in	O
mediation	O
of	O
XLID	B-Disease
in	O
individuals	O
with	O
OGT	O
mutations	O
.	O
	
	
Haplotype	O
structure	O
of	O
the	O
beta	O
adrenergic	O
receptor	O
genes	O
in	O
US	O
Caucasians	O
and	O
African	O
Americans	O
.	O
	
The	O
beta	O
-	O
adrenergic	O
receptors	O
(	O
beta	O
-	O
AR	O
)	O
are	O
G	O
protein	O
-	O
coupled	O
receptors	O
activated	O
by	O
epinephrine	B-Chemical
and	O
norepinephrine	B-Chemical
and	O
are	O
involved	O
in	O
a	O
variety	O
of	O
their	O
physiological	O
functions	O
.	O
	
Previously	O
","	O
three	O
beta	O
-	O
AR	O
genes	O
(	O
ADRB1	O
","	O
ADRB2	O
and	O
ADRB3	O
)	O
were	O
resequenced	O
","	O
identifying	O
polymorphisms	O
that	O
were	O
used	O
in	O
genetic	O
association	O
studies	O
of	O
cardiovascular	B-Disease
and	I-Disease
metabolic	I-Disease
disorders	I-Disease
.	O
	
These	O
studies	O
have	O
produced	O
intriguing	O
but	O
inconsistent	O
results	O
","	O
potentially	O
because	O
the	O
known	O
functional	O
variants	O
:	O
ADRB1	O
Arg389Gly	O
and	O
Gly49Ser	O
","	O
ADRB2	O
Arg16Gly	O
and	O
Gln27Glu	O
","	O
and	O
ADRB3	O
Arg64Trp	O
provided	O
an	O
incomplete	O
picture	O
of	O
the	O
total	O
functional	O
diversity	O
at	O
these	O
genes	O
.	O
	
Therefore	O
","	O
we	O
created	O
marker	O
panels	O
for	O
each	O
beta	O
-	O
AR	O
gene	O
that	O
included	O
the	O
known	O
functional	O
markers	O
and	O
also	O
other	O
markers	O
evenly	O
spaced	O
and	O
with	O
sufficient	O
density	O
to	O
identify	O
haplotype	O
block	O
structure	O
and	O
to	O
maximize	O
haplotype	O
diversity	O
.	O
	
A	O
total	O
of	O
27	O
markers	O
were	O
genotyped	O
in	O
96	O
US	O
Caucasians	O
and	O
96	O
African	O
Americans	O
.	O
	
In	O
both	O
populations	O
and	O
for	O
each	O
gene	O
","	O
a	O
single	O
block	O
with	O
little	O
evidence	O
of	O
historical	O
recombination	O
was	O
observed	O
.	O
	
For	O
each	O
gene	O
","	O
haplotype	O
captured	O
most	O
of	O
the	O
information	O
content	O
of	O
each	O
functional	O
locus	O
","	O
even	O
if	O
that	O
locus	O
was	O
not	O
genotyped	O
","	O
and	O
presumably	O
haplotype	O
would	O
capture	O
the	O
signal	O
from	O
unknown	O
functional	O
loci	O
whose	O
alleles	O
are	O
of	O
moderate	O
abundance	O
.	O
	
This	O
study	O
demonstrates	O
the	O
utility	O
of	O
using	O
beta	O
-	O
AR	O
gene	O
haplotype	O
maps	O
and	O
marker	O
panels	O
as	O
tools	O
for	O
linkage	O
studies	O
on	O
beta	O
-	O
AR	O
function	O
.	O
	
	
New	O
mutations	O
","	O
hotspots	O
","	O
and	O
founder	O
effects	O
in	O
Brazilian	O
patients	O
with	O
steroid	B-Disease
5alpha	I-Disease
-	I-Disease
reductase	I-Disease
deficiency	I-Disease
type	I-Disease
2	I-Disease
.	O
	
Mutations	O
of	O
the	O
steroid	O
5alpha	O
-	O
reductase	O
type	O
2	O
(	O
SRD5A2	O
)	O
gene	O
in	O
46	O
","	O
XY	O
subjects	O
cause	O
masculinization	O
defects	O
of	O
varying	O
degrees	O
","	O
due	O
to	O
reduced	O
or	O
impaired	O
enzymatic	O
activity	O
.	O
	
In	O
this	O
study	O
","	O
sequence	O
abnormalities	O
of	O
the	O
SRD5A2	O
gene	O
were	O
assessed	O
by	O
polymerase	O
chain	O
reaction	O
with	O
specific	O
primers	O
and	O
automated	O
sequencing	O
analysis	O
in	O
DNA	O
samples	O
from	O
20	O
patients	O
with	O
suspected	O
steroid	B-Disease
5alpha	I-Disease
-	I-Disease
reductase	I-Disease
type	I-Disease
2	I-Disease
deficiency	I-Disease
from	O
18	O
Brazilian	O
families	O
.	O
	
Eleven	O
subjects	O
presented	O
SRD5A2	O
homozygous	O
single	O
-	O
base	O
mutations	O
(	O
two	O
first	O
cousins	O
and	O
four	O
unrelated	O
patients	O
with	O
G183S	O
","	O
two	O
with	O
R246W	O
","	O
one	O
with	O
del642T	O
","	O
one	O
with	O
G196S	O
","	O
and	O
one	O
with	O
217_218insC	O
plus	O
the	O
A49T	O
variant	O
in	O
heterozygosis	O
)","	O
whereas	O
four	O
were	O
compound	O
heterozygotes	O
(	O
one	O
with	O
Q126R	O
/	O
IVS3	O
+	O
1G	O
>	O
A	O
","	O
one	O
with	O
Q126R	O
/	O
del418T	O
","	O
and	O
two	O
brothers	O
with	O
Q126R	O
/	O
G158R	O
).	O
	
Three	O
patients	O
were	O
heterozygous	O
for	O
A207D	O
","	O
G196S	O
","	O
and	O
R266W	O
substitutions	O
.	O
	
The	O
V89L	O
polymorphism	O
was	O
found	O
in	O
heterozygosis	O
in	O
one	O
of	O
them	O
(	O
with	O
A207D	O
)	O
and	O
in	O
one	O
case	O
with	O
an	O
otherwise	O
normal	O
gene	O
sequence	O
.	O
	
The	O
A49T	O
variant	O
was	O
also	O
detected	O
in	O
heterozygosis	O
in	O
the	O
second	O
case	O
without	O
other	O
sequencing	O
abnormalities	O
.	O
	
Four	O
patients	O
harbor	O
yet	O
non	O
-	O
described	O
SRD5A2	O
gene	O
mutations	O
:	O
a	O
single	O
nucleotide	O
deletion	O
(	O
del642T	O
)","	O
a	O
G158R	O
amino	O
acid	O
substitution	O
","	O
a	O
splice	O
junction	O
mutation	O
(	O
IVS3	O
+	O
1G	O
>	O
A	O
)","	O
and	O
the	O
insertion	O
of	O
a	O
cytosine	O
(	O
217_218insC	O
)	O
occurring	O
at	O
a	O
CCCC	O
motif	O
.	O
	
This	O
is	O
the	O
first	O
report	O
of	O
a	O
single	O
-	O
nucleotide	O
insertion	O
in	O
the	O
coding	O
sequence	O
of	O
the	O
SRD5A2	O
gene	O
.	O
	
In	O
addition	O
to	O
these	O
new	O
mutations	O
","	O
this	O
investigation	O
reveals	O
the	O
prevalence	O
of	O
G183S	O
substitution	O
among	O
a	O
subset	O
of	O
African	O
-	O
Brazilian	O
patients	O
and	O
presents	O
evidences	O
of	O
the	O
recurrence	O
of	O
already	O
known	O
mutations	O
.	O
	
	
Functional	O
characterization	O
of	O
SLCO1B1	O
(	O
OATP	O
-	O
C	O
)	O
variants	O
","	O
SLCO1B1	O
*	O
5	O
","	O
SLCO1B1	O
*	O
15	O
and	O
SLCO1B1	O
*	O
15	O
+	O
C1007G	O
","	O
by	O
using	O
transient	O
expression	O
systems	O
of	O
HeLa	O
and	O
HEK293	O
cells	O
.	O
	
OBJECTIVES	O
:	O
SLCO1B1	O
*	O
5	O
and	O
SLCO1B1	O
*	O
15	O
have	O
been	O
reported	O
to	O
reduce	O
the	O
clearance	O
of	O
pravastatin	B-Chemical
in	O
healthy	O
volunteers	O
.	O
	
However	O
","	O
there	O
remains	O
controversy	O
in	O
the	O
effects	O
of	O
SLCO1B1	O
*	O
5	O
on	O
the	O
activity	O
of	O
OATP1B1	O
in	O
vitro	O
.	O
	
In	O
addition	O
","	O
the	O
effect	O
of	O
SLCO1B1	O
*	O
15	O
on	O
the	O
function	O
of	O
OATP1B1	O
has	O
not	O
been	O
studied	O
using	O
cDNA	O
-	O
expression	O
systems	O
.	O
	
Object	O
of	O
the	O
present	O
study	O
was	O
to	O
study	O
the	O
influence	O
of	O
SLCO1B1	O
*	O
5	O
","	O
*	O
15	O
and	O
*	O
15	O
+	O
C1007G	O
","	O
a	O
novel	O
haplotype	O
found	O
in	O
a	O
patient	O
with	O
pravastatin	B-Chemical
-	O
induced	O
myopathy	B-Disease
","	O
on	O
the	O
functional	O
properties	O
of	O
OATP1B1	O
by	O
transient	O
expression	O
systems	O
of	O
HEK293	O
and	O
HeLa	O
cells	O
using	O
endogenous	O
conjugates	O
and	O
statins	O
as	O
substrates	O
.	O
	
METHODS	O
:	O
Transporting	O
assays	O
for	O
endogenous	O
substrates	O
were	O
performed	O
using	O
tritium	B-Chemical
labeled	O
estradiol	B-Chemical
-	I-Chemical
17beta	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
glucuronide	I-Chemical
and	O
estrone	B-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
sulfate	I-Chemical
.	O
	
Quantitation	O
of	O
pravastatin	B-Chemical
","	O
atorvastatin	B-Chemical
","	O
cerivastatin	B-Chemical
and	O
simvastatin	B-Chemical
were	O
carried	O
out	O
using	O
HPLC	O
tandem	O
mass	O
spectrometry	O
.	O
	
RESULTS	O
:	O
The	O
transporting	O
activities	O
of	O
cells	O
expressing	O
SLCO1B1	O
*	O
5	O
","	O
*	O
15	O
and	O
*	O
15	O
+	O
C1007G	O
decreased	O
significantly	O
but	O
those	O
of	O
SLCO1B1	O
*	O
1b	O
","	O
*	O
1a	O
+	O
C1007G	O
and	O
*	O
1b	O
+	O
C1007G	O
were	O
not	O
altered	O
for	O
all	O
of	O
the	O
substrates	O
tested	O
except	O
for	O
simvastatin	B-Chemical
.	O
	
Kinetic	O
analysis	O
of	O
pravastatin	B-Chemical
and	O
atorvastatin	B-Chemical
showed	O
that	O
Km	O
values	O
were	O
not	O
altered	O
but	O
Vmax	O
values	O
decreased	O
significantly	O
in	O
cells	O
expressing	O
SLCO1B1	O
*	O
5	O
","	O
*	O
15	O
and	O
*	O
15	O
+	O
C1007G	O
.	O
	
Immunocytochemical	O
study	O
showed	O
that	O
SLCO1B1	O
*	O
5	O
","	O
*	O
15	O
and	O
*	O
15	O
+	O
C1007G	O
proteins	O
are	O
localized	O
not	O
only	O
at	O
the	O
plasma	O
membrane	O
but	O
also	O
in	O
the	O
intracellular	O
space	O
.	O
	
CONCLUSIONS	O
:	O
These	O
findings	O
suggest	O
that	O
521T	O
>	O
C	O
","	O
existing	O
commonly	O
in	O
SLCO1B1	O
*	O
5	O
","	O
*	O
15	O
and	O
*	O
15	O
+	O
C1007G	O
","	O
is	O
the	O
key	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
that	O
determines	O
the	O
functional	O
properties	O
of	O
SLCO1B1	O
*	O
5	O
","	O
*	O
15	O
and	O
*	O
15	O
+	O
C1007G	O
allelic	O
proteins	O
and	O
that	O
decreased	O
activities	O
of	O
these	O
variant	O
proteins	O
are	O
mainly	O
caused	O
by	O
a	O
sorting	O
error	O
produced	O
by	O
this	O
SNP	O
.	O
	
	
Identification	O
of	O
the	O
nuclear	O
localization	O
motif	O
in	O
the	O
ETV6	O
(	O
TEL	O
)	O
protein	O
.	O
	
ETV6	O
","	O
or	O
Translocation	O
-	O
Ets	O
-	O
Leukemia	O
(	O
TEL	O
)","	O
is	O
an	O
ETS	O
family	O
transcriptional	O
repressor	O
that	O
is	O
essential	O
for	O
establishing	O
hematopoiesis	O
in	O
neonatal	O
bone	O
marrow	O
","	O
and	O
is	O
frequently	O
a	O
target	O
of	O
chromosomal	O
translocations	O
in	O
human	O
cancer	B-Disease
.	O
	
ETV6	O
is	O
predominantly	O
a	O
nuclear	O
phosphoprotein	O
that	O
represses	O
transcription	O
by	O
binding	O
directly	O
to	O
the	O
promoters	O
of	O
target	O
genes	O
.	O
	
The	O
nuclear	O
localization	O
mechanism	O
of	O
ETV6	O
","	O
however	O
","	O
is	O
not	O
well	O
understood	O
.	O
	
In	O
this	O
report	O
","	O
we	O
provide	O
evidence	O
that	O
a	O
nuclear	O
localization	O
signal	O
(	O
NLS	O
)	O
exists	O
in	O
the	O
C	O
-	O
terminal	O
region	O
of	O
ETV6	O
.	O
	
ETV6	O
proteins	O
with	O
mutations	O
outside	O
of	O
amino	O
acids	O
332	O
-	O
452	O
localize	O
to	O
the	O
nucleus	O
","	O
whereas	O
proteins	O
with	O
mutations	O
within	O
amino	O
acids	O
332	O
-	O
452	O
remain	O
in	O
the	O
cytoplasm	O
.	O
	
Furthermore	O
","	O
when	O
a	O
fragment	O
of	O
ETV6	O
comprised	O
of	O
amino	O
acids	O
332	O
-	O
452	O
was	O
fused	O
to	O
cytoplasmic	O
beta	O
-	O
galactosidase	O
protein	O
","	O
the	O
fusion	O
protein	O
was	O
able	O
to	O
enter	O
the	O
nucleus	O
.	O
	
These	O
results	O
strongly	O
indicate	O
that	O
residues	O
332	O
-	O
452	O
mediate	O
nuclear	O
localization	O
of	O
ETV6	O
.	O
	
	
Genotyping	O
of	O
five	O
chinese	O
patients	O
with	O
17alpha	B-Disease
-	I-Disease
hydroxylase	I-Disease
deficiency	I-Disease
diagnosed	O
through	O
high	O
-	O
performance	O
liquid	O
chromatography	O
serum	O
adrenal	O
profile	O
:	O
identification	O
of	O
two	O
novel	O
CYP17	O
mutations	O
.	O
	
CONTEXT	O
:	O
17alpha	B-Disease
-	I-Disease
Hydroxylase	I-Disease
deficiency	I-Disease
is	O
a	O
rare	O
form	O
of	O
congenital	B-Disease
adrenal	I-Disease
hyperplasia	I-Disease
caused	O
by	O
CYP17	O
gene	O
mutations	O
.	O
	
OBJECTIVE	O
:	O
Five	O
Chinese	O
patients	O
with	O
17alpha	B-Disease
-	I-Disease
hydroxylase	I-Disease
deficiency	I-Disease
were	O
genotyped	O
.	O
	
PATIENTS	O
:	O
The	O
five	O
patients	O
derived	O
from	O
four	O
families	O
living	O
in	O
Shandong	O
Province	O
","	O
China	O
.	O
	
The	O
diagnosis	O
of	O
17alpha	B-Disease
-	I-Disease
hydroxylase	I-Disease
deficiency	I-Disease
was	O
initially	O
established	O
through	O
HPLC	O
serum	O
adrenal	O
profiles	O
in	O
Qilu	O
Hospital	O
","	O
China	O
","	O
from	O
1983	O
-	O
1993	O
.	O
	
RESULTS	O
:	O
Three	O
CYP17	O
gene	O
mutations	O
were	O
identified	O
from	O
these	O
patients	O
.	O
	
Among	O
them	O
","	O
V311fs	O
and	O
Y329fs	O
are	O
two	O
novel	O
frame	O
-	O
shifting	O
mutations	O
.	O
	
V311fs	O
is	O
an	O
8	O
-	O
bp	O
nucleotide	O
(	O
TTAAATGG	O
)	O
deletion	O
in	O
exon	O
5	O
.	O
	
Y329fs	O
is	O
a	O
deletion	O
-	O
insertion	O
combined	O
mutation	O
(	O
TAC	O
-->	O
AA	O
)	O
at	O
codon	O
329	O
in	O
exon	O
6	O
.	O
	
Two	O
homozygotes	O
for	O
Y329fs	O
and	O
one	O
compound	O
heterozygote	O
for	O
Y329fs	O
and	O
V311fs	O
were	O
identified	O
from	O
three	O
different	O
families	O
.	O
	
Two	O
homozygous	O
sisters	O
for	O
the	O
D487_S488_F489	O
deletion	O
were	O
identified	O
.	O
	
CONCLUSION	O
:	O
The	O
results	O
confirmed	O
the	O
diagnostic	O
value	O
of	O
the	O
HPLC	O
serum	O
adrenal	O
profile	O
for	O
17alpha	B-Disease
-	I-Disease
hydroxylase	I-Disease
deficiency	I-Disease
.	O
	
The	O
D487_S488_F489	O
deletion	O
had	O
been	O
identified	O
in	O
two	O
previously	O
genotyped	O
Chinese	O
families	O
.	O
	
In	O
our	O
present	O
study	O
","	O
a	O
third	O
Chinese	O
family	O
with	O
this	O
mutation	O
was	O
identified	O
","	O
suggesting	O
that	O
this	O
mutation	O
is	O
a	O
prevalent	O
CYP17	O
mutation	O
in	O
the	O
Chinese	O
population	O
.	O
	
The	O
identification	O
of	O
Y329fs	O
mutation	O
in	O
addition	O
to	O
three	O
previously	O
identified	O
mutations	O
at	O
codon	O
329	O
suggests	O
that	O
codon	O
329	O
is	O
an	O
unstable	O
point	O
of	O
the	O
CYP17	O
gene	O
.	O
	
The	O
mutations	O
identified	O
from	O
our	O
five	O
patients	O
appear	O
to	O
be	O
random	O
","	O
but	O
the	O
recurrence	O
of	O
the	O
Y329fs	O
mutation	O
may	O
be	O
attributed	O
to	O
a	O
founder	O
effect	O
.	O
	
Our	O
studies	O
suggest	O
that	O
17alpha	B-Disease
-	I-Disease
hydroxylase	I-Disease
deficiency	I-Disease
may	O
not	O
be	O
rare	O
in	O
the	O
Chinese	O
population	O
.	O
	
	
A	O
dramatic	O
drop	B-Disease
in	I-Disease
blood	I-Disease
pressure	I-Disease
following	O
prehospital	O
GTN	B-Chemical
administration	O
.	O
	
A	O
male	O
in	O
his	O
sixties	O
with	O
no	O
history	O
of	O
cardiac	O
chest	B-Disease
pain	I-Disease
awoke	O
with	O
chest	B-Disease
pain	I-Disease
following	O
an	O
afternoon	O
sleep	O
.	O
	
The	O
patient	O
did	O
not	O
self	O
medicate	O
.	O
	
The	O
patient	O
'	O
s	O
observations	O
were	O
within	O
normal	O
limits	O
","	O
he	O
was	O
administered	O
oxygen	B-Chemical
via	O
a	O
face	O
mask	O
and	O
glyceryl	B-Chemical
trinitrate	I-Chemical
(	O
GTN	B-Chemical
).	O
	
Several	O
minutes	O
after	O
the	O
GTN	B-Chemical
the	O
patient	O
experienced	O
a	O
sudden	O
drop	B-Disease
in	I-Disease
blood	I-Disease
pressure	I-Disease
and	O
heart	O
rate	O
","	O
this	O
was	O
rectified	O
by	O
atropine	B-Chemical
sulphate	I-Chemical
and	O
a	O
fluid	O
challenge	O
.	O
	
There	O
was	O
no	O
further	O
deterioration	O
in	O
the	O
patient	O
'	O
s	O
condition	O
during	O
transport	O
to	O
hospital	O
.	O
	
There	O
are	O
very	O
few	O
documented	O
case	O
like	O
this	O
in	O
the	O
prehospital	O
scientific	O
literature	O
.	O
	
The	O
cause	O
appears	O
to	O
be	O
the	O
Bezold	O
-	O
Jarish	O
reflex	O
","	O
stimulation	O
of	O
the	O
ventricular	O
walls	O
which	O
in	O
turn	O
decreases	O
sympathetic	O
outflow	O
from	O
the	O
vasomotor	O
centre	O
.	O
	
Prehospital	O
care	O
providers	O
who	O
are	O
managing	O
any	O
patient	O
with	O
a	O
syncopal	B-Disease
episode	I-Disease
that	O
fails	O
to	O
recover	O
within	O
a	O
reasonable	O
time	O
frame	O
should	O
consider	O
the	O
Bezold	O
-	O
Jarisch	O
reflex	O
as	O
the	O
cause	O
and	O
manage	O
the	O
patient	O
accordingly	O
.	O
	
	
RNASEL	O
and	O
RNASEL	O
-	O
inhibitor	O
variation	O
and	O
prostate	B-Disease
cancer	I-Disease
risk	O
in	O
Afro	O
-	O
Caribbeans	O
.	O
	
BACKGROUND	O
:	O
Afro	O
-	O
Caribbeans	O
from	O
Tobago	O
are	O
at	O
high	O
risk	O
of	O
developing	O
prostate	B-Disease
cancer	I-Disease
.	O
	
This	O
elevated	O
risk	O
of	O
prostate	B-Disease
cancer	I-Disease
is	O
shared	O
by	O
populations	O
of	O
African	O
ancestry	O
living	O
in	O
diverse	O
environments	O
in	O
the	O
Western	O
hemisphere	O
.	O
	
Variation	O
in	O
the	O
ribonuclease	O
L	O
(	O
RNASEL	O
)	O
gene	O
has	O
recently	O
been	O
reported	O
to	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
prostate	B-Disease
cancer	I-Disease
.	O
	
However	O
","	O
whether	O
RNASEL	O
variation	O
contributes	O
to	O
the	O
increased	O
risk	O
of	O
prostate	B-Disease
cancer	I-Disease
observed	O
in	O
populations	O
of	O
African	O
ancestry	O
remains	O
unclear	O
.	O
	
METHODS	O
:	O
We	O
resequenced	O
the	O
positional	O
candidate	O
gene	O
RNASEL	O
in	O
48	O
prostate	B-Disease
cancer	I-Disease
cases	O
and	O
genotyped	O
the	O
previously	O
reported	O
R462Q	O
and	O
D541E	O
polymorphisms	O
in	O
230	O
prostate	B-Disease
cancer	I-Disease
cases	O
and	O
458	O
controls	O
.	O
	
We	O
also	O
examined	O
the	O
inhibitor	O
of	O
RNASEL	O
(	O
ABCE1	O
)	O
for	O
variation	O
associated	O
with	O
prostate	B-Disease
cancer	I-Disease
risk	O
.	O
	
RESULTS	O
:	O
We	O
found	O
no	O
evidence	O
of	O
association	O
between	O
R462Q	O
and	O
D541E	O
polymorphisms	O
and	O
prostate	B-Disease
cancer	I-Disease
risk	O
in	O
our	O
case	O
/	O
control	O
analysis	O
.	O
	
A	O
novel	O
variant	O
(	O
K294E	O
)	O
was	O
identified	O
in	O
a	O
single	O
heterozygous	O
individual	O
with	O
prostate	B-Disease
cancer	I-Disease
.	O
	
We	O
also	O
observed	O
a	O
20	O
bp	O
insertion	O
/	O
deletion	O
polymorphism	O
1	O
","	O
109	O
bp	O
upstream	O
of	O
the	O
initiation	O
codon	O
","	O
but	O
this	O
variant	O
was	O
not	O
associated	O
with	O
prostate	B-Disease
cancer	I-Disease
.	O
	
We	O
identified	O
16	O
single	O
nucleotide	O
polymorphisms	O
in	O
the	O
ABCE1	O
gene	O
","	O
only	O
3	O
of	O
which	O
had	O
a	O
minor	O
allele	O
frequency	O
>	O
5	O
%.	O
	
A	O
common	O
A	O
/	O
G	O
transition	O
-	O
1	O
","	O
71	O
bp	O
from	O
the	O
transcriptional	O
start	O
site	O
was	O
genotyped	O
and	O
showed	O
no	O
evidence	O
of	O
association	O
with	O
prostate	B-Disease
cancer	I-Disease
.	O
	
CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
common	O
variation	O
in	O
the	O
putative	O
prostate	B-Disease
cancer	I-Disease
susceptibility	O
gene	O
","	O
RNASEL	O
","	O
or	O
its	O
inhibitor	O
does	O
not	O
contribute	O
significantly	O
to	O
prostate	B-Disease
cancer	I-Disease
risk	O
in	O
this	O
Afro	O
-	O
Caribbean	O
population	O
.	O
	
	
Exaggerated	O
expression	O
of	O
inflammatory	B-Disease
mediators	O
in	O
vasoactive	O
intestinal	O
polypeptide	O
knockout	O
(	O
VIP	O
-/-)	O
mice	O
with	O
cyclophosphamide	B-Chemical
(	O
CYP	B-Chemical
)-	O
induced	O
cystitis	B-Disease
.	O
	
Vasoactive	O
intestinal	O
polypeptide	O
(	O
VIP	O
)	O
is	O
an	O
immunomodulatory	O
neuropeptide	O
distributed	O
in	O
micturition	O
pathways	O
.	O
	
VIP	O
(-/-)	O
mice	O
exhibit	O
altered	O
bladder	O
function	O
and	O
neurochemical	O
properties	O
in	O
micturition	O
pathways	O
after	O
cyclophosphamide	B-Chemical
(	O
CYP	B-Chemical
)-	O
induced	O
cystitis	B-Disease
.	O
	
Given	O
VIP	O
'	O
s	O
role	O
as	O
an	O
anti	O
-	O
inflammatory	B-Disease
mediator	O
","	O
we	O
hypothesized	O
that	O
VIP	O
(-/-)	O
mice	O
would	O
exhibit	O
enhanced	O
inflammatory	B-Disease
mediator	O
expression	O
after	O
cystitis	B-Disease
.	O
	
A	O
mouse	O
inflammatory	B-Disease
cytokine	O
and	O
receptor	O
RT2	O
profiler	O
array	O
was	O
used	O
to	O
determine	O
regulated	O
transcripts	O
in	O
the	O
urinary	O
bladder	O
of	O
wild	O
type	O
(	O
WT	O
)	O
and	O
VIP	O
(-/-)	O
mice	O
with	O
or	O
without	O
CYP	B-Chemical
-	O
induced	O
cystitis	B-Disease
(	O
150	O
mg	O
/	O
kg	O
";"	O
i	O
.	O
p	O
.	O
	
";"	O
48	O
h	O
).	O
	
Four	O
binary	O
comparisons	O
were	O
made	O
:	O
WT	O
control	O
versus	O
CYP	B-Chemical
treatment	O
(	O
48	O
h	O
)","	O
VIP	O
(-/-)	O
control	O
versus	O
CYP	B-Chemical
treatment	O
(	O
48	O
h	O
)","	O
WT	O
control	O
versus	O
VIP	O
(-/-)	O
control	O
","	O
and	O
WT	O
with	O
CYP	B-Chemical
treatment	O
(	O
48	O
h	O
)	O
versus	O
VIP	O
(-/-)	O
with	O
CYP	B-Chemical
treatment	O
(	O
48	O
h	O
).	O
	
The	O
genes	O
presented	O
represent	O
(	O
1	O
)	O
greater	O
than	O
1	O
.	O
5	O
-	O
fold	O
change	O
in	O
either	O
direction	O
and	O
(	O
2	O
)	O
the	O
p	O
value	O
is	O
less	O
than	O
0	O
.	O
5	O
for	O
the	O
comparison	O
being	O
made	O
.	O
	
Several	O
regulated	O
genes	O
were	O
validated	O
using	O
enzyme	O
-	O
linked	O
immunoassays	O
including	O
IL	O
-	O
1beta	O
and	O
CXCL1	O
.	O
	
CYP	B-Chemical
treatment	O
significantly	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
1	O
)	O
increased	O
expression	O
of	O
CXCL1	O
and	O
IL	O
-	O
1beta	O
in	O
the	O
urinary	O
bladder	O
of	O
WT	O
and	O
VIP	O
(-/-)	O
mice	O
","	O
but	O
expression	O
in	O
VIP	O
(-/-)	O
mice	O
with	O
CYP	B-Chemical
treatment	O
was	O
significantly	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
1	O
)	O
greater	O
(	O
4	O
.	O
2	O
-	O
to	O
13	O
-	O
fold	O
increase	O
)	O
than	O
that	O
observed	O
in	O
WT	O
urinary	O
bladder	O
(	O
3	O
.	O
6	O
-	O
to	O
5	O
-	O
fold	O
increase	O
).	O
	
The	O
data	O
suggest	O
that	O
in	O
VIP	O
(-/-)	O
mice	O
with	O
bladder	B-Disease
inflammation	I-Disease
","	O
inflammatory	B-Disease
mediators	O
are	O
increased	O
above	O
that	O
observed	O
in	O
WT	O
with	O
CYP	B-Chemical
.	O
	
This	O
shift	O
in	O
balance	O
may	O
contribute	O
to	O
increased	O
bladder	B-Disease
dysfunction	I-Disease
in	O
VIP	O
(-/-)	O
mice	O
with	O
bladder	B-Disease
inflammation	I-Disease
and	O
altered	O
neurochemical	O
expression	O
in	O
micturition	O
pathways	O
.	O
	
	
mToR	B-Chemical
inhibitors	I-Chemical
-	O
induced	O
proteinuria	B-Disease
:	O
mechanisms	O
","	O
significance	O
","	O
and	O
management	O
.	O
	
Massive	O
urinary	O
protein	O
excretion	O
has	O
been	O
observed	O
after	O
conversion	O
from	O
calcineurin	B-Chemical
inhibitors	I-Chemical
to	O
mammalian	B-Chemical
target	I-Chemical
of	I-Chemical
rapamycin	I-Chemical
(	I-Chemical
mToR	I-Chemical
)	I-Chemical
inhibitors	I-Chemical
","	O
especially	O
sirolimus	B-Chemical
","	O
in	O
renal	O
transplant	O
recipients	O
with	O
chronic	B-Disease
allograft	I-Disease
nephropathy	I-Disease
.	O
	
Because	O
proteinuria	B-Disease
is	O
a	O
major	O
predictive	O
factor	O
of	O
poor	O
transplantation	O
outcome	O
","	O
many	O
studies	O
focused	O
on	O
this	O
adverse	O
event	O
during	O
the	O
past	O
years	O
.	O
	
Whether	O
proteinuria	B-Disease
was	O
due	O
to	O
sirolimus	B-Chemical
or	O
only	O
a	O
consequence	O
of	O
calcineurin	B-Chemical
inhibitors	I-Chemical
withdrawal	O
remained	O
unsolved	O
until	O
high	O
range	O
proteinuria	B-Disease
has	O
been	O
observed	O
during	O
sirolimus	B-Chemical
therapy	O
in	O
islet	O
transplantation	O
and	O
in	O
patients	O
who	O
received	O
sirolimus	B-Chemical
de	O
novo	O
.	O
	
Podocyte	O
injury	O
and	O
focal	O
segmental	O
glomerulosclerosis	B-Disease
have	O
been	O
related	O
to	O
mToR	O
inhibition	O
in	O
some	O
patients	O
","	O
but	O
the	O
pathways	O
underlying	O
these	O
lesions	O
remain	O
hypothetic	O
.	O
	
We	O
discuss	O
herein	O
the	O
possible	O
mechanisms	O
and	O
the	O
significance	O
of	O
mToR	O
blockade	O
-	O
induced	O
proteinuria	B-Disease
.	O
	
	
A	O
case	O
of	O
Bernard	B-Disease
-	I-Disease
Soulier	I-Disease
Syndrome	I-Disease
due	O
to	O
a	O
homozygous	O
four	O
bases	O
deletion	O
(	O
TGAG	O
)	O
of	O
GPIbalpha	O
gene	O
:	O
lack	O
of	O
GPIbalpha	O
but	O
absence	O
of	O
bleeding	B-Disease
.	O
	
More	O
than	O
20	O
DNA	O
mutations	O
with	O
different	O
inheritance	O
pattern	O
have	O
been	O
described	O
in	O
patients	O
with	O
Bernard	B-Disease
-	I-Disease
Soulier	I-Disease
Syndrome	I-Disease
(	O
BSS	B-Disease
)","	O
leading	O
to	O
abnormal	O
or	O
absent	O
synthesis	O
and	O
/	O
or	O
expression	O
of	O
GPIbalpha	O
.	O
	
Clinical	O
phenotype	O
shows	O
considerable	O
variation	O
between	O
individuals	O
","	O
such	O
as	O
bleeding	B-Disease
","	O
platelet	O
count	O
and	O
the	O
percentage	O
of	O
large	O
platelets	O
.	O
	
We	O
describe	O
in	O
a	O
BSS	B-Disease
patient	O
the	O
first	O
case	O
of	O
homozygous	O
four	O
bases	O
deletion	O
(	O
TGAG	O
)	O
in	O
the	O
gpIbalpha	O
gene	O
coding	O
sequence	O
","	O
leading	O
to	O
a	O
premature	O
stop	O
codon	O
.	O
	
In	O
the	O
propositus	O
","	O
blood	O
smears	O
revealed	O
giant	O
platelets	O
(	O
30	O
x	O
10	O
(	O
9	O
)	O
platelets	O
/	O
L	O
)","	O
and	O
platelet	O
agglutination	O
to	O
ristocetin	B-Chemical
was	O
absent	O
.	O
	
Propositus	O
'	O
parents	O
are	O
consanguineous	O
.	O
	
His	O
father	O
and	O
paternal	O
grandmother	O
showed	O
a	O
mild	O
thrombocytopenia	B-Disease
(	O
108	O
x	O
10	O
(	O
9	O
)/	O
L	O
and	O
120	O
x	O
10	O
(	O
9	O
)/	O
L	O
platelets	O
respectively	O
)	O
while	O
mothers	O
and	O
sister	O
'	O
s	O
referred	O
normal	O
platelet	O
counts	O
.	O
	
The	O
surface	O
expression	O
of	O
GPIbalpha	O
was	O
practically	O
undetectable	O
by	O
flow	O
-	O
cytometry	O
and	O
western	O
blot	O
in	O
the	O
patient	O
and	O
was	O
reduced	O
in	O
the	O
father	O
.	O
	
Proband	O
'	O
s	O
DNA	O
analysis	O
revealed	O
a	O
homozygous	O
four	O
-	O
base	O
-	O
pair	O
deletion	O
(	O
TGAG	O
)","	O
starting	O
from	O
the	O
last	O
base	O
of	O
the	O
codon	O
for	O
Ser39	O
","	O
leading	O
to	O
a	O
coding	O
frame	O
shift	O
with	O
a	O
new	O
termination	O
codon	O
after	O
11	O
novel	O
amino	O
acids	O
.	O
	
The	O
same	O
mutation	O
was	O
seen	O
in	O
heterozygosis	O
in	O
both	O
parents	O
.	O
	
This	O
is	O
the	O
first	O
report	O
of	O
GPIbalpha	O
TGAG	O
deletion	O
in	O
homozygous	O
state	O
even	O
if	O
the	O
defect	O
has	O
already	O
been	O
described	O
in	O
a	O
case	O
of	O
compound	O
heterozygosis	O
.	O
	
Surprisingly	O
","	O
the	O
propositus	O
does	O
not	O
report	O
any	O
spontaneous	O
bleeding	B-Disease
tendency	I-Disease
.	O
	
	
Identification	O
and	O
molecular	O
characterization	O
of	O
six	O
novel	O
mutations	O
in	O
the	O
UDP	O
-	O
N	O
-	O
acetylglucosamine	O
-	O
1	O
-	O
phosphotransferase	O
gamma	O
subunit	O
(	O
GNPTG	O
)	O
gene	O
in	O
patients	O
with	O
mucolipidosis	B-Disease
III	I-Disease
gamma	I-Disease
.	O
	
Mucolipidosis	B-Disease
type	I-Disease
III	I-Disease
(	O
MLIII	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
affecting	O
lysosomal	O
hydrolase	O
trafficking	O
.	O
	
In	O
a	O
study	O
of	O
10	O
patients	O
from	O
seven	O
families	O
with	O
a	O
clinical	O
phenotype	O
and	O
enzymatic	O
diagnosis	O
of	O
MLIII	B-Disease
","	O
six	O
novel	O
GNPTG	O
gene	O
mutations	O
were	O
identified	O
.	O
	
These	O
included	O
missense	O
(	O
p	O
.	O
T286M	O
)	O
and	O
nonsense	O
(	O
p	O
.	O
W111X	O
)	O
mutations	O
and	O
a	O
transition	O
in	O
the	O
obligate	O
AG	O
-	O
dinucleotide	O
of	O
the	O
intron	O
8	O
acceptor	O
splice	O
site	O
(	O
c	O
.	O
610	O
-	O
2A	O
>	O
G	O
).	O
	
Three	O
microdeletions	O
were	O
also	O
identified	O
","	O
two	O
of	O
which	O
(	O
c	O
.	O
611delG	O
and	O
c	O
.	O
640_667del28	O
)	O
were	O
located	O
within	O
the	O
coding	O
region	O
whereas	O
one	O
(	O
c	O
.	O
609	O
+	O
28_610	O
-	O
16del	O
)	O
was	O
located	O
entirely	O
within	O
intron	O
8	O
.	O
	
RT	O
-	O
PCR	O
analysis	O
of	O
the	O
c	O
.	O
610	O
-	O
2A	O
>	O
G	O
transition	O
demonstrated	O
that	O
the	O
change	O
altered	O
splicing	O
","	O
leading	O
to	O
the	O
production	O
of	O
two	O
distinct	O
aberrantly	O
spliced	O
forms	O
","	O
viz	O
.	O
	
the	O
skipping	O
of	O
exon	O
9	O
(	O
p	O
.	O
G204_K247del	O
)	O
or	O
the	O
retention	O
of	O
introns	O
8	O
and	O
9	O
(	O
p	O
.	O
G204VfsX28	O
).	O
	
RT	O
-	O
PCR	O
analysis	O
","	O
performed	O
on	O
a	O
patient	O
homozygous	O
for	O
the	O
intronic	O
deletion	O
(	O
c	O
.	O
609	O
+	O
28_610	O
-	O
16del	O
)","	O
failed	O
to	O
detect	O
any	O
GNPTG	O
RNA	O
transcripts	O
.	O
	
To	O
determine	O
whether	O
c	O
.	O
609	O
+	O
28_610	O
-	O
16del	O
allele	O
-	O
derived	O
transcripts	O
were	O
subject	O
to	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
(	O
NMD	O
)","	O
patient	O
fibroblasts	O
were	O
incubated	O
with	O
the	O
protein	O
synthesis	O
inhibitor	O
anisomycin	B-Chemical
.	O
	
An	O
RT	O
-	O
PCR	O
fragment	O
retaining	O
43	O
bp	O
of	O
intron	O
8	O
was	O
consistently	O
detected	O
suggesting	O
that	O
the	O
33	O
-	O
bp	O
genomic	O
deletion	O
had	O
elicited	O
NMD	O
.	O
	
Quantitative	O
real	O
-	O
time	O
PCR	O
and	O
GNPTG	O
western	O
blot	O
analysis	O
confirmed	O
that	O
the	O
homozygous	O
microdeletion	O
p	O
.	O
G204VfsX17	O
had	O
elicited	O
NMD	O
resulting	O
in	O
failure	O
to	O
synthesize	O
GNPTG	O
protein	O
.	O
	
Analysis	O
of	O
the	O
sequences	O
surrounding	O
the	O
microdeletion	O
breakpoints	O
revealed	O
either	O
intrinsic	O
repetitivity	O
of	O
the	O
deleted	O
region	O
or	O
short	O
direct	O
repeats	O
adjacent	O
to	O
the	O
breakpoint	O
junctions	O
.	O
	
This	O
is	O
consistent	O
with	O
these	O
repeats	O
having	O
mediated	O
the	O
microdeletions	O
via	O
replication	O
slippage	O
and	O
supports	O
the	O
view	O
that	O
the	O
mutational	O
spectrum	O
of	O
the	O
GNPTG	O
gene	O
is	O
strongly	O
influenced	O
by	O
the	O
properties	O
of	O
the	O
local	O
DNA	O
sequence	O
environment	O
.	O
	
	
A	O
cross	O
-	O
sectional	O
evaluation	O
of	O
the	O
effect	O
of	O
risperidone	B-Chemical
and	O
selective	B-Chemical
serotonin	I-Chemical
reuptake	I-Chemical
inhibitors	I-Chemical
on	O
bone	O
mineral	O
density	O
in	O
boys	O
.	O
	
OBJECTIVE	O
:	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
risperidone	B-Chemical
-	O
induced	O
hyperprolactinemia	B-Disease
on	O
trabecular	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
in	O
children	O
and	O
adolescents	O
.	O
	
METHOD	O
:	O
Medically	O
healthy	O
7	O
-	O
to	O
17	O
-	O
year	O
-	O
old	O
males	O
chronically	O
treated	O
","	O
in	O
a	O
naturalistic	O
setting	O
","	O
with	O
risperidone	B-Chemical
were	O
recruited	O
for	O
this	O
cross	O
-	O
sectional	O
study	O
through	O
child	O
psychiatry	O
outpatient	O
clinics	O
between	O
November	O
2005	O
and	O
June	O
2007	O
.	O
	
Anthropometric	O
measurements	O
and	O
laboratory	O
testing	O
were	O
conducted	O
.	O
	
The	O
clinical	O
diagnoses	O
were	O
based	O
on	O
chart	O
review	O
","	O
and	O
developmental	O
and	O
treatment	O
history	O
was	O
obtained	O
from	O
the	O
medical	O
record	O
.	O
	
Volumetric	O
BMD	O
of	O
the	O
ultradistal	O
radius	O
was	O
measured	O
using	O
peripheral	O
quantitative	O
computed	O
tomography	O
","	O
and	O
areal	O
BMD	O
of	O
the	O
lumbar	O
spine	O
was	O
estimated	O
using	O
dual	O
-	O
energy	O
x	O
-	O
ray	O
absorptiometry	O
.	O
	
RESULTS	O
:	O
Hyperprolactinemia	B-Disease
was	O
present	O
in	O
49	O
%	O
of	O
83	O
boys	O
(	O
n	O
=	O
41	O
)	O
treated	O
with	O
risperidone	B-Chemical
for	O
a	O
mean	O
of	O
2	O
.	O
9	O
years	O
.	O
	
Serum	O
testosterone	B-Chemical
concentration	O
increased	O
with	O
pubertal	O
status	O
but	O
was	O
not	O
affected	O
by	O
hyperprolactinemia	B-Disease
.	O
	
As	O
expected	O
","	O
bone	O
mineral	O
content	O
and	O
BMD	O
increased	O
with	O
sexual	O
maturity	O
.	O
	
After	O
adjusting	O
for	O
the	O
stage	O
of	O
sexual	O
development	O
and	O
height	O
and	O
BMI	O
z	O
scores	O
","	O
serum	O
prolactin	O
was	O
negatively	O
associated	O
with	O
trabecular	O
volumetric	O
BMD	O
at	O
the	O
ultradistal	O
radius	O
(	O
P	O
<	O
.	O
3	O
).	O
	
Controlling	O
for	O
relevant	O
covariates	O
","	O
we	O
also	O
found	O
treatment	O
with	O
selective	B-Chemical
serotonin	I-Chemical
reuptake	I-Chemical
inhibitors	I-Chemical
(	O
SSRIs	B-Chemical
)	O
to	O
be	O
associated	O
with	O
lower	O
trabecular	O
BMD	O
at	O
the	O
radius	O
(	O
P	O
=	O
.	O
3	O
)	O
and	O
BMD	O
z	O
score	O
at	O
the	O
lumbar	O
spine	O
(	O
P	O
<	O
.	O
5	O
).	O
	
These	O
findings	O
became	O
more	O
marked	O
when	O
the	O
analysis	O
was	O
restricted	O
to	O
non	O
-	O
Hispanic	O
white	O
patients	O
.	O
	
Of	O
13	O
documented	O
fractures	B-Disease
","	O
3	O
occurred	O
after	O
risperidone	B-Chemical
and	O
SSRIs	B-Chemical
were	O
started	O
","	O
and	O
none	O
occurred	O
in	O
patients	O
with	O
hyperprolactinemia	B-Disease
.	O
	
CONCLUSIONS	O
:	O
This	O
is	O
the	O
first	O
study	O
to	O
link	O
risperidone	B-Chemical
-	O
induced	O
hyperprolactinemia	B-Disease
and	O
SSRI	B-Chemical
treatment	O
to	O
lower	O
BMD	O
in	O
children	O
and	O
adolescents	O
.	O
	
Future	O
research	O
should	O
evaluate	O
the	O
longitudinal	O
course	O
of	O
this	O
adverse	O
event	O
to	O
determine	O
its	O
temporal	O
stability	O
and	O
whether	O
a	O
higher	O
fracture	B-Disease
rate	O
ensues	O
.	O
	
	
The	O
GALT	O
rush	O
:	O
high	O
carrier	O
frequency	O
of	O
an	O
unusual	O
deletion	O
mutation	O
of	O
the	O
GALT	O
gene	O
in	O
the	O
Ashkenazi	O
population	O
.	O
	
Classic	B-Disease
galactosemia	I-Disease
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
of	I-Disease
galactose	I-Disease
metabolism	I-Disease
manifesting	O
in	O
the	O
first	O
weeks	O
of	O
life	O
following	O
exposure	O
to	O
a	O
milk	O
-	O
based	O
diet	O
.	O
	
Despite	O
the	O
benefit	O
of	O
avoidance	O
of	O
lactose	B-Chemical
","	O
many	O
patients	O
suffer	O
from	O
long	O
-	O
term	O
complications	O
including	O
neurological	B-Disease
deficits	I-Disease
and	O
ovarian	B-Disease
failure	I-Disease
.	O
	
To	O
date	O
","	O
over	O
230	O
mutations	O
have	O
been	O
described	O
in	O
the	O
GALT	O
gene	O
resulting	O
in	O
galactosemia	B-Disease
.	O
	
Recently	O
","	O
an	O
unusual	O
mutation	O
was	O
characterized	O
causing	O
a	O
5	O
.	O
5	O
kb	O
deletion	O
","	O
with	O
a	O
relatively	O
high	O
carrier	O
rate	O
in	O
subjects	O
of	O
Ashkenazi	O
Jewish	O
(	O
AJ	O
)	O
descent	O
.	O
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
estimate	O
the	O
carrier	O
frequency	O
of	O
this	O
mutation	O
in	O
the	O
AJ	O
population	O
in	O
Israel	O
.	O
	
For	O
this	O
purpose	O
we	O
developed	O
a	O
high	O
-	O
throughput	O
methodology	O
to	O
genotype	O
both	O
normal	O
and	O
deleted	O
alleles	O
using	O
a	O
chip	O
-	O
based	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
-	O
time	O
-	O
of	O
-	O
flight	O
(	O
MALDI	O
-	O
TOF	O
)	O
mass	O
spectrometer	O
and	O
Multiplex	O
PCR	O
.	O
	
DNA	O
samples	O
of	O
760	O
anonymous	O
AJ	O
subjects	O
were	O
submitted	O
for	O
analysis	O
","	O
subsequently	O
detecting	O
six	O
individuals	O
heterozygous	O
for	O
the	O
GALT	O
deletion	O
mutation	O
","	O
giving	O
a	O
carrier	O
frequency	O
of	O
1	O
in	O
127	O
(	O
0	O
.	O
79	O
%).	O
	
Based	O
on	O
these	O
results	O
","	O
we	O
suggest	O
that	O
the	O
method	O
described	O
here	O
provides	O
a	O
basis	O
for	O
genetic	O
screening	O
and	O
prenatal	O
counseling	O
and	O
can	O
potentially	O
reduce	O
the	O
morbidity	O
and	O
mortality	O
associated	O
with	O
delayed	O
diagnosis	O
of	O
galactosemia	B-Disease
in	O
this	O
patient	O
population	O
.	O
	
	
Long	O
-	O
term	O
oral	O
galactose	B-Chemical
treatment	O
prevents	O
cognitive	B-Disease
deficits	I-Disease
in	O
male	O
Wistar	O
rats	O
treated	O
intracerebroventricularly	O
with	O
streptozotocin	B-Chemical
.	O
	
Basic	O
and	O
clinical	O
research	O
has	O
demonstrated	O
that	O
dementia	B-Disease
of	O
sporadic	O
Alzheimer	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
sAD	B-Disease
)	O
type	O
is	O
associated	O
with	O
dysfunction	O
of	O
the	O
insulin	O
-	O
receptor	O
(	O
IR	O
)	O
system	O
followed	O
by	O
decreased	O
glucose	B-Chemical
transport	O
via	O
glucose	B-Chemical
transporter	O
GLUT4	O
and	O
decreased	O
glucose	B-Chemical
metabolism	O
in	O
brain	O
cells	O
.	O
	
An	O
alternative	O
source	O
of	O
energy	O
is	O
d	B-Chemical
-	I-Chemical
galactose	I-Chemical
(	O
the	O
C	O
-	O
4	O
-	O
epimer	O
of	O
d	B-Chemical
-	I-Chemical
glucose	I-Chemical
)	O
which	O
is	O
transported	O
into	O
the	O
brain	O
by	O
insulin	O
-	O
independent	O
GLUT3	O
transporter	O
where	O
it	O
might	O
be	O
metabolized	O
to	O
glucose	B-Chemical
via	O
the	O
Leloir	O
pathway	O
.	O
	
Exclusively	O
parenteral	O
daily	O
injections	O
of	O
galactose	B-Chemical
induce	O
memory	B-Disease
deterioration	I-Disease
in	O
rodents	O
and	O
are	O
used	O
to	O
generate	O
animal	O
aging	O
model	O
","	O
but	O
the	O
effects	O
of	O
oral	O
galactose	B-Chemical
treatment	O
on	O
cognitive	O
functions	O
have	O
never	O
been	O
tested	O
.	O
	
We	O
have	O
investigated	O
the	O
effects	O
of	O
continuous	O
daily	O
oral	O
galactose	B-Chemical
(	O
200	O
mg	O
/	O
kg	O
/	O
day	O
)	O
treatment	O
on	O
cognitive	B-Disease
deficits	I-Disease
in	O
streptozotocin	B-Chemical
-	O
induced	O
(	O
STZ	B-Chemical
-	O
icv	O
)	O
rat	O
model	O
of	O
sAD	B-Disease
","	O
tested	O
by	O
Morris	O
Water	O
Maze	O
and	O
Passive	O
Avoidance	O
test	O
","	O
respectively	O
.	O
	
One	O
month	O
of	O
oral	O
galactose	B-Chemical
treatment	O
initiated	O
immediately	O
after	O
the	O
STZ	B-Chemical
-	O
icv	O
administration	O
","	O
successfully	O
prevented	O
development	O
of	O
the	O
STZ	B-Chemical
-	O
icv	O
-	O
induced	O
cognitive	B-Disease
deficits	I-Disease
.	O
	
Beneficial	O
effect	O
of	O
oral	O
galactose	B-Chemical
was	O
independent	O
of	O
the	O
rat	O
age	O
and	O
of	O
the	O
galactose	B-Chemical
dose	O
ranging	O
from	O
100	O
to	O
300	O
mg	O
/	O
kg	O
/	O
day	O
.	O
	
Additionally	O
","	O
oral	O
galactose	B-Chemical
administration	O
led	O
to	O
the	O
appearance	O
of	O
galactose	B-Chemical
in	O
the	O
blood	O
.	O
	
The	O
increase	O
of	O
galactose	B-Chemical
concentration	O
in	O
the	O
cerebrospinal	O
fluid	O
was	O
several	O
times	O
lower	O
after	O
oral	O
than	O
after	O
parenteral	O
administration	O
of	O
the	O
same	O
galactose	B-Chemical
dose	O
.	O
	
Oral	O
galactose	B-Chemical
exposure	O
might	O
have	O
beneficial	O
effects	O
on	O
learning	O
and	O
memory	O
ability	O
and	O
could	O
be	O
worth	O
investigating	O
for	O
improvement	O
of	O
cognitive	B-Disease
deficits	I-Disease
associated	O
with	O
glucose	B-Disease
hypometabolism	I-Disease
in	O
AD	B-Disease
.	O
	
	
NOTCH1	O
and	O
SOX10	O
are	O
Essential	O
for	O
Proliferation	O
and	O
Radiation	O
Resistance	O
of	O
Cancer	B-Disease
Stem	O
-	O
Like	O
Cells	O
in	O
Adenoid	B-Disease
Cystic	I-Disease
Carcinoma	I-Disease
.	O
	
PURPOSE	O
:	O
Although	O
the	O
existence	O
of	O
cancer	B-Disease
stem	O
cells	O
(	O
CSC	O
)	O
in	O
adenoid	B-Disease
cystic	I-Disease
carcinoma	I-Disease
(	O
ACC	B-Disease
)	O
has	O
been	O
proposed	O
","	O
lack	O
of	O
assays	O
for	O
their	O
propagation	O
and	O
uncertainty	O
about	O
molecular	O
markers	O
prevented	O
their	O
characterization	O
.	O
	
Our	O
objective	O
was	O
to	O
isolate	O
CSC	O
from	O
ACC	B-Disease
and	O
provide	O
insight	O
into	O
signaling	O
pathways	O
that	O
support	O
their	O
propagation	O
.	O
	
EXPERIMENTAL	O
DESIGN	O
:	O
To	O
isolate	O
CSC	O
from	O
ACC	B-Disease
and	O
characterize	O
them	O
","	O
we	O
used	O
ROCK	O
inhibitor	O
-	O
supplemented	O
cell	O
culture	O
","	O
immunomagnetic	O
cell	O
sorting	O
","	O
andin	O
vitro	O
/	O
in	O
vivoassays	O
for	O
CSC	O
viability	O
and	O
tumorigenicity	O
.	O
	
RESULTS	O
:	O
We	O
identified	O
in	O
ACC	B-Disease
CD133	O
-	O
positive	O
CSC	O
that	O
expressed	O
NOTCH1	O
and	O
SOX10	O
","	O
formed	O
spheroids	O
","	O
and	O
initiated	O
tumors	B-Disease
in	O
nude	O
mice	O
.	O
	
CD133	O
(+)	O
ACC	B-Disease
cells	O
produced	O
activated	O
NOTCH1	O
(	O
N1ICD	O
)	O
and	O
generated	O
CD133	O
(-)	O
cells	O
that	O
expressed	O
JAG1	O
as	O
well	O
as	O
neural	O
differentiation	O
factors	O
NR2F1	O
","	O
NR2F2	O
","	O
and	O
p27Kip1	O
.	O
	
Knockdowns	O
of	O
NOTCH1	O
","	O
SOX10	O
","	O
and	O
their	O
common	O
effector	O
FABP7	O
had	O
negative	O
effects	O
on	O
each	O
other	O
","	O
inhibited	O
spheroidogenesis	O
","	O
and	O
induced	O
cell	O
death	O
pointing	O
at	O
their	O
essential	O
roles	O
in	O
CSC	O
maintenance	O
.	O
	
Downstream	O
effects	O
of	O
FABP7	O
knockdown	O
included	O
suppression	O
of	O
a	O
broad	O
spectrum	O
of	O
genes	O
involved	O
in	O
proliferation	O
","	O
ribosome	O
biogenesis	O
","	O
and	O
metabolism	O
.	O
	
Among	O
proliferation	O
-	O
linked	O
NOTCH1	O
/	O
FABP7	O
targets	O
","	O
we	O
identified	O
SKP2	O
and	O
its	O
substrate	O
p27Kip1	O
.	O
	
A	O
g	O
-	O
secretase	O
inhibitor	O
","	O
DAPT	B-Chemical
","	O
selectively	O
depleted	O
CD133	O
(+)	O
cells	O
","	O
suppressed	O
N1ICD	O
and	O
SKP2	O
","	O
induced	O
p27Kip1	O
","	O
inhibited	O
ACC	B-Disease
growthin	O
vivo	O
","	O
and	O
sensitized	O
CD133	O
(+)	O
cells	O
to	O
radiation	O
.	O
	
CONCLUSIONS	O
:	O
These	O
results	O
establish	O
in	O
the	O
majority	O
of	O
ACC	B-Disease
the	O
presence	O
of	O
a	O
previously	O
uncharacterized	O
population	O
of	O
CD133	O
(+)	O
cells	O
with	O
neural	O
stem	O
properties	O
","	O
which	O
are	O
driven	O
by	O
SOX10	O
","	O
NOTCH1	O
","	O
and	O
FABP7	O
.	O
	
Sensitivity	O
of	O
these	O
cells	O
to	O
Notch	O
inhibition	O
and	O
their	O
dependence	O
on	O
SKP2	O
offer	O
new	O
opportunities	O
for	O
targeted	O
ACC	B-Disease
therapies	O
.	O
	
	
Cone	B-Disease
dystrophy	I-Disease
with	I-Disease
supernormal	I-Disease
rod	I-Disease
response	I-Disease
is	O
strictly	O
associated	O
with	O
mutations	O
in	O
KCNV2	O
.	O
	
PURPOSE	O
:	O
Cone	B-Disease
dystrophy	I-Disease
with	I-Disease
supernormal	I-Disease
rod	I-Disease
response	I-Disease
(	O
CDSRR	B-Disease
)	O
is	O
a	O
retinal	B-Disease
disorder	I-Disease
characterized	O
by	O
reduced	O
visual	O
acuity	O
","	O
color	B-Disease
vision	I-Disease
defects	I-Disease
","	O
and	O
specific	O
alterations	O
of	O
ERG	O
responses	O
that	O
feature	O
elevated	O
scotopic	O
b	O
-	O
wave	O
amplitudes	O
at	O
high	O
luminance	O
intensities	O
.	O
	
Mutations	O
in	O
PDE6H	O
and	O
in	O
KCNV2	O
have	O
been	O
described	O
in	O
CDSRR	B-Disease
.	O
	
A	O
combined	O
clinical	O
and	O
genetic	O
study	O
was	O
conducted	O
in	O
a	O
cohort	O
of	O
patients	O
with	O
CDSRR	B-Disease
","	O
to	O
substantiate	O
these	O
prior	O
RESULTS	O
:	O
Seventeen	O
patients	O
from	O
13	O
families	O
underwent	O
a	O
detailed	O
ophthalmic	O
examination	O
including	O
color	O
vision	O
testing	O
","	O
Goldmann	O
visual	O
fields	O
","	O
fundus	O
photography	O
","	O
Ganzfeld	O
and	O
multifocal	O
ERGs	O
","	O
and	O
optical	O
coherence	O
tomography	O
.	O
	
The	O
coding	O
sequences	O
and	O
flanking	O
intron	O
/	O
UTR	O
sequences	O
of	O
PDE6C	O
and	O
KCNV2	O
were	O
screened	O
for	O
mutations	O
by	O
means	O
of	O
DHPLC	O
and	O
direct	O
DNA	O
sequencing	O
of	O
PCR	O
-	O
amplified	O
genomic	O
DNA	O
.	O
	
results	O
.	O
	
Whereas	O
no	O
mutations	O
were	O
detected	O
in	O
the	O
PDE6H	O
gene	O
","	O
mutations	O
in	O
KCNV2	O
were	O
identified	O
in	O
all	O
patients	O
","	O
in	O
either	O
the	O
homozygous	O
or	O
compound	O
heterozygous	O
state	O
.	O
	
Ten	O
of	O
the	O
11	O
identified	O
mutations	O
were	O
novel	O
","	O
including	O
three	O
missense	O
and	O
six	O
truncating	O
mutations	O
and	O
one	O
gross	O
deletion	O
.	O
	
The	O
mutations	O
concordantly	O
segregate	O
in	O
all	O
available	O
families	O
according	O
a	O
recessive	O
mode	O
of	O
inheritance	O
.	O
	
The	O
CDSRR	B-Disease
phenotype	O
was	O
associated	O
with	O
reduced	O
visual	O
acuity	O
of	O
variable	O
degree	O
and	O
color	B-Disease
vision	I-Disease
defects	I-Disease
.	O
	
Macular	O
defects	O
ranging	O
from	O
mild	O
pigmentary	O
changes	O
to	O
distinct	O
foveal	O
atrophy	B-Disease
were	O
present	O
in	O
nine	O
patients	O
.	O
	
Progression	O
of	O
the	O
disease	O
was	O
observed	O
in	O
only	O
three	O
of	O
seven	O
patients	O
with	O
follow	O
-	O
up	O
data	O
.	O
	
CONCLUSIONS	O
:	O
The	O
phenotype	O
of	O
cone	B-Disease
dystrophy	I-Disease
with	I-Disease
supernormal	I-Disease
rod	I-Disease
response	I-Disease
is	O
tightly	O
linked	O
with	O
mutations	O
in	O
KCNV2	O
.	O
	
	
Novel	O
CACNA1S	O
mutation	O
causes	O
autosomal	O
dominant	O
hypokalemic	B-Disease
periodic	I-Disease
paralysis	I-Disease
in	O
a	O
South	O
American	O
family	O
.	O
	
Hypokalaemic	B-Disease
periodic	I-Disease
paralysis	I-Disease
(	O
HypoPP	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
disorder	I-Disease
","	O
which	O
is	O
characterized	O
by	O
periodic	O
attacks	O
of	O
muscle	B-Disease
weakness	I-Disease
associated	O
with	O
a	O
decrease	O
in	O
the	O
serum	O
potassium	B-Chemical
level	O
.	O
	
A	O
major	O
disease	O
-	O
causing	O
gene	O
for	O
HypoPP	B-Disease
has	O
been	O
identified	O
as	O
CACNA1S	O
","	O
which	O
encodes	O
the	O
skeletal	O
muscle	O
calcium	O
channel	O
alpha	O
-	O
subunit	O
with	O
four	O
transmembrane	O
domains	O
(	O
I	O
-	O
IV	O
)","	O
each	O
with	O
six	O
transmembrane	O
segments	O
(	O
S1	O
-	O
S6	O
).	O
	
To	O
date	O
","	O
all	O
CACNA1S	O
mutations	O
identified	O
in	O
HypoPP	B-Disease
patients	O
are	O
located	O
within	O
the	O
voltage	O
-	O
sensor	O
S4	O
segment	O
.	O
	
In	O
this	O
study	O
we	O
report	O
a	O
novel	O
CACNA1S	O
mutation	O
in	O
a	O
new	O
region	O
of	O
the	O
protein	O
","	O
the	O
S3	O
segment	O
of	O
domain	O
III	O
.	O
	
We	O
characterized	O
a	O
four	O
-	O
generation	O
South	O
American	O
family	O
with	O
HypoPP	B-Disease
.	O
	
Genetic	O
analysis	O
identified	O
a	O
novel	O
V876E	O
mutation	O
in	O
all	O
HypoPP	B-Disease
patients	O
in	O
the	O
family	O
","	O
but	O
not	O
in	O
normal	O
family	O
members	O
or	O
160	O
control	O
people	O
.	O
	
Clinical	O
analysis	O
indicates	O
that	O
mutation	O
V876E	O
is	O
associated	O
with	O
a	O
severe	O
outcome	O
as	O
characterized	O
by	O
a	O
very	O
early	O
age	O
of	O
onset	O
","	O
complete	O
penetrance	O
and	O
a	O
severe	O
prognosis	O
including	O
death	B-Disease
.	O
	
These	O
results	O
identify	O
a	O
new	O
mutation	O
in	O
CACNA1S	O
and	O
expand	O
the	O
spectrum	O
of	O
CACNA1S	O
mutations	O
associated	O
with	O
HypoPP	B-Disease
.	O
	
	
Independent	O
and	O
cooperative	O
roles	O
of	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
","	O
nuclear	O
factor	O
-	O
kappaB	O
","	O
and	O
bone	O
morphogenetic	O
protein	O
-	O
2	O
in	O
regulation	O
of	O
metastasis	B-Disease
and	O
osteomimicry	O
of	O
prostate	B-Disease
cancer	I-Disease
cells	O
and	O
differentiation	O
and	O
mineralization	O
of	O
MC3T3	O
-	O
E1	O
osteoblast	O
-	O
like	O
cells	O
.	O
	
The	O
molecular	O
mechanisms	O
involved	O
in	O
prostate	B-Disease
cancer	I-Disease
(	I-Disease
PC	I-Disease
)	I-Disease
metastasis	I-Disease
and	O
bone	O
remodeling	O
are	O
poorly	O
understood	O
.	O
	
We	O
recently	O
reported	O
that	O
phosphoinositide	O
3	O
-	O
kinase	O
(	O
PI3K	O
)/	O
protein	O
kinase	O
B	O
(	O
Akt	O
)	O
mediates	O
transcriptional	O
regulation	O
and	O
activation	O
of	O
bone	O
morphogenetic	O
protein	O
(	O
BMP	O
)-	O
2	O
signaling	O
by	O
nuclear	O
factor	O
(	O
NF	O
)-	O
kappaB	O
in	O
bone	O
metastatic	O
prostate	B-Disease
cancer	I-Disease
cells	O
.	O
	
In	O
the	O
present	O
study	O
","	O
we	O
demonstrate	O
that	O
NF	O
-	O
kappaB	O
","	O
whether	O
activated	O
by	O
recombinant	O
human	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)-	O
alpha	O
or	O
by	O
ectopic	O
expression	O
of	O
the	O
p65	O
subunit	O
","	O
is	O
involved	O
in	O
extracellular	O
matrix	O
adhesion	O
and	O
invasion	O
of	O
osteotropic	O
PC	O
-	O
3	O
and	O
C4	O
-	O
2B	O
","	O
but	O
not	O
LNCaP	O
","	O
cells	O
.	O
	
The	O
enhanced	O
metastatic	O
potential	O
was	O
associated	O
with	O
transcriptional	O
upregulation	O
of	O
osteopontin	O
","	O
osteocalcin	O
","	O
and	O
collagen	O
IA1	O
in	O
osteotropic	O
PC	B-Disease
cells	O
","	O
suggesting	O
their	O
role	O
in	O
osteomimicry	O
of	O
PC	B-Disease
cells	O
.	O
	
Unlike	O
BMP	O
-	O
4	O
","	O
BMP	O
-	O
2	O
protein	O
enhanced	O
the	O
invasive	O
properties	O
of	O
C4	O
-	O
2B	O
cells	O
","	O
but	O
not	O
in	O
LNCaP	O
cells	O
.	O
	
Also	O
","	O
this	O
effect	O
was	O
nullified	O
by	O
Noggin	O
.	O
	
In	O
addition	O
","	O
BMP	O
-	O
2	O
mediates	O
TNF	O
-	O
alpha	O
-	O
induced	O
invasion	O
of	O
C4	O
-	O
2B	O
cells	O
in	O
a	O
NF	O
-	O
kappaB	O
-	O
dependent	O
fashion	O
.	O
	
TNF	O
-	O
alpha	O
or	O
conditioned	O
media	O
(	O
CM	O
)	O
of	O
TNF	O
-	O
alpha	O
-	O
stimulated	O
C4	O
-	O
2B	O
cells	O
upregulated	O
BMP	O
-	O
2	O
and	O
BMP	O
-	O
dependent	O
Smad	O
transcripts	O
and	O
inhibited	O
receptor	O
activator	O
of	O
NF	O
-	O
kappaB	O
ligand	O
transcripts	O
in	O
RAW	O
264	O
.	O
7	O
preosteoclast	O
cells	O
","	O
respectively	O
","	O
implying	O
that	O
this	O
factor	O
may	O
contribute	O
to	O
suppression	O
of	O
osteoclastogenesis	O
via	O
direct	O
and	O
paracrine	O
mechanisms	O
.	O
	
In	O
contrast	O
","	O
CM	O
of	O
TNF	O
-	O
alpha	O
-	O
stimulate	O
or	O
BMP2	O
-	O
stimulated	O
C4	O
-	O
2B	O
cells	O
induced	O
in	O
vitro	O
mineralization	O
of	O
MC3T3	O
-	O
E1	O
osteoblast	O
cells	O
in	O
a	O
BMP	O
-	O
2	O
-	O
dependent	O
and	O
NF	O
-	O
kappaB	O
-	O
dependent	O
manner	O
","	O
respectively	O
.	O
	
Taken	O
together	O
","	O
the	O
results	O
suggest	O
that	O
mutual	O
interactions	O
between	O
these	O
factors	O
may	O
be	O
pivotal	O
not	O
only	O
in	O
enhancing	O
the	O
osteomimicry	O
and	O
metastatic	O
potential	O
of	O
PC	B-Disease
cells	O
","	O
but	O
also	O
in	O
bone	O
remodeling	O
and	O
in	O
shifting	O
the	O
balance	O
from	O
osteoclastogenesis	O
towards	O
osteoblastogenesis	O
.	O
	
	
Association	O
study	O
of	O
polymorphisms	O
in	O
the	O
promoter	O
region	O
of	O
DRD4	O
with	O
schizophrenia	B-Disease
","	O
depression	B-Disease
","	O
and	O
heroin	B-Disease
addiction	I-Disease
.	O
	
This	O
study	O
investigated	O
the	O
possible	O
association	O
between	O
three	O
functional	O
polymorphisms	O
in	O
the	O
promoter	O
region	O
of	O
the	O
dopamine	O
D4	O
receptor	O
(	O
DRD4	O
)	O
gene	O
and	O
schizophrenia	B-Disease
","	O
depression	B-Disease
","	O
and	O
heroin	B-Disease
addiction	I-Disease
.	O
	
Genomic	O
DNA	O
was	O
isolated	O
from	O
the	O
venous	O
blood	O
leukocytes	O
of	O
322	O
unrelated	O
patients	O
with	O
schizophrenia	B-Disease
","	O
156	O
patients	O
with	O
depression	B-Disease
","	O
300	O
patients	O
with	O
heroin	B-Disease
addiction	I-Disease
","	O
and	O
300	O
healthy	O
unrelated	O
individuals	O
.	O
	
Polymorphisms	O
in	O
the	O
promoter	O
region	O
of	O
DRD4	O
(-	O
120	O
bp	O
duplication	O
","	O
-	O
616C	O
/	O
G	O
","	O
and	O
-	O
521C	O
/	O
T	O
)	O
were	O
genotyped	O
using	O
allele	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
analysis	O
.	O
	
Genotype	O
and	O
allele	O
were	O
analyzed	O
using	O
SPSS	O
11	O
.	O
5	O
software	O
.	O
	
Results	O
of	O
this	O
analysis	O
indicated	O
that	O
there	O
is	O
a	O
strong	O
finding	O
of	O
-	O
120	O
bp	O
duplication	O
allele	O
frequencies	O
with	O
schizophrenia	B-Disease
(	O
p	O
=	O
0	O
.	O
8	O
)	O
and	O
weak	O
finding	O
with	O
-	O
1240	O
L	O
/	O
S	O
and	O
for	O
paranoid	B-Disease
schizophrenia	I-Disease
(	O
p	O
=	O
0	O
.	O
22	O
).	O
	
Interestingly	O
","	O
there	O
is	O
a	O
stronger	O
finding	O
with	O
-	O
521	O
C	O
/	O
T	O
allele	O
frequencies	O
with	O
heroin	B-Disease
dependence	I-Disease
(	O
p	O
=	O
0	O
.	O
2	O
).	O
	
These	O
observations	O
strongly	O
suggest	O
that	O
the	O
-	O
120	O
-	O
bp	O
duplication	O
polymorphism	O
of	O
DRD4	O
is	O
associated	O
with	O
schizophrenia	B-Disease
and	O
that	O
the	O
-	O
521	O
C	O
/	O
T	O
polymorphism	O
is	O
associated	O
with	O
heroin	B-Disease
addiction	I-Disease
.	O
	
	
Novel	O
CRELD1	O
gene	O
mutations	O
in	O
patients	O
with	O
atrioventricular	B-Disease
septal	I-Disease
defect	I-Disease
.	O
	
BACKGROUND	O
:	O
Atrioventricular	B-Disease
septal	I-Disease
defects	I-Disease
(	O
AVSDs	B-Disease
)	O
occur	O
as	O
clinical	O
defects	O
of	O
several	O
different	O
syndromes	O
","	O
as	O
autosomal	B-Disease
dominant	I-Disease
defects	I-Disease
","	O
and	O
as	O
sporadically	O
occurring	O
malformations	B-Disease
.	O
	
Consequently	O
","	O
there	O
is	O
genetic	O
heterogeneity	O
","	O
but	O
until	O
recently	O
","	O
little	O
is	O
known	O
about	O
the	O
genes	O
involving	O
in	O
the	O
pathogenesis	O
of	O
AVSD	B-Disease
.	O
	
CRELD1	O
gene	O
","	O
a	O
novel	O
cell	O
adhesion	O
molecule	O
","	O
is	O
a	O
candidate	O
gene	O
for	O
AVSD	B-Disease
.	O
	
METHODS	O
:	O
This	O
study	O
included	O
133	O
patients	O
with	O
AVSD	B-Disease
and	O
200	O
healthy	O
controls	O
.	O
	
Peripheral	O
blood	O
samples	O
were	O
collected	O
and	O
genomic	O
DNA	O
was	O
extracted	O
from	O
the	O
leukocytes	O
.	O
	
CRELD1	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
with	O
specific	O
primers	O
.	O
	
The	O
sequences	O
of	O
PCR	O
products	O
were	O
compared	O
between	O
the	O
patients	O
and	O
controls	O
.	O
	
RESULTS	O
:	O
In	O
a	O
patient	O
","	O
a	O
C	O
-	O
to	O
-	O
G	O
transition	O
was	O
identified	O
at	O
nucleotide	O
857	O
in	O
exon	O
8	O
that	O
resulted	O
in	O
a	O
substitution	O
of	O
alanine	O
for	O
proline	O
at	O
amino	O
acid	O
286	O
in	O
the	O
first	O
calcium	B-Chemical
-	O
binding	O
EGF	O
domain	O
.	O
	
This	O
patient	O
had	O
an	O
isolated	O
partial	O
AVSD	B-Disease
and	O
the	O
mutation	O
was	O
inherited	O
from	O
her	O
mother	O
.	O
	
Another	O
mutation	O
was	O
detected	O
in	O
a	O
patient	O
with	O
a	O
partial	O
AVSD	B-Disease
and	O
evidence	O
of	O
Down	B-Disease
syndrome	I-Disease
.	O
	
The	O
heterozygous	O
c	O
.	O
973G	O
>	O
A	O
transition	O
in	O
exon	O
9	O
resulted	O
in	O
a	O
substitution	O
of	O
lysine	O
for	O
glutamic	O
acid	O
at	O
amino	O
acid	O
325	O
(	O
E325K	O
)	O
in	O
the	O
second	O
calcium	B-Chemical
-	O
binding	O
EGF	O
domain	O
.	O
	
CONCLUSIONS	O
:	O
Two	O
novel	O
CRELD1	O
mutations	O
were	O
identified	O
in	O
the	O
calcium	B-Chemical
-	O
binding	O
EGF	O
domain	O
in	O
patients	O
with	O
AVSD	B-Disease
.	O
	
CRELD1	O
is	O
likely	O
to	O
be	O
an	O
AVSD	B-Disease
-	O
susceptibility	O
gene	O
and	O
CRELD1	O
mutations	O
may	O
increase	O
the	O
risk	O
of	O
developing	O
a	O
heart	B-Disease
defect	I-Disease
rather	O
than	O
being	O
a	O
direct	O
causative	O
mutation	O
.	O
	
	
Impact	O
of	O
	
host	O
genetic	O
background	O
and	O
disease	O
progression	O
on	O
HIV	O
-	O
1	O
intrahost	O
evolutionary	O
processes	O
:	O
efficient	O
hypothesis	O
testing	O
through	O
hierarchical	O
phylogenetic	O
models	O
.	O
	
The	O
interplay	O
between	O
C	O
-	O
C	O
chemokine	O
receptor	O
type	O
5	O
(	O
CCR5	O
)	O
host	O
genetic	O
background	O
","	O
disease	O
progression	O
","	O
and	O
intrahost	O
HIV	O
-	O
1	O
evolutionary	O
dynamics	O
remains	O
unclear	O
because	O
differences	O
in	O
viral	O
evolution	O
between	O
hosts	O
limit	O
the	O
ability	O
to	O
draw	O
conclusions	O
across	O
hosts	O
stratified	O
into	O
clinically	O
relevant	O
populations	O
.	O
	
Similar	O
inference	O
problems	O
are	O
proliferating	O
across	O
many	O
measurably	O
evolving	O
pathogens	O
for	O
which	O
intrahost	O
sequence	O
samples	O
are	O
readily	O
available	O
.	O
	
To	O
this	O
end	O
","	O
we	O
propose	O
novel	O
hierarchical	O
phylogenetic	O
models	O
(	O
HPMs	O
)	O
that	O
incorporate	O
fixed	O
effects	O
to	O
test	O
for	O
differences	O
in	O
dynamics	O
across	O
host	O
populations	O
in	O
a	O
formal	O
statistical	O
framework	O
employing	O
stochastic	O
search	O
variable	O
selection	O
and	O
model	O
averaging	O
.	O
	
To	O
clarify	O
the	O
role	O
of	O
CCR5	O
host	O
genetic	O
background	O
and	O
disease	O
progression	O
on	O
viral	O
evolutionary	O
patterns	O
","	O
we	O
obtain	O
gp120	O
envelope	O
sequences	O
from	O
clonal	O
HIV	O
-	O
1	O
variants	O
isolated	O
at	O
multiple	O
time	O
points	O
in	O
the	O
course	O
of	O
infection	B-Disease
from	O
populations	O
of	O
HIV	B-Disease
-	I-Disease
1	I-Disease
-	I-Disease
infected	I-Disease
individuals	O
who	O
only	O
harbored	O
CCR5	O
-	O
using	O
HIV	O
-	O
1	O
variants	O
at	O
all	O
time	O
points	O
.	O
	
Presence	O
or	O
absence	O
of	O
a	O
CCR5	O
wt	O
/	O
DD32	O
genotype	O
and	O
progressive	O
or	O
long	O
-	O
term	O
nonprogressive	O
course	O
of	O
infection	B-Disease
stratify	O
the	O
clinical	O
populations	O
in	O
a	O
two	O
-	O
way	O
design	O
.	O
	
As	O
compared	O
with	O
the	O
standard	O
approach	O
of	O
analyzing	O
sequences	O
from	O
each	O
patient	O
independently	O
","	O
the	O
HPM	O
provides	O
more	O
efficient	O
estimation	O
of	O
evolutionary	O
parameters	O
such	O
as	O
nucleotide	O
substitution	O
rates	O
and	O
d	O
(	O
N	O
)/	O
d	O
(	O
S	O
)	O
rate	O
ratios	O
","	O
as	O
shown	O
by	O
significant	O
shrinkage	O
of	O
the	O
estimator	O
variance	O
.	O
	
The	O
fixed	O
effects	O
also	O
correct	O
for	O
nonindependence	O
of	O
data	O
between	O
populations	O
and	O
results	O
in	O
even	O
further	O
shrinkage	O
of	O
individual	O
patient	O
estimates	O
.	O
	
Model	O
selection	O
suggests	O
an	O
association	O
between	O
nucleotide	O
substitution	O
rate	O
and	O
disease	O
progression	O
","	O
but	O
a	O
role	O
for	O
CCR5	O
genotype	O
remains	O
elusive	O
.	O
	
Given	O
the	O
absence	O
of	O
clear	O
d	O
(	O
N	O
)/	O
d	O
(	O
S	O
)	O
differences	O
between	O
patient	O
groups	O
","	O
delayed	O
onset	O
of	O
AIDS	B-Disease
symptoms	O
appears	O
to	O
be	O
solely	O
associated	O
with	O
lower	O
viral	O
replication	O
rates	O
rather	O
than	O
with	O
differences	O
in	O
selection	O
on	O
amino	O
acid	O
fixation	O
.	O
	
	
Late	O
-	O
onset	O
scleroderma	B-Disease
renal	I-Disease
crisis	I-Disease
induced	O
by	O
tacrolimus	B-Chemical
and	O
prednisolone	B-Chemical
:	O
a	O
case	O
report	O
.	O
	
Scleroderma	B-Disease
renal	I-Disease
crisis	I-Disease
(	O
SRC	B-Disease
)	O
is	O
a	O
rare	O
complication	O
of	O
systemic	B-Disease
sclerosis	I-Disease
(	O
SSc	B-Disease
)	O
but	O
can	O
be	O
severe	O
enough	O
to	O
require	O
temporary	O
or	O
permanent	O
renal	O
replacement	O
therapy	O
.	O
	
Moderate	O
to	O
high	O
dose	O
corticosteroid	B-Chemical
use	O
is	O
recognized	O
as	O
a	O
major	O
risk	O
factor	O
for	O
SRC	B-Disease
.	O
	
Furthermore	O
","	O
there	O
have	O
been	O
reports	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
precipitated	O
by	O
cyclosporine	B-Chemical
in	O
patients	O
with	O
SSc	B-Disease
.	O
	
In	O
this	O
article	O
","	O
we	O
report	O
a	O
patient	O
with	O
SRC	B-Disease
induced	O
by	O
tacrolimus	B-Chemical
and	O
corticosteroids	B-Chemical
.	O
	
The	O
aim	O
of	O
this	O
work	O
is	O
to	O
call	O
attention	O
to	O
the	O
risk	O
of	O
tacrolimus	B-Chemical
use	O
in	O
patients	O
with	O
SSc	B-Disease
.	O
	
	
TIPE2	O
Inhibits	O
Lung	B-Disease
Cancer	I-Disease
Growth	O
Attributing	O
to	O
Promotion	O
of	O
Apoptosis	O
by	O
Regulating	O
Some	O
Apoptotic	O
Molecules	O
Expression	O
.	O
	
Recent	O
studies	O
found	O
that	O
TIPE2	O
was	O
involved	O
in	O
cancer	B-Disease
development	O
.	O
	
However	O
","	O
little	O
is	O
known	O
about	O
TIPE2	O
in	O
lung	B-Disease
cancer	I-Disease
.	O
	
Our	O
study	O
aims	O
to	O
clarify	O
the	O
role	O
of	O
TIPE2	O
in	O
lung	B-Disease
carcinogenesis	I-Disease
.	O
	
We	O
examined	O
the	O
expression	O
of	O
TIPE2	O
in	O
lung	B-Disease
squamous	I-Disease
cancer	I-Disease
(	O
LSC	B-Disease
)","	O
small	B-Disease
cell	I-Disease
lung	I-Disease
cancer	I-Disease
and	O
lung	B-Disease
adenocarcinoma	I-Disease
(	O
AdC	B-Disease
)	O
tissues	O
and	O
found	O
that	O
TIPE2	O
expression	O
was	O
lost	O
in	O
small	B-Disease
cell	I-Disease
lung	I-Disease
cancer	I-Disease
","	O
compared	O
with	O
adjacent	O
non	O
-	O
tumor	B-Disease
tissues	O
.	O
	
Overexpression	O
of	O
TIPE2	O
significantly	O
inhibited	O
the	O
growth	O
of	O
lung	B-Disease
cancer	I-Disease
cell	O
H446	O
in	O
vitro	O
and	O
even	O
suppressed	O
tumor	B-Disease
formation	O
in	O
vivo	O
.	O
	
Flow	O
cytometry	O
analysis	O
found	O
TIPE2	O
overexpression	O
promoted	O
apoptosis	O
of	O
H446	O
.	O
	
In	O
TIPE2	O
over	O
-	O
expression	O
cells	O
","	O
caspase	O
-	O
3	O
","	O
caspase	O
-	O
9	O
","	O
and	O
Bax	O
were	O
significantly	O
up	O
-	O
regulated	O
while	O
Bcl	O
-	O
2	O
was	O
down	O
-	O
regulated	O
.	O
	
Moreover	O
","	O
coincident	O
results	O
were	O
shown	O
by	O
immunohistochemistry	O
in	O
tumors	B-Disease
from	O
nude	O
mice	O
.	O
	
TIPE2	O
inhibited	O
the	O
phosphorylation	O
of	O
Akt	O
","	O
while	O
promoting	O
the	O
phosphorylation	O
of	O
P38	O
","	O
but	O
had	O
no	O
effect	O
on	O
IkBa	O
and	O
ERK	O
pathway	O
.	O
	
Taken	O
together	O
","	O
TIPE2	O
promoted	O
lung	B-Disease
cancer	I-Disease
cell	O
apoptosis	O
through	O
affecting	O
apoptosis	O
-	O
related	O
molecules	O
caspase	O
-	O
3	O
","	O
caspase	O
-	O
9	O
","	O
Bcl	O
-	O
2	O
and	O
Bax	O
","	O
possibly	O
via	O
regulating	O
P38	O
and	O
Akt	O
pathways	O
","	O
indicating	O
that	O
TIPE2	O
might	O
be	O
a	O
novel	O
marker	O
for	O
lung	B-Disease
cancer	I-Disease
diagnosis	O
and	O
therapy	O
.	O
	
	
Metabolic	O
Symbiosis	O
Enables	O
Adaptive	O
Resistance	O
to	O
Anti	O
-	O
angiogenic	O
Therapy	O
that	O
Is	O
Dependent	O
on	O
mTOR	O
Signaling	O
.	O
	
Therapeutic	O
targeting	O
of	O
tumor	B-Disease
angiogenesis	O
with	O
VEGF	O
inhibitors	O
results	O
in	O
demonstrable	O
","	O
but	O
transitory	O
efficacy	O
in	O
certain	O
human	O
tumors	B-Disease
and	O
mouse	O
models	O
of	O
cancer	B-Disease
","	O
limited	O
by	O
unconventional	O
forms	O
of	O
adaptive	O
/	O
evasive	O
resistance	O
.	O
	
In	O
one	O
such	O
mouse	O
model	O
","	O
potent	O
angiogenesis	O
inhibitors	O
elicit	O
compartmental	O
reorganization	O
of	O
cancer	B-Disease
cells	O
around	O
remaining	O
blood	O
vessels	O
.	O
	
The	O
glucose	O
and	O
lactate	O
transporters	O
GLUT1	O
and	O
MCT4	O
are	O
induced	O
in	O
distal	O
hypoxic	B-Disease
cells	O
in	O
a	O
HIF1a	O
-	O
dependent	O
fashion	O
","	O
indicative	O
of	O
glycolysis	O
.	O
	
Tumor	B-Disease
cells	O
proximal	O
to	O
blood	O
vessels	O
instead	O
express	O
the	O
lactate	O
transporter	O
MCT1	O
","	O
and	O
p	O
-	O
S6	O
","	O
the	O
latter	O
reflecting	O
mTOR	O
signaling	O
.	O
	
Normoxic	B-Disease
cancer	I-Disease
cells	O
import	O
and	O
metabolize	O
lactate	B-Chemical
","	O
resulting	O
in	O
upregulation	O
of	O
mTOR	O
signaling	O
via	O
glutamine	B-Chemical
metabolism	O
enhanced	O
by	O
lactate	B-Chemical
catabolism	O
.	O
	
Thus	O
","	O
metabolic	O
symbiosis	O
is	O
established	O
in	O
the	O
face	O
of	O
angiogenesis	O
inhibition	O
","	O
whereby	O
hypoxic	O
cancer	B-Disease
cells	O
import	O
glucose	B-Chemical
and	O
export	O
lactate	B-Chemical
","	O
while	O
normoxic	O
cells	O
import	O
and	O
catabolize	O
lactate	B-Chemical
.	O
	
mTOR	O
signaling	O
inhibition	O
disrupts	O
this	O
metabolic	O
symbiosis	O
","	O
associated	O
with	O
upregulation	O
of	O
the	O
glucose	O
transporter	O
GLUT2	O
.	O
	
	
Metallothionein	O
-	O
1	O
as	O
a	O
biomarker	O
of	O
altered	O
redox	O
metabolism	O
in	O
hepatocellular	B-Disease
carcinoma	I-Disease
cells	O
exposed	O
to	O
sorafenib	B-Chemical
.	O
	
BACKGROUND	O
:	O
Sorafenib	B-Chemical
","	O
a	O
kinase	O
inhibitor	O
active	O
against	O
various	O
solid	O
tumours	B-Disease
","	O
induces	O
oxidative	O
stress	O
and	O
ferroptosis	O
","	O
a	O
new	O
form	O
of	O
oxidative	O
necrosis	B-Disease
","	O
in	O
some	O
cancer	B-Disease
cells	O
.	O
	
Clinically	O
-	O
applicable	O
biomarkers	O
that	O
reflect	O
the	O
impact	O
of	O
sorafenib	B-Chemical
on	O
the	O
redox	O
metabolism	O
of	O
cancer	B-Disease
cells	O
are	O
lacking	O
.	O
	
METHODS	O
:	O
We	O
used	O
gene	O
expression	O
microarrays	O
","	O
real	O
-	O
time	O
PCR	O
","	O
immunoblot	O
","	O
protein	O
-	O
specific	O
ELISA	O
","	O
and	O
gene	O
reporter	O
constructs	O
encoding	O
the	O
enzyme	O
luciferase	O
to	O
study	O
the	O
response	O
of	O
a	O
panel	O
of	O
cancer	B-Disease
cells	O
to	O
sorafenib	B-Chemical
.	O
	
Tumour	B-Disease
explants	O
prepared	O
from	O
surgical	O
hepatocellular	B-Disease
carcinoma	I-Disease
(	O
HCC	B-Disease
)	O
samples	O
and	O
serum	O
samples	O
obtained	O
from	O
HCC	B-Disease
patients	O
receiving	O
sorafenib	B-Chemical
were	O
also	O
used	O
.	O
	
RESULTS	O
:	O
We	O
observed	O
that	O
genes	O
of	O
the	O
metallothionein	O
-	O
1	O
(	O
MT1	O
)	O
family	O
are	O
induced	O
in	O
the	O
HCC	B-Disease
cell	O
line	O
Huh7	O
exposed	O
to	O
sorafenib	B-Chemical
.	O
	
Sorafenib	B-Chemical
increased	O
the	O
expression	O
of	O
MT1G	O
mRNA	O
in	O
a	O
panel	O
of	O
human	O
cancer	B-Disease
cells	O
","	O
an	O
effect	O
that	O
was	O
not	O
observed	O
with	O
eight	O
other	O
clinically	O
-	O
approved	O
kinase	O
inhibitors	O
.	O
	
We	O
identified	O
the	O
minimal	O
region	O
of	O
the	O
MT1G	O
promoter	O
that	O
confers	O
inducibility	O
by	O
sorafenib	B-Chemical
to	O
a	O
133	O
base	O
pair	O
region	O
containing	O
an	O
Anti	O
-	O
oxidant	O
Response	O
Element	O
(	O
ARE	O
)	O
and	O
showed	O
the	O
essential	O
role	O
of	O
the	O
transcription	O
factor	O
NRF2	O
(	O
Nuclear	O
factor	O
erythroid	O
2	O
-	O
Related	O
Factor	O
2	O
).	O
	
We	O
examined	O
the	O
clinical	O
relevance	O
of	O
our	O
findings	O
by	O
analysing	O
the	O
regulation	O
of	O
MT1G	O
in	O
five	O
tumour	B-Disease
explants	O
prepared	O
from	O
surgical	O
HCC	B-Disease
samples	O
.	O
	
Finally	O
","	O
we	O
showed	O
that	O
the	O
protein	O
levels	O
of	O
MT1	O
increase	O
in	O
the	O
serum	O
of	O
some	O
HCC	B-Disease
patients	O
receiving	O
sorafenib	B-Chemical
","	O
and	O
found	O
an	O
association	O
with	O
reduced	O
overall	O
survival	O
.	O
	
CONCLUSION	O
:	O
These	O
findings	O
indicate	O
that	O
MT1	O
constitute	O
a	O
biomarker	O
adapted	O
for	O
exploring	O
the	O
impact	O
of	O
sorafenib	B-Chemical
on	O
the	O
redox	O
metabolism	O
of	O
cancer	B-Disease
cells	O
.	O
	
	
FGFR1	O
and	O
NTRK3	O
actionable	O
alterations	O
in	O
Wild	O
-	O
Type	O
gastrointestinal	B-Disease
stromal	I-Disease
tumors	I-Disease
.	O
	
BACKGROUND	O
:	O
About	O
10	O
-	O
15	O
%	O
of	O
adult	O
","	O
and	O
most	O
pediatric	O
","	O
gastrointestinal	B-Disease
stromal	I-Disease
tumors	I-Disease
(	O
GIST	B-Disease
)	O
lack	O
mutations	O
in	O
KIT	O
","	O
PDGFRA	O
","	O
SDHx	O
","	O
or	O
RAS	O
pathway	O
components	O
(	O
KRAS	O
","	O
BRAF	O
","	O
NF1	O
).	O
	
The	O
identification	O
of	O
additional	O
mutated	O
genes	O
in	O
this	O
rare	O
subset	O
of	O
tumors	B-Disease
can	O
have	O
important	O
clinical	O
benefit	O
to	O
identify	O
altered	O
biological	O
pathways	O
and	O
select	O
targeted	O
therapies	O
.	O
	
METHODS	O
:	O
We	O
performed	O
comprehensive	O
genomic	O
profiling	O
(	O
CGP	O
)	O
for	O
coding	O
regions	O
in	O
more	O
than	O
300	O
cancer	B-Disease
-	O
related	O
genes	O
of	O
186	O
GISTs	B-Disease
to	O
assess	O
for	O
their	O
somatic	O
alterations	O
.	O
	
RESULTS	O
:	O
We	O
identified	O
24	O
GIST	B-Disease
lacking	O
alterations	O
in	O
the	O
canonical	O
KIT	O
/	O
PDGFRA	O
/	O
RAS	O
pathways	O
","	O
including	O
12	O
without	O
SDHx	O
alterations	O
.	O
	
These	O
24	O
patients	O
were	O
mostly	O
adults	O
(	O
96	O
%).	O
	
The	O
tumors	B-Disease
had	O
a	O
46	O
%	O
rate	O
of	O
nodal	B-Disease
metastases	I-Disease
.	O
	
These	O
24	O
GIST	B-Disease
were	O
more	O
commonly	O
mutated	O
at	O
7	O
genes	O
:	O
ARID1B	O
","	O
ATR	O
","	O
FGFR1	O
","	O
LTK	O
","	O
SUFU	O
","	O
PARK2	O
and	O
ZNF217	O
.	O
	
Two	O
tumors	B-Disease
harbored	O
FGFR1	O
gene	O
fusions	O
(	O
FGFR1	O
-	O
HOOK3	O
","	O
FGFR1	O
-	O
TACC1	O
)	O
and	O
one	O
harbored	O
an	O
ETV6	O
-	O
NTRK3	O
fusion	O
that	O
responded	O
to	O
TRK	O
inhibition	O
.	O
	
In	O
an	O
independent	O
sample	O
set	O
","	O
we	O
identified	O
5	O
GIST	B-Disease
cases	O
lacking	O
alterations	O
in	O
the	O
KIT	O
/	O
PDGFRA	O
/	O
SDHx	O
/	O
RAS	O
pathways	O
","	O
including	O
two	O
additional	O
cases	O
with	O
FGFR1	O
-	O
TACC1	O
and	O
ETV6	O
-	O
NTRK3	O
fusions	O
.	O
	
CONCLUSIONS	O
:	O
Using	O
patient	O
demographics	O
","	O
tumor	B-Disease
characteristics	O
","	O
and	O
CGP	O
","	O
we	O
show	O
that	O
GIST	B-Disease
lacking	O
alterations	O
in	O
canonical	O
genes	O
occur	O
in	O
younger	O
patients	O
","	O
frequently	O
metastasize	B-Disease
to	I-Disease
lymph	I-Disease
nodes	I-Disease
","	O
and	O
most	O
contain	O
deleterious	O
genomic	O
alterations	O
","	O
including	O
gene	O
fusions	O
involving	O
FGFR1	O
and	O
NTRK3	O
.	O
	
If	O
confirmed	O
in	O
larger	O
series	O
","	O
routine	O
testing	O
for	O
these	O
translocations	O
may	O
be	O
indicated	O
for	O
this	O
subset	O
of	O
GIST	B-Disease
.	O
	
Moreover	O
","	O
these	O
findings	O
can	O
be	O
used	O
to	O
guide	O
personalized	O
treatments	O
for	O
patients	O
with	O
GIST	B-Disease
.	O
	
Trial	O
registration	O
NCT	O
2576431	O
.	O
	
Registered	O
October	O
12	O
","	O
2015	O
.	O
	
	
TIEG1	O
deficiency	O
confers	O
enhanced	O
myocardial	O
protection	O
in	O
the	O
infarcted	B-Disease
heart	I-Disease
by	O
mediating	O
the	O
Pten	O
/	O
Akt	O
signalling	O
pathway	O
.	O
	
The	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)-	O
b	O
-	O
inducible	O
early	O
gene	O
-	O
1	O
(	O
TIEG1	O
)	O
plays	O
a	O
crucial	O
role	O
in	O
modulating	O
cell	O
apoptosis	O
and	O
proliferation	O
in	O
a	O
number	O
of	O
diseases	O
","	O
including	O
pancreatic	B-Disease
cancer	I-Disease
","	O
leukaemia	B-Disease
and	O
osteoporosis	B-Disease
.	O
	
However	O
","	O
the	O
functional	O
role	O
of	O
TIEG1	O
in	O
the	O
heart	O
has	O
not	O
been	O
fully	O
defined	O
.	O
	
In	O
this	O
study	O
","	O
we	O
first	O
investigated	O
the	O
role	O
of	O
TIEG1	O
in	O
ischaemic	B-Disease
heart	I-Disease
disease	I-Disease
.	O
	
For	O
in	O
vitro	O
experiments	O
","	O
cardiomyocytes	O
were	O
isolated	O
from	O
both	O
TIEG1	O
knockout	O
(	O
KO	O
)	O
and	O
wile	O
-	O
type	O
(	O
WT	O
)	O
mice	O
","	O
and	O
the	O
apoptotic	O
ratios	O
were	O
evaluated	O
after	O
a	O
48	O
-	O
h	O
ischaemic	O
insult	O
.	O
	
A	O
cell	O
proliferation	O
assay	O
was	O
performed	O
after	O
7	O
days	O
of	O
incubation	O
under	O
normoxic	O
conditions	O
.	O
	
In	O
addition	O
","	O
the	O
angiogenic	O
capacity	O
of	O
endothelial	O
cells	O
was	O
determined	O
by	O
tube	O
formation	O
assay	O
.	O
	
For	O
in	O
vivo	O
experiments	O
","	O
a	O
model	O
of	O
myocardial	B-Disease
infarction	I-Disease
(	O
MI	B-Disease
)	O
was	O
established	O
using	O
both	O
TIEG1	O
KO	O
and	O
WT	O
mice	O
.	O
	
Echocardiography	O
was	O
performed	O
at	O
3	O
and	O
28	O
days	O
post	O
-	O
MI	B-Disease
","	O
whereas	O
the	O
haemodynamics	O
test	O
was	O
performed	O
28	O
days	O
post	O
-	O
MI	B-Disease
.	O
	
Histological	O
analyses	O
of	O
apoptosis	O
","	O
proliferation	O
","	O
angiogenesis	O
and	O
infarct	B-Disease
zone	O
assessments	O
were	O
performed	O
using	O
terminal	O
deoxynucleotidyltransferase	O
-	O
mediated	O
dUTP	B-Chemical
nick	O
-	O
end	O
labelling	O
(	O
TUNEL	O
)	O
staining	O
","	O
BrdU	O
immunostaining	O
","	O
a	O
-	O
smooth	O
muscle	O
actin	O
(	O
a	O
-	O
SMA	O
)/	O
CD31	O
immunostaining	O
and	O
Masson	O
'	O
s	O
trichrome	O
staining	O
","	O
respectively	O
.	O
	
Changes	O
in	O
the	O
expression	O
of	O
related	O
proteins	O
caused	O
by	O
TIEG1	O
deficiency	O
were	O
confirmed	O
using	O
both	O
reverse	O
transcription	O
-	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
qPCR	O
)	O
and	O
western	O
blot	O
analysis	O
.	O
	
Our	O
results	O
demonstrated	O
that	O
the	O
absence	O
of	O
TIEG1	O
prevented	O
cardiomyocytes	O
from	O
undergoing	O
apoptosis	O
and	O
promoted	O
higher	O
proliferation	O
";"	O
it	O
stimulated	O
the	O
proliferation	O
of	O
endothelial	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
	
Improved	O
cardiac	O
function	O
and	O
less	O
scar	O
formation	O
were	O
observed	O
in	O
TIEG1	O
KO	O
mice	O
","	O
and	O
we	O
also	O
observed	O
the	O
altered	O
expression	O
of	O
phosphatase	O
and	O
tensin	O
homolog	O
(	O
Pten	O
)","	O
Akt	O
and	O
Bcl	O
-	O
2	O
/	O
Bax	O
","	O
as	O
well	O
as	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
).	O
	
On	O
the	O
whole	O
","	O
our	O
findings	O
indicate	O
that	O
the	O
absence	O
of	O
TIEG1	O
plays	O
a	O
cardioprotective	O
role	O
in	O
ischaemic	B-Disease
heart	I-Disease
disease	I-Disease
by	O
promoting	O
changes	O
in	O
Pten	O
/	O
Akt	O
signalling	O
.	O
	
	
An	O
autosomal	B-Disease
dominant	I-Disease
cerebellar	I-Disease
ataxia	I-Disease
linked	O
to	O
chromosome	O
16q22	O
.	O
1	O
is	O
associated	O
with	O
a	O
single	O
-	O
nucleotide	O
substitution	O
in	O
the	O
5	O
'	O
untranslated	O
region	O
of	O
the	O
gene	O
encoding	O
a	O
protein	O
with	O
spectrin	O
repeat	O
and	O
Rho	O
guanine	O
-	O
nucleotide	O
exchange	O
-	O
factor	O
domains	O
.	O
	
Autosomal	B-Disease
dominant	I-Disease
cerebellar	I-Disease
ataxia	I-Disease
(	O
ADCA	B-Disease
)	O
is	O
a	O
group	O
of	O
heterogeneous	O
neurodegenerative	B-Disease
disorders	I-Disease
.	O
	
By	O
positional	O
cloning	O
","	O
we	O
have	O
identified	O
the	O
gene	O
strongly	O
associated	O
with	O
a	O
form	O
of	O
degenerative	B-Disease
ataxia	I-Disease
(	O
chromosome	O
16q22	O
.	O
1	O
-	O
linked	O
ADCA	B-Disease
)	O
that	O
clinically	O
shows	O
progressive	O
pure	O
cerebellar	B-Disease
ataxia	I-Disease
.	O
	
Detailed	O
examination	O
by	O
use	O
of	O
audiogram	O
suggested	O
that	O
sensorineural	B-Disease
hearing	I-Disease
impairment	I-Disease
may	O
be	O
associated	O
with	O
ataxia	B-Disease
in	O
our	O
families	O
.	O
	
After	O
restricting	O
the	O
candidate	O
region	O
in	O
chromosome	O
16q22	O
.	O
1	O
by	O
haplotype	O
analysis	O
","	O
we	O
found	O
that	O
all	O
patients	O
from	O
52	O
unrelated	O
Japanese	O
families	O
harbor	O
a	O
heterozygous	O
C	O
-->	O
T	O
single	O
-	O
nucleotide	O
substitution	O
","	O
16	O
nt	O
upstream	O
of	O
the	O
putative	O
translation	O
initiation	O
site	O
of	O
the	O
gene	O
for	O
a	O
hypothetical	O
protein	O
DKFZP434I216	O
","	O
which	O
we	O
have	O
called	O
puratrophin	O
-	O
1	O
(	O
Purkinje	O
cell	O
atrophy	O
associated	O
protein	O
-	O
1	O
).	O
	
The	O
full	O
-	O
length	O
puratrophin	O
-	O
1	O
mRNA	O
had	O
an	O
open	O
reading	O
frame	O
of	O
3	O
","	O
576	O
nt	O
","	O
predicted	O
to	O
contain	O
important	O
domains	O
","	O
including	O
the	O
spectrin	O
repeat	O
and	O
the	O
guanine	O
-	O
nucleotide	O
exchange	O
factor	O
(	O
GEF	O
)	O
for	O
Rho	O
GTPases	O
","	O
followed	O
by	O
the	O
Dbl	O
-	O
homologous	O
domain	O
","	O
which	O
indicates	O
the	O
role	O
of	O
puratrophin	O
-	O
1	O
in	O
intracellular	O
signaling	O
and	O
actin	O
dynamics	O
at	O
the	O
Golgi	O
apparatus	O
.	O
	
Puratrophin	O
-	O
1	O
--	O
normally	O
expressed	O
in	O
a	O
wide	O
range	O
of	O
cells	O
","	O
including	O
epithelial	O
hair	O
cells	O
in	O
the	O
cochlea	O
--	O
was	O
aggregated	O
in	O
Purkinje	O
cells	O
of	O
the	O
chromosome	O
16q22	O
.	O
1	O
-	O
linked	O
ADCA	B-Disease
brains	O
.	O
	
Consistent	O
with	O
the	O
protein	O
prediction	O
data	O
of	O
puratrophin	O
-	O
1	O
","	O
the	O
Golgi	O
-	O
apparatus	O
membrane	O
protein	O
and	O
spectrin	O
also	O
formed	O
aggregates	O
in	O
Purkinje	O
cells	O
.	O
	
The	O
present	O
study	O
highlights	O
the	O
importance	O
of	O
the	O
5	O
'	O
untranslated	O
region	O
(	O
UTR	O
)	O
in	O
identification	O
of	O
genes	O
of	O
human	O
disease	O
","	O
suggests	O
that	O
a	O
single	O
-	O
nucleotide	O
substitution	O
in	O
the	O
5	O
'	O
UTR	O
could	O
be	O
associated	O
with	O
protein	O
aggregation	O
","	O
and	O
indicates	O
that	O
the	O
GEF	O
protein	O
is	O
associated	O
with	O
cerebellar	B-Disease
degeneration	I-Disease
in	O
humans	O
.	O
	
	
Delineation	O
of	O
the	O
clinical	O
phenotype	O
associated	O
with	O
OPHN1	O
mutations	O
based	O
on	O
the	O
clinical	O
and	O
neuropsychological	O
evaluation	O
of	O
three	O
families	O
.	O
	
Recent	O
reports	O
have	O
demonstrated	O
that	O
mutations	O
in	O
the	O
OPHN1	O
gene	O
were	O
responsible	O
for	O
a	O
syndromic	O
rather	O
than	O
non	O
-	O
specific	O
mental	B-Disease
retardation	I-Disease
.	O
	
Abnormalities	O
of	O
the	O
posterior	O
fossa	O
with	O
cerebellar	B-Disease
hypoplasia	I-Disease
have	O
been	O
demonstrated	O
in	O
all	O
male	O
patients	O
reported	O
to	O
date	O
.	O
	
We	O
report	O
here	O
a	O
new	O
family	O
with	O
X	B-Disease
-	I-Disease
linked	I-Disease
mental	I-Disease
retardation	I-Disease
due	O
to	O
mutation	O
in	O
OPHN1	O
and	O
present	O
unpublished	O
data	O
about	O
two	O
families	O
previously	O
reported	O
","	O
concerning	O
the	O
facial	O
and	O
psychological	O
phenotype	O
of	O
affected	O
males	O
and	O
carrier	O
females	O
.	O
	
Our	O
study	O
confirms	O
that	O
cerebellar	B-Disease
hypoplasia	I-Disease
is	O
a	O
hallmark	O
of	O
this	O
syndrome	O
.	O
	
In	O
addition	O
","	O
affected	O
males	O
display	O
facial	O
similarities	O
that	O
can	O
help	O
the	O
diagnosis	O
.	O
	
Most	O
carrier	O
females	O
have	O
mild	O
mental	B-Disease
retardation	I-Disease
and	O
subtle	O
facial	O
changes	O
.	O
	
	
McArdle	B-Disease
disease	I-Disease
:	O
the	O
mutation	O
spectrum	O
of	O
PYGM	O
in	O
a	O
large	O
Italian	O
cohort	O
.	O
	
Deficiency	B-Disease
of	I-Disease
the	I-Disease
muscle	I-Disease
isozyme	I-Disease
of	I-Disease
glycogen	I-Disease
phosphorylase	I-Disease
is	O
causative	O
of	O
McArdle	B-Disease
disease	I-Disease
or	O
Glycogen	B-Disease
storage	I-Disease
disease	I-Disease
type	I-Disease
V	I-Disease
(	O
GSD	B-Disease
-	I-Disease
V	I-Disease
)","	O
the	O
most	O
common	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
of	O
glycogen	B-Chemical
metabolism	O
.	O
	
The	O
typical	O
clinical	O
presentation	O
is	O
characterized	O
by	O
exercise	O
intolerance	O
with	O
cramps	B-Disease
","	O
and	O
recurrent	O
myoglobinuria	B-Disease
.	O
	
To	O
date	O
","	O
46	O
mutations	O
in	O
the	O
PYGM	O
gene	O
have	O
been	O
detected	O
in	O
GSD	B-Disease
-	I-Disease
V	I-Disease
patients	O
.	O
	
We	O
report	O
the	O
mutational	O
spectrum	O
in	O
68	O
Italian	O
patients	O
.	O
	
We	O
identified	O
30	O
different	O
mutations	O
in	O
the	O
PYGM	O
gene	O
","	O
including	O
19	O
mutations	O
that	O
have	O
not	O
been	O
reported	O
previously	O
.	O
	
The	O
novel	O
mutations	O
include	O
:	O
eight	O
missense	O
mutations	O
(	O
c	O
.	O
475G	O
>	O
A	O
","	O
p	O
.	O
G159R	O
";"	O
c	O
.	O
689C	O
>	O
G	O
","	O
p	O
.	O
P230R	O
";"	O
c	O
.	O
1094C	O
>	O
T	O
","	O
p	O
.	O
A365E	O
";"	O
c	O
.	O
1151C	O
>	O
A	O
","	O
p	O
.	O
A384D	O
";"	O
c	O
.	O
1182C	O
>	O
T	O
","	O
p	O
.	O
R428C	O
";"	O
c	O
.	O
1471C	O
>	O
T	O
","	O
p	O
.	O
R491C	O
";"	O
c	O
.	O
2444A	O
>	O
C	O
","	O
p	O
.	O
D815A	O
";"	O
c	O
.	O
2477G	O
>	O
C	O
","	O
p	O
.	O
W826S	O
)","	O
two	O
nonsense	O
mutations	O
(	O
c	O
.	O
1475G	O
>	O
A	O
","	O
p	O
.	O
W492X	O
";"	O
c	O
.	O
1627A	O
>	O
T	O
","	O
p	O
.	O
K543X	O
)","	O
five	O
splice	O
site	O
mutations	O
(	O
c	O
.	O
855	O
+	O
1G	O
>	O
C	O
";"	O
c	O
.	O
1092	O
+	O
1G	O
>	O
A	O
";"	O
c	O
.	O
1093	O
-	O
1G	O
>	O
T	O
";"	O
c	O
.	O
1239	O
+	O
1G	O
>	O
A	O
";"	O
c	O
.	O
2380	O
+	O
1G	O
>	O
A	O
)","	O
and	O
four	O
deletions	O
(	O
c	O
.	O
715_717delGTC	O
","	O
p	O
.	O
V239del	O
";"	O
c	O
.	O
304delA	O
","	O
p	O
.	O
N102DfsX4	O
";"	O
c	O
.	O
1970_2177del	O
","	O
p	O
.	O
V657_G726	O
";"	O
c	O
.	O
2113_2114delGG	O
","	O
p	O
.	O
G705RfsX16	O
).	O
	
Whereas	O
we	O
confirmed	O
lack	O
of	O
direct	O
correlation	O
between	O
the	O
clinical	O
phenotype	O
and	O
the	O
genotype	O
","	O
we	O
also	O
found	O
that	O
the	O
so	O
-	O
called	O
'	O
common	O
mutation	O
'	O
(	O
p	O
.	O
R50X	O
)	O
accounted	O
for	O
about	O
43	O
%	O
of	O
alleles	O
in	O
our	O
cohort	O
and	O
that	O
no	O
population	O
-	O
related	O
mutations	O
are	O
clearly	O
identified	O
in	O
Italian	O
patients	O
.	O
	
	
Gastrointestinal	O
tolerability	O
of	O
etoricoxib	B-Chemical
in	O
rheumatoid	B-Disease
arthritis	I-Disease
patients	O
:	O
results	O
of	O
the	O
etoricoxib	B-Chemical
vs	O
diclofenac	B-Chemical
sodium	I-Chemical
gastrointestinal	O
tolerability	O
and	O
effectiveness	O
trial	O
(	O
EDGE	O
-	O
II	O
).	O
	
OBJECTIVE	O
:	O
A	O
randomised	O
","	O
double	O
-	O
blind	O
study	O
to	O
compare	O
the	O
gastrointestinal	O
(	O
GI	O
)	O
tolerability	O
","	O
safety	O
and	O
efficacy	O
of	O
etoricoxib	B-Chemical
and	O
diclofenac	B-Chemical
in	O
patients	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
(	O
RA	B-Disease
).	O
	
PATIENTS	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
4086	O
patients	O
(	O
mean	O
age	O
60	O
.	O
8	O
years	O
)	O
diagnosed	O
with	O
RA	B-Disease
were	O
enrolled	O
and	O
received	O
etoricoxib	B-Chemical
90	O
mg	O
daily	O
(	O
n	O
=	O
2032	O
)	O
or	O
diclofenac	B-Chemical
75	O
mg	O
twice	O
daily	O
(	O
n	O
=	O
2054	O
).	O
	
Use	O
of	O
gastroprotective	O
agents	O
and	O
low	O
-	O
dose	O
aspirin	B-Chemical
was	O
allowed	O
.	O
	
The	O
prespecified	O
primary	O
end	O
point	O
consisted	O
of	O
the	O
cumulative	O
rate	O
of	O
patient	O
discontinuations	O
due	O
to	O
clinical	O
and	O
laboratory	O
GI	B-Disease
adverse	I-Disease
experiences	I-Disease
(	O
AEs	O
).	O
	
General	O
safety	O
was	O
also	O
assessed	O
","	O
including	O
adjudicated	O
thrombotic	B-Disease
cardiovascular	I-Disease
event	O
data	O
.	O
	
Efficacy	O
was	O
evaluated	O
using	O
the	O
Patient	O
Global	O
Assessment	O
of	O
Disease	O
Status	O
(	O
PGADS	O
";"	O
0	O
-	O
4	O
point	O
scale	O
).	O
	
RESULTS	O
:	O
Mean	O
(	O
SD	O
";"	O
maximum	O
)	O
duration	O
of	O
treatment	O
was	O
19	O
.	O
3	O
(	O
10	O
.	O
3	O
";"	O
32	O
.	O
9	O
)	O
and	O
19	O
.	O
1	O
(	O
10	O
.	O
4	O
";"	O
33	O
.	O
1	O
)	O
months	O
in	O
the	O
etoricoxib	B-Chemical
and	O
diclofenac	B-Chemical
groups	O
","	O
respectively	O
.	O
	
The	O
cumulative	O
discontinuation	O
rate	O
due	O
to	O
GI	B-Disease
AEs	I-Disease
was	O
significantly	O
lower	O
with	O
etoricoxib	B-Chemical
than	O
diclofenac	B-Chemical
(	O
5	O
.	O
2	O
vs	O
8	O
.	O
5	O
events	O
per	O
100	O
patient	O
-	O
years	O
","	O
respectively	O
";"	O
hazard	O
ratio	O
0	O
.	O
62	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
47	O
","	O
0	O
.	O
81	O
";"	O
p	O
<	O
or	O
=	O
0	O
.	O
1	O
)).	O
	
The	O
incidence	O
of	O
discontinuations	O
for	O
hypertension	B-Disease
-	O
related	O
and	O
oedema	B-Disease
-	O
related	O
AEs	O
were	O
significantly	O
higher	O
with	O
etoricoxib	B-Chemical
(	O
2	O
.	O
5	O
%	O
and	O
1	O
.	O
1	O
%	O
respectively	O
)	O
compared	O
with	O
diclofenac	B-Chemical
(	O
1	O
.	O
5	O
%	O
and	O
0	O
.	O
4	O
%	O
respectively	O
";"	O
p	O
<	O
0	O
.	O
1	O
for	O
hypertension	B-Disease
and	O
p	O
<	O
0	O
.	O
1	O
for	O
oedema	B-Disease
).	O
	
Etoricoxib	B-Chemical
and	O
diclofenac	B-Chemical
treatment	O
resulted	O
in	O
similar	O
efficacy	O
(	O
PGADS	O
mean	O
changes	O
from	O
baseline	O
-	O
0	O
.	O
62	O
vs	O
-	O
0	O
.	O
58	O
","	O
respectively	O
).	O
	
CONCLUSIONS	O
:	O
Etoricoxib	B-Chemical
90	O
mg	O
demonstrated	O
a	O
significantly	O
lower	O
risk	O
for	O
discontinuing	O
treatment	O
due	O
to	O
GI	B-Disease
AEs	I-Disease
compared	O
with	O
diclofenac	B-Chemical
150	O
mg	O
.	O
	
Discontinuations	O
from	O
renovascular	O
AEs	O
","	O
although	O
less	O
common	O
than	O
discontinuations	O
from	O
GI	B-Disease
AEs	I-Disease
","	O
were	O
significantly	O
higher	O
with	O
etoricoxib	B-Chemical
.	O
	
	
GATA4	O
mutations	O
in	O
486	O
Chinese	O
patients	O
with	O
congenital	B-Disease
heart	I-Disease
disease	I-Disease
.	O
	
Recent	O
studies	O
have	O
reported	O
germline	O
mutations	O
in	O
GATA4	O
gene	O
in	O
some	O
types	O
of	O
congenital	B-Disease
heart	I-Disease
disease	I-Disease
(	O
CHD	B-Disease
).	O
	
However	O
","	O
the	O
prevalence	O
of	O
GATA4	O
mutations	O
in	O
CHD	B-Disease
and	O
the	O
correlation	O
between	O
the	O
GATA4	O
genotype	O
and	O
CHD	B-Disease
phenotype	O
have	O
not	O
been	O
extensively	O
studied	O
.	O
	
We	O
screened	O
germline	O
mutations	O
in	O
the	O
coding	O
exons	O
and	O
the	O
flanking	O
intron	O
sequences	O
of	O
the	O
GATA4	O
gene	O
in	O
486	O
CHD	B-Disease
patients	O
by	O
denaturing	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
DHPLC	O
)","	O
and	O
confirmed	O
the	O
mutations	O
by	O
sequencing	O
.	O
	
Nine	O
distinct	O
mutations	O
including	O
one	O
small	O
deletion	O
mutation	O
(	O
46delS	O
)","	O
two	O
small	O
insertion	O
mutations	O
(	O
118	O
-	O
119insA	O
and	O
125	O
-	O
126insAA	O
)","	O
and	O
six	O
non	O
-	O
synonymous	O
mutations	O
(	O
A6V	O
","	O
P163S	O
","	O
E359K	O
","	O
P407Q	O
","	O
S429T	O
and	O
A442V	O
)	O
were	O
identified	O
in	O
12	O
of	O
the	O
486	O
patients	O
(	O
nine	O
with	O
ventricular	B-Disease
septal	I-Disease
defect	I-Disease
","	O
two	O
with	O
Tetralogy	B-Disease
of	I-Disease
Fallot	I-Disease
","	O
and	O
one	O
with	O
endocardial	B-Disease
cushion	I-Disease
defect	I-Disease
).	O
	
Of	O
them	O
","	O
two	O
patients	O
carrying	O
E359K	O
mutation	O
were	O
from	O
two	O
generations	O
in	O
one	O
family	O
with	O
ventricular	B-Disease
septal	I-Disease
defect	I-Disease
(	O
VSD	B-Disease
).	O
	
Interestingly	O
","	O
a	O
nucleotide	O
insertion	O
of	O
c	O
.	O
1146	O
+	O
25insA	O
in	O
exon	O
6	O
was	O
detected	O
in	O
five	O
VSD	B-Disease
patients	O
","	O
but	O
not	O
in	O
486	O
normal	O
healthy	O
controls	O
.	O
	
Our	O
findings	O
are	O
useful	O
in	O
understanding	O
the	O
prevalence	O
of	O
GATA4	O
mutations	O
and	O
the	O
correlation	O
between	O
the	O
GATA4	O
genotype	O
and	O
the	O
CHD	B-Disease
phenotype	O
in	O
Chinese	O
patients	O
.	O
	
	
Serum	O
-	O
and	O
glucocorticoid	O
-	O
inducible	O
kinase	O
1	O
in	O
doxorubicin	B-Chemical
-	O
induced	O
nephrotic	B-Disease
syndrome	I-Disease
.	O
	
Doxorubicin	B-Chemical
-	O
induced	O
nephropathy	B-Disease
leads	O
to	O
epithelial	O
sodium	B-Chemical
channel	O
(	O
ENaC	O
)-	O
dependent	O
volume	B-Disease
retention	I-Disease
and	O
renal	B-Disease
fibrosis	I-Disease
.	O
	
The	O
aldosterone	B-Chemical
-	O
sensitive	O
serum	O
-	O
and	O
glucocorticoid	O
-	O
inducible	O
kinase	O
SGK1	O
has	O
been	O
shown	O
to	O
participate	O
in	O
the	O
stimulation	O
of	O
ENaC	O
and	O
to	O
mediate	O
renal	B-Disease
fibrosis	I-Disease
following	O
mineralocorticoid	B-Chemical
and	O
salt	B-Chemical
excess	O
.	O
	
The	O
present	O
study	O
was	O
performed	O
to	O
elucidate	O
the	O
role	O
of	O
SGK1	O
in	O
the	O
volume	B-Disease
retention	I-Disease
and	O
fibrosis	B-Disease
during	O
nephrotic	B-Disease
syndrome	I-Disease
.	O
	
To	O
this	O
end	O
","	O
doxorubicin	B-Chemical
(	O
15	O
mug	O
/	O
g	O
body	O
wt	O
)	O
was	O
injected	O
intravenously	O
into	O
gene	O
-	O
targeted	O
mice	O
lacking	O
SGK1	O
(	O
sgk1	O
(-/-))	O
and	O
their	O
wild	O
-	O
type	O
littermates	O
(	O
sgk1	O
(+/+)).	O
	
Doxorubicin	B-Chemical
treatment	O
resulted	O
in	O
heavy	O
proteinuria	B-Disease
(>	O
100	O
mg	O
protein	O
/	O
mg	O
crea	B-Chemical
)	O
in	O
15	O
/	O
44	O
of	O
sgk1	O
(+/+)	O
and	O
15	O
/	O
44	O
of	O
sgk1	O
(-/-)	O
mice	O
leading	O
to	O
severe	O
nephrotic	B-Disease
syndrome	I-Disease
with	O
ascites	B-Disease
","	O
lipidemia	B-Disease
","	O
and	O
hypoalbuminemia	B-Disease
in	O
both	O
genotypes	O
.	O
	
Plasma	O
aldosterone	B-Chemical
levels	O
increased	O
in	O
nephrotic	B-Disease
mice	O
of	O
both	O
genotypes	O
and	O
was	O
followed	O
by	O
increased	O
SGK1	O
protein	O
expression	O
in	O
sgk1	O
(+/+)	O
mice	O
.	O
	
Urinary	O
sodium	B-Chemical
excretion	O
reached	O
signficantly	O
lower	O
values	O
in	O
sgk1	O
(+/+)	O
mice	O
(	O
15	O
+/-	O
5	O
mumol	O
/	O
mg	O
crea	B-Chemical
)	O
than	O
in	O
sgk1	O
(-/-)	O
mice	O
(	O
35	O
+/-	O
5	O
mumol	O
/	O
mg	O
crea	B-Chemical
)	O
and	O
was	O
associated	O
with	O
a	O
significantly	O
higher	O
body	O
weight	B-Disease
gain	I-Disease
in	O
sgk1	O
(+/+)	O
compared	O
with	O
sgk1	O
(-/-)	O
mice	O
(+	O
6	O
.	O
6	O
+/-	O
0	O
.	O
7	O
vs	O
.	O
	
+	O
4	O
.	O
1	O
+/-	O
0	O
.	O
8	O
g	O
).	O
	
During	O
the	O
course	O
of	O
nephrotic	B-Disease
syndrome	I-Disease
","	O
serum	O
urea	B-Chemical
concentrations	O
increased	O
significantly	O
faster	O
in	O
sgk1	O
(-/-)	O
mice	O
than	O
in	O
sgk1	O
(+/+)	O
mice	O
leading	O
to	O
uremia	B-Disease
and	O
a	O
reduced	O
median	O
survival	O
in	O
sgk1	O
(-/-)	O
mice	O
(	O
29	O
vs	O
.	O
	
40	O
days	O
in	O
sgk1	O
(+/+)	O
mice	O
).	O
	
In	O
conclusion	O
","	O
gene	O
-	O
targeted	O
mice	O
lacking	O
SGK1	O
showed	O
blunted	O
volume	B-Disease
retention	I-Disease
","	O
yet	O
were	O
not	O
protected	O
against	O
renal	B-Disease
fibrosis	I-Disease
during	O
experimental	O
nephrotic	B-Disease
syndrome	I-Disease
.	O
	
	
Antithrombotic	B-Chemical
drug	I-Chemical
use	O
","	O
cerebral	B-Disease
microbleeds	I-Disease
","	O
and	O
intracerebral	B-Disease
hemorrhage	I-Disease
:	O
a	O
systematic	O
review	O
of	O
published	O
and	O
unpublished	O
studies	O
.	O
	
BACKGROUND	O
AND	O
PURPOSE	O
:	O
Cerebral	B-Disease
microbleeds	I-Disease
(	O
MB	B-Disease
)	O
are	O
potential	O
risk	O
factors	O
for	O
intracerebral	B-Disease
hemorrhage	I-Disease
(	O
ICH	B-Disease
)","	O
but	O
it	O
is	O
unclear	O
if	O
they	O
are	O
a	O
contraindication	O
to	O
using	O
antithrombotic	B-Chemical
drugs	I-Chemical
.	O
	
Insights	O
could	O
be	O
gained	O
by	O
pooling	O
data	O
on	O
MB	B-Disease
frequency	O
stratified	O
by	O
antithrombotic	O
use	O
in	O
cohorts	O
with	O
ICH	B-Disease
and	O
ischemic	B-Disease
stroke	I-Disease
(	O
IS	B-Disease
)/	O
transient	B-Disease
ischemic	I-Disease
attack	I-Disease
(	O
TIA	B-Disease
).	O
	
METHODS	O
:	O
We	O
performed	O
a	O
systematic	O
review	O
of	O
published	O
and	O
unpublished	O
data	O
from	O
cohorts	O
with	O
stroke	B-Disease
or	O
TIA	B-Disease
to	O
compare	O
the	O
presence	O
of	O
MB	B-Disease
in	O
:	O
(	O
1	O
)	O
antithrombotic	O
users	O
vs	O
nonantithrombotic	O
users	O
with	O
ICH	B-Disease
";"	O
(	O
2	O
)	O
antithrombotic	O
users	O
vs	O
nonusers	O
with	O
IS	B-Disease
/	O
TIA	B-Disease
";"	O
and	O
(	O
3	O
)	O
ICH	B-Disease
vs	O
ischemic	B-Disease
events	O
stratified	O
by	O
antithrombotic	O
use	O
.	O
	
We	O
also	O
analyzed	O
published	O
and	O
unpublished	O
follow	O
-	O
up	O
data	O
to	O
determine	O
the	O
risk	O
of	O
ICH	B-Disease
in	O
antithrombotic	O
users	O
with	O
MB	B-Disease
.	O
	
RESULTS	O
:	O
In	O
a	O
pooled	O
analysis	O
of	O
1460	O
ICH	B-Disease
and	O
3817	O
IS	B-Disease
/	O
TIA	B-Disease
","	O
MB	B-Disease
were	O
more	O
frequent	O
in	O
ICH	B-Disease
vs	O
IS	B-Disease
/	O
TIA	B-Disease
in	O
all	O
treatment	O
groups	O
","	O
but	O
the	O
excess	O
increased	O
from	O
2	O
.	O
8	O
(	O
odds	O
ratio	O
";"	O
range	O
","	O
2	O
.	O
3	O
-	O
3	O
.	O
5	O
)	O
in	O
nonantithrombotic	O
users	O
to	O
5	O
.	O
7	O
(	O
range	O
","	O
3	O
.	O
4	O
-	O
9	O
.	O
7	O
)	O
in	O
antiplatelet	O
users	O
and	O
8	O
.	O
0	O
(	O
range	O
","	O
3	O
.	O
5	O
-	O
17	O
.	O
8	O
)	O
in	O
warfarin	B-Chemical
users	O
(	O
P	O
difference	O
=	O
0	O
.	O
1	O
).	O
	
There	O
was	O
also	O
an	O
excess	O
of	O
MB	B-Disease
in	O
warfarin	B-Chemical
users	O
vs	O
nonusers	O
with	O
ICH	B-Disease
(	O
OR	O
","	O
2	O
.	O
7	O
";"	O
95	O
%	O
CI	O
","	O
1	O
.	O
6	O
-	O
4	O
.	O
4	O
";"	O
P	O
<	O
0	O
.	O
1	O
)	O
but	O
none	O
in	O
warfarin	B-Chemical
users	O
with	O
IS	B-Disease
/	O
TIA	B-Disease
(	O
OR	O
","	O
1	O
.	O
3	O
";"	O
95	O
%	O
CI	O
","	O
0	O
.	O
9	O
-	O
1	O
.	O
7	O
";"	O
P	O
=	O
0	O
.	O
33	O
";"	O
P	O
difference	O
=	O
0	O
.	O
1	O
).	O
	
There	O
was	O
a	O
smaller	O
excess	O
of	O
MB	B-Disease
in	O
antiplatelet	O
users	O
vs	O
nonusers	O
with	O
ICH	B-Disease
(	O
OR	O
","	O
1	O
.	O
7	O
";"	O
95	O
%	O
CI	O
","	O
1	O
.	O
3	O
-	O
2	O
.	O
3	O
";"	O
P	O
<	O
0	O
.	O
1	O
)","	O
but	O
findings	O
were	O
similar	O
for	O
antiplatelet	O
users	O
with	O
IS	B-Disease
/	O
TIA	B-Disease
(	O
OR	O
","	O
1	O
.	O
4	O
";"	O
95	O
%	O
CI	O
","	O
1	O
.	O
2	O
-	O
1	O
.	O
7	O
";"	O
P	O
<	O
0	O
.	O
1	O
";"	O
P	O
difference	O
=	O
0	O
.	O
25	O
).	O
	
In	O
pooled	O
follow	O
-	O
up	O
data	O
for	O
768	O
antithrombotic	O
users	O
","	O
presence	O
of	O
MB	B-Disease
at	O
baseline	O
was	O
associated	O
with	O
a	O
substantially	O
increased	O
risk	O
of	O
subsequent	O
ICH	B-Disease
(	O
OR	O
","	O
12	O
.	O
1	O
";"	O
95	O
%	O
CI	O
","	O
3	O
.	O
4	O
-	O
42	O
.	O
5	O
";"	O
P	O
<	O
0	O
.	O
1	O
).	O
	
CONCLUSIONS	O
:	O
The	O
excess	O
of	O
MB	B-Disease
in	O
warfarin	B-Chemical
users	O
with	O
ICH	B-Disease
compared	O
to	O
other	O
groups	O
suggests	O
that	O
MB	B-Disease
increase	O
the	O
risk	O
of	O
warfarin	B-Chemical
-	O
associated	O
ICH	B-Disease
.	O
	
Limited	O
prospective	O
data	O
corroborate	O
these	O
findings	O
","	O
but	O
larger	O
prospective	O
studies	O
are	O
urgently	O
required	O
.	O
	
	
The	O
dopamine	O
b	O
-	O
hydroxylase	O
-	O
1021C	O
/	O
T	O
polymorphism	O
is	O
associated	O
with	O
the	O
risk	O
of	O
Alzheimer	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
in	O
the	O
Epistasis	O
Project	O
.	O
	
BACKGROUND	O
:	O
The	O
loss	O
of	O
noradrenergic	O
neurones	O
of	O
the	O
locus	O
coeruleus	O
is	O
a	O
major	O
feature	O
of	O
Alzheimer	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
AD	B-Disease
).	O
	
Dopamine	O
b	O
-	O
hydroxylase	O
(	O
DBH	O
)	O
catalyses	O
the	O
conversion	O
of	O
dopamine	B-Chemical
to	O
noradrenaline	B-Chemical
.	O
	
Interactions	O
have	O
been	O
reported	O
between	O
the	O
low	O
-	O
activity	O
-	O
1021T	O
allele	O
(	O
rs1611115	O
)	O
of	O
DBH	O
and	O
polymorphisms	O
of	O
the	O
pro	O
-	O
inflammatory	B-Disease
cytokine	O
genes	O
","	O
IL1A	O
and	O
IL6	O
","	O
contributing	O
to	O
the	O
risk	O
of	O
AD	B-Disease
.	O
	
We	O
therefore	O
examined	O
the	O
associations	O
with	O
AD	B-Disease
of	O
the	O
DBH	O
-	O
1021T	O
allele	O
and	O
of	O
the	O
above	O
interactions	O
in	O
the	O
Epistasis	O
Project	O
","	O
with	O
1757	O
cases	O
of	O
AD	B-Disease
and	O
6294	O
elderly	O
controls	O
.	O
	
METHODS	O
:	O
We	O
genotyped	O
eight	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
the	O
three	O
genes	O
","	O
DBH	O
","	O
IL1A	O
and	O
IL6	O
.	O
	
We	O
used	O
logistic	O
regression	O
models	O
and	O
synergy	O
factor	O
analysis	O
to	O
examine	O
potential	O
interactions	O
and	O
associations	O
with	O
AD	B-Disease
.	O
	
RESULTS	O
:	O
We	O
found	O
that	O
the	O
presence	O
of	O
the	O
-	O
1021T	O
allele	O
was	O
associated	O
with	O
AD	B-Disease
:	O
odds	O
ratio	O
=	O
1	O
.	O
2	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
1	O
.	O
6	O
-	O
1	O
.	O
4	O
","	O
p	O
=	O
0	O
.	O
5	O
).	O
	
This	O
association	O
was	O
nearly	O
restricted	O
to	O
men	O
<	O
75	O
years	O
old	O
:	O
odds	O
ratio	O
=	O
2	O
.	O
2	O
(	O
1	O
.	O
4	O
-	O
3	O
.	O
3	O
","	O
0	O
.	O
4	O
).	O
	
We	O
also	O
found	O
an	O
interaction	O
between	O
the	O
presence	O
of	O
DBH	O
-	O
1021T	O
and	O
the	O
-	O
889TT	O
genotype	O
(	O
rs1800587	O
)	O
of	O
IL1A	O
:	O
synergy	O
factor	O
=	O
1	O
.	O
9	O
(	O
1	O
.	O
2	O
-	O
3	O
.	O
1	O
","	O
0	O
.	O
5	O
).	O
	
All	O
these	O
results	O
were	O
consistent	O
between	O
North	O
Europe	O
and	O
North	O
Spain	O
.	O
	
CONCLUSIONS	O
:	O
Extensive	O
","	O
previous	O
evidence	O
(	O
reviewed	O
here	O
)	O
indicates	O
an	O
important	O
role	O
for	O
noradrenaline	B-Chemical
in	O
the	O
control	O
of	O
inflammation	B-Disease
in	O
the	O
brain	O
.	O
	
Thus	O
","	O
the	O
-	O
1021T	O
allele	O
with	O
presumed	O
low	O
activity	O
may	O
be	O
associated	O
with	O
misregulation	O
of	O
inflammation	B-Disease
","	O
which	O
could	O
contribute	O
to	O
the	O
onset	O
of	O
AD	B-Disease
.	O
	
We	O
suggest	O
that	O
such	O
misregulation	O
is	O
the	O
predominant	O
mechanism	O
of	O
the	O
association	O
we	O
report	O
here	O
.	O
	
	
Variation	O
in	O
IL10	O
and	O
other	O
genes	O
involved	O
in	O
the	O
immune	O
response	O
and	O
in	O
oxidation	O
and	O
prostate	B-Disease
cancer	I-Disease
recurrence	O
.	O
	
BACKGROUND	O
:	O
To	O
evaluate	O
the	O
association	O
of	O
variation	O
in	O
genes	O
involved	O
in	O
immune	O
response	O
","	O
including	O
IL10	O
","	O
production	O
and	O
detoxification	O
of	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
","	O
and	O
repair	O
of	O
oxidative	O
DNA	O
damage	O
with	O
risk	O
of	O
recurrence	O
after	O
surgery	O
for	O
localized	O
prostate	B-Disease
cancer	I-Disease
.	O
	
METHODS	O
:	O
We	O
conducted	O
a	O
nested	O
case	O
-	O
control	O
study	O
of	O
men	O
who	O
had	O
a	O
radical	O
prostatectomy	O
in	O
1993	O
to	O
2001	O
.	O
	
A	O
total	O
of	O
484	O
recurrence	O
cases	O
and	O
484	O
controls	O
were	O
matched	O
on	O
age	O
","	O
race	O
","	O
and	O
pathologic	O
stage	O
and	O
grade	O
.	O
	
Germline	O
DNA	O
was	O
extracted	O
from	O
paraffin	B-Chemical
-	O
embedded	O
unaffected	O
lymph	O
nodes	O
.	O
	
We	O
genotyped	O
candidate	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNP	O
)	O
in	O
IL10	O
","	O
CRP	O
","	O
GPX1	O
","	O
GSR	O
","	O
GSTP1	O
","	O
hOGG1	O
","	O
IL1B	O
","	O
IL1RN	O
","	O
IL6	O
","	O
IL8	O
","	O
MPO	O
","	O
NOS2	O
","	O
NOS3	O
","	O
SOD1	O
","	O
SOD2	O
","	O
SOD3	O
","	O
TLR4	O
","	O
and	O
TNF	O
and	O
tagging	O
SNPs	O
in	O
IL10	O
","	O
CRP	O
","	O
GSR	O
","	O
IL1RN	O
","	O
IL6	O
","	O
NOS2	O
","	O
and	O
NOS3	O
.	O
	
We	O
used	O
conditional	O
logistic	O
regression	O
to	O
estimate	O
OR	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
).	O
	
RESULTS	O
:	O
The	O
minor	O
allele	O
(	O
A	O
)	O
in	O
IL10	O
rs1800872	O
","	O
known	O
to	O
produce	O
less	O
interleukin	O
-	O
10	O
(	O
IL	O
-	O
10	O
)","	O
was	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
recurrence	O
(	O
OR	O
=	O
1	O
.	O
76	O
","	O
95	O
%	O
CI	O
:	O
1	O
.	O
0	O
-	O
3	O
.	O
10	O
)","	O
and	O
the	O
minor	O
allele	O
(	O
G	O
)	O
in	O
rs1800896	O
","	O
known	O
to	O
produce	O
more	O
IL	O
-	O
10	O
","	O
was	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
recurrence	O
(	O
OR	O
=	O
0	O
.	O
66	O
","	O
95	O
%	O
CI	O
:	O
0	O
.	O
48	O
-	O
0	O
.	O
91	O
).	O
	
We	O
also	O
observed	O
associations	O
for	O
candidate	O
SNPs	O
in	O
CRP	O
","	O
GSTP1	O
","	O
and	O
IL1B	O
.	O
	
A	O
common	O
IL10	O
haplotype	O
and	O
2	O
common	O
NOS2	O
haplotypes	O
were	O
associated	O
with	O
recurrence	O
.	O
	
CONCLUSION	O
:	O
Variation	O
in	O
IL10	O
","	O
CRP	O
","	O
GSTP1	O
","	O
IL1B	O
","	O
and	O
NOS2	O
was	O
associated	O
with	O
prostate	B-Disease
cancer	I-Disease
recurrence	O
independent	O
of	O
pathologic	O
prognostic	O
factors	O
.	O
	
IMPACT	O
:	O
This	O
study	O
supports	O
that	O
genetic	O
variation	O
in	O
immune	O
response	O
and	O
oxidation	O
influence	O
prostate	B-Disease
cancer	I-Disease
recurrence	O
risk	O
and	O
suggests	O
genetic	O
variation	O
in	O
these	O
pathways	O
may	O
inform	O
prognosis	O
.	O
	
	
Negative	O
Selection	O
and	O
Chromosome	B-Disease
Instability	I-Disease
Induced	O
by	O
Mad2	O
Overexpression	O
Delay	O
Breast	B-Disease
Cancer	I-Disease
but	O
Facilitate	O
Oncogene	O
-	O
Independent	O
Outgrowth	O
.	O
	
Chromosome	B-Disease
instability	I-Disease
(	O
CIN	B-Disease
)	O
is	O
associated	O
with	O
poor	O
survival	O
and	O
therapeutic	O
outcome	O
in	O
a	O
number	O
of	O
malignancies	B-Disease
.	O
	
Despite	O
this	O
correlation	O
","	O
CIN	B-Disease
can	O
also	O
lead	O
to	O
growth	O
disadvantages	O
.	O
	
Here	O
","	O
we	O
show	O
that	O
simultaneous	O
overexpression	O
of	O
the	O
mitotic	O
checkpoint	O
protein	O
Mad2	O
with	O
Kras	O
(	O
G12D	O
)	O
or	O
Her2	O
in	O
mammary	O
glands	O
of	O
adult	O
mice	O
results	O
in	O
mitotic	O
checkpoint	O
overactivation	O
and	O
a	O
delay	O
in	O
tumor	B-Disease
onset	O
.	O
	
Time	O
-	O
lapse	O
imaging	O
of	O
organotypic	O
cultures	O
and	O
pathologic	O
analysis	O
prior	O
to	O
tumor	B-Disease
establishment	O
reveals	O
error	O
-	O
prone	O
mitosis	O
","	O
mitotic	O
arrest	O
","	O
and	O
cell	O
death	O
.	O
	
Nonetheless	O
","	O
Mad2	O
expression	O
persists	O
and	O
increases	O
karyotype	O
complexity	O
in	O
Kras	O
tumors	B-Disease
.	O
	
Faced	O
with	O
the	O
selective	O
pressure	O
of	O
oncogene	O
withdrawal	O
","	O
Mad2	O
-	O
positive	O
tumors	B-Disease
have	O
a	O
higher	O
frequency	O
of	O
developing	O
persistent	O
subclones	O
that	O
avoid	O
remission	O
and	O
continue	O
to	O
grow	O
.	O
	
	
Analysis	O
of	O
Serum	O
Cytokines	O
and	O
Single	O
-	O
Nucleotide	O
Polymorphisms	O
of	O
SOD1	O
","	O
SOD2	O
","	O
and	O
CAT	O
in	O
Erysipelas	B-Disease
Patients	O
.	O
	
Increased	O
free	O
radical	O
production	O
had	O
been	O
documented	O
in	O
group	O
A	O
(	O
beta	O
-	O
hemolytic	O
)	O
streptococcus	B-Disease
infection	I-Disease
cases	O
.	O
	
Comparing	O
71	O
erysipelas	B-Disease
patients	O
to	O
55	O
age	O
-	O
matched	O
healthy	O
individuals	O
","	O
we	O
sought	O
for	O
CAT	O
","	O
SOD1	O
","	O
and	O
SOD2	O
single	O
polymorphism	O
mutation	O
(	O
SNPs	O
)	O
interactions	O
with	O
erysipelas	B-Disease
'	O
predisposition	O
and	O
serum	O
cytokine	O
levels	O
in	O
the	O
acute	O
and	O
recovery	O
phases	O
of	O
erysipelas	B-Disease
infection	I-Disease
.	O
	
Whereas	O
female	O
patients	O
had	O
a	O
higher	O
predisposition	O
to	O
erysipelas	B-Disease
","	O
male	O
patients	O
were	O
prone	O
to	O
having	O
a	O
facial	O
localization	O
of	O
the	O
infection	B-Disease
.	O
	
The	O
presence	O
of	O
SOD1	O
G7958	O
","	O
SOD2	O
T2734	O
","	O
and	O
CAT	O
C262	O
alleles	O
was	O
linked	O
to	O
erysipelas	B-Disease
'	O
predisposition	O
.	O
	
T	O
and	O
C	O
alleles	O
of	O
SOD2	O
T2734C	O
individually	O
were	O
linked	O
to	O
patients	O
with	O
bullous	O
and	O
erythematous	B-Disease
erysipelas	I-Disease
","	O
respectively	O
.	O
	
G	O
and	O
A	O
alleles	O
of	O
SOD1	O
G7958A	O
individually	O
were	O
associated	O
with	O
lower	O
limbs	O
and	O
higher	O
body	O
part	O
localizations	O
of	O
the	O
infection	B-Disease
","	O
respectively	O
.	O
	
Serum	O
levels	O
of	O
IL	O
-	O
1beta	O
","	O
CCL11	O
","	O
IL	O
-	O
2Ralpha	O
","	O
CXCL9	O
","	O
TRAIL	O
","	O
PDGF	O
-	O
BB	O
","	O
and	O
CCL4	O
were	O
associated	O
with	O
symptoms	O
accompanying	O
the	O
infection	B-Disease
","	O
while	O
IL	O
-	O
6	O
","	O
IL	O
-	O
9	O
","	O
IL	O
-	O
10	O
","	O
IL	O
-	O
13	O
","	O
IL	O
-	O
15	O
","	O
IL	O
-	O
17	O
","	O
G	O
-	O
CSF	O
","	O
and	O
VEGF	O
were	O
associated	O
with	O
predisposition	O
and	O
recurrence	O
of	O
erysipelas	B-Disease
.	O
	
While	O
variations	O
of	O
IL	O
-	O
1beta	O
","	O
IL	O
-	O
7	O
","	O
IL	O
-	O
8	O
","	O
IL	O
-	O
17	O
","	O
CCL5	O
","	O
and	O
HGF	O
were	O
associated	O
with	O
the	O
SOD2	O
T2734C	O
SNP	O
","	O
variations	O
of	O
PDFG	O
-	O
BB	O
and	O
CCL2	O
were	O
associated	O
with	O
the	O
CAT	O
C262T	O
SNP	O
.	O
	
	
An	O
Ag	O
-	O
globin	O
G	O
->	O
A	O
gene	O
polymorphism	O
associated	O
with	O
b	O
(	O
0	O
)	O
39	O
thalassemia	O
globin	O
gene	O
and	O
high	O
fetal	O
hemoglobin	O
production	O
.	O
	
BACKGROUND	O
:	O
Increase	O
of	O
the	O
expression	O
of	O
g	O
-	O
globin	O
gene	O
and	O
high	O
production	O
of	O
fetal	O
hemoglobin	O
(	O
HbF	O
)	O
in	O
b	B-Disease
-	I-Disease
thalassemia	I-Disease
patients	O
is	O
widely	O
accepted	O
as	O
associated	O
with	O
a	O
milder	O
or	O
even	O
asymptomatic	O
disease	O
.	O
	
The	O
search	O
for	O
HbF	O
-	O
associated	O
polymorphisms	O
(	O
such	O
as	O
the	O
XmnI	O
","	O
BCL11A	O
and	O
MYB	O
polymorphisms	O
)	O
has	O
recently	O
gained	O
great	O
attention	O
","	O
in	O
order	O
to	O
stratify	O
b	B-Disease
-	I-Disease
thalassemia	I-Disease
patients	O
with	O
respect	O
to	O
expectancy	O
of	O
the	O
first	O
transfusion	O
","	O
need	O
for	O
annual	O
intake	O
of	O
blood	O
","	O
response	O
to	O
HbF	O
inducers	O
(	O
the	O
most	O
studied	O
of	O
which	O
is	O
hydroxyurea	O
).	O
	
METHODS	O
:	O
Ag	O
-	O
globin	O
gene	O
sequencing	O
was	O
performed	O
on	O
genomic	O
DNA	O
isolated	O
from	O
a	O
total	O
of	O
75	O
b	B-Disease
-	I-Disease
thalassemia	I-Disease
patients	O
","	O
including	O
31	O
b	O
(	O
0	O
)	O
39	O
/	O
b	O
(	O
0	O
)	O
39	O
","	O
33	O
b	O
(	O
0	O
)	O
39	O
/	O
b	O
(+)	O
IVSI	O
-	O
110	O
","	O
9	O
b	O
(+)	O
IVSI	O
-	O
110	O
/	O
b	O
(+)	O
IVSI	O
-	O
110	O
","	O
one	O
b	O
(	O
0	O
)	O
IVSI	O
-	O
1	O
/	O
b	O
(+)	O
IVSI	O
-	O
6	O
and	O
one	O
b	O
(	O
0	O
)	O
39	O
/	O
b	O
(+)	O
IVSI	O
-	O
6	O
.	O
	
RESULTS	O
:	O
The	O
results	O
show	O
that	O
the	O
rs368698783	O
polymorphism	O
is	O
present	O
in	O
b	B-Disease
-	I-Disease
thalassemia	I-Disease
patients	O
in	O
the	O
5	O
'	O
UTR	O
sequence	O
(+	O
25	O
)	O
of	O
the	O
Ag	O
-	O
globin	O
gene	O
","	O
known	O
to	O
affect	O
the	O
LYAR	O
(	O
human	O
homologue	O
of	O
mouse	O
Ly	O
-	O
1	O
antibody	O
reactive	O
clone	O
)	O
binding	O
site	O
5	O
'-	O
GGTTAT	O
-	O
3	O
'.	O
	
This	O
Ag	O
(+	O
25	O
G	O
->	O
A	O
)	O
polymorphism	O
is	O
associated	O
with	O
the	O
Gg	O
-	O
globin	O
-	O
XmnI	O
polymorphism	O
and	O
both	O
are	O
linked	O
with	O
the	O
b	O
(	O
0	O
)	O
39	O
-	O
globin	O
gene	O
","	O
but	O
not	O
with	O
the	O
b	O
(+)	O
IVSI	O
-	O
110	O
-	O
globin	O
gene	O
.	O
	
In	O
agreement	O
with	O
the	O
expectation	O
that	O
this	O
mutation	O
alters	O
the	O
LYAR	O
binding	O
activity	O
","	O
we	O
found	O
that	O
the	O
Ag	O
(+	O
25	O
G	O
->	O
A	O
)	O
and	O
Gg	O
-	O
globin	O
-	O
XmnI	O
polymorphisms	O
are	O
associated	O
with	O
high	O
HbF	O
in	O
erythroid	O
precursor	O
cells	O
isolated	O
from	O
b	B-Disease
(	I-Disease
0	I-Disease
)	I-Disease
39	I-Disease
/	I-Disease
b	I-Disease
(	I-Disease
0	I-Disease
)	I-Disease
39	I-Disease
thalassemia	I-Disease
patients	O
.	O
	
CONCLUSIONS	O
:	O
As	O
a	O
potential	O
explanation	O
of	O
our	O
findings	O
","	O
we	O
hypothesize	O
that	O
in	O
b	B-Disease
-	I-Disease
thalassemia	I-Disease
the	O
Gg	O
-	O
globin	O
-	O
XmnI	O
/	O
Ag	O
-	O
globin	O
-(	O
G	O
->	O
A	O
)	O
genotype	O
is	O
frequently	O
under	O
genetic	O
linkage	O
with	O
b	B-Disease
(	I-Disease
0	I-Disease
)-	I-Disease
thalassemia	I-Disease
mutations	O
","	O
but	O
not	O
with	O
the	O
b	B-Disease
(+)-	I-Disease
thalassemia	I-Disease
mutation	O
here	O
studied	O
(	O
i	O
.	O
e	O
.	O
	
b	O
(+)	O
IVSI	O
-	O
110	O
)	O
and	O
that	O
this	O
genetic	O
combination	O
has	O
been	O
selected	O
within	O
the	O
population	O
of	O
b	B-Disease
(	I-Disease
0	I-Disease
)-	I-Disease
thalassemia	I-Disease
patients	O
","	O
due	O
to	O
functional	O
association	O
with	O
high	O
HbF	O
.	O
	
Here	O
we	O
describe	O
the	O
characterization	O
of	O
the	O
rs368698783	O
(+	O
25	O
G	O
->	O
A	O
)	O
polymorphism	O
of	O
the	O
Ag	O
-	O
globin	O
gene	O
associated	O
in	O
b	B-Disease
(	I-Disease
0	I-Disease
)	I-Disease
39	I-Disease
thalassemia	I-Disease
patients	O
with	O
high	O
HbF	O
in	O
erythroid	O
precursor	O
cells	O
.	O
	
	
POLG	O
mutations	O
associated	O
with	O
Alpers	B-Disease
'	I-Disease
syndrome	I-Disease
and	O
mitochondrial	B-Disease
DNA	I-Disease
depletion	I-Disease
.	O
	
Alpers	B-Disease
'	I-Disease
syndrome	I-Disease
is	O
a	O
fatal	O
neurogenetic	B-Disease
disorder	I-Disease
first	O
described	O
more	O
than	O
70	O
years	O
ago	O
.	O
	
It	O
is	O
an	O
autosomal	O
recessive	O
","	O
developmental	O
mitochondrial	B-Disease
DNA	I-Disease
depletion	I-Disease
disorder	O
characterized	O
by	O
deficiency	O
in	O
mitochondrial	O
DNA	O
polymerase	O
gamma	O
(	O
POLG	O
)	O
catalytic	O
activity	O
","	O
refractory	O
seizures	B-Disease
","	O
neurodegeneration	B-Disease
","	O
and	O
liver	B-Disease
disease	I-Disease
.	O
	
In	O
two	O
unrelated	O
pedigrees	O
of	O
Alpers	B-Disease
'	I-Disease
syndrome	I-Disease
","	O
each	O
affected	O
child	O
was	O
found	O
to	O
carry	O
a	O
homozygous	O
mutation	O
in	O
exon	O
17	O
of	O
the	O
POLG	O
locus	O
that	O
led	O
to	O
a	O
Glu873Stop	O
mutation	O
just	O
upstream	O
of	O
the	O
polymerase	O
domain	O
of	O
the	O
protein	O
.	O
	
In	O
addition	O
","	O
each	O
affected	O
child	O
was	O
heterozygous	O
for	O
the	O
G1681A	O
mutation	O
in	O
exon	O
7	O
that	O
led	O
to	O
an	O
Ala467Thr	O
substitution	O
in	O
POLG	O
","	O
within	O
the	O
linker	O
region	O
of	O
the	O
protein	O
.	O
	
	
People	O
aged	O
over	O
75	O
in	O
atrial	B-Disease
fibrillation	I-Disease
on	O
warfarin	B-Chemical
:	O
the	O
rate	O
of	O
major	O
hemorrhage	B-Disease
and	O
stroke	B-Disease
in	O
more	O
than	O
500	O
patient	O
-	O
years	O
of	O
follow	O
-	O
up	O
.	O
	
OBJECTIVES	O
:	O
To	O
determine	O
the	O
incidence	O
of	O
major	O
hemorrhage	B-Disease
and	O
stroke	B-Disease
in	O
people	O
aged	O
76	O
and	O
older	O
with	O
atrial	B-Disease
fibrillation	I-Disease
on	O
adjusted	O
-	O
dose	O
warfarin	B-Chemical
who	O
had	O
been	O
recently	O
been	O
admitted	O
to	O
hospital	O
.	O
	
DESIGN	O
:	O
A	O
retrospective	O
observational	O
cohort	O
study	O
.	O
	
SETTING	O
:	O
A	O
major	O
healthcare	O
network	O
involving	O
four	O
tertiary	O
hospitals	O
.	O
	
PARTICIPANTS	O
:	O
Two	O
hundred	O
thirty	O
-	O
five	O
patients	O
aged	O
76	O
and	O
older	O
admitted	O
to	O
a	O
major	O
healthcare	O
network	O
between	O
July	O
1	O
","	O
2001	O
","	O
and	O
June	O
30	O
","	O
2002	O
","	O
with	O
atrial	B-Disease
fibrillation	I-Disease
on	O
warfarin	B-Chemical
were	O
enrolled	O
.	O
	
MEASUREMENTS	O
:	O
Information	O
regarding	O
major	O
bleeding	B-Disease
episodes	O
","	O
strokes	B-Disease
","	O
and	O
warfarin	B-Chemical
use	O
was	O
obtained	O
from	O
patients	O
","	O
relatives	O
","	O
primary	O
physicians	O
","	O
and	O
medical	O
records	O
.	O
	
RESULTS	O
:	O
Two	O
hundred	O
twenty	O
-	O
eight	O
patients	O
(	O
42	O
%	O
men	O
)	O
with	O
a	O
mean	O
age	O
of	O
81	O
.	O
1	O
(	O
range	O
76	O
-	O
94	O
)	O
were	O
included	O
in	O
the	O
analysis	O
.	O
	
Total	O
follow	O
-	O
up	O
on	O
warfarin	B-Chemical
was	O
530	O
years	O
(	O
mean	O
28	O
months	O
).	O
	
There	O
were	O
53	O
major	O
hemorrhages	B-Disease
","	O
for	O
an	O
annual	O
rate	O
of	O
10	O
.	O
0	O
%","	O
including	O
24	O
(	O
45	O
.	O
3	O
%)	O
life	O
-	O
threatening	O
and	O
five	O
(	O
9	O
.	O
4	O
%)	O
fatal	O
bleeds	B-Disease
.	O
	
The	O
annual	O
stroke	B-Disease
rate	O
after	O
initiation	O
of	O
warfarin	B-Chemical
was	O
2	O
.	O
6	O
%.	O
	
CONCLUSION	O
:	O
The	O
rate	O
of	O
major	O
hemorrhage	B-Disease
was	O
high	O
in	O
this	O
old	O
","	O
frail	O
group	O
","	O
but	O
excluding	O
fatalities	O
","	O
resulted	O
in	O
no	O
long	O
-	O
term	O
sequelae	O
","	O
and	O
the	O
stroke	B-Disease
rate	O
on	O
warfarin	B-Chemical
was	O
low	O
","	O
demonstrating	O
how	O
effective	O
warfarin	B-Chemical
treatment	O
is	O
.	O
	
	
Disruption	O
of	O
a	O
synaptotagmin	O
(	O
SYT14	O
)	O
associated	O
with	O
neurodevelopmental	B-Disease
abnormalities	I-Disease
.	O
	
We	O
report	O
cytogenetic	O
and	O
molecular	O
studies	O
of	O
a	O
de	O
novo	O
","	O
apparently	O
balanced	O
t	O
(	O
1	O
";"	O
3	O
)(	O
q32	O
.	O
1	O
";"	O
q25	O
.	O
1	O
)	O
identified	O
in	O
a	O
12	O
-	O
year	O
-	O
old	O
female	O
(	O
designated	O
DGAP128	O
)	O
with	O
cerebral	B-Disease
atrophy	I-Disease
","	O
macrocephaly	B-Disease
seizures	I-Disease
","	O
and	O
developmental	B-Disease
delay	I-Disease
.	O
	
A	O
combination	O
of	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
and	O
Southern	O
blot	O
analysis	O
demonstrated	O
disruption	O
of	O
a	O
synaptotagmin	O
gene	O
(	O
SYT14	O
)	O
at	O
the	O
1q32	O
breakpoint	O
.	O
	
Expression	O
of	O
SYT14	O
in	O
human	O
brain	O
was	O
confirmed	O
using	O
Northern	O
analysis	O
.	O
	
Because	O
members	O
of	O
the	O
synaptotagmin	O
family	O
of	O
proteins	O
function	O
as	O
sensors	O
that	O
link	O
changes	O
in	O
calcium	B-Chemical
levels	O
with	O
a	O
variety	O
of	O
biological	O
processes	O
","	O
including	O
neurotransmission	O
and	O
hormone	O
-	O
responsiveness	O
","	O
SYT14	O
is	O
an	O
intriguing	O
candidate	O
gene	O
for	O
the	O
abnormal	O
development	O
in	O
this	O
child	O
.	O
	
This	O
is	O
the	O
first	O
known	O
constitutional	O
rearrangement	O
of	O
SYT14	O
","	O
and	O
further	O
systematic	O
genetic	O
analysis	O
and	O
clinical	O
studies	O
of	O
DGAP128	O
may	O
offer	O
unique	O
insights	O
into	O
the	O
role	O
of	O
SYT14	O
in	O
neurodevelopment	O
.	O
	
	
Isoproterenol	B-Chemical
induces	O
primary	O
loss	O
of	O
dystrophin	O
in	O
rat	O
hearts	O
:	O
correlation	O
with	O
myocardial	B-Disease
injury	I-Disease
.	O
	
The	O
mechanism	O
of	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
damage	I-Disease
is	O
unknown	O
","	O
but	O
a	O
mismatch	O
of	O
oxygen	B-Chemical
supply	O
vs	O
.	O
	
demand	O
following	O
coronary	O
hypotension	B-Disease
and	O
myocardial	B-Disease
hyperactivity	I-Disease
is	O
the	O
best	O
explanation	O
for	O
the	O
complex	O
morphological	O
alterations	O
observed	O
.	O
	
Severe	O
alterations	O
in	O
the	O
structural	O
integrity	O
of	O
the	O
sarcolemma	O
of	O
cardiomyocytes	O
have	O
been	O
demonstrated	O
to	O
be	O
caused	O
by	O
isoproterenol	B-Chemical
.	O
	
Taking	O
into	O
account	O
that	O
the	O
sarcolemmal	O
integrity	O
is	O
stabilized	O
by	O
the	O
dystrophin	O
-	O
glycoprotein	O
complex	O
(	O
DGC	O
)	O
that	O
connects	O
actin	O
and	O
laminin	O
in	O
contractile	O
machinery	O
and	O
extracellular	O
matrix	O
and	O
by	O
integrins	O
","	O
this	O
study	O
tests	O
the	O
hypothesis	O
that	O
isoproterenol	B-Chemical
affects	O
sarcolemmal	O
stability	O
through	O
changes	O
in	O
the	O
DGC	O
and	O
integrins	O
.	O
	
We	O
found	O
different	O
sensitivity	O
of	O
the	O
DGC	O
and	O
integrin	O
to	O
isoproterenol	B-Chemical
subcutaneous	O
administration	O
.	O
	
Immunofluorescent	O
staining	O
revealed	O
that	O
dystrophin	O
is	O
the	O
most	O
sensitive	O
among	O
the	O
structures	O
connecting	O
the	O
actin	O
in	O
the	O
cardiomyocyte	O
cytoskeleton	O
and	O
the	O
extracellular	O
matrix	O
.	O
	
The	O
sarcomeric	O
actin	O
dissolution	O
occurred	O
after	O
the	O
reduction	O
or	O
loss	O
of	O
dystrophin	O
.	O
	
Subsequently	O
","	O
after	O
lysis	O
of	O
myofilaments	O
","	O
gamma	O
-	O
sarcoglycan	O
","	O
beta	O
-	O
dystroglycan	O
","	O
beta1	O
-	O
integrin	O
","	O
and	O
laminin	O
alpha	O
-	O
2	O
expressions	O
were	O
reduced	O
followed	O
by	O
their	O
breakdown	O
","	O
as	O
epiphenomena	O
of	O
the	O
myocytolytic	O
process	O
.	O
	
In	O
conclusion	O
","	O
administration	O
of	O
isoproterenol	B-Chemical
to	O
rats	O
results	O
in	O
primary	O
loss	O
of	O
dystrophin	O
","	O
the	O
most	O
sensitive	O
among	O
the	O
structural	O
proteins	O
that	O
form	O
the	O
DGC	O
that	O
connects	O
the	O
extracellular	O
matrix	O
and	O
the	O
cytoskeleton	O
in	O
cardiomyocyte	O
.	O
	
These	O
changes	O
","	O
related	O
to	O
ischaemic	B-Disease
injury	I-Disease
","	O
explain	O
the	O
severe	O
alterations	O
in	O
the	O
structural	O
integrity	O
of	O
the	O
sarcolemma	O
of	O
cardiomyocytes	O
and	O
hence	O
severe	O
and	O
irreversible	O
injury	O
induced	O
by	O
isoproterenol	B-Chemical
.	O
	
	
Vitamin	B-Chemical
E	I-Chemical
reduces	O
cardiovascular	B-Disease
disease	I-Disease
in	O
individuals	O
with	O
diabetes	B-Disease
mellitus	I-Disease
and	O
the	O
haptoglobin	O
2	O
-	O
2	O
genotype	O
.	O
	
AIMS	O
:	O
Individuals	O
with	O
both	O
diabetes	B-Disease
mellitus	I-Disease
(	O
DM	B-Disease
)	O
and	O
the	O
Haptoglobin	O
(	O
Hp	O
)	O
2	O
-	O
2	O
genotype	O
are	O
at	O
increased	O
risk	O
of	O
cardiovascular	B-Disease
disease	I-Disease
.	O
	
As	O
the	O
antioxidant	O
function	O
of	O
the	O
Hp	O
2	O
-	O
2	O
protein	O
is	O
impaired	O
","	O
we	O
sought	O
to	O
test	O
the	O
pharmacogenomic	O
hypothesis	O
that	O
antioxidant	B-Chemical
vitamin	I-Chemical
E	I-Chemical
supplementation	O
would	O
provide	O
cardiovascular	O
protection	O
to	O
Hp	O
2	O
-	O
2	O
DM	B-Disease
individuals	O
.	O
	
MATERIALS	O
&	O
METHODS	O
:	O
We	O
determined	O
the	O
Hp	O
genotype	O
on	O
DM	B-Disease
participants	O
from	O
two	O
trials	O
(	O
HOPE	O
and	O
ICARE	O
)	O
and	O
assessed	O
the	O
effect	O
of	O
vitamin	B-Chemical
E	I-Chemical
by	O
Hp	O
genotype	O
on	O
their	O
common	O
prespecified	O
outcome	O
","	O
the	O
composite	O
of	O
stroke	B-Disease
","	O
myocardial	B-Disease
infarction	I-Disease
and	O
cardiovascular	B-Disease
death	I-Disease
.	O
	
Data	O
was	O
analyzed	O
with	O
a	O
fixed	O
-	O
effect	O
model	O
.	O
	
These	O
results	O
were	O
input	O
into	O
a	O
simulation	O
model	O
","	O
the	O
Evidence	O
Based	O
Medicine	O
Integrator	O
","	O
in	O
order	O
to	O
estimate	O
their	O
long	O
-	O
term	O
implications	O
in	O
a	O
real	O
-	O
world	O
population	O
from	O
Kaiser	O
Permanente	O
(	O
CA	O
","	O
USA	O
).	O
	
RESULTS	O
:	O
Meta	O
-	O
analysis	O
of	O
the	O
two	O
trials	O
demonstrated	O
a	O
significant	O
overall	O
reduction	O
in	O
the	O
composite	O
end	O
point	O
in	O
Hp	O
2	O
-	O
2	O
DM	B-Disease
individuals	O
with	O
vitamin	B-Chemical
E	I-Chemical
(	O
odds	O
ratio	O
:	O
0	O
.	O
58	O
";"	O
95	O
%	O
CI	O
:	O
0	O
.	O
40	O
-	O
0	O
.	O
86	O
";"	O
p	O
=	O
0	O
.	O
6	O
).	O
	
There	O
was	O
a	O
statistically	O
significant	O
interaction	O
between	O
the	O
Hp	O
genotype	O
and	O
vitamin	B-Chemical
E	I-Chemical
on	O
the	O
composite	O
end	O
point	O
.	O
	
In	O
these	O
trials	O
","	O
Hp	O
typing	O
of	O
69	O
DM	B-Disease
individuals	O
and	O
treating	O
those	O
with	O
the	O
Hp	O
2	O
-	O
2	O
with	O
vitamin	B-Chemical
E	I-Chemical
prevented	O
one	O
myocardial	B-Disease
infarct	I-Disease
","	O
stroke	B-Disease
or	O
cardiovascular	B-Disease
death	I-Disease
.	O
	
Lifelong	O
administration	O
of	O
vitamin	B-Chemical
E	I-Chemical
to	O
Hp	O
2	O
-	O
2	O
DM	B-Disease
individuals	O
in	O
the	O
Kaiser	O
population	O
would	O
increase	O
their	O
life	O
expectancy	O
by	O
3	O
years	O
.	O
	
CONCLUSION	O
:	O
A	O
pharmacogenomic	O
strategy	O
of	O
screening	O
DM	B-Disease
individuals	O
for	O
the	O
Hp	O
genotype	O
and	O
treating	O
those	O
with	O
Hp	O
2	O
-	O
2	O
with	O
vitamin	B-Chemical
E	I-Chemical
appears	O
to	O
be	O
highly	O
clinically	O
effective	O
.	O
	
	
Association	O
study	O
of	O
complement	O
factor	O
H	O
","	O
C2	O
","	O
CFB	O
","	O
and	O
C3	O
and	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
in	O
a	O
Han	O
Chinese	O
population	O
.	O
	
PURPOSE	O
:	O
Genes	O
in	O
the	O
complement	O
pathway	O
","	O
including	O
complement	O
factor	O
H	O
(	O
CFH	O
)","	O
C2	O
/	O
BF	O
","	O
and	O
C3	O
","	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
).	O
	
Genetic	O
variants	O
","	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)","	O
in	O
these	O
genes	O
were	O
geno	O
-	O
typed	O
for	O
a	O
case	O
-	O
control	O
association	O
study	O
in	O
a	O
mainland	O
Han	O
Chinese	O
population	O
.	O
	
METHODS	O
:	O
One	O
hundred	O
and	O
fifty	O
-	O
eight	O
patients	O
with	O
wet	O
AMD	B-Disease
","	O
80	O
patients	O
with	O
soft	O
drusen	B-Disease
","	O
and	O
220	O
matched	O
control	O
subjects	O
were	O
recruited	O
among	O
Han	O
Chinese	O
in	O
mainland	O
China	O
.	O
	
Seven	O
SNPs	O
in	O
CFH	O
and	O
two	O
SNPs	O
in	O
C2	O
","	O
CFB	O
'","	O
and	O
C3	O
were	O
genotyped	O
using	O
the	O
ABI	O
SNaPshot	O
method	O
.	O
	
A	O
deletion	O
of	O
84	O
","	O
682	O
base	O
pairs	O
covering	O
the	O
CFHR1	O
and	O
CFHR3	O
genes	O
was	O
detected	O
by	O
direct	O
polymerase	O
chain	O
reaction	O
and	O
gel	O
electrophoresis	O
.	O
	
RESULTS	O
:	O
Four	O
SNPs	O
","	O
including	O
rs3753394	O
(	O
P	O
=	O
0	O
.	O
276	O
)","	O
rs800292	O
(	O
P	O
=	O
0	O
.	O
266	O
)","	O
rs1061170	O
(	O
P	O
=	O
0	O
.	O
514	O
)","	O
and	O
rs1329428	O
(	O
P	O
=	O
0	O
.	O
89	O
)","	O
in	O
CFH	O
showed	O
a	O
significant	O
association	O
with	O
wet	O
AMD	B-Disease
in	O
the	O
cohort	O
of	O
this	O
study	O
.	O
	
A	O
haplotype	O
containing	O
these	O
four	O
SNPs	O
(	O
CATA	O
)	O
significantly	O
increased	O
protection	O
of	O
wet	O
AMD	B-Disease
with	O
a	O
P	O
value	O
of	O
0	O
.	O
5	O
and	O
an	O
odds	O
ratio	O
of	O
0	O
.	O
29	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
0	O
.	O
15	O
-	O
0	O
.	O
60	O
).	O
	
Unlike	O
in	O
other	O
populations	O
","	O
rs2274700	O
and	O
rs1410996	O
did	O
not	O
show	O
a	O
significant	O
association	O
with	O
AMD	B-Disease
in	O
the	O
Chinese	O
population	O
of	O
this	O
study	O
.	O
	
None	O
of	O
the	O
SNPs	O
in	O
CFH	O
showed	O
a	O
significant	O
association	O
with	O
drusen	B-Disease
","	O
and	O
none	O
of	O
the	O
SNPs	O
in	O
CFH	O
","	O
C2	O
","	O
CFB	O
","	O
and	O
C3	O
showed	O
a	O
significant	O
association	O
with	O
either	O
wet	O
AMD	B-Disease
or	O
drusen	B-Disease
in	O
the	O
cohort	O
of	O
this	O
study	O
.	O
	
The	O
CFHR1	O
and	O
CFHR3	O
deletion	O
was	O
not	O
polymorphic	O
in	O
the	O
Chinese	O
population	O
and	O
was	O
not	O
associated	O
with	O
wet	O
AMD	B-Disease
or	O
drusen	B-Disease
.	O
	
CONCLUSION	O
:	O
This	O
study	O
showed	O
that	O
SNPs	O
rs3753394	O
(	O
P	O
=	O
0	O
.	O
276	O
)","	O
rs800292	O
(	O
P	O
=	O
0	O
.	O
266	O
)","	O
rs1061170	O
(	O
P	O
=	O
0	O
.	O
514	O
)","	O
and	O
rs1329428	O
(	O
P	O
=	O
0	O
.	O
89	O
)","	O
but	O
not	O
rs7535263	O
","	O
rs1410996	O
","	O
or	O
rs2274700	O
","	O
in	O
CFH	O
were	O
significantly	O
associated	O
with	O
wet	O
AMD	B-Disease
in	O
a	O
mainland	O
Han	O
Chinese	O
population	O
.	O
	
This	O
study	O
showed	O
that	O
CFH	O
was	O
more	O
likely	O
to	O
be	O
AMD	B-Disease
susceptibility	O
gene	O
at	O
Chr	O
.	O
1q31	O
based	O
on	O
the	O
finding	O
that	O
the	O
CFHR1	O
and	O
CFHR3	O
deletion	O
was	O
not	O
polymorphic	O
in	O
the	O
cohort	O
of	O
this	O
study	O
","	O
and	O
none	O
of	O
the	O
SNPs	O
that	O
were	O
significantly	O
associated	O
with	O
AMD	B-Disease
in	O
a	O
white	O
population	O
in	O
C2	O
","	O
CFB	O
","	O
and	O
C3	O
genes	O
showed	O
a	O
significant	O
association	O
with	O
AMD	B-Disease
.	O
	
	
Alternative	O
splicing	O
at	O
a	O
NAGNAG	O
acceptor	O
site	O
as	O
a	O
novel	O
phenotype	O
modifier	O
.	O
	
Approximately	O
30	O
%	O
of	O
alleles	O
causing	O
genetic	O
disorders	O
generate	O
premature	O
termination	O
codons	O
(	O
PTCs	O
)","	O
which	O
are	O
usually	O
associated	O
with	O
severe	O
phenotypes	O
.	O
	
However	O
","	O
bypassing	O
the	O
deleterious	O
stop	O
codon	O
can	O
lead	O
to	O
a	O
mild	O
disease	O
outcome	O
.	O
	
Splicing	O
at	O
NAGNAG	O
tandem	O
splice	O
sites	O
has	O
been	O
reported	O
to	O
result	O
in	O
insertion	O
or	O
deletion	O
(	O
indel	O
)	O
of	O
three	O
nucleotides	O
.	O
	
We	O
identified	O
such	O
a	O
mechanism	O
as	O
the	O
origin	O
of	O
the	O
mild	O
to	O
asymptomatic	O
phenotype	O
observed	O
in	O
cystic	B-Disease
fibrosis	I-Disease
patients	O
homozygous	O
for	O
the	O
E831X	O
mutation	O
(	O
2623G	O
>	O
T	O
)	O
in	O
the	O
CFTR	O
gene	O
.	O
	
Analyses	O
performed	O
on	O
nasal	O
epithelial	O
cell	O
mRNA	O
detected	O
three	O
distinct	O
isoforms	O
","	O
a	O
considerably	O
more	O
complex	O
situation	O
than	O
expected	O
for	O
a	O
single	O
nucleotide	O
substitution	O
.	O
	
Structure	O
-	O
function	O
studies	O
and	O
in	O
silico	O
analyses	O
provided	O
the	O
first	O
experimental	O
evidence	O
of	O
an	O
indel	O
of	O
a	O
stop	O
codon	O
by	O
alternative	O
splicing	O
at	O
a	O
NAGNAG	O
acceptor	O
site	O
.	O
	
In	O
addition	O
to	O
contributing	O
to	O
proteome	O
plasticity	O
","	O
alternative	O
splicing	O
at	O
a	O
NAGNAG	O
tandem	O
site	O
can	O
thus	O
remove	O
a	O
disease	O
-	O
causing	O
UAG	O
stop	O
codon	O
.	O
	
This	O
molecular	O
study	O
reveals	O
a	O
naturally	O
occurring	O
mechanism	O
where	O
the	O
effect	O
of	O
either	O
modifier	O
genes	O
or	O
epigenetic	O
factors	O
could	O
be	O
suspected	O
.	O
	
This	O
finding	O
is	O
of	O
importance	O
for	O
genetic	O
counseling	O
as	O
well	O
as	O
for	O
deciding	O
appropriate	O
therapeutic	O
strategies	O
.	O
	
	
In	O
vivo	O
characterization	O
of	O
a	O
dual	O
adenosine	B-Chemical
A2A	I-Chemical
/	I-Chemical
A1	I-Chemical
receptor	I-Chemical
antagonist	I-Chemical
in	O
animal	O
models	O
of	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
	
The	O
in	O
vivo	O
characterization	O
of	O
a	O
dual	O
adenosine	B-Chemical
A	I-Chemical
(	I-Chemical
2A	I-Chemical
)/	I-Chemical
A	I-Chemical
(	I-Chemical
1	I-Chemical
)	I-Chemical
receptor	I-Chemical
antagonist	I-Chemical
in	O
several	O
animal	O
models	O
of	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
is	O
described	O
.	O
	
Discovery	O
and	O
scale	O
-	O
up	O
syntheses	O
of	O
compound	O
1	O
are	O
described	O
in	O
detail	O
","	O
highlighting	O
optimization	O
steps	O
that	O
increased	O
the	O
overall	O
yield	O
of	O
1	O
from	O
10	O
.	O
0	O
%	O
to	O
30	O
.	O
5	O
%.	O
	
Compound	O
1	O
is	O
a	O
potent	O
A	B-Chemical
(	I-Chemical
2A	I-Chemical
)/	I-Chemical
A	I-Chemical
(	I-Chemical
1	I-Chemical
)	I-Chemical
receptor	I-Chemical
antagonist	I-Chemical
in	O
vitro	O
(	O
A	O
(	O
2A	O
)	O
K	O
(	O
i	O
)	O
=	O
4	O
.	O
1	O
nM	O
";"	O
A	O
(	O
1	O
)	O
K	O
(	O
i	O
)	O
=	O
17	O
.	O
0	O
nM	O
)	O
that	O
has	O
excellent	O
activity	O
","	O
after	O
oral	O
administration	O
","	O
across	O
a	O
number	O
of	O
animal	O
models	O
of	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
including	O
mouse	O
and	O
rat	O
models	O
of	O
haloperidol	B-Chemical
-	O
induced	O
catalepsy	B-Disease
","	O
mouse	O
model	O
of	O
reserpine	B-Chemical
-	O
induced	O
akinesia	B-Disease
","	O
rat	O
6	B-Chemical
-	I-Chemical
hydroxydopamine	I-Chemical
(	O
6	B-Chemical
-	I-Chemical
OHDA	I-Chemical
)	O
lesion	O
model	O
of	O
drug	O
-	O
induced	O
rotation	O
","	O
and	O
MPTP	B-Chemical
-	O
treated	O
non	O
-	O
human	O
primate	O
model	O
.	O
	
	
Loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
PTPN11	O
cause	O
metachondromatosis	B-Disease
","	O
but	O
not	O
Ollier	B-Disease
disease	I-Disease
or	O
Maffucci	B-Disease
syndrome	I-Disease
.	O
	
Metachondromatosis	B-Disease
(	O
MC	B-Disease
)	O
is	O
a	O
rare	O
","	O
autosomal	O
dominant	O
","	O
incompletely	O
penetrant	O
combined	O
exostosis	B-Disease
and	O
enchondromatosis	B-Disease
tumor	I-Disease
syndrome	I-Disease
.	O
	
MC	B-Disease
is	O
clinically	O
distinct	O
from	O
other	O
multiple	B-Disease
exostosis	I-Disease
or	O
multiple	B-Disease
enchondromatosis	I-Disease
syndromes	I-Disease
and	O
is	O
unlinked	O
to	O
EXT1	O
and	O
EXT2	O
","	O
the	O
genes	O
responsible	O
for	O
autosomal	O
dominant	O
multiple	B-Disease
osteochondromas	I-Disease
(	O
MO	B-Disease
).	O
	
To	O
identify	O
a	O
gene	O
for	O
MC	B-Disease
","	O
we	O
performed	O
linkage	O
analysis	O
with	O
high	O
-	O
density	O
SNP	O
arrays	O
in	O
a	O
single	O
family	O
","	O
used	O
a	O
targeted	O
array	O
to	O
capture	O
exons	O
and	O
promoter	O
sequences	O
from	O
the	O
linked	O
interval	O
in	O
16	O
participants	O
from	O
11	O
MC	B-Disease
families	O
","	O
and	O
sequenced	O
the	O
captured	O
DNA	O
using	O
high	O
-	O
throughput	O
parallel	O
sequencing	O
technologies	O
.	O
	
DNA	O
capture	O
and	O
parallel	O
sequencing	O
identified	O
heterozygous	O
putative	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
PTPN11	O
in	O
4	O
of	O
the	O
11	O
families	O
.	O
	
Sanger	O
sequence	O
analysis	O
of	O
PTPN11	O
coding	O
regions	O
in	O
a	O
total	O
of	O
17	O
MC	B-Disease
families	O
identified	O
mutations	O
in	O
10	O
of	O
them	O
(	O
5	O
frameshift	O
","	O
2	O
nonsense	O
","	O
and	O
3	O
splice	O
-	O
site	O
mutations	O
).	O
	
Copy	O
number	O
analysis	O
of	O
sequencing	O
reads	O
from	O
a	O
second	O
targeted	O
capture	O
that	O
included	O
the	O
entire	O
PTPN11	O
gene	O
identified	O
an	O
additional	O
family	O
with	O
a	O
15	O
kb	O
deletion	O
spanning	O
exon	O
7	O
of	O
PTPN11	O
.	O
	
Microdissected	O
MC	B-Disease
lesions	O
from	O
two	O
patients	O
with	O
PTPN11	O
mutations	O
demonstrated	O
loss	O
-	O
of	O
-	O
heterozygosity	O
for	O
the	O
wild	O
-	O
type	O
allele	O
.	O
	
We	O
next	O
sequenced	O
PTPN11	O
in	O
DNA	O
samples	O
from	O
54	O
patients	O
with	O
the	O
multiple	O
enchondromatosis	B-Disease
disorders	I-Disease
Ollier	I-Disease
disease	I-Disease
or	O
Maffucci	B-Disease
syndrome	I-Disease
","	O
but	O
found	O
no	O
coding	O
sequence	O
PTPN11	O
mutations	O
.	O
	
We	O
conclude	O
that	O
heterozygous	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
PTPN11	O
are	O
a	O
frequent	O
cause	O
of	O
MC	B-Disease
","	O
that	O
lesions	O
in	O
patients	O
with	O
MC	B-Disease
appear	O
to	O
arise	O
following	O
a	O
second	O
hit	O
","	O
that	O
MC	B-Disease
may	O
be	O
locus	O
heterogeneous	O
since	O
1	O
familial	O
and	O
5	O
sporadically	O
occurring	O
cases	O
lacked	O
obvious	O
disease	O
-	O
causing	O
PTPN11	O
mutations	O
","	O
and	O
that	O
PTPN11	O
mutations	O
are	O
not	O
a	O
common	O
cause	O
of	O
Ollier	B-Disease
disease	I-Disease
or	O
Maffucci	B-Disease
syndrome	I-Disease
.	O
	
	
Risk	O
factors	O
and	O
predictors	O
of	O
levodopa	B-Chemical
-	O
induced	O
dyskinesia	B-Disease
among	O
multiethnic	O
Malaysians	O
with	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
	
Chronic	O
pulsatile	O
levodopa	B-Chemical
therapy	O
for	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
leads	O
to	O
the	O
development	O
of	O
motor	O
fluctuations	O
and	O
dyskinesia	B-Disease
.	O
	
We	O
studied	O
the	O
prevalence	O
and	O
predictors	O
of	O
levodopa	B-Chemical
-	O
induced	O
dyskinesia	B-Disease
among	O
multiethnic	O
Malaysian	O
patients	O
with	O
PD	B-Disease
.	O
	
METHODS	O
:	O
This	O
is	O
a	O
cross	O
-	O
sectional	O
study	O
involving	O
95	O
patients	O
with	O
PD	B-Disease
on	O
uninterrupted	O
levodopa	B-Chemical
therapy	O
for	O
at	O
least	O
6	O
months	O
.	O
	
The	O
instrument	O
used	O
was	O
the	O
UPDRS	O
questionnaires	O
.	O
	
The	O
predictors	O
of	O
dyskinesia	B-Disease
were	O
determined	O
using	O
multivariate	O
logistic	O
regression	O
analysis	O
.	O
	
RESULTS	O
:	O
The	O
mean	O
age	O
was	O
65	O
.	O
6	O
+	O
8	O
.	O
5	O
years	O
.	O
	
The	O
mean	O
onset	O
age	O
was	O
58	O
.	O
5	O
+	O
9	O
.	O
8	O
years	O
.	O
	
The	O
median	O
disease	O
duration	O
was	O
6	O
(	O
7	O
)	O
years	O
.	O
	
Dyskinesia	B-Disease
was	O
present	O
in	O
44	O
%	O
(	O
n	O
=	O
42	O
)	O
with	O
median	O
levodopa	B-Chemical
therapy	O
of	O
3	O
years	O
.	O
	
There	O
were	O
64	O
.	O
3	O
%	O
Chinese	O
","	O
31	O
%	O
Malays	O
","	O
and	O
3	O
.	O
7	O
%	O
Indians	O
and	O
other	O
ethnic	O
groups	O
.	O
	
Eighty	O
-	O
one	O
percent	O
of	O
patients	O
with	O
dyskinesia	B-Disease
had	O
clinical	O
fluctuations	O
.	O
	
Patients	O
with	O
dyskinesia	B-Disease
had	O
lower	O
onset	O
age	O
(	O
p	O
<	O
0	O
.	O
1	O
)","	O
longer	O
duration	O
of	O
levodopa	B-Chemical
therapy	O
(	O
p	O
<	O
0	O
.	O
1	O
)","	O
longer	O
disease	O
duration	O
(	O
p	O
<	O
0	O
.	O
1	O
)","	O
higher	O
total	O
daily	O
levodopa	B-Chemical
dose	O
(	O
p	O
<	O
0	O
.	O
1	O
)","	O
and	O
higher	O
total	O
UPDRS	O
scores	O
(	O
p	O
=	O
0	O
.	O
5	O
)	O
than	O
patients	O
without	O
dyskinesia	B-Disease
.	O
	
The	O
three	O
significant	O
predictors	O
of	O
dyskinesia	B-Disease
were	O
duration	O
of	O
levodopa	B-Chemical
therapy	O
","	O
onset	O
age	O
","	O
and	O
total	O
daily	O
levodopa	B-Chemical
dose	O
.	O
	
CONCLUSIONS	O
:	O
The	O
prevalence	O
of	O
levodopa	B-Chemical
-	O
induced	O
dyskinesia	B-Disease
in	O
our	O
patients	O
was	O
44	O
%.	O
	
The	O
most	O
significant	O
predictors	O
were	O
duration	O
of	O
levodopa	B-Chemical
therapy	O
","	O
total	O
daily	O
levodopa	B-Chemical
dose	O
","	O
and	O
onset	O
age	O
.	O
	
	
VPAC2	O
(	O
vasoactive	O
intestinal	O
peptide	O
receptor	O
type	O
2	O
)	O
receptor	O
deficient	O
mice	O
develop	O
exacerbated	O
experimental	B-Disease
autoimmune	I-Disease
encephalomyelitis	I-Disease
with	O
increased	O
Th1	O
/	O
Th17	O
and	O
reduced	O
Th2	O
/	O
Treg	O
responses	O
.	O
	
Vasoactive	O
intestinal	O
peptide	O
(	O
VIP	O
)	O
and	O
pituitary	O
adenylyl	O
cyclase	O
-	O
activating	O
polypeptide	O
(	O
PACAP	O
)	O
are	O
two	O
structurally	O
-	O
related	O
neuropeptides	O
with	O
widespread	O
expression	O
in	O
the	O
central	O
and	O
peripheral	O
nervous	O
systems	O
.	O
	
Although	O
these	O
peptides	O
have	O
been	O
repeatedly	O
shown	O
to	O
exert	O
potent	O
anti	O
-	O
inflammatory	B-Disease
actions	O
when	O
administered	O
in	O
animal	O
models	O
of	O
inflammatory	B-Disease
disease	I-Disease
","	O
mice	O
deficient	O
in	O
VIP	O
and	O
PACAP	O
were	O
recently	O
shown	O
to	O
exhibit	O
different	O
phenotypes	O
(	O
ameliorated	O
and	O
exacerbated	O
","	O
respectively	O
)	O
in	O
response	O
to	O
experimental	B-Disease
autoimmune	I-Disease
encephalomyelitis	I-Disease
(	O
EAE	B-Disease
).	O
	
Therefore	O
","	O
elucidating	O
what	O
are	O
the	O
specific	O
immunoregulatory	O
roles	O
played	O
by	O
each	O
of	O
their	O
receptor	O
subtypes	O
(	O
VPAC1	O
","	O
VPAC2	O
","	O
and	O
PAC1	O
)	O
is	O
critical	O
.	O
	
In	O
this	O
study	O
","	O
we	O
found	O
that	O
mice	O
with	O
a	O
genetic	O
deletion	O
of	O
VIPR2	O
","	O
encoding	O
the	O
VPAC2	O
receptor	O
","	O
exhibited	O
exacerbated	O
(	O
MOG35	O
-	O
55	O
)-	O
induced	O
EAE	B-Disease
compared	O
to	O
wild	O
type	O
mice	O
","	O
characterized	O
by	O
enhanced	O
clinical	O
and	O
histopathological	O
features	O
","	O
increased	O
proinflammatory	O
cytokines	O
(	O
TNF	O
-	O
alpha	O
","	O
IL	O
-	O
6	O
","	O
IFN	O
-	O
gamma	O
(	O
Th1	O
)","	O
and	O
IL	O
-	O
17	O
(	O
Th17	O
))	O
and	O
reduced	O
anti	O
-	O
inflammatory	O
cytokines	O
(	O
IL	O
-	O
10	O
","	O
TGFbeta	O
","	O
and	O
IL	O
-	O
4	O
(	O
Th2	O
))	O
in	O
the	O
CNS	O
and	O
lymph	O
nodes	O
.	O
	
Moreover	O
","	O
the	O
abundance	O
and	O
proliferative	O
index	O
of	O
lymph	O
node	O
","	O
thymus	O
and	O
CNS	O
CD4	O
(+)	O
CD25	O
(+)	O
FoxP3	O
(+)	O
Tregs	O
were	O
strikingly	O
reduced	O
in	O
VPAC2	O
-	O
deficient	O
mice	O
with	O
EAE	B-Disease
.	O
	
Finally	O
","	O
the	O
in	O
vitro	O
suppressive	O
activity	O
of	O
lymph	O
node	O
and	O
splenic	O
Tregs	O
from	O
VPAC2	O
-	O
deficient	O
mice	O
was	O
impaired	O
.	O
	
Overall	O
","	O
our	O
results	O
demonstrate	O
critical	O
protective	O
roles	O
for	O
PACAP	O
and	O
the	O
VPAC2	O
receptor	O
against	O
autoimmunity	O
","	O
promoting	O
the	O
expansion	O
and	O
maintenance	O
of	O
the	O
Treg	O
pool	O
.	O
	
	
Alcohol	B-Chemical
consumption	O
and	O
prostate	B-Disease
cancer	I-Disease
incidence	O
and	O
progression	O
:	O
A	O
Mendelian	O
randomisation	O
study	O
.	O
	
Prostate	B-Disease
cancer	I-Disease
is	O
the	O
most	O
common	O
cancer	B-Disease
in	O
men	O
in	O
developed	O
countries	O
","	O
and	O
is	O
a	O
target	O
for	O
risk	O
reduction	O
strategies	O
.	O
	
The	O
effects	O
of	O
alcohol	B-Chemical
consumption	O
on	O
prostate	B-Disease
cancer	I-Disease
incidence	O
and	O
survival	O
remain	O
unclear	O
","	O
potentially	O
due	O
to	O
methodological	O
limitations	O
of	O
observational	O
studies	O
.	O
	
In	O
this	O
study	O
","	O
we	O
investigated	O
the	O
associations	O
of	O
genetic	O
variants	O
in	O
alcohol	B-Chemical
-	O
metabolising	O
genes	O
with	O
prostate	B-Disease
cancer	I-Disease
incidence	O
and	O
survival	O
.	O
	
We	O
analysed	O
data	O
from	O
23	O
","	O
868	O
men	O
with	O
prostate	B-Disease
cancer	I-Disease
and	O
23	O
","	O
51	O
controls	O
from	O
25	O
studies	O
within	O
the	O
international	O
PRACTICAL	O
Consortium	O
.	O
	
Study	O
-	O
specific	O
associations	O
of	O
68	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
8	O
alcohol	B-Chemical
-	O
metabolising	O
genes	O
(	O
Alcohol	O
Dehydrogenases	O
(	O
ADHs	O
)	O
and	O
Aldehyde	O
Dehydrogenases	O
(	O
ALDHs	O
))	O
with	O
prostate	B-Disease
cancer	I-Disease
diagnosis	O
and	O
prostate	B-Disease
cancer	I-Disease
-	O
specific	O
mortality	O
","	O
by	O
grade	O
","	O
were	O
assessed	O
using	O
logistic	O
and	O
Cox	O
regression	O
models	O
","	O
respectively	O
.	O
	
The	O
data	O
across	O
the	O
25	O
studies	O
were	O
meta	O
-	O
analysed	O
using	O
fixed	O
-	O
effect	O
and	O
random	O
-	O
effects	O
models	O
.	O
	
We	O
found	O
little	O
evidence	O
that	O
variants	O
in	O
alcohol	B-Chemical
metabolising	O
genes	O
were	O
associated	O
with	O
prostate	B-Disease
cancer	I-Disease
diagnosis	O
.	O
	
Four	O
variants	O
in	O
two	O
genes	O
exceeded	O
the	O
multiple	O
testing	O
threshold	O
for	O
associations	O
with	O
prostate	B-Disease
cancer	I-Disease
mortality	O
in	O
fixed	O
-	O
effect	O
meta	O
-	O
analyses	O
.	O
	
SNPs	O
within	O
ALDH1A2	O
associated	O
with	O
prostate	B-Disease
cancer	I-Disease
mortality	O
were	O
rs1441817	O
(	O
fixed	O
effects	O
hazard	O
ratio	O
","	O
HRfixed	O
=	O
0	O
.	O
78	O
";"	O
95	O
%	O
confidence	O
interval	O
(	O
95	O
%	O
CI	O
):	O
0	O
.	O
66	O
","	O
0	O
.	O
91	O
";"	O
p	O
values	O
=	O
0	O
.	O
2	O
");"	O
rs12910509	O
","	O
HRfixed	O
=	O
0	O
.	O
76	O
";"	O
95	O
%	O
CI	O
:	O
0	O
.	O
64	O
","	O
0	O
.	O
91	O
";"	O
p	O
values	O
=	O
0	O
.	O
3	O
");"	O
and	O
rs8041922	O
(	O
HRfixed	O
=	O
0	O
.	O
76	O
";"	O
95	O
%	O
CI	O
:	O
0	O
.	O
64	O
","	O
0	O
.	O
91	O
";"	O
p	O
values	O
=	O
0	O
.	O
2	O
).	O
	
These	O
SNPs	O
were	O
in	O
linkage	O
disequilibrium	O
with	O
each	O
other	O
.	O
	
In	O
ALDH1B1	O
","	O
rs10973794	O
(	O
HRfixed	O
=	O
1	O
.	O
43	O
";"	O
95	O
%	O
CI	O
:	O
1	O
.	O
14	O
","	O
1	O
.	O
79	O
";"	O
p	O
values	O
=	O
0	O
.	O
2	O
)	O
was	O
associated	O
with	O
prostate	B-Disease
cancer	I-Disease
mortality	O
in	O
men	O
with	O
low	O
-	O
grade	O
prostate	B-Disease
cancer	I-Disease
.	O
	
These	O
results	O
suggest	O
that	O
alcohol	B-Chemical
consumption	O
is	O
unlikely	O
to	O
affect	O
prostate	B-Disease
cancer	I-Disease
incidence	O
","	O
but	O
it	O
may	O
influence	O
disease	O
progression	O
.	O
	
	
Acute	O
low	B-Disease
back	I-Disease
pain	I-Disease
during	O
intravenous	O
administration	O
of	O
amiodarone	B-Chemical
:	O
a	O
report	O
of	O
two	O
cases	O
.	O
	
Amiodarone	B-Chemical
represents	O
an	O
effective	O
antiarrhythmic	B-Chemical
drug	I-Chemical
for	O
cardioversion	O
of	O
recent	O
-	O
onset	O
atrial	B-Disease
fibrillation	I-Disease
(	O
AF	B-Disease
)	O
and	O
maintenance	O
of	O
sinus	O
rhythm	O
.	O
	
We	O
briefly	O
describe	O
two	O
patients	O
suffering	O
from	O
recent	O
-	O
onset	O
atrial	B-Disease
fibrillation	I-Disease
","	O
who	O
experienced	O
an	O
acute	O
devastating	O
low	B-Disease
back	I-Disease
pain	I-Disease
a	O
few	O
minutes	O
after	O
initiation	O
of	O
intravenous	O
amiodarone	B-Chemical
loading	O
.	O
	
Notably	O
","	O
this	O
side	O
effect	O
has	O
not	O
been	O
ever	O
reported	O
in	O
the	O
medical	O
literature	O
.	O
	
Clinicians	O
should	O
be	O
aware	O
of	O
this	O
reaction	O
since	O
prompt	O
termination	O
of	O
parenteral	O
administration	O
leads	O
to	O
complete	O
resolution	O
.	O
	
	
Common	O
dihydrofolate	O
reductase	O
19	O
-	O
base	O
pair	O
deletion	O
allele	O
:	O
a	O
novel	O
risk	O
factor	O
for	O
preterm	B-Disease
delivery	I-Disease
.	O
	
BACKGROUND	O
:	O
Folate	B-Chemical
is	O
critical	O
for	O
cell	O
division	O
","	O
a	O
major	O
feature	O
of	O
in	O
utero	O
development	O
.	O
	
Dihydrofolate	O
reductase	O
(	O
DHFR	O
)	O
is	O
required	O
to	O
convert	O
the	O
folic	B-Chemical
acid	I-Chemical
used	O
in	O
supplements	O
and	O
for	O
food	O
fortification	O
and	O
the	O
dihydrofolate	B-Chemical
produced	O
by	O
thymidylate	O
synthase	O
during	O
DNA	O
synthesis	O
to	O
the	O
reduced	O
folate	B-Chemical
forms	O
used	O
by	O
the	O
cell	O
.	O
	
OBJECTIVE	O
:	O
We	O
aimed	O
to	O
determine	O
whether	O
a	O
common	O
","	O
recently	O
discovered	O
deletion	O
polymorphism	O
in	O
the	O
DHFR	O
gene	O
is	O
a	O
risk	O
factor	O
for	O
preterm	B-Disease
delivery	I-Disease
or	O
low	O
birth	O
weight	O
.	O
	
DESIGN	O
:	O
We	O
studied	O
324	O
pregnant	O
women	O
from	O
Camden	O
","	O
NJ	O
.	O
	
Folate	B-Chemical
intake	O
was	O
computed	O
from	O
folate	B-Chemical
supplement	O
intake	O
plus	O
the	O
mean	O
of	O
two	O
24	O
-	O
h	O
recalls	O
completed	O
during	O
the	O
course	O
of	O
pregnancy	O
.	O
	
Genomic	O
DNA	O
was	O
extracted	O
from	O
the	O
women	O
'	O
s	O
leukocytes	O
and	O
genotyped	O
.	O
	
RESULTS	O
:	O
Women	O
with	O
a	O
deletion	O
allele	O
had	O
a	O
significantly	O
greater	O
risk	O
of	O
preterm	B-Disease
delivery	I-Disease
[	O
adjusted	O
odds	O
ratio	O
(	O
AOR	O
):	O
3	O
.	O
0	O
";"	O
95	O
%	O
CI	O
:	O
1	O
.	O
0	O
","	O
8	O
.	O
8	O
";"	O
P	O
<	O
0	O
.	O
5	O
]	O
than	O
did	O
those	O
without	O
a	O
deletion	O
allele	O
.	O
	
Women	O
with	O
both	O
a	O
DHFR	O
deletion	O
allele	O
and	O
low	O
folate	B-Chemical
intake	O
(<	O
400	O
microg	O
/	O
d	O
from	O
diet	O
plus	O
supplements	O
)	O
had	O
a	O
significantly	O
greater	O
risk	O
of	O
preterm	B-Disease
delivery	I-Disease
(	O
AOR	O
:	O
5	O
.	O
5	O
";"	O
95	O
%	O
CI	O
:	O
1	O
.	O
5	O
","	O
20	O
.	O
4	O
";"	O
P	O
=	O
0	O
.	O
1	O
)	O
and	O
a	O
significantly	O
greater	O
risk	O
of	O
having	O
an	O
infant	O
with	O
a	O
low	O
birth	O
weight	O
(	O
AOR	O
:	O
8	O
.	O
3	O
";"	O
95	O
%	O
CI	O
:	O
1	O
.	O
8	O
","	O
38	O
.	O
6	O
";"	O
P	O
=	O
0	O
.	O
1	O
)	O
than	O
did	O
women	O
without	O
a	O
deletion	O
allele	O
and	O
with	O
a	O
folate	B-Chemical
intake	O
>/=	O
400	O
microg	O
/	O
d	O
.	O
	
CONCLUSIONS	O
:	O
The	O
DHFR	O
19	O
-	O
base	O
pair	O
deletion	O
allele	O
may	O
be	O
a	O
risk	O
factor	O
for	O
preterm	B-Disease
delivery	I-Disease
.	O
	
In	O
the	O
presence	O
of	O
low	O
dietary	O
folate	B-Chemical
","	O
the	O
allele	O
may	O
also	O
be	O
a	O
risk	O
factor	O
for	O
low	O
birth	O
weight	O
.	O
	
This	O
may	O
be	O
a	O
gene	O
-	O
environment	O
interaction	O
.	O
	
	
Mild	O
glycine	B-Disease
encephalopathy	I-Disease
(	O
NKH	B-Disease
)	O
in	O
a	O
large	O
kindred	O
due	O
to	O
a	O
silent	O
exonic	O
GLDC	O
splice	O
mutation	O
.	O
	
BACKGROUND	O
:	O
Classic	O
neonatal	O
-	O
onset	O
glycine	B-Disease
encephalopathy	I-Disease
(	O
GE	B-Disease
)	O
is	O
devastating	O
and	O
life	O
threatening	O
.	O
	
Milder	O
","	O
later	O
onset	O
variants	O
have	O
been	O
reported	O
but	O
were	O
usually	O
sporadic	O
and	O
incompletely	O
defined	O
.	O
	
OBJECTIVE	O
:	O
To	O
determine	O
the	O
clinical	O
and	O
biochemical	O
phenotype	O
and	O
molecular	O
basis	O
of	O
mild	O
GE	B-Disease
in	O
nine	O
children	O
from	O
a	O
consanguineous	O
Israeli	O
Bedouin	O
kindred	O
.	O
	
METHODS	O
:	O
Genomic	O
DNA	O
was	O
screened	O
for	O
GLDC	O
","	O
AMT	O
","	O
and	O
GCSH	O
gene	O
mutations	O
.	O
	
GLDC	O
expression	O
in	O
lymphoblasts	O
was	O
studied	O
by	O
Northern	O
blot	O
and	O
reverse	O
transcriptase	O
PCR	O
analysis	O
.	O
	
RESULTS	O
:	O
Clinical	O
features	O
included	O
hypotonia	B-Disease
","	O
abnormal	B-Disease
movements	I-Disease
","	O
convulsions	B-Disease
","	O
and	O
moderate	O
mental	B-Disease
retardation	I-Disease
with	O
relative	O
sparing	O
of	O
gross	O
motor	O
function	O
","	O
activities	O
of	O
daily	O
living	O
skills	O
","	O
and	O
receptive	O
language	O
.	O
	
Aggression	B-Disease
and	O
irritability	B-Disease
were	O
prominent	O
.	O
	
CSF	O
-	O
to	O
-	O
plasma	O
glycine	O
ratio	O
was	O
mildly	O
to	O
moderately	O
elevated	O
.	O
	
All	O
nine	O
patients	O
were	O
homozygous	O
and	O
their	O
parents	O
heterozygous	O
for	O
a	O
novel	O
","	O
translationally	O
silent	O
GLDC	O
exon	O
22	O
transversion	O
c	O
.	O
2607C	O
>	O
A	O
.	O
	
Lymphoblast	O
GLDC	O
mRNA	O
levels	O
were	O
considerably	O
reduced	O
.	O
	
Three	O
aberrantly	O
spliced	O
cDNA	O
species	O
were	O
identified	O
:	O
exon	O
22	O
and	O
exon	O
22	O
to	O
23	O
skipping	O
","	O
and	O
insertion	O
of	O
an	O
87	O
-	O
base	O
pair	O
cryptic	O
exon	O
.	O
	
Homozygosity	O
for	O
c	O
.	O
2607C	O
>	O
A	O
was	O
also	O
identified	O
in	O
an	O
unrelated	O
but	O
haplotypically	O
identical	O
patient	O
with	O
an	O
unusually	O
favorable	O
outcome	O
despite	O
severe	O
neonatal	O
-	O
onset	O
GE	B-Disease
.	O
	
Mutation	O
analysis	O
enabled	O
prenatal	O
diagnosis	O
of	O
three	O
unaffected	O
and	O
one	O
affected	O
pregnancies	O
.	O
	
CONCLUSIONS	O
:	O
The	O
mutation	O
in	O
this	O
kindred	O
led	O
to	O
missplicing	O
and	O
reduced	O
GLDC	O
(	O
glycine	O
decarboxylase	O
)	O
expression	O
.	O
	
The	O
4	O
to	O
6	O
%	O
of	O
normally	O
spliced	O
GLDC	O
mRNA	O
in	O
the	O
patients	O
may	O
account	O
for	O
their	O
relatively	O
favorable	O
clinical	O
outcome	O
compared	O
with	O
patients	O
with	O
classic	O
glycine	B-Disease
encephalopathy	I-Disease
.	O
	
	
A	O
family	O
with	O
two	O
consecutive	O
nonsense	O
mutations	O
in	O
BMPR1A	O
causing	O
juvenile	B-Disease
polyposis	I-Disease
.	O
	
We	O
describe	O
a	O
novel	O
germline	O
mutation	O
of	O
BMPR1A	O
in	O
a	O
family	O
with	O
juvenile	B-Disease
polyposis	I-Disease
and	O
colon	B-Disease
cancer	I-Disease
.	O
	
This	O
mutation	O
consists	O
of	O
two	O
consecutive	O
substitutions	O
(	O
735	O
-	O
6	O
TG	O
>	O
AT	O
)	O
that	O
cause	O
two	O
nonsense	O
mutations	O
(	O
Y245X	O
","	O
G246X	O
)","	O
inherited	O
in	O
an	O
autosomal	O
dominant	O
fashion	O
","	O
on	O
one	O
parental	O
chromosome	O
.	O
	
This	O
mutation	O
caused	O
protein	O
truncation	O
","	O
and	O
represents	O
a	O
novel	O
case	O
of	O
consecutive	O
nonsense	O
mutations	O
in	O
human	O
disease	O
.	O
	
	
Anticipation	O
in	O
familial	O
lattice	B-Disease
corneal	I-Disease
dystrophy	I-Disease
type	I-Disease
I	I-Disease
with	O
R124C	O
mutation	O
in	O
the	O
TGFBI	O
(	O
BIGH3	O
)	O
gene	O
.	O
	
PURPOSE	O
:	O
To	O
report	O
the	O
clinical	O
","	O
ophthalmic	O
","	O
and	O
genetic	O
characteristics	O
for	O
lattice	B-Disease
corneal	I-Disease
dystrophy	I-Disease
type	I-Disease
I	I-Disease
(	O
LCDI	B-Disease
)	O
in	O
a	O
Chilean	O
family	O
.	O
	
METHODS	O
:	O
Six	O
affected	O
family	O
members	O
were	O
examined	O
clinically	O
including	O
visual	O
acuity	O
","	O
color	O
cornea	O
photography	O
","	O
applanation	O
tonography	O
","	O
and	O
fundoscopy	O
.	O
	
Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
leukocytes	O
from	O
six	O
affected	O
and	O
three	O
unaffected	O
members	O
of	O
a	O
family	O
with	O
lattice	B-Disease
corneal	I-Disease
dystrophy	I-Disease
type	I-Disease
I	I-Disease
.	O
Exon	O
4	O
of	O
the	O
transforming	O
growth	O
factor	O
-	O
induced	O
gene	O
(	O
TGFBI	O
)	O
was	O
screened	O
for	O
the	O
most	O
frequent	O
mutation	O
","	O
R124C	O
","	O
in	O
the	O
proband	O
by	O
sequencing	O
.	O
	
We	O
also	O
designed	O
a	O
rapid	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
PCR	O
-	O
RFLP	O
)	O
method	O
to	O
analyze	O
the	O
same	O
mutation	O
","	O
amplifying	O
exon	O
4	O
and	O
digesting	O
with	O
PstI	O
restriction	O
enzyme	O
.	O
	
Using	O
this	O
strategy	O
","	O
we	O
analyzed	O
the	O
mutation	O
in	O
six	O
affected	O
and	O
three	O
healthy	O
family	O
members	O
.	O
	
RESULTS	O
:	O
Three	O
generations	O
of	O
family	O
members	O
were	O
positively	O
diagnosed	O
with	O
lattice	B-Disease
corneal	I-Disease
dystrophy	I-Disease
.	O
	
Six	O
participants	O
demonstrated	O
LCD1	B-Disease
in	O
both	O
eyes	O
","	O
most	O
of	O
whom	O
were	O
symmetric	O
.	O
	
Age	O
at	O
onset	O
of	O
symptoms	O
was	O
variable	O
(	O
3	O
-	O
42	O
years	O
old	O
).	O
	
Moreover	O
","	O
in	O
this	O
family	O
","	O
the	O
age	O
of	O
onset	O
of	O
the	O
disease	O
decreased	O
in	O
succeeding	O
generations	O
","	O
which	O
could	O
be	O
interpreted	O
as	O
anticipation	O
.	O
	
Visual	O
acuity	O
varied	O
from	O
1	O
.	O
0	O
to	O
0	O
.	O
13	O
.	O
	
Two	O
patients	O
","	O
ages	O
69	O
and	O
44	O
years	O
old	O
","	O
demonstrated	O
a	O
degree	O
of	O
severity	O
Bad	O
according	O
to	O
best	O
-	O
corrected	O
vision	O
and	O
corneal	O
commitment	O
.	O
	
The	O
exon	O
4	O
sequence	O
of	O
TGFBI	O
of	O
the	O
proband	O
exhibits	O
the	O
heterozygous	O
single	O
-	O
nucleotide	O
mutation	O
","	O
C417T	O
","	O
leading	O
to	O
amino	O
acid	O
substitution	O
(	O
R124C	O
)	O
in	O
the	O
encoded	O
TGF	O
-	O
induced	O
protein	O
.	O
	
Using	O
PCR	O
-	O
RFLP	O
","	O
we	O
confirmed	O
the	O
heterozygous	O
mutation	O
in	O
six	O
affected	O
family	O
members	O
and	O
excluded	O
it	O
in	O
three	O
healthy	O
members	O
.	O
	
CONCLUSIONS	O
:	O
The	O
R124C	O
mutation	O
in	O
TGFBI	O
cosegregated	O
with	O
LCD	B-Disease
type	I-Disease
I	I-Disease
in	O
the	O
investigated	O
family	O
.	O
	
This	O
is	O
the	O
first	O
report	O
of	O
a	O
molecular	O
analysis	O
of	O
LCD	B-Disease
type	I-Disease
I	I-Disease
in	O
Chilean	O
patients	O
.	O
	
The	O
early	O
onset	O
affected	O
persons	O
in	O
the	O
fourth	O
generation	O
raises	O
the	O
possibility	O
of	O
anticipation	O
.	O
	
	
Novel	O
suppressors	O
of	O
alpha	O
-	O
synuclein	O
toxicity	B-Disease
identified	O
using	O
yeast	O
.	O
	
The	O
mechanism	O
by	O
which	O
the	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
-	O
related	O
protein	O
alpha	O
-	O
synuclein	O
(	O
alpha	O
-	O
syn	O
)	O
causes	O
neurodegeneration	B-Disease
has	O
not	O
been	O
elucidated	O
.	O
	
To	O
determine	O
the	O
genes	O
that	O
protect	O
cells	O
from	O
alpha	O
-	O
syn	O
","	O
we	O
used	O
a	O
genetic	O
screen	O
to	O
identify	O
suppressors	O
of	O
the	O
super	O
sensitivity	O
of	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
expressing	O
alpha	O
-	O
syn	O
to	O
killing	O
by	O
hydrogen	B-Chemical
peroxide	I-Chemical
.	O
	
Forty	O
genes	O
in	O
ubiquitin	O
-	O
dependent	O
protein	O
catabolism	O
","	O
protein	O
biosynthesis	O
","	O
vesicle	O
trafficking	O
and	O
the	O
response	O
to	O
stress	O
were	O
identified	O
.	O
	
Five	O
of	O
the	O
forty	O
genes	O
--	O
ENT3	O
","	O
IDP3	O
","	O
JEM1	O
","	O
ARG2	O
and	O
HSP82	O
--	O
ranked	O
highest	O
in	O
their	O
ability	O
to	O
block	O
alpha	O
-	O
syn	O
-	O
induced	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
accumulation	O
","	O
and	O
these	O
five	O
genes	O
were	O
characterized	O
in	O
more	O
detail	O
.	O
	
The	O
deletion	O
of	O
any	O
of	O
these	O
five	O
genes	O
enhanced	O
the	O
toxicity	B-Disease
of	O
alpha	O
-	O
syn	O
as	O
judged	O
by	O
growth	O
defects	O
compared	O
with	O
wild	O
-	O
type	O
cells	O
expressing	O
alpha	O
-	O
syn	O
","	O
which	O
indicates	O
that	O
these	O
genes	O
protect	O
cells	O
from	O
alpha	O
-	O
syn	O
.	O
	
Strikingly	O
","	O
four	O
of	O
the	O
five	O
genes	O
are	O
specific	O
for	O
alpha	O
-	O
syn	O
in	O
that	O
they	O
fail	O
to	O
protect	O
cells	O
from	O
the	O
toxicity	B-Disease
of	O
the	O
two	O
inherited	O
mutants	O
A30P	O
or	O
A53T	O
.	O
	
This	O
finding	O
suggests	O
that	O
alpha	O
-	O
syn	O
causes	O
toxicity	B-Disease
to	O
cells	O
through	O
a	O
different	O
pathway	O
than	O
these	O
two	O
inherited	O
mutants	O
.	O
	
Lastly	O
","	O
overexpression	O
of	O
Ent3p	O
","	O
which	O
is	O
a	O
clathrin	B-Chemical
adapter	O
protein	O
involved	O
in	O
protein	O
transport	O
between	O
the	O
Golgi	O
and	O
the	O
vacuole	O
","	O
causes	O
alpha	O
-	O
syn	O
to	O
redistribute	O
from	O
the	O
plasma	O
membrane	O
into	O
cytoplasmic	O
vesicular	O
structures	O
.	O
	
Our	O
interpretation	O
is	O
that	O
Ent3p	O
mediates	O
the	O
transport	O
of	O
alpha	O
-	O
syn	O
to	O
the	O
vacuole	O
for	O
proteolytic	O
degradation	O
.	O
	
A	O
similar	O
clathrin	B-Chemical
adaptor	O
protein	O
","	O
epsinR	O
","	O
exists	O
in	O
humans	O
.	O
	
	
Study	O
of	O
a	O
Taiwanese	O
family	O
with	O
oculopharyngeal	B-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O
	
BACKGROUND	O
:	O
Oculopharyngeal	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
OPMD	B-Disease
)	O
is	O
a	O
late	O
onset	O
autosomal	B-Disease
dominant	I-Disease
muscle	I-Disease
disorder	I-Disease
.	O
	
OPMD	B-Disease
is	O
caused	O
by	O
a	O
short	O
trinucleotide	O
repeat	O
expansion	O
encoding	O
an	O
expanded	O
polyalanine	B-Chemical
tract	O
in	O
the	O
polyadenylate	O
binding	O
-	O
protein	O
nuclear	O
1	O
(	O
PABPN1	O
)	O
gene	O
.	O
	
We	O
identified	O
and	O
characterized	O
a	O
PABPN1	O
mutation	O
in	O
a	O
Taiwanese	O
family	O
with	O
OPMD	B-Disease
.	O
	
METHODS	O
:	O
The	O
phenotypic	O
and	O
genotypic	O
characteristics	O
of	O
all	O
subjects	O
were	O
evaluated	O
in	O
a	O
Taiwanese	O
OPMD	B-Disease
family	O
.	O
	
Genetic	O
alterations	O
in	O
the	O
PABPN1	O
gene	O
were	O
identified	O
using	O
PCR	O
and	O
DNA	O
sequencing	O
.	O
	
RESULTS	O
:	O
Ten	O
subjects	O
with	O
OPMD	B-Disease
(	O
6	O
symptomatic	O
and	O
4	O
asymptomatic	O
)	O
within	O
the	O
Taiwanese	O
family	O
carried	O
a	O
novel	O
mutation	O
in	O
the	O
PABPN1	O
gene	O
.	O
	
The	O
normal	O
(	O
GCG	O
)	O
6	O
(	O
GCA	O
)	O
3GCG	O
sequence	O
was	O
replaced	O
by	O
(	O
GCG	O
)	O
6	O
(	O
GCA	O
)(	O
GCG	O
)	O
4	O
(	O
GCA	O
)	O
3GCG	O
due	O
to	O
an	O
insertion	O
of	O
(	O
GCG	O
)	O
4GCA	O
into	O
the	O
normal	O
allele	O
in	O
the	O
Taiwanese	O
OPMD	B-Disease
subjects	O
.	O
	
CONCLUSIONS	O
:	O
In	O
contrast	O
to	O
a	O
single	O
GCG	O
expansion	O
in	O
most	O
of	O
OPMD	B-Disease
patients	O
in	O
the	O
literature	O
","	O
an	O
insertion	O
of	O
(	O
GCG	O
)	O
4GCA	O
in	O
the	O
PABPN1	O
gene	O
was	O
found	O
in	O
the	O
Taiwanese	O
OPMD	B-Disease
subjects	O
.	O
	
The	O
identification	O
of	O
this	O
mutation	O
appears	O
to	O
support	O
the	O
molecular	O
mechanism	O
of	O
unequal	O
cross	O
-	O
over	O
of	O
two	O
PABPN1	O
alleles	O
.	O
	
	
TAK1	O
is	O
an	O
essential	O
regulator	O
of	O
BMP	O
signalling	O
in	O
cartilage	O
.	O
	
TGFbeta	O
activated	O
kinase	O
1	O
(	O
TAK1	O
)","	O
a	O
member	O
of	O
the	O
MAPKKK	O
family	O
","	O
controls	O
diverse	O
functions	O
ranging	O
from	O
innate	O
and	O
adaptive	O
immune	O
system	O
activation	O
to	O
vascular	O
development	O
and	O
apoptosis	O
.	O
	
To	O
analyse	O
the	O
in	O
vivo	O
function	O
of	O
TAK1	O
in	O
cartilage	O
","	O
we	O
generated	O
mice	O
with	O
a	O
conditional	O
deletion	O
of	O
Tak1	O
driven	O
by	O
the	O
collagen	O
2	O
promoter	O
.	O
	
Tak1	O
(	O
col2	O
)	O
mice	O
displayed	O
severe	O
chondrodysplasia	B-Disease
with	O
runting	O
","	O
impaired	O
formation	O
of	O
secondary	O
centres	O
of	O
ossification	O
","	O
and	O
joint	B-Disease
abnormalities	I-Disease
including	O
elbow	B-Disease
dislocation	I-Disease
and	O
tarsal	B-Disease
fusion	I-Disease
.	O
	
This	O
phenotype	O
resembled	O
that	O
of	O
bone	O
morphogenetic	O
protein	O
receptor	O
(	O
BMPR	O
)	O
1	O
and	O
Gdf5	O
-	O
deficient	O
mice	O
.	O
	
BMPR	O
signalling	O
was	O
markedly	O
impaired	O
in	O
TAK1	O
-	O
deficient	O
chondrocytes	O
as	O
evidenced	O
by	O
reduced	O
expression	O
of	O
known	O
BMP	O
target	O
genes	O
as	O
well	O
as	O
reduced	O
phosphorylation	O
of	O
Smad1	O
/	O
5	O
/	O
8	O
and	O
p38	O
/	O
Jnk	O
/	O
Erk	O
MAP	O
kinases	O
.	O
	
TAK1	O
mediates	O
Smad1	O
phosphorylation	O
at	O
C	O
-	O
terminal	O
serine	O
residues	O
.	O
	
These	O
findings	O
provide	O
the	O
first	O
in	O
vivo	O
evidence	O
in	O
a	O
mammalian	O
system	O
that	O
TAK1	O
is	O
required	O
for	O
BMP	O
signalling	O
and	O
functions	O
as	O
an	O
upstream	O
activating	O
kinase	O
for	O
Smad1	O
/	O
5	O
/	O
8	O
in	O
addition	O
to	O
its	O
known	O
role	O
in	O
regulating	O
MAP	O
kinase	O
pathways	O
.	O
	
Our	O
experiments	O
reveal	O
an	O
essential	O
role	O
for	O
TAK1	O
in	O
the	O
morphogenesis	O
","	O
growth	O
","	O
and	O
maintenance	O
of	O
cartilage	O
.	O
	
	
Effect	O
of	O
the	O
abrogation	O
of	O
TGF	O
-	O
beta1	O
by	O
antisense	O
oligonucleotides	B-Chemical
on	O
the	O
expression	O
of	O
TGF	O
-	O
beta	O
-	O
isoforms	O
and	O
their	O
receptors	O
I	O
and	O
II	O
in	O
isolated	O
fibroblasts	O
from	O
keloid	B-Disease
scars	I-Disease
.	O
	
Disequilibrium	O
of	O
dermal	O
wound	O
repair	O
can	O
result	O
in	O
continued	O
accumulation	O
of	O
ECM	O
and	O
excessive	O
scar	O
formation	O
.	O
	
In	O
susceptible	O
genetically	O
predisposed	O
individuals	O
","	O
keloid	B-Disease
formation	O
can	O
be	O
observed	O
.	O
	
Keloid	B-Disease
disease	I-Disease
represents	O
a	O
benign	O
dermal	O
fibroproliferative	O
tumor	B-Disease
that	O
is	O
unique	O
to	O
humans	O
.	O
	
TGF	O
-	O
beta	O
is	O
known	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
pathogenesis	O
of	O
this	O
disease	O
which	O
is	O
still	O
not	O
fully	O
understood	O
.	O
	
The	O
isoforms	O
TGF	O
-	O
beta1	O
and	O
TGF	O
-	O
beta2	O
have	O
profibrotic	O
properties	O
","	O
whereas	O
TGF	O
-	O
beta3	O
may	O
have	O
antifibrotic	O
functions	O
.	O
	
TGF	O
-	O
beta	O
exerts	O
its	O
influence	O
by	O
binding	O
to	O
type	O
I	O
and	O
type	O
II	O
TGF	O
-	O
beta	O
receptors	O
","	O
thereby	O
forming	O
a	O
complex	O
and	O
activating	O
specific	O
downstream	O
effector	O
molecules	O
.	O
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
TGF	O
-	O
beta1	O
targeting	O
by	O
antisense	O
oligonucleotides	B-Chemical
on	O
the	O
RNA	O
synthesis	O
and	O
protein	O
expression	O
of	O
TGF	O
-	O
beta	O
isoforms	O
and	O
their	O
receptors	O
in	O
keloid	B-Disease
-	O
derived	O
fibroblasts	O
.	O
	
In	O
tissue	O
samples	O
with	O
normal	O
fibroblasts	O
(	O
NFs	O
)	O
serving	O
as	O
control	O
samples	O
","	O
expression	O
of	O
TGF	O
-	O
beta1	O
and	O
-	O
beta2	O
was	O
decreased	O
when	O
compared	O
to	O
keloid	B-Disease
fibroblasts	O
(	O
KFs	O
)","	O
while	O
expression	O
of	O
TGF	O
-	O
beta3	O
and	O
of	O
TGF	O
-	O
betaRII	O
was	O
significantly	O
higher	O
in	O
NFs	O
.	O
	
In	O
the	O
ELISA	O
assay	O
","	O
abrogation	O
of	O
TGF	O
-	O
beta1	O
led	O
to	O
a	O
significant	O
decrease	O
in	O
TGF	O
-	O
beta1	O
and	O
-	O
beta2	O
(	O
p	O
<	O
0	O
.	O
5	O
).	O
	
Expression	O
of	O
TGF	O
-	O
beta2	O
mRNA	O
was	O
reduced	O
.	O
	
Expression	O
of	O
TGF	O
-	O
beta3	O
mRNA	O
revealed	O
contrary	O
patterns	O
in	O
KFs	O
from	O
different	O
patients	O
while	O
expression	O
of	O
TGF	O
-	O
betaRI	O
was	O
found	O
to	O
be	O
equal	O
during	O
the	O
measurement	O
period	O
.	O
	
TGF	O
-	O
betaRII	O
mRNA	O
expression	O
was	O
increased	O
after	O
48	O
and	O
72	O
h	O
respectively	O
.	O
	
There	O
is	O
growing	O
evidence	O
for	O
a	O
regulatory	O
mechanism	O
between	O
TGF	O
-	O
beta1	O
and	O
its	O
receptors	O
.	O
	
Our	O
findings	O
support	O
this	O
theory	O
by	O
suggesting	O
interrelations	O
between	O
the	O
different	O
TGF	O
-	O
beta	O
isoforms	O
and	O
their	O
receptors	O
.	O
	
Abnormal	O
response	O
of	O
KFs	O
to	O
TGF	O
-	O
betamight	O
reflect	O
a	O
modification	O
in	O
the	O
regulatory	O
pathway	O
that	O
occurs	O
at	O
the	O
receptor	O
level	O
or	O
during	O
intracellular	O
trans	O
-	O
duction	O
.	O
	
Improving	O
the	O
understanding	O
of	O
TGF	O
-	O
beta	O
in	O
keloid	B-Disease
disease	I-Disease
could	O
lead	O
to	O
the	O
development	O
of	O
clinically	O
useful	O
therapeutic	O
modalities	O
for	O
treatment	O
of	O
keloid	B-Disease
disease	I-Disease
or	O
even	O
allow	O
identification	O
of	O
preventive	O
strategies	O
.	O
	
	
Brat	O
promotes	O
stem	O
cell	O
differentiation	O
via	O
control	O
of	O
a	O
bistable	O
switch	O
that	O
restricts	O
BMP	O
signaling	O
.	O
	
Drosophila	O
ovarian	O
germline	O
stem	O
cells	O
(	O
GSCs	O
)	O
are	O
maintained	O
by	O
Dpp	O
signaling	O
and	O
the	O
Pumilio	O
(	O
Pum	O
)	O
and	O
Nanos	O
(	O
Nos	O
)	O
translational	O
repressors	O
.	O
	
Upon	O
division	O
","	O
Dpp	O
signaling	O
is	O
extinguished	O
","	O
and	O
Nos	O
is	O
downregulated	O
in	O
one	O
daughter	O
cell	O
","	O
causing	O
it	O
to	O
switch	O
to	O
a	O
differentiating	O
cystoblast	O
(	O
CB	O
).	O
	
However	O
","	O
downstream	O
effectors	O
of	O
Pum	O
-	O
Nos	O
remain	O
unknown	O
","	O
and	O
how	O
CBs	O
lose	O
their	O
responsiveness	O
to	O
Dpp	O
is	O
unclear	O
.	O
	
Here	O
","	O
we	O
identify	O
Brain	O
Tumor	O
(	O
Brat	O
)	O
as	O
a	O
potent	O
differentiation	O
factor	O
and	O
target	O
of	O
Pum	O
-	O
Nos	O
regulation	O
.	O
	
Brat	O
is	O
excluded	O
from	O
GSCs	O
by	O
Pum	O
-	O
Nos	O
but	O
functions	O
with	O
Pum	O
in	O
CBs	O
to	O
translationally	O
repress	O
distinct	O
targets	O
","	O
including	O
the	O
Mad	O
and	O
dMyc	O
mRNAs	O
.	O
	
Regulation	O
of	O
both	O
targets	O
simultaneously	O
lowers	O
cellular	O
responsiveness	O
to	O
Dpp	O
signaling	O
","	O
forcing	O
the	O
cell	O
to	O
become	O
refractory	O
to	O
the	O
self	O
-	O
renewal	O
signal	O
.	O
	
Mathematical	O
modeling	O
elucidates	O
bistability	O
of	O
cell	O
fate	O
in	O
the	O
Brat	O
-	O
mediated	O
system	O
","	O
revealing	O
how	O
autoregulation	O
of	O
GSC	O
number	O
can	O
arise	O
from	O
Brat	O
coupling	O
extracellular	O
Dpp	O
regulation	O
to	O
intracellular	O
interpretation	O
.	O
	
	
Two	O
novel	O
mutations	O
of	O
the	O
PAX6	O
gene	O
causing	O
different	O
phenotype	O
in	O
a	O
cohort	O
of	O
Chinese	O
patients	O
.	O
	
PURPOSE	O
:	O
Aniridia	B-Disease
(	O
AN	B-Disease
)	O
is	O
a	O
rare	O
congenital	B-Disease
panocular	I-Disease
disorder	I-Disease
caused	O
by	O
the	O
mutations	O
of	O
the	O
paired	O
box	O
homeotic	O
gene	O
6	O
(	O
PAX6	O
)	O
gene	O
.	O
	
The	O
PAX6	O
gene	O
is	O
also	O
involved	O
in	O
other	O
anterior	B-Disease
segment	I-Disease
malformations	I-Disease
including	O
Peters	B-Disease
anomaly	I-Disease
.	O
	
We	O
studied	O
the	O
PAX6	O
gene	O
mutations	O
in	O
a	O
cohort	O
of	O
affected	O
individuals	O
with	O
different	O
clinical	O
phenotype	O
including	O
AN	B-Disease
","	O
coloboma	B-Disease
of	I-Disease
iris	I-Disease
and	I-Disease
choroid	I-Disease
","	O
or	O
anterior	B-Disease
segment	I-Disease
malformations	I-Disease
.	O
	
PATIENTS	O
AND	O
METHODS	O
:	O
Six	O
unrelated	O
families	O
and	O
10	O
sporadic	O
patients	O
were	O
examined	O
clinically	O
.	O
	
After	O
informed	O
consent	O
was	O
obtained	O
","	O
genomic	O
DNA	O
was	O
extracted	O
from	O
the	O
venous	O
blood	O
of	O
all	O
participants	O
.	O
	
Mutation	O
screening	O
of	O
all	O
exons	O
of	O
the	O
PAX6	O
gene	O
was	O
performed	O
by	O
direct	O
sequencing	O
of	O
PCR	O
-	O
amplified	O
DNA	O
fragments	O
.	O
	
Multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
(	O
MLPA	O
)	O
was	O
performed	O
to	O
detect	O
large	O
deletions	O
.	O
	
RESULTS	O
:	O
By	O
clinical	O
examination	O
","	O
the	O
patients	O
and	O
the	O
pedigrees	O
were	O
divided	O
into	O
the	O
following	O
three	O
groups	O
:	O
AN	B-Disease
","	O
coloboma	B-Disease
of	I-Disease
iris	I-Disease
and	I-Disease
choroids	I-Disease
","	O
and	O
the	O
anterior	B-Disease
segment	I-Disease
malformations	I-Disease
including	O
peters	B-Disease
anomaly	I-Disease
.	O
	
Sequencing	O
of	O
the	O
PAX6	O
gene	O
","	O
three	O
intragenic	O
mutations	O
including	O
a	O
novel	O
heterozygous	O
splicing	O
-	O
site	O
mutations	O
c	O
.	O
357	O
-	O
3C	O
>	O
G	O
(	O
p	O
.	O
Ser119fsX	O
)	O
were	O
identified	O
in	O
the	O
patients	O
of	O
the	O
AN	B-Disease
group	O
.	O
	
A	O
novel	O
missense	O
mutation	O
c	O
.	O
643T	O
>	O
C	O
(	O
p	O
.	O
S216P	O
)	O
was	O
detected	O
in	O
the	O
anterior	B-Disease
segment	I-Disease
malformation	I-Disease
group	O
.	O
	
The	O
mutation	O
p	O
.	O
S216P	O
located	O
in	O
the	O
homeodomain	O
region	O
of	O
the	O
PAX6	O
caused	O
the	O
phenotype	O
of	O
Peters	B-Disease
anomaly	I-Disease
in	O
family	O
A6	O
with	O
different	O
expressing	O
.	O
	
Through	O
MLPA	O
analysis	O
","	O
a	O
large	O
deletion	O
including	O
the	O
whole	O
PAX6	O
gene	O
and	O
DKFZ	O
p686k1684	O
gene	O
was	O
detected	O
in	O
one	O
sporadic	O
patient	O
from	O
the	O
AN	B-Disease
group	O
.	O
	
Neither	O
intragenic	O
mutation	O
nor	O
large	O
deletion	O
was	O
identified	O
in	O
the	O
group	O
with	O
coloboma	B-Disease
of	I-Disease
iris	I-Disease
and	I-Disease
choroid	I-Disease
.	O
	
CONCLUSION	O
:	O
Our	O
findings	O
further	O
confirmed	O
that	O
different	O
kind	O
of	O
mutations	O
might	O
cause	O
different	O
ocular	O
phenotype	O
","	O
and	O
clearly	O
clinical	O
phenotype	O
classification	O
might	O
increase	O
the	O
mutation	O
detection	O
rate	O
of	O
the	O
PAX6	O
gene	O
.	O
	
	
Effects	O
of	O
ginsenosides	B-Chemical
on	O
opioid	B-Chemical
-	O
induced	O
hyperalgesia	B-Disease
in	O
mice	O
.	O
	
Opioid	B-Chemical
-	O
induced	O
hyperalgesia	B-Disease
(	O
OIH	B-Disease
)	O
is	O
characterized	O
by	O
nociceptive	O
sensitization	O
caused	O
by	O
the	O
cessation	O
of	O
chronic	O
opioid	B-Chemical
use	O
.	O
	
OIH	B-Disease
can	O
limit	O
the	O
clinical	O
use	O
of	O
opioid	B-Chemical
analgesics	O
and	O
complicate	O
withdrawal	O
from	O
opioid	B-Disease
addiction	I-Disease
.	O
	
In	O
this	O
study	O
","	O
we	O
investigated	O
the	O
effects	O
of	O
Re	B-Chemical
","	I-Chemical
Rg1	I-Chemical
","	I-Chemical
and	I-Chemical
Rb1	I-Chemical
ginsenosides	I-Chemical
","	O
the	O
bioactive	O
components	O
of	O
ginseng	O
","	O
on	O
OIH	B-Disease
.	O
	
OIH	B-Disease
was	O
achieved	O
in	O
mice	O
after	O
subcutaneous	O
administration	O
of	O
morphine	B-Chemical
for	O
7	O
consecutive	O
days	O
three	O
times	O
per	O
day	O
.	O
	
During	O
withdrawal	O
(	O
days	O
8	O
and	O
9	O
)","	O
these	O
mice	O
were	O
administered	O
Re	B-Chemical
","	O
Rg1	B-Chemical
","	O
or	O
Rb1	B-Chemical
intragastrically	O
two	O
times	O
per	O
day	O
.	O
	
On	O
the	O
test	O
day	O
(	O
day	O
10	O
)","	O
mice	O
were	O
subjected	O
to	O
the	O
thermal	O
sensitivity	O
test	O
and	O
the	O
acetic	B-Chemical
acid	I-Chemical
-	O
induced	O
writhing	O
test	O
.	O
	
Re	B-Chemical
(	O
300	O
mg	O
/	O
kg	O
)	O
inhibited	O
OIH	B-Disease
in	O
both	O
the	O
thermal	O
sensitivity	O
test	O
and	O
the	O
acetic	B-Chemical
acid	I-Chemical
-	O
induced	O
writhing	O
test	O
.	O
	
However	O
","	O
the	O
Rg1	B-Chemical
and	I-Chemical
Rb1	I-Chemical
ginsenosides	I-Chemical
failed	O
to	O
prevent	O
OIH	B-Disease
in	O
either	O
test	O
.	O
	
Furthermore	O
","	O
Rg1	B-Chemical
showed	O
a	O
tendency	O
to	O
aggravate	O
OIH	B-Disease
in	O
the	O
acetic	B-Chemical
acid	I-Chemical
-	O
induced	O
writhing	O
test	O
.	O
	
Our	O
data	O
suggested	O
that	O
the	O
ginsenoside	B-Chemical
Re	I-Chemical
","	O
but	O
not	O
Rg1	B-Chemical
or	O
Rb1	B-Chemical
","	O
may	O
contribute	O
toward	O
reversal	O
of	O
OIH	B-Disease
.	O
	
	
Long	O
-	O
Lived	O
CD4	O
+	O
IFN	O
-	O
g	O
+	O
T	O
Cells	O
rather	O
than	O
Short	O
-	O
Lived	O
CD4	O
+	O
IFN	O
-	O
g	O
+	O
IL	O
-	O
10	O
+	O
T	O
Cells	O
Initiate	O
Rapid	O
IL	O
-	O
10	O
Production	O
To	O
Suppress	O
Anamnestic	O
T	O
Cell	O
Responses	O
during	O
Secondary	O
Malaria	B-Disease
Infection	I-Disease
.	O
	
CD4	O
(+)	O
T	O
cells	O
that	O
produce	O
IFN	O
-	O
g	O
are	O
the	O
source	O
of	O
host	O
-	O
protective	O
IL	O
-	O
10	O
during	O
primary	O
infection	B-Disease
with	O
a	O
number	O
of	O
different	O
pathogens	O
","	O
including	O
Plasmodium	O
spp	O
.	O
	
The	O
fate	O
of	O
these	O
CD4	O
(+)	O
IFN	O
-	O
g	O
(+)	O
IL	O
-	O
10	O
(+)	O
T	O
cells	O
following	O
clearance	O
of	O
primary	O
infection	B-Disease
and	O
their	O
subsequent	O
influence	O
on	O
the	O
course	O
of	O
repeated	O
infections	O
is	O
","	O
however	O
","	O
presently	O
unknown	O
.	O
	
In	O
this	O
study	O
","	O
utilizing	O
IFN	O
-	O
g	O
-	O
yellow	O
fluorescent	O
protein	O
(	O
YFP	O
)	O
and	O
IL	O
-	O
10	O
-	O
GFP	O
dual	O
reporter	O
mice	O
","	O
we	O
show	O
that	O
primary	O
malaria	B-Disease
infection	I-Disease
-	O
induced	O
CD4	O
(+)	O
YFP	O
(+)	O
GFP	O
(+)	O
T	O
cells	O
have	O
limited	O
memory	O
potential	O
","	O
do	O
not	O
stably	O
express	O
IL	O
-	O
10	O
","	O
and	O
are	O
disproportionately	O
lost	O
from	O
the	O
Ag	O
-	O
experienced	O
CD4	O
(+)	O
T	O
cell	O
memory	O
population	O
during	O
the	O
maintenance	O
phase	O
postinfection	O
.	O
	
CD4	O
(+)	O
YFP	O
(+)	O
GFP	O
(+)	O
T	O
cells	O
generally	O
exhibited	O
a	O
short	O
-	O
lived	O
effector	O
rather	O
than	O
effector	O
memory	O
T	O
cell	O
phenotype	O
postinfection	O
and	O
expressed	O
high	O
levels	O
of	O
PD	O
-	O
1	O
","	O
Lag	O
-	O
3	O
","	O
and	O
TIGIT	O
","	O
indicative	O
of	O
cellular	O
exhaustion	O
.	O
	
Consistently	O
","	O
the	O
surviving	O
CD4	O
(+)	O
YFP	O
(+)	O
GFP	O
(+)	O
T	O
cell	O
-	O
derived	O
cells	O
were	O
unresponsive	O
and	O
failed	O
to	O
proliferate	O
during	O
the	O
early	O
phase	O
of	O
secondary	O
infection	B-Disease
.	O
	
In	O
contrast	O
","	O
CD4	O
(+)	O
YFP	O
(+)	O
GFP	O
(-)	O
T	O
cell	O
-	O
derived	O
cells	O
expanded	O
rapidly	O
and	O
upregulated	O
IL	O
-	O
10	O
expression	O
during	O
secondary	O
infection	B-Disease
.	O
	
Correspondingly	O
","	O
CD4	O
(+)	O
T	O
cells	O
were	O
the	O
major	O
producers	O
within	O
an	O
accelerated	O
and	O
amplified	O
IL	O
-	O
10	O
response	O
during	O
the	O
early	O
stage	O
of	O
secondary	O
malaria	B-Disease
infection	I-Disease
.	O
	
Notably	O
","	O
IL	O
-	O
10	O
exerted	O
quantitatively	O
stronger	O
regulatory	O
effects	O
on	O
innate	O
and	O
CD4	O
(+)	O
T	O
cell	O
responses	O
during	O
primary	O
and	O
secondary	O
infections	O
","	O
respectively	O
.	O
	
The	O
results	O
in	O
this	O
study	O
significantly	O
improve	O
our	O
understanding	O
of	O
the	O
durability	O
of	O
IL	O
-	O
10	O
-	O
producing	O
CD4	O
(+)	O
T	O
cells	O
postinfection	O
and	O
provide	O
information	O
on	O
how	O
IL	O
-	O
10	O
may	O
contribute	O
to	O
optimized	O
parasite	O
control	O
and	O
prevention	O
of	O
immune	O
-	O
mediated	O
pathology	O
during	O
repeated	O
malaria	B-Disease
infections	I-Disease
.	O
	
	
Atorvastatin	B-Chemical
protects	O
against	O
contrast	B-Disease
-	I-Disease
induced	I-Disease
nephropathy	I-Disease
via	O
anti	O
-	O
apoptosis	O
by	O
the	O
upregulation	O
of	O
Hsp27	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O
	
Contrast	B-Disease
-	I-Disease
induced	I-Disease
nephropathy	I-Disease
(	O
CIN	B-Disease
)	O
is	O
an	O
iatrogenic	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
occurring	O
following	O
the	O
intravascular	O
injection	O
of	O
iodinated	O
radiographic	O
contrast	O
medium	O
.	O
	
However	O
","	O
the	O
regulatory	O
mechanisms	O
for	O
CIN	B-Disease
remain	O
to	O
be	O
fully	O
elucidated	O
.	O
	
The	O
present	O
study	O
aimed	O
to	O
investigate	O
whether	O
atorvastatin	B-Chemical
protects	O
against	O
CIN	B-Disease
via	O
anti	O
-	O
apoptotic	O
effects	O
by	O
the	O
upregulation	O
of	O
Hsp27	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O
	
To	O
determine	O
whether	O
atorvastatin	B-Chemical
attenuated	O
CIN	B-Disease
","	O
the	O
inflammatory	B-Disease
response	O
and	O
apoptosis	O
in	O
vivo	O
and	O
in	O
vitro	O
","	O
a	O
rat	O
model	O
of	O
iopamidol	B-Chemical
-	O
induced	O
CIN	B-Disease
was	O
used	O
","	O
and	O
human	O
embryonic	O
proximal	O
tubule	O
(	O
HK2	O
)	O
cell	O
damage	O
was	O
assessed	O
.	O
	
The	O
rats	O
were	O
assigned	O
into	O
four	O
groups	O
(	O
n	O
=	O
10	O
per	O
group	O
)","	O
as	O
follows	O
:	O
Control	O
rats	O
";"	O
rats	O
+	O
atorvastatin	B-Chemical
";"	O
rats	O
+	O
iopamidol	B-Chemical
";"	O
rats	O
+	O
iopamidol	B-Chemical
+	O
atorvastatin	B-Chemical
.	O
	
In	O
vitro	O
","	O
the	O
HK2	O
cells	O
were	O
treated	O
with	O
iopamidol	B-Chemical
in	O
the	O
presence	O
or	O
absence	O
of	O
atorvastatin	B-Chemical
","	O
heat	O
shock	O
protein	O
(	O
Hsp	O
)	O
27	O
small	O
interfering	O
(	O
si	O
)	O
RNA	O
or	O
pcDNA3	O
.	O
1	O
-	O
Hsp27	O
.	O
	
The	O
renal	O
tissues	O
were	O
examined	O
histopathologically	O
and	O
collected	O
for	O
western	O
blot	O
analysis	O
.	O
	
The	O
results	O
showed	O
that	O
atorvastatin	B-Chemical
ameliorated	O
the	O
apoptosis	B-Disease
and	I-Disease
deterioration	I-Disease
of	I-Disease
renal	I-Disease
function	I-Disease
(	O
P	O
<	O
0	O
.	O
5	O
).	O
	
Furthermore	O
","	O
atorvastatin	B-Chemical
reduced	O
the	O
iopamidol	B-Chemical
-	O
induced	O
activity	O
of	O
B	O
cell	O
lymphoma	O
-	O
2	O
(	O
Bcl	O
-	O
2	O
)-	O
associated	O
X	O
protein	O
(	O
Bax	O
)/	O
caspase	O
-	O
3	O
and	O
increased	O
the	O
expression	O
of	O
Bcl	O
-	O
2	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O
	
Notably	O
","	O
following	O
treatment	O
with	O
Hsp27	O
siRNA	O
or	O
pcDNA3	O
.	O
1	O
-	O
Hsp27	O
","	O
it	O
was	O
found	O
that	O
iopamidol	B-Chemical
enhanced	O
or	O
weakened	O
the	O
upregulation	O
of	O
Bax	O
/	O
caspase	O
-	O
3	O
and	O
downregulation	O
of	O
Bcl	O
-	O
2	O
in	O
the	O
HK2	O
cells	O
","	O
respectively	O
.	O
	
The	O
results	O
of	O
the	O
present	O
study	O
suggested	O
that	O
atorvastatin	B-Chemical
protected	O
against	O
contrast	B-Disease
-	I-Disease
induced	I-Disease
renal	I-Disease
tubular	I-Disease
cell	I-Disease
apoptosis	I-Disease
through	O
the	O
upregulation	O
of	O
Hsp27	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O
	
	
Deletion	O
of	O
endothelial	O
cell	O
-	O
specific	O
liver	O
kinase	O
B1	O
increases	O
angiogenesis	O
and	O
tumor	B-Disease
growth	O
via	O
vascular	O
endothelial	O
growth	O
factor	O
.	O
	
Liver	O
kinase	O
B1	O
(	O
LKB1	O
)	O
is	O
a	O
serine	O
/	O
threonine	O
protein	O
kinase	O
ubiquitously	O
expressed	O
in	O
mammalian	O
cells	O
.	O
	
It	O
was	O
first	O
identified	O
in	O
Peutz	B-Disease
-	I-Disease
Jeghers	I-Disease
syndrome	I-Disease
as	O
a	O
tumor	B-Disease
suppressor	O
gene	O
.	O
	
Whether	O
endothelial	O
LKB1	O
regulates	O
angiogenesis	O
and	O
tumor	B-Disease
growth	O
is	O
unknown	O
.	O
	
In	O
this	O
study	O
","	O
we	O
generated	O
endothelial	O
cell	O
-	O
specific	O
LKB1	O
-	O
knockout	O
(	O
LKB1	O
(	O
endo	O
-/-))	O
mice	O
by	O
crossbreeding	O
vascular	O
endothelial	O
-	O
cadherin	O
-	O
Cre	O
mice	O
with	O
LKB1	O
(	O
flox	O
/	O
flox	O
)	O
mice	O
.	O
	
Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
level	O
was	O
highly	O
co	O
-	O
stained	O
in	O
endothelial	O
cells	O
but	O
not	O
in	O
macrophages	O
in	O
LKB1	O
(	O
endo	O
-/-)	O
mice	O
.	O
	
Consistently	O
","	O
LKB1	O
(	O
endo	O
-/-)	O
mouse	O
tissues	O
including	O
the	O
lung	O
","	O
skin	O
","	O
kidney	O
and	O
liver	O
showed	O
increased	O
vascular	O
permeability	O
.	O
	
Tumors	B-Disease
implanted	O
in	O
LKB1	O
(	O
endo	O
-/-)	O
mice	O
but	O
not	O
macrophage	O
-	O
specific	O
LKB1	O
-	O
knockout	O
mice	O
grew	O
faster	O
and	O
showed	O
enhanced	O
vascular	O
permeability	O
and	O
increased	O
angiogenesis	O
as	O
compared	O
with	O
those	O
implanted	O
in	O
wild	O
-	O
type	O
mice	O
.	O
	
Injection	O
of	O
VEGF	O
-	O
neutralizing	O
antibody	O
but	O
not	O
the	O
isotype	O
-	O
matched	O
control	O
antibody	O
decreased	O
endothelial	O
-	O
cell	O
angiogenesis	O
and	O
tumor	B-Disease
growth	O
in	O
vivo	O
.	O
	
Furthermore	O
","	O
LKB1	O
deletion	O
enhanced	O
mouse	O
retinal	O
and	O
cell	O
angiogenesis	O
","	O
and	O
knockdown	O
of	O
VEGF	O
by	O
small	O
-	O
interfering	O
RNA	O
decreased	O
endothelial	O
cell	O
proliferation	O
and	O
migration	O
.	O
	
Re	O
-	O
expression	O
of	O
LKB1	O
or	O
knockdown	O
of	O
VEGF	O
receptor	O
2	O
decreased	O
the	O
overproliferation	O
and	O
-	O
migration	O
observed	O
in	O
LKB1	O
(	O
endo	O
-/-)	O
cells	O
.	O
	
Mechanistically	O
","	O
LKB1	O
could	O
bind	O
to	O
the	O
VEGF	O
transcription	O
factor	O
","	O
specificity	O
protein	O
1	O
(	O
Sp1	O
)","	O
which	O
then	O
inhibited	O
the	O
binding	O
of	O
Sp1	O
to	O
the	O
VEGF	O
promoter	O
to	O
reduce	O
VEGF	O
expression	O
.	O
	
Endothelial	O
LKB1	O
may	O
regulate	O
endothelial	O
angiogenesis	O
and	O
tumor	B-Disease
growth	O
by	O
modulating	O
Sp1	O
-	O
mediated	O
VEGF	O
expression	O
.	O
	
	
Paraoxonase	O
1	O
polymorphisms	O
and	O
survival	O
.	O
	
The	O
antioxidant	O
enzyme	O
paraoxonase	O
1	O
(	O
PON1	O
)	O
has	O
previously	O
been	O
suggested	O
to	O
confer	O
protection	O
against	O
coronary	B-Disease
heart	I-Disease
disease	I-Disease
(	O
CHD	B-Disease
)","	O
one	O
of	O
the	O
main	O
causes	O
of	O
death	B-Disease
in	O
the	O
Western	O
world	O
.	O
	
Two	O
coding	O
polymorphisms	O
","	O
55M	O
/	O
L	O
and	O
192Q	O
/	O
R	O
","	O
and	O
a	O
promoter	O
variant	O
","	O
-	O
107C	O
/	O
T	O
","	O
has	O
been	O
extensively	O
studied	O
with	O
respect	O
to	O
susceptibility	O
to	O
CHD	B-Disease
.	O
	
In	O
this	O
study	O
","	O
we	O
have	O
investigated	O
the	O
impact	O
of	O
these	O
three	O
polymorphisms	O
on	O
mortality	O
using	O
a	O
sample	O
of	O
1932	O
Danish	O
individuals	O
aged	O
47	O
-	O
93	O
years	O
","	O
previously	O
used	O
in	O
gene	O
-	O
longevity	O
studies	O
.	O
	
A	O
cross	O
-	O
sectional	O
study	O
comparing	O
the	O
genotype	O
distribution	O
of	O
the	O
three	O
polymorphisms	O
separately	O
as	O
well	O
as	O
the	O
haplotype	O
distribution	O
in	O
different	O
age	O
groups	O
did	O
not	O
reveal	O
any	O
difference	O
.	O
	
However	O
","	O
a	O
longitudinal	O
follow	O
-	O
up	O
study	O
on	O
survival	O
in	O
the	O
same	O
sample	O
indicated	O
that	O
192RR	O
homozygotes	O
have	O
a	O
poorer	O
survival	O
compared	O
to	O
QQ	O
homozygotes	O
(	O
hazard	O
rate	O
:	O
1	O
.	O
38	O
","	O
P	O
=	O
0	O
.	O
4	O
).	O
	
We	O
hereafter	O
used	O
an	O
independent	O
sample	O
of	O
541	O
Danish	O
individuals	O
from	O
the	O
oldest	O
cohort	O
and	O
confirmed	O
the	O
initial	O
findings	O
(	O
hazard	O
rate	O
:	O
1	O
.	O
38	O
","	O
P	O
=	O
0	O
.	O
9	O
).	O
	
In	O
both	O
samples	O
","	O
the	O
effect	O
was	O
most	O
pronounced	O
in	O
women	O
.	O
	
Using	O
self	O
-	O
reported	O
data	O
on	O
ischemic	B-Disease
heart	I-Disease
disease	I-Disease
to	O
evaluate	O
the	O
impact	O
of	O
the	O
PON	O
192Q	O
/	O
R	O
polymorphism	O
on	O
susceptibility	O
to	O
CHD	B-Disease
","	O
we	O
found	O
only	O
a	O
nonsignificant	O
trend	O
of	O
192RR	O
homozygosity	O
in	O
women	O
being	O
a	O
risk	O
factor	O
.	O
	
Our	O
results	O
thus	O
indicates	O
that	O
PON1	O
192RR	O
homozygosity	O
is	O
associated	O
with	O
increased	O
mortality	O
in	O
women	O
in	O
the	O
second	O
half	O
of	O
life	O
and	O
that	O
this	O
increased	O
mortality	O
is	O
possibly	O
related	O
to	O
CHD	B-Disease
severity	O
and	O
survival	O
after	O
CHD	B-Disease
rather	O
than	O
susceptibility	O
to	O
development	O
of	O
CHD	B-Disease
.	O
	
	
Human	O
TBX1	O
missense	O
mutations	O
cause	O
gain	O
of	O
function	O
resulting	O
in	O
the	O
same	O
phenotype	O
as	O
22q11	B-Disease
.	I-Disease
2	I-Disease
deletions	I-Disease
.	O
	
Deletion	B-Disease
22q11	I-Disease
.	I-Disease
2	I-Disease
syndrome	I-Disease
is	O
the	O
most	O
frequent	O
known	O
microdeletion	O
syndrome	O
and	O
is	O
associated	O
with	O
a	O
highly	O
variable	O
phenotype	O
","	O
including	O
DiGeorge	B-Disease
and	I-Disease
Shprintzen	I-Disease
(	I-Disease
velocardiofacial	I-Disease
)	I-Disease
syndromes	I-Disease
.	O
	
Although	O
haploinsufficiency	O
of	O
the	O
T	O
-	O
box	O
transcription	O
factor	O
gene	O
TBX1	O
is	O
thought	O
to	O
cause	O
the	O
phenotype	O
","	O
to	O
date	O
","	O
only	O
four	O
different	O
point	O
mutations	O
in	O
TBX1	O
have	O
been	O
reported	O
in	O
association	O
with	O
six	O
of	O
the	O
major	O
features	O
of	O
22q11	B-Disease
.	I-Disease
2	I-Disease
deletion	I-Disease
syndrome	I-Disease
.	O
	
Although	O
","	O
for	O
the	O
two	O
truncating	O
mutations	O
","	O
loss	O
of	O
function	O
was	O
previously	O
shown	O
","	O
the	O
pathomechanism	O
of	O
the	O
missense	O
mutations	O
remains	O
unknown	O
.	O
	
We	O
report	O
a	O
novel	O
heterozygous	O
missense	O
mutation	O
","	O
H194Q	O
","	O
in	O
a	O
familial	O
case	O
of	O
Shprintzen	B-Disease
syndrome	I-Disease
and	O
show	O
that	O
this	O
and	O
the	O
two	O
previously	O
reported	O
missense	O
mutations	O
result	O
in	O
gain	O
of	O
function	O
","	O
possibly	O
through	O
stabilization	O
of	O
the	O
protein	O
dimer	O
DNA	O
complex	O
.	O
	
We	O
therefore	O
conclude	O
that	O
TBX1	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
can	O
result	O
in	O
the	O
same	O
phenotypic	O
spectrum	O
as	O
haploinsufficiency	O
caused	O
by	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
or	O
deletions	O
.	O
	
	
Polymorphic	O
MLH1	O
and	O
risk	O
of	O
cancer	B-Disease
after	O
methylating	O
chemotherapy	O
for	O
Hodgkin	B-Disease
lymphoma	I-Disease
.	O
	
BACKGROUND	O
AND	O
OBJECTIVE	O
:	O
Methylating	O
agents	O
are	O
effective	O
chemotherapy	O
agents	O
for	O
Hodgkin	B-Disease
lymphoma	I-Disease
","	O
but	O
are	O
associated	O
with	O
the	O
development	O
of	O
second	O
primary	O
cancers	B-Disease
.	O
	
Cytotoxicity	B-Disease
of	O
methylating	O
agents	O
is	O
mediated	O
primarily	O
by	O
the	O
DNA	O
mismatch	O
repair	O
(	O
MMR	O
)	O
system	O
.	O
	
Loss	O
of	O
MLH1	O
","	O
a	O
major	O
component	O
of	O
DNA	O
MMR	O
","	O
results	O
in	O
tolerance	O
to	O
the	O
cytotoxic	B-Disease
effects	O
of	O
methylating	O
agents	O
and	O
persistence	O
of	O
mutagenised	O
cells	O
at	O
high	O
risk	O
of	O
malignant	O
transformation	O
.	O
	
We	O
hypothesised	O
that	O
a	O
common	O
substitution	O
in	O
the	O
basal	O
promoter	O
of	O
MLH1	O
(	O
position	O
-	O
93	O
","	O
rs1800734	O
)	O
modifies	O
the	O
risk	O
of	O
cancer	B-Disease
after	O
methylating	O
chemotherapy	O
.	O
	
METHODS	O
:	O
133	O
patients	O
who	O
developed	O
cancer	B-Disease
following	O
chemotherapy	O
and	O
/	O
or	O
radiotherapy	O
(	O
n	O
=	O
133	O
)","	O
420	O
patients	O
diagnosed	O
with	O
de	O
novo	O
myeloid	B-Disease
leukaemia	I-Disease
","	O
242	O
patients	O
diagnosed	O
with	O
primary	B-Disease
Hodgkin	I-Disease
lymphoma	I-Disease
","	O
and	O
1177	O
healthy	O
controls	O
were	O
genotyped	O
for	O
the	O
MLH1	O
-	O
93	O
polymorphism	O
by	O
allelic	O
discrimination	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
assay	O
.	O
	
Odds	O
ratios	O
and	O
95	O
%	O
confidence	O
intervals	O
for	O
cancer	B-Disease
risk	O
by	O
MLH1	O
-	O
93	O
polymorphism	O
status	O
","	O
and	O
stratified	O
by	O
previous	O
exposure	O
to	O
methylating	O
chemotherapy	O
","	O
were	O
calculated	O
using	O
unconditional	O
logistic	O
regression	O
.	O
	
RESULTS	O
:	O
Carrier	O
frequency	O
of	O
the	O
MLH1	O
-	O
93	O
variant	O
was	O
higher	O
in	O
patients	O
who	O
developed	O
therapy	O
related	O
acute	B-Disease
myeloid	I-Disease
leukaemia	I-Disease
(	O
t	O
-	O
AML	B-Disease
)	O
(	O
75	O
.	O
0	O
%","	O
n	O
=	O
12	O
)	O
or	O
breast	B-Disease
cancer	I-Disease
(	O
53	O
.	O
3	O
%.	O
	
n	O
=	O
15	O
)	O
after	O
methylating	O
chemotherapy	O
for	O
Hodgkin	B-Disease
lymphoma	I-Disease
compared	O
to	O
patients	O
without	O
previous	O
methylating	O
exposure	O
(	O
t	O
-	O
AML	B-Disease
","	O
30	O
.	O
4	O
%","	O
n	O
=	O
69	O
";"	O
breast	B-Disease
cancer	I-Disease
patients	O
","	O
27	O
.	O
2	O
%","	O
n	O
=	O
22	O
).	O
	
The	O
MLH1	O
-	O
93	O
variant	O
allele	O
was	O
also	O
over	O
-	O
represented	O
in	O
t	O
-	O
AML	B-Disease
cases	O
when	O
compared	O
to	O
de	O
novo	O
AML	B-Disease
cases	O
(	O
36	O
.	O
9	O
%","	O
n	O
=	O
420	O
)	O
and	O
healthy	O
controls	O
(	O
36	O
.	O
3	O
%","	O
n	O
=	O
952	O
)","	O
and	O
was	O
associated	O
with	O
a	O
significantly	O
increased	O
risk	O
of	O
developing	O
t	O
-	O
AML	B-Disease
(	O
odds	O
ratio	O
5	O
.	O
31	O
","	O
95	O
%	O
confidence	O
interval	O
1	O
.	O
40	O
to	O
20	O
.	O
15	O
)","	O
but	O
only	O
in	O
patients	O
previously	O
treated	O
with	O
a	O
methylating	O
agent	O
.	O
	
CONCLUSIONS	O
:	O
These	O
data	O
support	O
the	O
hypothesis	O
that	O
the	O
common	O
polymorphism	O
at	O
position	O
-	O
93	O
in	O
the	O
core	O
promoter	O
of	O
MLH1	O
defines	O
a	O
risk	O
allele	O
for	O
the	O
development	O
of	O
cancer	B-Disease
after	O
methylating	O
chemotherapy	O
for	O
Hodgkin	B-Disease
lymphoma	I-Disease
.	O
	
However	O
","	O
replication	O
of	O
this	O
finding	O
in	O
larger	O
studies	O
is	O
suggested	O
.	O
	
	
Identification	O
of	O
novel	O
susceptibility	O
genes	O
in	O
childhood	O
-	O
onset	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
using	O
a	O
uniquely	O
designed	O
candidate	O
gene	O
pathway	O
platform	O
.	O
	
OBJECTIVE	O
:	O
Childhood	O
-	O
onset	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
(	O
SLE	B-Disease
)	O
presents	O
a	O
unique	O
subgroup	O
of	O
patients	O
for	O
genetic	O
study	O
.	O
	
The	O
present	O
study	O
was	O
undertaken	O
to	O
identify	O
susceptibility	O
genes	O
contributing	O
to	O
SLE	B-Disease
","	O
using	O
a	O
novel	O
candidate	O
gene	O
pathway	O
microarray	O
platform	O
to	O
investigate	O
gene	O
expression	O
in	O
patients	O
with	O
childhood	O
-	O
onset	O
SLE	B-Disease
and	O
both	O
of	O
their	O
parents	O
.	O
	
METHODS	O
:	O
Utilizing	O
bioinformatic	O
tools	O
","	O
a	O
platform	O
of	O
9	O
","	O
412	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
from	O
1	O
","	O
204	O
genes	O
was	O
designed	O
and	O
validated	O
.	O
	
Molecular	O
inversion	O
probes	O
and	O
high	O
-	O
throughput	O
SNP	O
technologies	O
were	O
used	O
for	O
assay	O
development	O
.	O
	
Seven	O
hundred	O
fifty	O
three	O
subjects	O
","	O
corresponding	O
to	O
251	O
full	O
trios	O
of	O
childhood	O
-	O
onset	O
SLE	B-Disease
families	O
","	O
were	O
genotyped	O
and	O
analyzed	O
using	O
transmission	O
disequilibrium	O
testing	O
(	O
TDT	O
)	O
and	O
multitest	O
corrections	O
.	O
	
RESULTS	O
:	O
Family	O
-	O
based	O
TDT	O
showed	O
a	O
significant	O
association	O
of	O
SLE	B-Disease
with	O
a	O
N673S	O
polymorphism	O
in	O
the	O
P	O
-	O
selectin	O
gene	O
(	O
SELP	O
)	O
(	O
P	O
=	O
5	O
.	O
74	O
x	O
10	O
(-	O
6	O
))	O
and	O
a	O
C203S	O
polymorphism	O
in	O
the	O
interleukin	O
-	O
1	O
receptor	O
-	O
associated	O
kinase	O
1	O
gene	O
(	O
IRAK1	O
)	O
(	O
P	O
=	O
9	O
.	O
58	O
x	O
10	O
(-	O
6	O
)).	O
	
These	O
2	O
SNPs	O
had	O
a	O
FALSE	O
discovery	O
rate	O
for	O
multitest	O
correction	O
of	O
<	O
0	O
.	O
5	O
","	O
and	O
therefore	O
a	O
>	O
95	O
%	O
probability	O
of	O
being	O
considered	O
as	O
proven	O
.	O
	
Furthermore	O
","	O
7	O
additional	O
SNPs	O
showed	O
q	O
values	O
of	O
<	O
0	O
.	O
5	O
","	O
suggesting	O
association	O
with	O
SLE	B-Disease
and	O
providing	O
a	O
direction	O
for	O
followup	O
studies	O
.	O
	
These	O
additional	O
genes	O
notably	O
included	O
TNFRSF6	O
(	O
Fas	O
)	O
and	O
IRF5	O
","	O
supporting	O
previous	O
findings	O
of	O
their	O
association	O
with	O
SLE	B-Disease
pathogenesis	O
.	O
	
CONCLUSION	O
:	O
SELP	O
and	O
IRAK1	O
were	O
identified	O
as	O
novel	O
SLE	B-Disease
-	O
associated	O
genes	O
with	O
a	O
high	O
degree	O
of	O
significance	O
","	O
suggesting	O
new	O
directions	O
in	O
understanding	O
the	O
pathogenesis	O
of	O
SLE	B-Disease
.	O
	
The	O
overall	O
design	O
and	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
the	O
candidate	O
gene	O
pathway	O
microarray	O
platform	O
used	O
provides	O
a	O
novel	O
and	O
powerful	O
approach	O
that	O
is	O
generally	O
applicable	O
in	O
identifying	O
genetic	O
foundations	O
of	O
complex	O
diseases	O
.	O
	
	
Protective	O
effects	O
of	O
antithrombin	B-Chemical
on	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
nephrosis	B-Disease
in	O
rats	O
.	O
	
We	O
investigated	O
the	O
effects	O
of	O
antithrombin	B-Chemical
","	O
a	O
plasma	O
inhibitor	O
of	O
coagulation	O
factors	O
","	O
in	O
rats	O
with	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	O
nephrosis	B-Disease
","	O
which	O
is	O
an	O
experimental	O
model	O
of	O
human	O
nephrotic	B-Disease
syndrome	I-Disease
.	O
	
Antithrombin	B-Chemical
(	O
50	O
or	O
500	O
IU	O
/	O
kg	O
/	O
i	O
.	O
v	O
.)	O
	
was	O
administered	O
to	O
rats	O
once	O
a	O
day	O
for	O
10	O
days	O
immediately	O
after	O
the	O
injection	O
of	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
(	O
50	O
mg	O
/	O
kg	O
/	O
i	O
.	O
v	O
.).	O
	
Treatment	O
with	O
antithrombin	B-Chemical
attenuated	O
the	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	O
hematological	B-Disease
abnormalities	I-Disease
.	O
	
Puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	O
renal	B-Disease
dysfunction	I-Disease
and	O
hyperlipidemia	B-Disease
were	O
also	O
suppressed	O
.	O
	
Histopathological	O
examination	O
revealed	O
severe	O
renal	B-Disease
damage	I-Disease
such	O
as	O
proteinaceous	O
casts	O
in	O
tubuli	O
and	O
tubular	O
expansion	O
in	O
the	O
kidney	O
of	O
control	O
rats	O
","	O
while	O
an	O
improvement	O
of	O
the	O
damage	O
was	O
seen	O
in	O
antithrombin	B-Chemical
-	O
treated	O
rats	O
.	O
	
In	O
addition	O
","	O
antithrombin	B-Chemical
treatment	O
markedly	O
suppressed	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	O
apoptosis	O
of	O
renal	O
tubular	O
epithelial	O
cells	O
.	O
	
Furthermore	O
","	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	O
increases	O
in	O
renal	O
cytokine	O
content	O
were	O
also	O
decreased	O
.	O
	
These	O
findings	O
suggest	O
that	O
thrombin	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	O
nephrotic	B-Disease
syndrome	I-Disease
.	O
	
Treatment	O
with	O
antithrombin	B-Chemical
may	O
be	O
clinically	O
effective	O
in	O
patients	O
with	O
nephrotic	B-Disease
syndrome	I-Disease
.	O
	
	
Neurofibromin	O
1	O
(	O
NF1	O
)	O
defects	O
are	O
common	O
in	O
human	O
ovarian	B-Disease
serous	I-Disease
carcinomas	I-Disease
and	O
co	O
-	O
occur	O
with	O
TP53	O
mutations	O
.	O
	
Ovarian	B-Disease
serous	I-Disease
carcinoma	I-Disease
(	O
OSC	B-Disease
)	O
is	O
the	O
most	O
common	O
and	O
lethal	O
histologic	O
type	O
of	O
ovarian	B-Disease
epithelial	I-Disease
malignancy	I-Disease
.	O
	
Mutations	O
of	O
TP53	O
and	O
dysfunction	O
of	O
the	O
Brca1	O
and	O
/	O
or	O
Brca2	O
tumor	B-Disease
-	O
suppressor	O
proteins	O
have	O
been	O
implicated	O
in	O
the	O
molecular	O
pathogenesis	O
of	O
a	O
large	O
fraction	O
of	O
OSCs	B-Disease
","	O
but	O
frequent	O
somatic	O
mutations	O
in	O
other	O
well	O
-	O
established	O
tumor	B-Disease
-	O
suppressor	O
genes	O
have	O
not	O
been	O
identified	O
.	O
	
Using	O
a	O
genome	O
-	O
wide	O
screen	O
of	O
DNA	O
copy	O
number	O
alterations	O
in	O
36	O
primary	O
OSCs	B-Disease
","	O
we	O
identified	O
two	O
tumors	B-Disease
with	O
apparent	O
homozygous	O
deletions	O
of	O
the	O
NF1	O
gene	O
.	O
	
Subsequently	O
","	O
18	O
ovarian	B-Disease
carcinoma	I-Disease
-	O
derived	O
cell	O
lines	O
and	O
41	O
primary	O
OSCs	B-Disease
were	O
evaluated	O
for	O
NF1	O
alterations	O
.	O
	
Markedly	O
reduced	O
or	O
absent	O
expression	O
of	O
Nf1	O
protein	O
was	O
observed	O
in	O
6	O
of	O
the	O
18	O
cell	O
lines	O
","	O
and	O
using	O
the	O
protein	O
truncation	O
test	O
and	O
sequencing	O
of	O
cDNA	O
and	O
genomic	O
DNA	O
","	O
NF1	O
mutations	O
resulting	O
in	O
deletion	O
of	O
exons	O
and	O
/	O
or	O
aberrant	O
splicing	O
of	O
NF1	O
transcripts	O
were	O
detected	O
in	O
5	O
of	O
the	O
6	O
cell	O
lines	O
with	O
loss	O
of	O
NF1	O
expression	O
.	O
	
Similarly	O
","	O
NF1	O
alterations	O
including	O
homozygous	O
deletions	O
and	O
splicing	O
mutations	O
were	O
identified	O
in	O
9	O
(	O
22	O
%)	O
of	O
41	O
primary	O
OSCs	B-Disease
.	O
	
As	O
expected	O
","	O
tumors	B-Disease
and	O
cell	O
lines	O
with	O
NF1	O
defects	O
lacked	O
mutations	O
in	O
KRAS	O
or	O
BRAF	O
but	O
showed	O
Ras	O
pathway	O
activation	O
based	O
on	O
immunohistochemical	O
detection	O
of	O
phosphorylated	O
MAPK	O
(	O
primary	O
tumors	B-Disease
)	O
or	O
increased	O
levels	O
of	O
GTP	B-Chemical
-	O
bound	O
Ras	O
(	O
cell	O
lines	O
).	O
	
The	O
TP53	O
tumor	B-Disease
-	O
suppressor	O
gene	O
was	O
mutated	O
in	O
all	O
OSCs	B-Disease
with	O
documented	O
NF1	O
mutation	O
","	O
suggesting	O
that	O
the	O
pathways	O
regulated	O
by	O
these	O
two	O
tumor	B-Disease
-	O
suppressor	O
proteins	O
often	O
cooperate	O
in	O
the	O
development	O
of	O
ovarian	B-Disease
carcinomas	I-Disease
with	O
serous	O
differentiation	O
.	O
	
	
Melanocortin	O
-	O
4	O
receptor	O
activation	O
inhibits	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
activity	O
and	O
promotes	O
insulin	O
signaling	O
.	O
	
The	O
melanocortin	O
system	O
is	O
crucial	O
to	O
regulation	O
of	O
energy	O
homeostasis	O
.	O
	
The	O
melanocortin	O
receptor	O
type	O
4	O
(	O
MC4R	O
)	O
modulates	O
insulin	O
signaling	O
via	O
effects	O
on	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
).	O
	
The	O
melanocortin	O
agonist	O
NDP	B-Chemical
-	I-Chemical
MSH	I-Chemical
dose	O
-	O
dependently	O
inhibited	O
JNK	O
activity	O
in	O
HEK293	O
cells	O
stably	O
expressing	O
the	O
human	O
MC4R	O
";"	O
effects	O
were	O
reversed	O
by	O
melanocortin	O
receptor	O
antagonist	O
.	O
	
NDP	B-Chemical
-	I-Chemical
MSH	I-Chemical
time	O
-	O
and	O
dose	O
-	O
dependently	O
inhibited	O
IRS	O
-	O
1	O
(	O
ser307	O
)	O
phosphorylation	O
","	O
effects	O
also	O
reversed	O
by	O
a	O
specific	O
melanocortin	O
receptor	O
antagonist	O
.	O
	
NDP	B-Chemical
-	I-Chemical
MSH	I-Chemical
augmented	O
insulin	O
-	O
stimulated	O
AKT	O
phosphorylation	O
in	O
vitro	O
.	O
	
The	O
melanocortin	O
agonist	O
melanotan	B-Chemical
II	I-Chemical
increased	O
insulin	O
-	O
stimulated	O
AKT	O
phosphorylation	O
in	O
the	O
rat	O
hypothalamus	O
in	O
vivo	O
.	O
	
NDP	B-Chemical
-	I-Chemical
MSH	I-Chemical
increased	O
insulin	O
-	O
stimulated	O
glucose	B-Chemical
uptake	O
in	O
hypothalamic	O
GT1	O
-	O
1	O
cells	O
.	O
	
The	O
current	O
study	O
shows	O
that	O
the	O
melanocortinergic	O
system	O
interacts	O
with	O
insulin	O
signaling	O
via	O
novel	O
effects	O
on	O
JNK	O
activity	O
.	O
	
	
The	O
association	O
between	O
tranexamic	B-Chemical
acid	I-Chemical
and	O
convulsive	B-Disease
seizures	I-Disease
after	O
cardiac	O
surgery	O
:	O
a	O
multivariate	O
analysis	O
in	O
11	O
529	O
patients	O
.	O
	
Because	O
of	O
a	O
lack	O
of	O
contemporary	O
data	O
regarding	O
seizures	B-Disease
after	O
cardiac	O
surgery	O
","	O
we	O
undertook	O
a	O
retrospective	O
analysis	O
of	O
prospectively	O
collected	O
data	O
from	O
11	O
529	O
patients	O
in	O
whom	O
cardiopulmonary	O
bypass	O
was	O
used	O
from	O
January	O
2004	O
to	O
December	O
2010	O
.	O
	
A	O
convulsive	B-Disease
seizure	I-Disease
was	O
defined	O
as	O
a	O
transient	O
episode	O
of	O
disturbed	O
brain	O
function	O
characterised	O
by	O
abnormal	B-Disease
involuntary	I-Disease
motor	I-Disease
movements	I-Disease
.	O
	
Multivariate	O
regression	O
analysis	O
was	O
performed	O
to	O
identify	O
independent	O
predictors	O
of	O
postoperative	O
seizures	B-Disease
.	O
	
A	O
total	O
of	O
100	O
(	O
0	O
.	O
9	O
%)	O
patients	O
developed	O
postoperative	O
convulsive	B-Disease
seizures	I-Disease
.	O
	
Generalised	B-Disease
and	I-Disease
focal	I-Disease
seizures	I-Disease
were	O
identified	O
in	O
68	O
and	O
32	O
patients	O
","	O
respectively	O
.	O
	
The	O
median	O
(	O
IQR	O
[	O
range	O
])	O
time	O
after	O
surgery	O
when	O
the	O
seizure	B-Disease
occurred	O
was	O
7	O
(	O
6	O
-	O
12	O
[	O
1	O
-	O
216	O
])	O
h	O
and	O
8	O
(	O
6	O
-	O
11	O
[	O
4	O
-	O
18	O
])	O
h	O
","	O
respectively	O
.	O
	
Epileptiform	O
findings	O
on	O
electroencephalography	O
were	O
seen	O
in	O
19	O
patients	O
.	O
	
Independent	O
predictors	O
of	O
postoperative	O
seizures	B-Disease
included	O
age	O
","	O
female	O
sex	O
","	O
redo	O
cardiac	O
surgery	O
","	O
calcification	B-Disease
of	I-Disease
ascending	I-Disease
aorta	I-Disease
","	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
","	O
deep	O
hypothermic	B-Disease
circulatory	O
arrest	O
","	O
duration	O
of	O
aortic	O
cross	O
-	O
clamp	O
and	O
tranexamic	B-Chemical
acid	I-Chemical
.	O
	
When	O
tested	O
in	O
a	O
multivariate	O
regression	O
analysis	O
","	O
tranexamic	B-Chemical
acid	I-Chemical
was	O
a	O
strong	O
independent	O
predictor	O
of	O
seizures	B-Disease
(	O
OR	O
14	O
.	O
3	O
","	O
95	O
%	O
CI	O
5	O
.	O
5	O
-	O
36	O
.	O
7	O
";"	O
p	O
<	O
0	O
.	O
1	O
).	O
	
Patients	O
with	O
convulsive	B-Disease
seizures	I-Disease
had	O
2	O
.	O
5	O
times	O
higher	O
in	O
-	O
hospital	O
mortality	O
rates	O
and	O
twice	O
the	O
length	O
of	O
hospital	O
stay	O
compared	O
with	O
patients	O
without	O
convulsive	B-Disease
seizures	I-Disease
.	O
	
Mean	O
(	O
IQR	O
[	O
range	O
])	O
length	O
of	O
stay	O
in	O
the	O
intensive	O
care	O
unit	O
was	O
115	O
(	O
49	O
-	O
228	O
[	O
32	O
-	O
481	O
])	O
h	O
in	O
patients	O
with	O
convulsive	B-Disease
seizures	I-Disease
compared	O
with	O
26	O
(	O
22	O
-	O
69	O
[	O
14	O
-	O
1080	O
])	O
h	O
in	O
patients	O
without	O
seizures	B-Disease
(	O
p	O
<	O
0	O
.	O
1	O
).	O
	
Convulsive	B-Disease
seizures	I-Disease
are	O
a	O
serious	O
postoperative	B-Disease
complication	I-Disease
after	O
cardiac	O
surgery	O
.	O
	
As	O
tranexamic	B-Chemical
acid	I-Chemical
is	O
the	O
only	O
modifiable	O
factor	O
","	O
its	O
administration	O
","	O
particularly	O
in	O
doses	O
exceeding	O
80	O
mg	O
.	O
kg	O
(-	O
1	O
)","	O
should	O
be	O
weighed	O
against	O
the	O
risk	O
of	O
postoperative	O
seizures	B-Disease
.	O
	
	
Changes	O
in	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
during	O
pancreatic	B-Disease
cancer	I-Disease
development	O
and	O
progression	O
in	O
a	O
genetically	O
engineered	O
	
";"	O
Pdx1	O
-	O
Cre	O
mouse	O
(	O
KC	O
)	O
model	O
.	O
	
Differential	O
expression	O
of	O
microRNAs	O
(	O
miRNAs	O
)	O
has	O
been	O
demonstrated	O
in	O
various	O
cancers	B-Disease
","	O
including	O
pancreatic	B-Disease
cancer	I-Disease
(	O
PC	B-Disease
).	O
	
Due	O
to	O
the	O
lack	O
of	O
tissue	O
samples	O
from	O
early	O
-	O
stages	O
of	O
PC	B-Disease
","	O
the	O
stage	O
-	O
specific	O
alteration	O
of	O
miRNAs	O
during	O
PC	B-Disease
initiation	O
and	O
progression	O
is	O
largely	O
unknown	O
.	O
	
In	O
this	O
study	O
","	O
we	O
investigated	O
the	O
global	O
miRNA	O
expression	O
profile	O
and	O
their	O
processing	O
machinery	O
during	O
PC	B-Disease
progression	O
using	O
the	O
	
";"	O
Pdx1	O
-	O
Cre	O
(	O
KC	O
)	O
mouse	O
model	O
.	O
	
At	O
25	O
weeks	O
","	O
the	O
miRNA	O
microarray	O
analysis	O
revealed	O
significant	O
downregulation	O
of	O
miR	O
-	O
150	O
","	O
miR	O
-	O
494	O
","	O
miR	O
-	O
138	O
","	O
miR	O
-	O
148a	O
","	O
miR	O
-	O
216a	O
","	O
and	O
miR	O
-	O
217	O
and	O
upregulation	O
of	O
miR	O
-	O
146b	O
","	O
miR	O
-	O
205	O
","	O
miR	O
-	O
31	O
","	O
miR	O
-	O
192	O
","	O
and	O
miR	O
-	O
21	O
in	O
KC	O
mice	O
compared	O
to	O
controls	O
.	O
	
Further	O
","	O
expression	O
of	O
miRNA	O
biosynthetic	O
machinery	O
including	O
Dicer	O
","	O
Exportin	O
-	O
5	O
","	O
TRKRA	O
","	O
and	O
TARBP2	O
were	O
downregulated	O
","	O
while	O
DGCR8	O
and	O
Ago2	O
were	O
upregulated	O
in	O
KC	O
mice	O
.	O
	
In	O
addition	O
","	O
from	O
10	O
to	O
50	O
weeks	O
of	O
age	O
","	O
stage	O
-	O
specific	O
expression	O
profiling	O
of	O
miRNA	O
in	O
KC	O
mice	O
revealed	O
downregulation	O
of	O
miR	O
-	O
216	O
","	O
miR	O
-	O
217	O
","	O
miR	O
-	O
100	O
","	O
miR	O
-	O
345	O
","	O
miR	O
-	O
141	O
","	O
miR	O
-	O
483	O
-	O
3p	O
","	O
miR	O
-	O
26b	O
","	O
miR	O
-	O
150	O
","	O
miR	O
-	O
195	O
","	O
Let	O
-	O
7b	O
and	O
Let	O
-	O
96	O
and	O
upregulation	O
of	O
miR	O
-	O
21	O
","	O
miR	O
-	O
205	O
","	O
miR	O
-	O
146b	O
","	O
miR	O
-	O
34c	O
","	O
miR	O
-	O
1273	O
","	O
miR	O
-	O
223	O
and	O
miR	O
-	O
195	O
compared	O
to	O
control	O
mice	O
.	O
	
Interestingly	O
","	O
the	O
differential	O
expression	O
of	O
miRNA	O
in	O
mice	O
also	O
corroborated	O
with	O
the	O
miRNA	O
expression	O
in	O
human	O
PC	B-Disease
cell	O
lines	O
and	O
tissue	O
samples	O
";"	O
ectopic	O
expression	O
of	O
Let	O
-	O
7b	O
in	O
CD18	O
/	O
HPAF	O
and	O
Capan1	O
cells	O
resulted	O
in	O
the	O
downregulation	O
of	O
KRAS	O
and	O
MSST1	O
expression	O
.	O
	
Overall	O
","	O
the	O
present	O
study	O
aids	O
an	O
understanding	O
of	O
miRNA	O
expression	O
patterns	O
during	O
PC	B-Disease
pathogenesis	O
and	O
helps	O
to	O
facilitate	O
the	O
identification	O
of	O
promising	O
and	O
novel	O
early	O
diagnostic	O
/	O
prognostic	O
markers	O
and	O
therapeutic	O
targets	O
.	O
	
	
DNA	O
-	O
damage	O
response	O
gene	O
GADD45A	O
induces	O
differentiation	O
in	O
hematopoietic	O
stem	O
cells	O
without	O
inhibiting	O
cell	O
cycle	O
or	O
survival	O
.	O
	
Hematopoietic	O
stem	O
cells	O
(	O
HSCs	O
)	O
maintain	O
blood	O
cell	O
production	O
life	O
-	O
long	O
by	O
their	O
unique	O
abilities	O
of	O
self	O
-	O
renewal	O
and	O
differentiation	O
into	O
all	O
blood	O
cell	O
lineages	O
.	O
	
Growth	O
arrest	O
and	O
DNA	O
-	O
damage	O
-	O
inducible	O
45	O
alpha	O
(	O
GADD45A	O
)	O
is	O
induced	O
by	O
genotoxic	O
stress	O
in	O
HSCs	O
.	O
	
GADD45A	O
has	O
been	O
implicated	O
in	O
cell	O
cycle	O
control	O
","	O
cell	O
death	O
and	O
senescence	O
","	O
as	O
well	O
as	O
in	O
DNA	O
-	O
damage	O
repair	O
.	O
	
In	O
general	O
","	O
GADD45A	O
provides	O
cellular	O
stability	O
by	O
either	O
arresting	O
the	O
cell	O
cycle	O
progression	O
until	O
DNA	O
damage	O
is	O
repaired	O
or	O
","	O
in	O
cases	O
of	O
fatal	O
damage	O
","	O
by	O
inducing	O
apoptosis	O
.	O
	
However	O
","	O
the	O
function	O
of	O
GADD45A	O
in	O
hematopoiesis	O
remains	O
controversial	O
.	O
	
We	O
revealed	O
the	O
changes	O
in	O
murine	O
HSC	O
fate	O
control	O
orchestrated	O
by	O
the	O
expression	O
of	O
GADD45A	O
at	O
single	O
cell	O
resolution	O
.	O
	
In	O
contrast	O
to	O
other	O
cellular	O
systems	O
","	O
GADD45A	O
expression	O
did	O
not	O
cause	O
a	O
cell	O
cycle	O
arrest	O
or	O
an	O
alteration	O
in	O
the	O
decision	O
between	O
cell	O
survival	O
and	O
apoptosis	O
in	O
HSCs	O
.	O
	
Strikingly	O
","	O
GADD45A	O
strongly	O
induced	O
and	O
accelerated	O
the	O
differentiation	O
program	O
in	O
HSCs	O
.	O
	
Continuous	O
tracking	O
of	O
individual	O
HSCs	O
and	O
their	O
progeny	O
via	O
time	O
-	O
lapse	O
microscopy	O
elucidated	O
that	O
once	O
GADD45A	O
was	O
expressed	O
","	O
HSCs	O
differentiate	O
into	O
committed	O
progenitors	O
within	O
29	O
hours	O
.	O
	
GADD45A	O
-	O
expressing	O
HSCs	O
failed	O
to	O
long	O
-	O
term	O
reconstitute	O
the	O
blood	O
of	O
recipients	O
by	O
inducing	O
multilineage	O
differentiation	O
in	O
vivo	O
.	O
	
Importantly	O
","	O
g	O
-	O
irradiation	O
of	O
HSCs	O
induced	O
their	O
differentiation	O
by	O
upregulating	O
endogenous	O
GADD45A	O
.	O
	
The	O
differentiation	O
induction	O
by	O
GADD45A	O
was	O
transmitted	O
by	O
activating	O
p38	O
Mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
signaling	O
and	O
allowed	O
the	O
generation	O
of	O
megakaryocytic	O
-	O
erythroid	O
","	O
myeloid	O
","	O
and	O
lymphoid	O
lineages	O
.	O
	
These	O
data	O
indicate	O
that	O
genotoxic	O
stress	O
-	O
induced	O
GADD45A	O
expression	O
in	O
HSCs	O
prevents	O
their	O
fatal	O
transformation	O
by	O
directing	O
them	O
into	O
differentiation	O
and	O
thereby	O
clearing	O
them	O
from	O
the	O
system	O
.	O
	
	
Cisplatin	B-Chemical
induces	O
tolerogenic	O
dendritic	O
cells	O
in	O
response	O
to	O
TLR	O
agonists	O
via	O
the	O
abundant	O
production	O
of	O
IL	O
-	O
10	O
","	O
thereby	O
promoting	O
Th2	O
-	O
and	O
Tr1	O
-	O
biased	O
T	O
-	O
cell	O
immunity	O
.	O
	
Although	O
many	O
advantageous	O
roles	O
of	O
cisplatin	B-Chemical
(	O
cis	B-Chemical
-	I-Chemical
diamminedichloroplatinum	I-Chemical
(	O
II	O
)","	O
CDDP	B-Chemical
)	O
have	O
been	O
reported	O
in	O
cancer	B-Disease
therapy	O
","	O
the	O
immunomodulatory	O
roles	O
of	O
cisplatin	B-Chemical
in	O
the	O
phenotypic	O
and	O
functional	O
alterations	O
of	O
dendritic	O
cells	O
(	O
DCs	O
)	O
are	O
poorly	O
understood	O
.	O
	
Here	O
","	O
we	O
investigated	O
the	O
effect	O
of	O
cisplatin	B-Chemical
on	O
the	O
functionality	O
of	O
DCs	O
and	O
the	O
changes	O
in	O
signaling	O
pathways	O
activated	O
upon	O
toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
stimulation	O
.	O
	
Cisplatin	B-Chemical
-	O
treated	O
DCs	O
down	O
-	O
regulated	O
the	O
expression	O
of	O
cell	O
surface	O
molecules	O
(	O
CD80	O
","	O
CD86	O
","	O
MHC	O
class	O
I	O
and	O
II	O
)	O
and	O
up	O
-	O
regulated	O
endocytic	O
capacity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
	
Upon	O
stimulation	O
with	O
various	O
TLR	O
agonists	O
","	O
cisplatin	B-Chemical
-	O
treated	O
DCs	O
showed	O
markedly	O
increased	O
IL	O
-	O
10	O
production	O
through	O
activation	O
of	O
the	O
p38	O
MAPK	O
and	O
NF	O
-	O
kappaB	O
signaling	O
pathways	O
without	O
altering	O
the	O
levels	O
of	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
12p70	O
","	O
indicating	O
the	O
cisplatin	B-Chemical
-	O
mediated	O
induction	O
of	O
tolerogenic	O
DCs	O
.	O
	
This	O
effect	O
was	O
dependent	O
on	O
the	O
production	O
of	O
IL	O
-	O
10	O
from	O
DCs	O
","	O
as	O
neither	O
DCs	O
isolated	O
from	O
IL	O
-	O
10	O
-/-	O
mice	O
nor	O
IL	O
-	O
10	O
-	O
neutralized	O
DCs	O
generated	O
tolerogenic	O
DCs	O
.	O
	
Interestingly	O
","	O
DCs	O
that	O
were	O
co	O
-	O
treated	O
with	O
cisplatin	B-Chemical
and	O
lipopolysaccharide	B-Chemical
(	O
LPS	B-Chemical
)	O
exhibited	O
a	O
decreased	O
immunostimulatory	O
capacity	O
for	O
inducing	O
the	O
proliferation	O
of	O
Th1	O
-	O
and	O
Th17	O
-	O
type	O
T	O
cells	O
";"	O
instead	O
","	O
these	O
DCs	O
contributed	O
to	O
Th2	O
-	O
type	O
T	O
cell	O
immunity	O
.	O
	
Furthermore	O
","	O
in	O
vitro	O
and	O
in	O
vivo	O
investigations	O
revealed	O
a	O
unique	O
T	O
cell	O
population	O
","	O
IL	O
-	O
10	O
-	O
producing	O
CD3	O
+	O
CD4	O
+	O
LAG	O
-	O
3	O
+	O
CD49b	O
+	O
CD25	O
-	O
Foxp3	O
-	O
Tr1	O
cells	O
","	O
that	O
was	O
significantly	O
increased	O
without	O
altering	O
the	O
Foxp3	O
+	O
regulatory	O
T	O
cell	O
population	O
.	O
	
Taken	O
together	O
","	O
our	O
results	O
suggest	O
that	O
cisplatin	B-Chemical
induces	O
immune	O
-	O
suppressive	O
tolerogenic	O
DCs	O
in	O
TLR	B-Chemical
agonist	I-Chemical
-	O
induced	O
inflammatory	B-Disease
conditions	O
via	O
abundant	O
IL	O
-	O
10	O
production	O
","	O
thereby	O
skewing	O
Th	O
cell	O
differentiation	O
towards	O
Th2	O
and	O
Tr1	O
cells	O
.	O
	
This	O
relationship	O
may	O
provide	O
cancer	B-Disease
cells	O
with	O
an	O
opportunity	O
to	O
evade	O
the	O
immune	O
system	O
.	O
	
	
Hsp90beta	O
is	O
involved	O
in	O
the	O
development	O
of	O
high	O
salt	B-Chemical
-	O
diet	O
-	O
induced	O
nephropathy	B-Disease
via	O
interaction	O
with	O
various	O
signalling	O
proteins	O
.	O
	
A	O
high	O
-	O
salt	B-Chemical
diet	O
often	O
leads	O
to	O
a	O
local	O
intrarenal	O
increase	O
in	O
renal	B-Disease
hypoxia	I-Disease
and	O
oxidative	O
stress	O
","	O
which	O
are	O
responsible	O
for	O
an	O
excess	O
production	O
of	O
pathogenic	O
substances	O
.	O
	
Here	O
","	O
Wistar	O
Kyoto	O
/	O
spontaneous	O
hypertensive	B-Disease
(	O
WKY	O
/	O
SHR	O
)	O
rats	O
fed	O
a	O
high	O
-	O
salt	B-Chemical
diet	O
developed	O
severe	O
proteinuria	B-Disease
","	O
resulting	O
from	O
pronounced	O
renal	B-Disease
inflammation	I-Disease
","	O
fibrosis	B-Disease
and	O
tubular	O
epithelial	O
cell	O
apoptosis	O
.	O
	
All	O
these	O
were	O
mainly	O
non	O
-	O
pressure	O
-	O
related	O
effects	O
.	O
	
Hsp90beta	O
","	O
TGF	O
-	O
beta	O
","	O
HIF	O
-	O
1alpha	O
","	O
TNF	O
-	O
alpha	O
","	O
IL	O
-	O
6	O
and	O
MCP	O
-	O
1	O
were	O
shown	O
to	O
be	O
highly	O
expressed	O
in	O
response	O
to	O
salt	B-Chemical
loading	O
.	O
	
Next	O
","	O
we	O
found	O
that	O
Hsp90beta	O
might	O
play	O
the	O
key	O
role	O
in	O
non	O
-	O
pressure	O
-	O
related	O
effects	O
of	O
salt	B-Chemical
loading	O
through	O
a	O
series	O
of	O
cellular	O
signalling	O
events	O
","	O
including	O
the	O
NF	O
-	O
kappaB	O
","	O
p38	O
activation	O
and	O
Bcl	O
-	O
2	O
inactivation	O
.	O
	
Hsp90beta	O
was	O
previously	O
proven	O
to	O
regulate	O
the	O
upstream	O
mediators	O
in	O
multiple	O
cellular	O
signalling	O
cascades	O
through	O
stabilizing	O
and	O
maintaining	O
their	O
activities	O
.	O
	
In	O
our	O
study	O
","	O
17	B-Chemical
-	I-Chemical
dimethylaminoethylamino	I-Chemical
-	I-Chemical
17	I-Chemical
-	I-Chemical
demethoxygeldanamycin	I-Chemical
(	O
17	B-Chemical
-	I-Chemical
DMAG	I-Chemical
)	O
or	O
Hsp90beta	O
knockdown	O
dramatically	O
alleviated	O
the	O
high	O
-	O
salt	B-Chemical
-	O
diet	O
-	O
induced	O
proteinuria	B-Disease
and	O
renal	B-Disease
damage	I-Disease
without	O
altering	O
blood	O
pressure	O
significantly	O
","	O
when	O
it	O
reversed	O
activations	O
of	O
NF	O
-	O
kappaB	O
","	O
mTOR	O
and	O
p38	O
signalling	O
cascades	O
.	O
	
Meanwhile	O
","	O
Co	O
-	O
IP	O
results	O
demonstrated	O
that	O
Hsp90beta	O
could	O
interact	O
with	O
and	O
stabilize	O
TAK1	O
","	O
AMPKalpha	O
","	O
IKKalpha	O
/	O
beta	O
","	O
HIF	O
-	O
1alpha	O
and	O
Raptor	O
","	O
whereas	O
Hsp90beta	O
inhibition	O
disrupted	O
this	O
process	O
.	O
	
In	O
addition	O
","	O
Hsp90beta	O
inhibition	O
-	O
mediated	O
renal	O
improvements	O
also	O
accompanied	O
the	O
reduction	O
of	O
renal	O
oxidative	O
stress	O
.	O
	
In	O
conclusion	O
","	O
salt	B-Chemical
loading	O
indeed	O
exhibited	O
non	O
-	O
pressure	O
-	O
related	O
impacts	O
on	O
proteinuria	B-Disease
and	O
renal	B-Disease
dysfunction	I-Disease
in	O
WKY	O
/	O
SHR	O
rats	O
.	O
	
Hsp90beta	O
inhibition	O
caused	O
the	O
destabilization	O
of	O
upstream	O
mediators	O
in	O
various	O
pathogenic	O
signalling	O
events	O
","	O
thereby	O
effectively	O
ameliorating	O
this	O
nephropathy	B-Disease
owing	O
to	O
renal	B-Disease
hypoxia	I-Disease
and	O
oxidative	O
stress	O
.	O
	
	
Angiotensin	O
II	O
subtype	O
1a	O
receptor	O
signaling	O
in	O
resident	O
hepatic	O
macrophages	O
induces	O
liver	B-Disease
metastasis	I-Disease
formation	O
.	O
	
Liver	B-Disease
metastases	I-Disease
from	O
colorectal	B-Disease
cancer	I-Disease
(	O
CRC	B-Disease
)	O
are	O
a	O
clinically	O
significant	O
problem	O
.	O
	
The	O
renin	O
-	O
angiotensin	O
system	O
is	O
involved	O
in	O
tumor	B-Disease
growth	O
and	O
metastases	B-Disease
.	O
	
This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
role	O
of	O
angiotensin	O
II	O
subtype	O
receptor	O
1a	O
(	O
AT1a	O
)	O
in	O
the	O
formation	O
of	O
liver	B-Disease
metastasis	I-Disease
in	O
CRC	B-Disease
.	O
	
A	O
model	O
of	O
liver	B-Disease
metastasis	I-Disease
was	O
developed	O
by	O
intrasplenic	O
injection	O
of	O
mouse	O
colon	B-Disease
cancer	I-Disease
(	O
CMT	O
-	O
93	O
)	O
into	O
AT1a	O
knockout	O
mice	O
(	O
AT1aKO	O
)	O
and	O
wild	O
-	O
type	O
(	O
C57BL	O
/	O
6	O
)	O
mice	O
(	O
WT	O
).	O
	
Compared	O
with	O
WT	O
mice	O
","	O
the	O
liver	O
weight	O
and	O
liver	B-Disease
metastatic	I-Disease
rate	O
were	O
significantly	O
lower	O
in	O
AT1aKO	O
.	O
	
The	O
mRNA	O
levels	O
of	O
CD31	O
","	O
transforming	O
growth	O
factor	O
-	O
b1	O
(	O
TGF	O
-	O
b1	O
)","	O
and	O
F4	O
/	O
80	O
were	O
suppressed	O
in	O
AT1aKO	O
compared	O
with	O
WT	O
.	O
	
Double	O
immunofluorescence	O
analysis	O
showed	O
that	O
the	O
number	O
of	O
accumulated	O
F4	O
/	O
80	O
(+)	O
cells	O
expressing	O
TGF	O
-	O
b1	O
in	O
metastatic	O
areas	O
was	O
higher	O
in	O
WT	O
than	O
in	O
AT1aKO	O
.	O
	
The	O
AT1aKO	O
bone	O
marrow	O
(	O
BM	O
)	O
(	O
AT1aKO	O
-	O
BM	O
)>	O
WT	O
showed	O
suppressed	O
formation	O
of	O
liver	B-Disease
metastasis	I-Disease
compared	O
with	O
WT	O
-	O
BM	O
>	O
WT	O
.	O
	
However	O
","	O
the	O
formation	O
of	O
metastasis	B-Disease
was	O
further	O
suppressed	O
in	O
WT	O
-	O
BM	O
>	O
AT1aKO	O
compared	O
with	O
AT1aKO	O
-	O
BM	O
>	O
WT	O
.	O
	
In	O
addition	O
","	O
accumulated	O
F4	O
/	O
80	O
(+)	O
cells	O
in	O
the	O
liver	B-Disease
metastasis	I-Disease
were	O
not	O
BM	O
-	O
derived	O
F4	O
/	O
80	O
(+)	O
cells	O
","	O
but	O
mainly	O
resident	O
hepatic	O
F4	O
/	O
80	O
(+)	O
cells	O
","	O
and	O
these	O
resident	O
hepatic	O
F4	O
/	O
80	O
(+)	O
cells	O
were	O
positive	O
for	O
TGF	O
-	O
b1	O
.	O
	
Angiotensin	O
II	O
enhanced	O
TGF	O
-	O
b1	O
expression	O
in	O
Kupffer	O
cells	O
.	O
	
Treatment	O
of	O
WT	O
with	O
clodronate	B-Chemical
liposomes	O
suppressed	O
liver	B-Disease
metastasis	I-Disease
by	O
diminishing	O
TGF	O
-	O
b1	O
(+)	O
F4	O
/	O
80	O
(+)	O
cells	O
accumulation	O
.	O
	
The	O
formation	O
of	O
liver	B-Disease
metastasis	I-Disease
correlated	O
with	O
collagen	O
deposition	O
in	O
the	O
metastatic	O
area	O
","	O
which	O
was	O
dependent	O
on	O
AT1a	O
signaling	O
.	O
	
These	O
results	O
suggested	O
that	O
resident	O
hepatic	O
macrophages	O
induced	O
liver	B-Disease
metastasis	I-Disease
formation	O
by	O
induction	O
of	O
TGF	O
-	O
b1	O
through	O
AT1a	O
signaling	O
.	O
	
	
Polymorphisms	O
in	O
the	O
SLC2A2	O
(	O
GLUT2	O
)	O
gene	O
are	O
associated	O
with	O
the	O
conversion	O
from	O
impaired	B-Disease
glucose	I-Disease
tolerance	I-Disease
to	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
:	O
the	O
Finnish	O
Diabetes	B-Disease
Prevention	O
Study	O
.	O
	
Impaired	B-Disease
insulin	I-Disease
secretion	I-Disease
is	O
a	O
fundamental	O
defect	O
in	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
.	O
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
the	O
genes	O
regulating	O
insulin	O
secretion	O
(	O
SLC2A2	O
[	O
encoding	O
GLUT2	O
]","	O
GCK	O
","	O
TCF1	O
[	O
encoding	O
HNF	O
-	O
1alpha	O
]","	O
HNF4A	O
","	O
GIP	O
","	O
and	O
GLP1R	O
)	O
are	O
associated	O
with	O
the	O
conversion	O
from	O
impaired	B-Disease
glucose	I-Disease
tolerance	I-Disease
(	O
IGT	B-Disease
)	O
to	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
in	O
participants	O
of	O
the	O
Finnish	O
Diabetes	B-Disease
Prevention	O
Study	O
.	O
	
With	O
the	O
exception	O
of	O
SLC2A2	O
","	O
other	O
genes	O
were	O
not	O
associated	O
with	O
the	O
risk	O
of	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
.	O
	
All	O
four	O
SNPs	O
of	O
SLC2A2	O
predicted	O
the	O
conversion	O
to	O
diabetes	B-Disease
","	O
and	O
rs5393	O
(	O
AA	O
genotype	O
)	O
increased	O
the	O
risk	O
of	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
in	O
the	O
entire	O
study	O
population	O
by	O
threefold	O
(	O
odds	O
ratio	O
3	O
.	O
4	O
","	O
95	O
%	O
CI	O
1	O
.	O
34	O
-	O
6	O
.	O
88	O
","	O
P	O
=	O
0	O
.	O
8	O
).	O
	
The	O
risk	O
for	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
in	O
the	O
AA	O
genotype	O
carriers	O
was	O
increased	O
in	O
the	O
control	O
group	O
(	O
5	O
.	O
56	O
[	O
1	O
.	O
78	O
-	O
17	O
.	O
39	O
]","	O
P	O
=	O
0	O
.	O
3	O
)	O
but	O
not	O
in	O
the	O
intervention	O
group	O
.	O
	
We	O
conclude	O
that	O
the	O
SNPs	O
of	O
SLC2A2	O
predict	O
the	O
conversion	O
to	O
diabetes	B-Disease
in	O
obese	B-Disease
subjects	O
with	O
IGT	B-Disease
.	O
	
	
Peroxisomal	O
proliferator	O
activated	O
receptor	O
-	O
gamma	O
deficiency	O
in	O
a	O
Canadian	O
kindred	O
with	O
familial	B-Disease
partial	I-Disease
lipodystrophy	I-Disease
type	I-Disease
3	I-Disease
(	O
FPLD3	B-Disease
).	O
	
BACKGROUND	O
:	O
Familial	B-Disease
partial	I-Disease
lipodystrophy	I-Disease
(	I-Disease
Dunnigan	I-Disease
)	I-Disease
type	I-Disease
3	I-Disease
(	O
FPLD3	B-Disease
","	O
Mendelian	B-Disease
Inheritance	I-Disease
in	I-Disease
Man	I-Disease
[	I-Disease
MIM	I-Disease
]	I-Disease
604367	I-Disease
)	O
results	O
from	O
heterozygous	O
mutations	O
in	O
PPARG	O
encoding	O
peroxisomal	O
proliferator	O
-	O
activated	O
receptor	O
-	O
gamma	O
.	O
	
Both	O
dominant	O
-	O
negative	O
and	O
haploinsufficiency	O
mechanisms	O
have	O
been	O
suggested	O
for	O
this	O
condition	O
.	O
	
METHODS	O
:	O
We	O
present	O
a	O
Canadian	O
FPLD3	B-Disease
kindred	O
with	O
an	O
affected	O
mother	O
who	O
had	O
loss	O
of	O
fat	O
on	O
arms	O
and	O
legs	O
","	O
but	O
no	O
increase	O
in	O
facial	O
","	O
neck	O
","	O
suprascapular	O
or	O
abdominal	O
fat	O
.	O
	
She	O
had	O
profound	O
insulin	B-Disease
resistance	I-Disease
","	O
diabetes	B-Disease
","	O
severe	O
hypertriglyceridemia	B-Disease
and	O
relapsing	O
pancreatitis	B-Disease
","	O
while	O
her	O
pre	O
-	O
pubescent	O
daughter	O
had	O
normal	O
fat	O
distribution	O
but	O
elevated	O
plasma	O
triglycerides	B-Chemical
and	O
C	B-Chemical
-	I-Chemical
peptide	I-Chemical
and	O
depressed	O
high	B-Chemical
-	I-Chemical
density	I-Chemical
lipoprotein	I-Chemical
cholesterol	I-Chemical
.	O
	
RESULTS	O
:	O
The	O
mother	O
and	O
daughter	O
were	O
each	O
heterozygous	O
for	O
PPARG	O
nonsense	O
mutation	O
Y355X	O
","	O
whose	O
protein	O
product	O
in	O
vitro	O
was	O
transcriptionally	O
inactive	O
with	O
no	O
dominant	O
-	O
negative	O
activity	O
against	O
the	O
wild	O
-	O
type	O
receptor	O
.	O
	
In	O
addition	O
the	O
mutant	O
protein	O
appeared	O
to	O
be	O
markedly	O
unstable	O
.	O
	
CONCLUSION	O
:	O
Taken	O
together	O
with	O
previous	O
studies	O
of	O
human	O
PPARG	O
mutations	O
","	O
these	O
findings	O
suggest	O
that	O
PPAR	O
-	O
gamma	O
deficiency	O
due	O
either	O
to	O
haploinsufficiency	O
or	O
to	O
substantial	O
activity	O
loss	O
due	O
to	O
dominant	O
negative	O
interference	O
of	O
the	O
normal	O
allele	O
product	O
'	O
s	O
function	O
can	O
each	O
contribute	O
to	O
the	O
FPLD3	B-Disease
phenotype	O
.	O
	
	
Catechol	O
-	O
O	O
-	O
methyltransferase	O
(	O
COMT	O
)	O
gene	O
variants	O
:	O
possible	O
association	O
of	O
the	O
Val158Met	O
variant	O
with	O
opiate	B-Disease
addiction	I-Disease
in	O
Hispanic	O
women	O
.	O
	
Catechol	O
-	O
O	O
-	O
methyltransferase	O
(	O
COMT	O
)	O
catalyzes	O
the	O
breakdown	O
of	O
catechol	B-Chemical
neurotransmitters	I-Chemical
","	O
including	O
dopamine	B-Chemical
","	O
which	O
plays	O
a	O
prominent	O
role	O
in	O
drug	O
reward	O
.	O
	
A	O
common	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)","	O
G472A	O
","	O
codes	O
for	O
a	O
Val158Met	O
substitution	O
and	O
results	O
in	O
a	O
fourfold	O
down	O
regulation	O
of	O
enzyme	O
activity	O
.	O
	
We	O
sequenced	O
exon	O
IV	O
of	O
COMT	O
gene	O
in	O
search	O
for	O
novel	O
polymorphisms	O
and	O
then	O
genotyped	O
four	O
out	O
of	O
five	O
identified	O
by	O
direct	O
sequencing	O
","	O
using	O
TaqMan	O
assay	O
on	O
266	O
opioid	B-Chemical
-	O
dependent	O
and	O
173	O
control	O
subjects	O
.	O
	
Genotype	O
frequencies	O
of	O
the	O
G472A	O
SNP	O
varied	O
significantly	O
(	O
P	O
=	O
0	O
.	O
29	O
)	O
among	O
the	O
three	O
main	O
ethnic	O
/	O
cultural	O
groups	O
(	O
Caucasians	O
","	O
Hispanics	O
","	O
and	O
African	O
Americans	O
).	O
	
Using	O
a	O
genotype	O
test	O
","	O
we	O
found	O
a	O
trend	O
to	O
point	O
-	O
wise	O
association	O
(	O
P	O
=	O
0	O
.	O
53	O
)	O
of	O
the	O
G472A	O
SNP	O
in	O
Hispanic	O
subjects	O
with	O
opiate	B-Disease
addiction	I-Disease
.	O
	
Further	O
analysis	O
of	O
G472A	O
genotypes	O
in	O
Hispanic	O
subjects	O
with	O
data	O
stratified	O
by	O
gender	O
identified	O
a	O
point	O
-	O
wise	O
significant	O
(	O
P	O
=	O
0	O
.	O
49	O
)	O
association	O
of	O
G	O
/	O
A	O
and	O
A	O
/	O
A	O
genotypes	O
with	O
opiate	B-Disease
addiction	I-Disease
in	O
women	O
","	O
but	O
not	O
men	O
.	O
	
These	O
point	O
-	O
wise	O
significant	O
results	O
are	O
not	O
significant	O
experiment	O
-	O
wise	O
(	O
at	O
P	O
<	O
0	O
.	O
5	O
)	O
after	O
correction	O
for	O
multiple	O
testing	O
.	O
	
No	O
significant	O
association	O
was	O
found	O
with	O
haplotypes	O
of	O
the	O
three	O
most	O
common	O
SNPs	O
.	O
	
Linkage	O
disequilibrium	O
patterns	O
were	O
similar	O
for	O
the	O
three	O
ethnic	O
/	O
cultural	O
groups	O
.	O
	
	
Depletion	O
of	O
mitochondrial	O
DNA	O
in	O
fibroblast	O
cultures	O
from	O
patients	O
with	O
POLG1	O
mutations	O
is	O
a	O
consequence	O
of	O
catalytic	O
mutations	O
.	O
	
We	O
investigated	O
clinical	O
and	O
cellular	O
phenotypes	O
of	O
24	O
children	O
with	O
mutations	O
in	O
the	O
catalytic	O
(	O
alpha	O
)	O
subunit	O
of	O
the	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
gamma	O
polymerase	O
(	O
POLG1	O
).	O
	
Twenty	O
-	O
one	O
had	O
Alpers	B-Disease
syndrome	I-Disease
","	O
the	O
commonest	O
severe	O
POLG1	O
autosomal	O
recessive	O
phenotype	O
","	O
comprising	O
hepatoencephalopathy	B-Disease
and	O
often	O
mtDNA	O
depletion	O
.	O
	
The	O
cellular	O
mtDNA	O
content	O
reflected	O
the	O
genotype	O
more	O
closely	O
than	O
did	O
clinical	O
features	O
.	O
	
Patients	O
with	O
tissue	O
depletion	O
of	O
mtDNA	O
all	O
had	O
at	O
least	O
one	O
allele	O
with	O
either	O
a	O
missense	O
mutation	O
in	O
a	O
catalytic	O
domain	O
or	O
a	O
nonsense	O
mutation	O
.	O
	
Four	O
out	O
of	O
12	O
patients	O
exhibited	O
a	O
progressive	O
","	O
mosaic	O
pattern	O
of	O
mtDNA	O
depletion	O
in	O
cultured	O
fibroblasts	O
.	O
	
All	O
these	O
patients	O
had	O
mutations	O
in	O
a	O
catalytic	O
domain	O
in	O
both	O
POLG1	O
alleles	O
","	O
in	O
either	O
the	O
polymerase	O
or	O
exonuclease	O
domain	O
or	O
both	O
.	O
	
The	O
tissue	O
mtDNA	O
content	O
of	O
patients	O
who	O
had	O
two	O
linker	O
mutations	O
was	O
normal	O
","	O
and	O
their	O
phenotypes	O
the	O
mildest	O
.	O
	
Epilepsy	B-Disease
and	O
/	O
or	O
movement	B-Disease
disorder	I-Disease
were	O
major	O
features	O
in	O
all	O
21	O
.	O
	
Previous	O
studies	O
have	O
implicated	O
replication	O
stalling	O
as	O
a	O
mechanism	O
for	O
mtDNA	O
depletion	O
.	O
	
The	O
mosaic	O
cellular	O
depletion	O
that	O
we	O
have	O
demonstrated	O
in	O
cell	O
cultures	O
may	O
be	O
a	O
manifestation	O
of	O
severe	O
replication	O
stalling	O
.	O
	
One	O
patient	O
with	O
a	O
severe	O
cellular	O
and	O
clinical	O
phenotype	O
was	O
a	O
compound	O
heterozygote	O
with	O
POLG1	O
mutations	O
in	O
the	O
polymerase	O
and	O
exonuclease	O
domain	O
intrans	O
.	O
	
This	O
suggests	O
that	O
POLG1	O
requires	O
both	O
polymerase	O
and	O
3	O
'-	O
5	O
'	O
exonuclease	O
activity	O
in	O
the	O
same	O
molecule	O
.	O
	
This	O
is	O
consistent	O
with	O
current	O
functional	O
models	O
for	O
eukaryotic	O
DNA	O
polymerases	O
","	O
which	O
alternate	O
between	O
polymerizing	O
and	O
editing	O
modes	O
","	O
as	O
determined	O
by	O
competition	O
between	O
these	O
two	O
active	O
sites	O
for	O
the	O
3	O
'	O
end	O
of	O
the	O
DNA	O
.	O
	
	
Mutations	O
in	O
phospholipase	O
C	O
epsilon	O
1	O
are	O
not	O
sufficient	O
to	O
cause	O
diffuse	B-Disease
mesangial	I-Disease
sclerosis	I-Disease
.	O
	
Diffuse	B-Disease
mesangial	I-Disease
sclerosis	I-Disease
occurs	O
as	O
an	O
isolated	O
abnormality	O
or	O
as	O
a	O
part	O
of	O
a	O
syndrome	O
.	O
	
Recently	O
","	O
mutations	O
in	O
phospholipase	O
C	O
epsilon	O
1	O
(	O
PLCE1	O
)	O
were	O
found	O
to	O
cause	O
a	O
nonsyndromic	O
","	O
autosomal	O
recessive	O
form	O
of	O
this	O
disease	O
.	O
	
Here	O
we	O
describe	O
three	O
children	O
from	O
one	O
consanguineous	O
kindred	O
of	O
Pakistani	O
origin	O
with	O
diffuse	B-Disease
mesangial	I-Disease
sclerosis	I-Disease
who	O
presented	O
with	O
congenital	B-Disease
or	I-Disease
infantile	I-Disease
nephrotic	I-Disease
syndrome	I-Disease
.	O
	
Homozygous	O
mutations	O
in	O
PLCE1	O
(	O
also	O
known	O
as	O
KIAA1516	O
","	O
PLCE	O
","	O
or	O
NPHS3	O
)	O
were	O
identified	O
following	O
genome	O
-	O
wide	O
mapping	O
of	O
single	O
-	O
nucleotide	O
polymorphisms	O
.	O
	
All	O
affected	O
children	O
were	O
homozygous	O
for	O
a	O
four	O
-	O
basepair	O
deletion	O
in	O
exon	O
3	O
","	O
which	O
created	O
a	O
premature	O
translational	O
stop	O
codon	O
.	O
	
Analysis	O
of	O
the	O
asymptomatic	O
father	O
of	O
two	O
of	O
the	O
children	O
revealed	O
that	O
he	O
was	O
also	O
homozygous	O
for	O
the	O
same	O
mutation	O
.	O
	
We	O
conclude	O
this	O
nonpenetrance	O
may	O
be	O
due	O
to	O
compensatory	O
mutations	O
at	O
a	O
second	O
locus	O
and	O
that	O
mutation	O
within	O
PLCE1	O
is	O
not	O
always	O
sufficient	O
to	O
cause	O
diffuse	B-Disease
mesangial	I-Disease
sclerosis	I-Disease
.	O
	
	
Seizures	B-Disease
associated	O
with	O
levofloxacin	B-Chemical
:	O
case	O
presentation	O
and	O
literature	O
review	O
.	O
	
PURPOSE	O
:	O
We	O
present	O
a	O
case	O
of	O
a	O
patient	O
who	O
developed	O
seizures	B-Disease
shortly	O
after	O
initiating	O
treatment	O
with	O
levofloxacin	B-Chemical
and	O
to	O
discuss	O
the	O
potential	O
drug	O
-	O
drug	O
interactions	O
related	O
to	O
the	O
inhibition	O
of	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
1A2	O
in	O
this	O
case	O
","	O
as	O
well	O
as	O
in	O
other	O
cases	O
","	O
of	O
levofloxacin	B-Chemical
-	O
induced	O
seizures	B-Disease
.	O
	
METHODS	O
:	O
Several	O
biomedical	O
databases	O
were	O
searched	O
including	O
MEDLINE	O
","	O
Cochrane	O
and	O
Ovid	O
.	O
	
The	O
main	O
search	O
terms	O
utilized	O
were	O
case	O
report	O
and	O
levofloxacin	B-Chemical
.	O
	
The	O
search	O
was	O
limited	O
to	O
studies	O
published	O
in	O
English	O
.	O
	
RESULTS	O
:	O
Six	O
cases	O
of	O
levofloxacin	B-Chemical
-	O
induced	O
seizures	B-Disease
have	O
been	O
reported	O
in	O
the	O
literature	O
.	O
	
Drug	O
-	O
drug	O
interactions	O
related	O
to	O
the	O
inhibition	O
of	O
CYP1A2	O
by	O
levofloxacin	B-Chemical
are	O
likely	O
involved	O
in	O
the	O
clinical	O
outcome	O
of	O
these	O
cases	O
.	O
	
CONCLUSIONS	O
:	O
Clinicians	O
are	O
exhorted	O
to	O
pay	O
close	O
attention	O
when	O
initiating	O
levofloxacin	B-Chemical
therapy	O
in	O
patients	O
taking	O
medications	O
with	O
epileptogenic	O
properties	O
that	O
are	O
CYP1A2	O
substrates	O
.	O
	
	
Fatal	O
carbamazepine	B-Chemical
induced	O
fulminant	O
eosinophilic	O
(	O
hypersensitivity	B-Disease
)	O
myocarditis	B-Disease
:	O
emphasis	O
on	O
anatomical	O
and	O
histological	O
characteristics	O
","	O
mechanisms	O
and	O
genetics	O
of	O
drug	B-Disease
hypersensitivity	I-Disease
and	O
differential	O
diagnosis	O
.	O
	
The	O
most	O
severe	O
adverse	O
reactions	O
to	O
carbamazepine	B-Chemical
have	O
been	O
observed	O
in	O
the	O
haemopoietic	O
system	O
","	O
the	O
liver	O
and	O
the	O
cardiovascular	O
system	O
.	O
	
A	O
frequently	O
fatal	O
","	O
although	O
exceptionally	O
rare	O
side	O
effect	O
of	O
carbamazepine	B-Chemical
is	O
necrotizing	O
eosinophilic	O
(	O
hypersensitivity	B-Disease
)	O
myocarditis	B-Disease
.	O
	
We	O
report	O
a	O
case	O
of	O
hypersensitivity	B-Disease
myocarditis	I-Disease
secondary	O
to	O
administration	O
of	O
carbamazepine	B-Chemical
.	O
	
Acute	O
hypersensitivity	B-Disease
myocarditis	I-Disease
was	O
not	O
suspected	O
clinically	O
","	O
and	O
the	O
diagnosis	O
was	O
made	O
post	O
-	O
mortem	O
.	O
	
Histology	O
revealed	O
diffuse	O
infiltration	O
of	O
the	O
myocardium	O
by	O
eosinophils	O
and	O
lymphocytes	O
with	O
myocyte	O
damage	O
.	O
	
Clinically	O
","	O
death	B-Disease
was	O
due	O
to	O
cardiogenic	B-Disease
shock	I-Disease
.	O
	
To	O
best	O
of	O
our	O
knowledge	O
this	O
is	O
the	O
second	O
case	O
of	O
fatal	O
carbamazepine	B-Chemical
induced	O
myocarditis	B-Disease
reported	O
in	O
English	O
literature	O
.	O
	
	
Lack	O
of	O
association	O
between	O
ADRA2B	O
-	O
4825	O
gene	O
insertion	O
/	O
deletion	O
polymorphism	O
and	O
migraine	B-Disease
in	O
Chinese	O
Han	O
population	O
.	O
	
OBJECTIVE	O
:	O
The	O
present	O
study	O
aimed	O
to	O
estimate	O
the	O
association	O
between	O
susceptibility	O
to	O
migraine	B-Disease
and	O
the	O
12	O
-	O
nucleotide	O
insertion	O
/	O
deletion	O
(	O
indel	O
)	O
polymorphism	O
in	O
promoter	O
region	O
of	O
alpha	O
(	O
2B	O
)-	O
adrenergic	O
receptor	O
gene	O
(	O
ADRA2B	O
).	O
	
METHODS	O
:	O
A	O
case	O
-	O
control	O
study	O
was	O
carried	O
out	O
in	O
Chinese	O
Han	O
population	O
","	O
including	O
368	O
cases	O
of	O
migraine	B-Disease
and	O
517	O
controls	O
.	O
	
Genomic	O
DNA	O
was	O
extracted	O
from	O
blood	O
samples	O
","	O
and	O
DNA	O
fragments	O
containing	O
the	O
site	O
of	O
polymorphism	O
were	O
amplified	O
by	O
PCR	O
.	O
	
Data	O
were	O
adjusted	O
for	O
sex	O
","	O
age	O
","	O
migraine	B-Disease
history	O
and	O
family	O
history	O
","	O
and	O
analyzed	O
using	O
a	O
logistic	O
regression	O
model	O
.	O
	
RESULTS	O
:	O
There	O
was	O
no	O
association	O
between	O
indel	O
polymorphism	O
and	O
migraine	B-Disease
","	O
at	O
either	O
the	O
allele	O
or	O
the	O
genotype	O
level	O
.	O
	
CONCLUSION	O
:	O
These	O
findings	O
do	O
not	O
support	O
a	O
functional	O
significance	O
of	O
ADRA2B	O
indel	O
polymorphism	O
at	O
position	O
-	O
4825	O
relative	O
to	O
the	O
start	O
codon	O
in	O
the	O
far	O
upstream	O
region	O
of	O
the	O
promoter	O
in	O
the	O
present	O
migraine	B-Disease
subjects	O
.	O
	
	
A	O
novel	O
apolipoprotein	O
E	O
mutation	O
","	O
ApoE	O
Osaka	O
(	O
Arg158	O
Pro	O
)","	O
in	O
a	O
dyslipidemic	B-Disease
patient	O
with	O
lipoprotein	B-Disease
glomerulopathy	I-Disease
.	O
	
Lipoprotein	B-Disease
glomerulopathy	I-Disease
(	O
LPG	B-Disease
)	O
is	O
a	O
rare	O
disease	O
characterized	O
by	O
the	O
presence	O
of	O
thrombuslike	O
deposition	O
in	O
markedly	O
dilated	O
glomerular	O
capillaries	O
and	O
is	O
often	O
accompanied	O
by	O
an	O
increased	O
serum	O
apolipoprotein	O
E	O
(	O
apoE	O
)	O
level	O
.	O
	
Several	O
gene	O
mutations	O
of	O
apoE	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
LPG	B-Disease
.	O
	
In	O
the	O
current	O
study	O
","	O
we	O
report	O
an	O
LPG	B-Disease
patient	O
with	O
a	O
novel	O
apoE	O
mutation	O
","	O
apoE	O
Osaka	O
.	O
	
The	O
patient	O
was	O
a	O
45	O
-	O
year	O
-	O
old	O
man	O
who	O
was	O
hospitalized	O
due	O
to	O
nephrotic	B-Disease
syndrome	I-Disease
.	O
	
Light	O
and	O
electron	O
microscopic	O
observations	O
of	O
renal	O
biopsy	O
clearly	O
showed	O
characteristic	O
findings	O
of	O
LPG	B-Disease
","	O
including	O
lamellate	B-Disease
thrombi	I-Disease
in	O
the	O
lumen	O
of	O
dilated	O
glomerular	O
capillaries	O
.	O
	
His	O
apoE	O
phenotype	O
was	O
apoE3	O
/	O
2	O
and	O
he	O
had	O
mild	O
dyslipidemia	B-Disease
with	O
a	O
mid	O
-	O
band	O
on	O
polyacrylamide	B-Chemical
gel	O
electrophoresis	O
.	O
	
It	O
is	O
intriguing	O
that	O
the	O
serum	O
apoE	O
level	O
was	O
within	O
normal	O
limits	O
.	O
	
We	O
determined	O
the	O
sequence	O
of	O
the	O
apoE	O
gene	O
using	O
direct	O
sequencing	O
of	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
products	O
.	O
	
ApoE	O
gene	O
analysis	O
showed	O
a	O
nucleotide	O
substitution	O
of	O
G	O
to	O
C	O
at	O
codon	O
158	O
of	O
exon	O
4	O
.	O
	
This	O
mutation	O
denoted	O
an	O
amino	O
acid	O
substitution	O
of	O
arginine	O
residue	O
for	O
the	O
proline	O
residue	O
at	O
position	O
158	O
of	O
apoE	O
.	O
	
The	O
result	O
of	O
PCR	O
associated	O
with	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
also	O
suggested	O
that	O
this	O
mutation	O
is	O
heterozygous	O
.	O
	
It	O
is	O
possible	O
that	O
apoE	O
Osaka	O
mutation	O
causes	O
a	O
conformational	O
change	O
of	O
apoE	O
protein	O
and	O
affects	O
the	O
interaction	O
between	O
abnormal	O
apoE	O
-	O
containing	O
lipoproteins	O
and	O
the	O
endothelial	O
cells	O
of	O
glomerular	O
capillaries	O
.	O
	
The	O
precise	O
mechanism	O
of	O
LPG	B-Disease
related	O
with	O
apoE	O
Osaka	O
","	O
however	O
","	O
remains	O
to	O
be	O
elucidated	O
.	O
	
	
PTCH1	O
gene	O
mutations	O
in	O
exon	O
17	O
and	O
loss	O
of	O
heterozygosity	O
on	O
D9S180	O
microsatellite	O
in	O
sporadic	O
and	O
inherited	O
human	O
basal	B-Disease
cell	I-Disease
carcinomas	I-Disease
.	O
	
BACKGROUND	O
:	O
Basal	B-Disease
cell	I-Disease
carcinomas	I-Disease
(	O
BCCs	B-Disease
)	O
are	O
the	O
most	O
frequent	O
human	O
cancer	B-Disease
that	O
results	O
from	O
malignant	O
transformation	O
of	O
basal	O
cells	O
in	O
the	O
epidermis	O
.	O
	
Gorlin	B-Disease
syndrome	I-Disease
is	O
a	O
rare	O
inherited	B-Disease
autosomal	I-Disease
dominant	I-Disease
disease	I-Disease
that	O
predisposes	O
with	O
multiple	O
BCCs	B-Disease
and	O
other	O
birth	B-Disease
defects	I-Disease
.	O
	
Both	O
sporadic	O
and	O
inherited	O
BCCs	B-Disease
are	O
associated	O
with	O
mutations	O
in	O
the	O
tumor	B-Disease
suppressor	O
gene	O
PTCH1	O
","	O
but	O
there	O
is	O
still	O
uncertainty	O
on	O
the	O
role	O
of	O
its	O
homolog	O
PTCH2	O
.	O
	
OBJECTIVES	O
:	O
To	O
search	O
for	O
mutations	O
and	O
genomic	O
instability	O
in	O
sporadic	O
and	O
inherited	O
BCCs	B-Disease
.	O
	
METHODS	O
:	O
DNA	O
obtained	O
from	O
leukocytes	O
and	O
tumor	B-Disease
cells	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
regarding	O
five	O
exons	O
of	O
PTCH1	O
and	O
PTCH2	O
and	O
neighboring	O
microsatellites	O
.	O
	
Exons	O
were	O
sequenced	O
and	O
compared	O
with	O
the	O
GenBank	O
database	O
.	O
	
RESULTS	O
:	O
Only	O
D9S180	O
","	O
of	O
six	O
microsatellites	O
","	O
showed	O
loss	O
of	O
heterozygosity	O
in	O
three	O
BCCs	B-Disease
(	O
two	O
sporadic	O
and	O
one	O
inherited	O
).	O
	
One	O
sporadic	O
BCC	B-Disease
presented	O
the	O
mutation	O
g	O
.	O
2885G	O
>	O
C	O
in	O
exon	O
17	O
of	O
PTCH1	O
","	O
which	O
predicts	O
the	O
substitution	O
p	O
.	O
R962T	O
in	O
an	O
external	O
domain	O
of	O
the	O
protein	O
.	O
	
In	O
addition	O
","	O
the	O
leukocytes	O
and	O
tumor	B-Disease
cells	O
of	O
one	O
patient	O
with	O
Gorlin	B-Disease
syndrome	I-Disease
showed	O
the	O
mutation	O
g	O
.	O
2839T	O
>	O
G	O
in	O
the	O
same	O
exon	O
and	O
gene	O
","	O
which	O
predicts	O
a	O
p	O
.	O
E947stop	O
and	O
truncated	O
protein	O
.	O
	
All	O
control	O
and	O
tumor	B-Disease
samples	O
presented	O
IVS9	O
+	O
217T	O
in	O
intron	O
9	O
of	O
PTCH1	O
.	O
	
CONCLUSION	O
:	O
Mutations	O
found	O
in	O
the	O
PTCH1	O
gene	O
and	O
neighboring	O
repetitive	O
sequences	O
may	O
have	O
contributed	O
to	O
the	O
development	O
of	O
the	O
studied	O
BCCs	B-Disease
.	O
	
	
Novel	O
compound	O
heterozygous	O
mutation	O
of	O
MLYCD	O
in	O
a	O
Chinese	O
patient	O
with	O
malonic	B-Disease
aciduria	I-Disease
.	O
	
A	O
3	O
-	O
year	O
-	O
old	O
Chinese	O
boy	O
presented	O
with	O
prominent	O
clinical	O
features	O
of	O
malonic	B-Disease
aciduria	I-Disease
","	O
including	O
developmental	B-Disease
delay	I-Disease
","	O
short	B-Disease
stature	I-Disease
","	O
brain	B-Disease
abnormalities	I-Disease
and	O
massive	O
excretion	O
of	O
malonic	B-Chemical
acid	I-Chemical
and	O
methylmalonic	B-Chemical
acid	I-Chemical
.	O
	
Molecular	O
characterization	O
by	O
DNA	O
sequencing	O
analysis	O
and	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
of	O
the	O
MLYCD	O
gene	O
revealed	O
a	O
heterozygous	O
mutation	O
(	O
c	O
.	O
920T	O
>	O
G	O
","	O
p	O
.	O
Leu307Arg	O
)	O
in	O
the	O
patient	O
and	O
his	O
father	O
and	O
a	O
heterozygous	O
deletion	O
comprising	O
exon	O
1	O
in	O
the	O
patient	O
and	O
his	O
mother	O
.	O
	
The	O
missense	O
mutation	O
(	O
c	O
.	O
920T	O
>	O
G	O
)	O
was	O
not	O
found	O
in	O
100	O
healthy	O
controls	O
and	O
has	O
not	O
been	O
reported	O
previously	O
.	O
	
Our	O
findings	O
expand	O
the	O
number	O
of	O
reported	O
cases	O
and	O
add	O
a	O
novel	O
entry	O
to	O
the	O
repertoire	O
of	O
MLYCD	O
mutations	O
.	O
	
	
Sepsis	B-Disease
-	O
induced	O
changes	O
in	O
amino	O
acid	O
transporters	O
and	O
leucine	B-Chemical
signaling	O
via	O
mTOR	O
in	O
skeletal	O
muscle	O
.	O
	
The	O
present	O
study	O
tested	O
the	O
hypothesis	O
that	O
sepsis	B-Disease
-	O
induced	O
leucine	B-Chemical
(	O
Leu	B-Chemical
)	O
resistance	O
in	O
skeletal	O
muscle	O
is	O
associated	O
with	O
a	O
down	O
-	O
regulation	O
of	O
amino	O
acid	O
transporters	O
important	O
in	O
regulating	O
Leu	B-Chemical
flux	O
or	O
an	O
impairment	O
in	O
the	O
formation	O
of	O
the	O
Leu	B-Chemical
-	O
sensitive	O
mTOR	O
-	O
Ragulator	O
complex	O
.	O
	
Sepsis	B-Disease
in	O
adult	O
male	O
rats	O
decreased	O
basal	O
protein	O
synthesis	O
in	O
gastrocnemius	O
","	O
associated	O
with	O
a	O
reduction	O
in	O
mTOR	O
activation	O
as	O
indicated	O
by	O
decreased	O
4E	O
-	O
BP1	O
and	O
S6K1	O
phosphorylation	O
.	O
	
The	O
ability	O
of	O
oral	O
Leu	B-Chemical
to	O
increase	O
protein	O
synthesis	O
and	O
mTOR	O
kinase	O
after	O
1	O
h	O
was	O
largely	O
prevented	O
in	O
sepsis	B-Disease
.	O
	
Sepsis	B-Disease
increased	O
CAT1	O
","	O
LAT2	O
and	O
SNAT2	O
mRNA	O
content	O
two	O
-	O
to	O
fourfold	O
","	O
but	O
only	O
the	O
protein	O
content	O
for	O
CAT1	O
(	O
20	O
%	O
decrease	O
)	O
differed	O
significantly	O
.	O
	
Conversely	O
","	O
sepsis	B-Disease
decreased	O
the	O
proton	O
-	O
assisted	O
amino	O
acid	O
transporter	O
(	O
PAT	O
)-	O
2	O
mRNA	O
by	O
60	O
%","	O
but	O
without	O
a	O
coordinate	O
change	O
in	O
PAT2	O
protein	O
.	O
	
There	O
was	O
no	O
sepsis	B-Disease
or	O
Leu	B-Chemical
effect	O
on	O
the	O
protein	O
content	O
for	O
RagA	O
-	O
D	O
","	O
LAMTOR	O
-	O
1	O
and	O
-	O
2	O
","	O
raptor	O
","	O
Rheb	O
or	O
mTOR	O
in	O
muscle	O
.	O
	
The	O
binding	O
of	O
mTOR	O
","	O
PRAS40	O
and	O
RagC	O
to	O
raptor	O
did	O
not	O
differ	O
for	O
control	O
and	O
septic	O
muscle	O
in	O
the	O
basal	O
condition	O
";"	O
however	O
","	O
the	O
Leu	B-Chemical
-	O
induced	O
decrease	O
in	O
PRAS40	O
raptor	O
and	O
increase	O
in	O
RagC	O
raptor	O
seen	O
in	O
control	O
muscle	O
was	O
absent	O
in	O
sepsis	B-Disease
.	O
	
The	O
intracellular	O
Leu	B-Chemical
concentration	O
was	O
increased	O
in	O
septic	O
muscle	O
","	O
compared	O
to	O
basal	O
control	O
conditions	O
","	O
and	O
oral	O
Leu	B-Chemical
further	O
increased	O
the	O
intracellular	O
Leu	B-Chemical
concentration	O
similarly	O
in	O
both	O
control	O
and	O
septic	O
rats	O
.	O
	
Hence	O
","	O
while	O
alterations	O
in	O
select	O
amino	O
acid	O
transporters	O
are	O
not	O
associated	O
with	O
development	O
of	O
sepsis	B-Disease
-	O
induced	O
Leu	B-Chemical
resistance	O
","	O
the	O
Leu	B-Chemical
-	O
stimulated	O
binding	O
of	O
raptor	O
with	O
RagC	O
and	O
the	O
recruitment	O
of	O
mTOR	O
/	O
raptor	O
to	O
the	O
endosome	O
-	O
lysosomal	O
compartment	O
may	O
partially	O
explain	O
the	O
inability	O
of	O
Leu	B-Chemical
to	O
fully	O
activate	O
mTOR	O
and	O
muscle	O
protein	O
synthesis	O
.	O
	
	
Star	O
-	O
PAP	O
","	O
a	O
poly	O
(	O
A	O
)	O
polymerase	O
","	O
functions	O
as	O
a	O
tumor	B-Disease
suppressor	O
in	O
an	O
orthotopic	O
human	O
breast	B-Disease
cancer	I-Disease
model	O
.	O
	
Star	O
-	O
PAP	O
is	O
a	O
noncanonical	O
poly	O
(	O
A	O
)	O
polymerase	O
and	O
required	O
for	O
the	O
expression	O
of	O
a	O
select	O
set	O
of	O
mRNAs	O
.	O
	
However	O
","	O
the	O
pathological	O
role	O
of	O
Star	O
-	O
PAP	O
in	O
cancer	B-Disease
largely	O
remains	O
unknown	O
.	O
	
In	O
this	O
study	O
","	O
we	O
observed	O
decreased	O
expression	O
of	O
Star	O
-	O
PAP	O
in	O
breast	B-Disease
cancer	I-Disease
cell	O
lines	O
and	O
tissues	O
.	O
	
Ectopic	O
Star	O
-	O
PAP	O
expression	O
inhibited	O
proliferation	O
as	O
well	O
as	O
colony	O
-	O
forming	O
ability	O
of	O
breast	B-Disease
cancer	I-Disease
cells	O
.	O
	
In	O
breast	B-Disease
cancer	I-Disease
patients	O
","	O
high	O
levels	O
of	O
Star	O
-	O
PAP	O
correlated	O
with	O
an	O
improved	O
prognosis	O
.	O
	
Moreover	O
","	O
by	O
regulating	O
the	O
expression	O
of	O
BIK	O
(	O
BCL2	O
-	O
interacting	O
killer	O
)","	O
Star	O
-	O
PAP	O
induced	O
apoptosis	O
of	O
breast	B-Disease
cancer	I-Disease
cells	O
through	O
the	O
mitochondrial	O
pathway	O
.	O
	
The	O
growth	O
of	O
breast	B-Disease
cancer	I-Disease
xenografts	O
in	O
NOD	O
/	O
SCID	B-Disease
mice	O
was	O
also	O
inhibited	O
by	O
the	O
doxycycline	B-Chemical
-	O
induced	O
Star	O
-	O
PAP	O
overexpression	O
.	O
	
Furthermore	O
","	O
Star	O
-	O
PAP	O
sensitized	O
breast	B-Disease
cancer	I-Disease
cells	O
to	O
chemotherapy	O
drugs	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
	
In	O
mammary	O
epithelial	O
cells	O
","	O
Star	O
-	O
PAP	O
knockdown	O
partially	O
transformed	O
these	O
cells	O
and	O
induced	O
them	O
to	O
undergo	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
).	O
	
These	O
findings	O
suggested	O
that	O
Star	O
-	O
PAP	O
possesses	O
tumor	B-Disease
-	O
suppressing	O
activity	O
and	O
can	O
be	O
a	O
valuable	O
target	O
for	O
developing	O
new	O
cancer	B-Disease
therapeutic	O
strategies	O
.	O
	
	
Lack	O
of	O
major	O
involvement	O
of	O
human	O
uroplakin	O
genes	O
in	O
vesicoureteral	B-Disease
reflux	I-Disease
:	O
implications	O
for	O
disease	O
heterogeneity	O
.	O
	
BACKGROUND	O
:	O
Primary	O
vesicoureteral	B-Disease
reflux	I-Disease
(	O
VUR	B-Disease
)	O
is	O
a	O
hereditary	B-Disease
disorder	I-Disease
characterized	O
by	O
the	O
retrograde	O
flow	O
of	O
urine	O
into	O
the	O
ureters	O
and	O
kidneys	O
.	O
	
It	O
affects	O
about	O
1	O
%	O
of	O
the	O
young	O
children	O
and	O
is	O
thus	O
one	O
of	O
the	O
most	O
common	O
hereditary	B-Disease
diseases	I-Disease
.	O
	
Its	O
associated	O
nephropathy	B-Disease
is	O
an	O
important	O
cause	O
of	O
end	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
failure	I-Disease
in	O
children	O
and	O
adults	O
.	O
	
Recent	O
studies	O
indicate	O
that	O
genetic	O
ablation	O
of	O
mouse	O
uroplakin	O
(	O
UP	O
)	O
III	O
gene	O
","	O
which	O
encodes	O
a	O
47	O
kD	O
urothelial	O
-	O
specific	O
integral	O
membrane	O
protein	O
forming	O
urothelial	O
plaques	O
","	O
causes	O
VUR	B-Disease
and	O
hydronephrosis	B-Disease
.	O
	
METHODS	O
:	O
To	O
begin	O
to	O
determine	O
whether	O
mutations	O
in	O
UP	O
genes	O
might	O
play	O
a	O
role	O
in	O
human	O
VUR	B-Disease
","	O
we	O
genotyped	O
all	O
four	O
UP	O
genes	O
in	O
76	O
patients	O
with	O
radiologically	O
proven	O
primary	O
VUR	B-Disease
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
and	O
sequencing	O
of	O
all	O
their	O
exons	O
plus	O
50	O
to	O
150	O
bp	O
of	O
flanking	O
intronic	O
sequences	O
.	O
	
RESULTS	O
:	O
Eighteen	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
were	O
identified	O
","	O
seven	O
of	O
which	O
were	O
missense	O
","	O
with	O
no	O
truncation	O
or	O
frame	O
shift	O
mutations	O
.	O
	
Since	O
healthy	O
relatives	O
of	O
the	O
VUR	B-Disease
probands	O
are	O
not	O
reliable	O
negative	O
controls	O
for	O
VUR	B-Disease
","	O
we	O
used	O
a	O
population	O
of	O
90	O
race	O
-	O
matched	O
","	O
healthy	O
individuals	O
","	O
unrelated	O
to	O
the	O
VUR	B-Disease
patients	O
","	O
as	O
controls	O
to	O
perform	O
an	O
association	O
study	O
.	O
	
Most	O
of	O
the	O
SNPs	O
were	O
not	O
found	O
to	O
be	O
significantly	O
associated	O
with	O
VUR	B-Disease
.	O
	
However	O
","	O
SNP1	O
of	O
UP	O
Ia	O
gene	O
affecting	O
a	O
C	O
to	O
T	O
conversion	O
and	O
an	O
Ala7Val	O
change	O
","	O
and	O
SNP7	O
of	O
UP	O
III	O
affecting	O
a	O
C	O
to	O
G	O
conversion	O
and	O
a	O
Pro154Ala	O
change	O
","	O
were	O
marginally	O
associated	O
with	O
VUR	B-Disease
(	O
both	O
P	O
=	O
0	O
.	O
8	O
).	O
	
Studies	O
of	O
additional	O
cases	O
yielded	O
a	O
second	O
set	O
of	O
data	O
that	O
","	O
in	O
combination	O
with	O
the	O
first	O
set	O
","	O
confirmed	O
a	O
weak	O
association	O
of	O
UP	O
III	O
SNP7	O
in	O
VUR	B-Disease
(	O
P	O
=	O
0	O
.	O
36	O
adjusted	O
for	O
both	O
subsets	O
of	O
cases	O
vs	O
.	O
	
controls	O
).	O
	
CONCLUSION	O
:	O
Such	O
a	O
weak	O
association	O
and	O
the	O
lack	O
of	O
families	O
with	O
simple	O
dominant	O
Mendelian	O
inheritance	O
suggest	O
that	O
missense	O
changes	O
of	O
uroplakin	O
genes	O
cannot	O
play	O
a	O
dominant	O
role	O
in	O
causing	O
VUR	B-Disease
in	O
humans	O
","	O
although	O
they	O
may	O
be	O
weak	O
risk	O
factors	O
contributing	O
to	O
a	O
complex	O
polygenic	O
disease	O
.	O
	
The	O
fact	O
that	O
no	O
truncation	O
or	O
frame	O
shift	O
mutations	O
have	O
been	O
found	O
in	O
any	O
of	O
the	O
VUR	B-Disease
patients	O
","	O
coupled	O
with	O
our	O
recent	O
finding	O
that	O
some	O
breeding	O
pairs	O
of	O
UP	O
III	O
knockout	O
mice	O
yield	O
litters	O
that	O
show	O
not	O
only	O
VUR	B-Disease
","	O
but	O
also	O
severe	O
hydronephrosis	B-Disease
and	O
neonatal	B-Disease
death	I-Disease
","	O
raises	O
the	O
possibility	O
that	O
major	O
uroplakin	O
mutations	O
could	O
be	O
embryonically	O
or	O
postnatally	O
lethal	O
in	O
humans	O
.	O
	
	
Does	O
domperidone	B-Chemical
potentiate	O
mirtazapine	B-Chemical
-	O
associated	O
restless	B-Disease
legs	I-Disease
syndrome	I-Disease
?	O
	
There	O
is	O
now	O
evidence	O
to	O
suggest	O
a	O
central	O
role	O
for	O
the	O
dopaminergic	O
system	O
in	O
restless	B-Disease
legs	I-Disease
syndrome	I-Disease
(	O
RLS	B-Disease
).	O
	
For	O
example	O
","	O
the	O
symptoms	O
of	O
RLS	B-Disease
can	O
be	O
dramatically	O
improved	O
by	O
levodopa	B-Chemical
and	O
dopamine	B-Chemical
agonists	O
","	O
whereas	O
central	O
dopamine	B-Chemical
D2	I-Chemical
receptor	I-Chemical
antagonists	I-Chemical
can	O
induce	O
or	O
aggravate	O
RLS	B-Disease
symptoms	O
.	O
	
To	O
our	O
knowledge	O
","	O
there	O
is	O
no	O
previous	O
report	O
regarding	O
whether	O
domperidone	B-Chemical
","	O
a	O
peripheral	O
dopamine	O
D2	O
receptor	O
antagonist	O
","	O
can	O
also	O
induce	O
or	O
aggravate	O
symptoms	O
of	O
RLS	B-Disease
.	O
	
Mirtazapine	B-Chemical
","	O
the	O
first	O
noradrenergic	B-Chemical
and	I-Chemical
specific	I-Chemical
serotonergic	I-Chemical
antidepressant	I-Chemical
(	O
NaSSA	B-Chemical
)","	O
has	O
been	O
associated	O
with	O
RLS	B-Disease
in	O
several	O
recent	O
publications	O
.	O
	
The	O
authors	O
report	O
here	O
a	O
depressed	B-Disease
patient	O
comorbid	O
with	O
postprandial	B-Disease
dyspepsia	I-Disease
who	O
developed	O
RLS	B-Disease
after	O
mirtazapine	B-Chemical
had	O
been	O
added	O
to	O
his	O
domperidone	B-Chemical
therapy	O
.	O
	
Our	O
patient	O
started	O
to	O
have	O
symptoms	O
of	O
RLS	B-Disease
only	O
after	O
he	O
had	O
been	O
treated	O
with	O
mirtazapine	B-Chemical
","	O
and	O
his	O
RLS	B-Disease
symptoms	O
resolved	O
completely	O
upon	O
discontinuation	O
of	O
his	O
mirtazapine	B-Chemical
.	O
	
Such	O
a	O
temporal	O
relationship	O
between	O
the	O
use	O
of	O
mirtazapine	B-Chemical
and	O
the	O
symptoms	O
of	O
RLS	B-Disease
in	O
our	O
patient	O
did	O
not	O
support	O
a	O
potentiating	O
effect	O
of	O
domperione	B-Chemical
on	O
mirtazapine	B-Chemical
-	O
associated	O
RLS	B-Disease
.	O
	
However	O
","	O
physicians	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
that	O
mirtazapine	B-Chemical
can	O
be	O
associated	O
with	O
RLS	B-Disease
in	O
some	O
individuals	O
","	O
especially	O
those	O
receiving	O
concomitant	O
dopamine	B-Chemical
D2	I-Chemical
receptor	I-Chemical
antagonists	I-Chemical
.	O
	
	
Regional	O
analysis	O
on	O
the	O
occurrence	O
of	O
oral	B-Disease
clefts	I-Disease
in	O
South	O
America	O
.	O
	
The	O
aim	O
of	O
this	O
work	O
was	O
to	O
search	O
for	O
unequal	O
birth	O
prevalence	O
rates	O
(	O
BPRs	O
)	O
of	O
cleft	B-Disease
lip	I-Disease
+/-	O
cleft	B-Disease
palate	I-Disease
(	O
CL	B-Disease
/	I-Disease
P	I-Disease
)","	O
and	O
cleft	B-Disease
palate	I-Disease
only	O
(	O
CPO	B-Disease
)","	O
among	O
different	O
geographic	O
areas	O
in	O
South	O
America	O
","	O
and	O
to	O
analyze	O
phenotypic	O
characteristics	O
and	O
associated	O
risk	O
factors	O
in	O
each	O
identified	O
cluster	O
.	O
	
Included	O
were	O
5	O
","	O
128	O
CL	B-Disease
/	I-Disease
P	I-Disease
cases	O
","	O
1	O
","	O
745	O
CPO	B-Disease
cases	O
","	O
and	O
3	O
","	O
712	O
controls	O
(	O
like	O
-	O
sexed	O
","	O
non	O
-	O
malformed	O
liveborn	O
infant	O
","	O
born	O
immediately	O
after	O
a	O
malformed	O
one	O
","	O
in	O
the	O
same	O
hospital	O
)","	O
over	O
4	O
","	O
199	O
","	O
630	O
consecutive	O
births	O
.	O
	
They	O
were	O
ascertained	O
between	O
1967	O
and	O
2004	O
","	O
in	O
190	O
maternity	O
hospitals	O
of	O
the	O
ECLAMC	O
(	O
Estudio	O
Colaborativo	O
Latinoamericano	O
de	O
Malformaciones	O
Congenitas	O
)	O
network	O
","	O
in	O
102	O
cities	O
of	O
all	O
10	O
South	O
American	O
countries	O
.	O
	
Non	O
-	O
predefined	O
geographical	O
areas	O
with	O
significantly	O
unusual	O
cleft	O
BPRs	O
were	O
identified	O
with	O
Kulldorf	O
and	O
Nagarwalla	O
'	O
s	O
spatial	O
scan	O
statistic	O
","	O
employing	O
number	O
of	O
cases	O
and	O
births	O
","	O
and	O
exact	O
location	O
of	O
each	O
hospital	O
.	O
	
Expected	O
values	O
were	O
cleft	O
BPRs	O
registered	O
for	O
the	O
entire	O
ECLAMC	O
hospital	O
network	O
.	O
	
Syndromic	O
and	O
non	O
-	O
syndromic	O
clefts	B-Disease
were	O
considered	O
for	O
cluster	O
analysis	O
","	O
and	O
phenotypic	O
characterization	O
","	O
while	O
only	O
non	O
-	O
syndromic	O
for	O
risk	O
factor	O
analysis	O
.	O
	
Seven	O
clusters	O
for	O
CL	B-Disease
/	I-Disease
P	I-Disease
","	O
and	O
four	O
for	O
CPO	B-Disease
","	O
with	O
unusual	O
BPRs	O
were	O
identified	O
.	O
	
CL	B-Disease
/	I-Disease
P	I-Disease
cases	O
in	O
high	O
BPR	O
areas	O
were	O
more	O
severe	O
than	O
elsewhere	O
in	O
the	O
sample	O
","	O
similar	O
to	O
a	O
previous	O
ECLAMC	O
report	O
on	O
microtia	B-Disease
.	O
	
For	O
CL	B-Disease
/	I-Disease
P	I-Disease
","	O
high	O
BPR	O
clusters	O
were	O
associated	O
with	O
high	O
altitude	O
above	O
sea	O
level	O
","	O
Amerindian	O
ancestry	O
","	O
and	O
low	O
socioeconomic	O
strata	O
";"	O
low	O
BPR	O
clusters	O
showed	O
association	O
with	O
African	O
Black	O
ancestry	O
.	O
	
Advanced	O
maternal	O
age	O
","	O
a	O
recognized	O
risk	O
factor	O
for	O
CPO	B-Disease
","	O
was	O
also	O
associated	O
with	O
the	O
only	O
identified	O
geographic	O
cluster	O
for	O
CPO	B-Disease
.	O
	
	
L1503R	O
is	O
a	O
member	O
of	O
group	O
I	O
mutation	O
and	O
has	O
dominant	O
-	O
negative	O
effect	O
on	O
secretion	O
of	O
full	O
-	O
length	O
VWF	O
multimers	O
:	O
an	O
analysis	O
of	O
two	O
patients	O
with	O
type	B-Disease
2A	I-Disease
von	I-Disease
Willebrand	I-Disease
disease	I-Disease
.	O
	
Type	B-Disease
2A	I-Disease
von	I-Disease
Willebrand	I-Disease
disease	I-Disease
(	O
VWD	B-Disease
)	O
is	O
characterized	O
by	O
decreased	O
platelet	O
-	O
dependent	O
function	O
of	O
von	O
Willebrand	O
factor	O
(	O
VWF	O
");"	O
this	O
in	O
turn	O
is	O
associated	O
with	O
an	O
absence	O
of	O
high	O
-	O
molecular	O
-	O
weight	O
multimers	O
.	O
	
Sequence	O
analysis	O
of	O
the	O
VWF	O
gene	O
from	O
two	O
unrelated	O
type	B-Disease
2A	I-Disease
VWD	I-Disease
patients	O
showed	O
an	O
identical	O
","	O
novel	O
","	O
heterozygous	O
T	O
-->	O
G	O
transversion	O
at	O
nucleotide	O
4508	O
","	O
resulting	O
in	O
the	O
substitution	O
of	O
L1503R	O
in	O
the	O
VWF	O
A2	O
domain	O
.	O
	
This	O
substitution	O
","	O
which	O
was	O
not	O
found	O
in	O
60	O
unrelated	O
normal	O
individuals	O
","	O
was	O
introduced	O
into	O
a	O
full	O
-	O
length	O
VWF	O
cDNA	O
and	O
subsequently	O
expressed	O
in	O
293T	O
cells	O
.	O
	
Only	O
trace	O
amount	O
of	O
the	O
mutant	O
VWF	O
protein	O
was	O
secreted	O
but	O
most	O
of	O
the	O
same	O
was	O
retained	O
in	O
293T	O
cells	O
.	O
	
Co	O
-	O
transfection	O
experiment	O
of	O
both	O
wild	O
-	O
type	O
and	O
mutant	O
plasmids	O
indicated	O
the	O
dominant	O
-	O
negative	O
mechanism	O
of	O
disease	O
development	O
";"	O
as	O
more	O
of	O
mutant	O
DNA	O
was	O
transfected	O
","	O
VWF	O
secretion	O
was	O
impaired	O
in	O
the	O
media	O
","	O
whereas	O
more	O
of	O
VWF	O
was	O
stored	O
in	O
the	O
cell	O
lysates	O
.	O
	
Molecular	O
dynamic	O
simulations	O
of	O
structural	O
changes	O
induced	O
by	O
L1503R	O
indicated	O
that	O
the	O
mean	O
value	O
of	O
all	O
-	O
atom	O
root	O
-	O
mean	O
-	O
squared	O
-	O
deviation	O
was	O
shifted	O
from	O
those	O
with	O
wild	O
type	O
or	O
another	O
mutation	O
L1503Q	O
that	O
has	O
been	O
reported	O
to	O
be	O
a	O
group	O
II	O
mutation	O
","	O
which	O
is	O
susceptible	O
to	O
ADAMTS13	O
proteolysis	O
.	O
	
Protein	O
instability	O
of	O
L1503R	O
may	O
be	O
responsible	O
for	O
its	O
intracellular	O
retention	O
and	O
perhaps	O
the	O
larger	O
VWF	O
multimers	O
","	O
containing	O
more	O
mutant	O
VWF	O
subunits	O
","	O
are	O
likely	O
to	O
be	O
mal	O
-	O
processed	O
and	O
retained	O
within	O
the	O
cell	O
.	O
	
	
Is	O
the	O
European	O
spatial	O
distribution	O
of	O
the	O
HIV	O
-	O
1	O
-	O
resistant	O
CCR5	O
-	O
Delta32	O
allele	O
formed	O
by	O
a	O
breakdown	O
of	O
the	O
pathocenosis	O
due	O
to	O
the	O
historical	O
Roman	O
expansion	O
?	O
	
We	O
studied	O
the	O
possible	O
effects	O
of	O
the	O
expansion	O
of	O
ancient	O
Mediterranean	O
civilizations	O
during	O
the	O
five	O
centuries	O
before	O
and	O
after	O
Christ	O
on	O
the	O
European	O
distribution	O
of	O
the	O
mutant	O
allele	O
for	O
the	O
chemokine	O
receptor	O
gene	O
CCR5	O
which	O
has	O
a	O
32	O
-	O
bp	O
deletion	O
(	O
CCR5	O
-	O
Delta32	O
).	O
	
There	O
is	O
a	O
strong	O
evidence	O
for	O
the	O
unitary	O
origin	O
of	O
the	O
CCR5	O
-	O
Delta32	O
mutation	O
","	O
this	O
it	O
is	O
found	O
principally	O
in	O
Europe	O
and	O
Western	O
Asia	O
","	O
with	O
generally	O
a	O
north	O
-	O
south	O
downhill	O
cline	O
frequency	O
.	O
	
Homozygous	O
carriers	O
of	O
this	O
mutation	O
show	O
a	O
resistance	O
to	O
HIV	B-Disease
-	I-Disease
1	I-Disease
infection	I-Disease
and	O
a	O
slower	O
progression	O
towards	O
AIDS	B-Disease
.	O
	
However	O
","	O
HIV	O
has	O
clearly	O
emerged	O
too	O
recently	O
to	O
have	O
been	O
the	O
selective	O
force	O
on	O
CCR5	O
.	O
	
Our	O
analyses	O
showed	O
strong	O
negative	O
correlations	O
in	O
Europe	O
between	O
the	O
allele	O
frequency	O
and	O
two	O
historical	O
parameters	O
","	O
i	O
.	O
e	O
.	O
	
the	O
first	O
colonization	O
dates	O
by	O
the	O
great	O
ancient	O
Mediterranean	O
civilizations	O
","	O
and	O
the	O
distances	O
from	O
the	O
Northern	O
frontiers	O
of	O
the	O
Roman	O
Empire	O
in	O
its	O
greatest	O
expansion	O
.	O
	
Moreover	O
","	O
other	O
studies	O
have	O
shown	O
that	O
the	O
deletion	O
frequencies	O
in	O
both	O
German	O
Bronze	O
Age	O
and	O
Swedish	O
Neolithic	O
populations	O
were	O
similar	O
to	O
those	O
found	O
in	O
the	O
corresponding	O
modern	O
populations	O
","	O
and	O
this	O
deletion	O
has	O
been	O
found	O
in	O
ancient	O
DNA	O
of	O
around	O
7000	O
years	O
ago	O
","	O
suggesting	O
that	O
in	O
the	O
past	O
","	O
the	O
deletion	O
frequency	O
could	O
have	O
been	O
relatively	O
high	O
in	O
European	O
populations	O
.	O
	
In	O
addition	O
","	O
in	O
West	O
Nile	O
virus	O
pathogenesis	O
","	O
CCR5	O
plays	O
an	O
antimicrobial	O
role	O
showing	O
that	O
host	O
genetic	O
factors	O
are	O
highly	O
pathogen	O
-	O
specific	O
.	O
	
Our	O
results	O
added	O
to	O
all	O
these	O
previous	O
data	O
suggest	O
that	O
the	O
actual	O
European	O
allele	O
frequency	O
distribution	O
might	O
not	O
be	O
due	O
to	O
genes	O
spreading	O
","	O
but	O
to	O
a	O
negative	O
selection	O
resulting	O
in	O
the	O
spread	O
of	O
pathogens	O
principally	O
during	O
Roman	O
expansion	O
.	O
	
Indeed	O
","	O
as	O
gene	O
flows	O
from	O
colonizers	O
to	O
European	O
native	O
populations	O
were	O
extremely	O
low	O
","	O
the	O
mutational	O
changes	O
might	O
be	O
associated	O
with	O
vulnerability	O
to	O
imported	O
infections	B-Disease
.	O
	
To	O
date	O
","	O
the	O
nature	O
of	O
the	O
parasites	O
remains	O
unknown	O
";"	O
however	O
","	O
zoonoses	O
could	O
be	O
incriminated	O
.	O
	
	
The	O
human	O
AHR	O
:	O
identification	O
of	O
single	O
nucleotide	O
polymorphisms	O
from	O
six	O
ethnic	O
populations	O
.	O
	
BACKGROUND	O
:	O
The	O
effects	O
of	O
2	B-Chemical
","	I-Chemical
3	I-Chemical
","	I-Chemical
7	I-Chemical
","	I-Chemical
8	I-Chemical
-	I-Chemical
tetrachlorodibenzo	I-Chemical
-	I-Chemical
p	I-Chemical
-	I-Chemical
dioxin	I-Chemical
and	O
related	O
dioxin	B-Chemical
-	O
like	O
chemicals	O
are	O
mediated	O
through	O
binding	O
-	O
dependent	O
activation	O
of	O
the	O
cytosolic	O
aryl	O
hydrocarbon	O
receptor	O
(	O
AHR	O
).	O
	
The	O
human	O
AHR	O
is	O
a	O
low	O
-	O
affinity	O
receptor	O
relative	O
to	O
most	O
rodents	O
","	O
but	O
some	O
reports	O
suggest	O
that	O
there	O
may	O
be	O
individuals	O
with	O
polymorphic	O
high	O
-	O
affinity	O
receptors	O
","	O
thereby	O
possibly	O
increasing	O
the	O
sensitivity	O
to	O
dioxins	B-Chemical
in	O
such	O
people	O
.	O
	
METHODS	O
:	O
Although	O
no	O
polymorphisms	O
have	O
been	O
reported	O
in	O
the	O
ligand	O
binding	O
region	O
of	O
the	O
AHR	O
in	O
the	O
over	O
100	O
reported	O
sequences	O
","	O
we	O
sequenced	O
108	O
additional	O
human	O
AHR	O
genes	O
in	O
an	O
effort	O
to	O
further	O
identify	O
single	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
within	O
the	O
open	O
reading	O
frames	O
of	O
the	O
AHR	O
locus	O
.	O
	
The	O
DNA	O
was	O
sequenced	O
from	O
six	O
ethnic	O
populations	O
that	O
included	O
Japanese	O
","	O
Chinese	O
","	O
European	O
/	O
Caucasian	O
","	O
African	O
-	O
American	O
","	O
South	O
East	O
Asian	O
","	O
and	O
Hispanic	O
.	O
	
RESULTS	O
:	O
Six	O
exonic	O
SNPs	O
were	O
identified	O
";"	O
four	O
had	O
been	O
described	O
as	O
previously	O
reported	O
and	O
two	O
seem	O
to	O
be	O
novel	O
.	O
	
Four	O
of	O
the	O
SNPs	O
identified	O
lead	O
to	O
amino	O
acid	O
changes	O
in	O
the	O
AHR	O
protein	O
and	O
two	O
of	O
the	O
SNPs	O
lead	O
to	O
synonymous	O
substitutions	O
.	O
	
An	O
additional	O
four	O
SNPs	O
have	O
been	O
reported	O
elsewhere	O
that	O
were	O
not	O
identified	O
in	O
the	O
current	O
analysis	O
.	O
	
With	O
these	O
new	O
sequences	O
","	O
more	O
than	O
200	O
human	O
AHR	O
gene	O
sequences	O
have	O
been	O
analyzed	O
for	O
SNPs	O
.	O
	
CONCLUSION	O
:	O
The	O
results	O
indicate	O
a	O
very	O
limited	O
presence	O
of	O
polymorphisms	O
in	O
the	O
core	O
ligand	O
binding	O
region	O
of	O
the	O
human	O
AHR	O
.	O
	
Other	O
regions	O
","	O
such	O
as	O
the	O
transactivation	O
domain	O
","	O
seem	O
to	O
be	O
slightly	O
more	O
polymorphic	O
in	O
the	O
human	O
population	O
and	O
the	O
impact	O
on	O
functionality	O
should	O
be	O
further	O
examined	O
.	O
	
	
Permeability	O
","	O
ultrastructural	O
changes	O
","	O
and	O
distribution	O
of	O
novel	O
proteins	O
in	O
the	O
glomerular	O
barrier	O
in	O
early	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
nephrosis	B-Disease
.	O
	
BACKGROUND	O
/	O
AIMS	O
:	O
It	O
is	O
still	O
unclear	O
what	O
happens	O
in	O
the	O
glomerulus	O
when	O
proteinuria	B-Disease
starts	O
.	O
	
Using	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
nephrosis	B-Disease
(	O
PAN	B-Disease
)	O
rats	O
","	O
we	O
studied	O
early	O
ultrastructural	O
and	O
permeability	O
changes	O
in	O
relation	O
to	O
the	O
expression	O
of	O
the	O
podocyte	O
-	O
associated	O
molecules	O
nephrin	O
","	O
a	O
-	O
actinin	O
","	O
dendrin	O
","	O
and	O
plekhh2	O
","	O
the	O
last	O
two	O
of	O
which	O
were	O
only	O
recently	O
discovered	O
in	O
podocytes	O
.	O
	
METHODS	O
:	O
Using	O
immune	O
stainings	O
","	O
semiquantitative	O
measurement	O
was	O
performed	O
under	O
the	O
electron	O
microscope	O
.	O
	
Permeability	O
was	O
assessed	O
using	O
isolated	O
kidney	O
perfusion	O
with	O
tracers	O
.	O
	
Possible	O
effects	O
of	O
ACE	O
inhibition	O
were	O
tested	O
.	O
	
RESULTS	O
:	O
By	O
day	O
2	O
","	O
some	O
patchy	O
foot	O
process	O
effacement	O
","	O
but	O
no	O
proteinuria	B-Disease
","	O
appeared	O
.	O
	
The	O
amount	O
of	O
nephrin	O
was	O
reduced	O
in	O
both	O
diseased	O
and	O
normal	O
areas	O
.	O
	
The	O
other	O
proteins	O
showed	O
few	O
changes	O
","	O
which	O
were	O
limited	O
to	O
diseased	O
areas	O
.	O
	
By	O
day	O
4	O
","	O
foot	O
process	O
effacement	O
was	O
complete	O
and	O
proteinuria	B-Disease
appeared	O
in	O
parallel	O
with	O
signs	O
of	O
size	O
barrier	O
damage	O
.	O
	
Nephrin	O
decreased	O
further	O
","	O
while	O
dendrin	O
and	O
plekhh2	O
also	O
decreased	O
but	O
a	O
-	O
actinin	O
remained	O
unchanged	O
.	O
	
ACE	O
inhibition	O
had	O
no	O
significant	O
protective	O
effect	O
.	O
	
CONCLUSIONS	O
:	O
PAN	B-Disease
glomeruli	O
already	O
showed	O
significant	O
pathology	O
by	O
day	O
4	O
","	O
despite	O
relatively	O
mild	O
proteinuria	B-Disease
.	O
	
This	O
was	O
preceded	O
by	O
altered	O
nephrin	O
expression	O
","	O
supporting	O
its	O
pivotal	O
role	O
in	O
podocyte	O
morphology	O
.	O
	
The	O
novel	O
proteins	O
dendrin	O
and	O
plekhh2	O
were	O
both	O
reduced	O
","	O
suggesting	O
roles	O
in	O
PAN	B-Disease
","	O
whereas	O
a	O
-	O
actinin	O
was	O
unchanged	O
.	O
	
	
SLURP1	O
mutation	O
-	O
impaired	O
T	O
-	O
cell	O
activation	O
in	O
a	O
family	O
with	O
mal	B-Disease
de	I-Disease
Meleda	I-Disease
.	O
	
BACKGROUND	O
:	O
Mal	B-Disease
de	I-Disease
Meleda	I-Disease
(	O
MDM	B-Disease
)	O
is	O
palmoplantar	B-Disease
erythrokeratoderma	I-Disease
with	O
an	O
autosomal	O
recessive	O
inheritance	O
and	O
is	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
gene	O
encoding	O
SLURP	O
-	O
1	O
(	O
lymphocyte	O
antigen	O
6	O
/	O
urokinase	O
-	O
type	O
plasminogen	O
activator	O
receptor	O
related	O
protein	O
-	O
1	O
).	O
	
SLURP	O
-	O
1	O
is	O
an	O
allosteric	O
agonist	O
to	O
the	O
nicotinic	O
acetylcholine	O
receptor	O
(	O
nAchR	O
)	O
and	O
it	O
regulates	O
epidermal	O
homeostasis	O
.	O
	
In	O
addition	O
","	O
murine	O
studies	O
have	O
shown	O
that	O
nAchR	O
signalling	O
is	O
important	O
for	O
the	O
regulation	O
of	O
T	O
-	O
cell	O
function	O
.	O
	
Among	O
the	O
family	O
members	O
","	O
patients	O
with	O
the	O
homozygous	O
SLURP1	O
(	O
previously	O
known	O
as	O
ARS	O
component	O
B	O
)	O
mutation	O
are	O
prone	O
to	O
melanoma	B-Disease
and	O
viral	B-Disease
infection	I-Disease
","	O
which	O
might	O
link	O
to	O
defective	O
T	O
-	O
cell	O
function	O
as	O
well	O
as	O
a	O
derangement	O
of	O
epidermal	O
homeostasis	O
.	O
	
OBJECTIVES	O
:	O
To	O
investigate	O
the	O
association	O
of	O
the	O
SLURP1	O
gene	O
mutation	O
with	O
T	O
-	O
cell	O
activation	O
in	O
a	O
Taiwanese	O
family	O
with	O
MDM	B-Disease
.	O
	
To	O
test	O
that	O
SLURP	O
-	O
1	O
is	O
essential	O
for	O
T	O
-	O
cell	O
activation	O
.	O
	
METHODS	O
:	O
Human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
were	O
isolated	O
from	O
a	O
Taiwanese	O
MDM	B-Disease
family	O
bearing	O
the	O
G	O
to	O
A	O
substitution	O
in	O
nucleotide	O
256	O
in	O
the	O
SLURP1	O
gene	O
","	O
corresponding	O
to	O
a	O
glycine	O
to	O
arginine	O
substitution	O
at	O
amino	O
acid	O
86	O
(	O
G86R	O
)	O
in	O
the	O
SLURP	O
-	O
1	O
protein	O
.	O
	
PBMCs	O
from	O
homozygotes	O
and	O
wild	O
-	O
type	O
controls	O
were	O
stimulated	O
with	O
anti	O
-	O
CD3	O
/	O
anti	O
-	O
CD28	O
antibodies	O
and	O
the	O
level	O
of	O
T	O
-	O
cell	O
activation	O
was	O
determined	O
by	O
the	O
stimulation	O
index	O
.	O
	
RESULTS	O
:	O
PBMCs	O
with	O
the	O
heterozygous	O
and	O
homozygous	O
SLURP	O
-	O
1	O
G86R	O
mutation	O
had	O
defective	O
T	O
-	O
cell	O
activation	O
.	O
	
This	O
was	O
restored	O
by	O
the	O
addition	O
of	O
0	O
5	O
ug	O
mL	O
(-	O
1	O
)	O
recombinant	O
human	O
SLURP	O
-	O
1	O
protein	O
.	O
	
CONCLUSIONS	O
:	O
Patients	O
with	O
MDM	B-Disease
with	O
the	O
homozygous	O
SLURP	O
-	O
1	O
G86R	O
mutation	O
may	O
have	O
an	O
impaired	O
T	O
-	O
cell	O
activation	O
.	O
	
The	O
presence	O
of	O
wild	O
-	O
type	O
SLURP	O
-	O
1	O
is	O
essential	O
for	O
normal	O
T	O
-	O
cell	O
activation	O
.	O
	
	
Resequencing	O
of	O
IRS2	O
reveals	O
rare	O
variants	O
for	O
obesity	B-Disease
but	O
not	O
fasting	O
glucose	B-Chemical
homeostasis	O
in	O
Hispanic	O
children	O
.	O
	
Our	O
objective	O
was	O
to	O
resequence	O
insulin	O
receptor	O
substrate	O
2	O
(	O
IRS2	O
)	O
to	O
identify	O
variants	O
associated	O
with	O
obesity	B-Disease
-	O
and	O
diabetes	B-Disease
-	O
related	O
traits	O
in	O
Hispanic	O
children	O
.	O
	
Exonic	O
and	O
intronic	O
segments	O
","	O
5	O
'	O
and	O
3	O
'	O
flanking	O
regions	O
of	O
IRS2	O
(	O
14	O
.	O
5	O
kb	O
)","	O
were	O
bidirectionally	O
sequenced	O
for	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
discovery	O
in	O
934	O
Hispanic	O
children	O
using	O
3730XL	O
DNA	O
Sequencers	O
.	O
	
Additionally	O
","	O
15	O
SNPs	O
derived	O
from	O
Illumina	O
HumanOmni1	O
-	O
Quad	O
BeadChips	O
were	O
analyzed	O
.	O
	
Measured	O
genotype	O
analysis	O
tested	O
associations	O
between	O
SNPs	O
and	O
obesity	B-Disease
and	O
diabetes	B-Disease
-	O
related	O
traits	O
.	O
	
Bayesian	O
quantitative	O
trait	O
nucleotide	O
analysis	O
was	O
used	O
to	O
statistically	O
infer	O
the	O
most	O
likely	O
functional	O
polymorphisms	O
.	O
	
A	O
total	O
of	O
140	O
SNPs	O
were	O
identified	O
with	O
minor	O
allele	O
frequencies	O
(	O
MAF	O
)	O
ranging	O
from	O
0	O
.	O
1	O
to	O
0	O
.	O
47	O
.	O
	
Forty	O
-	O
two	O
of	O
the	O
70	O
coding	O
SNPs	O
result	O
in	O
nonsynonymous	O
amino	O
acid	O
substitutions	O
relative	O
to	O
the	O
consensus	O
sequence	O
";"	O
28	O
SNPs	O
were	O
detected	O
in	O
the	O
promoter	O
","	O
12	O
in	O
introns	O
","	O
28	O
in	O
the	O
3	O
'-	O
UTR	O
","	O
and	O
2	O
in	O
the	O
5	O
'-	O
UTR	O
.	O
	
Two	O
insertion	O
/	O
deletions	O
(	O
indels	O
)	O
were	O
detected	O
.	O
	
Ten	O
independent	O
rare	O
SNPs	O
(	O
MAF	O
=	O
0	O
.	O
1	O
-	O
0	O
.	O
9	O
)	O
were	O
associated	O
with	O
obesity	B-Disease
-	O
related	O
traits	O
(	O
P	O
=	O
0	O
.	O
1	O
-	O
0	O
.	O
2	O
).	O
	
SNP	O
10510452_139	O
in	O
the	O
promoter	O
region	O
was	O
shown	O
to	O
have	O
a	O
high	O
posterior	O
probability	O
(	O
P	O
=	O
0	O
.	O
77	O
-	O
0	O
.	O
86	O
)	O
of	O
influencing	O
BMI	O
","	O
fat	O
mass	O
","	O
and	O
waist	O
circumference	O
in	O
Hispanic	O
children	O
.	O
	
SNP	O
10510452_139	O
contributed	O
between	O
2	O
and	O
4	O
%	O
of	O
the	O
population	O
variance	O
in	O
body	O
weight	O
and	O
composition	O
.	O
	
None	O
of	O
the	O
SNPs	O
or	O
indels	O
were	O
associated	O
with	O
diabetes	B-Disease
-	O
related	O
traits	O
or	O
accounted	O
for	O
a	O
previously	O
identified	O
quantitative	O
trait	O
locus	O
on	O
chromosome	O
13	O
for	O
fasting	O
serum	O
glucose	B-Chemical
.	O
	
Rare	O
but	O
not	O
common	O
IRS2	O
variants	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
body	O
weight	O
but	O
not	O
an	O
essential	O
role	O
in	O
fasting	O
glucose	B-Chemical
homeostasis	O
in	O
Hispanic	O
children	O
.	O
	
	
Takotsubo	B-Disease
syndrome	I-Disease
(	O
or	O
apical	B-Disease
ballooning	I-Disease
syndrome	I-Disease
)	O
secondary	O
to	O
Zolmitriptan	B-Chemical
.	O
	
Takotsubo	B-Disease
syndrome	I-Disease
(	O
TS	B-Disease
)","	O
also	O
known	O
as	O
broken	B-Disease
heart	I-Disease
syndrome	I-Disease
","	O
is	O
characterized	O
by	O
left	O
ventricle	O
apical	O
ballooning	O
with	O
elevated	O
cardiac	O
biomarkers	O
and	O
electrocardiographic	O
changes	O
suggestive	O
of	O
an	O
acute	B-Disease
coronary	I-Disease
syndrome	I-Disease
(	O
ie	O
","	O
ST	O
-	O
segment	O
elevation	O
","	O
T	O
wave	O
inversions	O
","	O
and	O
pathologic	O
Q	O
waves	O
).	O
	
We	O
report	O
a	O
case	O
of	O
54	O
-	O
year	O
-	O
old	O
woman	O
with	O
medical	O
history	O
of	O
mitral	B-Disease
valve	I-Disease
prolapse	I-Disease
and	O
migraines	B-Disease
","	O
who	O
was	O
admitted	O
to	O
the	O
hospital	O
for	O
substernal	O
chest	B-Disease
pain	I-Disease
and	O
electrocardiogram	O
demonstrated	O
1	O
/	O
2	O
mm	O
ST	O
-	O
segment	O
elevation	O
in	O
leads	O
II	O
","	O
III	O
","	O
aVF	O
","	O
V5	O
","	O
and	O
V6	O
and	O
positive	O
troponin	O
I	O
.	O
Emergent	O
coronary	O
angiogram	O
revealed	O
normal	O
coronary	O
arteries	O
with	O
moderately	O
reduced	O
left	O
ventricular	O
ejection	O
fraction	O
with	O
wall	O
motion	B-Disease
abnormalities	I-Disease
consistent	O
with	O
TS	B-Disease
.	O
	
Detailed	O
history	O
obtained	O
retrospectively	O
revealed	O
that	O
the	O
patient	O
took	O
zolmitriptan	B-Chemical
sparingly	O
only	O
when	O
she	O
had	O
migraines	B-Disease
.	O
	
But	O
before	O
this	O
event	O
","	O
she	O
was	O
taking	O
zolmitriptan	B-Chemical
2	O
-	O
3	O
times	O
daily	O
for	O
several	O
days	O
because	O
of	O
a	O
persistent	O
migraine	B-Disease
headache	I-Disease
.	O
	
She	O
otherwise	O
reported	O
that	O
she	O
is	O
quite	O
active	O
","	O
rides	O
horses	O
","	O
and	O
does	O
show	O
jumping	O
without	O
any	O
limitations	O
in	O
her	O
physical	O
activity	O
.	O
	
There	O
was	O
no	O
evidence	O
of	O
any	O
recent	O
stress	O
or	O
status	B-Disease
migrainosus	I-Disease
.	O
	
Extensive	O
literature	O
search	O
revealed	O
multiple	O
cases	O
of	O
coronary	B-Disease
artery	I-Disease
vasospasm	I-Disease
secondary	O
to	O
zolmitriptan	B-Chemical
","	O
but	O
none	O
of	O
the	O
cases	O
were	O
associated	O
with	O
TS	B-Disease
.	O
	
	
CD25	O
(+)	O
Bcl6	O
(	O
low	O
)	O
T	O
follicular	O
helper	O
cells	O
provide	O
help	O
to	O
maturing	O
B	O
cells	O
in	O
germinal	O
centers	O
of	O
human	O
tonsil	O
.	O
	
The	O
majority	O
of	O
CXCR5	O
(+)	O
PD1	O
(+)	O
CD4	O
(+)	O
T	O
follicular	O
helper	O
(	O
Tfh	O
)	O
cells	O
(	O
>	O
90	O
%)	O
are	O
CD25	O
(-)	O
Bcl6	O
(	O
hi	O
)	O
","	O
while	O
a	O
small	O
subpopulation	O
(	O
<	O
10	O
%)	O
are	O
CD25	O
(+)	O
Bcl6	O
(	O
low	O
)	O
but	O
do	O
not	O
express	O
FoxP3	O
and	O
are	O
not	O
T	O
regulatory	O
cells	O
.	O
	
We	O
purified	O
T	O
:	O
B	O
-	O
cell	O
conjugates	O
from	O
tonsils	O
and	O
found	O
they	O
were	O
enriched	O
for	O
the	O
CD25	O
(+)	O
Bcl6	O
(	O
low	O
)	O
Tfh	O
-	O
cell	O
subpopulation	O
.	O
	
In	O
response	O
to	O
IL	O
-	O
2	O
","	O
these	O
CD25	O
(+)	O
Tfh	O
cells	O
increased	O
expression	O
of	O
costimulatory	O
molecules	O
ICOS	O
or	O
OX40	O
","	O
upregulated	O
transcription	O
factor	O
cMaf	O
","	O
produced	O
cytokines	O
IL	O
-	O
21	O
","	O
IL	O
-	O
17	O
","	O
and	O
IL	O
-	O
10	O
","	O
and	O
raised	O
the	O
levels	O
of	O
antiapoptotic	O
protein	O
Bcl2	O
.	O
	
Conjugates	O
formed	O
with	O
CD25	O
(+)	O
BCl6	O
(	O
low	O
)	O
Tfh	O
cells	O
included	O
B	O
cells	O
expressing	O
higher	O
levels	O
of	O
activation	O
-	O
induced	O
cytidine	O
deaminase	O
(	O
AID	O
)","	O
memory	O
marker	O
CD45RO	O
","	O
surface	O
IgG	O
or	O
IgA	O
","	O
and	O
MHC	O
class	O
II	O
compared	O
to	O
B	O
-	O
cell	O
conjugates	O
including	O
CD25	O
(-)	O
Bcl6	O
(	O
hi	O
)	O
Tfh	O
cells	O
.	O
	
While	O
IL	O
-	O
2	O
suppresses	O
early	O
Tfh	O
-	O
cell	O
differentiation	O
","	O
Tfh	O
-	O
cell	O
recognition	O
of	O
antigen	O
-	O
presenting	O
B	O
cells	O
and	O
signaling	O
through	O
the	O
T	O
-	O
cell	O
receptor	O
likely	O
triggers	O
expression	O
of	O
the	O
high	O
-	O
affinity	O
IL	O
-	O
2	O
receptor	O
and	O
responses	O
to	O
IL	O
-	O
2	O
including	O
downregulation	O
of	O
Bcl6	O
.	O
	
CD25	O
expression	O
on	O
Tfh	O
cells	O
and	O
local	O
production	O
of	O
IL	O
-	O
2	O
in	O
tonsil	O
or	O
lymph	O
node	O
may	O
support	O
B	O
helper	O
T	O
-	O
cell	O
function	O
during	O
later	O
stages	O
of	O
B	O
-	O
cell	O
maturation	O
and	O
the	O
development	O
of	O
immune	O
memory	O
.	O
	
	
Differential	O
expression	O
of	O
filamin	O
B	O
splice	O
variants	O
in	O
giant	B-Disease
cell	I-Disease
tumor	I-Disease
cells	O
.	O
	
Giant	B-Disease
cell	I-Disease
tumor	I-Disease
of	I-Disease
bone	I-Disease
(	O
GCT	B-Disease
)	O
is	O
the	O
most	O
commonly	O
reported	O
non	O
-	O
malignant	O
bone	B-Disease
tumor	I-Disease
in	O
Hong	O
Kong	O
.	O
	
This	O
kind	O
of	O
tumor	B-Disease
usually	O
affects	O
people	O
aged	O
20	O
-	O
40	O
years	O
.	O
	
Also	O
","	O
it	O
is	O
well	O
known	O
for	O
recurrence	O
locally	O
","	O
especially	O
when	O
the	O
tumor	B-Disease
cannot	O
be	O
removed	O
completely	O
.	O
	
Filamins	O
are	O
actin	O
-	O
binding	O
proteins	O
which	O
contain	O
three	O
family	O
members	O
","	O
filamin	O
A	O
","	O
B	O
and	O
C	O
.	O
They	O
are	O
the	O
products	O
of	O
three	O
different	O
genes	O
","	O
FLNA	O
","	O
FLNB	O
and	O
FLNC	O
","	O
which	O
can	O
generate	O
various	O
transcript	O
variants	O
in	O
different	O
cell	O
types	O
.	O
	
In	O
this	O
study	O
","	O
we	O
focused	O
on	O
the	O
effects	O
of	O
FLNBv2	O
and	O
FLNBv4	O
toward	O
GCT	B-Disease
cells	O
.	O
	
The	O
only	O
difference	O
between	O
FLNBv2	O
and	O
FLNBv4	O
is	O
that	O
FLNBv4	O
does	O
not	O
contain	O
hinge	O
1	O
region	O
.	O
	
We	O
found	O
that	O
the	O
relative	O
abundance	O
of	O
FLNBv4	O
varies	O
among	O
different	O
GCT	B-Disease
cell	O
lines	O
while	O
the	O
expression	O
level	O
of	O
FLNBv4	O
in	O
normal	O
osteoblasts	O
was	O
only	O
marginally	O
detectable	O
.	O
	
In	O
the	O
functional	O
aspect	O
","	O
overexpression	O
of	O
FLNBv4	O
led	O
to	O
upregulation	O
of	O
RANKL	O
","	O
OCN	O
","	O
OPG	O
and	O
RUNX2	O
","	O
which	O
are	O
closely	O
related	O
to	O
GCT	B-Disease
cell	O
survival	O
and	O
differentiation	O
.	O
	
Moreover	O
","	O
FLNBv4	O
can	O
have	O
a	O
negative	O
effect	O
on	O
cell	O
viability	O
of	O
GCT	B-Disease
cells	O
when	O
compare	O
with	O
FLNBv2	O
.	O
	
In	O
conclusion	O
","	O
splicing	O
variants	O
of	O
FLNB	O
are	O
differentially	O
expressed	O
in	O
GCT	B-Disease
cells	O
and	O
may	O
play	O
a	O
role	O
in	O
the	O
proliferation	O
and	O
differentiation	O
of	O
tumor	B-Disease
cells	O
.	O
	
	
Spirulina	O
lipopolysaccharides	B-Chemical
inhibit	O
tumor	B-Disease
growth	O
in	O
a	O
Toll	O
-	O
like	O
receptor	O
4	O
-	O
dependent	O
manner	O
by	O
altering	O
the	O
cytokine	O
milieu	O
from	O
interleukin	O
-	O
17	O
/	O
interleukin	O
-	O
23	O
to	O
interferon	O
-	O
g	O
.	O
	
Th17	O
cells	O
and	O
the	O
cytokine	O
they	O
produce	O
","	O
interleukin	O
(	O
IL	O
)-	O
17	O
","	O
play	O
an	O
important	O
role	O
in	O
tumor	B-Disease
progression	O
in	O
humans	O
and	O
in	O
mice	O
.	O
	
IL	O
-	O
6	O
and	O
IL	O
-	O
23	O
are	O
critical	O
cytokines	O
for	O
the	O
differentiation	O
and	O
propagation	O
of	O
Th17	O
cells	O
","	O
respectively	O
.	O
	
Bacterial	O
lipopolysaccharides	B-Chemical
(	O
LPS	B-Chemical
)	O
are	O
known	O
to	O
stimulate	O
immune	O
cells	O
to	O
produce	O
such	O
inflammatory	O
cytokines	O
.	O
	
Contrary	O
to	O
Escherichia	O
coli	O
(	O
E	O
.	O
coli	O
)	O
LPS	B-Chemical
","	O
LPS	B-Chemical
from	O
Spirulina	O
has	O
low	O
toxicity	B-Disease
and	O
barely	O
induces	O
in	O
vivo	O
production	O
of	O
IL	O
-	O
6	O
and	O
IL	O
-	O
23	O
in	O
mice	O
.	O
	
We	O
examined	O
the	O
antitumor	O
effects	O
of	O
Spirulina	O
LPS	B-Chemical
compared	O
to	O
E	O
.	O
coli	O
LPS	B-Chemical
in	O
an	O
MH134	O
hepatoma	B-Disease
model	O
.	O
	
Administration	O
of	O
Spirulina	O
LPS	B-Chemical
suppressed	O
tumor	B-Disease
growth	O
in	O
C3H	O
/	O
HeN	O
mice	O
","	O
but	O
not	O
in	O
Toll	O
-	O
like	O
receptor	O
4	O
(	O
TLR4	O
)-	O
mutant	O
C3H	O
/	O
HeJ	O
mice	O
","	O
by	O
reducing	O
serum	O
levels	O
of	O
IL	O
-	O
17	O
and	O
IL	O
-	O
23	O
","	O
while	O
increasing	O
interferon	O
(	O
IFN	O
)-	O
g	O
levels	O
.	O
	
The	O
antitumor	O
activity	O
and	O
IFN	O
-	O
g	O
production	O
were	O
mediated	O
by	O
T	O
cells	O
.	O
	
Moreover	O
","	O
in	O
vitro	O
experiments	O
showed	O
that	O
Spirulina	O
LPS	B-Chemical
impaired	O
the	O
antigen	O
-	O
presenting	O
function	O
that	O
supports	O
the	O
generation	O
of	O
IL	O
-	O
17	O
-	O
producing	O
cells	O
in	O
a	O
toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
4	O
-	O
dependent	O
manner	O
.	O
	
Of	O
note	O
","	O
injection	O
of	O
anti	O
-	O
IL	O
-	O
17	O
antibody	O
in	O
tumor	B-Disease
-	O
bearing	O
C3H	O
/	O
HeN	O
mice	O
in	O
the	O
absence	O
of	O
Spirulina	O
LPS	B-Chemical
markedly	O
suppressed	O
tumor	B-Disease
growth	O
and	O
augmented	O
IFN	O
-	O
g	O
responses	O
.	O
	
Thus	O
","	O
our	O
results	O
support	O
the	O
notion	O
that	O
IFN	O
-	O
g	O
and	O
IL	O
-	O
17	O
/	O
IL	O
-	O
23	O
mutually	O
regulate	O
Th17	O
and	O
Th1	O
responses	O
in	O
tumor	B-Disease
-	O
bearing	O
hosts	O
","	O
and	O
Spirulina	O
LPS	B-Chemical
modulates	O
the	O
balance	O
of	O
the	O
IFN	O
-	O
g	O
-	O
IL	O
-	O
17	O
/	O
IL	O
-	O
23	O
axis	O
towards	O
IFN	O
-	O
g	O
production	O
","	O
which	O
leads	O
to	O
tumor	B-Disease
inhibition	O
.	O
	
Furthermore	O
","	O
Spirulina	O
LPS	B-Chemical
effectively	O
inhibited	O
the	O
spontaneous	O
development	O
of	O
mammary	B-Disease
tumors	I-Disease
.	O
	
This	O
study	O
has	O
important	O
implications	O
for	O
the	O
exploitation	O
of	O
TLR	O
-	O
based	O
immunomodulators	O
for	O
cancer	B-Disease
immunotherapy	O
.	O
	
	
Insulin	O
-	O
like	O
growth	O
factor	O
1	O
receptor	O
-	O
mediated	O
cell	O
survival	O
in	O
hypoxia	B-Disease
depends	O
on	O
the	O
promotion	O
of	O
autophagy	O
via	O
suppression	O
of	O
the	O
PI3K	O
/	O
Akt	O
/	O
mTOR	O
signaling	O
pathway	O
.	O
	
Hypoxia	B-Disease
is	O
widely	O
accepted	O
as	O
a	O
fundamental	O
biological	O
phenomenon	O
","	O
which	O
is	O
strongly	O
associated	O
with	O
tissue	O
damage	O
and	O
cell	O
viability	O
under	O
stress	O
conditions	O
.	O
	
Insulin	O
-	O
like	O
growth	O
factor	O
-	O
1	O
(	O
IGF	O
-	O
1	O
)	O
is	O
known	O
to	O
protect	O
tissues	O
from	O
multiple	O
types	O
of	O
damage	O
","	O
and	O
protect	O
cells	O
from	O
apoptosis	O
.	O
	
Hypoxia	B-Disease
is	O
a	O
regulatory	O
factor	O
of	O
the	O
IGF	O
system	O
","	O
however	O
the	O
role	O
of	O
the	O
IGF	O
-	O
1	O
receptor	O
(	O
IGF	O
-	O
1R	O
)	O
in	O
hypoxia	B-Disease
-	O
induced	O
apoptosis	O
remains	O
unclear	O
.	O
	
The	O
present	O
study	O
investigated	O
the	O
potential	O
mechanisms	O
associated	O
with	O
IGF	O
-	O
1R	O
-	O
associated	O
apoptosis	O
under	O
hypoxic	B-Disease
conditions	O
.	O
	
Mouse	O
embryonic	O
fibroblasts	O
exhibiting	O
disruption	O
or	O
overexpression	O
of	O
IGF	O
-	O
1R	O
(	O
R	O
-	O
cells	O
and	O
R	O
+	O
cells	O
)	O
were	O
used	O
to	O
examine	O
the	O
level	O
of	O
apoptosis	O
","	O
autophagy	O
","	O
and	O
production	O
of	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
(	O
ROS	B-Chemical
).	O
	
The	O
autophagy	O
inhibitor	O
3	B-Chemical
-	I-Chemical
methyladenine	I-Chemical
was	O
used	O
to	O
assess	O
the	O
effect	O
of	O
autophagy	O
on	O
ROS	B-Chemical
production	O
and	O
apoptosis	O
under	O
hypoxic	B-Disease
conditions	O
.	O
	
A	O
potential	O
downstream	O
signaling	O
pathway	O
involving	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI3K	O
)/	O
threonine	O
protein	O
kinase	O
B	O
(	O
Akt	O
)/	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
was	O
identifiedby	O
western	O
blot	O
analysis	O
.	O
	
The	O
results	O
demonstrated	O
that	O
hypoxia	B-Disease
induced	O
apoptosis	O
","	O
increased	O
ROS	B-Chemical
production	O
","	O
and	O
promoted	O
autophagy	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
relative	O
to	O
that	O
observed	O
under	O
normoxia	O
.	O
	
R	O
+	O
cells	O
exhibited	O
a	O
lower	O
percentage	O
of	O
apoptotic	O
cells	O
","	O
lower	O
ROS	B-Chemical
production	O
","	O
and	O
higher	O
levels	O
of	O
autophagy	O
when	O
compared	O
to	O
that	O
of	O
R	O
-	O
cells	O
.	O
	
In	O
addition	O
","	O
inhibition	O
of	O
autophagy	O
led	O
to	O
increased	O
ROS	B-Chemical
production	O
and	O
a	O
higher	O
percentage	O
of	O
apoptotic	O
cells	O
in	O
the	O
two	O
cell	O
types	O
.	O
	
Furthermore	O
","	O
IGF	O
-	O
1R	O
is	O
related	O
with	O
PI3K	O
/	O
Akt	O
/	O
mTOR	O
signaling	O
pathway	O
and	O
enhanced	O
autophagy	O
-	O
associated	O
protein	O
expression	O
","	O
which	O
was	O
verified	O
following	O
treatment	O
with	O
the	O
PI3K	O
inhibitor	O
LY294002	B-Chemical
.	O
	
These	O
results	O
indicated	O
that	O
IGF	O
-	O
1R	O
may	O
increase	O
cell	O
viability	O
under	O
hypoxic	B-Disease
conditions	O
by	O
promoting	O
autophagy	O
and	O
scavenging	O
ROS	B-Chemical
production	O
","	O
which	O
is	O
closed	O
with	O
PI3K	O
/	O
Akt	O
/	O
mTOR	O
signaling	O
pathway	O
.	O
	
	
Increased	O
expression	O
and	O
apical	O
targeting	O
of	O
renal	O
ENaC	O
subunits	O
in	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	O
nephrotic	B-Disease
syndrome	I-Disease
in	O
rats	O
.	O
	
Nephrotic	B-Disease
syndrome	I-Disease
is	O
often	O
accompanied	O
by	O
sodium	B-Chemical
retention	O
and	O
generalized	O
edema	B-Disease
.	O
	
However	O
","	O
the	O
molecular	O
basis	O
for	O
the	O
decreased	O
renal	O
sodium	B-Chemical
excretion	O
remains	O
undefined	O
.	O
	
We	O
hypothesized	O
that	O
epithelial	O
Na	O
channel	O
(	O
ENaC	O
)	O
subunit	O
dysregulation	O
may	O
be	O
responsible	O
for	O
the	O
increased	O
sodium	B-Chemical
retention	O
.	O
	
An	O
experimental	O
group	O
of	O
rats	O
was	O
treated	O
with	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
(	O
PAN	B-Chemical
";"	O
180	O
mg	O
/	O
kg	O
iv	O
)","	O
whereas	O
the	O
control	O
group	O
received	O
only	O
vehicle	O
.	O
	
After	O
7	O
days	O
","	O
PAN	B-Chemical
treatment	O
induced	O
significant	O
proteinuria	B-Disease
","	O
hypoalbuminemia	B-Disease
","	O
decreased	O
urinary	O
sodium	B-Chemical
excretion	O
","	O
and	O
extensive	O
ascites	B-Disease
.	O
	
The	O
protein	O
abundance	O
of	O
alpha	O
-	O
ENaC	O
and	O
beta	O
-	O
ENaC	O
was	O
increased	O
in	O
the	O
inner	O
stripe	O
of	O
the	O
outer	O
medulla	O
(	O
ISOM	O
)	O
and	O
in	O
the	O
inner	O
medulla	O
(	O
IM	O
)	O
but	O
was	O
not	O
altered	O
in	O
the	O
cortex	O
.	O
	
gamma	O
-	O
ENaC	O
abundance	O
was	O
increased	O
in	O
the	O
cortex	O
","	O
ISOM	O
","	O
and	O
IM	O
.	O
	
Immunoperoxidase	O
brightfield	O
-	O
and	O
laser	O
-	O
scanning	O
confocal	O
fluorescence	O
microscopy	O
demonstrated	O
increased	O
targeting	O
of	O
alpha	O
-	O
ENaC	O
","	O
beta	O
-	O
ENaC	O
","	O
and	O
gamma	O
-	O
ENaC	O
subunits	O
to	O
the	O
apical	O
plasma	O
membrane	O
in	O
the	O
distal	O
convoluted	O
tubule	O
(	O
DCT2	O
)","	O
connecting	O
tubule	O
","	O
and	O
cortical	O
and	O
medullary	O
collecting	O
duct	O
segments	O
.	O
	
Immunoelectron	O
microscopy	O
further	O
revealed	O
an	O
increased	O
labeling	O
of	O
alpha	O
-	O
ENaC	O
in	O
the	O
apical	O
plasma	O
membrane	O
of	O
cortical	O
collecting	O
duct	O
principal	O
cells	O
of	O
PAN	B-Chemical
-	O
treated	O
rats	O
","	O
indicating	O
enhanced	O
apical	O
targeting	O
of	O
alpha	O
-	O
ENaC	O
subunits	O
.	O
	
In	O
contrast	O
","	O
the	O
protein	O
abundances	O
of	O
Na	O
(+)/	O
H	O
(+)	O
exchanger	O
type	O
3	O
(	O
NHE3	O
)","	O
Na	O
(+)-	O
K	O
(+)-	O
2Cl	O
(-)	O
cotransporter	O
(	O
BSC	O
-	O
1	O
)","	O
and	O
thiazide	O
-	O
sensitive	O
Na	O
(+)-	O
Cl	O
(-)	O
cotransporter	O
(	O
TSC	O
)	O
were	O
decreased	O
.	O
	
Moreover	O
","	O
the	O
abundance	O
of	O
the	O
alpha	O
(	O
1	O
)-	O
subunit	O
of	O
the	O
Na	O
-	O
K	O
-	O
ATPase	O
was	O
decreased	O
in	O
the	O
cortex	O
and	O
ISOM	O
","	O
but	O
it	O
remained	O
unchanged	O
in	O
the	O
IM	O
.	O
	
In	O
conclusion	O
","	O
the	O
increased	O
or	O
sustained	O
expression	O
of	O
ENaC	O
subunits	O
combined	O
with	O
increased	O
apical	O
targeting	O
in	O
the	O
DCT2	O
","	O
connecting	O
tubule	O
","	O
and	O
collecting	O
duct	O
are	O
likely	O
to	O
play	O
a	O
role	O
in	O
the	O
sodium	B-Chemical
retention	O
associated	O
with	O
PAN	B-Chemical
-	O
induced	O
nephrotic	B-Disease
syndrome	I-Disease
.	O
	
The	O
decreased	O
abundance	O
of	O
NHE3	O
","	O
BSC	O
-	O
1	O
","	O
TSC	O
","	O
and	O
Na	O
-	O
K	O
-	O
ATPase	O
may	O
play	O
a	O
compensatory	O
role	O
to	O
promote	O
sodium	B-Chemical
excretion	O
.	O
	
	
Differential	O
modulation	O
by	O
estrogen	B-Chemical
of	O
alpha2	O
-	O
adrenergic	O
and	O
I1	O
-	O
imidazoline	O
receptor	O
-	O
mediated	O
hypotension	B-Disease
in	O
female	O
rats	O
.	O
	
We	O
have	O
recently	O
shown	O
that	O
estrogen	B-Chemical
negatively	O
modulates	O
the	O
hypotensive	B-Disease
effect	O
of	O
clonidine	B-Chemical
(	O
mixed	O
alpha2	O
-/	O
I1	O
-	O
receptor	O
agonist	O
)	O
in	O
female	O
rats	O
and	O
implicates	O
the	O
cardiovascular	O
autonomic	O
control	O
in	O
this	O
interaction	O
.	O
	
The	O
present	O
study	O
investigated	O
whether	O
this	O
effect	O
of	O
estrogen	B-Chemical
involves	O
interaction	O
with	O
alpha2	O
-	O
and	O
/	O
or	O
I1	O
-	O
receptors	O
.	O
	
Changes	O
evoked	O
by	O
a	O
single	O
intraperitoneal	O
injection	O
of	O
rilmenidine	B-Chemical
(	O
600	O
microg	O
/	O
kg	O
)	O
or	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
(	O
100	O
mg	O
/	O
kg	O
)","	O
selective	O
I1	O
-	O
and	O
alpha2	O
-	O
receptor	O
agonists	O
","	O
respectively	O
","	O
in	O
blood	O
pressure	O
","	O
hemodynamic	O
variability	O
","	O
and	O
locomotor	O
activity	O
were	O
assessed	O
in	O
radiotelemetered	O
sham	O
-	O
operated	O
and	O
ovariectomized	O
(	O
Ovx	O
)	O
Sprague	O
-	O
Dawley	O
female	O
rats	O
with	O
or	O
without	O
12	O
-	O
wk	O
estrogen	B-Chemical
replacement	O
.	O
	
Three	O
time	O
domain	O
indexes	O
of	O
hemodynamic	O
variability	O
were	O
employed	O
:	O
the	O
standard	O
deviation	O
of	O
mean	O
arterial	O
pressure	O
as	O
a	O
measure	O
of	O
blood	O
pressure	O
variability	O
and	O
the	O
standard	O
deviation	O
of	O
beat	O
-	O
to	O
-	O
beat	O
intervals	O
(	O
SDRR	O
)	O
and	O
the	O
root	O
mean	O
square	O
of	O
successive	O
differences	O
in	O
R	O
-	O
wave	O
-	O
to	O
-	O
R	O
-	O
wave	O
intervals	O
as	O
measures	O
of	O
heart	O
rate	O
variability	O
.	O
	
In	O
sham	O
-	O
operated	O
rats	O
","	O
rilmenidine	B-Chemical
or	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
elicited	O
similar	O
hypotension	B-Disease
that	O
lasted	O
at	O
least	O
5	O
h	O
and	O
was	O
associated	O
with	O
reductions	O
in	O
standard	O
deviation	O
of	O
mean	O
arterial	O
pressure	O
.	O
	
SDRR	O
was	O
reduced	O
only	O
by	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
.	O
	
Ovx	O
significantly	O
enhanced	O
the	O
hypotensive	B-Disease
response	O
to	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
","	O
in	O
contrast	O
to	O
no	O
effect	O
on	O
rilmenidine	B-Chemical
hypotension	B-Disease
.	O
	
The	O
enhanced	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
hypotension	B-Disease
in	O
Ovx	O
rats	O
was	O
paralleled	O
with	O
further	O
reduction	O
in	O
SDRR	O
and	O
a	B-Disease
reduced	I-Disease
locomotor	I-Disease
activity	I-Disease
.	O
	
Estrogen	O
replacement	O
(	O
17beta	B-Chemical
-	I-Chemical
estradiol	I-Chemical
subcutaneous	O
pellet	O
","	O
14	O
.	O
2	O
microg	O
/	O
day	O
","	O
12	O
wk	O
)	O
of	O
Ovx	O
rats	O
restored	O
the	O
hemodynamic	O
and	O
locomotor	O
effects	O
of	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
to	O
sham	O
-	O
operated	O
levels	O
.	O
	
These	O
findings	O
suggest	O
that	O
estrogen	B-Chemical
downregulates	O
alpha2	O
-	O
but	O
not	O
I1	O
-	O
receptor	O
-	O
mediated	O
hypotension	B-Disease
and	O
highlight	O
a	O
role	O
for	O
the	O
cardiac	O
autonomic	O
control	O
in	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
-	O
estrogen	B-Chemical
interaction	O
.	O
	
	
The	O
effects	O
of	O
sevoflurane	B-Chemical
on	O
lidocaine	B-Chemical
-	O
induced	O
convulsions	B-Disease
.	O
	
The	O
influence	O
of	O
sevoflurane	B-Chemical
on	O
lidocaine	B-Chemical
-	O
induced	O
convulsions	B-Disease
was	O
studied	O
in	O
cats	O
.	O
	
The	O
convulsive	B-Disease
threshold	O
(	O
mean	O
+/-	O
SD	O
)	O
was	O
41	O
.	O
4	O
+/-	O
6	O
.	O
5	O
mg	O
.	O
	
l	O
(-	O
1	O
)	O
with	O
lidocaine	B-Chemical
infusion	O
(	O
6	O
mg	O
.	O
kg	O
(-	O
1	O
).	O
min	O
(-	O
1	O
))","	O
increasing	O
significantly	O
to	O
66	O
.	O
6	O
+/-	O
10	O
.	O
9	O
mg	O
.	O
	
l	O
(-	O
1	O
)	O
when	O
the	O
end	O
-	O
tidal	O
concentration	O
of	O
sevoflurane	B-Chemical
was	O
0	O
.	O
8	O
%.	O
	
However	O
","	O
the	O
threshold	O
(	O
61	O
.	O
6	O
+/-	O
8	O
.	O
7	O
mg	O
.	O
	
l	O
(-	O
1	O
))	O
during	O
1	O
.	O
6	O
%	O
sevoflurane	B-Chemical
was	O
not	O
significant	O
from	O
that	O
during	O
0	O
.	O
8	O
%	O
sevoflurane	B-Chemical
","	O
indicating	O
a	O
celling	O
effect	O
.	O
	
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
convulsive	B-Disease
threshold	O
between	O
sevoflurane	B-Chemical
and	O
enflurane	B-Chemical
.	O
	
The	O
rise	O
in	O
blood	O
pressure	O
became	O
less	O
marked	O
when	O
higher	O
concentrations	O
of	O
sevoflurane	B-Chemical
or	O
enflurane	B-Chemical
were	O
administered	O
and	O
the	O
blood	O
pressure	O
at	O
convulsions	B-Disease
decreased	O
significantly	O
in	O
1	O
.	O
6	O
%	O
sevoflurane	B-Chemical
","	O
and	O
in	O
0	O
.	O
8	O
%	O
and	O
1	O
.	O
6	O
%	O
enflurane	B-Chemical
.	O
	
However	O
","	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
lidocaine	B-Chemical
concentrations	O
measured	O
when	O
the	O
systolic	O
blood	O
pressure	O
became	O
70	O
mmHg	O
.	O
	
Apamin	B-Chemical
","	O
a	O
selective	O
blocker	O
of	O
calcium	B-Chemical
-	O
dependent	O
potassium	B-Chemical
channels	O
","	O
was	O
administered	O
intracerebroventricularly	O
in	O
rats	O
anesthetized	O
with	O
0	O
.	O
8	O
%	O
sevoflurane	B-Chemical
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
anticonvulsive	O
effects	O
.	O
	
Apamin	B-Chemical
(	O
10	O
ng	O
)	O
had	O
a	O
tendency	O
to	O
decrease	O
the	O
convulsive	B-Disease
threshold	O
(	O
21	O
.	O
6	O
+/-	O
2	O
.	O
2	O
to	O
19	O
.	O
9	O
+/-	O
2	O
.	O
5	O
mg	O
.	O
	
l	O
(-	O
1	O
))	O
but	O
this	O
was	O
not	O
statistically	O
significant	O
.	O
	
It	O
is	O
suggested	O
that	O
sevoflurane	B-Chemical
reduces	O
the	O
convulsive	B-Disease
effect	O
of	O
lidocaine	B-Chemical
toxicity	B-Disease
but	O
carries	O
some	O
risk	O
due	O
to	O
circulatory	O
depression	B-Disease
.	O
	
	
Effects	O
of	O
the	O
antidepressant	O
trazodone	B-Chemical
","	O
a	O
5	O
-	O
HT	O
2A	O
/	O
2C	O
receptor	O
antagonist	O
","	O
on	O
dopamine	B-Chemical
-	O
dependent	O
behaviors	O
in	O
rats	O
.	O
	
RATIONALE	O
:	O
5	B-Chemical
-	I-Chemical
Hydroxytryptamine	I-Chemical
","	O
via	O
stimulation	O
of	O
5	O
-	O
HT	O
2C	O
receptors	O
","	O
exerts	O
a	O
tonic	O
inhibitory	O
influence	O
on	O
dopaminergic	O
neurotransmission	O
","	O
whereas	O
activation	O
of	O
5	O
-	O
HT	O
2A	O
receptors	O
enhances	O
stimulated	O
DAergic	O
neurotransmission	O
.	O
	
The	O
antidepressant	O
trazodone	B-Chemical
is	O
a	O
5	O
-	O
HT	O
2A	O
/	O
2C	O
receptor	O
antagonist	O
.	O
	
OBJECTIVES	O
:	O
To	O
evaluate	O
the	O
effect	O
of	O
trazodone	B-Chemical
treatment	O
on	O
behaviors	O
dependent	O
on	O
the	O
functional	O
status	O
of	O
the	O
nigrostriatal	O
DAergic	O
system	O
.	O
	
METHODS	O
:	O
The	O
effect	O
of	O
pretreatment	O
with	O
trazodone	B-Chemical
on	O
dexamphetamine	B-Chemical
-	O
and	O
apomorphine	B-Chemical
-	O
induced	O
oral	B-Disease
stereotypies	I-Disease
","	O
on	O
catalepsy	B-Disease
induced	O
by	O
haloperidol	B-Chemical
and	O
apomorphine	B-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
","	O
i	O
.	O
p	O
.	O
	
)","	O
on	O
ergometrine	B-Chemical
-	O
induced	O
wet	O
dog	O
shake	O
(	O
WDS	O
)	O
behavior	O
and	O
fluoxetine	B-Chemical
-	O
induced	O
penile	O
erections	O
was	O
studied	O
in	O
rats	O
.	O
	
We	O
also	O
investigated	O
whether	O
trazodone	B-Chemical
induces	O
catalepsy	B-Disease
in	O
rats	O
.	O
	
RESULTS	O
:	O
Trazodone	B-Chemical
at	O
2	O
.	O
5	O
-	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
	
did	O
not	O
induce	O
catalepsy	B-Disease
","	O
and	O
did	O
not	O
antagonize	O
apomorphine	B-Chemical
(	O
1	O
.	O
5	O
and	O
3	O
mg	O
/	O
kg	O
)	O
stereotypy	O
and	O
apomorphine	B-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)-	O
induced	O
catalepsy	B-Disease
.	O
	
However	O
","	O
pretreatment	O
with	O
5	O
","	O
10	O
and	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
	
trazodone	B-Chemical
enhanced	O
dexamphetamine	B-Chemical
stereotypy	O
","	O
and	O
antagonized	O
haloperidol	B-Chemical
catalepsy	B-Disease
","	O
ergometrine	B-Chemical
-	O
induced	O
WDS	O
behavior	O
and	O
fluoxetine	B-Chemical
-	O
induced	O
penile	O
erections	O
.	O
	
Trazodone	B-Chemical
at	O
30	O
","	O
40	O
and	O
50	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
	
induced	O
catalepsy	B-Disease
and	O
antagonized	O
apomorphine	B-Chemical
and	O
dexamphetamine	B-Chemical
stereotypies	O
.	O
	
CONCLUSIONS	O
:	O
Our	O
results	O
indicate	O
that	O
trazodone	B-Chemical
at	O
2	O
.	O
5	O
-	O
20	O
mg	O
/	O
kg	O
does	O
not	O
block	O
pre	O
-	O
and	O
postsynaptic	O
striatal	O
D2	O
DA	O
receptors	O
","	O
while	O
at	O
30	O
","	O
40	O
and	O
50	O
mg	O
/	O
kg	O
it	O
blocks	O
postsynaptic	O
striatal	O
D2	O
DA	O
receptors	O
.	O
	
Furthermore	O
","	O
at	O
5	O
","	O
10	O
and	O
20	O
mg	O
/	O
kg	O
","	O
trazodone	B-Chemical
blocks	O
5	O
-	O
HT	O
2A	O
and	O
5	O
-	O
HT	O
2C	O
receptors	O
.	O
	
We	O
suggest	O
that	O
trazodone	B-Chemical
(	O
5	O
","	O
10	O
and	O
20	O
mg	O
/	O
kg	O
)","	O
by	O
blocking	O
the	O
5	O
-	O
HT	O
2C	O
receptors	O
","	O
releases	O
the	O
nigrostriatal	O
DAergic	O
neurons	O
from	O
tonic	O
inhibition	O
caused	O
by	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
","	O
and	O
thereby	O
potentiates	O
dexamphetamine	B-Chemical
stereotypy	O
and	O
antagonizes	O
haloperidol	B-Chemical
catalepsy	B-Disease
.	O
	
	
Glucose	B-Chemical
metabolism	O
in	O
patients	O
with	O
schizophrenia	B-Disease
treated	O
with	O
atypical	O
antipsychotic	B-Chemical
agents	I-Chemical
:	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	B-Chemical
tolerance	O
test	O
and	O
minimal	O
model	O
analysis	O
.	O
	
BACKGROUND	O
:	O
While	O
the	O
incidence	O
of	O
new	O
-	O
onset	O
diabetes	B-Disease
mellitus	I-Disease
may	O
be	O
increasing	O
in	O
patients	O
with	O
schizophrenia	B-Disease
treated	O
with	O
certain	O
atypical	O
antipsychotic	B-Chemical
agents	I-Chemical
","	O
it	O
remains	O
unclear	O
whether	O
atypical	O
agents	O
are	O
directly	O
affecting	O
glucose	B-Chemical
metabolism	O
or	O
simply	O
increasing	O
known	O
risk	O
factors	O
for	O
diabetes	B-Disease
.	O
	
OBJECTIVE	O
:	O
To	O
study	O
the	O
2	O
drugs	O
most	O
clearly	O
implicated	O
(	O
clozapine	B-Chemical
and	O
olanzapine	B-Chemical
)	O
and	O
risperidone	B-Chemical
using	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	B-Chemical
tolerance	O
test	O
.	O
	
DESIGN	O
:	O
A	O
cross	O
-	O
sectional	O
design	O
in	O
stable	O
","	O
treated	O
patients	O
with	O
schizophrenia	B-Disease
evaluated	O
using	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	B-Chemical
tolerance	O
test	O
and	O
the	O
Bergman	O
minimal	O
model	O
analysis	O
.	O
	
SETTING	O
:	O
Subjects	O
were	O
recruited	O
from	O
an	O
urban	O
community	O
mental	O
health	O
clinic	O
and	O
were	O
studied	O
at	O
a	O
general	O
clinical	O
research	O
center	O
.	O
	
Patients	O
Fifty	O
subjects	O
signed	O
informed	O
consent	O
and	O
41	O
underwent	O
the	O
frequently	O
sampled	O
intravenous	O
glucose	B-Chemical
tolerance	O
test	O
.	O
	
Thirty	O
-	O
six	O
nonobese	O
subjects	O
with	O
schizophrenia	B-Disease
or	O
schizoaffective	B-Disease
disorder	I-Disease
","	O
matched	O
by	O
body	O
mass	O
index	O
and	O
treated	O
with	O
either	O
clozapine	B-Chemical
","	O
olanzapine	B-Chemical
","	O
or	O
risperidone	B-Chemical
","	O
were	O
included	O
in	O
the	O
analysis	O
.	O
	
MAIN	O
OUTCOME	O
MEASURES	O
:	O
Fasting	O
plasma	O
glucose	B-Chemical
and	O
fasting	O
serum	O
insulin	B-Chemical
levels	O
","	O
insulin	O
sensitivity	O
index	O
","	O
homeostasis	O
model	O
assessment	O
of	O
insulin	B-Disease
resistance	I-Disease
","	O
and	O
glucose	B-Chemical
effectiveness	O
.	O
	
RESULTS	O
:	O
The	O
mean	O
+/-	O
SD	O
duration	O
of	O
treatment	O
with	O
the	O
identified	O
atypical	O
antipsychotic	B-Chemical
agent	I-Chemical
was	O
68	O
.	O
3	O
+/-	O
28	O
.	O
9	O
months	O
(	O
clozapine	B-Chemical
)","	O
29	O
.	O
5	O
+/-	O
17	O
.	O
5	O
months	O
(	O
olanzapine	B-Chemical
)","	O
and	O
40	O
.	O
9	O
+/-	O
33	O
.	O
7	O
(	O
risperidone	B-Chemical
).	O
	
Fasting	O
serum	O
insulin	B-Chemical
concentrations	O
differed	O
among	O
groups	O
(	O
F	O
(	O
33	O
)	O
=	O
3	O
.	O
35	O
";"	O
P	O
=	O
.	O
47	O
)	O
(	O
clozapine	B-Chemical
>	O
olanzapine	B-Chemical
>	O
risperidone	B-Chemical
)	O
with	O
significant	O
differences	O
between	O
clozapine	B-Chemical
and	O
risperidone	B-Chemical
(	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
32	O
";"	O
P	O
=	O
.	O
3	O
)	O
and	O
olanzapine	B-Chemical
and	O
risperidone	B-Chemical
(	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
15	O
";"	O
P	O
=	O
.	O
4	O
).	O
	
There	O
was	O
a	O
significant	O
difference	O
in	O
insulin	O
sensitivity	O
index	O
among	O
groups	O
(	O
F	O
(	O
33	O
)	O
=	O
10	O
.	O
66	O
";"	O
P	O
<.	O
1	O
)	O
(	O
clozapine	B-Chemical
<	O
olanzapine	B-Chemical
<	O
risperidone	B-Chemical
)","	O
with	O
subjects	O
who	O
received	O
clozapine	B-Chemical
and	O
olanzapine	B-Chemical
exhibiting	O
significant	O
insulin	B-Disease
resistance	I-Disease
compared	O
with	O
subjects	O
who	O
were	O
treated	O
with	O
risperidone	B-Chemical
(	O
clozapine	B-Chemical
vs	O
risperidone	B-Chemical
","	O
t	O
(	O
33	O
)	O
=	O
-	O
4	O
.	O
29	O
";"	O
P	O
<.	O
1	O
";"	O
olanzapine	B-Chemical
vs	O
risperidone	B-Chemical
","	O
t	O
(	O
33	O
)	O
=	O
-	O
3	O
.	O
62	O
";"	O
P	O
=	O
.	O
1	O
[	O
P	O
<.	O
1	O
]).	O
	
The	O
homeostasis	O
model	O
assessment	O
of	O
insulin	B-Disease
resistance	I-Disease
also	O
differed	O
significantly	O
among	O
groups	O
(	O
F	O
(	O
33	O
)	O
=	O
4	O
.	O
92	O
";"	O
P	O
=	O
.	O
1	O
)	O
(	O
clozapine	B-Chemical
>	O
olanzapine	B-Chemical
>	O
risperidone	B-Chemical
)	O
(	O
clozapine	B-Chemical
vs	O
risperidone	B-Chemical
","	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
94	O
";"	O
P	O
=	O
.	O
6	O
";"	O
olanzapine	B-Chemical
vs	O
risperidone	B-Chemical
","	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
42	O
";"	O
P	O
=	O
.	O
2	O
).	O
	
There	O
was	O
a	O
significant	O
difference	O
among	O
groups	O
in	O
glucose	B-Chemical
effectiveness	O
(	O
F	O
(	O
30	O
)	O
=	O
4	O
.	O
18	O
";"	O
P	O
=	O
.	O
2	O
)	O
(	O
clozapine	B-Chemical
<	O
olanzapine	B-Chemical
<	O
risperidone	B-Chemical
)	O
with	O
significant	O
differences	O
between	O
clozapine	B-Chemical
and	O
risperidone	B-Chemical
(	O
t	O
(	O
30	O
)	O
=	O
-	O
2	O
.	O
59	O
";"	O
P	O
=	O
.	O
2	O
)	O
and	O
olanzapine	B-Chemical
and	O
risperidone	B-Chemical
(	O
t	O
(	O
30	O
)	O
=	O
-	O
2	O
.	O
34	O
","	O
P	O
=	O
.	O
3	O
).	O
	
CONCLUSIONS	O
:	O
Both	O
nonobese	O
clozapine	B-Chemical
-	O
and	O
olanzapine	B-Chemical
-	O
treated	O
groups	O
displayed	O
significant	O
insulin	B-Disease
resistance	I-Disease
and	O
impairment	O
of	O
glucose	B-Chemical
effectiveness	O
compared	O
with	O
risperidone	B-Chemical
-	O
treated	O
subjects	O
.	O
	
Patients	O
taking	O
clozapine	B-Chemical
and	O
olanzapine	B-Chemical
must	O
be	O
examined	O
for	O
insulin	B-Disease
resistance	I-Disease
and	O
its	O
consequences	O
.	O
	
	
Valproic	B-Chemical
acid	I-Chemical
I	O
:	O
time	O
course	O
of	O
lipid	B-Chemical
peroxidation	O
biomarkers	O
","	O
liver	B-Disease
toxicity	I-Disease
","	O
and	O
valproic	B-Chemical
acid	I-Chemical
metabolite	O
levels	O
in	O
rats	O
.	O
	
A	O
single	O
dose	O
of	O
valproic	B-Chemical
acid	I-Chemical
(	O
VPA	B-Chemical
)","	O
which	O
is	O
a	O
widely	O
used	O
antiepileptic	B-Chemical
drug	I-Chemical
","	O
is	O
associated	O
with	O
oxidative	O
stress	O
in	O
rats	O
","	O
as	O
recently	O
demonstrated	O
by	O
elevated	O
levels	O
of	O
15	B-Chemical
-	I-Chemical
F	I-Chemical
(	I-Chemical
2t	I-Chemical
)-	I-Chemical
isoprostane	I-Chemical
(	O
15	B-Chemical
-	I-Chemical
F	I-Chemical
(	I-Chemical
2t	I-Chemical
)-	I-Chemical
IsoP	I-Chemical
).	O
	
To	O
determine	O
whether	O
there	O
was	O
a	O
temporal	O
relationship	O
between	O
VPA	B-Chemical
-	O
associated	O
oxidative	O
stress	O
and	O
hepatotoxicity	B-Disease
","	O
adult	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
treated	O
ip	O
with	O
VPA	B-Chemical
(	O
500	O
mg	O
/	O
kg	O
)	O
or	O
0	O
.	O
9	O
%	O
saline	O
(	O
vehicle	O
)	O
once	O
daily	O
for	O
2	O
","	O
4	O
","	O
7	O
","	O
10	O
","	O
or	O
14	O
days	O
.	O
	
Oxidative	O
stress	O
was	O
assessed	O
by	O
determining	O
plasma	O
and	O
liver	O
levels	O
of	O
15	B-Chemical
-	I-Chemical
F	I-Chemical
(	I-Chemical
2t	I-Chemical
)-	I-Chemical
IsoP	I-Chemical
","	O
lipid	B-Chemical
hydroperoxides	I-Chemical
(	O
LPO	B-Chemical
)","	O
and	O
thiobarbituric	B-Chemical
acid	I-Chemical
reactive	I-Chemical
substances	I-Chemical
(	O
TBARs	B-Chemical
).	O
	
Plasma	O
and	O
liver	O
15	B-Chemical
-	I-Chemical
F	I-Chemical
(	I-Chemical
2t	I-Chemical
)-	I-Chemical
IsoP	I-Chemical
were	O
elevated	O
and	O
reached	O
a	O
plateau	O
after	O
day	O
2	O
of	O
VPA	B-Chemical
treatment	O
compared	O
to	O
control	O
.	O
	
Liver	O
LPO	B-Chemical
levels	O
were	O
not	O
elevated	O
until	O
day	O
7	O
of	O
treatment	O
(	O
1	O
.	O
8	O
-	O
fold	O
versus	O
control	O
","	O
p	O
<	O
0	O
.	O
5	O
).	O
	
Liver	O
and	O
plasma	O
TBARs	B-Chemical
were	O
not	O
increased	O
until	O
14	O
days	O
(	O
2	O
-	O
fold	O
vs	O
.	O
	
control	O
","	O
p	O
<	O
0	O
.	O
5	O
).	O
	
Liver	B-Disease
toxicity	I-Disease
was	O
evaluated	O
based	O
on	O
serum	O
levels	O
of	O
alpha	O
-	O
glutathione	O
S	O
-	O
transferase	O
(	O
alpha	O
-	O
GST	O
)	O
and	O
by	O
histology	O
.	O
	
Serum	O
alpha	O
-	O
GST	O
levels	O
were	O
significantly	O
elevated	O
by	O
day	O
4	O
","	O
which	O
corresponded	O
to	O
hepatotoxicity	B-Disease
as	O
shown	O
by	O
the	O
increasing	O
incidence	O
of	O
inflammation	B-Disease
of	I-Disease
the	I-Disease
liver	I-Disease
capsule	I-Disease
","	O
necrosis	B-Disease
","	O
and	O
steatosis	B-Disease
throughout	O
the	O
study	O
.	O
	
The	O
liver	O
levels	O
of	O
beta	O
-	O
oxidation	O
metabolites	O
of	O
VPA	B-Chemical
were	O
decreased	O
by	O
day	O
14	O
","	O
while	O
the	O
levels	O
of	O
4	B-Chemical
-	I-Chemical
ene	I-Chemical
-	I-Chemical
VPA	I-Chemical
and	O
(	O
E	O
)-	O
2	B-Chemical
","	I-Chemical
4	I-Chemical
-	I-Chemical
diene	I-Chemical
-	I-Chemical
VPA	I-Chemical
were	O
not	O
elevated	O
throughout	O
the	O
study	O
.	O
	
Overall	O
","	O
these	O
findings	O
indicate	O
that	O
VPA	B-Chemical
treatment	O
results	O
in	O
oxidative	O
stress	O
","	O
as	O
measured	O
by	O
levels	O
of	O
15	B-Chemical
-	I-Chemical
F	I-Chemical
(	I-Chemical
2t	I-Chemical
)-	I-Chemical
IsoP	I-Chemical
","	O
which	O
precedes	O
the	O
onset	O
of	O
necrosis	B-Disease
","	O
steatosis	B-Disease
","	O
and	O
elevated	O
levels	O
of	O
serum	O
alpha	O
-	O
GST	O
.	O
	
	
Safety	O
of	O
celecoxib	B-Chemical
in	O
patients	O
with	O
adverse	O
skin	B-Disease
reactions	I-Disease
to	O
acetaminophen	B-Chemical
(	O
paracetamol	B-Chemical
)	O
and	O
nimesulide	B-Chemical
associated	O
or	O
not	O
with	O
common	O
non	B-Chemical
-	I-Chemical
steroidal	I-Chemical
anti	I-Chemical
-	I-Chemical
inflammatory	I-Chemical
drugs	I-Chemical
.	O
	
BACKGROUND	O
:	O
Acetaminophen	B-Chemical
(	O
paracetamol	B-Chemical
--	O
P	B-Chemical
)	O
and	O
Nimesulide	B-Chemical
(	O
N	B-Chemical
)	O
are	O
widely	O
used	O
analgesic	O
-	O
antipyretic	B-Chemical
/	O
anti	B-Chemical
-	I-Chemical
inflammatory	I-Chemical
drugs	I-Chemical
.	O
	
The	O
rate	O
of	O
adverse	O
hypersensitivity	B-Disease
reactions	O
to	O
these	O
agents	O
is	O
generally	O
low	O
.	O
	
On	O
the	O
contrary	O
non	B-Chemical
-	I-Chemical
steroidal	I-Chemical
anti	I-Chemical
-	I-Chemical
inflammatory	I-Chemical
drugs	I-Chemical
(	O
NSAIDs	B-Chemical
)	O
are	O
commonly	O
involved	O
in	O
such	O
reactions	O
.	O
	
Celecoxib	B-Chemical
(	O
CE	B-Chemical
)	O
is	O
a	O
novel	O
drug	O
","	O
with	O
high	O
selectivity	O
and	O
affinity	O
for	O
COX	O
-	O
2	O
enzyme	O
.	O
	
OBJECTIVE	O
:	O
We	O
evaluated	O
the	O
tolerability	O
of	O
CE	B-Chemical
in	O
a	O
group	O
of	O
patients	O
with	O
documented	O
history	O
of	O
adverse	O
cutaneous	B-Disease
reactions	I-Disease
to	O
P	B-Chemical
and	O
N	B-Chemical
associated	O
or	O
not	O
to	O
classic	O
NSAIDs	B-Chemical
.	O
	
METHODS	O
:	O
We	O
studied	O
9	O
patients	O
with	O
hypersensitivity	B-Disease
to	O
P	B-Chemical
and	O
N	B-Chemical
with	O
or	O
without	O
associated	O
reactions	O
to	O
classic	O
NSAIDs	B-Chemical
.	O
	
The	O
diagnosis	O
of	O
P	B-Chemical
and	O
N	B-Chemical
-	O
induced	O
skin	B-Disease
reactions	I-Disease
was	O
based	O
in	O
vivo	O
challenge	O
.	O
	
The	O
placebo	O
was	O
blindly	O
administered	O
at	O
the	O
beginning	O
of	O
each	O
challenge	O
.	O
	
After	O
three	O
days	O
","	O
a	O
cumulative	O
dosage	O
of	O
200	O
mg	O
of	O
CE	B-Chemical
in	O
refracted	O
doses	O
were	O
given	O
.	O
	
After	O
2	O
-	O
3	O
days	O
","	O
a	O
single	O
dose	O
of	O
200	O
mg	O
was	O
administered	O
.	O
	
All	O
patients	O
were	O
observed	O
for	O
6	O
hours	O
after	O
each	O
challenge	O
","	O
and	O
controlled	O
again	O
after	O
24	O
hours	O
to	O
exclude	O
delayed	O
reactions	O
.	O
	
The	O
challenge	O
was	O
considered	O
positive	O
if	O
one	O
or	O
more	O
of	O
the	O
following	O
appeared	O
:	O
erythema	B-Disease
","	O
rush	O
or	O
urticaria	B-Disease
-	O
angioedema	B-Disease
.	O
	
RESULTS	O
:	O
No	O
reaction	O
was	O
observed	O
with	O
placebo	O
and	O
eight	O
patients	O
(	O
88	O
.	O
8	O
%)	O
tolerated	O
CE	B-Chemical
.	O
	
Only	O
one	O
patient	O
developed	O
a	O
moderate	O
angioedema	B-Disease
of	O
the	O
lips	O
.	O
	
CONCLUSION	O
:	O
Only	O
one	O
hypersensitivity	B-Disease
reaction	O
to	O
CE	B-Chemical
was	O
documented	O
among	O
9	O
P	B-Chemical
and	O
N	B-Chemical
-	O
highly	O
NSAIDs	B-Chemical
intolerant	O
patients	O
.	O
	
Thus	O
","	O
we	O
conclude	O
that	O
CE	B-Chemical
is	O
a	O
reasonably	O
safe	O
alternative	O
to	O
be	O
used	O
in	O
subjects	O
who	O
do	O
not	O
tolerate	O
P	B-Chemical
and	O
N	B-Chemical
.	O
	
	
Dexrazoxane	B-Chemical
protects	O
against	O
myelosuppression	B-Disease
from	O
the	O
DNA	O
cleavage	O
-	O
enhancing	O
drugs	O
etoposide	B-Chemical
and	O
daunorubicin	B-Chemical
but	O
not	O
doxorubicin	B-Chemical
.	O
	
PURPOSE	O
:	O
The	O
anthracyclines	B-Chemical
daunorubicin	I-Chemical
and	O
doxorubicin	B-Chemical
and	O
the	O
epipodophyllotoxin	B-Chemical
etoposide	I-Chemical
are	O
potent	O
DNA	O
cleavage	O
-	O
enhancing	O
drugs	O
that	O
are	O
widely	O
used	O
in	O
clinical	O
oncology	O
";"	O
however	O
","	O
myelosuppression	B-Disease
and	O
cardiac	B-Disease
toxicity	I-Disease
limit	O
their	O
use	O
.	O
	
Dexrazoxane	B-Chemical
(	O
ICRF	B-Chemical
-	I-Chemical
187	I-Chemical
)	O
is	O
recommended	O
for	O
protection	O
against	O
anthracycline	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O
	
EXPERIMENTAL	O
DESIGN	O
:	O
Because	O
of	O
their	O
widespread	O
use	O
","	O
the	O
hematologic	B-Disease
toxicity	I-Disease
following	O
coadministration	O
of	O
dexrazoxane	B-Chemical
and	O
these	O
three	O
structurally	O
different	O
DNA	O
cleavage	O
enhancers	O
was	O
investigated	O
:	O
Sensitivity	O
of	O
human	O
and	O
murine	O
blood	O
progenitor	O
cells	O
to	O
etoposide	B-Chemical
","	O
daunorubicin	B-Chemical
","	O
and	O
doxorubicin	B-Chemical
+/-	O
dexrazoxane	B-Chemical
was	O
determined	O
in	O
granulocyte	O
-	O
macrophage	O
colony	O
forming	O
assays	O
.	O
	
Likewise	O
","	O
in	O
vivo	O
","	O
B6D2F1	O
mice	O
were	O
treated	O
with	O
etoposide	B-Chemical
","	O
daunorubicin	B-Chemical
","	O
and	O
doxorubicin	B-Chemical
","	O
with	O
or	O
without	O
dexrazoxane	B-Chemical
over	O
a	O
wide	O
range	O
of	O
doses	O
:	O
posttreatment	O
","	O
a	O
full	O
hematologic	O
evaluation	O
was	O
done	O
.	O
	
RESULTS	O
:	O
Nontoxic	O
doses	O
of	O
dexrazoxane	B-Chemical
reduced	O
myelosuppression	B-Disease
and	O
weight	B-Disease
loss	I-Disease
from	O
daunorubicin	B-Chemical
and	O
etoposide	B-Chemical
in	O
mice	O
and	O
antagonized	O
their	O
antiproliferative	O
effects	O
in	O
the	O
colony	O
assay	O
";"	O
however	O
","	O
dexrazoxane	B-Chemical
neither	O
reduced	O
myelosuppression	B-Disease
","	O
weight	B-Disease
loss	I-Disease
","	O
nor	O
the	O
in	O
vitro	O
cytotoxicity	B-Disease
from	O
doxorubicin	B-Chemical
.	O
	
CONCLUSION	O
:	O
Although	O
our	O
findings	O
support	O
the	O
observation	O
that	O
dexrazoxane	B-Chemical
reduces	O
neither	O
hematologic	O
activity	O
nor	O
antitumor	O
activity	O
from	O
doxorubicin	B-Chemical
clinically	O
","	O
the	O
potent	O
antagonism	O
of	O
daunorubicin	B-Chemical
activity	O
raises	O
concern	O
";"	O
a	O
possible	O
interference	O
with	O
anticancer	O
efficacy	O
certainly	O
would	O
call	O
for	O
renewed	O
attention	O
.	O
	
Our	O
data	O
also	O
suggest	O
that	O
significant	O
etoposide	B-Chemical
dose	O
escalation	O
is	O
perhaps	O
possible	O
by	O
the	O
use	O
of	O
dexrazoxane	B-Chemical
.	O
	
Clinical	O
trials	O
in	O
patients	O
with	O
brain	O
metastases	B-Disease
combining	O
dexrazoxane	B-Chemical
and	O
high	O
doses	O
of	O
etoposide	B-Chemical
is	O
ongoing	O
with	O
the	O
aim	O
of	O
improving	O
efficacy	O
without	O
aggravating	O
hematologic	B-Disease
toxicity	I-Disease
.	O
	
If	O
successful	O
","	O
this	O
represents	O
an	O
exciting	O
mechanism	O
for	O
pharmacologic	O
regulation	O
of	O
side	O
effects	O
from	O
cytotoxic	B-Disease
chemotherapy	O
.	O
	
	
The	O
selective	O
5	O
-	O
HT6	O
receptor	O
antagonist	O
Ro4368554	B-Chemical
restores	O
memory	O
performance	O
in	O
cholinergic	B-Chemical
and	O
serotonergic	B-Chemical
models	O
of	O
memory	B-Disease
deficiency	I-Disease
in	O
the	O
rat	O
.	O
	
Antagonists	O
at	O
serotonin	O
type	O
6	O
(	O
5	O
-	O
HT	O
(	O
6	O
))	O
receptors	O
show	O
activity	O
in	O
models	O
of	O
learning	O
and	O
memory	O
.	O
	
Although	O
the	O
underlying	O
mechanism	O
(	O
s	O
)	O
are	O
not	O
well	O
understood	O
","	O
these	O
effects	O
may	O
involve	O
an	O
increase	O
in	O
acetylcholine	B-Chemical
(	O
ACh	B-Chemical
)	O
levels	O
.	O
	
The	O
present	O
study	O
sought	O
to	O
characterize	O
the	O
cognitive	O
-	O
enhancing	O
effects	O
of	O
the	O
5	O
-	O
HT	O
(	O
6	O
)	O
antagonist	O
Ro4368554	B-Chemical
(	O
3	B-Chemical
-	I-Chemical
benzenesulfonyl	I-Chemical
-	I-Chemical
7	I-Chemical
-(	I-Chemical
4	I-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
piperazin	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
yl	I-Chemical
)	I-Chemical
1H	I-Chemical
-	I-Chemical
indole	I-Chemical
)	O
in	O
a	O
rat	O
object	O
recognition	O
task	O
employing	O
a	O
cholinergic	B-Chemical
(	O
scopolamine	B-Chemical
pretreatment	O
)	O
and	O
a	O
serotonergic	B-Chemical
-	O
(	O
tryptophan	B-Chemical
(	O
TRP	B-Chemical
)	O
depletion	O
)	O
deficient	O
model	O
","	O
and	O
compared	O
its	O
pattern	O
of	O
action	O
with	O
that	O
of	O
the	O
acetylcholinesterase	O
inhibitor	O
metrifonate	B-Chemical
.	O
	
Initial	O
testing	O
in	O
a	O
time	O
-	O
dependent	O
forgetting	O
task	O
employing	O
a	O
24	O
-	O
h	O
delay	O
between	O
training	O
and	O
testing	O
showed	O
that	O
metrifonate	B-Chemical
improved	O
object	O
recognition	O
(	O
at	O
10	O
and	O
30	O
mg	O
/	O
kg	O
","	O
p	O
.	O
o	O
.	O
	
)","	O
whereas	O
Ro4368554	B-Chemical
was	O
inactive	O
.	O
	
Both	O
","	O
Ro4368554	B-Chemical
(	O
3	O
and	O
10	O
mg	O
/	O
kg	O
","	O
intraperitoneally	O
(	O
i	O
.	O
p	O
.))	O
	
and	O
metrifonate	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
","	O
p	O
.	O
o	O
.","	O
respectively	O
)	O
reversed	O
memory	B-Disease
deficits	I-Disease
induced	O
by	O
scopolamine	B-Chemical
and	O
TRP	B-Chemical
depletion	O
(	O
10	O
mg	O
/	O
kg	O
","	O
i	O
.	O
p	O
.","	O
and	O
3	O
mg	O
/	O
kg	O
","	O
p	O
.	O
o	O
.","	O
respectively	O
).	O
	
In	O
conclusion	O
","	O
although	O
Ro4368554	B-Chemical
did	O
not	O
improve	O
a	O
time	O
-	O
related	O
retention	O
deficit	O
","	O
it	O
reversed	O
a	O
cholinergic	B-Chemical
and	O
a	O
serotonergic	B-Chemical
memory	B-Disease
deficit	I-Disease
","	O
suggesting	O
that	O
both	O
mechanisms	O
may	O
be	O
involved	O
in	O
the	O
facilitation	O
of	O
object	O
memory	O
by	O
Ro4368554	B-Chemical
and	O
","	O
possibly	O
","	O
other	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
(	I-Chemical
6	I-Chemical
)	I-Chemical
receptor	I-Chemical
antagonists	I-Chemical
.	O
	
	
Microinjection	O
of	O
ritanserin	B-Chemical
into	O
the	O
CA1	O
region	O
of	O
hippocampus	O
improves	O
scopolamine	B-Chemical
-	O
induced	O
amnesia	B-Disease
in	O
adult	O
male	O
rats	O
.	O
	
The	O
effect	O
of	O
ritanserin	B-Chemical
(	O
5	O
-	O
HT2	O
antagonist	O
)	O
on	O
scopolamine	B-Chemical
(	O
muscarinic	O
cholinergic	O
antagonist	O
)-	O
induced	O
amnesia	B-Disease
in	O
Morris	O
water	O
maze	O
(	O
MWM	O
)	O
was	O
investigated	O
.	O
	
Rats	O
were	O
divided	O
into	O
eight	O
groups	O
and	O
bilaterally	O
cannulated	O
into	O
CA1	O
region	O
of	O
the	O
hippocampus	O
.	O
	
One	O
week	O
later	O
","	O
they	O
received	O
repeatedly	O
vehicles	O
(	O
saline	O
","	O
DMSO	B-Chemical
","	O
saline	O
+	O
DMSO	B-Chemical
)","	O
scopolamine	B-Chemical
(	O
2	O
microg	O
/	O
0	O
.	O
5	O
microl	O
saline	O
/	O
side	O
";"	O
30	O
min	O
before	O
training	O
)","	O
ritanserin	B-Chemical
(	O
2	O
","	O
4	O
and	O
8	O
microg	O
/	O
0	O
.	O
5	O
microl	O
DMSO	B-Chemical
/	O
side	O
";"	O
20	O
min	O
before	O
training	O
)	O
and	O
scopolamine	B-Chemical
(	O
2	O
microg	O
/	O
0	O
.	O
5	O
microl	O
";"	O
30	O
min	O
before	O
ritanserin	B-Chemical
injection	O
)+	O
ritanserin	B-Chemical
(	O
4	O
microg	O
/	O
0	O
.	O
5	O
microl	O
DMSO	B-Chemical
)	O
through	O
cannulae	O
each	O
day	O
.	O
	
Animals	O
were	O
tested	O
for	O
four	O
consecutive	O
days	O
(	O
4	O
trial	O
/	O
day	O
)	O
in	O
MWM	O
during	O
which	O
the	O
position	O
of	O
hidden	O
platform	O
was	O
unchanged	O
.	O
	
In	O
the	O
fifth	O
day	O
","	O
the	O
platform	O
was	O
elevated	O
above	O
the	O
water	O
surface	O
in	O
another	O
position	O
to	O
evaluate	O
the	O
function	O
of	O
motor	O
","	O
motivational	O
and	O
visual	O
systems	O
.	O
	
The	O
results	O
showed	O
a	O
significant	O
increase	O
in	O
escape	O
latencies	O
and	O
traveled	O
distances	O
to	O
find	O
platform	O
in	O
scopolamine	B-Chemical
-	O
treated	O
group	O
as	O
compared	O
to	O
saline	O
group	O
.	O
	
Ritanserin	B-Chemical
-	O
treated	O
rats	O
(	O
4	O
microg	O
/	O
0	O
.	O
5	O
microl	O
/	O
side	O
)	O
showed	O
a	O
significant	O
decrease	O
in	O
the	O
mentioned	O
parameters	O
as	O
compared	O
to	O
DMSO	B-Chemical
-	O
treated	O
group	O
.	O
	
However	O
","	O
scopolamine	B-Chemical
and	O
ritanserin	B-Chemical
co	O
-	O
administration	O
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
escape	O
latencies	O
and	O
traveled	O
distances	O
as	O
compared	O
to	O
the	O
scopolamine	B-Chemical
-	O
treated	O
rats	O
.	O
	
Our	O
findings	O
show	O
that	O
microinjection	O
of	O
ritanserin	B-Chemical
into	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
improves	O
the	O
scopolamine	B-Chemical
-	O
induced	O
amnesia	B-Disease
.	O
	
	
Memory	O
function	O
and	O
serotonin	O
transporter	O
promoter	O
gene	O
polymorphism	O
in	O
ecstasy	B-Chemical
(	O
MDMA	B-Chemical
)	O
users	O
.	O
	
Although	O
3	B-Chemical
","	I-Chemical
4	I-Chemical
-	I-Chemical
methylenedioxymethamphetamine	I-Chemical
(	O
MDMA	B-Chemical
or	O
ecstasy	B-Chemical
)	O
has	O
been	O
shown	O
to	O
damage	O
brain	O
serotonin	B-Chemical
(	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
)	O
neurons	O
in	O
animals	O
and	O
possibly	O
humans	O
","	O
little	O
is	O
known	O
about	O
the	O
long	O
-	O
term	O
consequences	O
of	O
MDMA	B-Chemical
-	O
induced	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
neurotoxic	B-Disease
lesions	I-Disease
on	O
functions	O
in	O
which	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
is	O
involved	O
","	O
such	O
as	O
cognitive	O
function	O
.	O
	
Because	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
transporters	O
play	O
a	O
key	O
element	O
in	O
the	O
regulation	O
of	O
synaptic	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
transmission	O
it	O
may	O
be	O
important	O
to	O
control	O
for	O
the	O
potential	O
covariance	O
effect	O
of	O
a	O
polymorphism	O
in	O
the	O
5	O
-	O
HT	O
transporter	O
promoter	O
gene	O
region	O
(	O
5	O
-	O
HTTLPR	O
)	O
when	O
studying	O
the	O
effects	O
of	O
MDMA	B-Chemical
as	O
well	O
as	O
cognitive	O
functioning	O
.	O
	
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
moderate	O
and	O
heavy	O
MDMA	B-Chemical
use	O
on	O
cognitive	O
function	O
","	O
as	O
well	O
as	O
the	O
effects	O
of	O
long	O
-	O
term	O
abstention	O
from	O
MDMA	B-Chemical
","	O
in	O
subjects	O
genotyped	O
for	O
5	O
-	O
HTTLPR	O
.	O
	
A	O
second	O
aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
whether	O
these	O
effects	O
differ	O
for	O
females	O
and	O
males	O
.	O
	
Fifteen	O
moderate	O
MDMA	B-Chemical
users	O
(<	O
55	O
lifetime	O
tablets	O
)","	O
22	O
heavy	O
MDMA	B-Chemical
+	O
users	O
(>	O
55	O
lifetime	O
tablets	O
)","	O
16	O
ex	O
-	O
MDMA	B-Chemical
+	O
users	O
(	O
last	O
tablet	O
>	O
1	O
year	O
ago	O
)	O
and	O
13	O
controls	O
were	O
compared	O
on	O
a	O
battery	O
of	O
neuropsychological	O
tests	O
.	O
	
DNA	O
from	O
peripheral	O
nuclear	O
blood	O
cells	O
was	O
genotyped	O
for	O
5	O
-	O
HTTLPR	O
using	O
standard	O
polymerase	O
chain	O
reaction	O
methods	O
.	O
A	O
significant	O
group	O
effect	O
was	O
observed	O
only	O
on	O
memory	O
function	O
tasks	O
(	O
p	O
=	O
0	O
.	O
4	O
)	O
but	O
not	O
on	O
reaction	O
times	O
(	O
p	O
=	O
0	O
.	O
61	O
)	O
or	O
attention	O
/	O
executive	O
functioning	O
(	O
p	O
=	O
0	O
.	O
59	O
).	O
	
Heavy	O
and	O
ex	O
-	O
MDMA	B-Chemical
+	O
users	O
performed	O
significantly	O
poorer	O
on	O
memory	O
tasks	O
than	O
controls	O
.	O
	
In	O
contrast	O
","	O
no	O
evidence	O
of	O
memory	B-Disease
impairment	I-Disease
was	O
observed	O
in	O
moderate	O
MDMA	B-Chemical
users	O
.	O
	
No	O
significant	O
effect	O
of	O
5	O
-	O
HTTLPR	O
or	O
gender	O
was	O
observed	O
.	O
	
While	O
the	O
use	O
of	O
MDMA	B-Chemical
in	O
quantities	O
that	O
may	O
be	O
considered	O
moderate	O
is	O
not	O
associated	O
with	O
impaired	B-Disease
memory	I-Disease
functioning	I-Disease
","	O
heavy	O
use	O
of	O
MDMA	B-Chemical
use	O
may	O
lead	O
to	O
long	O
lasting	O
memory	B-Disease
impairments	I-Disease
.	O
	
No	O
effect	O
of	O
5	O
-	O
HTTLPR	O
or	O
gender	O
on	O
memory	O
function	O
or	O
MDMA	B-Chemical
use	O
was	O
observed	O
.	O
	
	
Role	O
of	O
mangiferin	B-Chemical
on	O
biochemical	O
alterations	O
and	O
antioxidant	O
status	O
in	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O
	
The	O
current	O
study	O
dealt	O
with	O
the	O
protective	O
role	O
of	O
mangiferin	B-Chemical
","	O
a	O
polyphenol	B-Chemical
from	O
Mangifera	O
indica	O
Linn	O
.	O
	
(	O
Anacardiaceae	O
)","	O
on	O
isoproterenol	B-Chemical
(	O
ISPH	B-Chemical
)-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
(	O
MI	B-Disease
)	O
in	O
rats	O
through	O
its	O
antioxidative	O
mechanism	O
.	O
	
Subcutaneous	O
injection	O
of	O
ISPH	B-Chemical
(	O
200	O
mg	O
/	O
kg	O
body	O
weight	O
in	O
1	O
ml	O
saline	O
)	O
to	O
rats	O
for	O
2	O
consecutive	O
days	O
caused	O
myocardial	B-Disease
damage	I-Disease
in	O
rat	O
heart	O
","	O
which	O
was	O
determined	O
by	O
the	O
increased	O
activity	O
of	O
serum	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
and	O
creatine	O
phosphokinase	O
isoenzymes	O
(	O
CK	O
-	O
MB	O
)","	O
increased	O
uric	B-Chemical
acid	I-Chemical
level	O
and	O
reduced	O
plasma	O
iron	B-Chemical
binding	O
capacity	O
.	O
	
The	O
protective	O
role	O
of	O
mangiferin	B-Chemical
was	O
analyzed	O
by	O
triphenyl	B-Chemical
tetrazolium	I-Chemical
chloride	I-Chemical
(	O
TTC	B-Chemical
)	O
test	O
used	O
for	O
macroscopic	O
enzyme	O
mapping	O
assay	O
of	O
the	O
ischemic	B-Disease
myocardium	I-Disease
.	O
	
The	O
heart	O
tissue	O
antioxidant	O
enzymes	O
such	O
as	O
superoxide	O
dismutase	O
","	O
catalase	O
","	O
glutathione	O
peroxidase	O
","	O
glutathione	O
transferase	O
and	O
glutathione	O
reductase	O
activities	O
","	O
non	O
-	O
enzymic	O
antioxidants	O
such	O
as	O
cerruloplasmin	O
","	O
Vitamin	B-Chemical
C	I-Chemical
","	O
Vitamin	B-Chemical
E	I-Chemical
and	O
glutathione	B-Chemical
levels	O
were	O
altered	O
in	O
MI	B-Disease
rats	O
.	O
	
Upon	O
pretreatment	O
with	O
mangiferin	B-Chemical
(	O
100	O
mg	O
/	O
kg	O
body	O
weight	O
suspended	O
in	O
2	O
ml	O
of	O
dimethyl	B-Chemical
sulphoxide	I-Chemical
)	O
given	O
intraperitoneally	O
for	O
28	O
days	O
to	O
MI	B-Disease
rats	O
protected	O
the	O
above	O
-	O
mentioned	O
parameters	O
to	O
fall	O
from	O
the	O
normal	O
levels	O
.	O
	
Activities	O
of	O
heart	O
tissue	O
enzymic	O
antioxidants	O
and	O
serum	O
non	O
-	O
enzymic	O
antioxidants	O
levels	O
rose	O
significantly	O
upon	O
mangiferin	B-Chemical
administration	O
as	O
compared	O
to	O
ISPH	B-Chemical
-	O
induced	O
MI	B-Disease
rats	O
.	O
	
From	O
the	O
present	O
study	O
it	O
is	O
concluded	O
that	O
mangiferin	B-Chemical
exerts	O
a	O
beneficial	O
effect	O
against	O
ISPH	B-Chemical
-	O
induced	O
MI	B-Disease
due	O
to	O
its	O
antioxidant	O
potential	O
","	O
which	O
regulated	O
the	O
tissues	O
defense	O
system	O
against	O
cardiac	B-Disease
damage	I-Disease
.	O
	
	
Cardiovascular	O
risk	O
with	O
cyclooxygenase	B-Chemical
inhibitors	I-Chemical
:	O
general	O
problem	O
with	O
substance	O
specific	O
differences	O
?	O
	
Randomised	O
clinical	O
trials	O
and	O
observational	O
studies	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
myocardial	B-Disease
infarction	I-Disease
","	O
stroke	B-Disease
","	O
hypertension	B-Disease
and	O
heart	B-Disease
failure	I-Disease
during	O
treatment	O
with	O
cyclooxygenase	B-Chemical
inhibitors	I-Chemical
.	O
	
Adverse	O
cardiovascular	O
effects	O
occurred	O
mainly	O
","	O
but	O
not	O
exclusively	O
","	O
in	O
patients	O
with	O
concomitant	O
risk	O
factors	O
.	O
	
Cyclooxygenase	B-Chemical
inhibitors	I-Chemical
cause	O
complex	O
changes	O
in	O
renal	O
","	O
vascular	O
and	O
cardiac	O
prostanoid	B-Chemical
profiles	O
thereby	O
increasing	O
vascular	O
resistance	O
and	O
fluid	O
retention	O
.	O
	
The	O
incidence	O
of	O
cardiovascular	B-Disease
adverse	I-Disease
events	I-Disease
tends	O
to	O
increase	O
with	O
the	O
daily	O
dose	O
and	O
total	O
exposure	O
time	O
.	O
	
A	O
comparison	O
of	O
individual	O
selective	O
and	O
unselective	O
cyclooxygenase	B-Chemical
inhibitors	I-Chemical
suggests	O
substance	O
-	O
specific	O
differences	O
","	O
which	O
may	O
depend	O
on	O
differences	O
in	O
pharmacokinetic	O
parameters	O
or	O
inhibitory	O
potency	O
and	O
may	O
be	O
contributed	O
by	O
prostaglandin	B-Chemical
-	O
independent	O
effects	O
.	O
	
Diagnostic	O
markers	O
such	O
as	O
N	B-Chemical
-	I-Chemical
terminal	I-Chemical
pro	I-Chemical
brain	I-Chemical
natriuretic	I-Chemical
peptide	I-Chemical
(	O
NT	B-Chemical
-	I-Chemical
proBNP	I-Chemical
)	O
or	O
high	O
-	O
sensitive	O
C	O
-	O
reactive	O
protein	O
might	O
help	O
in	O
the	O
early	O
identification	O
of	O
patients	O
at	O
risk	O
","	O
thus	O
avoiding	O
the	O
occurrence	O
of	O
serious	O
cardiovascular	B-Disease
toxicity	I-Disease
.	O
	
	
Impact	O
of	O
alcohol	B-Chemical
exposure	O
after	O
pregnancy	O
recognition	O
on	O
ultrasonographic	O
fetal	O
growth	O
measures	O
.	O
	
BACKGROUND	O
:	O
More	O
than	O
3	O
decades	O
after	O
Jones	O
and	O
Smith	O
(	O
1973	O
)	O
reported	O
on	O
the	O
devastation	O
caused	O
by	O
alcohol	B-Chemical
exposure	O
on	O
fetal	O
development	O
","	O
the	O
rates	O
of	O
heavy	O
drinking	O
during	O
pregnancy	O
remain	O
relatively	O
unchanged	O
.	O
	
Early	O
identification	O
of	O
fetal	O
alcohol	B-Chemical
exposure	O
and	O
maternal	O
abstinence	O
led	O
to	O
better	O
infant	O
outcomes	O
.	O
	
This	O
study	O
examined	O
the	O
utility	O
of	O
biometry	O
for	O
detecting	O
alcohol	B-Chemical
-	O
related	O
fetal	O
growth	B-Disease
impairment	I-Disease
.	O
	
METHODS	O
:	O
We	O
obtained	O
fetal	O
ultrasound	O
measures	O
from	O
routine	O
ultrasound	O
examinations	O
for	O
167	O
pregnant	O
hazardous	O
drinkers	O
who	O
were	O
enrolled	O
in	O
a	O
brief	O
alcohol	B-Chemical
intervention	O
study	O
.	O
	
The	O
fetal	O
measures	O
for	O
women	O
who	O
quit	O
after	O
learning	O
of	O
their	O
pregnancies	O
were	O
compared	O
with	O
measures	O
for	O
women	O
who	O
continued	O
some	O
drinking	O
throughout	O
the	O
course	O
of	O
their	O
pregnancies	O
.	O
	
Because	O
intensity	O
of	O
alcohol	B-Chemical
consumption	O
is	O
associated	O
with	O
poorer	O
fetal	O
outcomes	O
","	O
separate	O
analyses	O
were	O
conducted	O
for	O
the	O
heavy	O
(	O
average	O
of	O
>	O
or	O
=	O
5	O
drinks	O
per	O
drinking	O
day	O
)	O
alcohol	B-Chemical
consumers	O
.	O
	
Fetal	O
measures	O
from	O
the	O
heavy	O
-	O
exposed	O
fetuses	O
were	O
also	O
compared	O
with	O
measures	O
from	O
a	O
nondrinking	O
group	O
that	O
was	O
representative	O
of	O
normal	O
","	O
uncomplicated	O
pregnancies	O
from	O
our	O
clinics	O
.	O
	
Analyses	O
of	O
covariance	O
were	O
used	O
to	O
determine	O
whether	O
there	O
were	O
differences	O
between	O
groups	O
after	O
controlling	O
for	O
influences	O
of	O
gestational	O
age	O
and	O
drug	B-Disease
abuse	I-Disease
.	O
	
RESULTS	O
:	O
Nearly	O
half	O
of	O
the	O
pregnant	O
drinkers	O
abstained	O
after	O
learning	O
of	O
their	O
pregnancies	O
.	O
	
When	O
women	O
reportedly	O
quit	O
drinking	O
early	O
in	O
their	O
pregnancies	O
","	O
fetal	O
growth	O
measures	O
were	O
not	O
significantly	O
different	O
from	O
a	O
non	O
-	O
alcohol	B-Chemical
-	O
exposed	O
group	O
","	O
regardless	O
of	O
prior	O
drinking	O
patterns	O
.	O
	
Any	O
alcohol	B-Chemical
consumption	O
postpregnancy	O
recognition	O
among	O
the	O
heavy	O
drinkers	O
resulted	O
in	O
reduced	B-Disease
cerebellar	I-Disease
growth	I-Disease
as	O
well	O
as	O
decreased	B-Disease
cranial	I-Disease
to	I-Disease
body	I-Disease
growth	I-Disease
in	O
comparison	O
with	O
women	O
who	O
either	O
quit	O
drinking	O
or	O
who	O
were	O
nondrinkers	O
.	O
	
Amphetamine	B-Chemical
abuse	O
was	O
predictive	O
of	O
larger	O
cranial	O
to	O
body	O
growth	O
ratios	O
.	O
	
CONCLUSIONS	O
:	O
Alterations	O
in	O
fetal	O
biometric	O
measurements	O
were	O
observed	O
among	O
the	O
heavy	O
drinkers	O
only	O
when	O
they	O
continued	O
drinking	O
after	O
becoming	O
aware	O
of	O
their	O
pregnancies	O
.	O
	
Although	O
the	O
reliance	O
on	O
self	O
-	O
reported	O
drinking	O
is	O
a	O
limitation	O
in	O
this	O
study	O
","	O
these	O
findings	O
support	O
the	O
benefits	O
of	O
early	O
abstinence	O
and	O
the	O
potential	O
for	O
ultrasound	O
examinations	O
in	O
the	O
detection	O
of	O
fetal	O
alcohol	B-Chemical
effects	O
.	O
	
	
Down	O
-	O
regulation	O
of	O
norepinephrine	O
transporter	O
function	O
induced	O
by	O
chronic	O
administration	O
of	O
desipramine	B-Chemical
linking	O
to	O
the	O
alteration	O
of	O
sensitivity	O
of	O
local	O
-	O
anesthetics	B-Chemical
-	O
induced	O
convulsions	B-Disease
and	O
the	O
counteraction	O
by	O
co	O
-	O
administration	O
with	O
local	O
anesthetics	B-Chemical
.	O
	
Alterations	O
of	O
norepinephrine	O
transporter	O
(	O
NET	O
)	O
function	O
by	O
chronic	O
inhibition	O
of	O
NET	O
in	O
relation	O
to	O
sensitization	O
to	O
seizures	B-Disease
induce	O
by	O
cocaine	B-Chemical
and	O
local	O
anesthetics	B-Chemical
were	O
studied	O
in	O
mice	O
.	O
	
Daily	O
administration	O
of	O
desipramine	B-Chemical
","	O
an	O
inhibitor	O
of	O
the	O
NET	O
","	O
for	O
5	O
days	O
decreased	O
[(	B-Chemical
3	I-Chemical
)	I-Chemical
H	I-Chemical
]	I-Chemical
norepinephrine	I-Chemical
uptake	O
in	O
the	O
P2	O
fractions	O
of	O
hippocampus	O
but	O
not	O
cortex	O
","	O
striatum	O
or	O
amygdalae	O
.	O
	
Co	O
-	O
administration	O
of	O
lidocaine	B-Chemical
","	O
bupivacaine	B-Chemical
or	O
tricaine	B-Chemical
with	O
desipramine	B-Chemical
reversed	O
this	O
effect	O
.	O
	
Daily	O
treatment	O
of	O
cocaine	B-Chemical
increased	O
[(	B-Chemical
3	I-Chemical
)	I-Chemical
H	I-Chemical
]	I-Chemical
norepinephrine	I-Chemical
uptake	O
into	O
the	O
hippocampus	O
.	O
	
Daily	O
administration	O
of	O
desipramine	B-Chemical
increased	O
the	O
incidence	O
of	O
appearance	O
of	O
lidocaine	B-Chemical
-	O
induced	O
convulsions	B-Disease
and	O
decreased	O
that	O
of	O
cocaine	B-Chemical
-	O
induced	O
convulsions	B-Disease
.	O
	
Co	O
-	O
administration	O
of	O
lidocaine	B-Chemical
with	O
desipramine	B-Chemical
reversed	O
the	O
changes	O
of	O
convulsive	B-Disease
activity	O
of	O
lidocaine	B-Chemical
and	O
cocaine	B-Chemical
induced	O
by	O
repeated	O
administration	O
of	O
desipramine	B-Chemical
.	O
	
These	O
results	O
suggest	O
that	O
down	O
-	O
regulation	O
of	O
hippocampal	O
NET	O
induced	O
by	O
chronic	O
administration	O
of	O
desipramine	B-Chemical
may	O
be	O
relevant	O
to	O
desipramine	B-Chemical
-	O
induced	O
sensitization	O
of	O
lidocaine	B-Chemical
convulsions	B-Disease
.	O
	
Inhibition	O
of	O
Na	B-Chemical
(+)	I-Chemical
channels	O
by	O
local	O
anesthetics	B-Chemical
may	O
regulate	O
desipramine	B-Chemical
-	O
induced	O
down	O
-	O
regulation	O
of	O
NET	O
function	O
.	O
	
Repeated	O
administration	O
of	O
cocaine	B-Chemical
induces	O
up	O
-	O
regulation	O
of	O
hippocampal	O
NET	O
function	O
.	O
	
Desipramine	B-Chemical
-	O
induced	O
sensitization	O
of	O
lidocaine	B-Chemical
seizures	B-Disease
may	O
have	O
a	O
mechanism	O
distinct	O
from	O
kindling	O
resulting	O
from	O
repeated	O
administration	O
of	O
cocaine	B-Chemical
.	O
	
	
Pharmacological	O
evidence	O
for	O
the	O
potential	O
of	O
Daucus	O
carota	O
in	O
the	O
management	O
of	O
cognitive	B-Disease
dysfunctions	I-Disease
.	O
	
The	O
present	O
study	O
was	O
aimed	O
at	O
investigating	O
the	O
effects	O
of	O
Daucus	O
carota	O
seeds	O
on	O
cognitive	O
functions	O
","	O
total	O
serum	O
cholesterol	B-Chemical
levels	O
and	O
brain	O
cholinesterase	O
activity	O
in	O
mice	O
.	O
	
The	O
ethanolic	O
extract	B-Chemical
of	I-Chemical
Daucus	I-Chemical
carota	I-Chemical
seeds	I-Chemical
(	O
DCE	B-Chemical
)	O
was	O
administered	O
orally	O
in	O
three	O
doses	O
(	O
100	O
","	O
200	O
","	O
400	O
mg	O
/	O
kg	O
)	O
for	O
seven	O
successive	O
days	O
to	O
different	O
groups	O
of	O
young	O
and	O
aged	O
mice	O
.	O
	
Elevated	O
plus	O
maze	O
and	O
passive	O
avoidance	O
apparatus	O
served	O
as	O
the	O
exteroceptive	O
behavioral	O
models	O
for	O
testing	O
memory	O
.	O
	
Diazepam	B-Chemical
-","	O
scopolamine	B-Chemical
-	O
and	O
ageing	O
-	O
induced	O
amnesia	B-Disease
served	O
as	O
the	O
interoceptive	O
behavioral	O
models	O
.	O
	
DCE	B-Chemical
(	O
200	O
","	O
400	O
mg	O
/	O
kg	O
","	O
p	O
.	O
o	O
.)	O
	
showed	O
significant	O
improvement	O
in	O
memory	O
scores	O
of	O
young	O
and	O
aged	O
mice	O
.	O
	
The	O
extent	O
of	O
memory	O
improvement	O
evoked	O
by	O
DCE	B-Chemical
was	O
23	O
%	O
at	O
the	O
dose	O
of	O
200	O
mg	O
/	O
kg	O
and	O
35	O
%	O
at	O
the	O
dose	O
of	O
400	O
mg	O
/	O
kg	O
in	O
young	O
mice	O
using	O
elevated	O
plus	O
maze	O
.	O
	
Similarly	O
","	O
significant	O
improvements	O
in	O
memory	O
scores	O
were	O
observed	O
using	O
passive	O
avoidance	O
apparatus	O
and	O
aged	O
mice	O
.	O
	
Furthermore	O
","	O
DCE	B-Chemical
reversed	O
the	O
amnesia	B-Disease
induced	O
by	O
scopolamine	B-Chemical
(	O
0	O
.	O
4	O
mg	O
/	O
kg	O
","	O
i	O
.	O
p	O
.)	O
	
and	O
diazepam	B-Chemical
(	O
1	O
mg	O
/	O
kg	O
","	O
i	O
.	O
p	O
.).	O
	
Daucus	B-Chemical
carota	I-Chemical
extract	I-Chemical
(	O
200	O
","	O
400	O
mg	O
/	O
kg	O
","	O
p	O
.	O
o	O
.)	O
	
reduced	O
significantly	O
the	O
brain	O
acetylcholinesterase	O
activity	O
and	O
cholesterol	B-Chemical
levels	O
in	O
young	O
and	O
aged	O
mice	O
.	O
	
The	O
extent	O
of	O
inhibition	O
of	O
brain	O
cholinesterase	O
activity	O
evoked	O
by	O
DCE	B-Chemical
at	O
the	O
dose	O
of	O
400	O
mg	O
/	O
kg	O
was	O
22	O
%	O
in	O
young	O
and	O
19	O
%	O
in	O
aged	O
mice	O
.	O
	
There	O
was	O
a	O
remarkable	O
reduction	O
in	O
total	O
cholesterol	B-Chemical
level	O
as	O
well	O
","	O
to	O
the	O
extent	O
of	O
23	O
%	O
in	O
young	O
and	O
21	O
%	O
in	O
aged	O
animals	O
with	O
this	O
dose	O
of	O
DCE	B-Chemical
.	O
	
Therefore	O
","	O
DCE	B-Chemical
may	O
prove	O
to	O
be	O
a	O
useful	O
remedy	O
for	O
the	O
management	O
of	O
cognitive	B-Disease
dysfunctions	I-Disease
on	O
account	O
of	O
its	O
multifarious	O
beneficial	O
effects	O
such	O
as	O
","	O
memory	O
improving	O
property	O
","	O
cholesterol	B-Chemical
lowering	O
property	O
and	O
anticholinesterase	O
activity	O
.	O
	
	
Mechanisms	O
of	O
hypertension	B-Disease
induced	O
by	O
nitric	B-Chemical
oxide	I-Chemical
(	O
NO	B-Chemical
)	O
deficiency	O
:	O
focus	O
on	O
venous	O
function	O
.	O
	
Loss	O
of	O
endothelial	O
cell	O
-	O
derived	O
nitric	B-Chemical
oxide	I-Chemical
(	O
NO	B-Chemical
)	O
in	O
hypertension	B-Disease
is	O
a	O
hallmark	O
of	O
arterial	B-Disease
dysfunction	I-Disease
.	O
	
Experimental	O
hypertension	B-Disease
created	O
by	O
the	O
removal	O
of	O
NO	B-Chemical
","	O
however	O
","	O
involves	O
mechanisms	O
in	O
addition	O
to	O
decreased	O
arterial	O
vasodilator	O
activity	O
.	O
	
These	O
include	O
augmented	O
endothelin	O
-	O
1	O
(	O
ET	O
-	O
1	O
)	O
release	O
","	O
increased	O
sympathetic	O
nervous	O
system	O
activity	O
","	O
and	O
elevated	O
tissue	O
oxidative	O
stress	O
.	O
	
We	O
hypothesized	O
that	O
increased	O
venous	O
smooth	O
muscle	O
(	O
venomotor	O
)	O
tone	O
plays	O
a	O
role	O
in	O
Nomega	B-Chemical
-	I-Chemical
nitro	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arginine	I-Chemical
(	O
LNNA	B-Chemical
)	O
hypertension	B-Disease
through	O
these	O
mechanisms	O
.	O
	
Rats	O
were	O
treated	O
with	O
the	O
NO	O
synthase	O
inhibitor	O
LNNA	B-Chemical
(	O
0	O
.	O
5	O
g	O
/	O
L	O
in	O
drinking	O
water	O
)	O
for	O
2	O
weeks	O
.	O
	
Mean	O
arterial	O
pressure	O
of	O
conscious	O
rats	O
was	O
119	O
+/-	O
2	O
mm	O
Hg	O
in	O
control	O
and	O
194	O
+/-	O
5	O
mm	O
Hg	O
in	O
LNNA	B-Chemical
rats	O
(	O
P	O
<	O
0	O
.	O
5	O
).	O
	
Carotid	O
arteries	O
and	O
vena	O
cava	O
were	O
removed	O
for	O
measurement	O
of	O
isometric	O
contraction	O
.	O
	
Maximal	O
contraction	O
to	O
norepinephrine	B-Chemical
was	O
modestly	O
reduced	O
in	O
arteries	O
from	O
LNNA	B-Chemical
compared	O
with	O
control	O
rats	O
whereas	O
the	O
maximum	O
contraction	O
to	O
ET	O
-	O
1	O
was	O
significantly	O
reduced	O
(	O
54	O
%	O
control	O
).	O
	
Maximum	O
contraction	O
of	O
vena	O
cava	O
to	O
norepinephrine	B-Chemical
(	O
37	O
%	O
control	O
)	O
also	O
was	O
reduced	O
but	O
no	O
change	O
in	O
response	O
to	O
ET	O
-	O
1	O
was	O
observed	O
.	O
	
Mean	O
circulatory	O
filling	O
pressure	O
","	O
an	O
in	O
vivo	O
measure	O
of	O
venomotor	O
tone	O
","	O
was	O
not	O
elevated	O
in	O
LNNA	B-Chemical
hypertension	B-Disease
at	O
1	O
or	O
2	O
weeks	O
after	O
LNNA	B-Chemical
.	O
	
The	O
superoxide	B-Chemical
scavenger	O
tempol	B-Chemical
(	O
30	O
","	O
100	O
","	O
and	O
300	O
micromol	O
kg	O
(-	O
1	O
)","	O
IV	O
)	O
did	O
not	O
change	O
arterial	O
pressure	O
in	O
control	O
rats	O
but	O
caused	O
a	O
dose	O
-	O
dependent	O
decrease	O
in	O
LNNA	B-Chemical
rats	O
(-	O
18	O
+/-	O
8	O
","	O
-	O
26	O
+/-	O
15	O
","	O
and	O
-	O
54	O
+/-	O
11	O
mm	O
Hg	O
).	O
	
Similarly	O
","	O
ganglionic	O
blockade	O
with	O
hexamethonium	B-Chemical
caused	O
a	O
significantly	O
greater	O
fall	O
in	O
LNNA	B-Chemical
hypertensive	B-Disease
rats	O
(	O
76	O
+/-	O
9	O
mm	O
Hg	O
)	O
compared	O
with	O
control	O
rats	O
(	O
35	O
+/-	O
10	O
mm	O
Hg	O
).	O
	
Carotid	O
arteries	O
","	O
vena	O
cava	O
","	O
and	O
sympathetic	O
ganglia	O
from	O
LNNA	B-Chemical
rats	O
had	O
higher	O
basal	O
levels	O
of	O
superoxide	B-Chemical
compared	O
with	O
those	O
from	O
control	O
rats	O
.	O
	
These	O
data	O
suggest	O
that	O
while	O
NO	B-Chemical
deficiency	O
increases	O
oxidative	O
stress	O
and	O
sympathetic	O
activity	O
in	O
both	O
arterial	O
and	O
venous	O
vessels	O
","	O
the	O
impact	O
on	O
veins	O
does	O
not	O
make	O
a	O
major	O
contribution	O
to	O
this	O
form	O
of	O
hypertension	B-Disease
.	O
	
	
Anticonvulsant	O
effect	O
of	O
eslicarbazepine	B-Chemical
acetate	I-Chemical
(	O
BIA	B-Chemical
2	I-Chemical
-	I-Chemical
93	I-Chemical
)	O
on	O
seizures	B-Disease
induced	O
by	O
microperfusion	O
of	O
picrotoxin	B-Chemical
in	O
the	O
hippocampus	O
of	O
freely	O
moving	O
rats	O
.	O
	
Eslicarbazepine	B-Chemical
acetate	I-Chemical
(	O
BIA	B-Chemical
2	I-Chemical
-	I-Chemical
93	I-Chemical
","	O
S	B-Chemical
-(-)-	I-Chemical
10	I-Chemical
-	I-Chemical
acetoxy	I-Chemical
-	I-Chemical
10	I-Chemical
","	I-Chemical
11	I-Chemical
-	I-Chemical
dihydro	I-Chemical
-	I-Chemical
5H	I-Chemical
-	I-Chemical
dibenzo	I-Chemical
/	I-Chemical
b	I-Chemical
","	I-Chemical
f	I-Chemical
/	I-Chemical
azepine	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
carboxamide	I-Chemical
)	O
is	O
a	O
novel	O
antiepileptic	B-Chemical
drug	I-Chemical
","	O
now	O
in	O
Phase	O
III	O
clinical	O
trials	O
","	O
designed	O
with	O
the	O
aim	O
of	O
improving	O
efficacy	O
and	O
safety	O
in	O
comparison	O
with	O
the	O
structurally	O
related	O
drugs	O
carbamazepine	B-Chemical
(	O
CBZ	B-Chemical
)	O
and	O
oxcarbazepine	B-Chemical
(	O
OXC	B-Chemical
).	O
	
We	O
have	O
studied	O
the	O
effects	O
of	O
oral	O
treatment	O
with	O
eslicarbazepine	B-Chemical
acetate	I-Chemical
on	O
a	O
whole	O
-	O
animal	O
model	O
in	O
which	O
partial	O
seizures	B-Disease
can	O
be	O
elicited	O
repeatedly	O
on	O
different	O
days	O
without	O
changes	O
in	O
threshold	O
or	O
seizure	B-Disease
patterns	O
.	O
	
In	O
the	O
animals	O
treated	O
with	O
threshold	O
doses	O
of	O
picrotoxin	B-Chemical
","	O
the	O
average	O
number	O
of	O
seizures	B-Disease
was	O
2	O
.	O
3	O
+/-	O
1	O
.	O
2	O
","	O
and	O
average	O
seizure	B-Disease
duration	O
was	O
39	O
.	O
5	O
+/-	O
8	O
.	O
4s	O
.	O
	
Pre	O
-	O
treatment	O
with	O
a	O
dose	O
of	O
30	O
mg	O
/	O
kg	O
2h	O
before	O
picrotoxin	B-Chemical
microperfusion	O
prevented	O
seizures	B-Disease
in	O
the	O
75	O
%	O
of	O
the	O
rats	O
.	O
	
Lower	O
doses	O
(	O
3	O
and	O
10mg	O
/	O
kg	O
)	O
did	O
not	O
suppress	O
seizures	B-Disease
","	O
however	O
","	O
after	O
administration	O
of	O
10mg	O
/	O
kg	O
","	O
significant	O
reductions	O
in	O
seizures	B-Disease
duration	O
(	O
24	O
.	O
3	O
+/-	O
6	O
.	O
8s	O
)	O
and	O
seizure	B-Disease
number	O
(	O
1	O
.	O
6	O
+/-	O
0	O
.	O
34	O
)	O
were	O
found	O
.	O
	
No	O
adverse	O
effects	O
of	O
eslicarbazepine	B-Chemical
acetate	I-Chemical
were	O
observed	O
in	O
the	O
behavioral	O
/	O
EEG	O
patterns	O
studied	O
","	O
including	O
sleep	O
/	O
wakefulness	O
cycle	O
","	O
at	O
the	O
doses	O
studied	O
.	O
	
	
Anti	O
-	O
oxidant	O
effects	O
of	O
atorvastatin	B-Chemical
in	O
dexamethasone	B-Chemical
-	O
induced	O
hypertension	B-Disease
in	O
the	O
rat	O
.	O
	
1	O
.	O
	
Dexamethasone	B-Chemical
(	O
Dex	B-Chemical
)-	O
induced	O
hypertension	B-Disease
is	O
characterized	O
by	O
endothelial	O
dysfunction	O
associated	O
with	O
nitric	B-Chemical
oxide	I-Chemical
(	O
NO	B-Chemical
)	O
deficiency	O
and	O
increased	O
superoxide	B-Chemical
(	O
O2	B-Chemical
-)	I-Chemical
production	O
.	O
	
Atorvastatin	B-Chemical
(	O
Ato	B-Chemical
)	O
possesses	O
pleiotropic	O
properties	O
that	O
have	O
been	O
reported	O
to	O
improve	O
endothelial	O
function	O
through	O
increased	O
availability	O
of	O
NO	B-Chemical
and	O
reduced	O
O2	B-Chemical
-	I-Chemical
production	O
in	O
various	O
forms	O
of	O
hypertension	B-Disease
.	O
	
In	O
the	O
present	O
study	O
","	O
we	O
investigated	O
whether	O
50	O
mg	O
/	O
kg	O
per	O
day	O
","	O
p	O
.	O
o	O
.","	O
Ato	B-Chemical
could	O
prevent	O
endothelial	O
NO	O
synthase	O
(	O
eNOS	O
)	O
downregulation	O
and	O
the	O
increase	O
in	O
O2	B-Chemical
-	I-Chemical
in	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
","	O
thereby	O
reducing	O
blood	O
pressure	O
.	O
	
2	O
.	O
	
Male	O
SD	O
rats	O
(	O
n	O
=	O
30	O
)	O
were	O
treated	O
with	O
Ato	B-Chemical
(	O
50	O
mg	O
/	O
kg	O
per	O
day	O
in	O
drinking	O
water	O
)	O
or	O
tap	O
water	O
for	O
15	O
days	O
.	O
	
Dexamethasone	B-Chemical
(	O
10	O
microg	O
/	O
kg	O
per	O
day	O
","	O
s	O
.	O
c	O
.)	O
	
or	O
saline	O
was	O
started	O
after	O
4	O
days	O
in	O
Ato	B-Chemical
-	O
treated	O
and	O
non	O
-	O
treated	O
rats	O
and	O
continued	O
for	O
11	O
-	O
13	O
days	O
.	O
	
Systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
was	O
measured	O
on	O
alternate	O
days	O
using	O
the	O
tail	O
-	O
cuff	O
method	O
.	O
	
Endothelial	O
function	O
was	O
assessed	O
by	O
acetylcholine	B-Chemical
-	O
induced	O
vasorelaxation	O
and	O
phenylephrine	B-Chemical
-	O
induced	O
vasoconstriction	O
in	O
aortic	O
segments	O
.	O
	
Vascular	O
eNOS	O
mRNA	O
was	O
assessed	O
by	O
semi	O
-	O
quantitative	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
.	O
	
3	O
.	O
	
In	O
rats	O
treated	O
with	O
Dex	B-Chemical
alone	O
","	O
SBP	O
was	O
increased	O
from	O
109	O
+/-	O
2	O
to	O
133	O
+/-	O
2	O
mmHg	O
on	O
Days	O
4	O
and	O
Day	O
14	O
","	O
respectively	O
(	O
P	O
<	O
0	O
.	O
1	O
).	O
	
In	O
the	O
Ato	B-Chemical
+	O
Dex	B-Chemical
group	O
","	O
SBP	O
was	O
increased	O
from	O
113	O
+/-	O
2	O
to	O
119	O
+/-	O
2	O
mmHg	O
on	O
Days	O
4	O
to	O
14	O
","	O
respectively	O
(	O
P	O
<	O
0	O
.	O
1	O
)","	O
but	O
was	O
significantly	O
lower	O
than	O
SBP	O
in	O
the	O
group	O
treated	O
with	O
Dex	B-Chemical
alone	O
(	O
P	O
<	O
0	O
.	O
5	O
).	O
	
Endothelial	O
-	O
dependent	O
relaxation	O
and	O
eNOS	O
mRNA	O
expression	O
were	O
greater	O
in	O
the	O
Dex	B-Chemical
+	O
Ato	B-Chemical
group	O
than	O
in	O
the	O
Dex	B-Chemical
only	O
group	O
(	O
P	O
<	O
0	O
.	O
5	O
and	O
P	O
<	O
0	O
.	O
1	O
","	O
respectively	O
).	O
	
Aortic	O
superoxide	B-Chemical
production	O
was	O
lower	O
in	O
the	O
Dex	B-Chemical
+	O
Ato	B-Chemical
group	O
compared	O
with	O
the	O
group	O
treated	O
with	O
Dex	B-Chemical
alone	O
(	O
P	O
<	O
0	O
.	O
1	O
).	O
	
4	O
.	O
	
Treatment	O
with	O
Ato	B-Chemical
improved	O
endothelial	O
function	O
","	O
reduced	O
superoxide	B-Chemical
production	O
and	O
reduced	O
SBP	O
in	O
Dex	B-Chemical
-	O
treated	O
SD	O
rats	O
.	O
	
	
Behavioral	O
effects	O
of	O
pubertal	O
anabolic	B-Chemical
androgenic	I-Chemical
steroid	I-Chemical
exposure	O
in	O
male	O
rats	O
with	O
low	O
serotonin	B-Chemical
.	O
	
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
interactive	O
effects	O
of	O
chronic	O
anabolic	B-Chemical
androgenic	I-Chemical
steroid	I-Chemical
(	O
AAS	B-Chemical
)	O
exposure	O
and	O
brain	O
serotonin	B-Chemical
(	O
5	B-Chemical
-	I-Chemical
hydroxytryptamine	I-Chemical
","	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
)	O
depletion	O
on	O
behavior	O
of	O
pubertal	O
male	O
rats	O
.	O
	
Serotonin	B-Chemical
was	O
depleted	O
beginning	O
on	O
postnatal	O
day	O
26	O
with	O
parachlorophenylalanine	B-Chemical
(	O
PCPA	B-Chemical
100	O
mg	O
/	O
kg	O
","	O
every	O
other	O
day	O
");"	O
controls	O
received	O
saline	O
.	O
	
At	O
puberty	O
(	O
P40	O
)","	O
half	O
the	O
PCPA	B-Chemical
-	O
treated	O
rats	O
and	O
half	O
the	O
saline	O
-	O
treated	O
rats	O
began	O
treatment	O
with	O
testosterone	B-Chemical
(	O
T	B-Chemical
","	O
5	O
mg	O
/	O
kg	O
","	O
5	O
days	O
/	O
week	O
).	O
	
Behavioral	O
measures	O
included	O
locomotion	O
","	O
irritability	B-Disease
","	O
copulation	O
","	O
partner	O
preference	O
","	O
and	O
aggression	B-Disease
.	O
	
Animals	O
were	O
tested	O
for	O
aggression	B-Disease
in	O
their	O
home	O
cage	O
","	O
both	O
with	O
and	O
without	O
physical	O
provocation	O
(	O
mild	O
tail	O
pinch	O
).	O
	
Brain	O
levels	O
of	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
and	O
its	O
metabolite	O
","	O
5	B-Chemical
-	I-Chemical
hydroxyindoleacetic	I-Chemical
acid	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
HIAA	I-Chemical
)","	O
were	O
determined	O
using	O
HPLC	O
.	O
	
PCPA	B-Chemical
significantly	O
and	O
substantially	O
depleted	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
and	O
5	B-Chemical
-	I-Chemical
HIAA	I-Chemical
in	O
all	O
brain	O
regions	O
examined	O
.	O
	
Chronic	O
T	B-Chemical
treatment	O
significantly	O
decreased	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
and	O
5	B-Chemical
-	I-Chemical
HIAA	I-Chemical
in	O
certain	O
brain	O
areas	O
","	O
but	O
to	O
a	O
much	O
lesser	O
extent	O
than	O
PCPA	B-Chemical
.	O
	
Chronic	O
exposure	O
to	O
PCPA	B-Chemical
alone	O
significantly	O
decreased	O
locomotor	O
activity	O
and	O
increased	O
irritability	B-Disease
but	O
had	O
no	O
effect	O
on	O
sexual	O
behavior	O
","	O
partner	O
preference	O
","	O
or	O
aggression	B-Disease
.	O
	
T	B-Chemical
alone	O
had	O
no	O
effect	O
on	O
locomotion	O
","	O
irritability	B-Disease
","	O
or	O
sexual	O
behavior	O
but	O
increased	O
partner	O
preference	O
and	O
aggression	B-Disease
.	O
	
The	O
most	O
striking	O
effect	O
of	O
combining	O
T	B-Chemical
+	O
PCPA	B-Chemical
was	O
a	O
significant	O
increase	O
in	O
attack	O
frequency	O
as	O
well	O
as	O
a	O
significant	O
decrease	O
in	O
the	O
latency	O
to	O
attack	O
","	O
particularly	O
following	O
physical	O
provocation	O
.	O
	
Based	O
on	O
these	O
data	O
","	O
it	O
can	O
be	O
speculated	O
that	O
pubertal	O
AAS	B-Chemical
users	O
with	O
low	O
central	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
may	O
be	O
especially	O
prone	O
to	O
exhibit	O
aggressive	B-Disease
behavior	I-Disease
.	O
	
	
In	O
vitro	O
characterization	O
of	O
parasympathetic	O
and	O
sympathetic	O
responses	O
in	O
cyclophosphamide	B-Chemical
-	O
induced	O
cystitis	B-Disease
in	O
the	O
rat	O
.	O
	
In	O
cyclophosphamide	B-Chemical
-	O
induced	O
cystitis	B-Disease
in	O
the	O
rat	O
","	O
detrusor	O
function	O
is	O
impaired	O
and	O
the	O
expression	O
and	O
effects	O
of	O
muscarinic	O
receptors	O
altered	O
.	O
	
Whether	O
or	O
not	O
the	O
neuronal	O
transmission	O
may	O
be	O
affected	O
by	O
cystitis	B-Disease
was	O
presently	O
investigated	O
.	O
	
Responses	O
of	O
urinary	O
strip	O
preparations	O
from	O
control	O
and	O
cyclophosphamide	B-Chemical
-	O
pretreated	O
rats	O
to	O
electrical	O
field	O
stimulation	O
and	O
to	O
agonists	O
were	O
assessed	O
in	O
the	O
absence	O
and	O
presence	O
of	O
muscarinic	B-Chemical
","	I-Chemical
adrenergic	I-Chemical
and	I-Chemical
purinergic	I-Chemical
receptor	I-Chemical
antagonists	I-Chemical
.	O
	
Generally	O
","	O
atropine	B-Chemical
reduced	O
contractions	O
","	O
but	O
in	O
contrast	O
to	O
controls	O
","	O
it	O
also	O
reduced	O
responses	O
to	O
low	O
electrical	O
field	O
stimulation	O
intensity	O
(	O
1	O
-	O
5	O
Hz	O
)	O
in	O
inflamed	O
preparations	O
.	O
	
In	O
both	O
types	O
","	O
purinoceptor	O
desensitization	O
with	O
alpha	B-Chemical
","	I-Chemical
beta	I-Chemical
-	I-Chemical
methylene	I-Chemical
adenosine	I-Chemical
-	I-Chemical
5	I-Chemical
'-	I-Chemical
triphosphate	I-Chemical
(	O
alpha	B-Chemical
","	I-Chemical
beta	I-Chemical
-	I-Chemical
meATP	I-Chemical
)	O
caused	O
further	O
reductions	O
at	O
low	O
frequencies	O
(<	O
10	O
Hz	O
).	O
	
The	O
muscarinic	O
receptor	O
antagonists	O
atropine	B-Chemical
","	O
4	B-Chemical
-	I-Chemical
diphenylacetoxy	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
methylpiperidine	I-Chemical
(	O
4	B-Chemical
-	I-Chemical
DAMP	I-Chemical
)	O
('	O
M	O
(	O
1	O
)/	O
M	O
(	O
3	O
)/	O
M	O
(	O
5	O
)-	O
selective	O
')","	O
methoctramine	B-Chemical
('	O
M	O
(	O
2	O
)-	O
selective	O
')	O
and	O
pirenzepine	B-Chemical
('	O
M	O
(	O
1	O
)-	O
selective	O
')	O
antagonized	O
the	O
tonic	O
component	O
of	O
the	O
electrical	O
field	O
stimulation	O
-	O
evoked	O
contractile	O
response	O
more	O
potently	O
than	O
the	O
phasic	O
component	O
.	O
	
4	B-Chemical
-	I-Chemical
DAMP	I-Chemical
inhibited	O
the	O
tonic	O
contractions	O
in	O
controls	O
more	O
potently	O
than	O
methoctramine	B-Chemical
and	O
pirenzepine	B-Chemical
.	O
	
In	O
inflamed	O
preparations	O
","	O
the	O
muscarinic	B-Chemical
receptor	I-Chemical
antagonism	I-Chemical
on	O
the	O
phasic	O
component	O
of	O
the	O
electrical	O
field	O
stimulation	O
-	O
evoked	O
contraction	O
was	O
decreased	O
and	O
the	O
pirenzepine	B-Chemical
and	O
4	B-Chemical
-	I-Chemical
DAMP	I-Chemical
antagonism	O
on	O
the	O
tonic	O
component	O
was	O
much	O
less	O
efficient	O
than	O
in	O
controls	O
.	O
	
In	O
contrast	O
to	O
controls	O
","	O
methoctramine	B-Chemical
increased	O
--	O
instead	O
of	O
decreased	O
--	O
the	O
tonic	O
responses	O
at	O
high	O
frequencies	O
.	O
	
While	O
contractions	O
to	O
carbachol	B-Chemical
and	O
ATP	B-Chemical
were	O
the	O
same	O
in	O
inflamed	O
and	O
in	O
control	O
strips	O
when	O
related	O
to	O
a	O
reference	O
potassium	B-Chemical
response	O
","	O
isoprenaline	B-Chemical
-	O
induced	O
relaxations	O
were	O
smaller	O
in	O
inflamed	O
strips	O
.	O
	
Thus	O
","	O
in	O
cystitis	B-Disease
substantial	O
changes	O
of	O
the	O
efferent	O
functional	O
responses	O
occur	O
.	O
	
While	O
postjunctional	O
beta	O
-	O
adrenoceptor	O
-	O
mediated	O
relaxations	O
are	O
reduced	O
","	O
effects	O
by	O
prejunctional	O
inhibitory	O
muscarinic	O
receptors	O
may	O
be	O
increased	O
.	O
	
	
Comparison	O
of	O
valsartan	B-Chemical
/	O
hydrochlorothiazide	B-Chemical
combination	O
therapy	O
at	O
doses	O
up	O
to	O
320	O
/	O
25	O
mg	O
versus	O
monotherapy	O
:	O
a	O
double	O
-	O
blind	O
","	O
placebo	O
-	O
controlled	O
study	O
followed	O
by	O
long	O
-	O
term	O
combination	O
therapy	O
in	O
hypertensive	B-Disease
adults	O
.	O
	
BACKGROUND	O
:	O
One	O
third	O
of	O
patients	O
treated	O
for	O
hypertension	B-Disease
attain	O
adequate	O
blood	O
pressure	O
(	O
BP	O
)	O
control	O
","	O
and	O
multidrug	O
regimens	O
are	O
often	O
required	O
.	O
	
Given	O
the	O
lifelong	O
nature	O
of	O
hypertension	B-Disease
","	O
there	O
is	O
a	O
need	O
to	O
evaluate	O
the	O
long	O
-	O
term	O
efficacy	O
and	O
tolerability	O
of	O
higher	O
doses	O
of	O
combination	O
anti	O
-	O
hypertensive	B-Disease
therapies	O
.	O
	
OBJECTIVE	O
:	O
This	O
study	O
investigated	O
the	O
efficacy	O
and	O
tolerability	O
of	O
valsartan	B-Chemical
(	O
VAL	B-Chemical
)	O
or	O
hydrochlorothiazide	B-Chemical
(	O
HCTZ	B-Chemical
)-	O
monotherapy	O
and	O
higher	O
-	O
dose	O
combinations	O
in	O
patients	O
with	O
essential	B-Disease
hypertension	I-Disease
.	O
	
METHODS	O
:	O
The	O
first	O
part	O
of	O
this	O
study	O
was	O
an	O
8	O
-	O
week	O
","	O
multicenter	O
","	O
randomized	O
","	O
double	O
-	O
blind	O
","	O
placebo	O
controlled	O
","	O
parallel	O
-	O
group	O
trial	O
.	O
	
Patients	O
with	O
essential	B-Disease
hypertension	I-Disease
(	O
mean	O
sitting	O
diastolic	O
BP	O
[	O
MSDBP	O
]","	O
>	O
or	O
=	O
95	O
mm	O
Hg	O
and	O
<	O
110	O
mm	O
Hg	O
)	O
were	O
randomized	O
to	O
1	O
of	O
8	O
treatment	O
groups	O
:	O
VAL	B-Chemical
160	O
or	O
320	O
mg	O
";"	O
HCTZ	B-Chemical
12	O
.	O
5	O
or	O
25	O
mg	O
";"	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
160	O
/	O
12	O
.	O
5	O
","	O
320	O
/	O
12	O
.	O
5	O
","	O
or	O
320	O
/	O
25	O
mg	O
";"	O
or	O
placebo	O
.	O
	
Mean	O
changes	O
in	O
MSDBP	O
and	O
mean	O
sitting	O
systolic	O
BP	O
(	O
MSSBP	O
)	O
were	O
analyzed	O
at	O
the	O
8	O
-	O
week	O
core	O
study	O
end	O
point	O
.	O
	
VAL	B-Chemical
/	O
HCTZ	B-Chemical
320	O
/	O
12	O
.	O
5	O
and	O
320	O
/	O
25	O
mg	O
were	O
further	O
investigated	O
in	O
a	O
54	O
-	O
week	O
","	O
open	O
-	O
label	O
extension	O
.	O
	
Response	O
was	O
defined	O
as	O
MSDBP	O
<	O
90	O
mm	O
Hg	O
or	O
a	O
>	O
or	O
=	O
10	O
mm	O
Hg	O
decrease	O
compared	O
to	O
baseline	O
.	O
	
Control	O
was	O
defined	O
as	O
MSDBP	O
<	O
90	O
mm	O
Hg	O
compared	O
with	O
baseline	O
.	O
	
Tolerability	O
was	O
assessed	O
by	O
monitoring	O
adverse	O
events	O
at	O
randomization	O
and	O
all	O
subsequent	O
study	O
visits	O
and	O
regular	O
evaluation	O
of	O
hematology	O
and	O
blood	O
chemistry	O
.	O
	
RESULTS	O
:	O
A	O
total	O
of	O
1346	O
patients	O
were	O
randomized	O
into	O
the	O
8	O
-	O
week	O
core	O
study	O
(	O
734	O
men	O
","	O
612	O
women	O
";"	O
924	O
white	O
","	O
291	O
black	O
","	O
23	O
Asian	O
","	O
108	O
other	O
";"	O
mean	O
age	O
","	O
52	O
.	O
7	O
years	O
";"	O
mean	O
weight	O
","	O
92	O
.	O
6	O
kg	O
).	O
	
All	O
active	O
treatments	O
were	O
associated	O
with	O
significantly	O
reduced	O
MSSBP	O
and	O
MSDBP	O
during	O
the	O
core	O
8	O
-	O
week	O
study	O
","	O
with	O
each	O
monotherapy	O
significantly	O
contributing	O
to	O
the	O
overall	O
effect	O
of	O
combination	O
therapy	O
(	O
VAL	B-Chemical
and	O
HCTZ	B-Chemical
","	O
P	O
<	O
0	O
.	O
1	O
).	O
	
Each	O
combination	O
was	O
associated	O
with	O
significantly	O
greater	O
reductions	O
in	O
MSSBP	O
and	O
MSDBP	O
compared	O
with	O
the	O
monotherapies	O
and	O
placebo	O
(	O
all	O
","	O
P	O
<	O
0	O
.	O
1	O
).	O
	
The	O
mean	O
reduction	O
in	O
MSSBP	O
/	O
MSDBP	O
with	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
320	O
/	O
25	O
mg	O
was	O
24	O
.	O
7	O
/	O
16	O
.	O
6	O
mm	O
Hg	O
","	O
compared	O
with	O
5	O
.	O
9	O
/	O
7	O
.	O
0	O
mm	O
Hg	O
with	O
placebo	O
.	O
	
The	O
reduction	O
in	O
MSSBP	O
was	O
significantly	O
greater	O
with	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
320	O
/	O
25	O
mg	O
compared	O
with	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
160	O
/	O
12	O
.	O
5	O
mg	O
(	O
P	O
<	O
0	O
.	O
2	O
).	O
	
Rates	O
of	O
response	O
and	O
BP	O
control	O
were	O
significantly	O
higher	O
in	O
the	O
groups	O
that	O
received	O
combination	O
treatment	O
compared	O
with	O
those	O
that	O
received	O
monotherapy	O
.	O
	
The	O
incidence	O
of	O
hypokalemia	B-Disease
was	O
lower	O
with	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
combinations	O
(	O
1	O
.	O
8	O
%-	O
6	O
.	O
1	O
%)	O
than	O
with	O
HCTZ	B-Chemical
monotherapies	O
(	O
7	O
.	O
1	O
%-	O
13	O
.	O
3	O
%).	O
	
The	O
majority	O
of	O
adverse	O
events	O
in	O
the	O
core	O
study	O
were	O
of	O
mild	O
to	O
moderate	O
severity	O
.	O
	
The	O
efficacy	O
and	O
tolerability	O
of	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
combinations	O
were	O
maintained	O
during	O
the	O
extension	O
(	O
797	O
patients	O
).	O
	
CONCLUSIONS	O
:	O
In	O
this	O
study	O
population	O
","	O
combination	O
therapies	O
with	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
were	O
associated	O
with	O
significantly	O
greater	O
BP	O
reductions	O
compared	O
with	O
either	O
monotherapy	O
","	O
were	O
well	O
tolerated	O
","	O
and	O
were	O
associated	O
with	O
less	O
hypokalemia	B-Disease
than	O
HCTZ	B-Chemical
alone	O
.	O
	
	
Role	O
of	O
xanthine	B-Chemical
oxidase	I-Chemical
in	O
dexamethasone	B-Chemical
-	O
induced	O
hypertension	B-Disease
in	O
rats	O
.	O
	
1	O
.	O
	
Glucocorticoid	B-Chemical
-	O
induced	O
hypertension	B-Disease
(	O
GC	B-Chemical
-	O
HT	B-Disease
)	O
in	O
the	O
rat	O
is	O
associated	O
with	O
nitric	B-Chemical
oxide	I-Chemical
-	O
redox	O
imbalance	O
.	O
	
2	O
.	O
	
We	O
studied	O
the	O
role	O
of	O
xanthine	B-Chemical
oxidase	I-Chemical
(	O
XO	B-Chemical
)","	O
which	O
is	O
implicated	O
in	O
the	O
production	O
of	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
","	O
in	O
dexamethasone	B-Chemical
-	O
induced	O
hypertension	B-Disease
(	O
dex	B-Chemical
-	O
HT	B-Disease
).	O
	
3	O
.	O
	
Thirty	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
divided	O
randomly	O
into	O
four	O
treatment	O
groups	O
:	O
saline	O
","	O
dexamethasone	B-Chemical
(	O
dex	B-Chemical
)","	O
allopurinol	B-Chemical
plus	O
saline	O
","	O
and	O
allopurinol	B-Chemical
plus	O
dex	B-Chemical
.	O
	
4	O
.	O
	
Systolic	O
blood	O
pressures	O
(	O
SBP	O
)	O
and	O
bodyweights	O
were	O
recorded	O
each	O
alternate	O
day	O
.	O
	
Thymus	O
weight	O
was	O
used	O
as	O
a	O
marker	O
of	O
glucocorticoid	B-Chemical
activity	O
","	O
and	O
serum	O
urate	B-Chemical
to	O
assess	O
XO	B-Chemical
inhibition	O
.	O
	
5	O
.	O
	
Dex	B-Chemical
increased	O
SBP	O
(	O
110	O
+/-	O
2	O
-	O
126	O
+/-	O
3	O
mmHg	O
";"	O
P	O
<	O
0	O
.	O
1	O
)	O
and	O
decreased	O
thymus	O
(	O
P	O
<	O
0	O
.	O
1	O
)	O
and	O
bodyweights	O
(	O
P	O
<	O
0	O
.	O
1	O
).	O
	
Allopurinol	B-Chemical
decreased	O
serum	O
urate	B-Chemical
from	O
76	O
+/-	O
5	O
to	O
30	O
+/-	O
3	O
micromol	O
/	O
L	O
(	O
P	O
<	O
0	O
.	O
1	O
)	O
in	O
saline	O
and	O
from	O
84	O
+/-	O
13	O
to	O
28	O
+/-	O
2	O
micromol	O
/	O
L	O
in	O
dex	B-Chemical
-	O
treated	O
(	O
P	O
<	O
0	O
.	O
1	O
)	O
groups	O
.	O
	
6	O
.	O
	
Allopurinol	B-Chemical
did	O
not	O
prevent	O
dex	B-Chemical
-	O
HT	B-Disease
.	O
	
This	O
","	O
together	O
with	O
our	O
previous	O
findings	O
that	O
allopurinol	B-Chemical
failed	O
to	O
prevent	O
adrenocorticotrophic	O
hormone	O
induced	O
hypertension	B-Disease
","	O
suggests	O
that	O
XO	B-Chemical
activity	O
is	O
not	O
a	O
major	O
determinant	O
of	O
GC	B-Chemical
-	O
HT	B-Disease
in	O
the	O
rat	O
.	O
	
	
Neuroprotective	O
effects	O
of	O
melatonin	B-Chemical
upon	O
the	O
offspring	O
cerebellar	O
cortex	O
in	O
the	O
rat	O
model	O
of	O
BCNU	B-Chemical
-	O
induced	O
cortical	B-Disease
dysplasia	I-Disease
.	O
	
Cortical	B-Disease
dysplasia	I-Disease
is	O
a	O
malformation	O
characterized	O
by	O
defects	O
in	O
proliferation	O
","	O
migration	O
and	O
maturation	O
.	O
	
This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
alterations	O
in	O
offspring	O
rat	O
cerebellum	O
induced	O
by	O
maternal	O
exposure	O
to	O
carmustine	B-Chemical
-[	O
1	B-Chemical
","	I-Chemical
3	I-Chemical
-	I-Chemical
bis	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
chloroethyl	I-Chemical
)-	I-Chemical
1	I-Chemical
-	I-Chemical
nitrosoure	I-Chemical
]	O
(	O
BCNU	B-Chemical
)	O
and	O
to	O
investigate	O
the	O
effects	O
of	O
exogenous	O
melatonin	B-Chemical
upon	O
cerebellar	O
BCNU	B-Chemical
-	O
induced	O
cortical	B-Disease
dysplasia	I-Disease
","	O
using	O
histological	O
and	O
biochemical	O
analyses	O
.	O
	
Pregnant	O
Wistar	O
rats	O
were	O
assigned	O
to	O
five	O
groups	O
:	O
intact	O
-	O
control	O
","	O
saline	O
-	O
control	O
","	O
melatonin	B-Chemical
-	O
treated	O
","	O
BCNU	B-Chemical
-	O
exposed	O
and	O
BCNU	B-Chemical
-	O
exposed	O
plus	O
melatonin	B-Chemical
.	O
	
Rats	O
were	O
exposed	O
to	O
BCNU	B-Chemical
on	O
embryonic	O
day	O
15	O
and	O
melatonin	B-Chemical
was	O
given	O
until	O
delivery	O
.	O
	
Immuno	O
/	O
histochemistry	O
and	O
electron	O
microscopy	O
were	O
carried	O
out	O
on	O
the	O
offspring	O
cerebellum	O
","	O
and	O
levels	O
of	O
malondialdehyde	B-Chemical
and	O
superoxide	B-Chemical
dismutase	O
were	O
determined	O
.	O
	
Histopathologically	O
","	O
typical	O
findings	O
were	O
observed	O
in	O
the	O
cerebella	O
from	O
the	O
control	O
groups	O
","	O
but	O
the	O
findings	O
consistent	O
with	O
early	O
embryonic	O
development	O
were	O
noted	O
in	O
BCNU	B-Chemical
-	O
exposed	O
cortical	B-Disease
dysplasia	I-Disease
group	O
.	O
	
There	O
was	O
a	O
marked	O
increase	O
in	O
the	O
number	O
of	O
TUNEL	O
positive	O
cells	O
and	O
nestin	O
positive	O
cells	O
in	O
BCNU	B-Chemical
-	O
exposed	O
group	O
","	O
but	O
a	O
decreased	O
immunoreactivity	O
to	O
glial	O
fibrillary	O
acidic	O
protein	O
","	O
synaptophysin	O
and	O
transforming	O
growth	O
factor	O
beta1	O
was	O
observed	O
","	O
indicating	O
a	O
delayed	O
maturation	O
","	O
and	O
melatonin	B-Chemical
significantly	O
reversed	O
these	O
changes	O
.	O
	
Malondialdehyde	B-Chemical
level	O
in	O
BCNU	B-Chemical
-	O
exposed	O
group	O
was	O
higher	O
than	O
those	O
in	O
control	O
groups	O
and	O
melatonin	B-Chemical
decreased	O
malondialdehyde	B-Chemical
levels	O
in	O
BCNU	B-Chemical
group	O
(	O
P	O
<	O
0	O
.	O
1	O
)","	O
while	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
superoxide	O
dismutase	O
levels	O
between	O
these	O
groups	O
.	O
	
These	O
data	O
suggest	O
that	O
exposure	O
of	O
animals	O
to	O
BCNU	B-Chemical
during	O
pregnancy	O
leads	O
to	O
delayed	O
maturation	O
of	O
offspring	O
cerebellum	O
and	O
melatonin	B-Chemical
protects	O
the	O
cerebellum	O
against	O
the	O
effects	O
of	O
BCNU	B-Chemical
.	O
	
	
Severe	O
rhabdomyolysis	B-Disease
and	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
secondary	O
to	O
concomitant	O
use	O
of	O
simvastatin	B-Chemical
","	O
amiodarone	B-Chemical
","	O
and	O
atazanavir	B-Chemical
.	O
	
OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
a	O
severe	O
interaction	O
between	O
simvastatin	B-Chemical
","	O
amiodarone	B-Chemical
","	O
and	O
atazanavir	B-Chemical
resulting	O
in	O
rhabdomyolysis	B-Disease
and	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O
	
BACKGROUND	O
:	O
A	O
72	O
-	O
year	O
-	O
old	O
white	O
man	O
with	O
underlying	O
human	O
immunodeficiency	O
virus	O
","	O
atrial	B-Disease
fibrillation	I-Disease
","	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
","	O
and	O
hyperlipidemia	B-Disease
presented	O
with	O
generalized	O
pain	B-Disease
","	O
fatigue	B-Disease
","	O
and	O
dark	O
orange	O
urine	O
for	O
3	O
days	O
.	O
	
The	O
patient	O
was	O
taking	O
80	O
mg	O
simvastatin	B-Chemical
at	O
bedtime	O
(	O
initiated	O
27	O
days	O
earlier	O
");"	O
amiodarone	B-Chemical
at	O
a	O
dose	O
of	O
400	O
mg	O
daily	O
for	O
7	O
days	O
","	O
then	O
200	O
mg	O
daily	O
(	O
initiated	O
19	O
days	O
earlier	O
");"	O
and	O
400	O
mg	O
atazanavir	B-Chemical
daily	O
(	O
initiated	O
at	O
least	O
2	O
years	O
previously	O
).	O
	
Laboratory	O
evaluation	O
revealed	O
66	O
","	O
680	O
U	O
/	O
L	O
creatine	B-Chemical
kinase	I-Chemical
","	O
93	O
mg	O
/	O
dL	O
blood	B-Chemical
urea	I-Chemical
nitrogen	I-Chemical
","	O
4	O
.	O
6	O
mg	O
/	O
dL	O
creatinine	B-Chemical
","	O
1579	O
U	O
/	O
L	O
aspartate	B-Chemical
aminotransferase	I-Chemical
","	O
and	O
738	O
U	O
/	O
L	O
alanine	B-Chemical
aminotransferase	I-Chemical
.	O
	
Simvastatin	B-Chemical
","	O
amiodarone	B-Chemical
","	O
and	O
the	O
patient	O
'	O
s	O
human	O
immunodeficiency	O
virus	O
medications	O
were	O
all	O
temporarily	O
discontinued	O
and	O
the	O
patient	O
was	O
given	O
forced	O
alkaline	O
diuresis	O
and	O
started	O
on	O
dialysis	O
.	O
	
Nine	O
days	O
later	O
the	O
patient	O
'	O
s	O
creatine	B-Chemical
kinase	I-Chemical
had	O
dropped	O
to	O
1695	O
U	O
/	O
L	O
and	O
creatinine	B-Chemical
was	O
3	O
.	O
3	O
mg	O
/	O
dL	O
.	O
	
The	O
patient	O
was	O
discharged	O
and	O
continued	O
outpatient	O
dialysis	O
for	O
1	O
month	O
until	O
his	O
renal	O
function	O
recovered	O
.	O
	
DISCUSSION	O
:	O
The	O
risk	O
of	O
rhabdomyolysis	B-Disease
is	O
increased	O
in	O
the	O
presence	O
of	O
concomitant	O
drugs	O
that	O
inhibit	O
simvastatin	B-Chemical
metabolism	O
.	O
	
Simvastatin	B-Chemical
is	O
metabolized	O
by	O
CYP3A4	O
.	O
	
Amiodarone	B-Chemical
and	O
atazanavir	B-Chemical
are	O
recognized	O
CYP3A4	O
inhibitors	O
.	O
	
CONCLUSIONS	O
:	O
Pharmacokinetic	O
differences	O
in	O
statins	B-Chemical
are	O
an	O
important	O
consideration	O
for	O
assessing	O
the	O
risk	O
of	O
potential	O
drug	O
interactions	O
.	O
	
In	O
patients	O
requiring	O
the	O
concurrent	O
use	O
of	O
statins	B-Chemical
and	O
CYP3A4	O
inhibitors	O
","	O
pravastatin	B-Chemical
","	O
fluvastatin	B-Chemical
","	O
and	O
rosuvastatin	B-Chemical
carry	O
the	O
lowest	O
risk	O
of	O
drug	O
interactions	O
";"	O
atorvastatin	B-Chemical
carries	O
moderate	O
risk	O
","	O
whereas	O
simvastatin	B-Chemical
and	O
lovastatin	B-Chemical
have	O
the	O
highest	O
risk	O
and	O
should	O
be	O
avoided	O
in	O
patients	O
taking	O
concomitant	O
CYP3A4	B-Chemical
inhibitors	I-Chemical
.	O
	
	
Mutations	O
associated	O
with	O
lamivudine	B-Chemical
-	O
resistance	O
in	O
therapy	O
-	O
na	O
ve	O
hepatitis	B-Disease
B	I-Disease
virus	I-Disease
(	I-Disease
HBV	I-Disease
)	I-Disease
infected	I-Disease
patients	O
with	O
and	O
without	O
HIV	B-Disease
co	I-Disease
-	I-Disease
infection	I-Disease
:	O
implications	O
for	O
antiretroviral	O
therapy	O
in	O
HBV	B-Disease
and	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
infected	I-Disease
South	O
African	O
patients	O
.	O
	
This	O
was	O
an	O
exploratory	O
study	O
to	O
investigate	O
lamivudine	B-Chemical
-	O
resistant	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
strains	O
in	O
selected	O
lamivudine	B-Chemical
-	O
na	O
ve	O
HBV	O
carriers	O
with	O
and	O
without	O
human	B-Disease
immunodeficiency	I-Disease
virus	I-Disease
(	I-Disease
HIV	I-Disease
)	I-Disease
co	I-Disease
-	I-Disease
infection	I-Disease
in	O
South	O
African	O
patients	O
.	O
	
Thirty	O
-	O
five	O
lamivudine	B-Chemical
-	O
na	O
ve	O
HBV	B-Disease
infected	I-Disease
patients	O
with	O
or	O
without	O
HIV	B-Disease
co	I-Disease
-	I-Disease
infection	I-Disease
were	O
studied	O
:	O
15	O
chronic	O
HBV	B-Disease
mono	I-Disease
-	I-Disease
infected	I-Disease
patients	O
and	O
20	O
HBV	B-Disease
-	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
infected	I-Disease
patients	O
.	O
	
The	O
latter	O
group	O
was	O
further	O
sub	O
-	O
divided	O
into	O
13	O
occult	O
HBV	O
(	O
HBsAg	B-Chemical
-	O
negative	O
)	O
and	O
7	O
overt	O
HBV	O
(	O
HBsAg	B-Chemical
-	O
positive	O
)	O
patients	O
.	O
	
HBsAg	B-Chemical
","	O
anti	O
-	O
HBs	O
","	O
anti	O
-	O
HBc	O
","	O
and	O
anti	O
-	O
HIV	O
1	O
/	O
2	O
were	O
determined	O
as	O
part	O
of	O
routine	O
diagnosis	O
using	O
Axsym	O
assays	O
(	O
Abbott	O
Laboratories	O
","	O
North	O
Chicago	O
","	O
IL	O
).	O
	
Serum	O
samples	O
were	O
PCR	O
amplified	O
with	O
HBV	O
reverse	O
transcriptase	O
(	O
RT	O
)	O
primers	O
","	O
followed	O
by	O
direct	O
sequencing	O
across	O
the	O
tyrosine	O
-	O
methionine	O
-	O
aspartate	O
-	O
aspartate	O
(	O
YMDD	O
)	O
motif	O
of	O
the	O
major	O
catalytic	O
region	O
in	O
the	O
C	O
domain	O
of	O
the	O
HBV	O
RT	O
enzyme	O
.	O
	
HBV	O
viral	O
load	O
was	O
performed	O
with	O
Amplicor	O
HBV	O
Monitor	O
test	O
v2	O
.	O
0	O
(	O
Roche	O
Diagnostics	O
","	O
Penzberg	O
","	O
Germany	O
).	O
	
HBV	O
lamivudine	B-Chemical
-	O
resistant	O
strains	O
were	O
detected	O
in	O
3	O
of	O
15	O
mono	O
-	O
infected	O
chronic	O
hepatitis	B-Disease
B	I-Disease
patients	O
and	O
10	O
of	O
20	O
HBV	B-Disease
-	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
infected	I-Disease
patients	O
.	O
	
To	O
the	O
best	O
of	O
our	O
knowledge	O
","	O
this	O
constitutes	O
the	O
first	O
report	O
of	O
HBV	O
lamivudine	B-Chemical
-	O
resistant	O
strains	O
in	O
therapy	O
-	O
na	O
ve	O
HBV	B-Disease
-	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
infected	I-Disease
patients	O
.	O
	
The	O
HBV	O
viral	O
loads	O
for	O
mono	O
-	O
infected	O
and	O
co	O
-	O
infected	O
patients	O
ranged	O
from	O
3	O
.	O
32	O
x	O
10	O
(	O
2	O
)	O
to	O
3	O
.	O
82	O
x	O
10	O
(	O
7	O
)	O
and	O
<	O
200	O
to	O
4	O
.	O
40	O
x	O
10	O
(	O
3	O
)	O
copies	O
/	O
ml	O
","	O
respectively	O
.	O
	
It	O
remains	O
to	O
be	O
seen	O
whether	O
such	O
pre	O
-	O
existing	O
antiviral	O
mutations	O
could	O
result	O
in	O
widespread	O
emergence	O
of	O
HBV	O
resistant	O
strains	O
when	O
lamivudine	B-Chemical
-	O
containing	O
highly	O
active	O
antiretroviral	O
(	O
ARV	O
)	O
treatment	O
(	O
HAART	O
)	O
regimens	O
become	O
widely	O
applied	O
in	O
South	O
Africa	O
","	O
as	O
this	O
is	O
likely	O
to	O
have	O
potential	O
implications	O
in	O
the	O
management	O
of	O
HBV	B-Disease
-	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
infected	I-Disease
patients	O
.	O
	
	
Anxiogenic	B-Disease
potential	O
of	O
ciprofloxacin	B-Chemical
and	O
norfloxacin	B-Chemical
in	O
rats	O
.	O
	
INTRODUCTION	O
:	O
The	O
possible	O
anxiogenic	B-Disease
effects	O
of	O
fluoroquinolones	B-Chemical
","	O
namely	O
ciprofloxacin	B-Chemical
and	O
norfloxacin	B-Chemical
","	O
were	O
investigated	O
in	O
adult	O
Charles	O
Foster	O
albino	O
rats	O
of	O
either	O
sex	O
","	O
weighing	O
150	O
-	O
200	O
g	O
.	O
METHODS	O
:	O
The	O
drugs	O
were	O
given	O
orally	O
","	O
in	O
doses	O
of	O
50	O
mg	O
/	O
kg	O
for	O
five	O
consecutive	O
days	O
and	O
the	O
experiments	O
were	O
performed	O
on	O
the	O
fifth	O
day	O
.	O
	
The	O
tests	O
included	O
open	O
-	O
field	O
exploratory	O
behaviour	O
","	O
elevated	O
plus	O
maze	O
and	O
elevated	O
zero	O
maze	O
","	O
social	O
interaction	O
and	O
novelty	O
-	O
suppressed	O
feeding	O
latency	O
behaviour	O
.	O
	
RESULTS	O
:	O
The	O
results	O
indicate	O
that	O
ciprofloxacin	B-Chemical
-	O
and	O
norfloxacin	B-Chemical
-	O
treated	O
rats	O
showed	O
anxious	B-Disease
behaviour	I-Disease
in	O
comparison	O
to	O
control	O
rats	O
in	O
all	O
the	O
parameters	O
studied	O
.	O
	
However	O
","	O
ciprofloxacin	B-Chemical
-	O
and	O
norfloxacin	B-Chemical
-	O
treated	O
rats	O
did	O
not	O
differ	O
significantly	O
from	O
each	O
other	O
in	O
various	O
behavioural	O
parameters	O
.	O
	
CONCLUSION	O
:	O
The	O
present	O
experimental	O
findings	O
substantiate	O
the	O
clinically	O
observed	O
anxiogenic	B-Disease
potential	O
of	O
ciprofloxacin	B-Chemical
and	O
norfloxacin	B-Chemical
.	O
	
	
Norepinephrine	B-Chemical
signaling	O
through	O
beta	O
-	O
adrenergic	O
receptors	O
is	O
critical	O
for	O
expression	O
of	O
cocaine	B-Chemical
-	O
induced	O
anxiety	B-Disease
.	O
	
BACKGROUND	O
:	O
Cocaine	B-Chemical
is	O
a	O
widely	O
abused	O
psychostimulant	O
that	O
has	O
both	O
rewarding	O
and	O
aversive	O
properties	O
.	O
	
While	O
the	O
mechanisms	O
underlying	O
cocaine	B-Chemical
'	O
s	O
rewarding	O
effects	O
have	O
been	O
studied	O
extensively	O
","	O
less	O
attention	O
has	O
been	O
paid	O
to	O
the	O
unpleasant	O
behavioral	O
states	O
induced	O
by	O
cocaine	B-Chemical
","	O
such	O
as	O
anxiety	B-Disease
.	O
	
METHODS	O
:	O
In	O
this	O
study	O
","	O
we	O
evaluated	O
the	O
performance	O
of	O
dopamine	O
beta	O
-	O
hydroxylase	O
knockout	O
(	O
Dbh	O
-/-)	O
mice	O
","	O
which	O
lack	O
norepinephrine	B-Chemical
(	O
NE	B-Chemical
)","	O
in	O
the	O
elevated	O
plus	O
maze	O
(	O
EPM	O
)	O
to	O
examine	O
the	O
contribution	O
of	O
noradrenergic	O
signaling	O
to	O
cocaine	B-Chemical
-	O
induced	O
anxiety	B-Disease
.	O
	
RESULTS	O
:	O
We	O
found	O
that	O
cocaine	B-Chemical
dose	O
-	O
dependently	O
increased	O
anxiety	B-Disease
-	O
like	O
behavior	O
in	O
control	O
(	O
Dbh	O
+/-)	O
mice	O
","	O
as	O
measured	O
by	O
a	O
decrease	O
in	O
open	O
arm	O
exploration	O
.	O
	
The	O
Dbh	O
-/-	O
mice	O
had	O
normal	O
baseline	O
performance	O
in	O
the	O
EPM	O
but	O
were	O
completely	O
resistant	O
to	O
the	O
anxiogenic	O
effects	O
of	O
cocaine	B-Chemical
.	O
	
Cocaine	B-Chemical
-	O
induced	O
anxiety	B-Disease
was	O
also	O
attenuated	O
in	O
Dbh	O
+/-	O
mice	O
following	O
administration	O
of	O
disulfiram	B-Chemical
","	O
a	O
dopamine	O
beta	O
-	O
hydroxylase	O
(	O
DBH	O
)	O
inhibitor	O
.	O
	
In	O
experiments	O
using	O
specific	O
adrenergic	B-Chemical
antagonists	I-Chemical
","	O
we	O
found	O
that	O
pretreatment	O
with	O
the	O
beta	O
-	O
adrenergic	O
receptor	O
antagonist	O
propranolol	B-Chemical
blocked	O
cocaine	B-Chemical
-	O
induced	O
anxiety	B-Disease
-	O
like	O
behavior	O
in	O
Dbh	O
+/-	O
and	O
wild	O
-	O
type	O
C57BL6	O
/	O
J	O
mice	O
","	O
while	O
the	O
alpha	O
(	O
1	O
)	O
antagonist	O
prazosin	B-Chemical
and	O
the	O
alpha	O
(	O
2	O
)	O
antagonist	O
yohimbine	B-Chemical
had	O
no	O
effect	O
.	O
	
CONCLUSIONS	O
:	O
These	O
results	O
indicate	O
that	O
noradrenergic	O
signaling	O
via	O
beta	O
-	O
adrenergic	O
receptors	O
is	O
required	O
for	O
cocaine	B-Chemical
-	O
induced	O
anxiety	B-Disease
in	O
mice	O
.	O
	
	
The	O
differential	O
effects	O
of	O
bupivacaine	B-Chemical
and	O
lidocaine	B-Chemical
on	O
prostaglandin	O
E2	O
release	O
","	O
cyclooxygenase	O
gene	O
expression	O
and	O
pain	B-Disease
in	O
a	O
clinical	O
pain	B-Disease
model	O
.	O
	
BACKGROUND	O
:	O
In	O
addition	O
to	O
blocking	O
nociceptive	O
input	O
from	O
surgical	O
sites	O
","	O
long	O
-	O
acting	O
local	O
anesthetics	O
might	O
directly	O
modulate	O
inflammation	B-Disease
.	O
	
In	O
the	O
present	O
study	O
","	O
we	O
describe	O
the	O
proinflammatory	O
effects	O
of	O
bupivacaine	B-Chemical
on	O
local	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
production	O
and	O
cyclooxygenase	O
(	O
COX	O
)	O
gene	O
expression	O
that	O
increases	O
postoperative	B-Disease
pain	I-Disease
in	O
human	O
subjects	O
.	O
	
METHODS	O
:	O
Subjects	O
(	O
n	O
=	O
114	O
)	O
undergoing	O
extraction	O
of	O
impacted	O
third	O
molars	O
received	O
either	O
2	O
%	O
lidocaine	B-Chemical
or	O
0	O
.	O
5	O
%	O
bupivacaine	B-Chemical
before	O
surgery	O
and	O
either	O
rofecoxib	B-Chemical
50	O
mg	O
or	O
placebo	O
orally	O
90	O
min	O
before	O
surgery	O
and	O
for	O
the	O
following	O
48	O
h	O
.	O
Oral	O
mucosal	O
biopsies	O
were	O
taken	O
before	O
surgery	O
and	O
48	O
h	O
after	O
surgery	O
.	O
	
After	O
extraction	O
","	O
a	O
microdialysis	O
probe	O
was	O
placed	O
at	O
the	O
surgical	O
site	O
for	O
PGE2	O
and	O
thromboxane	B-Chemical
B2	I-Chemical
(	O
TXB2	B-Chemical
)	O
measurements	O
.	O
	
RESULTS	O
:	O
The	O
bupivacaine	B-Chemical
/	O
rofecoxib	B-Chemical
group	O
reported	O
significantly	O
less	O
pain	B-Disease
","	O
as	O
assessed	O
by	O
a	O
visual	O
analog	O
scale	O
","	O
compared	O
with	O
the	O
other	O
three	O
treatment	O
groups	O
over	O
the	O
first	O
4	O
h	O
.	O
However	O
","	O
the	O
bupivacaine	B-Chemical
/	O
placebo	O
group	O
reported	O
significantly	O
more	O
pain	B-Disease
at	O
24	O
h	O
and	O
PGE2	O
levels	O
during	O
the	O
first	O
4	O
h	O
were	O
significantly	O
higher	O
than	O
the	O
other	O
three	O
treatment	O
groups	O
.	O
	
Moreover	O
","	O
bupivacaine	B-Chemical
significantly	O
increased	O
COX	O
-	O
2	O
gene	O
expression	O
at	O
48	O
h	O
as	O
compared	O
with	O
the	O
lidocaine	B-Chemical
/	O
placebo	O
group	O
.	O
	
Thromboxane	B-Chemical
levels	O
were	O
not	O
significantly	O
affected	O
by	O
any	O
of	O
the	O
treatments	O
","	O
indicating	O
that	O
the	O
effects	O
seen	O
were	O
attributable	O
to	O
inhibition	O
of	O
COX	O
-	O
2	O
","	O
but	O
not	O
COX	O
-	O
1	O
.	O
	
CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
bupivacaine	B-Chemical
stimulates	O
COX	O
-	O
2	O
gene	O
expression	O
after	O
tissue	B-Disease
injury	I-Disease
","	O
which	O
is	O
associated	O
with	O
higher	O
PGE2	O
production	O
and	O
pain	B-Disease
after	O
the	O
local	O
anesthetic	O
effect	O
dissipates	O
.	O
	
	
Clonidine	B-Chemical
for	O
attention	B-Disease
-	I-Disease
deficit	I-Disease
/	I-Disease
hyperactivity	I-Disease
disorder	I-Disease
:	O
II	O
.	O
	
ECG	O
changes	O
and	O
adverse	O
events	O
analysis	O
.	O
	
OBJECTIVE	O
:	O
To	O
examine	O
the	O
safety	O
and	O
tolerability	O
of	O
clonidine	B-Chemical
used	O
alone	O
or	O
with	O
methylphenidate	B-Chemical
in	O
children	O
with	O
attention	B-Disease
-	I-Disease
deficit	I-Disease
/	I-Disease
hyperactivity	I-Disease
disorder	I-Disease
(	O
ADHD	B-Disease
).	O
	
METHOD	O
:	O
In	O
a	O
16	O
-	O
week	O
multicenter	O
","	O
double	O
-	O
blind	O
trial	O
","	O
122	O
children	O
with	O
ADHD	B-Disease
were	O
randomly	O
assigned	O
to	O
clonidine	B-Chemical
(	O
n	O
=	O
31	O
)","	O
methylphenidate	B-Chemical
(	O
n	O
=	O
29	O
)","	O
clonidine	B-Chemical
and	O
methylphenidate	B-Chemical
(	O
n	O
=	O
32	O
)","	O
or	O
placebo	O
(	O
n	O
=	O
30	O
).	O
	
Doses	O
were	O
flexibly	O
titrated	O
up	O
to	O
0	O
.	O
6	O
mg	O
/	O
day	O
for	O
clonidine	B-Chemical
and	O
60	O
mg	O
/	O
day	O
for	O
methylphenidate	B-Chemical
(	O
both	O
with	O
divided	O
dosing	O
).	O
	
Groups	O
were	O
compared	O
regarding	O
adverse	O
events	O
and	O
changes	O
from	O
baseline	O
to	O
week	O
16	O
in	O
electrocardiograms	O
and	O
vital	O
signs	O
.	O
	
RESULTS	O
:	O
There	O
were	O
more	O
incidents	O
of	O
bradycardia	B-Disease
in	O
subjects	O
treated	O
with	O
clonidine	B-Chemical
compared	O
with	O
those	O
not	O
treated	O
with	O
clonidine	B-Chemical
(	O
17	O
.	O
5	O
%	O
versus	O
3	O
.	O
4	O
"%;"	O
p	O
=.	O
2	O
)","	O
but	O
no	O
other	O
significant	O
group	O
differences	O
regarding	O
electrocardiogram	O
and	O
other	O
cardiovascular	O
outcomes	O
.	O
	
There	O
were	O
no	O
suggestions	O
of	O
interactions	O
between	O
clonidine	B-Chemical
and	O
methylphenidate	B-Chemical
regarding	O
cardiovascular	O
outcomes	O
.	O
	
Moderate	O
or	O
severe	O
adverse	O
events	O
were	O
more	O
common	O
in	O
subjects	O
on	O
clonidine	B-Chemical
(	O
79	O
.	O
4	O
%	O
versus	O
49	O
.	O
2	O
"%;"	O
p	O
=.	O
6	O
)	O
but	O
not	O
associated	O
with	O
higher	O
rates	O
of	O
early	O
study	O
withdrawal	O
.	O
	
Drowsiness	B-Disease
was	O
common	O
on	O
clonidine	B-Chemical
","	O
but	O
generally	O
resolved	O
by	O
6	O
to	O
8	O
weeks	O
.	O
	
CONCLUSIONS	O
:	O
Clonidine	B-Chemical
","	O
used	O
alone	O
or	O
with	O
methylphenidate	B-Chemical
","	O
appears	O
safe	O
and	O
well	O
tolerated	O
in	O
childhood	O
ADHD	B-Disease
.	O
	
Physicians	O
prescribing	O
clonidine	B-Chemical
should	O
monitor	O
for	O
bradycardia	B-Disease
and	O
advise	O
patients	O
about	O
the	O
high	O
likelihood	O
of	O
initial	O
drowsiness	B-Disease
.	O
	
	
Azathioprine	B-Chemical
-	O
induced	O
suicidal	O
erythrocyte	O
death	O
.	O
	
BACKGROUND	O
:	O
Azathioprine	B-Chemical
is	O
widely	O
used	O
as	O
an	O
immunosuppressive	O
drug	O
.	O
	
The	O
side	O
effects	O
of	O
azathioprine	B-Chemical
include	O
anemia	B-Disease
","	O
which	O
has	O
been	O
attributed	O
to	O
bone	B-Disease
marrow	I-Disease
suppression	I-Disease
.	O
	
Alternatively	O
","	O
anemia	B-Disease
could	O
result	O
from	O
accelerated	O
suicidal	O
erythrocyte	O
death	O
or	O
eryptosis	O
","	O
which	O
is	O
characterized	O
by	O
exposure	O
of	O
phosphatidylserine	B-Chemical
(	O
PS	B-Chemical
)	O
at	O
the	O
erythrocyte	O
surface	O
and	O
by	O
cell	O
shrinkage	O
.	O
	
METHODS	O
:	O
The	O
present	O
experiments	O
explored	O
whether	O
azathioprine	B-Chemical
influences	O
eryptosis	O
.	O
	
According	O
to	O
annexin	O
V	O
binding	O
","	O
erythrocytes	O
from	O
patients	O
indeed	O
showed	O
a	O
significant	O
increase	O
of	O
PS	B-Chemical
exposure	O
within	O
1	O
week	O
of	O
treatment	O
with	O
azathioprine	B-Chemical
.	O
	
In	O
a	O
second	O
series	O
","	O
cytosolic	O
Ca2	B-Chemical
+	I-Chemical
activity	O
(	O
Fluo3	B-Chemical
fluorescence	O
)","	O
cell	O
volume	O
(	O
forward	O
scatter	O
)","	O
and	O
PS	B-Chemical
-	O
exposure	O
(	O
annexin	O
V	O
binding	O
)	O
were	O
determined	O
by	O
FACS	O
analysis	O
in	O
erythrocytes	O
from	O
healthy	O
volunteers	O
.	O
	
RESULTS	O
:	O
Exposure	O
to	O
azathioprine	B-Chemical
(>	O
or	O
=	O
2	O
microg	O
/	O
mL	O
)	O
for	O
48	O
hours	O
increased	O
cytosolic	O
Ca2	B-Chemical
+	I-Chemical
activity	O
and	O
annexin	O
V	O
binding	O
and	O
decreased	O
forward	O
scatter	O
.	O
	
The	O
effect	O
of	O
azathioprine	B-Chemical
on	O
both	O
annexin	O
V	O
binding	O
and	O
forward	O
scatter	O
was	O
significantly	O
blunted	O
in	O
the	O
nominal	O
absence	O
of	O
extracellular	O
Ca2	B-Chemical
+.	I-Chemical
	
CONCLUSIONS	O
:	O
Azathioprine	B-Chemical
triggers	O
suicidal	O
erythrocyte	O
death	O
","	O
an	O
effect	O
presumably	O
contributing	O
to	O
azathioprine	B-Chemical
-	O
induced	O
anemia	B-Disease
.	O
	
	
Methamphetamine	B-Chemical
-	O
induced	O
neurotoxicity	B-Disease
and	O
microglial	O
activation	O
are	O
not	O
mediated	O
by	O
fractalkine	O
receptor	O
signaling	O
.	O
	
Methamphetamine	B-Chemical
(	O
METH	B-Chemical
)	O
damages	O
dopamine	B-Chemical
(	O
DA	B-Chemical
)	O
nerve	O
endings	O
by	O
a	O
process	O
that	O
has	O
been	O
linked	O
to	O
microglial	O
activation	O
but	O
the	O
signaling	O
pathways	O
that	O
mediate	O
this	O
response	O
have	O
not	O
yet	O
been	O
delineated	O
.	O
	
Cardona	O
et	O
al	O
.	O
	
[	O
Nat	O
.	O
	
Neurosci	O
.	O
	
9	O
(	O
2006	O
)","	O
917	O
]	O
recently	O
identified	O
the	O
microglial	O
-	O
specific	O
fractalkine	O
receptor	O
(	O
CX3CR1	O
)	O
as	O
an	O
important	O
mediator	O
of	O
MPTP	B-Chemical
-	O
induced	O
neurodegeneration	B-Disease
of	O
DA	B-Chemical
neurons	O
.	O
	
Because	O
the	O
CNS	B-Disease
damage	I-Disease
caused	O
by	O
METH	B-Chemical
and	O
MPTP	B-Chemical
is	O
highly	O
selective	O
for	O
the	O
DA	B-Chemical
neuronal	O
system	O
in	O
mouse	O
models	O
of	O
neurotoxicity	B-Disease
","	O
we	O
hypothesized	O
that	O
the	O
CX3CR1	O
plays	O
a	O
role	O
in	O
METH	B-Chemical
-	O
induced	O
neurotoxicity	B-Disease
and	O
microglial	O
activation	O
.	O
	
Mice	O
in	O
which	O
the	O
CX3CR1	O
gene	O
has	O
been	O
deleted	O
and	O
replaced	O
with	O
a	O
cDNA	O
encoding	O
enhanced	B-Chemical
green	I-Chemical
fluorescent	I-Chemical
protein	I-Chemical
(	O
eGFP	B-Chemical
)	O
were	O
treated	O
with	O
METH	B-Chemical
and	O
examined	O
for	O
striatal	O
neurotoxicity	B-Disease
.	O
	
METH	B-Chemical
depleted	O
DA	B-Chemical
","	O
caused	O
microglial	O
activation	O
","	O
and	O
increased	O
body	O
temperature	O
in	O
CX3CR1	O
knockout	O
mice	O
to	O
the	O
same	O
extent	O
and	O
over	O
the	O
same	O
time	O
course	O
seen	O
in	O
wild	O
-	O
type	O
controls	O
.	O
	
The	O
effects	O
of	O
METH	B-Chemical
in	O
CX3CR1	O
knockout	O
mice	O
were	O
not	O
gender	O
-	O
dependent	O
and	O
did	O
not	O
extend	O
beyond	O
the	O
striatum	O
.	O
	
Striatal	O
microglia	O
expressing	O
eGFP	B-Chemical
constitutively	O
show	O
morphological	O
changes	O
after	O
METH	B-Chemical
that	O
are	O
characteristic	O
of	O
activation	O
.	O
	
This	O
response	O
was	O
restricted	O
to	O
the	O
striatum	O
and	O
contrasted	O
sharply	O
with	O
unresponsive	O
eGFP	B-Chemical
-	O
microglia	O
in	O
surrounding	O
brain	O
areas	O
that	O
are	O
not	O
damaged	O
by	O
METH	B-Chemical
.	O
	
We	O
conclude	O
from	O
these	O
studies	O
that	O
CX3CR1	O
signaling	O
does	O
not	O
modulate	O
METH	B-Chemical
neurotoxicity	B-Disease
or	O
microglial	O
activation	O
.	O
	
Furthermore	O
","	O
it	O
appears	O
that	O
striatal	O
-	O
resident	O
microglia	O
respond	O
to	O
METH	B-Chemical
with	O
an	O
activation	O
cascade	O
and	O
then	O
return	O
to	O
a	O
surveying	O
state	O
without	O
undergoing	O
apoptosis	O
or	O
migration	O
.	O
	
	
Spectrum	O
of	O
adverse	O
events	O
after	O
generic	O
HAART	O
in	O
southern	O
Indian	O
HIV	B-Disease
-	I-Disease
infected	I-Disease
patients	O
.	O
	
To	O
determine	O
the	O
incidence	O
of	O
clinically	O
significant	O
adverse	O
events	O
after	O
long	O
-	O
term	O
","	O
fixed	O
-	O
dose	O
","	O
generic	O
highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
use	O
among	O
HIV	B-Disease
-	I-Disease
infected	I-Disease
individuals	O
in	O
South	O
India	O
","	O
we	O
examined	O
the	O
experiences	O
of	O
3154	O
HIV	B-Disease
-	I-Disease
infected	I-Disease
individuals	O
who	O
received	O
a	O
minimum	O
of	O
3	O
months	O
of	O
generic	O
HAART	O
between	O
February	O
1996	O
and	O
December	O
2006	O
at	O
a	O
tertiary	O
HIV	O
care	O
referral	O
center	O
in	O
South	O
India	O
.	O
	
The	O
most	O
common	O
regimens	O
were	O
3TC	B-Chemical
+	O
d4T	B-Chemical
+	O
nevirapine	B-Chemical
(	O
NVP	B-Chemical
)	O
(	O
54	O
.	O
8	O
%)","	O
zidovudine	B-Chemical
(	O
AZT	B-Chemical
)	O
+	O
3TC	B-Chemical
+	O
NVP	B-Chemical
(	O
14	O
.	O
5	O
%)","	O
3TC	B-Chemical
+	O
d4T	B-Chemical
+	O
efavirenz	B-Chemical
(	O
EFV	B-Chemical
)	O
(	O
20	O
.	O
1	O
%)","	O
and	O
AZT	B-Chemical
+	O
3TC	B-Chemical
+	O
EFV	B-Chemical
(	O
5	O
.	O
4	O
%).	O
	
The	O
most	O
common	O
adverse	O
events	O
and	O
median	O
CD4	O
at	O
time	O
of	O
event	O
were	O
rash	B-Disease
(	O
15	O
.	O
2	O
"%;"	O
CD4	O
","	O
285	O
cells	O
/	O
microL	O
)	O
and	O
peripheral	B-Disease
neuropathy	I-Disease
(	O
9	O
.	O
0	O
%	O
and	O
348	O
cells	O
/	O
microL	O
).	O
	
Clinically	O
significant	O
anemia	B-Disease
(	O
hemoglobin	O
<	O
7	O
g	O
/	O
dL	O
)	O
was	O
observed	O
in	O
5	O
.	O
4	O
%	O
of	O
patients	O
(	O
CD4	O
","	O
165	O
cells	O
/	O
microL	O
)	O
and	O
hepatitis	B-Disease
(	O
clinical	O
jaundice	B-Disease
with	O
alanine	B-Chemical
aminotransferase	I-Chemical
>	O
5	O
times	O
upper	O
limits	O
of	O
normal	O
)	O
in	O
3	O
.	O
5	O
%	O
of	O
patients	O
(	O
CD4	O
","	O
260	O
cells	O
/	O
microL	O
).	O
	
Women	O
were	O
significantly	O
more	O
likely	O
to	O
experience	O
lactic	B-Disease
acidosis	I-Disease
","	O
while	O
men	O
were	O
significantly	O
more	O
likely	O
to	O
experience	O
immune	B-Disease
reconstitution	I-Disease
syndrome	I-Disease
(	O
p	O
<	O
0	O
.	O
5	O
).	O
	
Among	O
the	O
patients	O
with	O
1	O
year	O
of	O
follow	O
-	O
up	O
","	O
NVP	B-Chemical
therapy	O
was	O
significantly	O
associated	O
with	O
developing	O
rash	B-Disease
and	O
d4T	B-Chemical
therapy	O
with	O
developing	O
peripheral	B-Disease
neuropathy	I-Disease
(	O
p	O
<	O
0	O
.	O
5	O
).	O
	
Anemia	B-Disease
and	O
hepatitis	B-Disease
often	O
occur	O
within	O
12	O
weeks	O
of	O
initiating	O
generic	O
HAART	O
.	O
	
Frequent	O
and	O
early	O
monitoring	O
for	O
these	O
toxicities	B-Disease
is	O
warranted	O
in	O
developing	O
countries	O
where	O
generic	O
HAART	O
is	O
increasingly	O
available	O
.	O
	
	
Protective	O
effect	O
of	O
verapamil	B-Chemical
on	O
gastric	B-Disease
hemorrhagic	I-Disease
ulcers	I-Disease
in	O
severe	O
atherosclerotic	B-Disease
rats	O
.	O
	
Studies	O
concerning	O
with	O
pathogenesis	O
of	O
gastric	B-Disease
hemorrhage	I-Disease
and	O
mucosal	O
ulceration	O
produced	O
in	O
atherosclerotic	B-Disease
rats	O
are	O
lacking	O
.	O
	
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
examine	O
the	O
role	O
of	O
gastric	O
acid	O
back	O
-	O
diffusion	O
","	O
mast	O
cell	O
histamine	B-Chemical
release	O
","	O
lipid	B-Chemical
peroxide	I-Chemical
(	O
LPO	B-Chemical
)	O
generation	O
and	O
mucosal	O
microvascular	O
permeability	O
in	O
modulating	O
gastric	B-Disease
hemorrhage	I-Disease
and	I-Disease
ulcer	I-Disease
in	O
rats	O
with	O
atherosclerosis	B-Disease
induced	O
by	O
coadministration	O
of	O
vitamin	B-Chemical
D2	I-Chemical
and	O
cholesterol	B-Chemical
.	O
	
Additionally	O
","	O
the	O
protective	O
effect	O
of	O
verapamil	B-Chemical
on	O
this	O
ulcer	B-Disease
model	O
was	O
evaluated	O
.	O
	
Male	O
Wistar	O
rats	O
were	O
challenged	O
intragastrically	O
once	O
daily	O
for	O
9	O
days	O
with	O
1	O
.	O
0	O
ml	O
/	O
kg	O
of	O
corn	B-Chemical
oil	I-Chemical
containing	O
vitamin	B-Chemical
D2	I-Chemical
and	O
cholesterol	B-Chemical
to	O
induce	O
atherosclerosis	B-Disease
.	O
	
Control	O
rats	O
received	O
corn	B-Chemical
oil	I-Chemical
only	O
.	O
	
After	O
gastric	O
surgery	O
","	O
rat	O
stomachs	O
were	O
irrigated	O
for	O
3	O
h	O
with	O
either	O
simulated	O
gastric	O
juice	O
or	O
normal	O
saline	O
.	O
	
Gastric	O
acid	O
back	O
-	O
diffusion	O
","	O
mucosal	O
LPO	B-Chemical
generation	O
","	O
histamine	B-Chemical
concentration	O
","	O
microvascular	O
permeability	O
","	O
luminal	B-Chemical
hemoglobin	O
content	O
and	O
ulcer	B-Disease
areas	O
were	O
determined	O
.	O
	
Elevated	O
atherosclerotic	B-Disease
parameters	O
","	O
such	O
as	O
serum	O
calcium	B-Chemical
","	O
total	O
cholesterol	B-Chemical
and	O
low	B-Chemical
-	I-Chemical
density	I-Chemical
lipoprotein	I-Chemical
concentration	O
were	O
obtained	O
in	O
atherosclerotic	B-Disease
rats	O
.	O
	
Severe	O
gastric	B-Disease
ulcers	I-Disease
accompanied	O
with	O
increased	O
ulcerogenic	O
factors	O
","	O
including	O
gastric	O
acid	O
back	O
-	O
diffusion	O
","	O
histamine	B-Chemical
release	O
","	O
LPO	B-Chemical
generation	O
and	O
luminal	B-Chemical
hemoglobin	O
content	O
were	O
also	O
observed	O
in	O
these	O
rats	O
.	O
	
Moreover	O
","	O
a	O
positive	O
correlation	O
of	O
histamine	B-Chemical
to	O
gastric	B-Disease
hemorrhage	I-Disease
and	O
to	O
ulcer	B-Disease
was	O
found	O
in	O
those	O
atherosclerotic	B-Disease
rats	O
.	O
	
This	O
hemorrhagic	B-Disease
ulcer	I-Disease
and	O
various	O
ulcerogenic	O
parameters	O
were	O
dose	O
-	O
dependently	O
ameliorated	O
by	O
daily	O
intragastric	O
verapamil	B-Chemical
.	O
	
Atherosclerosis	B-Disease
could	O
produce	O
gastric	B-Disease
hemorrhagic	I-Disease
ulcer	I-Disease
via	O
aggravation	O
of	O
gastric	O
acid	O
back	O
-	O
diffusion	O
","	O
LPO	B-Chemical
generation	O
","	O
histamine	B-Chemical
release	O
and	O
microvascular	O
permeability	O
that	O
could	O
be	O
ameliorated	O
by	O
verapamil	B-Chemical
in	O
rats	O
.	O
	
	
Omitting	O
fentanyl	B-Chemical
reduces	O
nausea	B-Disease
and	O
vomiting	B-Disease
","	O
without	O
increasing	O
pain	B-Disease
","	O
after	O
sevoflurane	B-Chemical
for	O
day	O
surgery	O
.	O
	
BACKGROUND	O
AND	O
OBJECTIVE	O
:	O
Despite	O
advantages	O
of	O
induction	O
and	O
maintenance	O
of	O
anaesthesia	O
with	O
sevoflurane	B-Chemical
","	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	I-Disease
occurs	O
frequently	O
.	O
	
Fentanyl	B-Chemical
is	O
a	O
commonly	O
used	O
supplement	O
that	O
may	O
contribute	O
to	O
this	O
","	O
although	O
it	O
may	O
also	O
improve	O
analgesia	O
.	O
	
METHODS	O
:	O
This	O
double	O
-	O
blind	O
study	O
examined	O
the	O
incidence	O
and	O
severity	O
of	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	I-Disease
and	I-Disease
pain	I-Disease
in	O
the	O
first	O
24	O
h	O
after	O
sevoflurane	B-Chemical
anaesthesia	O
in	O
216	O
adult	O
day	O
surgery	O
patients	O
.	O
	
Patients	O
were	O
randomly	O
allocated	O
to	O
either	O
receive	O
or	O
not	O
receive	O
1	O
1	O
fentanyl	B-Chemical
","	O
while	O
a	O
third	O
group	O
received	O
dexamethasone	B-Chemical
in	O
addition	O
to	O
fentanyl	B-Chemical
.	O
	
RESULTS	O
:	O
Omission	O
of	O
fentanyl	B-Chemical
did	O
not	O
reduce	O
the	O
overall	O
incidence	O
of	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	I-Disease
","	O
but	O
did	O
reduce	O
the	O
incidence	O
of	O
vomiting	B-Disease
and	O
/	O
or	O
moderate	O
to	O
severe	O
nausea	B-Disease
prior	O
to	O
discharge	O
from	O
20	O
%	O
and	O
17	O
%	O
with	O
fentanyl	B-Chemical
and	O
fentanyl	B-Chemical
-	O
dexamethasone	B-Chemical
","	O
respectively	O
","	O
to	O
5	O
%	O
(	O
P	O
=	O
0	O
.	O
13	O
).	O
	
Antiemetic	O
requirements	O
were	O
reduced	O
from	O
24	O
%	O
and	O
31	O
%	O
to	O
7	O
%	O
(	O
P	O
=	O
0	O
.	O
12	O
).	O
	
Dexamethasone	B-Chemical
had	O
no	O
significant	O
effect	O
on	O
the	O
incidence	O
or	O
severity	O
of	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	I-Disease
.	O
	
Combining	O
the	O
two	O
fentanyl	B-Chemical
groups	O
revealed	O
further	O
significant	O
benefits	O
from	O
the	O
avoidance	O
of	O
opioids	O
","	O
reducing	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	I-Disease
and	O
nausea	B-Disease
prior	O
to	O
discharge	O
from	O
35	O
%	O
and	O
33	O
%	O
to	O
22	O
%	O
and	O
19	O
%	O
(	O
P	O
=	O
0	O
.	O
49	O
and	O
P	O
=	O
0	O
.	O
35	O
)","	O
respectively	O
","	O
while	O
nausea	B-Disease
in	O
the	O
first	O
24	O
h	O
was	O
decreased	O
from	O
42	O
%	O
to	O
27	O
%	O
(	O
P	O
=	O
0	O
.	O
34	O
).	O
	
Pain	B-Disease
severity	O
and	O
analgesic	O
requirements	O
were	O
unaffected	O
by	O
the	O
omission	O
of	O
fentanyl	B-Chemical
.	O
	
Fentanyl	B-Chemical
did	O
reduce	O
minor	O
intraoperative	O
movement	O
but	O
had	O
no	O
sevoflurane	B-Chemical
-	O
sparing	O
effect	O
and	O
increased	O
respiratory	B-Disease
depression	I-Disease
","	O
hypotension	B-Disease
and	O
bradycardia	B-Disease
.	O
	
CONCLUSION	O
:	O
As	O
fentanyl	B-Chemical
exacerbated	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	I-Disease
without	O
an	O
improvement	O
in	O
postoperative	B-Disease
pain	I-Disease
and	O
also	O
had	O
adverse	O
cardiorespiratory	O
effects	O
","	O
it	O
appears	O
to	O
be	O
an	O
unnecessary	O
and	O
possibly	O
detrimental	O
supplement	O
to	O
sevoflurane	B-Chemical
in	O
day	O
surgery	O
.	O
	
	
High	O
fat	B-Chemical
diet	O
-	O
fed	O
obese	B-Disease
rats	O
are	O
highly	O
sensitive	O
to	O
doxorubicin	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O
	
Often	O
","	O
chemotherapy	O
by	O
doxorubicin	B-Chemical
(	O
Adriamycin	B-Chemical
)	O
is	O
limited	O
due	O
to	O
life	O
threatening	O
cardiotoxicity	B-Disease
in	O
patients	O
during	O
and	O
posttherapy	O
.	O
	
Recently	O
","	O
we	O
have	O
shown	O
that	O
moderate	O
diet	O
restriction	O
remarkably	O
protects	O
against	O
doxorubicin	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O
	
This	O
cardioprotection	O
is	O
accompanied	O
by	O
decreased	O
cardiac	O
oxidative	O
stress	O
and	O
triglycerides	B-Chemical
and	O
increased	O
cardiac	O
fatty	B-Chemical
-	I-Chemical
acid	I-Chemical
oxidation	O
","	O
ATP	B-Chemical
synthesis	O
","	O
and	O
upregulated	O
JAK	O
/	O
STAT3	O
pathway	O
.	O
	
In	O
the	O
current	O
study	O
","	O
we	O
investigated	O
whether	O
a	O
physiological	O
intervention	O
by	O
feeding	O
40	O
%	O
high	O
fat	B-Chemical
diet	O
(	O
HFD	O
)","	O
which	O
induces	O
obesity	B-Disease
in	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
(	O
250	O
-	O
275	O
g	O
)","	O
sensitizes	O
to	O
doxorubicin	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O
	
A	O
LD	O
(	O
10	O
)	O
dose	O
(	O
8	O
mg	O
doxorubicin	B-Chemical
/	O
kg	O
","	O
ip	O
)	O
administered	O
on	O
day	O
43	O
of	O
the	O
HFD	O
feeding	O
regimen	O
led	O
to	O
higher	O
cardiotoxicity	B-Disease
","	O
cardiac	B-Disease
dysfunction	I-Disease
","	O
lipid	B-Chemical
peroxidation	O
","	O
and	O
80	O
%	O
mortality	O
in	O
the	O
obese	B-Disease
(	O
OB	B-Disease
)	O
rats	O
in	O
the	O
absence	O
of	O
any	O
significant	O
renal	B-Disease
or	I-Disease
hepatic	I-Disease
toxicity	I-Disease
.	O
	
Doxorubicin	B-Chemical
toxicokinetics	O
studies	O
revealed	O
no	O
change	O
in	O
accumulation	O
of	O
doxorubicin	B-Chemical
and	O
doxorubicinol	B-Chemical
(	O
toxic	O
metabolite	O
)	O
in	O
the	O
normal	O
diet	O
-	O
fed	O
(	O
ND	O
)	O
and	O
OB	B-Disease
hearts	O
.	O
	
Mechanistic	O
studies	O
revealed	O
that	O
OB	B-Disease
rats	O
are	O
sensitized	O
due	O
to	O
:	O
(	O
1	O
)	O
higher	O
oxyradical	O
stress	O
leading	O
to	O
upregulation	O
of	O
uncoupling	O
proteins	O
2	O
and	O
3	O
","	O
(	O
2	O
)	O
downregulation	O
of	O
cardiac	O
peroxisome	O
proliferators	O
activated	O
receptor	O
-	O
alpha	O
","	O
(	O
3	O
)	O
decreased	O
plasma	O
adiponectin	O
levels	O
","	O
(	O
4	O
)	O
decreased	O
cardiac	O
fatty	B-Chemical
-	I-Chemical
acid	I-Chemical
oxidation	O
(	O
666	O
.	O
9	O
+/-	O
14	O
.	O
0	O
nmol	O
/	O
min	O
/	O
g	O
heart	O
in	O
ND	O
versus	O
400	O
.	O
2	O
+/-	O
11	O
.	O
8	O
nmol	O
/	O
min	O
/	O
g	O
heart	O
in	O
OB	B-Disease
)","	O
(	O
5	O
)	O
decreased	O
mitochondrial	O
AMP	O
-	O
alpha2	O
protein	O
kinase	O
","	O
and	O
(	O
6	O
)	O
86	O
%	O
drop	O
in	O
cardiac	O
ATP	B-Chemical
levels	O
accompanied	O
by	O
decreased	O
ATP	B-Chemical
/	O
ADP	B-Chemical
ratio	O
after	O
doxorubicin	B-Chemical
administration	O
.	O
	
Decreased	O
cardiac	O
erythropoietin	O
and	O
increased	O
SOCS3	O
further	O
downregulated	O
the	O
cardioprotective	O
JAK	O
/	O
STAT3	O
pathway	O
.	O
	
In	O
conclusion	O
","	O
HFD	O
-	O
induced	O
obese	B-Disease
rats	O
are	O
highly	O
sensitized	O
to	O
doxorubicin	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
by	O
substantially	O
downregulating	O
cardiac	O
mitochondrial	O
ATP	B-Chemical
generation	O
","	O
increasing	O
oxidative	O
stress	O
and	O
downregulating	O
the	O
JAK	O
/	O
STAT3	O
pathway	O
.	O
	
	
Simvastatin	B-Chemical
-	I-Chemical
ezetimibe	I-Chemical
-	O
induced	O
hepatic	B-Disease
failure	I-Disease
necessitating	O
liver	O
transplantation	O
.	O
	
Abstract	O
Serum	B-Chemical
aminotransferase	I-Chemical
elevations	O
are	O
a	O
commonly	O
known	O
adverse	O
effect	O
of	O
3	O
-	O
hydroxy	O
-	O
3	O
-	O
methylglutaryl	O
coenzyme	O
A	O
reductase	O
inhibitor	O
(	O
statin	B-Chemical
)	O
therapy	O
.	O
	
However	O
","	O
hepatotoxic	B-Disease
events	O
have	O
not	O
been	O
widely	O
published	O
with	O
ezetimibe	B-Chemical
or	O
the	O
combination	O
agent	O
simvastatin	B-Chemical
-	I-Chemical
ezetimibe	I-Chemical
.	O
	
We	O
describe	O
a	O
70	O
-	O
year	O
-	O
old	O
Hispanic	O
woman	O
who	O
developed	O
fulminant	B-Disease
hepatic	I-Disease
failure	I-Disease
necessitating	O
liver	O
transplantation	O
10	O
weeks	O
after	O
conversion	O
from	O
simvastatin	B-Chemical
40	O
mg	O
/	O
day	O
to	O
simvastatin	B-Chemical
10	O
mg	O
-	O
ezetimibe	B-Chemical
40	O
mg	O
/	O
day	O
.	O
	
The	O
patient	O
'	O
s	O
lipid	B-Chemical
panel	O
had	O
been	O
maintained	O
with	O
simvastatin	B-Chemical
for	O
18	O
months	O
before	O
the	O
conversion	O
without	O
evidence	O
of	O
hepatotoxicity	B-Disease
.	O
	
A	O
routine	O
laboratory	O
work	O
-	O
up	O
10	O
weeks	O
after	O
conversion	O
revealed	O
elevated	O
serum	B-Chemical
aminotransferase	I-Chemical
levels	O
.	O
	
Simvastatinezetimibe	B-Chemical
and	O
escitalopram	B-Chemical
(	O
which	O
she	O
was	O
taking	O
for	O
depression	B-Disease
)	O
were	O
discontinued	O
","	O
and	O
other	O
potential	O
causes	O
of	O
hepatotoxicity	B-Disease
were	O
excluded	O
.	O
	
A	O
repeat	O
work	O
-	O
up	O
revealed	O
further	O
elevations	O
in	O
aminotransferase	B-Chemical
levels	O
","	O
and	O
liver	O
biopsy	O
revealed	O
evidence	O
of	O
moderate	O
-	O
to	O
-	O
severe	O
drug	B-Disease
toxicity	I-Disease
.	O
	
She	O
underwent	O
liver	O
transplantation	O
with	O
an	O
uneventful	O
postoperative	O
course	O
.	O
	
Her	O
aminotransferase	B-Chemical
levels	O
returned	O
to	O
normal	O
by	O
postoperative	O
day	O
23	O
","	O
and	O
her	O
2	O
-	O
year	O
follow	O
-	O
up	O
showed	O
no	O
adverse	O
events	O
.	O
	
Ezetimibe	B-Chemical
undergoes	O
extensive	O
glucuronidation	O
by	O
uridine	O
diphosphate	O
glucoronosyltransferases	O
(	O
UGT	O
)	O
in	O
the	O
intestine	O
and	O
liver	O
and	O
may	O
have	O
inhibited	O
the	O
glucuronidation	O
of	O
simvastatin	B-Chemical
hydroxy	I-Chemical
acid	I-Chemical
","	O
resulting	O
in	O
increased	O
simvastatin	B-Chemical
exposure	O
and	O
subsequent	O
hepatotoxicity	B-Disease
.	O
	
To	O
our	O
knowledge	O
","	O
this	O
is	O
the	O
first	O
case	O
report	O
of	O
simvastatin	B-Chemical
-	I-Chemical
ezetimibe	I-Chemical
-	O
induced	O
liver	B-Disease
failure	I-Disease
that	O
resulted	O
in	O
liver	O
transplantation	O
.	O
	
We	O
postulate	O
that	O
the	O
mechanism	O
of	O
the	O
simvastatinezetimibe	B-Chemical
-	O
induced	O
hepatotoxicity	B-Disease
is	O
the	O
increased	O
simvastatin	B-Chemical
exposure	O
by	O
ezetimibe	B-Chemical
inhibition	O
of	O
UGT	O
enzymes	O
.	O
	
Clinicians	O
should	O
be	O
aware	O
of	O
potential	O
hepatotoxicity	B-Disease
with	O
simvastatin	B-Chemical
-	I-Chemical
ezetimibe	I-Chemical
especially	O
in	O
elderly	O
patients	O
and	O
should	O
carefully	O
monitor	O
serum	B-Chemical
aminotransferase	I-Chemical
levels	O
when	O
starting	O
therapy	O
and	O
titrating	O
the	O
dosage	O
.	O
	
	
Massive	O
proteinuria	B-Disease
and	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
after	O
oral	O
bisphosphonate	B-Chemical
(	O
alendronate	B-Chemical
)	O
administration	O
in	O
a	O
patient	O
with	O
focal	B-Disease
segmental	I-Disease
glomerulosclerosis	I-Disease
.	O
	
A	O
61	O
-	O
year	O
-	O
old	O
Japanese	O
man	O
with	O
nephrotic	B-Disease
syndrome	I-Disease
due	O
to	O
focal	B-Disease
segmental	I-Disease
glomerulosclerosis	I-Disease
was	O
initially	O
responding	O
well	O
to	O
steroid	B-Chemical
therapy	O
.	O
	
The	O
amount	O
of	O
daily	O
urinary	O
protein	O
decreased	O
from	O
15	O
.	O
6	O
to	O
2	O
.	O
8	O
g	O
.	O
Within	O
14	O
days	O
of	O
the	O
oral	O
bisphosphonate	B-Chemical
(	O
alendronate	B-Chemical
sodium	I-Chemical
)	O
administration	O
","	O
the	O
amount	O
of	O
daily	O
urinary	O
protein	O
increased	O
rapidly	O
up	O
to	O
12	O
.	O
8	O
g	O
with	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O
	
After	O
discontinuing	O
the	O
oral	O
alendronate	B-Chemical
","	O
the	O
patient	O
underwent	O
six	O
cycles	O
of	O
hemodialysis	O
and	O
four	O
cycles	O
of	O
LDL	O
apheresis	O
.	O
	
Urinary	O
volume	O
and	O
serum	O
creatinine	B-Chemical
levels	O
recovered	O
to	O
the	O
normal	O
range	O
","	O
with	O
urinary	O
protein	O
disappearing	O
completely	O
within	O
40	O
days	O
.	O
	
This	O
report	O
demonstrates	O
that	O
not	O
only	O
intravenous	O
","	O
but	O
also	O
oral	O
bisphosphonates	B-Chemical
can	O
aggravate	O
proteinuria	B-Disease
and	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O
	
	
Risk	O
of	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
associated	O
with	O
initial	O
sulphonylurea	B-Chemical
treatment	O
of	O
patients	O
with	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
:	O
a	O
matched	O
case	O
-	O
control	O
study	O
.	O
	
AIMS	O
:	O
This	O
study	O
sought	O
to	O
assess	O
the	O
risk	O
of	O
developing	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
(	O
CAD	B-Disease
)	O
associated	O
with	O
initial	O
treatment	O
of	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
with	O
different	O
sulphonylureas	B-Chemical
.	O
	
METHODS	O
:	O
In	O
type	B-Disease
2	I-Disease
diabetic	I-Disease
patients	O
","	O
cases	O
who	O
developed	O
CAD	B-Disease
were	O
compared	O
retrospectively	O
with	O
controls	O
that	O
did	O
not	O
.	O
	
The	O
20	O
-	O
year	O
risk	O
of	O
CAD	B-Disease
at	O
diagnosis	O
of	O
diabetes	B-Disease
","	O
using	O
the	O
UKPDS	O
risk	O
engine	O
","	O
was	O
used	O
to	O
match	O
cases	O
with	O
controls	O
.	O
	
RESULTS	O
:	O
The	O
76	O
cases	O
of	O
CAD	B-Disease
were	O
compared	O
with	O
152	O
controls	O
.	O
	
The	O
hazard	O
of	O
developing	O
CAD	B-Disease
(	O
95	O
%	O
CI	O
)	O
associated	O
with	O
initial	O
treatment	O
increased	O
by	O
2	O
.	O
4	O
-	O
fold	O
(	O
1	O
.	O
3	O
-	O
4	O
.	O
3	O
","	O
P	O
=	O
0	O
.	O
4	O
)	O
with	O
glibenclamide	B-Chemical
";"	O
2	O
-	O
fold	O
(	O
0	O
.	O
9	O
-	O
4	O
.	O
6	O
","	O
P	O
=	O
0	O
.	O
99	O
)	O
with	O
glipizide	B-Chemical
";"	O
2	O
.	O
9	O
-	O
fold	O
(	O
1	O
.	O
6	O
-	O
5	O
.	O
1	O
","	O
P	O
=	O
0	O
.	O
0	O
)	O
with	O
either	O
","	O
and	O
was	O
unchanged	O
with	O
metformin	B-Chemical
.	O
	
The	O
hazard	O
decreased	O
0	O
.	O
3	O
-	O
fold	O
(	O
0	O
.	O
7	O
-	O
1	O
.	O
7	O
","	O
P	O
=	O
0	O
.	O
385	O
)	O
with	O
glimepiride	B-Chemical
","	O
0	O
.	O
4	O
-	O
fold	O
(	O
0	O
.	O
7	O
-	O
1	O
.	O
3	O
","	O
P	O
=	O
0	O
.	O
192	O
)	O
with	O
gliclazide	B-Chemical
","	O
and	O
0	O
.	O
4	O
-	O
fold	O
(	O
0	O
.	O
7	O
-	O
1	O
.	O
1	O
","	O
P	O
=	O
0	O
.	O
9	O
)	O
with	O
either	O
.	O
	
CONCLUSIONS	O
:	O
Initiating	O
treatment	O
of	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
with	O
glibenclamide	B-Chemical
or	O
glipizide	B-Chemical
is	O
associated	O
with	O
increased	O
risk	O
of	O
CAD	B-Disease
in	O
comparison	O
to	O
gliclazide	B-Chemical
or	O
glimepiride	B-Chemical
.	O
	
If	O
confirmed	O
","	O
this	O
may	O
be	O
important	O
because	O
most	O
Indian	O
patients	O
receive	O
the	O
cheaper	O
older	O
sulphonylureas	B-Chemical
","	O
and	O
present	O
guidelines	O
do	O
not	O
distinguish	O
between	O
individual	O
agents	O
.	O
	
	
Reduced	O
progression	O
of	O
adriamycin	B-Chemical
nephropathy	B-Disease
in	O
spontaneously	O
hypertensive	B-Disease
rats	O
treated	O
by	O
losartan	B-Chemical
.	O
	
BACKGROUND	O
:	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
antihypertensive	O
effects	O
of	O
angiotensin	O
II	O
type	O
-	O
1	O
receptor	O
blocker	O
","	O
losartan	B-Chemical
","	O
and	O
its	O
potential	O
in	O
slowing	O
down	O
renal	B-Disease
disease	I-Disease
progression	O
in	O
spontaneously	O
hypertensive	B-Disease
rats	O
(	O
SHR	O
)	O
with	O
adriamycin	B-Chemical
(	O
ADR	B-Chemical
)	O
nephropathy	B-Disease
.	O
	
METHODS	O
:	O
Six	O
-	O
month	O
-	O
old	O
female	O
SHR	O
were	O
randomly	O
selected	O
in	O
six	O
groups	O
.	O
	
Two	O
control	O
groups	O
(	O
SH	O
(	O
6	O
)","	O
SH	O
(	O
12	O
))	O
received	O
vehicle	O
.	O
	
Groups	O
ADR	B-Chemical
(	O
6	O
)","	O
ADR	B-Chemical
+	O
LOS	B-Chemical
(	O
6	O
)	O
and	O
ADR	B-Chemical
(	O
12	O
)","	O
and	O
ADR	B-Chemical
+	O
LOS	B-Chemical
(	O
12	O
)	O
received	O
ADR	B-Chemical
(	O
2	O
mg	O
/	O
kg	O
/	O
b	O
.	O
w	O
.	O
	
i	O
.	O
v	O
.)	O
	
twice	O
in	O
a	O
3	O
-	O
week	O
interval	O
.	O
	
Group	O
ADR	B-Chemical
+	O
LOS	B-Chemical
(	O
6	O
)	O
received	O
losartan	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
/	O
b	O
.	O
w	O
./	O
day	O
by	O
gavages	O
)	O
for	O
6	O
weeks	O
and	O
group	O
ADR	B-Chemical
+	O
LOS	B-Chemical
(	O
12	O
)	O
for	O
12	O
weeks	O
after	O
second	O
injection	O
of	O
ADR	B-Chemical
.	O
	
Animals	O
were	O
killed	O
after	O
6	O
or	O
12	O
weeks	O
","	O
respectively	O
.	O
	
Haemodynamic	O
measurements	O
were	O
performed	O
on	O
anaesthetized	O
animals	O
","	O
blood	O
and	O
urine	O
samples	O
were	O
taken	O
for	O
biochemical	O
analysis	O
and	O
the	O
left	O
kidney	O
was	O
processed	O
for	O
morphological	O
studies	O
.	O
	
RESULTS	O
:	O
Short	O
-	O
term	O
losartan	B-Chemical
treatment	O
","	O
besides	O
antihypertensive	O
effect	O
","	O
improved	O
glomerular	O
filtration	O
rate	O
and	O
ameliorated	O
glomerulosclerosis	B-Disease
resulting	O
in	O
decreased	O
proteinuria	B-Disease
.	O
	
Prolonged	O
treatment	O
with	O
losartan	B-Chemical
showed	O
further	O
reduction	O
of	O
glomerulosclerosis	B-Disease
associated	O
with	O
reduced	O
progression	O
of	O
tubular	O
atrophy	B-Disease
and	O
interstitial	B-Disease
fibrosis	I-Disease
","	O
thus	O
preventing	O
heavy	O
proteinuria	B-Disease
and	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
.	O
	
Losartan	B-Chemical
reduced	O
uraemia	B-Disease
and	O
increased	O
urea	B-Chemical
clearance	O
in	O
advanced	O
ADR	B-Chemical
nephropathy	B-Disease
in	O
SHR	O
.	O
	
Histological	O
examination	O
showed	O
that	O
losartan	B-Chemical
could	O
prevent	O
tubular	O
atrophy	B-Disease
","	O
interstitial	O
infiltration	O
and	O
fibrosis	B-Disease
in	O
ADR	B-Chemical
nephropathy	B-Disease
.	O
	
CONCLUSION	O
:	O
Losartan	B-Chemical
reduces	O
the	O
rate	O
of	O
progression	O
of	O
ADR	B-Chemical
-	O
induced	O
focal	B-Disease
segmental	I-Disease
glomerulosclerosis	I-Disease
to	O
end	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
disease	I-Disease
in	O
SHR	O
.	O
	
	
Effect	O
of	O
green	B-Chemical
tea	I-Chemical
and	O
vitamin	B-Chemical
E	I-Chemical
combination	O
in	O
isoproterenol	B-Chemical
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O
	
The	O
present	O
study	O
was	O
aimed	O
to	O
investigate	O
the	O
combined	O
effects	O
of	O
green	B-Chemical
tea	I-Chemical
and	O
vitamin	B-Chemical
E	I-Chemical
on	O
heart	O
weight	O
","	O
body	O
weight	O
","	O
serum	O
marker	O
enzymes	O
","	O
lipid	B-Chemical
peroxidation	O
","	O
endogenous	O
antioxidants	B-Chemical
and	O
membrane	O
bound	O
ATPases	O
in	O
isoproterenol	B-Chemical
(	O
ISO	B-Chemical
)-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O
	
Adult	O
male	O
albino	O
rats	O
","	O
treated	O
with	O
ISO	B-Chemical
(	O
200	O
mg	O
/	O
kg	O
","	O
s	O
.	O
c	O
.)	O
	
for	O
2	O
days	O
at	O
an	O
interval	O
of	O
24	O
h	O
caused	O
a	O
significant	O
(	O
P	O
<	O
0	O
.	O
5	O
)	O
elevation	O
of	O
heart	O
weight	O
","	O
serum	O
marker	O
enzymes	O
","	O
lipid	B-Chemical
peroxidation	O
and	O
Ca	B-Chemical
+	I-Chemical
2	I-Chemical
ATPase	I-Chemical
level	O
whereas	O
there	O
was	O
a	O
significant	O
(	O
P	O
<	O
0	O
.	O
5	O
)	O
decrease	O
in	O
body	O
weight	O
","	O
endogenous	O
antioxidants	B-Chemical
","	O
Na	B-Chemical
+/	I-Chemical
K	I-Chemical
+	I-Chemical
ATPase	I-Chemical
and	O
Mg	B-Chemical
+	I-Chemical
2	I-Chemical
ATPase	I-Chemical
levels	O
.	O
	
Administration	O
of	O
green	B-Chemical
tea	I-Chemical
(	O
100	O
mg	O
/	O
kg	O
/	O
day	O
","	O
p	O
.	O
o	O
.)	O
	
and	O
vitamin	B-Chemical
E	I-Chemical
(	O
100	O
mg	O
/	O
kg	O
/	O
day	O
","	O
p	O
.	O
o	O
.)	O
	
together	O
for	O
30	O
consecutive	O
days	O
and	O
challenged	O
with	O
ISO	B-Chemical
on	O
the	O
day	O
29th	O
and	O
30th	O
","	O
showed	O
a	O
significant	O
(	O
P	O
<	O
0	O
.	O
5	O
)	O
decrease	O
in	O
heart	O
weight	O
","	O
serum	O
marker	O
enzymes	O
","	O
lipid	B-Chemical
peroxidation	O
","	O
Ca	B-Chemical
+	I-Chemical
2	I-Chemical
ATPase	I-Chemical
and	O
a	O
significant	O
increase	O
in	O
the	O
body	O
weight	O
","	O
endogenous	O
antioxidants	B-Chemical
","	O
Na	B-Chemical
+/	I-Chemical
K	I-Chemical
+	I-Chemical
ATPase	I-Chemical
and	O
Mg	B-Chemical
+	I-Chemical
2	I-Chemical
ATPase	I-Chemical
when	O
compared	O
with	O
ISO	B-Chemical
treated	O
group	O
and	O
green	B-Chemical
tea	I-Chemical
or	O
vitamin	B-Chemical
E	I-Chemical
alone	O
treated	O
groups	O
.	O
	
These	O
findings	O
indicate	O
the	O
synergistic	O
protective	O
effect	O
of	O
green	B-Chemical
tea	I-Chemical
and	O
vitamin	B-Chemical
E	I-Chemical
during	O
ISO	B-Chemical
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O
	
	
The	O
biological	O
properties	O
of	O
the	O
optical	O
isomers	O
of	O
propranolol	B-Chemical
and	O
their	O
effects	O
on	O
cardiac	B-Disease
arrhythmias	I-Disease
.	O
	
1	O
.	O
	
The	O
optical	O
isomers	O
of	O
propranolol	B-Chemical
have	O
been	O
compared	O
for	O
their	O
beta	O
-	O
blocking	O
and	O
antiarrhythmic	O
activities	O
.	O
2	O
.	O
	
In	O
blocking	O
the	O
positive	O
inotropic	O
and	O
chronotropic	O
responses	O
to	O
isoprenaline	B-Chemical
","	O
(+)-	O
propranolol	B-Chemical
had	O
less	O
than	O
one	O
hundredth	O
the	O
potency	O
of	O
(-)-	O
propranolol	B-Chemical
.	O
	
At	O
dose	O
levels	O
of	O
(+)-	O
propranolol	B-Chemical
which	O
attenuated	O
the	O
responses	O
to	O
isoprenaline	B-Chemical
","	O
there	O
was	O
a	O
significant	O
prolongation	O
of	O
the	O
PR	O
interval	O
of	O
the	O
electrocardiogram	O
.	O
3	O
.	O
	
The	O
metabolic	O
responses	O
to	O
isoprenaline	B-Chemical
in	O
dogs	O
(	O
an	O
increase	O
in	O
circulating	O
glucose	B-Chemical
","	O
lactate	B-Chemical
and	O
free	O
fatty	B-Chemical
acids	I-Chemical
)	O
were	O
all	O
blocked	O
by	O
(-)-	O
propranolol	B-Chemical
.	O
	
(+)-	O
Propranolol	B-Chemical
had	O
no	O
effect	O
on	O
fatty	B-Chemical
acid	I-Chemical
mobilization	O
but	O
significantly	O
reduced	O
the	O
increments	O
in	O
both	O
lactate	B-Chemical
and	O
glucose	B-Chemical
.	O
4	O
.	O
	
Both	O
isomers	O
of	O
propranolol	B-Chemical
possessed	O
similar	O
depressant	O
potency	O
on	O
isolated	O
atrial	O
muscle	O
taken	O
from	O
guinea	O
-	O
pigs	O
.	O
5	O
.	O
	
The	O
isomers	O
of	O
propranolol	B-Chemical
exhibited	O
similar	O
local	O
anaesthetic	O
potencies	O
on	O
an	O
isolated	O
frog	O
nerve	O
preparation	O
at	O
a	O
level	O
approximately	O
three	O
times	O
that	O
of	O
procaine	B-Chemical
.	O
	
The	O
racemic	O
compound	O
was	O
significantly	O
less	O
potent	O
than	O
either	O
isomer	O
.	O
6	O
.	O
	
Both	O
isomers	O
of	O
propranolol	B-Chemical
were	O
capable	O
of	O
preventing	O
adrenaline	B-Chemical
-	O
induced	O
cardiac	B-Disease
arrhythmias	I-Disease
in	O
cats	O
anaesthetized	O
with	O
halothane	B-Chemical
","	O
but	O
the	O
mean	O
dose	O
of	O
(-)-	O
propranolol	B-Chemical
was	O
0	O
.	O
9	O
+/-	O
0	O
.	O
2	O
mg	O
/	O
kg	O
whereas	O
that	O
of	O
(+)-	O
propranolol	B-Chemical
was	O
4	O
.	O
2	O
+/-	O
1	O
.	O
2	O
mg	O
/	O
kg	O
.	O
	
At	O
the	O
effective	O
dose	O
level	O
of	O
(+)-	O
propranolol	B-Chemical
there	O
was	O
a	O
significant	O
prolongation	O
of	O
the	O
PR	O
interval	O
of	O
the	O
electrocardiogram	O
.	O
	
Blockade	O
of	O
arrhythmias	B-Disease
with	O
both	O
isomers	O
was	O
surmountable	O
by	O
increasing	O
the	O
dose	O
of	O
adrenaline	B-Chemical
.	O
7	O
.	O
	
Both	O
isomers	O
of	O
propranolol	B-Chemical
were	O
also	O
capable	O
of	O
reversing	O
ventricular	B-Disease
tachycardia	I-Disease
caused	O
by	O
ouabain	B-Chemical
in	O
anaesthetized	O
cats	O
and	O
dogs	O
.	O
	
The	O
dose	O
of	O
(-)-	O
propranolol	B-Chemical
was	O
significantly	O
smaller	O
than	O
that	O
of	O
(+)-	O
propranolol	B-Chemical
in	O
both	O
species	O
but	O
much	O
higher	O
than	O
that	O
required	O
to	O
produce	O
evidence	O
of	O
beta	O
-	O
blockade	O
.	O
8	O
.	O
	
The	O
implications	O
of	O
these	O
results	O
are	O
discussed	O
.	O
	
	
Cardioprotective	O
effect	O
of	O
salvianolic	B-Chemical
acid	I-Chemical
A	I-Chemical
on	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O
	
The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
cardioprotective	O
potential	O
of	O
salvianolic	B-Chemical
acid	I-Chemical
A	I-Chemical
on	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
.	O
	
Hemodynamic	O
parameters	O
and	O
lead	O
II	O
electrocardiograph	O
were	O
monitored	O
and	O
recorded	O
continuously	O
.	O
	
Cardiac	O
marker	O
enzymes	O
and	O
antioxidative	O
parameters	O
in	O
serum	O
and	O
heart	O
tissues	O
were	O
measured	O
.	O
	
Assay	O
for	O
mitochondrial	O
respiratory	O
function	O
and	O
histopathological	O
examination	O
of	O
heart	O
tissues	O
were	O
performed	O
.	O
	
Isoproterenol	B-Chemical
-	O
treated	O
rats	O
showed	O
significant	O
increases	O
in	O
the	O
levels	O
of	O
lactate	O
dehydrogenase	O
","	O
aspartate	O
transaminase	O
","	O
creatine	O
kinase	O
and	O
malondialdehyde	B-Chemical
and	O
significant	O
decreases	O
in	O
the	O
activities	O
of	O
superoxide	O
dismutase	O
","	O
catalase	O
and	O
glutathione	O
peroxidase	O
in	O
serum	O
and	O
heart	O
.	O
	
These	O
rats	O
also	O
showed	O
declines	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
","	O
maximum	O
and	O
minimum	O
rate	O
of	O
developed	O
left	O
ventricular	O
pressure	O
","	O
and	O
elevation	O
of	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
and	O
ST	O
-	O
segment	O
.	O
	
In	O
addition	O
","	O
mitochondrial	B-Disease
respiratory	I-Disease
dysfunction	I-Disease
characterized	O
by	O
decreased	O
respiratory	O
control	O
ratio	O
and	O
ADP	B-Chemical
/	O
O	O
was	O
observed	O
in	O
isoproterenol	B-Chemical
-	O
treated	O
rats	O
.	O
	
Administration	O
of	O
salvianolic	B-Chemical
acid	I-Chemical
A	I-Chemical
for	O
a	O
period	O
of	O
8	O
days	O
significantly	O
attenuated	O
isoproterenol	B-Chemical
-	O
induced	O
cardiac	B-Disease
dysfunction	I-Disease
and	O
myocardial	B-Disease
injury	I-Disease
and	O
improved	O
mitochondrial	O
respiratory	O
function	O
.	O
	
The	O
protective	O
role	O
of	O
salvianolic	B-Chemical
acid	I-Chemical
A	I-Chemical
against	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
damage	I-Disease
was	O
further	O
confirmed	O
by	O
histopathological	O
examination	O
.	O
	
The	O
results	O
of	O
our	O
study	O
suggest	O
that	O
salvianolic	B-Chemical
acid	I-Chemical
A	I-Chemical
possessing	O
antioxidant	O
activity	O
has	O
a	O
significant	O
protective	O
effect	O
against	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
.	O
	
	
Learning	B-Disease
and	I-Disease
memory	I-Disease
deficits	I-Disease
in	O
ecstasy	B-Chemical
users	O
and	O
their	O
neural	O
correlates	O
during	O
a	O
face	O
-	O
learning	O
task	O
.	O
	
It	O
has	O
been	O
consistently	O
shown	O
that	O
ecstasy	B-Chemical
users	O
display	O
impairments	B-Disease
in	I-Disease
learning	I-Disease
and	I-Disease
memory	I-Disease
performance	O
.	O
	
In	O
addition	O
","	O
working	O
memory	O
processing	O
in	O
ecstasy	B-Chemical
users	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
neural	O
alterations	O
in	O
hippocampal	O
and	O
/	O
or	O
cortical	O
regions	O
as	O
measured	O
by	O
functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
).	O
	
Using	O
functional	O
imaging	O
and	O
a	O
face	O
-	O
learning	O
task	O
","	O
we	O
investigated	O
neural	O
correlates	O
of	O
encoding	O
and	O
recalling	O
face	O
-	O
name	O
associations	O
in	O
20	O
recreational	O
drug	O
users	O
whose	O
predominant	O
drug	O
use	O
was	O
ecstasy	B-Chemical
and	O
20	O
controls	O
.	O
	
To	O
address	O
the	O
potential	O
confounding	O
effects	O
of	O
the	O
cannabis	B-Chemical
use	O
of	O
the	O
ecstasy	B-Chemical
using	O
group	O
","	O
a	O
second	O
analysis	O
included	O
14	O
previously	O
tested	O
cannabis	B-Chemical
users	O
(	O
Nestor	O
","	O
L	O
.","	O
Roberts	O
","	O
G	O
.","	O
Garavan	O
","	O
H	O
.","	O
Hester	O
","	O
R	O
.","	O
2008	O
.	O
	
Deficits	B-Disease
in	I-Disease
learning	I-Disease
and	I-Disease
memory	I-Disease
:	O
parahippocampal	O
hyperactivity	B-Disease
and	O
frontocortical	O
hypoactivity	O
in	O
cannabis	B-Chemical
users	O
.	O
	
Neuroimage	O
40	O
","	O
1328	O
-	O
1339	O
).	O
	
Ecstasy	B-Chemical
users	O
performed	O
significantly	O
worse	O
in	O
learning	O
and	O
memory	O
compared	O
to	O
controls	O
and	O
cannabis	B-Chemical
users	O
.	O
	
A	O
conjunction	O
analysis	O
of	O
the	O
encode	O
and	O
recall	O
phases	O
of	O
the	O
task	O
revealed	O
ecstasy	B-Chemical
-	O
specific	O
hyperactivity	B-Disease
in	O
bilateral	O
frontal	O
regions	O
","	O
left	O
temporal	O
","	O
right	O
parietal	O
","	O
bilateral	O
temporal	O
","	O
and	O
bilateral	O
occipital	O
brain	O
regions	O
.	O
	
Ecstasy	B-Chemical
-	O
specific	O
hypoactivity	O
was	O
evident	O
in	O
the	O
right	O
dorsal	O
anterior	O
cingulated	O
cortex	O
(	O
ACC	O
)	O
and	O
left	O
posterior	O
cingulated	O
cortex	O
.	O
	
In	O
both	O
ecstasy	B-Chemical
and	O
cannabis	B-Chemical
groups	O
brain	O
activation	O
was	O
decreased	O
in	O
the	O
right	O
medial	O
frontal	O
gyrus	O
","	O
left	O
parahippocampal	O
gyrus	O
","	O
left	O
dorsal	O
cingulate	O
gyrus	O
","	O
and	O
left	O
caudate	O
.	O
	
These	O
results	O
elucidated	O
ecstasy	B-Chemical
-	O
related	O
deficits	O
","	O
only	O
some	O
of	O
which	O
might	O
be	O
attributed	O
to	O
cannabis	B-Chemical
use	O
.	O
	
These	O
ecstasy	B-Chemical
-	O
specific	O
effects	O
may	O
be	O
related	O
to	O
the	O
vulnerability	O
of	O
isocortical	O
and	O
allocortical	O
regions	O
to	O
the	O
neurotoxic	B-Disease
effects	O
of	O
ecstasy	B-Chemical
.	O
	
	
Mice	O
lacking	O
mPGES	O
-	O
1	O
are	O
resistant	O
to	O
lithium	B-Chemical
-	O
induced	O
polyuria	B-Disease
.	O
	
Cyclooxygenase	O
-	O
2	O
activity	O
is	O
required	O
for	O
the	O
development	O
of	O
lithium	B-Chemical
-	O
induced	O
polyuria	B-Disease
.	O
	
However	O
","	O
the	O
involvement	O
of	O
a	O
specific	O
","	O
terminal	O
prostaglandin	B-Chemical
(	O
PG	B-Chemical
)	O
isomerase	O
has	O
not	O
been	O
evaluated	O
.	O
	
The	O
present	O
study	O
was	O
undertaken	O
to	O
assess	O
lithium	B-Chemical
-	O
induced	O
polyuria	B-Disease
in	O
mice	O
deficient	O
in	O
microsomal	O
prostaglandin	O
E	O
synthase	O
-	O
1	O
(	O
mPGES	O
-	O
1	O
).	O
	
A	O
2	O
-	O
wk	O
administration	O
of	O
LiCl	B-Chemical
(	O
4	O
mmol	O
.	O
kg	O
(-	O
1	O
).	O
day	O
(-	O
1	O
)	O
ip	O
)	O
in	O
mPGES	O
-	O
1	O
+/+	O
mice	O
led	O
to	O
a	O
marked	O
polyuria	B-Disease
with	O
hyposmotic	O
urine	O
.	O
	
This	O
was	O
associated	O
with	O
elevated	O
renal	O
mPGES	O
-	O
1	O
protein	O
expression	O
and	O
increased	O
urine	O
PGE	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
excretion	O
.	O
	
In	O
contrast	O
","	O
mPGES	O
-	O
1	O
-/-	O
mice	O
were	O
largely	O
resistant	O
to	O
lithium	B-Chemical
-	O
induced	O
polyuria	B-Disease
and	O
a	O
urine	O
concentrating	O
defect	O
","	O
accompanied	O
by	O
nearly	O
complete	O
blockade	O
of	O
high	O
urine	O
PGE	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
and	O
cAMP	B-Chemical
output	O
.	O
	
Immunoblotting	O
","	O
immunohistochemistry	O
","	O
and	O
quantitative	O
(	O
q	O
)	O
RT	O
-	O
PCR	O
consistently	O
detected	O
a	O
significant	O
decrease	O
in	O
aquaporin	O
-	O
2	O
(	O
AQP2	O
)	O
protein	O
expression	O
in	O
both	O
the	O
renal	O
cortex	O
and	O
medulla	O
of	O
lithium	B-Chemical
-	O
treated	O
+/+	O
mice	O
.	O
	
This	O
decrease	O
was	O
significantly	O
attenuated	O
in	O
the	O
-/-	O
mice	O
.	O
	
qRT	O
-	O
PCR	O
detected	O
similar	O
patterns	O
of	O
changes	O
in	O
AQP2	O
mRNA	O
in	O
the	O
medulla	O
but	O
not	O
in	O
the	O
cortex	O
.	O
	
Similarly	O
","	O
the	O
total	O
protein	O
abundance	O
of	O
the	O
Na	O
-	O
K	O
-	O
2Cl	O
cotransporter	O
(	O
NKCC2	O
)	O
in	O
the	O
medulla	O
but	O
not	O
in	O
the	O
cortex	O
of	O
the	O
+/+	O
mice	O
was	O
significantly	O
reduced	O
by	O
lithium	B-Chemical
treatment	O
.	O
	
In	O
contrast	O
","	O
the	O
dowregulation	O
of	O
renal	O
medullary	O
NKCC2	O
expression	O
was	O
significantly	O
attenuated	O
in	O
the	O
-/-	O
mice	O
.	O
	
We	O
conclude	O
that	O
mPGES	O
-	O
1	O
-	O
derived	O
PGE	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
mediates	O
lithium	B-Chemical
-	O
induced	O
polyuria	B-Disease
likely	O
via	O
inhibition	O
of	O
AQP2	O
and	O
NKCC2	O
expression	O
.	O
	
	
Dextran	B-Chemical
-	O
etodolac	B-Chemical
conjugates	O
:	O
synthesis	O
","	O
in	O
vitro	O
and	O
in	O
vivo	O
evaluation	O
.	O
	
Etodolac	B-Chemical
(	O
E	B-Chemical
)","	O
is	O
a	O
non	O
-	O
narcotic	O
analgesic	O
and	O
antiinflammatory	B-Chemical
drug	I-Chemical
.	O
	
A	O
biodegradable	O
polymer	O
dextran	B-Chemical
has	O
been	O
utilized	O
as	O
a	O
carrier	O
for	O
synthesis	O
of	O
etodolac	B-Chemical
-	O
dextran	B-Chemical
conjugates	O
(	O
ED	B-Chemical
)	O
to	O
improve	O
its	O
aqueous	O
solubility	O
and	O
reduce	O
gastrointestinal	O
side	O
effects	O
.	O
	
An	O
activated	O
moiety	O
","	O
i	O
.	O
e	O
.	O
	
N	B-Chemical
-	I-Chemical
acylimidazole	I-Chemical
derivative	O
of	O
etodolac	B-Chemical
(	O
EAI	B-Chemical
)","	O
was	O
condensed	O
with	O
the	O
polysaccharide	O
polymer	O
dextran	B-Chemical
of	O
different	O
molecular	O
weights	O
(	O
40000	O
","	O
60000	O
","	O
110000	O
and	O
200000	O
).	O
	
IR	O
spectral	O
data	O
confirmed	O
formation	O
of	O
ester	B-Chemical
bonding	O
in	O
the	O
conjugates	O
.	O
	
Etodolac	B-Chemical
contents	O
were	O
evaluated	O
by	O
UV	O
-	O
spectrophotometric	O
analysis	O
.	O
	
The	O
molecular	O
weights	O
were	O
determined	O
by	O
measuring	O
viscosity	O
using	O
the	O
Mark	O
-	O
Howink	O
-	O
Sakurada	O
equation	O
.	O
	
In	O
vitro	O
hydrolysis	O
of	O
ED	B-Chemical
was	O
done	O
in	O
aqueous	O
buffers	O
(	O
pH	O
1	O
.	O
2	O
","	O
7	O
.	O
4	O
","	O
9	O
)	O
and	O
in	O
80	O
%	O
(	O
v	O
/	O
v	O
)	O
human	O
plasma	O
(	O
pH	O
7	O
.	O
4	O
).	O
	
At	O
pH	O
9	O
","	O
a	O
higher	O
rate	O
of	O
etodolac	B-Chemical
release	O
from	O
ED	B-Chemical
was	O
observed	O
as	O
compared	O
to	O
aqueous	O
buffer	O
of	O
pH	O
7	O
.	O
4	O
and	O
80	O
%	O
human	O
plasma	O
(	O
pH	O
7	O
.	O
4	O
)","	O
following	O
first	O
-	O
order	O
kinetics	O
.	O
	
In	O
vivo	O
investigations	O
were	O
performed	O
in	O
animals	O
.	O
	
Acute	O
analgesic	O
and	O
antiinflammatory	O
activities	O
were	O
ascertained	O
using	O
acetic	B-Chemical
acid	I-Chemical
induced	O
writhing	O
model	O
(	O
mice	O
)	O
and	O
carrageenan	B-Chemical
-	O
induced	O
rat	O
paw	O
edema	B-Disease
model	O
","	O
respectively	O
.	O
	
In	O
comparison	O
to	O
control	O
","	O
E	B-Chemical
and	O
ED1	O
-	O
ED4	O
showed	O
highly	O
significant	O
analgesic	O
and	O
antiinflammatory	O
activities	O
(	O
p	O
<	O
0	O
.	O
1	O
).	O
	
Biological	O
evaluation	O
suggested	O
that	O
conjugates	O
(	O
ED1	O
-	O
ED4	O
)	O
retained	O
comparable	O
analgesic	O
and	O
antiinflammatory	O
activities	O
with	O
remarkably	O
reduced	O
ulcerogenicity	O
as	O
compared	O
to	O
their	O
parent	O
drug	O
--	O
etodolac	B-Chemical
.	O
	
	
The	O
antiarrhythmic	O
effect	O
and	O
possible	O
ionic	O
mechanisms	O
of	O
pilocarpine	B-Chemical
on	O
animal	O
models	O
.	O
	
This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
effects	O
of	O
pilocarpine	B-Chemical
and	O
explore	O
the	O
underlying	O
ionic	O
mechanism	O
","	O
using	O
both	O
aconitine	B-Chemical
-	O
induced	O
rat	O
and	O
ouabain	B-Chemical
-	O
induced	O
guinea	O
pig	O
arrhythmia	B-Disease
models	O
.	O
	
Confocal	O
microscopy	O
was	O
used	O
to	O
measure	O
intracellular	O
free	O
-	O
calcium	B-Chemical
concentrations	O
([	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+)](	I-Chemical
i	O
))	O
in	O
isolated	O
myocytes	O
.	O
	
The	O
current	O
data	O
showed	O
that	O
pilocarpine	B-Chemical
significantly	O
delayed	O
onset	O
of	O
arrhythmias	B-Disease
","	O
decreased	O
the	O
time	O
course	O
of	O
ventricular	B-Disease
tachycardia	I-Disease
and	I-Disease
fibrillation	I-Disease
","	O
reduced	O
arrhythmia	B-Disease
score	O
","	O
and	O
increased	O
the	O
survival	O
time	O
of	O
arrhythmic	B-Disease
rats	O
and	O
guinea	O
pigs	O
.	O
	
[	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+)](	I-Chemical
i	O
)	O
overload	O
induced	O
by	O
aconitine	B-Chemical
or	O
ouabain	B-Chemical
was	O
reduced	O
in	O
isolated	O
myocytes	O
pretreated	O
with	O
pilocarpine	B-Chemical
.	O
	
Moreover	O
","	O
M	O
(	O
3	O
)-	O
muscarinic	O
acetylcholine	O
receptor	O
(	O
mAChR	O
)	O
antagonist	O
4	B-Chemical
-	I-Chemical
DAMP	I-Chemical
(	O
4	B-Chemical
-	I-Chemical
diphenylacetoxy	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
methylpiperidine	I-Chemical
-	I-Chemical
methiodide	I-Chemical
)	O
partially	O
abolished	O
the	O
beneficial	O
effects	O
of	O
pilocarpine	B-Chemical
.	O
	
These	O
data	O
suggest	O
that	O
pilocarpine	B-Chemical
produced	O
antiarrhythmic	O
actions	O
on	O
arrhythmic	B-Disease
rat	O
and	O
guinea	O
pig	O
models	O
induced	O
by	O
aconitine	B-Chemical
or	O
ouabain	B-Chemical
via	O
stimulating	O
the	O
cardiac	O
M	O
(	O
3	O
)-	O
mAChR	O
.	O
	
The	O
mechanism	O
may	O
be	O
related	O
to	O
the	O
improvement	O
of	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+)	I-Chemical
handling	O
.	O
	
	
Nimodipine	B-Chemical
prevents	O
memory	B-Disease
impairment	I-Disease
caused	O
by	O
nitroglycerin	B-Chemical
-	O
induced	O
hypotension	B-Disease
in	O
adult	O
mice	O
.	O
	
BACKGROUND	O
:	O
Hypotension	B-Disease
and	O
a	O
resultant	O
decrease	O
in	O
cerebral	O
blood	O
flow	O
have	O
been	O
implicated	O
in	O
the	O
development	O
of	O
cognitive	B-Disease
dysfunction	I-Disease
.	O
	
We	O
tested	O
the	O
hypothesis	O
that	O
nimodipine	B-Chemical
(	O
NIMO	B-Chemical
)	O
administered	O
at	O
the	O
onset	O
of	O
nitroglycerin	B-Chemical
(	O
NTG	B-Chemical
)-	O
induced	O
hypotension	B-Disease
would	O
preserve	O
long	O
-	O
term	O
associative	O
memory	O
.	O
	
METHODS	O
:	O
The	O
passive	O
avoidance	O
(	O
PA	O
)	O
paradigm	O
was	O
used	O
to	O
assess	O
memory	O
retention	O
.	O
	
For	O
PA	O
training	O
","	O
latencies	O
(	O
seconds	O
)	O
were	O
recorded	O
for	O
entry	O
from	O
a	O
suspended	O
platform	O
into	O
a	O
Plexiglas	O
tube	O
where	O
a	O
shock	O
was	O
automatically	O
delivered	O
.	O
	
Latencies	O
were	O
recorded	O
48	O
h	O
later	O
for	O
a	O
testing	O
trial	O
.	O
	
Ninety	O
-	O
six	O
Swiss	O
-	O
Webster	O
mice	O
(	O
30	O
-	O
35	O
g	O
","	O
6	O
-	O
8	O
wk	O
)","	O
were	O
randomized	O
into	O
6	O
groups	O
1	O
)	O
saline	O
(	O
control	O
)","	O
2	O
)	O
NTG	B-Chemical
immediately	O
after	O
learning	O
","	O
3	O
)	O
NTG	B-Chemical
3	O
h	O
after	O
learning	O
","	O
4	O
)	O
NTG	B-Chemical
and	O
NIMO	B-Chemical
","	O
5	O
)	O
vehicle	O
","	O
and	O
6	O
)	O
NIMO	B-Chemical
alone	O
.	O
	
The	O
extent	O
of	O
hypotension	B-Disease
and	O
changes	O
in	O
brain	O
tissue	O
oxygenation	O
(	O
PbtO	O
(	O
2	O
))	O
and	O
in	O
cerebral	O
blood	O
flow	O
were	O
studied	O
in	O
a	O
separate	O
group	O
of	O
animals	O
.	O
	
RESULTS	O
:	O
All	O
groups	O
exhibited	O
similar	O
training	O
latencies	O
(	O
17	O
.	O
0	O
+/-	O
4	O
.	O
6	O
s	O
).	O
	
Mice	O
subjected	O
to	O
hypotensive	B-Disease
episodes	O
showed	O
a	O
significant	O
decrease	O
in	O
latency	O
time	O
(	O
178	O
+/-	O
156	O
s	O
)	O
compared	O
with	O
those	O
injected	O
with	O
saline	O
","	O
NTG	B-Chemical
+	O
NIMO	B-Chemical
","	O
or	O
delayed	O
NTG	B-Chemical
(	O
580	O
+/-	O
81	O
s	O
","	O
557	O
+/-	O
67	O
s	O
","	O
and	O
493	O
+/-	O
146	O
s	O
","	O
respectively	O
).	O
	
A	O
Kruskal	O
-	O
Wallis	O
1	O
-	O
way	O
analysis	O
of	O
variance	O
indicated	O
a	O
significant	O
difference	O
among	O
the	O
4	O
treatment	O
groups	O
(	O
H	O
=	O
15	O
.	O
34	O
";"	O
P	O
<	O
0	O
.	O
1	O
).	O
	
In	O
a	O
separate	O
group	O
of	O
mice	O
not	O
subjected	O
to	O
behavioral	O
studies	O
","	O
the	O
same	O
dose	O
of	O
NTG	B-Chemical
(	O
n	O
=	O
3	O
)	O
and	O
NTG	B-Chemical
+	O
NIMO	B-Chemical
(	O
n	O
=	O
3	O
)	O
caused	O
mean	O
arterial	O
blood	O
pressure	O
to	O
decrease	O
from	O
85	O
.	O
9	O
+/-	O
3	O
.	O
8	O
mm	O
Hg	O
sem	O
to	O
31	O
.	O
6	O
+/-	O
0	O
.	O
8	O
mm	O
Hg	O
sem	O
and	O
from	O
86	O
.	O
2	O
+/-	O
3	O
.	O
7	O
mm	O
Hg	O
sem	O
to	O
32	O
.	O
6	O
+/-	O
0	O
.	O
2	O
mm	O
Hg	O
sem	O
","	O
respectively	O
.	O
	
Mean	O
arterial	O
blood	O
pressure	O
in	O
mice	O
treated	O
with	O
NIMO	B-Chemical
alone	O
decreased	O
from	O
88	O
.	O
1	O
+/-	O
3	O
.	O
8	O
mm	O
Hg	O
to	O
80	O
.	O
0	O
+/-	O
2	O
.	O
9	O
mm	O
Hg	O
.	O
	
The	O
intergroup	O
difference	O
was	O
statistically	O
significant	O
(	O
P	O
<	O
0	O
.	O
5	O
).	O
	
PbtO	O
(	O
2	O
)	O
decreased	O
from	O
51	O
.	O
7	O
+/-	O
4	O
.	O
5	O
mm	O
Hg	O
sem	O
to	O
33	O
.	O
8	O
+/-	O
5	O
.	O
2	O
mm	O
Hg	O
sem	O
in	O
the	O
NTG	B-Chemical
group	O
and	O
from	O
38	O
.	O
6	O
+/-	O
6	O
.	O
1	O
mm	O
Hg	O
sem	O
to	O
25	O
.	O
4	O
+/-	O
2	O
.	O
0	O
mm	O
Hg	O
sem	O
in	O
the	O
NTG	B-Chemical
+	O
NIMO	B-Chemical
groups	O
","	O
respectively	O
.	O
	
There	O
were	O
no	O
significant	O
differences	O
among	O
groups	O
.	O
	
CONCLUSION	O
:	O
In	O
a	O
PA	O
retention	O
paradigm	O
","	O
the	O
injection	O
of	O
NTG	B-Chemical
immediately	O
after	O
learning	O
produced	O
a	O
significant	O
impairment	O
of	O
long	O
-	O
term	O
associative	O
memory	O
in	O
mice	O
","	O
whereas	O
delayed	O
induced	O
hypotension	B-Disease
had	O
no	O
effect	O
.	O
	
NIMO	B-Chemical
attenuated	O
the	O
disruption	O
in	O
consolidation	O
of	O
long	O
-	O
term	O
memory	O
caused	O
by	O
NTG	B-Chemical
but	O
did	O
not	O
improve	O
latency	O
in	O
the	O
absence	O
of	O
hypotension	B-Disease
.	O
	
The	O
observed	O
effect	O
of	O
NIMO	B-Chemical
may	O
have	O
been	O
attributable	O
to	O
the	O
preservation	O
of	O
calcium	B-Chemical
homeostasis	O
during	O
hypotension	B-Disease
","	O
because	O
there	O
were	O
no	O
differences	O
in	O
the	O
PbtO	O
(	O
2	O
)	O
indices	O
among	O
groups	O
.	O
	
	
Normalizing	O
effects	O
of	O
modafinil	B-Chemical
on	O
sleep	O
in	O
chronic	O
cocaine	B-Chemical
users	O
.	O
	
OBJECTIVE	O
:	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
morning	O
-	O
dosed	O
modafinil	B-Chemical
on	O
sleep	O
and	O
daytime	B-Disease
sleepiness	I-Disease
in	O
chronic	O
cocaine	B-Chemical
users	O
.	O
	
METHOD	O
:	O
Twenty	O
cocaine	B-Chemical
-	O
dependent	O
participants	O
were	O
randomly	O
assigned	O
to	O
receive	O
modafinil	B-Chemical
","	O
400	O
mg	O
(	O
N	O
=	O
10	O
)","	O
or	O
placebo	O
(	O
N	O
=	O
10	O
)	O
every	O
morning	O
at	O
7	O
:	O
30	O
a	O
.	O
m	O
.	O
	
for	O
16	O
days	O
in	O
an	O
inpatient	O
","	O
double	O
-	O
blind	O
randomized	O
trial	O
.	O
	
Participants	O
underwent	O
polysomnographic	O
sleep	O
recordings	O
on	O
days	O
1	O
to	O
3	O
","	O
7	O
to	O
9	O
","	O
and	O
14	O
to	O
16	O
(	O
first	O
","	O
second	O
","	O
and	O
third	O
weeks	O
of	O
abstinence	O
).	O
	
The	O
Multiple	O
Sleep	O
Latency	O
Test	O
was	O
performed	O
at	O
11	O
:	O
30	O
a	O
.	O
m	O
.","	O
2	O
:	O
0	O
p	O
.	O
m	O
.","	O
and	O
4	O
:	O
30	O
p	O
.	O
m	O
.	O
	
on	O
days	O
2	O
","	O
8	O
","	O
and	O
15	O
.	O
	
For	O
comparison	O
of	O
sleep	O
architecture	O
variables	O
","	O
12	O
healthy	O
comparison	O
participants	O
underwent	O
a	O
single	O
night	O
of	O
experimental	O
polysomnography	O
that	O
followed	O
1	O
night	O
of	O
accommodation	O
polysomnography	O
.	O
	
RESULTS	O
:	O
Progressive	O
abstinence	O
from	O
cocaine	B-Chemical
was	O
associated	O
with	O
worsening	O
of	O
all	O
measured	O
polysomnographic	O
sleep	O
outcomes	O
.	O
	
Compared	O
with	O
placebo	O
","	O
modafinil	B-Chemical
decreased	O
nighttime	O
sleep	O
latency	O
and	O
increased	O
slow	O
-	O
wave	O
sleep	O
time	O
in	O
cocaine	B-Chemical
-	O
dependent	O
participants	O
.	O
	
The	O
effect	O
of	O
modafinil	B-Chemical
interacted	O
with	O
the	O
abstinence	O
week	O
and	O
was	O
associated	O
with	O
longer	O
total	O
sleep	O
time	O
and	O
shorter	O
REM	O
sleep	O
latency	O
in	O
the	O
third	O
week	O
of	O
abstinence	O
.	O
	
Comparison	O
of	O
slow	O
-	O
wave	O
sleep	O
time	O
","	O
total	O
sleep	O
time	O
","	O
and	O
sleep	O
latency	O
in	O
cocaine	B-Chemical
-	O
dependent	O
and	O
healthy	O
participants	O
revealed	O
a	O
normalizing	O
effect	O
of	O
modafinil	B-Chemical
in	O
cocaine	B-Chemical
-	O
dependent	O
participants	O
.	O
	
Modafinil	B-Chemical
was	O
associated	O
with	O
increased	O
daytime	O
sleep	O
latency	O
","	O
as	O
measured	O
by	O
the	O
Multiple	O
Sleep	O
Latency	O
Test	O
","	O
and	O
a	O
nearly	O
significant	O
decrease	O
in	O
subjective	O
daytime	B-Disease
sleepiness	I-Disease
.	O
	
CONCLUSIONS	O
:	O
Morning	O
-	O
dosed	O
modafinil	B-Chemical
promotes	O
nocturnal	O
sleep	O
","	O
normalizes	O
sleep	O
architecture	O
","	O
and	O
decreases	O
daytime	B-Disease
sleepiness	I-Disease
in	O
abstinent	O
cocaine	B-Chemical
users	O
.	O
	
These	O
effects	O
may	O
be	O
relevant	O
in	O
the	O
treatment	O
of	O
cocaine	B-Chemical
dependence	O
.	O
	
	
Studies	O
of	O
synergy	O
between	O
morphine	B-Chemical
and	O
a	O
novel	O
sodium	B-Chemical
channel	I-Chemical
blocker	I-Chemical
","	O
CNSB002	B-Chemical
","	O
in	O
rat	O
models	O
of	O
inflammatory	B-Disease
and	O
neuropathic	B-Disease
pain	I-Disease
.	O
	
OBJECTIVE	O
:	O
This	O
study	O
determined	O
the	O
antihyperalgesic	O
effect	O
of	O
CNSB002	B-Chemical
","	O
a	O
sodium	B-Chemical
channel	I-Chemical
blocker	I-Chemical
with	O
antioxidant	O
properties	O
given	O
alone	O
and	O
in	O
combinations	O
with	O
morphine	B-Chemical
in	O
rat	O
models	O
of	O
inflammatory	B-Disease
and	O
neuropathic	B-Disease
pain	I-Disease
.	O
	
DESIGN	O
:	O
Dose	O
response	O
curves	O
for	O
nonsedating	O
doses	O
of	O
morphine	B-Chemical
and	O
CNSB002	B-Chemical
given	O
intraperitoneally	O
alone	O
and	O
together	O
in	O
combinations	O
were	O
constructed	O
for	O
antihyperalgesic	O
effect	O
using	O
paw	O
withdrawal	O
from	O
noxious	O
heat	O
in	O
two	O
rat	O
pain	B-Disease
models	O
:	O
carrageenan	B-Chemical
-	O
induced	O
paw	O
inflammation	B-Disease
and	O
streptozotocin	B-Chemical
(	O
STZ	B-Chemical
)-	O
induced	O
diabetic	B-Disease
neuropathy	I-Disease
.	O
	
RESULTS	O
:	O
The	O
maximum	O
nonsedating	O
doses	O
were	O
:	O
morphine	B-Chemical
","	O
3	O
.	O
2	O
mg	O
/	O
kg	O
";"	O
CNSB002	B-Chemical
10	O
.	O
0	O
mg	O
/	O
kg	O
";"	O
5	O
.	O
0	O
mg	O
/	O
kg	O
CNSB002	B-Chemical
with	O
morphine	B-Chemical
3	O
.	O
2	O
mg	O
/	O
kg	O
in	O
combination	O
.	O
	
The	O
doses	O
calculated	O
to	O
cause	O
50	O
%	O
reversal	O
of	O
hyperalgesia	B-Disease
(	O
ED50	O
)	O
were	O
7	O
.	O
54	O
(	O
1	O
.	O
81	O
)	O
and	O
4	O
.	O
83	O
(	O
1	O
.	O
54	O
)	O
in	O
the	O
carrageenan	B-Chemical
model	O
and	O
44	O
.	O
18	O
(	O
1	O
.	O
37	O
)	O
and	O
9	O
.	O
14	O
(	O
1	O
.	O
24	O
)	O
in	O
the	O
STZ	B-Chemical
-	O
induced	O
neuropathy	B-Disease
model	O
for	O
CNSB002	B-Chemical
and	O
morphine	B-Chemical
","	O
respectively	O
(	O
mg	O
/	O
kg	O
";"	O
mean	O
","	O
SEM	O
).	O
	
These	O
values	O
were	O
greater	O
than	O
the	O
maximum	O
nonsedating	O
doses	O
.	O
	
The	O
ED50	O
values	O
for	O
morphine	B-Chemical
when	O
given	O
in	O
combination	O
with	O
CNSB002	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
)	O
were	O
less	O
than	O
the	O
maximum	O
nonsedating	O
dose	O
:	O
0	O
.	O
56	O
(	O
1	O
.	O
55	O
)	O
in	O
the	O
carrageenan	B-Chemical
model	O
and	O
1	O
.	O
37	O
(	O
1	O
.	O
23	O
)	O
in	O
the	O
neuropathy	B-Disease
model	O
(	O
mg	O
/	O
kg	O
";"	O
mean	O
","	O
SEM	O
).	O
	
The	O
antinociception	O
after	O
morphine	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
)	O
was	O
increased	O
by	O
co	O
-	O
administration	O
with	O
CNSB002	B-Chemical
from	O
28	O
.	O
0	O
and	O
31	O
.	O
7	O
%	O
to	O
114	O
.	O
6	O
and	O
56	O
.	O
9	O
%	O
reversal	O
of	O
hyperalgesia	B-Disease
in	O
the	O
inflammatory	B-Disease
and	O
neuropathic	B-Disease
models	O
","	O
respectively	O
(	O
P	O
<	O
0	O
.	O
1	O
";"	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
-	O
significantly	O
greater	O
than	O
either	O
drug	O
given	O
alone	O
).	O
	
CONCLUSIONS	O
:	O
The	O
maximum	O
antihyperalgesic	O
effect	O
achievable	O
with	O
nonsedating	O
doses	O
of	O
morphine	B-Chemical
may	O
be	O
increased	O
significantly	O
when	O
the	O
drug	O
is	O
used	O
in	O
combination	O
with	O
CNSB002	B-Chemical
.	O
	
	
Coenzyme	B-Chemical
Q10	I-Chemical
treatment	O
ameliorates	O
acute	O
cisplatin	B-Chemical
nephrotoxicity	B-Disease
in	O
mice	O
.	O
	
The	O
nephroprotective	O
effect	O
of	O
coenzyme	B-Chemical
Q10	I-Chemical
was	O
investigated	O
in	O
mice	O
with	O
acute	B-Disease
renal	I-Disease
injury	I-Disease
induced	O
by	O
a	O
single	O
i	O
.	O
p	O
.	O
	
injection	O
of	O
cisplatin	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
).	O
	
Coenzyme	B-Chemical
Q10	I-Chemical
treatment	O
(	O
10	O
mg	O
/	O
kg	O
/	O
day	O
","	O
i	O
.	O
p	O
.)	O
	
was	O
applied	O
for	O
6	O
consecutive	O
days	O
","	O
starting	O
1	O
day	O
before	O
cisplatin	B-Chemical
administration	O
.	O
	
Coenzyme	B-Chemical
Q10	I-Chemical
significantly	O
reduced	O
blood	B-Chemical
urea	I-Chemical
nitrogen	I-Chemical
and	O
serum	O
creatinine	B-Chemical
levels	O
which	O
were	O
increased	O
by	O
cisplatin	B-Chemical
.	O
	
Coenzyme	B-Chemical
Q10	I-Chemical
significantly	O
compensated	O
deficits	O
in	O
the	O
antioxidant	O
defense	O
mechanisms	O
(	O
reduced	O
glutathione	B-Chemical
level	O
and	O
superoxide	O
dismutase	O
activity	O
)","	O
suppressed	O
lipid	B-Chemical
peroxidation	O
","	O
decreased	O
the	O
elevations	O
of	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
","	O
nitric	B-Chemical
oxide	I-Chemical
and	O
platinum	B-Chemical
ion	O
concentration	O
","	O
and	O
attenuated	O
the	O
reductions	O
of	O
selenium	B-Chemical
and	O
zinc	B-Chemical
ions	O
in	O
renal	O
tissue	O
resulted	O
from	O
cisplatin	B-Chemical
administration	O
.	O
	
Also	O
","	O
histopathological	O
renal	B-Disease
tissue	I-Disease
damage	I-Disease
mediated	O
by	O
cisplatin	B-Chemical
was	O
ameliorated	O
by	O
coenzyme	B-Chemical
Q10	I-Chemical
treatment	O
.	O
	
Immunohistochemical	O
analysis	O
revealed	O
that	O
coenzyme	B-Chemical
Q10	I-Chemical
significantly	O
decreased	O
the	O
cisplatin	B-Chemical
-	O
induced	O
overexpression	O
of	O
inducible	O
nitric	O
oxide	O
synthase	O
","	O
nuclear	O
factor	O
-	O
kappaB	O
","	O
caspase	O
-	O
3	O
and	O
p53	O
in	O
renal	O
tissue	O
.	O
	
It	O
was	O
concluded	O
that	O
coenzyme	B-Chemical
Q10	I-Chemical
represents	O
a	O
potential	O
therapeutic	O
option	O
to	O
protect	O
against	O
acute	O
cisplatin	B-Chemical
nephrotoxicity	B-Disease
commonly	O
encountered	O
in	O
clinical	O
practice	O
.	O
	
	
Efficacy	O
and	O
safety	O
of	O
asenapine	B-Chemical
in	O
a	O
placebo	O
-	O
and	O
haloperidol	B-Chemical
-	O
controlled	O
trial	O
in	O
patients	O
with	O
acute	O
exacerbation	O
of	O
schizophrenia	B-Disease
.	O
	
Asenapine	B-Chemical
is	O
approved	O
by	O
the	O
Food	O
and	O
Drugs	O
Administration	O
in	O
adults	O
for	O
acute	O
treatment	O
of	O
schizophrenia	B-Disease
or	O
of	O
manic	B-Disease
or	O
mixed	O
episodes	O
associated	O
with	O
bipolar	B-Disease
I	I-Disease
disorder	I-Disease
with	O
or	O
without	O
psychotic	B-Disease
features	O
.	O
	
In	O
a	O
double	O
-	O
blind	O
6	O
-	O
week	O
trial	O
","	O
458	O
patients	O
with	O
acute	O
schizophrenia	B-Disease
were	O
randomly	O
assigned	O
to	O
fixed	O
-	O
dose	O
treatment	O
with	O
asenapine	B-Chemical
at	O
5	O
mg	O
twice	O
daily	O
(	O
BID	O
)","	O
asenapine	B-Chemical
at	O
10	O
mg	O
BID	O
","	O
placebo	O
","	O
or	O
haloperidol	B-Chemical
at	O
4	O
mg	O
BID	O
(	O
to	O
verify	O
assay	O
sensitivity	O
).	O
	
With	O
last	O
observations	O
carried	O
forward	O
(	O
LOCF	O
)","	O
mean	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
total	O
score	O
reductions	O
from	O
baseline	O
to	O
endpoint	O
were	O
significantly	O
greater	O
with	O
asenapine	B-Chemical
at	O
5	O
mg	O
BID	O
(-	O
16	O
.	O
2	O
)	O
and	O
haloperidol	B-Chemical
(-	O
15	O
.	O
4	O
)	O
than	O
placebo	O
(-	O
10	O
.	O
7	O
";"	O
both	O
P	O
<	O
0	O
.	O
5	O
");"	O
using	O
mixed	O
model	O
for	O
repeated	O
measures	O
(	O
MMRM	O
)","	O
changes	O
at	O
day	O
42	O
were	O
significantly	O
greater	O
with	O
asenapine	B-Chemical
at	O
5	O
and	O
10	O
mg	O
BID	O
(-	O
21	O
.	O
3	O
and	O
-	O
19	O
.	O
4	O
","	O
respectively	O
)	O
and	O
haloperidol	B-Chemical
(-	O
20	O
.	O
0	O
)	O
than	O
placebo	O
(-	O
14	O
.	O
6	O
";"	O
all	O
P	O
<	O
0	O
.	O
5	O
).	O
	
On	O
the	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
positive	O
subscale	O
","	O
all	O
treatments	O
were	O
superior	O
to	O
placebo	O
with	O
LOCF	O
and	O
MMRM	O
";"	O
asenapine	B-Chemical
at	O
5	O
mg	O
BID	O
was	O
superior	O
to	O
placebo	O
on	O
the	O
negative	O
subscale	O
with	O
MMRM	O
and	O
on	O
the	O
general	O
psychopathology	O
subscale	O
with	O
LOCF	O
and	O
MMRM	O
.	O
	
Treatment	O
-	O
related	O
adverse	O
events	O
(	O
AEs	O
)	O
occurred	O
in	O
44	O
%	O
and	O
52	O
%","	O
57	O
%","	O
and	O
41	O
%	O
of	O
the	O
asenapine	B-Chemical
at	O
5	O
and	O
10	O
mg	O
BID	O
","	O
haloperidol	B-Chemical
","	O
and	O
placebo	O
groups	O
","	O
respectively	O
.	O
	
Extrapyramidal	B-Disease
symptoms	I-Disease
reported	O
as	O
AEs	O
occurred	O
in	O
15	O
%	O
and	O
18	O
%","	O
34	O
%","	O
and	O
10	O
%	O
of	O
the	O
asenapine	B-Chemical
at	O
5	O
and	O
10	O
mg	O
BID	O
","	O
haloperidol	B-Chemical
","	O
and	O
placebo	O
groups	O
","	O
respectively	O
.	O
	
Across	O
all	O
groups	O
","	O
no	O
more	O
than	O
5	O
%	O
of	O
patients	O
had	O
clinically	O
significant	O
weight	O
change	O
.	O
	
Post	O
hoc	O
analyses	O
indicated	O
that	O
efficacy	O
was	O
similar	O
with	O
asenapine	B-Chemical
and	O
haloperidol	B-Chemical
";"	O
greater	O
contrasts	O
were	O
seen	O
in	O
AEs	O
","	O
especially	O
extrapyramidal	B-Disease
symptoms	I-Disease
.	O
	
	
Salvage	O
therapy	O
with	O
nelarabine	B-Chemical
","	O
etoposide	B-Chemical
","	O
and	O
cyclophosphamide	B-Chemical
in	O
relapsed	O
/	O
refractory	O
paediatric	O
T	B-Disease
-	I-Disease
cell	I-Disease
lymphoblastic	I-Disease
leukaemia	I-Disease
and	I-Disease
lymphoma	I-Disease
.	O
	
A	O
combination	O
of	O
5	O
d	O
of	O
nelarabine	B-Chemical
(	O
AraG	B-Chemical
)	O
with	O
5	O
d	O
of	O
etoposide	B-Chemical
(	O
VP	B-Chemical
)	O
and	O
cyclophosphamide	B-Chemical
(	O
CPM	B-Chemical
)	O
and	O
prophylactic	O
intrathecal	O
chemotherapy	O
was	O
used	O
as	O
salvage	O
therapy	O
in	O
seven	O
children	O
with	O
refractory	O
or	O
relapsed	O
T	B-Disease
-	I-Disease
cell	I-Disease
leukaemia	I-Disease
or	I-Disease
lymphoma	I-Disease
.	O
	
The	O
most	O
common	O
side	O
effects	O
attributable	O
to	O
the	O
AraG	B-Chemical
included	O
Grade	O
2	O
and	O
3	O
sensory	O
and	O
motor	O
neuropathy	B-Disease
and	O
musculoskeletal	B-Disease
pain	I-Disease
.	O
	
Haematological	B-Disease
toxicity	I-Disease
was	O
greater	O
for	O
the	O
combination	O
than	O
AraG	B-Chemical
alone	O
","	O
although	O
median	O
time	O
to	O
neutrophil	O
and	O
platelet	O
recovery	O
was	O
consistent	O
with	O
other	O
salvage	O
therapies	O
.	O
	
All	O
patients	O
had	O
some	O
response	O
to	O
the	O
combined	O
therapy	O
and	O
five	O
of	O
the	O
seven	O
went	O
into	O
complete	O
remission	O
after	O
one	O
or	O
two	O
courses	O
of	O
AraG	B-Chemical
/	O
VP	B-Chemical
/	O
CPM	B-Chemical
.	O
	
Our	O
experience	O
supports	O
the	O
safety	O
of	O
giving	O
AraG	B-Chemical
as	O
salvage	O
therapy	O
in	O
synchrony	O
with	O
etoposide	B-Chemical
and	O
cyclophosphamide	B-Chemical
","	O
although	O
neurological	B-Disease
toxicity	I-Disease
must	O
be	O
closely	O
monitored	O
.	O
	
	
Dopamine	B-Chemical
is	O
not	O
essential	O
for	O
the	O
development	O
of	O
methamphetamine	B-Chemical
-	O
induced	O
neurotoxicity	B-Disease
.	O
	
It	O
is	O
widely	O
believed	O
that	O
dopamine	B-Chemical
(	O
DA	B-Chemical
)	O
mediates	O
methamphetamine	B-Chemical
(	O
METH	B-Chemical
)-	O
induced	O
toxicity	B-Disease
to	O
brain	O
dopaminergic	O
neurons	O
","	O
because	O
drugs	O
that	O
interfere	O
with	O
DA	B-Chemical
neurotransmission	O
decrease	O
toxicity	B-Disease
","	O
whereas	O
drugs	O
that	O
increase	O
DA	B-Chemical
neurotransmission	O
enhance	O
toxicity	B-Disease
.	O
	
However	O
","	O
temperature	O
effects	O
of	O
drugs	O
that	O
have	O
been	O
used	O
to	O
manipulate	O
brain	O
DA	B-Chemical
neurotransmission	O
confound	O
interpretation	O
of	O
the	O
data	O
.	O
	
Here	O
we	O
show	O
that	O
the	O
recently	O
reported	O
ability	O
of	O
L	B-Chemical
-	I-Chemical
dihydroxyphenylalanine	I-Chemical
to	O
reverse	O
the	O
protective	O
effect	O
of	O
alpha	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
para	I-Chemical
-	I-Chemical
tyrosine	I-Chemical
on	O
METH	B-Chemical
-	O
induced	O
DA	B-Chemical
neurotoxicity	B-Disease
is	O
also	O
confounded	O
by	O
drug	O
effects	O
on	O
body	O
temperature	O
.	O
	
Further	O
","	O
we	O
show	O
that	O
mice	O
genetically	O
engineered	O
to	O
be	O
deficient	O
in	O
brain	O
DA	B-Chemical
develop	O
METH	B-Chemical
neurotoxicity	B-Disease
","	O
as	O
long	O
as	O
the	O
thermic	O
effects	O
of	O
METH	B-Chemical
are	O
preserved	O
.	O
	
In	O
addition	O
","	O
we	O
demonstrate	O
that	O
mice	O
genetically	O
engineered	O
to	O
have	O
unilateral	O
brain	O
DA	B-Chemical
deficits	O
develop	O
METH	B-Chemical
-	O
induced	O
dopaminergic	B-Disease
deficits	I-Disease
that	O
are	O
of	O
comparable	O
magnitude	O
on	O
both	O
sides	O
of	O
the	O
brain	O
.	O
	
Taken	O
together	O
","	O
these	O
findings	O
demonstrate	O
that	O
DA	B-Chemical
is	O
not	O
essential	O
for	O
the	O
development	O
of	O
METH	B-Chemical
-	O
induced	O
dopaminergic	O
neurotoxicity	B-Disease
and	O
suggest	O
that	O
mechanisms	O
independent	O
of	O
DA	B-Chemical
warrant	O
more	O
intense	O
investigation	O
.	O
	
	
Glutamatergic	O
neurotransmission	O
mediated	O
by	O
NMDA	O
receptors	O
in	O
the	O
inferior	O
colliculus	O
can	O
modulate	O
haloperidol	B-Chemical
-	O
induced	O
catalepsy	B-Disease
.	O
	
The	O
inferior	O
colliculus	O
(	O
IC	O
)	O
is	O
primarily	O
involved	O
in	O
the	O
processing	O
of	O
auditory	O
information	O
","	O
but	O
it	O
is	O
distinguished	O
from	O
other	O
auditory	O
nuclei	O
in	O
the	O
brainstem	O
by	O
its	O
connections	O
with	O
structures	O
of	O
the	O
motor	O
system	O
.	O
	
Functional	O
evidence	O
relating	O
the	O
IC	O
to	O
motor	O
behavior	O
derives	O
from	O
experiments	O
showing	O
that	O
activation	O
of	O
the	O
IC	O
by	O
electrical	O
stimulation	O
or	O
excitatory	O
amino	O
acid	O
microinjection	O
causes	O
freezing	O
","	O
escape	O
-	O
like	O
behavior	O
","	O
and	O
immobility	O
.	O
	
However	O
","	O
the	O
nature	O
of	O
this	O
immobility	O
is	O
still	O
unclear	O
.	O
	
The	O
present	O
study	O
examined	O
the	O
influence	O
of	O
excitatory	O
amino	O
acid	O
-	O
mediated	O
mechanisms	O
in	O
the	O
IC	O
on	O
the	O
catalepsy	B-Disease
induced	O
by	O
the	O
dopamine	O
receptor	O
blocker	O
haloperidol	B-Chemical
administered	O
systemically	O
(	O
1	O
or	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
in	O
rats	O
.	O
	
Haloperidol	B-Chemical
-	O
induced	O
catalepsy	B-Disease
was	O
challenged	O
with	O
prior	O
intracollicular	O
microinjections	O
of	O
glutamate	O
NMDA	O
receptor	O
antagonists	O
","	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
(	O
15	O
or	O
30	O
mmol	O
/	O
0	O
.	O
5	O
microl	O
)	O
and	O
AP7	B-Chemical
(	O
10	O
or	O
20	O
nmol	O
/	O
0	O
.	O
5	O
microl	O
)","	O
or	O
of	O
the	O
NMDA	O
receptor	O
agonist	O
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
d	I-Chemical
-	I-Chemical
aspartate	I-Chemical
(	O
NMDA	B-Chemical
","	O
20	O
or	O
30	O
nmol	O
/	O
0	O
.	O
5	O
microl	O
).	O
	
The	O
results	O
showed	O
that	O
intracollicular	O
microinjection	O
of	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
and	O
AP7	B-Chemical
previous	O
to	O
systemic	O
injections	O
of	O
haloperidol	B-Chemical
significantly	O
attenuated	O
the	O
catalepsy	B-Disease
","	O
as	O
indicated	O
by	O
a	O
reduced	O
latency	O
to	O
step	O
down	O
from	O
a	O
horizontal	O
bar	O
.	O
	
Accordingly	O
","	O
intracollicular	O
microinjection	O
of	O
NMDA	B-Chemical
increased	O
the	O
latency	O
to	O
step	O
down	O
the	O
bar	O
.	O
	
These	O
findings	O
suggest	O
that	O
glutamate	B-Chemical
-	O
mediated	O
mechanisms	O
in	O
the	O
neural	O
circuits	O
at	O
the	O
IC	O
level	O
influence	O
haloperidol	B-Chemical
-	O
induced	O
catalepsy	B-Disease
and	O
participate	O
in	O
the	O
regulation	O
of	O
motor	O
activity	O
.	O
	
	
Curcumin	B-Chemical
ameliorates	O
cognitive	B-Disease
dysfunction	I-Disease
and	O
oxidative	O
damage	O
in	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
administered	O
rats	O
.	O
	
The	O
antiepileptic	B-Chemical
drugs	I-Chemical
","	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
are	O
well	O
known	O
to	O
cause	O
cognitive	B-Disease
impairment	I-Disease
on	O
chronic	O
use	O
.	O
	
The	O
increase	O
in	O
free	O
radical	O
generation	O
has	O
been	O
implicated	O
as	O
one	O
of	O
the	O
important	O
mechanisms	O
of	O
cognitive	B-Disease
impairment	I-Disease
by	O
antiepileptic	B-Chemical
drugs	I-Chemical
.	O
	
Curcumin	B-Chemical
has	O
shown	O
antioxidant	B-Chemical
","	O
anti	O
-	O
inflammatory	B-Disease
and	O
neuro	O
-	O
protective	O
properties	O
.	O
	
Therefore	O
","	O
the	O
present	O
study	O
was	O
carried	O
out	O
to	O
investigate	O
the	O
effect	O
of	O
chronic	O
curcumin	B-Chemical
administration	O
on	O
phenobarbitone	B-Chemical
-	O
and	O
carbamazepine	B-Chemical
-	O
induced	O
cognitive	B-Disease
impairment	I-Disease
and	O
oxidative	O
stress	O
in	O
rats	O
.	O
	
Pharmacokinetic	O
interactions	O
of	O
curcumin	B-Chemical
with	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
were	O
also	O
studied	O
.	O
	
Vehicle	O
/	O
drugs	O
were	O
administered	O
daily	O
for	O
21days	O
to	O
male	O
Wistar	O
rats	O
.	O
	
Passive	O
avoidance	O
paradigm	O
and	O
elevated	O
plus	O
maze	O
test	O
were	O
used	O
to	O
assess	O
cognitive	O
function	O
.	O
	
At	O
the	O
end	O
of	O
study	O
period	O
","	O
serum	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
","	O
whole	O
brain	O
malondialdehyde	B-Chemical
and	O
reduced	O
glutathione	B-Chemical
levels	O
were	O
estimated	O
.	O
	
The	O
administration	O
of	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
for	O
21days	O
caused	O
a	O
significant	O
impairment	B-Disease
of	I-Disease
learning	I-Disease
and	I-Disease
memory	I-Disease
as	O
well	O
as	O
an	O
increased	O
oxidative	O
stress	O
.	O
	
Concomitant	O
curcumin	B-Chemical
administration	O
prevented	O
the	O
cognitive	B-Disease
impairment	I-Disease
and	O
decreased	O
the	O
increased	O
oxidative	O
stress	O
induced	O
by	O
these	O
antiepileptic	B-Chemical
drugs	I-Chemical
.	O
	
Curcumin	B-Chemical
co	O
-	O
administration	O
did	O
not	O
cause	O
any	O
significant	O
alteration	O
in	O
the	O
serum	O
concentrations	O
of	O
both	O
phenobarbitone	B-Chemical
as	O
well	O
as	O
carbamazepine	B-Chemical
.	O
	
These	O
results	O
show	O
that	O
curcumin	B-Chemical
has	O
beneficial	O
effect	O
in	O
mitigating	O
the	O
deterioration	B-Disease
of	I-Disease
cognitive	I-Disease
functions	I-Disease
and	O
oxidative	O
damage	O
in	O
rats	O
treated	O
with	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
without	O
significantly	O
altering	O
their	O
serum	O
concentrations	O
.	O
	
The	O
findings	O
suggest	O
that	O
curcumin	B-Chemical
can	O
be	O
considered	O
as	O
a	O
potential	O
safe	O
and	O
effective	O
adjuvant	O
to	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
therapy	O
in	O
preventing	O
cognitive	B-Disease
impairment	I-Disease
associated	O
with	O
these	O
drugs	O
.	O
	
	
Effects	O
of	O
active	O
constituents	B-Chemical
of	I-Chemical
Crocus	I-Chemical
sativus	I-Chemical
L	I-Chemical
.","	I-Chemical
crocin	I-Chemical
on	O
streptozocin	B-Chemical
-	O
induced	O
model	O
of	O
sporadic	O
Alzheimer	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
in	O
male	O
rats	O
.	O
	
BACKGROUND	O
:	O
The	O
involvement	O
of	O
water	O
-	O
soluble	O
carotenoids	B-Chemical
","	O
crocins	B-Chemical
","	O
as	O
the	O
main	O
and	O
active	O
components	O
of	O
Crocus	B-Chemical
sativus	I-Chemical
L	I-Chemical
.	I-Chemical
extract	I-Chemical
in	O
learning	O
and	O
memory	O
processes	O
has	O
been	O
proposed	O
.	O
	
In	O
the	O
present	O
study	O
","	O
the	O
effect	O
of	O
crocins	B-Chemical
on	O
sporadic	O
Alzheimer	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
induced	O
by	O
intracerebroventricular	O
(	O
icv	O
)	O
streptozocin	B-Chemical
(	O
STZ	B-Chemical
)	O
in	O
male	O
rats	O
was	O
investigated	O
.	O
	
METHODS	O
:	O
Male	O
adult	O
Wistar	O
rats	O
(	O
n	O
=	O
90	O
and	O
260	O
-	O
290	O
g	O
)	O
were	O
divided	O
into	O
1	O
","	O
control	O
";"	O
2	O
and	O
3	O
","	O
crocins	B-Chemical
(	O
15	O
and	O
30	O
mg	O
/	O
kg	O
");"	O
4	O
","	O
STZ	B-Chemical
";"	O
5	O
and	O
6	O
","	O
STZ	B-Chemical
+	O
crocins	B-Chemical
(	O
15	O
and	O
30	O
mg	O
/	O
kg	O
)	O
groups	O
.	O
	
In	O
Alzheimer	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
groups	O
","	O
rats	O
were	O
injected	O
with	O
STZ	B-Chemical
-	O
icv	O
bilaterally	O
(	O
3	O
mg	O
/	O
kg	O
)	O
in	O
first	O
day	O
and	O
3	O
days	O
later	O
","	O
a	O
similar	O
STZ	B-Chemical
-	O
icv	O
application	O
was	O
repeated	O
.	O
	
In	O
STZ	B-Chemical
+	O
crocin	B-Chemical
animal	O
groups	O
","	O
crocin	B-Chemical
was	O
applied	O
in	O
doses	O
of	O
15	O
and	O
30	O
mg	O
/	O
kg	O
","	O
i	O
.	O
p	O
.","	O
one	O
day	O
pre	O
-	O
surgery	O
and	O
continued	O
for	O
three	O
weeks	O
.	O
	
Prescription	O
of	O
crocin	B-Chemical
in	O
each	O
dose	O
was	O
repeated	O
once	O
for	O
two	O
days	O
.	O
	
However	O
","	O
the	O
learning	O
and	O
memory	O
performance	O
was	O
assessed	O
using	O
passive	O
avoidance	O
paradigm	O
","	O
and	O
for	O
spatial	O
cognition	O
evaluation	O
","	O
Y	O
-	O
maze	O
task	O
was	O
used	O
.	O
	
RESULTS	O
:	O
It	O
was	O
found	O
out	O
that	O
crocin	B-Chemical
(	O
30	O
mg	O
/	O
kg	O
)-	O
treated	O
STZ	B-Chemical
-	O
injected	O
rats	O
show	O
higher	O
correct	O
choices	O
and	O
lower	O
errors	O
in	O
Y	O
-	O
maze	O
than	O
vehicle	O
-	O
treated	O
STZ	B-Chemical
-	O
injected	O
rats	O
.	O
	
In	O
addition	O
","	O
crocin	B-Chemical
in	O
the	O
mentioned	O
dose	O
could	O
significantly	O
attenuated	O
learning	B-Disease
and	I-Disease
memory	I-Disease
impairment	I-Disease
in	O
treated	O
STZ	B-Chemical
-	O
injected	O
group	O
in	O
passive	O
avoidance	O
test	O
.	O
	
CONCLUSION	O
:	O
Therefore	O
","	O
these	O
results	O
demonstrate	O
the	O
effectiveness	O
of	O
crocin	B-Chemical
(	O
30	O
mg	O
/	O
kg	O
)	O
in	O
antagonizing	O
the	O
cognitive	B-Disease
deficits	I-Disease
caused	O
by	O
STZ	B-Chemical
-	O
icv	O
in	O
rats	O
and	O
its	O
potential	O
in	O
the	O
treatment	O
of	O
neurodegenerative	B-Disease
diseases	I-Disease
such	O
as	O
Alzheimer	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
	
	
The	O
role	O
of	O
nitric	B-Chemical
oxide	I-Chemical
in	O
convulsions	B-Disease
induced	O
by	O
lindane	B-Chemical
in	O
rats	O
.	O
	
Lindane	B-Chemical
is	O
an	O
organochloride	B-Chemical
pesticide	I-Chemical
and	O
scabicide	B-Chemical
.	O
	
It	O
evokes	O
convulsions	B-Disease
mainly	O
trough	O
the	O
blockage	O
of	O
GABA	O
(	O
A	O
)	O
receptors	O
.	O
	
Nitric	B-Chemical
oxide	I-Chemical
(	O
NO	B-Chemical
)","	O
gaseous	O
neurotransmitter	O
","	O
has	O
contradictor	O
role	O
in	O
epileptogenesis	O
due	O
to	O
opposite	O
effects	O
of	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
","	O
precursor	O
of	O
NO	O
syntheses	O
(	O
NOS	O
)","	O
and	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
(	O
NOS	O
inhibitor	O
)	O
observed	O
in	O
different	O
epilepsy	B-Disease
models	O
.	O
	
The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
NO	B-Chemical
on	O
the	O
behavioral	O
and	O
EEG	O
characteristics	O
of	O
lindane	B-Chemical
-	O
induced	O
epilepsy	B-Disease
in	O
male	O
Wistar	O
albino	O
rats	O
.	O
	
The	O
administration	O
of	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
(	O
600	O
","	O
800	O
and	O
1000	O
mg	O
/	O
kg	O
","	O
i	O
.	O
p	O
.)	O
	
in	O
dose	O
-	O
dependent	O
manner	O
significantly	O
increased	O
convulsion	B-Disease
incidence	O
and	O
severity	O
and	O
shortened	O
latency	O
time	O
to	O
first	O
convulsion	B-Disease
elicited	O
by	O
lower	O
lindane	B-Chemical
dose	O
(	O
4	O
mg	O
/	O
kg	O
","	O
i	O
.	O
p	O
.).	O
	
On	O
the	O
contrary	O
","	O
pretreatment	O
with	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
(	O
500	O
","	O
700	O
and	O
900	O
mg	O
/	O
kg	O
","	O
i	O
.	O
p	O
.)	O
	
decreased	O
convulsion	B-Disease
incidence	O
and	O
severity	O
and	O
prolonged	O
latency	O
time	O
to	O
convulsion	B-Disease
following	O
injection	O
with	O
a	O
convulsive	B-Disease
dose	O
of	O
lindane	B-Chemical
(	O
8	O
mg	O
/	O
kg	O
","	O
i	O
.	O
p	O
.).	O
	
EEG	O
analyses	O
showed	O
increase	O
of	O
number	O
and	O
duration	O
of	O
ictal	O
periods	O
in	O
EEG	O
of	O
rats	O
receiving	O
l	B-Chemical
-	I-Chemical
arginine	I-Chemical
prior	O
to	O
lindane	B-Chemical
and	O
decrease	O
of	O
this	O
number	O
in	O
rats	O
pretreated	O
with	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
.	O
	
These	O
results	O
support	O
the	O
conclusion	O
that	O
NO	B-Chemical
plays	O
a	O
role	O
of	O
endogenous	O
convulsant	B-Disease
in	O
rat	O
model	O
of	O
lindane	B-Chemical
seizures	B-Disease
.	O
	
	
The	O
cytogenetic	O
action	O
of	O
ifosfamide	B-Chemical
","	O
mesna	B-Chemical
","	O
and	O
their	O
combination	O
on	O
peripheral	O
rabbit	O
lymphocytes	O
:	O
an	O
in	O
vivo	O
/	O
in	O
vitro	O
cytogenetic	O
study	O
.	O
	
Ifosfamide	B-Chemical
(	O
IFO	B-Chemical
)	O
is	O
an	O
alkylating	B-Chemical
nitrogen	I-Chemical
mustard	I-Chemical
","	O
administrated	O
as	O
an	O
antineoplasmic	O
agent	O
.	O
	
It	O
is	O
characterized	O
by	O
its	O
intense	O
urotoxic	O
action	O
","	O
leading	O
to	O
hemorrhagic	B-Disease
cystitis	I-Disease
.	O
	
This	O
side	O
effect	O
of	O
IFO	B-Chemical
raises	O
the	O
requirement	O
for	O
the	O
co	O
-	O
administration	O
with	O
sodium	B-Chemical
2	I-Chemical
-	I-Chemical
sulfanylethanesulfonate	I-Chemical
(	O
Mesna	B-Chemical
)	O
aiming	O
to	O
avoid	O
or	O
minimize	O
this	O
effect	O
.	O
	
IFO	B-Chemical
and	O
Mesna	B-Chemical
were	O
administrated	O
separately	O
on	O
rabbit	O
'	O
s	O
lymphocytes	O
in	O
vivo	O
","	O
which	O
were	O
later	O
developed	O
in	O
vitro	O
.	O
	
Cytogenetic	O
markers	O
for	O
sister	O
chromatid	O
exchanges	O
(	O
SCEs	O
)","	O
proliferation	O
rate	O
index	O
(	O
PRI	O
)	O
and	O
Mitotic	O
Index	O
were	O
recorded	O
.	O
	
Mesna	B-Chemical
'	O
s	O
action	O
","	O
in	O
conjunction	O
with	O
IFO	B-Chemical
reduces	O
the	O
frequency	O
of	O
SCEs	O
","	O
in	O
comparison	O
with	O
the	O
SCEs	O
recordings	O
obtained	O
when	O
IFO	B-Chemical
is	O
administered	O
alone	O
.	O
	
In	O
addition	O
to	O
this	O
","	O
when	O
high	O
concentrations	O
of	O
Mesna	B-Chemical
were	O
administered	O
alone	O
significant	O
reductions	O
of	O
the	O
PRI	O
were	O
noted	O
","	O
than	O
with	O
IFO	B-Chemical
acting	O
at	O
the	O
same	O
concentration	O
on	O
the	O
lymphocytes	O
.	O
	
Mesna	B-Chemical
significantly	O
reduces	O
IFO	B-Chemical
'	O
s	O
genotoxicity	B-Disease
","	O
while	O
when	O
administered	O
in	O
high	O
concentrations	O
it	O
acts	O
in	O
an	O
inhibitory	O
fashion	O
on	O
the	O
cytostatic	O
action	O
of	O
the	O
drug	O
.	O
	
	
Crocin	B-Chemical
improves	O
lipid	B-Chemical
dysregulation	O
in	O
subacute	O
diazinon	B-Chemical
exposure	O
through	O
ERK1	O
/	O
2	O
pathway	O
in	O
rat	O
liver	O
.	O
	
INTRODUCTION	O
:	O
Diazinon	B-Chemical
Yis	O
one	O
of	O
the	O
most	O
broadly	O
used	O
organophosphorus	B-Chemical
insecticides	O
in	O
agriculture	O
.	O
	
It	O
has	O
been	O
shown	O
that	O
exposure	O
to	O
diazinon	B-Chemical
may	O
interfere	O
with	O
lipid	B-Chemical
metabolism	O
.	O
	
Moreover	O
","	O
the	O
hypolipidemic	O
effect	O
of	O
crocin	B-Chemical
has	O
been	O
established	O
.	O
	
Earlier	O
studies	O
revealed	O
the	O
major	O
role	O
of	O
Extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
pathways	O
in	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
(	O
LDLr	O
)	O
expression	O
.	O
	
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
changes	O
in	O
the	O
regulation	O
of	O
lipid	B-Chemical
metabolism	O
","	O
ERK	O
and	O
LDLr	O
expression	O
in	O
the	O
liver	O
of	O
rats	O
exposed	O
to	O
subacute	O
diazinon	B-Chemical
.	O
	
Furthermore	O
ameliorating	O
effect	O
of	O
crocin	B-Chemical
on	O
diazinon	B-Chemical
induced	O
disturbed	O
cholesterol	B-Chemical
homeostasis	O
was	O
studied	O
.	O
	
METHODS	O
:	O
24	O
Rats	O
were	O
divided	O
into	O
4	O
groups	O
and	O
received	O
following	O
treatments	O
for	O
4	O
weeks	O
";"	O
Corn	B-Chemical
oil	I-Chemical
(	O
control	O
)","	O
diazinon	B-Chemical
(	O
15mg	O
/	O
kg	O
per	O
day	O
","	O
orally	O
)	O
and	O
crocin	B-Chemical
(	O
12	O
.	O
5	O
and	O
25mg	O
/	O
kg	O
per	O
day	O
","	O
intraperitoneally	O
)	O
in	O
combination	O
with	O
diazinon	B-Chemical
(	O
15	O
mg	O
/	O
kg	O
).	O
	
The	O
levels	O
of	O
cholesterol	B-Chemical
","	O
triglyceride	B-Chemical
and	O
LDL	B-Chemical
in	O
blood	O
of	O
rats	O
were	O
analyzed	O
.	O
	
Moreover	O
mRNA	O
levels	O
of	O
LDLr	O
and	O
ERK1	O
/	O
2	O
as	O
well	O
as	O
protein	O
levels	O
of	O
total	O
and	O
activated	O
forms	O
of	O
ERK1	O
/	O
2	O
in	O
rat	O
liver	O
were	O
evaluated	O
by	O
Western	O
blotting	O
and	O
quantitative	O
real	O
time	O
polymerase	O
chain	O
reaction	O
analysis	O
.	O
	
RESULTS	O
:	O
Our	O
data	O
showed	O
that	O
subacute	O
exposure	O
to	O
diazinon	B-Chemical
significantly	O
increased	O
concentrations	O
of	O
cholesterol	B-Chemical
","	O
triglyceride	B-Chemical
and	O
LDL	B-Chemical
.	O
	
Moreover	O
diazinon	B-Chemical
decreased	O
ERK1	O
/	O
2	O
protein	O
phosphorylation	O
and	O
LDLr	O
transcript	O
.	O
	
Crocin	B-Chemical
reduced	O
inhibition	O
of	O
ERK	O
activation	O
and	O
diazinon	B-Chemical
-	O
induced	O
hyperlipemia	B-Disease
and	O
increased	O
levels	O
of	O
LDLr	O
transcript	O
.	O
	
CONCLUSIONS	O
:	O
Crocin	B-Chemical
may	O
be	O
considered	O
as	O
a	O
novel	O
protective	O
agent	O
in	O
diazinon	B-Chemical
-	O
induced	O
hyperlipemia	B-Disease
through	O
modulating	O
of	O
ERK	O
pathway	O
and	O
increase	O
of	O
LDLr	O
expression	O
.	O
	
	
Cholecystokinin	B-Chemical
-	I-Chemical
octapeptide	I-Chemical
restored	O
morphine	B-Chemical
-	O
induced	O
hippocampal	O
long	O
-	O
term	O
potentiation	O
impairment	O
in	O
rats	O
.	O
	
Cholecystokinin	B-Chemical
-	I-Chemical
octapeptide	I-Chemical
(	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
)","	O
which	O
is	O
a	O
typical	O
brain	O
-	O
gut	O
peptide	O
","	O
exerts	O
a	O
wide	O
range	O
of	O
biological	O
activities	O
on	O
the	O
central	O
nervous	O
system	O
.	O
	
We	O
have	O
previously	O
reported	O
that	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
significantly	O
alleviated	O
morphine	B-Chemical
-	O
induced	O
amnesia	B-Disease
and	O
reversed	O
spine	O
density	O
decreases	O
in	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
in	O
morphine	B-Chemical
-	O
treated	O
animals	O
.	O
	
Here	O
","	O
we	O
investigated	O
the	O
effects	O
of	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
on	O
long	O
-	O
term	O
potentiation	O
(	O
LTP	O
)	O
in	O
the	O
lateral	O
perforant	O
path	O
(	O
LPP	O
)-	O
granule	O
cell	O
synapse	O
of	O
rat	O
dentate	O
gyrus	O
(	O
DG	O
)	O
in	O
acute	O
saline	O
or	O
morphine	B-Chemical
-	O
treated	O
rats	O
.	O
	
Population	O
spikes	O
(	O
PS	O
)","	O
which	O
were	O
evoked	O
by	O
stimulation	O
of	O
the	O
LPP	O
","	O
were	O
recorded	O
in	O
the	O
DG	O
region	O
.	O
	
Acute	O
morphine	B-Chemical
(	O
30mg	O
/	O
kg	O
","	O
s	O
.	O
c	O
.)	O
	
treatment	O
significantly	O
attenuated	O
hippocampal	O
LTP	O
and	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
(	O
1ug	O
","	O
i	O
.	O
c	O
.	O
v	O
.)	O
	
restored	O
the	O
amplitude	O
of	O
PS	O
that	O
was	O
attenuated	O
by	O
morphine	B-Chemical
injection	O
.	O
	
Furthermore	O
","	O
microinjection	O
of	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
(	O
0	O
.	O
1	O
and	O
1ug	O
","	O
i	O
.	O
c	O
.	O
v	O
.)	O
	
also	O
significantly	O
augmented	O
hippocampal	O
LTP	O
in	O
saline	O
-	O
treated	O
(	O
1ml	O
/	O
kg	O
","	O
s	O
.	O
c	O
.)	O
	
rats	O
.	O
	
Pre	O
-	O
treatment	O
of	O
the	O
CCK2	O
receptor	O
antagonist	O
L	B-Chemical
-	I-Chemical
365	I-Chemical
","	I-Chemical
260	I-Chemical
(	O
10ug	O
","	O
i	O
.	O
c	O
.	O
v	O
)	O
reversed	O
the	O
effects	O
of	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
","	O
but	O
the	O
CCK1	O
receptor	O
antagonist	O
L	B-Chemical
-	I-Chemical
364	I-Chemical
","	I-Chemical
718	I-Chemical
(	O
10ug	O
","	O
i	O
.	O
c	O
.	O
v	O
)	O
did	O
not	O
.	O
	
The	O
present	O
results	O
demonstrate	O
that	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
attenuates	O
the	O
effect	O
of	O
morphine	B-Chemical
on	O
hippocampal	O
LTP	O
through	O
CCK2	O
receptors	O
and	O
suggest	O
an	O
ameliorative	O
function	O
of	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
on	O
morphine	B-Chemical
-	O
induced	O
memory	B-Disease
impairment	I-Disease
.	O
	
	
Comparison	O
of	O
effects	O
of	O
isotonic	O
sodium	B-Chemical
chloride	I-Chemical
with	O
diltiazem	B-Chemical
in	O
prevention	O
of	O
contrast	B-Chemical
-	O
induced	O
nephropathy	B-Disease
.	O
	
INTRODUCTION	O
AND	O
OBJECTIVE	O
:	O
Contrast	B-Chemical
-	O
induced	O
nephropathy	B-Disease
(	O
CIN	B-Disease
)	O
significantly	O
increases	O
the	O
morbidity	O
and	O
mortality	O
of	O
patients	O
.	O
	
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
and	O
compare	O
the	O
protective	O
effects	O
of	O
isotonic	O
sodium	B-Chemical
chloride	I-Chemical
with	O
sodium	B-Chemical
bicarbonate	I-Chemical
infusion	O
and	O
isotonic	O
sodium	B-Chemical
chloride	I-Chemical
infusion	O
with	O
diltiazem	B-Chemical
","	O
a	O
calcium	B-Chemical
channel	O
blocker	O
","	O
in	O
preventing	O
CIN	B-Disease
.	O
	
MATERIALS	O
AND	O
METHODS	O
:	O
Our	O
study	O
included	O
patients	O
who	O
were	O
administered	O
30	O
-	O
60	O
mL	O
of	O
iodinated	O
contrast	B-Chemical
agent	O
for	O
percutaneous	O
coronary	O
angiography	O
(	O
PCAG	O
)","	O
all	O
with	O
creatinine	B-Chemical
values	O
between	O
1	O
.	O
1	O
and	O
3	O
.	O
1	O
mg	O
/	O
dL	O
.	O
	
Patients	O
were	O
divided	O
into	O
three	O
groups	O
and	O
each	O
group	O
had	O
20	O
patients	O
.	O
	
The	O
first	O
group	O
of	O
patients	O
was	O
administered	O
isotonic	O
sodium	B-Chemical
chloride	I-Chemical
";"	O
the	O
second	O
group	O
was	O
administered	O
a	O
solution	O
that	O
of	O
5	O
%	O
dextrose	B-Chemical
and	O
sodium	B-Chemical
bicarbonate	I-Chemical
","	O
while	O
the	O
third	O
group	O
was	O
administered	O
isotonic	O
sodium	B-Chemical
chloride	I-Chemical
before	O
and	O
after	O
the	O
contrast	B-Chemical
injection	O
.	O
	
The	O
third	O
group	O
received	O
an	O
additional	O
injection	O
of	O
diltiazem	B-Chemical
the	O
day	O
before	O
and	O
first	O
2	O
days	O
after	O
the	O
contrast	B-Chemical
injection	O
.	O
	
All	O
of	O
the	O
patients	O
'	O
plasma	O
blood	B-Chemical
urea	I-Chemical
nitrogen	I-Chemical
(	O
BUN	B-Chemical
)	O
and	O
creatinine	B-Chemical
levels	O
were	O
measured	O
on	O
the	O
second	O
and	O
seventh	O
day	O
after	O
the	O
administration	O
of	O
intravenous	O
contrast	B-Chemical
material	O
.	O
	
RESULTS	O
:	O
The	O
basal	O
creatinine	B-Chemical
levels	O
were	O
similar	O
for	O
all	O
three	O
groups	O
(	O
p	O
>	O
0	O
.	O
5	O
).	O
	
Among	O
a	O
total	O
of	O
60	O
patients	O
included	O
in	O
the	O
study	O
","	O
16	O
patients	O
developed	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
(	O
ARF	B-Disease
)	O
on	O
the	O
second	O
day	O
after	O
contrast	B-Chemical
material	O
was	O
injected	O
(	O
26	O
.	O
6	O
%).	O
	
The	O
number	O
of	O
patients	O
who	O
developed	O
ARF	B-Disease
on	O
the	O
second	O
day	O
after	O
the	O
injection	O
in	O
the	O
first	O
group	O
was	O
five	O
(	O
25	O
%)","	O
in	O
the	O
second	O
group	O
was	O
six	O
(	O
30	O
%)	O
and	O
the	O
third	O
group	O
was	O
five	O
(	O
25	O
%)	O
(	O
p	O
>	O
0	O
.	O
5	O
).	O
	
CONCLUSION	O
:	O
There	O
was	O
no	O
significant	O
difference	O
between	O
isotonic	O
sodium	B-Chemical
chloride	I-Chemical
","	O
sodium	B-Chemical
bicarbonate	I-Chemical
and	O
isotonic	O
sodium	B-Chemical
chloride	I-Chemical
with	O
diltiazem	B-Chemical
application	O
in	O
prevention	O
of	O
CIN	B-Disease
.	O
	
	
Prevention	O
of	O
etomidate	B-Chemical
-	O
induced	O
myoclonus	B-Disease
:	O
which	O
is	O
superior	O
:	O
Fentanyl	B-Chemical
","	O
midazolam	B-Chemical
","	O
or	O
a	O
combination	O
?	O
	
A	O
Retrospective	O
comparative	O
study	O
.	O
	
BACKGROUND	O
:	O
In	O
this	O
retrospective	O
comparative	O
study	O
","	O
we	O
aimed	O
to	O
compare	O
the	O
effectiveness	O
of	O
fentanyl	B-Chemical
","	O
midazolam	B-Chemical
","	O
and	O
a	O
combination	O
of	O
fentanyl	B-Chemical
and	O
midazolam	B-Chemical
to	O
prevent	O
etomidate	B-Chemical
-	O
induced	O
myoclonus	B-Disease
.	O
	
MATERIAL	O
AND	O
METHODS	O
:	O
This	O
study	O
was	O
performed	O
based	O
on	O
anesthesia	O
records	O
.	O
	
Depending	O
on	O
the	O
drugs	O
that	O
would	O
be	O
given	O
before	O
the	O
induction	O
of	O
anesthesia	O
with	O
etomidate	B-Chemical
","	O
the	O
patients	O
were	O
separated	O
into	O
4	O
groups	O
:	O
no	O
pretreatment	O
(	O
Group	O
NP	O
)","	O
fentanyl	B-Chemical
1	O
ug	O
.	O
kg	O
-	O
1	O
(	O
Group	O
F	O
)","	O
midazolam	B-Chemical
0	O
.	O
3	O
mg	O
.	O
kg	O
-	O
1	O
(	O
Group	O
M	O
)","	O
and	O
midazolam	B-Chemical
0	O
.	O
15	O
mg	O
.	O
kg	O
-	O
1	O
+	O
fentanyl	B-Chemical
0	O
.	O
5	O
ug	O
.	O
kg	O
-	O
1	O
(	O
Group	O
FM	O
).	O
	
Patients	O
who	O
received	O
the	O
same	O
anesthetic	O
procedure	O
were	O
selected	O
:	O
2	O
minutes	O
after	O
intravenous	O
injections	O
of	O
the	O
pretreatment	O
drugs	O
","	O
anesthesia	O
is	O
induced	O
with	O
0	O
.	O
3	O
mg	O
.	O
kg	O
-	O
1	O
etomidate	B-Chemical
injected	O
intravenously	O
over	O
a	O
period	O
of	O
20	O
-	O
30	O
seconds	O
.	O
	
Myoclonic	B-Disease
movements	I-Disease
are	O
evaluated	O
","	O
which	O
were	O
observed	O
and	O
graded	O
according	O
to	O
clinical	O
severity	O
during	O
the	O
2	O
minutes	O
after	O
etomidate	B-Chemical
injection	O
.	O
	
The	O
severity	O
of	O
pain	B-Disease
due	O
to	O
etomidate	B-Chemical
injection	O
","	O
mean	O
arterial	O
pressure	O
","	O
heart	O
rate	O
","	O
and	O
adverse	O
effects	O
were	O
also	O
evaluated	O
.	O
	
RESULTS	O
:	O
Study	O
results	O
showed	O
that	O
myoclonus	B-Disease
incidence	O
was	O
85	O
%","	O
40	O
%","	O
70	O
%","	O
and	O
25	O
%	O
in	O
Group	O
NP	O
","	O
Group	O
F	O
","	O
Group	O
M	O
","	O
and	O
Group	O
FM	O
","	O
respectively	O
","	O
and	O
were	O
significantly	O
lower	O
in	O
Group	O
F	O
and	O
Group	O
FM	O
.	O
	
CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
pretreatment	O
with	O
fentanyl	B-Chemical
or	O
combination	O
of	O
fentanyl	B-Chemical
and	O
midazolam	B-Chemical
was	O
effective	O
in	O
preventing	O
etomidate	B-Chemical
-	O
induced	O
myoclonus	B-Disease
.	O
	
	
Testosterone	B-Chemical
ameliorates	O
streptozotocin	B-Chemical
-	O
induced	O
memory	B-Disease
impairment	I-Disease
in	O
male	O
rats	O
.	O
	
AIM	O
:	O
To	O
study	O
the	O
effects	O
of	O
testosterone	B-Chemical
on	O
streptozotocin	B-Chemical
(	O
STZ	B-Chemical
)-	O
induced	O
memory	B-Disease
impairment	I-Disease
in	O
male	O
rats	O
.	O
	
METHODS	O
:	O
Adult	O
male	O
Wistar	O
rats	O
were	O
intracerebroventricularly	O
(	O
icv	O
)	O
infused	O
with	O
STZ	B-Chemical
(	O
750	O
ug	O
)	O
on	O
d	O
1	O
and	O
d	O
3	O
","	O
and	O
a	O
passive	O
avoidance	O
task	O
was	O
assessed	O
2	O
weeks	O
after	O
the	O
first	O
injection	O
of	O
STZ	B-Chemical
.	O
	
Castration	O
surgery	O
was	O
performed	O
in	O
another	O
group	O
of	O
rats	O
","	O
and	O
the	O
passive	O
avoidance	O
task	O
was	O
assessed	O
4	O
weeks	O
after	O
the	O
operation	O
.	O
	
Testosterone	B-Chemical
(	O
1	O
mg	O
.	O
kg	O
(-	O
1	O
).	O
d	O
(-	O
1	O
)","	O
sc	O
)","	O
the	O
androgen	O
receptor	O
antagonist	O
flutamide	B-Chemical
(	O
10	O
mg	O
.	O
kg	O
(-	O
1	O
).	O
d	O
(-	O
1	O
)","	O
ip	O
)","	O
the	O
estrogen	O
receptor	O
antagonist	O
tamoxifen	B-Chemical
(	O
1	O
mg	O
.	O
kg	O
(-	O
1	O
).	O
d	O
(-	O
1	O
)","	O
ip	O
)	O
or	O
the	O
aromatase	O
inhibitor	O
letrozole	B-Chemical
(	O
4	O
mg	O
.	O
kg	O
(-	O
1	O
).	O
d	O
(-	O
1	O
)","	O
ip	O
)	O
were	O
administered	O
for	O
6	O
d	O
after	O
the	O
first	O
injection	O
of	O
STZ	B-Chemical
.	O
	
RESULTS	O
:	O
STZ	B-Chemical
administration	O
and	O
castration	O
markedly	O
decreased	O
both	O
STL1	O
(	O
the	O
short	O
memory	O
)	O
and	O
STL2	O
(	O
the	O
long	O
memory	O
)	O
in	O
passive	O
avoidance	O
tests	O
.	O
	
Testosterone	B-Chemical
replacement	O
almost	O
restored	O
the	O
STL1	O
and	O
STL2	O
in	O
castrated	O
rats	O
","	O
and	O
significantly	O
prolonged	O
the	O
STL1	O
and	O
STL2	O
in	O
STZ	B-Chemical
-	O
treated	O
rats	O
.	O
	
Administration	O
of	O
flutamide	B-Chemical
","	O
letrozole	B-Chemical
or	O
tamoxifen	B-Chemical
significantly	O
impaired	O
the	O
memory	O
in	O
intact	O
rats	O
","	O
and	O
significantly	O
attenuated	O
the	O
testosterone	B-Chemical
replacement	O
in	O
improving	O
STZ	B-Chemical
-	O
and	O
castration	O
-	O
induced	O
memory	B-Disease
impairment	I-Disease
.	O
	
CONCLUSION	O
:	O
Testosterone	B-Chemical
administration	O
ameliorates	O
STZ	B-Chemical
-	O
and	O
castration	O
-	O
induced	O
memory	B-Disease
impairment	I-Disease
in	O
male	O
Wistar	O
rats	O
.	O
	
	
Rhabdomyolysis	B-Disease
in	O
a	O
hepatitis	B-Disease
C	I-Disease
virus	I-Disease
infected	I-Disease
patient	O
treated	O
with	O
telaprevir	B-Chemical
and	O
simvastatin	B-Chemical
.	O
	
A	O
46	O
-	O
year	O
old	O
man	O
with	O
a	O
chronic	O
hepatitis	B-Disease
C	I-Disease
virus	I-Disease
infection	I-Disease
received	O
triple	O
therapy	O
with	O
ribavirin	B-Chemical
","	O
pegylated	B-Chemical
interferon	I-Chemical
and	O
telaprevir	B-Chemical
.	O
	
The	O
patient	O
also	O
received	O
simvastatin	B-Chemical
.	O
	
One	O
month	O
after	O
starting	O
the	O
antiviral	O
therapy	O
","	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
hospital	O
because	O
he	O
developed	O
rhabdomyolysis	B-Disease
.	O
	
At	O
admission	O
simvastatin	B-Chemical
and	O
all	O
antiviral	B-Chemical
drugs	I-Chemical
were	O
discontinued	O
because	O
toxicity	B-Disease
due	O
to	O
a	O
drug	O
-	O
drug	O
interaction	O
was	O
suspected	O
.	O
	
The	O
creatine	B-Chemical
kinase	I-Chemical
peaked	O
at	O
62	O
","	O
246	O
IU	O
/	O
L	O
and	O
the	O
patient	O
was	O
treated	O
with	O
intravenous	O
normal	O
saline	O
.	O
	
The	O
patient	O
'	O
s	O
renal	O
function	O
remained	O
unaffected	O
.	O
	
Fourteen	O
days	O
after	O
hospitalization	O
","	O
creatine	B-Chemical
kinase	I-Chemical
level	O
had	O
returned	O
to	O
230	O
IU	O
/	O
L	O
and	O
the	O
patient	O
was	O
discharged	O
.	O
	
Telaprevir	B-Chemical
was	O
considered	O
the	O
probable	O
causative	O
agent	O
of	O
an	O
interaction	O
with	O
simvastatin	B-Chemical
according	O
to	O
the	O
Drug	O
Interaction	O
Probability	O
Scale	O
.	O
	
The	O
interaction	O
is	O
due	O
to	O
inhibition	O
of	O
CYP3A4	O
-	O
mediated	O
simvastatin	B-Chemical
clearance	O
.	O
	
Simvastatin	B-Chemical
plasma	O
concentration	O
increased	O
30	O
times	O
in	O
this	O
patient	O
and	O
statin	B-Chemical
induced	O
muscle	B-Disease
toxicity	I-Disease
is	O
related	O
to	O
the	O
concentration	O
of	O
the	O
statin	B-Chemical
in	O
blood	O
.	O
	
In	O
conclusion	O
","	O
with	O
this	O
case	O
we	O
illustrate	O
that	O
telaprevir	B-Chemical
as	O
well	O
as	O
statins	B-Chemical
are	O
susceptible	O
to	O
clinical	O
relevant	O
drug	O
-	O
drug	O
interactions	O
.	O
